evidence_id	assertion_id	disorder_id	disorder_name	source_file	section	section_index	path	evidence_index	reference	supports	evidence_source	snippet	explanation	raw_json
13	16	1	22q11.2 Deletion Syndrome	22q11.2_Deletion_Syndrome.yaml	treatments	0	evidence	0	PMID:20301696	SUPPORT	HUMAN_CLINICAL	Cardiac anomalies are treated as recommended by cardiologist	Cardiac management is part of standard care.	"{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""Cardiac management is part of standard care."", ""reference"": ""PMID:20301696"", ""snippet"": ""Cardiac anomalies are treated as recommended by cardiologist"", ""supports"": ""SUPPORT""}"
14	17	1	22q11.2 Deletion Syndrome	22q11.2_Deletion_Syndrome.yaml	treatments	1	evidence	0	PMID:20301696	SUPPORT	HUMAN_CLINICAL	calcium supplementation and referral to an endocrinologist	Calcium supplementation is recommended for hypocalcemia.	"{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""Calcium supplementation is recommended for hypocalcemia."", ""reference"": ""PMID:20301696"", ""snippet"": ""calcium supplementation and referral to an endocrinologist"", ""supports"": ""SUPPORT""}"
15	18	1	22q11.2 Deletion Syndrome	22q11.2_Deletion_Syndrome.yaml	treatments	2	evidence	0	PMID:20301696	SUPPORT	HUMAN_CLINICAL	rarely, prophylactic antibiotics, IVIG therapy, or thymus tissue implantation are required	Thymus transplantation is indicated for complete DiGeorge.	"{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""Thymus transplantation is indicated for complete DiGeorge."", ""reference"": ""PMID:20301696"", ""snippet"": ""rarely, prophylactic antibiotics, IVIG therapy, or thymus tissue implantation are required"", ""supports"": ""SUPPORT""}"
16	19	1	22q11.2 Deletion Syndrome	22q11.2_Deletion_Syndrome.yaml	treatments	3	evidence	0	PMID:20301696	SUPPORT	HUMAN_CLINICAL	speech therapy	Speech therapy is part of the recommended management.	"{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""Speech therapy is part of the recommended management."", ""reference"": ""PMID:20301696"", ""snippet"": ""speech therapy"", ""supports"": ""SUPPORT""}"
17	20	1	22q11.2 Deletion Syndrome	22q11.2_Deletion_Syndrome.yaml	treatments	4	evidence	0	PMID:20301696	SUPPORT	HUMAN_CLINICAL	Infants with lymphocyte abnormalities should not be immunized with live vaccines	Vaccine precautions based on immune status are recommended.	"{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""Vaccine precautions based on immune status are recommended."", ""reference"": ""PMID:20301696"", ""snippet"": ""Infants with lymphocyte abnormalities should not be immunized with live vaccines"", ""supports"": ""SUPPORT""}"
89	93	4	ATTR_Amyloidosis	ATTR_Amyloidosis.yaml	treatments	0	evidence	0	PMID:25872787	SUPPORT		Tafamidis treatment effectively achieved and maintained TTR stabilization and was well tolerated.	The study shows that tafamidis effectively stabilizes TTR, supporting the statement that it helps stabilize transthyretin.	"{""explanation"": ""The study shows that tafamidis effectively stabilizes TTR, supporting the statement that it helps stabilize transthyretin."", ""reference"": ""PMID:25872787"", ""snippet"": ""Tafamidis treatment effectively achieved and maintained TTR stabilization and was well tolerated."", ""supports"": ""SUPPORT""}"
90	93	4	ATTR_Amyloidosis	ATTR_Amyloidosis.yaml	treatments	0	evidence	1	PMID:31098895	SUPPORT		Tafamidis slowed deterioration of neurological function and maintained health-related quality of life in patients with early-stage ATTR-PN... TTR tetramers were stabilized in nearly all patients.	The evidence indicates that tafamidis stabilizes TTR tetramers, supporting the statement.	"{""explanation"": ""The evidence indicates that tafamidis stabilizes TTR tetramers, supporting the statement."", ""reference"": ""PMID:31098895"", ""snippet"": ""Tafamidis slowed deterioration of neurological function and maintained health-related quality of life in patients with early-stage ATTR-PN... TTR tetramers were stabilized in nearly all patients."", ""supports"": ""SUPPORT""}"
91	93	4	ATTR_Amyloidosis	ATTR_Amyloidosis.yaml	treatments	0	evidence	2	PMID:26800456	SUPPORT		Due to the data on efficacy, tolerability, safety, tafamidis and diflunisal became the first line anti-amyloid treatment in stage 1 TTR-FAP. Both drugs slow progression of the disease.	The study supports that tafamidis is effective in stabilizing TTR and preventing amyloid fibril formation.	"{""explanation"": ""The study supports that tafamidis is effective in stabilizing TTR and preventing amyloid fibril formation."", ""reference"": ""PMID:26800456"", ""snippet"": ""Due to the data on efficacy, tolerability, safety, tafamidis and diflunisal became the first line anti-amyloid treatment in stage 1 TTR-FAP. Both drugs slow progression of the disease."", ""supports"": ""SUPPORT""}"
92	93	4	ATTR_Amyloidosis	ATTR_Amyloidosis.yaml	treatments	0	evidence	3	PMID:29962408	SUPPORT		The mutations destabilize the tetramer and/or monomer of TTR, and thus the stabilization of TTR is a key strategy for the treatment of TTR-related amyloidosis.	The review supports that stabilizing TTR is crucial, and tafamidis is one of the compounds that achieve this.	"{""explanation"": ""The review supports that stabilizing TTR is crucial, and tafamidis is one of the compounds that achieve this."", ""reference"": ""PMID:29962408"", ""snippet"": ""The mutations destabilize the tetramer and/or monomer of TTR, and thus the stabilization of TTR is a key strategy for the treatment of TTR-related amyloidosis."", ""supports"": ""SUPPORT""}"
93	93	4	ATTR_Amyloidosis	ATTR_Amyloidosis.yaml	treatments	0	evidence	4	PMID:34609369	SUPPORT		Several TTR molecule stabilizers were developed successfully... Silencing the TTR gene using different strategies is flourishing.	The article states that TTR stabilizers, including tafamidis, have been successfully developed, supporting the statement.	"{""explanation"": ""The article states that TTR stabilizers, including tafamidis, have been successfully developed, supporting the statement."", ""reference"": ""PMID:34609369"", ""snippet"": ""Several TTR molecule stabilizers were developed successfully... Silencing the TTR gene using different strategies is flourishing."", ""supports"": ""SUPPORT""}"
94	94	4	ATTR_Amyloidosis	ATTR_Amyloidosis.yaml	treatments	1	evidence	0	PMID:30480471	SUPPORT		Patisiran is a novel RNA interference therapeutic that specifically reduces production of both wild-type and mutant transthyretin protein.	The abstract clearly states that patisiran reduces the production of transthyretin protein, which aligns with the statement.	"{""explanation"": ""The abstract clearly states that patisiran reduces the production of transthyretin protein, which aligns with the statement."", ""reference"": ""PMID:30480471"", ""snippet"": ""Patisiran is a novel RNA interference therapeutic that specifically reduces production of both wild-type and mutant transthyretin protein."", ""supports"": ""SUPPORT""}"
95	94	4	ATTR_Amyloidosis	ATTR_Amyloidosis.yaml	treatments	1	evidence	1	PMID:37599395	SUPPORT		Novel ribonucleic acid interference (RNAi) therapeutics such as patisiran and inotersen have been shown to benefit neurologic disease course and quality of life in patients with hereditary transthyretin amyloidosis (ATTRv).	The abstract mentions that patisiran, as an RNAi therapeutic, benefits patients with hereditary transthyretin amyloidosis, indicating its role in reducing transthyretin protein production.	"{""explanation"": ""The abstract mentions that patisiran, as an RNAi therapeutic, benefits patients with hereditary transthyretin amyloidosis, indicating its role in reducing transthyretin protein production."", ""reference"": ""PMID:37599395"", ""snippet"": ""Novel ribonucleic acid interference (RNAi) therapeutics such as patisiran and inotersen have been shown to benefit neurologic disease course and quality of life in patients with hereditary transthyretin amyloidosis (ATTRv)."", ""supports"": ""SUPPORT""}"
96	94	4	ATTR_Amyloidosis	ATTR_Amyloidosis.yaml	treatments	1	evidence	2	PMID:31131842	SUPPORT		Onpattro, also commonly known as patisiran, is a small interfering RNA (siRNA) molecule packaged within a lipid nanoparticle and is transported into the cell to target transthyretin gene (TTR) messenger mRNA (mRNA) by attaching to its complementary sequence. The target mRNA is degraded and both mutant and wild-type amyloid transthyretin (ATTR) protein production becomes suppressed.	The abstract explicitly states that patisiran targets and degrades transthyretin mRNA, thus reducing the production of transthyretin protein.	"{""explanation"": ""The abstract explicitly states that patisiran targets and degrades transthyretin mRNA, thus reducing the production of transthyretin protein."", ""reference"": ""PMID:31131842"", ""snippet"": ""Onpattro, also commonly known as patisiran, is a small interfering RNA (siRNA) molecule packaged within a lipid nanoparticle and is transported into the cell to target transthyretin gene (TTR) messenger mRNA (mRNA) by attaching to its complementary sequence. The target mRNA is degraded and both mutant and wild-type amyloid transthyretin (ATTR) protein production becomes suppressed."", ""supports"": ""SUPPORT""}"
97	95	4	ATTR_Amyloidosis	ATTR_Amyloidosis.yaml	treatments	2	evidence	0	PMID:30561247	SUPPORT		Inotersen/Tegsedi (Akcea Therapeutics, MA, USA) is a second-generation antisense oligonucleotide (ASO) specific for TTR that inhibits production of TTR by the liver.	The reference confirms that Inotersen reduces TTR protein production by inhibiting its production in the liver, which aligns with the statement.	"{""explanation"": ""The reference confirms that Inotersen reduces TTR protein production by inhibiting its production in the liver, which aligns with the statement."", ""reference"": ""PMID:30561247"", ""snippet"": ""Inotersen/Tegsedi (Akcea Therapeutics, MA, USA) is a second-generation antisense oligonucleotide (ASO) specific for TTR that inhibits production of TTR by the liver."", ""supports"": ""SUPPORT""}"
98	95	4	ATTR_Amyloidosis	ATTR_Amyloidosis.yaml	treatments	2	evidence	1	PMID:37599395	SUPPORT		'Aims: Novel ribonucleic acid interference (RNAi) therapeutics such as patisiran and inotersen have been shown to benefit neurologic disease course and quality of life in patients with hereditary transthyretin amyloidosis (ATTRv).	The reference supports that Inotersen is used to treat ATTR amyloidosis and implies its role in reducing TTR protein production.	"{""explanation"": ""The reference supports that Inotersen is used to treat ATTR amyloidosis and implies its role in reducing TTR protein production."", ""reference"": ""PMID:37599395"", ""snippet"": ""'Aims: Novel ribonucleic acid interference (RNAi) therapeutics such as patisiran and inotersen have been shown to benefit neurologic disease course and quality of life in patients with hereditary transthyretin amyloidosis (ATTRv)."", ""supports"": ""SUPPORT""}"
99	95	4	ATTR_Amyloidosis	ATTR_Amyloidosis.yaml	treatments	2	evidence	2	PMID:31343345	SUPPORT		Inotersen treatment for ATTR amyloidosis.	This reference title directly states that Inotersen is used for the treatment of ATTR amyloidosis, implying its role in reducing TTR protein production.	"{""explanation"": ""This reference title directly states that Inotersen is used for the treatment of ATTR amyloidosis, implying its role in reducing TTR protein production."", ""reference"": ""PMID:31343345"", ""snippet"": ""Inotersen treatment for ATTR amyloidosis."", ""supports"": ""SUPPORT""}"
100	96	4	ATTR_Amyloidosis	ATTR_Amyloidosis.yaml	treatments	3	evidence	0	PMID:25482846	SUPPORT		Orthotopic liver transplantation (OLT) was implemented as the inaugural disease-modifying therapy because the liver produces the circulating unstable TTR.	The literature supports liver transplantation as a therapy to address the production of unstable TTR in hereditary ATTR amyloidosis.	"{""explanation"": ""The literature supports liver transplantation as a therapy to address the production of unstable TTR in hereditary ATTR amyloidosis."", ""reference"": ""PMID:25482846"", ""snippet"": ""Orthotopic liver transplantation (OLT) was implemented as the inaugural disease-modifying therapy because the liver produces the circulating unstable TTR."", ""supports"": ""SUPPORT""}"
101	96	4	ATTR_Amyloidosis	ATTR_Amyloidosis.yaml	treatments	3	evidence	1	PMID:23797140	SUPPORT		Therefore, liver transplantation has become widely accepted as the ultimate curative treatment of this disease in order to prevent the ultimately fatal outcome and ameliorate disabling symptoms.	This reference supports the use of liver transplantation to reduce the production of mutant TTR in hereditary cases of ATTR amyloidosis.	"{""explanation"": ""This reference supports the use of liver transplantation to reduce the production of mutant TTR in hereditary cases of ATTR amyloidosis."", ""reference"": ""PMID:23797140"", ""snippet"": ""Therefore, liver transplantation has become widely accepted as the ultimate curative treatment of this disease in order to prevent the ultimately fatal outcome and ameliorate disabling symptoms."", ""supports"": ""SUPPORT""}"
102	97	4	ATTR_Amyloidosis	ATTR_Amyloidosis.yaml	treatments	4	evidence	0	PMID:32304420	SUPPORT		However, the end-stage heart failure is common and HTx could be offered to selected patients, especially if affected by light chain cardiac amyloidosis, to allow to perform the autologous stem cell transplantation after the cardiac transplant.	The statement is supported as heart transplantation is mentioned as a treatment for end-stage heart failure in patients with cardiac amyloidosis.	"{""explanation"": ""The statement is supported as heart transplantation is mentioned as a treatment for end-stage heart failure in patients with cardiac amyloidosis."", ""reference"": ""PMID:32304420"", ""snippet"": ""However, the end-stage heart failure is common and HTx could be offered to selected patients, especially if affected by light chain cardiac amyloidosis, to allow to perform the autologous stem cell transplantation after the cardiac transplant."", ""supports"": ""SUPPORT""}"
103	97	4	ATTR_Amyloidosis	ATTR_Amyloidosis.yaml	treatments	4	evidence	1	PMID:33621542	SUPPORT		Orthotopic heart transplantation (OHT) remains the definitive treatment for patients with end stage heart failure.	The statement is supported as orthotopic heart transplantation is identified as a definitive treatment for end-stage heart failure in amyloid cardiomyopathy patients.	"{""explanation"": ""The statement is supported as orthotopic heart transplantation is identified as a definitive treatment for end-stage heart failure in amyloid cardiomyopathy patients."", ""reference"": ""PMID:33621542"", ""snippet"": ""Orthotopic heart transplantation (OHT) remains the definitive treatment for patients with end stage heart failure."", ""supports"": ""SUPPORT""}"
104	97	4	ATTR_Amyloidosis	ATTR_Amyloidosis.yaml	treatments	4	evidence	2	PMID:34922822	SUPPORT		Heart Transplantation (HT) is a rational therapy for advanced transthyretin cardiac amyloidosis (ATTR-CA)...	The statement is supported as heart transplantation is described as a rational therapy for advanced transthyretin cardiac amyloidosis.	"{""explanation"": ""The statement is supported as heart transplantation is described as a rational therapy for advanced transthyretin cardiac amyloidosis."", ""reference"": ""PMID:34922822"", ""snippet"": ""Heart Transplantation (HT) is a rational therapy for advanced transthyretin cardiac amyloidosis (ATTR-CA)..."", ""supports"": ""SUPPORT""}"
105	98	4	ATTR_Amyloidosis	ATTR_Amyloidosis.yaml	treatments	5	evidence	0	PMID:33099432	SUPPORT		Supportive care manages the symptoms of organ involvement and the side effects of treatment.	The reference indicates that supportive care is used to manage the symptoms of organ involvement, which can include neuropathy, heart failure, and gastrointestinal issues.	"{""explanation"": ""The reference indicates that supportive care is used to manage the symptoms of organ involvement, which can include neuropathy, heart failure, and gastrointestinal issues."", ""reference"": ""PMID:33099432"", ""snippet"": ""Supportive care manages the symptoms of organ involvement and the side effects of treatment."", ""supports"": ""SUPPORT""}"
106	98	4	ATTR_Amyloidosis	ATTR_Amyloidosis.yaml	treatments	5	evidence	1	PMID:35235819	SUPPORT		Cardiac amyloidosis (CA) results in symptoms of heart failure, atrial and ventricular arrhythmias, conduction disturbances, and profound autonomic dysfunction.	The reference highlights the management of cardiovascular symptoms in cardiac amyloidosis, which is part of supportive care.	"{""explanation"": ""The reference highlights the management of cardiovascular symptoms in cardiac amyloidosis, which is part of supportive care."", ""reference"": ""PMID:35235819"", ""snippet"": ""Cardiac amyloidosis (CA) results in symptoms of heart failure, atrial and ventricular arrhythmias, conduction disturbances, and profound autonomic dysfunction."", ""supports"": ""SUPPORT""}"
107	98	4	ATTR_Amyloidosis	ATTR_Amyloidosis.yaml	treatments	5	evidence	2	PMID:35104443	SUPPORT		Systemic amyloidosis is characterized by extracellular deposition of insoluble fibrillar proteins in multiple tissues... The 2 most common forms, light chain (AL) and transthyretin (ATTR) amyloidosis can cause peripheral neuropathy and, rarely, myopathy.	The reference discusses the management of neuromuscular complications, including neuropathy, which is part of supportive care.	"{""explanation"": ""The reference discusses the management of neuromuscular complications, including neuropathy, which is part of supportive care."", ""reference"": ""PMID:35104443"", ""snippet"": ""Systemic amyloidosis is characterized by extracellular deposition of insoluble fibrillar proteins in multiple tissues... The 2 most common forms, light chain (AL) and transthyretin (ATTR) amyloidosis can cause peripheral neuropathy and, rarely, myopathy."", ""supports"": ""SUPPORT""}"
108	98	4	ATTR_Amyloidosis	ATTR_Amyloidosis.yaml	treatments	5	evidence	3	PMID:7588042	SUPPORT		The gastrointestinal manifestations of amyloidosis.	The reference discusses gastrointestinal issues related to amyloidosis, which are managed through supportive care.	"{""explanation"": ""The reference discusses gastrointestinal issues related to amyloidosis, which are managed through supportive care."", ""reference"": ""PMID:7588042"", ""snippet"": ""The gastrointestinal manifestations of amyloidosis."", ""supports"": ""SUPPORT""}"
129	127	6	Achondroplasia	Achondroplasia.yaml	treatments	0	evidence	0	PMID:31269546	SUPPORT	HUMAN_CLINICAL	Treatment resulted in a sustained increase in the annualized growth velocity for up to 42 months.	This NEJM phase 2 trial demonstrated that vosoritide treatment in children with achondroplasia resulted in sustained increases in growth velocity over 42 months of follow-up.	"{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""This NEJM phase 2 trial demonstrated that vosoritide treatment in children with achondroplasia resulted in sustained increases in growth velocity over 42 months of follow-up."", ""reference"": ""PMID:31269546"", ""snippet"": ""Treatment resulted in a sustained increase in the annualized growth velocity for up to 42 months."", ""supports"": ""SUPPORT""}"
185	186	8	Acne Vulgaris	Acne_Vulgaris.yaml	treatments	0	evidence	0	PMID:30674002	SUPPORT		Topical retinoids are safe and efficacious for the treatment of acne vulgaris.	This systematic review confirms the safety and efficacy of topical retinoids for acne treatment.	"{""explanation"": ""This systematic review confirms the safety and efficacy of topical retinoids for acne treatment."", ""reference"": ""PMID:30674002"", ""snippet"": ""Topical retinoids are safe and efficacious for the treatment of acne vulgaris."", ""supports"": ""SUPPORT""}"
186	187	8	Acne Vulgaris	Acne_Vulgaris.yaml	treatments	1	evidence	0	PMID:36927117	SUPPORT		Large-scale randomized, controlled clinical trials have demonstrated trifarotene to be safe, well tolerated, and efficacious in reducing both comedones and papules/pustules of acne.	This review summarizes randomized trials showing trifarotene efficacy across comedonal and inflammatory acne lesions.	"{""explanation"": ""This review summarizes randomized trials showing trifarotene efficacy across comedonal and inflammatory acne lesions."", ""reference"": ""PMID:36927117"", ""snippet"": ""Large-scale randomized, controlled clinical trials have demonstrated trifarotene to be safe, well tolerated, and efficacious in reducing both comedones and papules/pustules of acne."", ""supports"": ""SUPPORT""}"
187	188	8	Acne Vulgaris	Acne_Vulgaris.yaml	treatments	2	evidence	0	PMID:19761357	SUPPORT		BPO-containing combinations do not induce bacterial resistance and are important first-line treatments for mild to moderate acne vulgaris.	This review establishes benzoyl peroxide as an important first-line treatment for acne that does not promote bacterial resistance.	"{""explanation"": ""This review establishes benzoyl peroxide as an important first-line treatment for acne that does not promote bacterial resistance."", ""reference"": ""PMID:19761357"", ""snippet"": ""BPO-containing combinations do not induce bacterial resistance and are important first-line treatments for mild to moderate acne vulgaris."", ""supports"": ""SUPPORT""}"
188	189	8	Acne Vulgaris	Acne_Vulgaris.yaml	treatments	3	evidence	0	PMID:16086756	SUPPORT		topical antibiotics remain one of the cornerstones of acne management	This systematic review confirms topical antibiotics as a cornerstone treatment for acne.	"{""explanation"": ""This systematic review confirms topical antibiotics as a cornerstone treatment for acne."", ""reference"": ""PMID:16086756"", ""snippet"": ""topical antibiotics remain one of the cornerstones of acne management"", ""supports"": ""SUPPORT""}"
189	190	8	Acne Vulgaris	Acne_Vulgaris.yaml	treatments	4	evidence	0	PMID:41552868	SUPPORT		At week 24, 67% of participants achieved treatment success, and significant reductions from baseline in inflammatory (88%) and noninflammatory (68%) lesions were observed (p < 0.001, both).	This pooled analysis supports long-term efficacy of the triple-combination gel.	"{""explanation"": ""This pooled analysis supports long-term efficacy of the triple-combination gel."", ""reference"": ""PMID:41552868"", ""snippet"": ""At week 24, 67% of participants achieved treatment success, and significant reductions from baseline in inflammatory (88%) and noninflammatory (68%) lesions were observed (p < 0.001, both)."", ""supports"": ""SUPPORT""}"
190	191	8	Acne Vulgaris	Acne_Vulgaris.yaml	treatments	5	evidence	0	PMID:28542914	SUPPORT		isotretinoin therapy reduced acne lesion counts by a clinically relevant amount, and always by a greater amount than control, which was either placebo (two studies), oral antibiotics (seven studies) or other control	This systematic review confirms oral antibiotics as an established comparator treatment for acne in clinical trials.	"{""explanation"": ""This systematic review confirms oral antibiotics as an established comparator treatment for acne in clinical trials."", ""reference"": ""PMID:28542914"", ""snippet"": ""isotretinoin therapy reduced acne lesion counts by a clinically relevant amount, and always by a greater amount than control, which was either placebo (two studies), oral antibiotics (seven studies) or other control"", ""supports"": ""SUPPORT""}"
191	191	8	Acne Vulgaris	Acne_Vulgaris.yaml	treatments	5	evidence	1	PMID:36568833	SUPPORT		The overuse of topical and/or systemic antibiotics, the long treatment courses used for acne, and the availability of over-the-counter antibiotic preparations, have led to the worldwide emergence of resistant strains in acne patients.	This review documents antibiotic resistance concerns tied to prolonged acne antibiotic use, supporting stewardship in treatment.	"{""explanation"": ""This review documents antibiotic resistance concerns tied to prolonged acne antibiotic use, supporting stewardship in treatment."", ""reference"": ""PMID:36568833"", ""snippet"": ""The overuse of topical and/or systemic antibiotics, the long treatment courses used for acne, and the availability of over-the-counter antibiotic preparations, have led to the worldwide emergence of resistant strains in acne patients."", ""supports"": ""SUPPORT""}"
192	192	8	Acne Vulgaris	Acne_Vulgaris.yaml	treatments	6	evidence	0	PMID:33085149	SUPPORT		Oral isotretinoin is the most effective treatment for moderate to severe acne and its side effects are mostly dose-dependent.	This systematic review confirms oral isotretinoin as the most effective treatment for moderate to severe acne.	"{""explanation"": ""This systematic review confirms oral isotretinoin as the most effective treatment for moderate to severe acne."", ""reference"": ""PMID:33085149"", ""snippet"": ""Oral isotretinoin is the most effective treatment for moderate to severe acne and its side effects are mostly dose-dependent."", ""supports"": ""SUPPORT""}"
193	193	8	Acne Vulgaris	Acne_Vulgaris.yaml	treatments	7	evidence	0	PMID:28492054	SUPPORT		Hormone-based therapies including combined oral contraceptive medications and spironolactone are considered effective therapies to treat adult acne in women.	This systematic review confirms the efficacy of hormonal therapies including oral contraceptives and spironolactone for treating acne in women.	"{""explanation"": ""This systematic review confirms the efficacy of hormonal therapies including oral contraceptives and spironolactone for treating acne in women."", ""reference"": ""PMID:28492054"", ""snippet"": ""Hormone-based therapies including combined oral contraceptive medications and spironolactone are considered effective therapies to treat adult acne in women."", ""supports"": ""SUPPORT""}"
194	194	8	Acne Vulgaris	Acne_Vulgaris.yaml	treatments	8	evidence	0	PMID:37894698	SUPPORT		The findings of this comprehensive bibliographic review indicate that organic acid-based chemical peels represent effective and safe treatment options for individuals with acne-prone skin.	This review supports organic acid chemical peels as effective and safe adjuncts for acne-prone skin.	"{""explanation"": ""This review supports organic acid chemical peels as effective and safe adjuncts for acne-prone skin."", ""reference"": ""PMID:37894698"", ""snippet"": ""The findings of this comprehensive bibliographic review indicate that organic acid-based chemical peels represent effective and safe treatment options for individuals with acne-prone skin."", ""supports"": ""SUPPORT""}"
195	195	8	Acne Vulgaris	Acne_Vulgaris.yaml	treatments	9	evidence	0	PMID:31455112	SUPPORT		Peels with 30% AZA reduced acne lesions and normalized the activity of the sebaceous glands.	This study reports acne lesion reduction and sebum normalization with 30% azelaic acid peels.	"{""explanation"": ""This study reports acne lesion reduction and sebum normalization with 30% azelaic acid peels."", ""reference"": ""PMID:31455112"", ""snippet"": ""Peels with 30% AZA reduced acne lesions and normalized the activity of the sebaceous glands."", ""supports"": ""SUPPORT""}"
196	196	8	Acne Vulgaris	Acne_Vulgaris.yaml	treatments	10	evidence	0	PMID:39483653	SUPPORT		A 30% TCA peel is efficacious and well-tolerated for mild-to-moderate acne scars.	This split-face study supports TCA peels for improving acne scarring.	"{""explanation"": ""This split-face study supports TCA peels for improving acne scarring."", ""reference"": ""PMID:39483653"", ""snippet"": ""A 30% TCA peel is efficacious and well-tolerated for mild-to-moderate acne scars."", ""supports"": ""SUPPORT""}"
197	197	8	Acne Vulgaris	Acne_Vulgaris.yaml	treatments	11	evidence	0	PMID:41521693	SUPPORT		Ablative fractional CO2 laser is effective for acne scar treatment but is often associated with side effects such as erythema and dyspigmentation, along with prolonged recovery time.	This trial background notes efficacy of CO2 laser for acne scars with notable side effects.	"{""explanation"": ""This trial background notes efficacy of CO2 laser for acne scars with notable side effects."", ""reference"": ""PMID:41521693"", ""snippet"": ""Ablative fractional CO2 laser is effective for acne scar treatment but is often associated with side effects such as erythema and dyspigmentation, along with prolonged recovery time."", ""supports"": ""SUPPORT""}"
198	198	8	Acne Vulgaris	Acne_Vulgaris.yaml	treatments	12	evidence	0	PMID:41521693	SUPPORT		This study found that CE Ferulic led to enhanced wound healing, reduced erythema and melanin levels, and improved skin hydration following laser treatment, suggesting its beneficial application in combination with laser treatment to accelerate skin recovery.	This split-face trial supports antioxidant serum use after CO2 laser for acne scars.	"{""explanation"": ""This split-face trial supports antioxidant serum use after CO2 laser for acne scars."", ""reference"": ""PMID:41521693"", ""snippet"": ""This study found that CE Ferulic led to enhanced wound healing, reduced erythema and melanin levels, and improved skin hydration following laser treatment, suggesting its beneficial application in combination with laser treatment to accelerate skin recovery."", ""supports"": ""SUPPORT""}"
199	199	8	Acne Vulgaris	Acne_Vulgaris.yaml	treatments	13	evidence	0	PMID:34696155	SUPPORT		Studies have shown significant improvements in the overall picture of acne.	This systematic review reports clinical improvement in acne with blue light phototherapy.	"{""explanation"": ""This systematic review reports clinical improvement in acne with blue light phototherapy."", ""reference"": ""PMID:34696155"", ""snippet"": ""Studies have shown significant improvements in the overall picture of acne."", ""supports"": ""SUPPORT""}"
200	200	8	Acne Vulgaris	Acne_Vulgaris.yaml	treatments	14	evidence	0	PMID:39056372	SUPPORT		Overall, 92% of patients achieved partial remission of their acne lesions using visible light therapy.	This systematic review summarizes lesion improvement across visible light studies in acne.	"{""explanation"": ""This systematic review summarizes lesion improvement across visible light studies in acne."", ""reference"": ""PMID:39056372"", ""snippet"": ""Overall, 92% of patients achieved partial remission of their acne lesions using visible light therapy."", ""supports"": ""SUPPORT""}"
201	201	8	Acne Vulgaris	Acne_Vulgaris.yaml	treatments	15	evidence	0	PMID:39226531	SUPPORT		Newer indications, for which no approval has yet been granted, but which nevertheless have sufficient evidence of efficacy according to the study situation, are inflammatory (lichen sclerosus, acne) and infectious dermatoses (viral warts, cutaneous leishmaniasis, atypical mycobacteriosis).	This review identifies acne as an emerging indication for photodynamic therapy with supportive evidence.	"{""explanation"": ""This review identifies acne as an emerging indication for photodynamic therapy with supportive evidence."", ""reference"": ""PMID:39226531"", ""snippet"": ""Newer indications, for which no approval has yet been granted, but which nevertheless have sufficient evidence of efficacy according to the study situation, are inflammatory (lichen sclerosus, acne) and infectious dermatoses (viral warts, cutaneous leishmaniasis, atypical mycobacteriosis)."", ""supports"": ""SUPPORT""}"
202	202	8	Acne Vulgaris	Acne_Vulgaris.yaml	treatments	16	evidence	0	PMID:35084634	SUPPORT		The intralesional PRP injection and 1064 nm long-pulsed Nd:YAG laser are safe and effective methods for controlling inflammatory as well as non-inflammatory acne vulgaris in both adolescents and post-adolescent patients.	This randomized split-face study supports Nd:YAG laser and PRP injections for inflammatory acne vulgaris.	"{""explanation"": ""This randomized split-face study supports Nd:YAG laser and PRP injections for inflammatory acne vulgaris."", ""reference"": ""PMID:35084634"", ""snippet"": ""The intralesional PRP injection and 1064 nm long-pulsed Nd:YAG laser are safe and effective methods for controlling inflammatory as well as non-inflammatory acne vulgaris in both adolescents and post-adolescent patients."", ""supports"": ""SUPPORT""}"
203	203	8	Acne Vulgaris	Acne_Vulgaris.yaml	treatments	17	evidence	0	PMID:38271552	SUPPORT		New 1726 nm lasers specifically target the sebaceous gland, which is known to be pivotal in acne pathophysiology.	This review highlights 1726 nm lasers as a sebaceous gland-targeted treatment approach for acne.	"{""explanation"": ""This review highlights 1726 nm lasers as a sebaceous gland-targeted treatment approach for acne."", ""reference"": ""PMID:38271552"", ""snippet"": ""New 1726 nm lasers specifically target the sebaceous gland, which is known to be pivotal in acne pathophysiology."", ""supports"": ""SUPPORT""}"
282	235	9	Acquired Immunodeficiency Syndrome	Acquired_Immunodeficiency_Syndrome.yaml	treatments	0	evidence	0	PMID:11218297	SUPPORT		HIV patients who have detectable viral loads and/or evidence of immunologic dysfunction should be treated with a potent combination antiretroviral regimen.	This indicates that a combination of drugs is used to treat HIV by suppressing its replication and preserving immune function.	"{""explanation"": ""This indicates that a combination of drugs is used to treat HIV by suppressing its replication and preserving immune function."", ""reference"": ""PMID:11218297"", ""snippet"": ""HIV patients who have detectable viral loads and/or evidence of immunologic dysfunction should be treated with a potent combination antiretroviral regimen."", ""supports"": ""SUPPORT""}"
283	235	9	Acquired Immunodeficiency Syndrome	Acquired_Immunodeficiency_Syndrome.yaml	treatments	0	evidence	1	PMID:11424971	SUPPORT		Suppression of HIV-1 replication results in both laboratory and clinical evidence of immune restoration.	Antiretroviral therapies suppress HIV replication, leading to immune restoration, although incomplete.	"{""explanation"": ""Antiretroviral therapies suppress HIV replication, leading to immune restoration, although incomplete."", ""reference"": ""PMID:11424971"", ""snippet"": ""Suppression of HIV-1 replication results in both laboratory and clinical evidence of immune restoration."", ""supports"": ""SUPPORT""}"
284	235	9	Acquired Immunodeficiency Syndrome	Acquired_Immunodeficiency_Syndrome.yaml	treatments	0	evidence	2	PMID:21722892	SUPPORT		Antiretroviral medications may have direct toxicity on gametes and embryos.	While highlighting the side effects, it recognizes antiretroviral medications as a treatment strategy involving a combination of drugs.	"{""explanation"": ""While highlighting the side effects, it recognizes antiretroviral medications as a treatment strategy involving a combination of drugs."", ""reference"": ""PMID:21722892"", ""snippet"": ""Antiretroviral medications may have direct toxicity on gametes and embryos."", ""supports"": ""SUPPORT""}"
285	235	9	Acquired Immunodeficiency Syndrome	Acquired_Immunodeficiency_Syndrome.yaml	treatments	0	evidence	3	PMID:2550525	SUPPORT		Although many drugs have been developed, none appears singularly effective against all stages of HIV-1 infection.	This suggests the need for a combination of drugs to effectively treat HIV.	"{""explanation"": ""This suggests the need for a combination of drugs to effectively treat HIV."", ""reference"": ""PMID:2550525"", ""snippet"": ""Although many drugs have been developed, none appears singularly effective against all stages of HIV-1 infection."", ""supports"": ""SUPPORT""}"
286	235	9	Acquired Immunodeficiency Syndrome	Acquired_Immunodeficiency_Syndrome.yaml	treatments	0	evidence	4	PMID:31237209	SUPPORT		One of the key therapeutic strategies is Highly Active Antiretroviral Therapy (HAART) or 'AIDS cocktail' in a general sense, which is a customized combination of anti-retroviral drugs designed to combat the HIV infection.	This explicitly states that HAART is a combination of drugs used to treat HIV, aligning with the statement.	"{""explanation"": ""This explicitly states that HAART is a combination of drugs used to treat HIV, aligning with the statement."", ""reference"": ""PMID:31237209"", ""snippet"": ""One of the key therapeutic strategies is Highly Active Antiretroviral Therapy (HAART) or 'AIDS cocktail' in a general sense, which is a customized combination of anti-retroviral drugs designed to combat the HIV infection."", ""supports"": ""SUPPORT""}"
287	236	9	Acquired Immunodeficiency Syndrome	Acquired_Immunodeficiency_Syndrome.yaml	treatments	1	evidence	0	PMID:9389311	SUPPORT		The United States Public Health Service and the Infectious Diseases Society of America (USPHS/IDSA) have established disease-specific recommendations for use of prophylaxis for opportunistic infections in HIV-infected patients.	The abstract indicates that there are established guidelines for the use of prophylaxis to prevent opportunistic infections in HIV-infected patients, supporting the statement about preventive treatments.	"{""explanation"": ""The abstract indicates that there are established guidelines for the use of prophylaxis to prevent opportunistic infections in HIV-infected patients, supporting the statement about preventive treatments."", ""reference"": ""PMID:9389311"", ""snippet"": ""The United States Public Health Service and the Infectious Diseases Society of America (USPHS/IDSA) have established disease-specific recommendations for use of prophylaxis for opportunistic infections in HIV-infected patients."", ""supports"": ""SUPPORT""}"
288	236	9	Acquired Immunodeficiency Syndrome	Acquired_Immunodeficiency_Syndrome.yaml	treatments	1	evidence	1	PMID:2996829	SUPPORT		The infections most commonly encountered in patients with AIDS are Pneumocystis carinii pneumonia (58%), Candida esophagitis (31%), toxoplasmosis (21%), cytomegalovirus infections (15%), and herpes-simplex virus infections (12%).	The document discusses common opportunistic infections in AIDS patients, implying the need for preventive treatments to reduce these risks.	"{""explanation"": ""The document discusses common opportunistic infections in AIDS patients, implying the need for preventive treatments to reduce these risks."", ""reference"": ""PMID:2996829"", ""snippet"": ""The infections most commonly encountered in patients with AIDS are Pneumocystis carinii pneumonia (58%), Candida esophagitis (31%), toxoplasmosis (21%), cytomegalovirus infections (15%), and herpes-simplex virus infections (12%)."", ""supports"": ""SUPPORT""}"
289	236	9	Acquired Immunodeficiency Syndrome	Acquired_Immunodeficiency_Syndrome.yaml	treatments	1	evidence	2	PMID:2729337	SUPPORT		The subjects in this study are 24 women with AIDS who were treated by members of the Brown University medical faculty from June 1982 through June 1988... When zidovudine became available, it was administered to all remaining patients in the study. All subjects were counseled about HIV infection, its modes of transmission, and the early symptoms of opportunistic infections.	The study indicates that patients were informed about opportunistic infections and treatments were adjusted as new medications became available, supporting the statement about the use of prophylaxis.	"{""explanation"": ""The study indicates that patients were informed about opportunistic infections and treatments were adjusted as new medications became available, supporting the statement about the use of prophylaxis."", ""reference"": ""PMID:2729337"", ""snippet"": ""The subjects in this study are 24 women with AIDS who were treated by members of the Brown University medical faculty from June 1982 through June 1988... When zidovudine became available, it was administered to all remaining patients in the study. All subjects were counseled about HIV infection, its modes of transmission, and the early symptoms of opportunistic infections."", ""supports"": ""SUPPORT""}"
290	237	9	Acquired Immunodeficiency Syndrome	Acquired_Immunodeficiency_Syndrome.yaml	treatments	2	evidence	0	PMID:9336601	SUPPORT		Nevertheless, the prevention, diagnosis, and treatment of opportunistic infections remain important features of management of HIV infection.	The reference indicates that the treatment of opportunistic infections is a crucial aspect of HIV/AIDS management, supporting the statement that specific therapies target diagnosed opportunistic infections.	"{""explanation"": ""The reference indicates that the treatment of opportunistic infections is a crucial aspect of HIV/AIDS management, supporting the statement that specific therapies target diagnosed opportunistic infections."", ""reference"": ""PMID:9336601"", ""snippet"": ""Nevertheless, the prevention, diagnosis, and treatment of opportunistic infections remain important features of management of HIV infection."", ""supports"": ""SUPPORT""}"
291	237	9	Acquired Immunodeficiency Syndrome	Acquired_Immunodeficiency_Syndrome.yaml	treatments	2	evidence	1	PMID:2435201	SUPPORT		Approaches to the treatment of AIDS have involved attempts to reestablish immune competence as well as treat opportunistic infections.	This reference mentions that treating opportunistic infections is a key component in the approaches to AIDS treatment, providing support for the statement.	"{""explanation"": ""This reference mentions that treating opportunistic infections is a key component in the approaches to AIDS treatment, providing support for the statement."", ""reference"": ""PMID:2435201"", ""snippet"": ""Approaches to the treatment of AIDS have involved attempts to reestablish immune competence as well as treat opportunistic infections."", ""supports"": ""SUPPORT""}"
292	237	9	Acquired Immunodeficiency Syndrome	Acquired_Immunodeficiency_Syndrome.yaml	treatments	2	evidence	2	PMID:15119284	SUPPORT		While HIV is the culprit, most people who die of AIDS do not die of HIV, per se, but from the numerous infections that the body can no longer control due to the collapse of the immune system.	The document explains the importance of treating opportunistic infections, as they are the primary cause of mortality in AIDS patients, hence supporting the statement.	"{""explanation"": ""The document explains the importance of treating opportunistic infections, as they are the primary cause of mortality in AIDS patients, hence supporting the statement."", ""reference"": ""PMID:15119284"", ""snippet"": ""While HIV is the culprit, most people who die of AIDS do not die of HIV, per se, but from the numerous infections that the body can no longer control due to the collapse of the immune system."", ""supports"": ""SUPPORT""}"
293	237	9	Acquired Immunodeficiency Syndrome	Acquired_Immunodeficiency_Syndrome.yaml	treatments	2	evidence	3	PMID:9218066	SUPPORT		Complications which involve the gastrointestinal tract are common in these patients, because the gut is a major site for involvement by opportunistic infections and neoplasms in patients with the acquired immunodeficiency syndrome.	The reference discusses the importance of recognizing and treating gastrointestinal infections in AIDS patients, supporting the use of specific therapies for opportunistic infections as mentioned in the statement.	"{""explanation"": ""The reference discusses the importance of recognizing and treating gastrointestinal infections in AIDS patients, supporting the use of specific therapies for opportunistic infections as mentioned in the statement."", ""reference"": ""PMID:9218066"", ""snippet"": ""Complications which involve the gastrointestinal tract are common in these patients, because the gut is a major site for involvement by opportunistic infections and neoplasms in patients with the acquired immunodeficiency syndrome."", ""supports"": ""SUPPORT""}"
294	237	9	Acquired Immunodeficiency Syndrome	Acquired_Immunodeficiency_Syndrome.yaml	treatments	2	evidence	4	PMID:32216642	SUPPORT		The epidemiology and initial approach to diagnosis and treatment of HIV (including the newest antiretroviral guidelines), common syndromes and their management in the ICU, and typical comorbidities and opportunistic infections of patients with HIV infection are discussed.	This documentation emphasizes the management of opportunistic infections in the context of HIV, supporting the statement.	"{""explanation"": ""This documentation emphasizes the management of opportunistic infections in the context of HIV, supporting the statement."", ""reference"": ""PMID:32216642"", ""snippet"": ""The epidemiology and initial approach to diagnosis and treatment of HIV (including the newest antiretroviral guidelines), common syndromes and their management in the ICU, and typical comorbidities and opportunistic infections of patients with HIV infection are discussed."", ""supports"": ""SUPPORT""}"
295	237	9	Acquired Immunodeficiency Syndrome	Acquired_Immunodeficiency_Syndrome.yaml	treatments	2	evidence	5	PMID:2729337	SUPPORT		All opportunistic infections were treated by appropriate, specific antimicrobial therapy.	The study explicitly mentions the treatment of opportunistic infections with specific antimicrobial therapies, confirming support for the statement.	"{""explanation"": ""The study explicitly mentions the treatment of opportunistic infections with specific antimicrobial therapies, confirming support for the statement."", ""reference"": ""PMID:2729337"", ""snippet"": ""All opportunistic infections were treated by appropriate, specific antimicrobial therapy."", ""supports"": ""SUPPORT""}"
371	272	10	Addison's Disease	Addisons_Disease.yaml	treatments	0	evidence	0	PMID:18363515	PARTIAL		Starting doses of glucocorticoids should be 15 - 20 mg for hydrocortisone or 20 - 30 mg for cortisone acetate, divided into two or three doses, and preferentially weight-adjusted. There are indications that the synthetic glucocorticoids have undesirable metabolic long-term effects, which make them less suitable as first-line treatment.	The statement mentions prednisone, but the reference specifically discusses hydrocortisone and cortisone acetate, not prednisone.	"{""explanation"": ""The statement mentions prednisone, but the reference specifically discusses hydrocortisone and cortisone acetate, not prednisone."", ""reference"": ""PMID:18363515"", ""snippet"": ""Starting doses of glucocorticoids should be 15 - 20 mg for hydrocortisone or 20 - 30 mg for cortisone acetate, divided into two or three doses, and preferentially weight-adjusted. There are indications that the synthetic glucocorticoids have undesirable metabolic long-term effects, which make them less suitable as first-line treatment."", ""supports"": ""PARTIAL""}"
372	272	10	Addison's Disease	Addisons_Disease.yaml	treatments	0	evidence	1	PMID:22695777	PARTIAL		This necessitated an aggressive volume therapy in addition to an initial therapy with 100 mg hydrocortisone, 8 g glucose and a continuous administration of catecholamines.	The reference supports the use of hydrocortisone but does not mention prednisone.	"{""explanation"": ""The reference supports the use of hydrocortisone but does not mention prednisone."", ""reference"": ""PMID:22695777"", ""snippet"": ""This necessitated an aggressive volume therapy in addition to an initial therapy with 100 mg hydrocortisone, 8 g glucose and a continuous administration of catecholamines."", ""supports"": ""PARTIAL""}"
373	272	10	Addison's Disease	Addisons_Disease.yaml	treatments	0	evidence	2	PMID:23624135	PARTIAL		Patients with Addison's disease require lifelong treatment with glucocorticoids. At present, no glucocorticoid replacement therapy (GRT) can exactly mimic normal physiology.	The reference supports the need for glucocorticoid replacement therapy but does not specify prednisone.	"{""explanation"": ""The reference supports the need for glucocorticoid replacement therapy but does not specify prednisone."", ""reference"": ""PMID:23624135"", ""snippet"": ""Patients with Addison's disease require lifelong treatment with glucocorticoids. At present, no glucocorticoid replacement therapy (GRT) can exactly mimic normal physiology."", ""supports"": ""PARTIAL""}"
374	272	10	Addison's Disease	Addisons_Disease.yaml	treatments	0	evidence	3	PMID:35100642	PARTIAL		Addison's disease typically results from the autoimmune destruction of the adrenal cortex and requires lifelong replacement with glucocorticoids and mineralocorticoids.	The reference supports the need for glucocorticoid replacement but does not specify prednisone.	"{""explanation"": ""The reference supports the need for glucocorticoid replacement but does not specify prednisone."", ""reference"": ""PMID:35100642"", ""snippet"": ""Addison's disease typically results from the autoimmune destruction of the adrenal cortex and requires lifelong replacement with glucocorticoids and mineralocorticoids."", ""supports"": ""PARTIAL""}"
375	272	10	Addison's Disease	Addisons_Disease.yaml	treatments	0	evidence	4	PMID:33993277	PARTIAL		In primary but not in secondary adrenal insufficiency, mortality was higher with prednisolone.	The reference discusses prednisolone (a form of prednisone) but indicates higher mortality associated with its use in primary adrenal insufficiency.	"{""explanation"": ""The reference discusses prednisolone (a form of prednisone) but indicates higher mortality associated with its use in primary adrenal insufficiency."", ""reference"": ""PMID:33993277"", ""snippet"": ""In primary but not in secondary adrenal insufficiency, mortality was higher with prednisolone."", ""supports"": ""PARTIAL""}"
376	273	10	Addison's Disease	Addisons_Disease.yaml	treatments	1	evidence	0	PMID:476980	SUPPORT		In four others, PRA remained normal throughout the study, even after fludrocortisone had been discontinued, suggesting that the drug was unnecessary for the maintenance of normal sodium balance in these patients.	The study indicates that fludrocortisone is used in the management of Addison's disease, although not all patients may require it for maintaining normal sodium balance.	"{""explanation"": ""The study indicates that fludrocortisone is used in the management of Addison's disease, although not all patients may require it for maintaining normal sodium balance."", ""reference"": ""PMID:476980"", ""snippet"": ""In four others, PRA remained normal throughout the study, even after fludrocortisone had been discontinued, suggesting that the drug was unnecessary for the maintenance of normal sodium balance in these patients."", ""supports"": ""SUPPORT""}"
377	273	10	Addison's Disease	Addisons_Disease.yaml	treatments	1	evidence	1	PMID:24755997	SUPPORT		Conventional steroid replacement for Addison's disease consists of twice or three-times daily oral hydrocortisone and once-daily fludrocortisone.	This confirms the use of fludrocortisone as part of the conventional therapy for Addison's disease.	"{""explanation"": ""This confirms the use of fludrocortisone as part of the conventional therapy for Addison's disease."", ""reference"": ""PMID:24755997"", ""snippet"": ""Conventional steroid replacement for Addison's disease consists of twice or three-times daily oral hydrocortisone and once-daily fludrocortisone."", ""supports"": ""SUPPORT""}"
378	273	10	Addison's Disease	Addisons_Disease.yaml	treatments	1	evidence	2	PMID:25247653	SUPPORT		Many of these patients suffer from adrenal insufficiency and have to take either glucocorticoids or a combination of glucocorticoid and mineralocorticoid replacement therapy from birth to avoid life-threatening complications.	This reference supports the use of mineralocorticoid replacement therapy, which includes fludrocortisone, for managing adrenal insufficiency.	"{""explanation"": ""This reference supports the use of mineralocorticoid replacement therapy, which includes fludrocortisone, for managing adrenal insufficiency."", ""reference"": ""PMID:25247653"", ""snippet"": ""Many of these patients suffer from adrenal insufficiency and have to take either glucocorticoids or a combination of glucocorticoid and mineralocorticoid replacement therapy from birth to avoid life-threatening complications."", ""supports"": ""SUPPORT""}"
379	274	10	Addison's Disease	Addisons_Disease.yaml	treatments	2	evidence	0	PMID:28132947	SUPPORT		Treatment involves normalisation of sodium concentration and corticosteroids replacement.	The literature mentions the normalization of sodium concentration as part of the treatment for Addison's disease, which supports the statement about increased salt intake.	"{""explanation"": ""The literature mentions the normalization of sodium concentration as part of the treatment for Addison's disease, which supports the statement about increased salt intake."", ""reference"": ""PMID:28132947"", ""snippet"": ""Treatment involves normalisation of sodium concentration and corticosteroids replacement."", ""supports"": ""SUPPORT""}"
380	274	10	Addison's Disease	Addisons_Disease.yaml	treatments	2	evidence	1	PMID:20964584	SUPPORT		Primary adrenal insufficiency (i.e. Addison's disease) may well be recognized by clear hall-marks of the disease, such as pigmentation, salt craving, hypotension, and concomitant hyperkalemia.	The literature indicates salt craving as a hallmark of Addison's disease, supporting the need for increased salt intake.	"{""explanation"": ""The literature indicates salt craving as a hallmark of Addison's disease, supporting the need for increased salt intake."", ""reference"": ""PMID:20964584"", ""snippet"": ""Primary adrenal insufficiency (i.e. Addison's disease) may well be recognized by clear hall-marks of the disease, such as pigmentation, salt craving, hypotension, and concomitant hyperkalemia."", ""supports"": ""SUPPORT""}"
381	274	10	Addison's Disease	Addisons_Disease.yaml	treatments	2	evidence	2	PMID:18471672	PARTIAL		Mineral corticoids may be useful in complicated cases.	While this reference mentions mineral corticoids, which are related to sodium balance, it does not explicitly support or refute increased salt intake.	"{""explanation"": ""While this reference mentions mineral corticoids, which are related to sodium balance, it does not explicitly support or refute increased salt intake."", ""reference"": ""PMID:18471672"", ""snippet"": ""Mineral corticoids may be useful in complicated cases."", ""supports"": ""PARTIAL""}"
382	275	10	Addison's Disease	Addisons_Disease.yaml	treatments	3	evidence	0	PMID:19776201	SUPPORT		The endocrinologist has a responsibility to ensure that Addison's patients have adequate access to life-saving emergency injection materials and repeated, practical training sessions in how to use them, while the general practitioner plays a vital role as in arranging prompt emergency admissions.	The literature emphasizes the importance of emergency preparedness for Addison's patients, which implicitly supports the need for carrying an ID indicating their condition.	"{""explanation"": ""The literature emphasizes the importance of emergency preparedness for Addison's patients, which implicitly supports the need for carrying an ID indicating their condition."", ""reference"": ""PMID:19776201"", ""snippet"": ""The endocrinologist has a responsibility to ensure that Addison's patients have adequate access to life-saving emergency injection materials and repeated, practical training sessions in how to use them, while the general practitioner plays a vital role as in arranging prompt emergency admissions."", ""supports"": ""SUPPORT""}"
383	275	10	Addison's Disease	Addisons_Disease.yaml	treatments	3	evidence	1	PMID:31321757	SUPPORT		Progress in optimizing replacement therapy for patients with AD has allowed the patients to lead a normal life. However, continuous education of patients and health care professionals of ever-present danger of adrenal crisis is essential to save lives of patients with AD.	The mention of continuous education and the ever-present danger of adrenal crisis supports the need for patients to carry an ID for emergency situations.	"{""explanation"": ""The mention of continuous education and the ever-present danger of adrenal crisis supports the need for patients to carry an ID for emergency situations."", ""reference"": ""PMID:31321757"", ""snippet"": ""Progress in optimizing replacement therapy for patients with AD has allowed the patients to lead a normal life. However, continuous education of patients and health care professionals of ever-present danger of adrenal crisis is essential to save lives of patients with AD."", ""supports"": ""SUPPORT""}"
384	276	10	Addison's Disease	Addisons_Disease.yaml	treatments	4	evidence	0	PMID:18393745	SUPPORT		Patients with adrenal insufficiency (AI) require additional glucocorticoid doses during surgery or medical illness, but there is no universally accepted regimen for glucocorticoid supplementation therapy.	The literature supports the need for increased doses of corticosteroids during illness or stress for patients with Addison's Disease.	"{""explanation"": ""The literature supports the need for increased doses of corticosteroids during illness or stress for patients with Addison's Disease."", ""reference"": ""PMID:18393745"", ""snippet"": ""Patients with adrenal insufficiency (AI) require additional glucocorticoid doses during surgery or medical illness, but there is no universally accepted regimen for glucocorticoid supplementation therapy."", ""supports"": ""SUPPORT""}"
385	276	10	Addison's Disease	Addisons_Disease.yaml	treatments	4	evidence	1	PMID:29544234	SUPPORT		An adrenal crisis (Addisonian crisis) is an acute life-threatening complication of adrenal insufficiency. It occurs when hydrocortisone demand is not met by supplementation in the context of an infection - often gastrointestinal, fever, trauma, acute psychological or physical stress.	The literature supports the need for increased doses of corticosteroids during stress to prevent adrenal crisis.	"{""explanation"": ""The literature supports the need for increased doses of corticosteroids during stress to prevent adrenal crisis."", ""reference"": ""PMID:29544234"", ""snippet"": ""An adrenal crisis (Addisonian crisis) is an acute life-threatening complication of adrenal insufficiency. It occurs when hydrocortisone demand is not met by supplementation in the context of an infection - often gastrointestinal, fever, trauma, acute psychological or physical stress."", ""supports"": ""SUPPORT""}"
395	302	11	Adult T-Cell Leukemia/Lymphoma	Adult_T_Cell_Leukemia_Lymphoma.yaml	treatments	0	evidence	0	PMID:22042945	SUPPORT		The overall response rate ranged from 49% with chemotherapy alone to 81% with combined first-line therapy (chemotherapy with concurrent/sequential ZDV/IFN-).	Study shows chemotherapy alone achieves 49% response rate in aggressive ATLL, supporting modest efficacy.	"{""explanation"": ""Study shows chemotherapy alone achieves 49% response rate in aggressive ATLL, supporting modest efficacy."", ""reference"": ""PMID:22042945"", ""snippet"": ""The overall response rate ranged from 49% with chemotherapy alone to 81% with combined first-line therapy (chemotherapy with concurrent/sequential ZDV/IFN-)."", ""supports"": ""SUPPORT""}"
396	303	11	Adult T-Cell Leukemia/Lymphoma	Adult_T_Cell_Leukemia_Lymphoma.yaml	treatments	1	evidence	0	PMID:30573506	SUPPORT		mogamulizumab treatment resulted in 11% cORR, with a tolerable safety profile.	International phase II trial showed mogamulizumab demonstrated responses in relapsed/refractory ATLL where chemotherapy showed no activity.	"{""explanation"": ""International phase II trial showed mogamulizumab demonstrated responses in relapsed/refractory ATLL where chemotherapy showed no activity."", ""reference"": ""PMID:30573506"", ""snippet"": ""mogamulizumab treatment resulted in 11% cORR, with a tolerable safety profile."", ""supports"": ""SUPPORT""}"
397	304	11	Adult T-Cell Leukemia/Lymphoma	Adult_T_Cell_Leukemia_Lymphoma.yaml	treatments	2	evidence	0	PMID:30573506	SUPPORT		Allogeneic stem cell transplantation (allo-SCT) can significantly prolong survival, but there are few appropriate candidates	Study confirms allo-SCT prolongs survival but notes limited candidates due to age and prior treatment response requirements.	"{""explanation"": ""Study confirms allo-SCT prolongs survival but notes limited candidates due to age and prior treatment response requirements."", ""reference"": ""PMID:30573506"", ""snippet"": ""Allogeneic stem cell transplantation (allo-SCT) can significantly prolong survival, but there are few appropriate candidates"", ""supports"": ""SUPPORT""}"
398	305	11	Adult T-Cell Leukemia/Lymphoma	Adult_T_Cell_Leukemia_Lymphoma.yaml	treatments	3	evidence	0	PMID:22042945	SUPPORT		Use of ZDV/IFN- at any time prolonged survival in acute (P < .001) and lymphoma ATLL (P < .001) and was the sole factor associated with reduction in risk of death in aggressive ATLL	UK study demonstrated ZDV/IFN- significantly prolonged survival in both acute and lymphoma ATLL subtypes.	"{""explanation"": ""UK study demonstrated ZDV/IFN- significantly prolonged survival in both acute and lymphoma ATLL subtypes."", ""reference"": ""PMID:22042945"", ""snippet"": ""Use of ZDV/IFN- at any time prolonged survival in acute (P < .001) and lymphoma ATLL (P < .001) and was the sole factor associated with reduction in risk of death in aggressive ATLL"", ""supports"": ""SUPPORT""}"
410	355	13	Age-Related Macular Degeneration	Age_Related_Macular_Degeneration.yaml	treatments	0	evidence	0	PMID:38193957	SUPPORT		In exudative neovascular AMD, 94.6% of patients receiving monthly intravitreal anti-vascular endothelial growth factor (anti-VEGF) injections experience less than a 15-letter visual acuity loss after 12 months compared with 62.2% receiving sham treatment.	Demonstrates the efficacy of anti-VEGF therapy as first-line treatment for neovascular AMD, with significant preservation of visual acuity compared to placebo.	"{""explanation"": ""Demonstrates the efficacy of anti-VEGF therapy as first-line treatment for neovascular AMD, with significant preservation of visual acuity compared to placebo."", ""reference"": ""PMID:38193957"", ""snippet"": ""In exudative neovascular AMD, 94.6% of patients receiving monthly intravitreal anti-vascular endothelial growth factor (anti-VEGF) injections experience less than a 15-letter visual acuity loss after 12 months compared with 62.2% receiving sham treatment."", ""supports"": ""SUPPORT""}"
411	356	13	Age-Related Macular Degeneration	Age_Related_Macular_Degeneration.yaml	treatments	1	evidence	0	PMID:38193957	SUPPORT		Individuals with AMD who take nutritional supplements consisting of high-dose vitamin C, vitamin E, carotenoids, and zinc have a 20% probability to progress to late-stage AMD at 5 years vs a 28% probability for those taking a placebo.	Quantifies the protective effect of AREDS-type nutritional supplementation in reducing progression to late-stage AMD by approximately 8 percentage points over 5 years.	"{""explanation"": ""Quantifies the protective effect of AREDS-type nutritional supplementation in reducing progression to late-stage AMD by approximately 8 percentage points over 5 years."", ""reference"": ""PMID:38193957"", ""snippet"": ""Individuals with AMD who take nutritional supplements consisting of high-dose vitamin C, vitamin E, carotenoids, and zinc have a 20% probability to progress to late-stage AMD at 5 years vs a 28% probability for those taking a placebo."", ""supports"": ""SUPPORT""}"
434	376	14	Ainhum	Ainhum.yaml	treatments	0	evidence	0	PMID:31401977	SUPPORT	HUMAN_CLINICAL	She was managed surgically by excision of the band, disarticulated at right fifth metatarsophalangeal joint and skin closure.	Case report documents surgical excision and disarticulation as treatment.	"{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""Case report documents surgical excision and disarticulation as treatment."", ""reference"": ""PMID:31401977"", ""snippet"": ""She was managed surgically by excision of the band, disarticulated at right fifth metatarsophalangeal joint and skin closure."", ""supports"": ""SUPPORT""}"
461	399	15	Akinetopsia	Akinetopsia.yaml	treatments	0	evidence	0	PMID:39996018	SUPPORT	HUMAN_CLINICAL	Treatments were mostly successful when they were aimed at the underlying condition, while cases due to organic lesions tended to be therapy-resistant.	This review indicates treatment success when targeting the underlying condition and resistance in organic lesions.	"{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""This review indicates treatment success when targeting the underlying condition and resistance in organic lesions."", ""reference"": ""PMID:39996018"", ""snippet"": ""Treatments were mostly successful when they were aimed at the underlying condition, while cases due to organic lesions tended to be therapy-resistant."", ""supports"": ""SUPPORT""}"
462	400	15	Akinetopsia	Akinetopsia.yaml	treatments	1	evidence	0	PMID:25667833	SUPPORT	HUMAN_CLINICAL	We administered carbamazepine 200 mg/day, which suppressed his akinetopsic symptom completely.	This case report shows carbamazepine suppressed seizure-related akinetopsia.	"{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""This case report shows carbamazepine suppressed seizure-related akinetopsia."", ""reference"": ""PMID:25667833"", ""snippet"": ""We administered carbamazepine 200 mg/day, which suppressed his akinetopsic symptom completely."", ""supports"": ""SUPPORT""}"
559	434	17	Alhzeimer_Disease	Alhzeimer_Disease.yaml	treatments	0	evidence	0	PMID:24807367	SUPPORT		Donepezil, galantamine and rivastigmine are commonly used AChEIs in pharmacotherapy for AD, slowing the progression and controlling the symptoms of AD.	The literature supports that cholinesterase inhibitors, including donepezil and rivastigmine, are used to help with symptoms of Alzheimer's disease by slowing the progression and controlling cognitive symptoms.	"{""explanation"": ""The literature supports that cholinesterase inhibitors, including donepezil and rivastigmine, are used to help with symptoms of Alzheimer's disease by slowing the progression and controlling cognitive symptoms."", ""reference"": ""PMID:24807367"", ""snippet"": ""Donepezil, galantamine and rivastigmine are commonly used AChEIs in pharmacotherapy for AD, slowing the progression and controlling the symptoms of AD."", ""supports"": ""SUPPORT""}"
560	434	17	Alhzeimer_Disease	Alhzeimer_Disease.yaml	treatments	0	evidence	1	PMID:28671413	SUPPORT		Cholinesterase inhibitors, memantine, and a combination of a cholinesterase inhibitor and memantine have produced statistically significant but clinically small delays in various domains of cognitive and functional decline in select patients with Alzheimer disease.	The literature supports the use of cholinesterase inhibitors in delaying cognitive decline in Alzheimer's disease.	"{""explanation"": ""The literature supports the use of cholinesterase inhibitors in delaying cognitive decline in Alzheimer's disease."", ""reference"": ""PMID:28671413"", ""snippet"": ""Cholinesterase inhibitors, memantine, and a combination of a cholinesterase inhibitor and memantine have produced statistically significant but clinically small delays in various domains of cognitive and functional decline in select patients with Alzheimer disease."", ""supports"": ""SUPPORT""}"
561	434	17	Alhzeimer_Disease	Alhzeimer_Disease.yaml	treatments	0	evidence	2	PMID:35608903	SUPPORT		Two classes of drug - cholinesterase inhibitors (donepezil, galantamine and rivastigmine) and memantine - are widely licensed for dementia due to Alzheimer''s disease.	The literature confirms that cholinesterase inhibitors are licensed for use in Alzheimer's disease to alleviate symptoms and delay disease progression.	"{""explanation"": ""The literature confirms that cholinesterase inhibitors are licensed for use in Alzheimer's disease to alleviate symptoms and delay disease progression."", ""reference"": ""PMID:35608903"", ""snippet"": ""Two classes of drug - cholinesterase inhibitors (donepezil, galantamine and rivastigmine) and memantine - are widely licensed for dementia due to Alzheimer''s disease."", ""supports"": ""SUPPORT""}"
562	434	17	Alhzeimer_Disease	Alhzeimer_Disease.yaml	treatments	0	evidence	3	PMID:36412156	SUPPORT		Currently approved medications are symptomatic and include two classes: cholinesterase inhibitors, such as donepezil, and NMDA receptor antagonist memantine.	The literature supports that cholinesterase inhibitors are approved symptomatic treatments for Alzheimer's disease.	"{""explanation"": ""The literature supports that cholinesterase inhibitors are approved symptomatic treatments for Alzheimer's disease."", ""reference"": ""PMID:36412156"", ""snippet"": ""Currently approved medications are symptomatic and include two classes: cholinesterase inhibitors, such as donepezil, and NMDA receptor antagonist memantine."", ""supports"": ""SUPPORT""}"
563	434	17	Alhzeimer_Disease	Alhzeimer_Disease.yaml	treatments	0	evidence	4	PMID:9108896	SUPPORT		Donepezil is a specific and potent acetylcholinesterase inhibitor... Donepezil 5 or 10 mg/day was associated with significant improvements in cognitive function.	The literature supports that donepezil, a cholinesterase inhibitor, helps improve cognitive function in Alzheimer's disease.	"{""explanation"": ""The literature supports that donepezil, a cholinesterase inhibitor, helps improve cognitive function in Alzheimer's disease."", ""reference"": ""PMID:9108896"", ""snippet"": ""Donepezil is a specific and potent acetylcholinesterase inhibitor... Donepezil 5 or 10 mg/day was associated with significant improvements in cognitive function."", ""supports"": ""SUPPORT""}"
564	435	17	Alhzeimer_Disease	Alhzeimer_Disease.yaml	treatments	1	evidence	0	PMID:12768511	SUPPORT		Memantine, an antagonist of the glutamatergic NMDA receptor, has been recently approved for the treatment of advanced AD. Due to its action mechanism, memantine is considered a neuroprotective drug, whose utility has been demonstrated in preclinical studies, and a useful symptomatic treatment for AD and vascular dementia.	The abstract confirms that memantine, an NMDA receptor antagonist, is used to treat Alzheimer's Disease by regulating glutamate activity.	"{""explanation"": ""The abstract confirms that memantine, an NMDA receptor antagonist, is used to treat Alzheimer's Disease by regulating glutamate activity."", ""reference"": ""PMID:12768511"", ""snippet"": ""Memantine, an antagonist of the glutamatergic NMDA receptor, has been recently approved for the treatment of advanced AD. Due to its action mechanism, memantine is considered a neuroprotective drug, whose utility has been demonstrated in preclinical studies, and a useful symptomatic treatment for AD and vascular dementia."", ""supports"": ""SUPPORT""}"
565	435	17	Alhzeimer_Disease	Alhzeimer_Disease.yaml	treatments	1	evidence	1	PMID:27662322	SUPPORT		Studies indicate that the distinct outcomes of NMDAR-mediated responses are induced by regionalized receptor activities, followed by different downstream signaling pathways. The activation of synaptic NMDARs initiates plasticity and stimulates cell survival. In contrast, the activation of extrasynaptic NMDARs promotes cell death and thus contributes to the etiology of AD, which can be blocked by an AD drug, memantine, an NMDAR antagonist that selectively blocks the function of extrasynaptic NMDARs.	This abstract highlights that memantine, an NMDA receptor antagonist, helps in blocking the negative effects of excessive NMDAR activity in Alzheimer's Disease.	"{""explanation"": ""This abstract highlights that memantine, an NMDA receptor antagonist, helps in blocking the negative effects of excessive NMDAR activity in Alzheimer's Disease."", ""reference"": ""PMID:27662322"", ""snippet"": ""Studies indicate that the distinct outcomes of NMDAR-mediated responses are induced by regionalized receptor activities, followed by different downstream signaling pathways. The activation of synaptic NMDARs initiates plasticity and stimulates cell survival. In contrast, the activation of extrasynaptic NMDARs promotes cell death and thus contributes to the etiology of AD, which can be blocked by an AD drug, memantine, an NMDAR antagonist that selectively blocks the function of extrasynaptic NMDARs."", ""supports"": ""SUPPORT""}"
566	435	17	Alhzeimer_Disease	Alhzeimer_Disease.yaml	treatments	1	evidence	2	PMID:20943326	SUPPORT		The hypothesis proposed is restoration of medium spiny neurons in Huntington's disease using neural progenitor cell implantation and attenuation of glutamate mediated excitotoxicity using a partial glutamate antagonist - Memantine. Memantine can block the NMDA receptors and will prevent excess calcium influx into the neurons decreases the vulnerability of medium spiny neurons to glutamate mediated excitotoxicity.	Although primarily discussing Huntington's Disease, this abstract supports the idea that memantine, an NMDA receptor antagonist, regulates glutamate activity, which is relevant to Alzheimer's Disease treatment.	"{""explanation"": ""Although primarily discussing Huntington's Disease, this abstract supports the idea that memantine, an NMDA receptor antagonist, regulates glutamate activity, which is relevant to Alzheimer's Disease treatment."", ""reference"": ""PMID:20943326"", ""snippet"": ""The hypothesis proposed is restoration of medium spiny neurons in Huntington's disease using neural progenitor cell implantation and attenuation of glutamate mediated excitotoxicity using a partial glutamate antagonist - Memantine. Memantine can block the NMDA receptors and will prevent excess calcium influx into the neurons decreases the vulnerability of medium spiny neurons to glutamate mediated excitotoxicity."", ""supports"": ""SUPPORT""}"
567	436	17	Alhzeimer_Disease	Alhzeimer_Disease.yaml	treatments	2	evidence	0	PMID:35621327	SUPPORT		Cognitive stimulation was found to be an effective intervention for people with moderate Alzheimer's disease because it helped to maintain memory function, executive functions, and attention.	This study specifically highlights the effectiveness of cognitive stimulation in maintaining cognitive functions in patients with moderate Alzheimer's disease.	"{""explanation"": ""This study specifically highlights the effectiveness of cognitive stimulation in maintaining cognitive functions in patients with moderate Alzheimer's disease."", ""reference"": ""PMID:35621327"", ""snippet"": ""Cognitive stimulation was found to be an effective intervention for people with moderate Alzheimer's disease because it helped to maintain memory function, executive functions, and attention."", ""supports"": ""SUPPORT""}"
568	436	17	Alhzeimer_Disease	Alhzeimer_Disease.yaml	treatments	2	evidence	1	PMID:28671413	SUPPORT		Cognitive stimulation programs show benefit in maintenance of cognitive function and improved self-reported quality of life in patients with mild to moderate Alzheimer disease.	This reference supports the statement by indicating that cognitive stimulation programs help maintain cognitive function in patients with mild to moderate Alzheimer's disease.	"{""explanation"": ""This reference supports the statement by indicating that cognitive stimulation programs help maintain cognitive function in patients with mild to moderate Alzheimer's disease."", ""reference"": ""PMID:28671413"", ""snippet"": ""Cognitive stimulation programs show benefit in maintenance of cognitive function and improved self-reported quality of life in patients with mild to moderate Alzheimer disease."", ""supports"": ""SUPPORT""}"
569	436	17	Alhzeimer_Disease	Alhzeimer_Disease.yaml	treatments	2	evidence	2	PMID:37428401	PARTIAL		CS confers temporary, nonspecific benefits and might slightly reduce dementia risk for neurologically healthy individuals.	This reference indicates that cognitive stimulation offers temporary benefits and might reduce dementia risk, but it is less clear about long-term maintenance of cognitive function specifically in Alzheimer's disease.	"{""explanation"": ""This reference indicates that cognitive stimulation offers temporary benefits and might reduce dementia risk, but it is less clear about long-term maintenance of cognitive function specifically in Alzheimer's disease."", ""reference"": ""PMID:37428401"", ""snippet"": ""CS confers temporary, nonspecific benefits and might slightly reduce dementia risk for neurologically healthy individuals."", ""supports"": ""PARTIAL""}"
570	436	17	Alhzeimer_Disease	Alhzeimer_Disease.yaml	treatments	2	evidence	3	PMID:21643921	PARTIAL		Mental training and cognitive stimulation interventions in AD have been shown to be useful in increasing patients' ability in performing activities of daily living (ADL), allowing them to maintain relative independence.	This reference supports the utility of cognitive interventions in maintaining daily functioning, which is related to cognitive function, but does not directly address cognitive maintenance alone.	"{""explanation"": ""This reference supports the utility of cognitive interventions in maintaining daily functioning, which is related to cognitive function, but does not directly address cognitive maintenance alone."", ""reference"": ""PMID:21643921"", ""snippet"": ""Mental training and cognitive stimulation interventions in AD have been shown to be useful in increasing patients' ability in performing activities of daily living (ADL), allowing them to maintain relative independence."", ""supports"": ""PARTIAL""}"
571	436	17	Alhzeimer_Disease	Alhzeimer_Disease.yaml	treatments	2	evidence	4	PMID:27159433	SUPPORT		Interventions involving physical exercise and cognitive training have consistently shown positive effects on cognition in older adults.	This reference supports the statement by indicating that cognitive training, a form of cognitive therapy, has positive effects on cognition in older adults, including those with Alzheimer's disease.	"{""explanation"": ""This reference supports the statement by indicating that cognitive training, a form of cognitive therapy, has positive effects on cognition in older adults, including those with Alzheimer's disease."", ""reference"": ""PMID:27159433"", ""snippet"": ""Interventions involving physical exercise and cognitive training have consistently shown positive effects on cognition in older adults."", ""supports"": ""SUPPORT""}"
572	437	17	Alhzeimer_Disease	Alhzeimer_Disease.yaml	treatments	3	evidence	0	PMID:28809650	SUPPORT		Occupational therapy practitioners play a significant role in supporting adults with Alzheimer's disease and related major neurocognitive disorders, as well as their caregivers, through all phases of the disease process.	The reference highlights the role of occupational therapy in supporting individuals with Alzheimer's disease, which aligns with the statement that includes occupational therapy as part of supportive care.	"{""explanation"": ""The reference highlights the role of occupational therapy in supporting individuals with Alzheimer's disease, which aligns with the statement that includes occupational therapy as part of supportive care."", ""reference"": ""PMID:28809650"", ""snippet"": ""Occupational therapy practitioners play a significant role in supporting adults with Alzheimer's disease and related major neurocognitive disorders, as well as their caregivers, through all phases of the disease process."", ""supports"": ""SUPPORT""}"
573	437	17	Alhzeimer_Disease	Alhzeimer_Disease.yaml	treatments	3	evidence	1	PMID:38883339	SUPPORT		The telephone hotline is a useful component of dementia care in Germany and an important contribution to the National Dementia Strategy.	The reference discusses the importance of caregiver support through telephone counseling, aligning with the statement that includes caregiver support as part of supportive care.	"{""explanation"": ""The reference discusses the importance of caregiver support through telephone counseling, aligning with the statement that includes caregiver support as part of supportive care."", ""reference"": ""PMID:38883339"", ""snippet"": ""The telephone hotline is a useful component of dementia care in Germany and an important contribution to the National Dementia Strategy."", ""supports"": ""SUPPORT""}"
574	437	17	Alhzeimer_Disease	Alhzeimer_Disease.yaml	treatments	3	evidence	2	PMID:29361068	SUPPORT		This article first describes the educational, information, and support needs of individuals living dementia and their family caregivers across all stages of Alzheimer's.	The reference discusses the support needs of individuals with Alzheimer's disease and their caregivers, which aligns with the statement that includes caregiver support as part of supportive care.	"{""explanation"": ""The reference discusses the support needs of individuals with Alzheimer's disease and their caregivers, which aligns with the statement that includes caregiver support as part of supportive care."", ""reference"": ""PMID:29361068"", ""snippet"": ""This article first describes the educational, information, and support needs of individuals living dementia and their family caregivers across all stages of Alzheimer's."", ""supports"": ""SUPPORT""}"
575	437	17	Alhzeimer_Disease	Alhzeimer_Disease.yaml	treatments	3	evidence	3	PMID:27651009	PARTIAL		Cholinesterase inhibitors and memantine are used from 15 years, in Alzheimer's disease. Benefits have been demonstrated according to cognition, activities of daily living, affective symptoms and behavior, and global impression of change.	The reference primarily discusses pharmacological treatments, with some mention of activities of daily living, but does not specifically address occupational therapy or speech therapy.	"{""explanation"": ""The reference primarily discusses pharmacological treatments, with some mention of activities of daily living, but does not specifically address occupational therapy or speech therapy."", ""reference"": ""PMID:27651009"", ""snippet"": ""Cholinesterase inhibitors and memantine are used from 15 years, in Alzheimer's disease. Benefits have been demonstrated according to cognition, activities of daily living, affective symptoms and behavior, and global impression of change."", ""supports"": ""PARTIAL""}"
576	438	17	Alhzeimer_Disease	Alhzeimer_Disease.yaml	treatments	4	evidence	0	PMID:35503939	SUPPORT		The aim of this review is to emphasize the importance of mental activity and aerobic physical exercise as one of the most important health-related activities which may delay the onset or slow down the progression of Alzheimer's dementia.	The review highlights the importance of mental and physical exercise in potentially slowing the progression of Alzheimer's disease.	"{""explanation"": ""The review highlights the importance of mental and physical exercise in potentially slowing the progression of Alzheimer's disease."", ""reference"": ""PMID:35503939"", ""snippet"": ""The aim of this review is to emphasize the importance of mental activity and aerobic physical exercise as one of the most important health-related activities which may delay the onset or slow down the progression of Alzheimer's dementia."", ""supports"": ""SUPPORT""}"
577	438	17	Alhzeimer_Disease	Alhzeimer_Disease.yaml	treatments	4	evidence	1	PMID:32579499	SUPPORT		Combined with the prevention of AD risk factors such as heart disease, diabetes, and with more recent evidence, microbiome dysfunction, there is a substantial foundation for diet as a modifiable risk factor and preventative measure for AD.	The review suggests that a healthy diet can be a preventative measure for Alzheimer's disease, supporting the role of lifestyle modifications.	"{""explanation"": ""The review suggests that a healthy diet can be a preventative measure for Alzheimer's disease, supporting the role of lifestyle modifications."", ""reference"": ""PMID:32579499"", ""snippet"": ""Combined with the prevention of AD risk factors such as heart disease, diabetes, and with more recent evidence, microbiome dysfunction, there is a substantial foundation for diet as a modifiable risk factor and preventative measure for AD."", ""supports"": ""SUPPORT""}"
578	438	17	Alhzeimer_Disease	Alhzeimer_Disease.yaml	treatments	4	evidence	2	PMID:37321363	SUPPORT		Results showed that eating a healthy diet with plenty of fruits and vegetables, and participation in leisure and physical activities may protect against cognitive decline and cognitive impairment among oldest-old regardless of the APOE genotype.	The systematic review indicates that lifestyle factors such as diet and physical activities may protect against cognitive decline, supporting the statement.	"{""explanation"": ""The systematic review indicates that lifestyle factors such as diet and physical activities may protect against cognitive decline, supporting the statement."", ""reference"": ""PMID:37321363"", ""snippet"": ""Results showed that eating a healthy diet with plenty of fruits and vegetables, and participation in leisure and physical activities may protect against cognitive decline and cognitive impairment among oldest-old regardless of the APOE genotype."", ""supports"": ""SUPPORT""}"
579	438	17	Alhzeimer_Disease	Alhzeimer_Disease.yaml	treatments	4	evidence	3	PMID:38129775	SUPPORT		Rehabilitation approaches to support memory and behavioral/lifestyle interventions are recognized as promising strategies for preserving or improving cognitive health.	The intervention described combines lifestyle modifications and memory support to improve cognitive health, supporting the statement.	"{""explanation"": ""The intervention described combines lifestyle modifications and memory support to improve cognitive health, supporting the statement."", ""reference"": ""PMID:38129775"", ""snippet"": ""Rehabilitation approaches to support memory and behavioral/lifestyle interventions are recognized as promising strategies for preserving or improving cognitive health."", ""supports"": ""SUPPORT""}"
607	472	19	Alpha-1 Antitrypsin Deficiency	Alpha_1_Antitrypsin_Deficiency.yaml	treatments	0	evidence	0	PMID:22500781	SUPPORT		Specific therapy for lung-affected individuals with AATD is augmentation therapy, which consists of intravenous infusion of purified human plasma-derived alpha-1 antitrypsin (AAT).	This review describes augmentation therapy as the specific treatment for alpha-1 antitrypsin deficiency.	"{""explanation"": ""This review describes augmentation therapy as the specific treatment for alpha-1 antitrypsin deficiency."", ""reference"": ""PMID:22500781"", ""snippet"": ""Specific therapy for lung-affected individuals with AATD is augmentation therapy, which consists of intravenous infusion of purified human plasma-derived alpha-1 antitrypsin (AAT)."", ""supports"": ""SUPPORT""}"
608	473	19	Alpha-1 Antitrypsin Deficiency	Alpha_1_Antitrypsin_Deficiency.yaml	treatments	1	evidence	0	PMID:35715315	SUPPORT		Assessed by CO transfer alteration and CT scan, risk of pulmonary emphysema is increased by tobacco consumption.	Establishes smoking as a major modifiable risk factor that significantly increases emphysema risk in AAT deficiency	"{""explanation"": ""Establishes smoking as a major modifiable risk factor that significantly increases emphysema risk in AAT deficiency"", ""reference"": ""PMID:35715315"", ""snippet"": ""Assessed by CO transfer alteration and CT scan, risk of pulmonary emphysema is increased by tobacco consumption."", ""supports"": ""SUPPORT""}"
609	474	19	Alpha-1 Antitrypsin Deficiency	Alpha_1_Antitrypsin_Deficiency.yaml	treatments	2	evidence	0	PMID:34356027	SUPPORT		Most important treatment is smoking cessation, pulmonary rehabilitation and inhaled medication according to current guidelines.	Confirms inhaled bronchodilators as part of standard treatment guidelines for AAT deficiency-related COPD	"{""explanation"": ""Confirms inhaled bronchodilators as part of standard treatment guidelines for AAT deficiency-related COPD"", ""reference"": ""PMID:34356027"", ""snippet"": ""Most important treatment is smoking cessation, pulmonary rehabilitation and inhaled medication according to current guidelines."", ""supports"": ""SUPPORT""}"
610	475	19	Alpha-1 Antitrypsin Deficiency	Alpha_1_Antitrypsin_Deficiency.yaml	treatments	3	evidence	0	PMID:20301692	SUPPORT		Lung transplantation may be an appropriate option for individuals with end-stage lung disease.	Establishes lung transplantation as appropriate therapeutic option for end-stage AAT deficiency-related emphysema	"{""explanation"": ""Establishes lung transplantation as appropriate therapeutic option for end-stage AAT deficiency-related emphysema"", ""reference"": ""PMID:20301692"", ""snippet"": ""Lung transplantation may be an appropriate option for individuals with end-stage lung disease."", ""supports"": ""SUPPORT""}"
611	476	19	Alpha-1 Antitrypsin Deficiency	Alpha_1_Antitrypsin_Deficiency.yaml	treatments	4	evidence	0	PMID:20301692	SUPPORT		Liver transplantation is the definitive treatment for severe disease (will restore AAT levels).	Establishes liver transplantation as definitive curative treatment that restores normal AAT production from donor liver	"{""explanation"": ""Establishes liver transplantation as definitive curative treatment that restores normal AAT production from donor liver"", ""reference"": ""PMID:20301692"", ""snippet"": ""Liver transplantation is the definitive treatment for severe disease (will restore AAT levels)."", ""supports"": ""SUPPORT""}"
612	476	19	Alpha-1 Antitrypsin Deficiency	Alpha_1_Antitrypsin_Deficiency.yaml	treatments	4	evidence	1	PMID:33824927	SUPPORT		Rarely, patients require liver transplant and typically the patient outcomes are excellent.	Documents excellent outcomes in AAT deficiency patients undergoing liver transplantation	"{""explanation"": ""Documents excellent outcomes in AAT deficiency patients undergoing liver transplantation"", ""reference"": ""PMID:33824927"", ""snippet"": ""Rarely, patients require liver transplant and typically the patient outcomes are excellent."", ""supports"": ""SUPPORT""}"
613	476	19	Alpha-1 Antitrypsin Deficiency	Alpha_1_Antitrypsin_Deficiency.yaml	treatments	4	evidence	2	PMID:37144533	SUPPORT		PiZZ individuals harbor an up to 20 times higher risk of liver fibrosis and cirrhosis than noncarriers and liver transplantation is currently the only available therapeutic option.	Confirms liver transplantation as essential therapeutic option for severe ZZ genotype liver disease	"{""explanation"": ""Confirms liver transplantation as essential therapeutic option for severe ZZ genotype liver disease"", ""reference"": ""PMID:37144533"", ""snippet"": ""PiZZ individuals harbor an up to 20 times higher risk of liver fibrosis and cirrhosis than noncarriers and liver transplantation is currently the only available therapeutic option."", ""supports"": ""SUPPORT""}"
614	476	19	Alpha-1 Antitrypsin Deficiency	Alpha_1_Antitrypsin_Deficiency.yaml	treatments	4	evidence	3	PMID:36808684	SUPPORT		Our case provides initial evidence that A1ATD heterozygote donors may be safely used for pediatric patients with A1ATD, thus expanding the donor pool.	Documents that heterozygous donors can be successfully used for AAT deficiency recipients, expanding available donor options	"{""explanation"": ""Documents that heterozygous donors can be successfully used for AAT deficiency recipients, expanding available donor options"", ""reference"": ""PMID:36808684"", ""snippet"": ""Our case provides initial evidence that A1ATD heterozygote donors may be safely used for pediatric patients with A1ATD, thus expanding the donor pool."", ""supports"": ""SUPPORT""}"
673	549	22	Amyotrophic Lateral Sclerosis	Amyotrophic_Lateral_Sclerosis.yaml	treatments	0	evidence	0	PMID:8302340	SUPPORT		The antiglutamate agent riluzole appears to slow the progression of amyotrophic lateral sclerosis, and it may improve survival in patients with disease of bulbar onset.	Landmark trial demonstrating riluzole's survival benefit in ALS patients.	"{""explanation"": ""Landmark trial demonstrating riluzole's survival benefit in ALS patients."", ""reference"": ""PMID:8302340"", ""snippet"": ""The antiglutamate agent riluzole appears to slow the progression of amyotrophic lateral sclerosis, and it may improve survival in patients with disease of bulbar onset."", ""supports"": ""SUPPORT""}"
674	550	22	Amyotrophic Lateral Sclerosis	Amyotrophic_Lateral_Sclerosis.yaml	treatments	1	evidence	0	PMID:28522181	SUPPORT		Edaravone showed efficacy in a small subset of people with ALS who met criteria identified in post-hoc analysis of a previous phase 3 study, showing a significantly smaller decline of ALSFRS-R score compared with placebo.	Phase 3 trial demonstrating edaravone slows functional decline in early-stage ALS patients.	"{""explanation"": ""Phase 3 trial demonstrating edaravone slows functional decline in early-stage ALS patients."", ""reference"": ""PMID:28522181"", ""snippet"": ""Edaravone showed efficacy in a small subset of people with ALS who met criteria identified in post-hoc analysis of a previous phase 3 study, showing a significantly smaller decline of ALSFRS-R score compared with placebo."", ""supports"": ""SUPPORT""}"
675	550	22	Amyotrophic Lateral Sclerosis	Amyotrophic_Lateral_Sclerosis.yaml	treatments	1	evidence	1	PMID:35006266	REFUTE		although long-term intravenous edaravone therapy for patients with ALS was feasible and mainly well tolerated, it was not associated with any disease-modifying benefit.	Real-world cohort study found long-term intravenous edaravone well tolerated but without additional disease-modifying benefit versus standard therapy.	"{""explanation"": ""Real-world cohort study found long-term intravenous edaravone well tolerated but without additional disease-modifying benefit versus standard therapy."", ""reference"": ""PMID:35006266"", ""snippet"": ""although long-term intravenous edaravone therapy for patients with ALS was feasible and mainly well tolerated, it was not associated with any disease-modifying benefit."", ""supports"": ""REFUTE""}"
676	551	22	Amyotrophic Lateral Sclerosis	Amyotrophic_Lateral_Sclerosis.yaml	treatments	2	evidence	0	PMID:32640130	SUPPORT		In adults with ALS due to SOD1 mutations, CSF SOD1 concentrations decreased at the highest concentration of tofersen administered intrathecally over a period of 12 weeks.	Phase 1-2 trial demonstrating tofersen reduces CSF SOD1 levels in SOD1-ALS patients.	"{""explanation"": ""Phase 1-2 trial demonstrating tofersen reduces CSF SOD1 levels in SOD1-ALS patients."", ""reference"": ""PMID:32640130"", ""snippet"": ""In adults with ALS due to SOD1 mutations, CSF SOD1 concentrations decreased at the highest concentration of tofersen administered intrathecally over a period of 12 weeks."", ""supports"": ""SUPPORT""}"
677	552	22	Amyotrophic Lateral Sclerosis	Amyotrophic_Lateral_Sclerosis.yaml	treatments	3	evidence	0	PMID:16426990	SUPPORT		This subgroup showed improvement in several measures of quality of life and a median survival benefit of 205 days (p=0.006) with maintained quality of life for most of this period.	Randomized controlled trial demonstrated non-invasive ventilation improves quality of life and extends survival in ALS patients with preserved bulbar function.	"{""explanation"": ""Randomized controlled trial demonstrated non-invasive ventilation improves quality of life and extends survival in ALS patients with preserved bulbar function."", ""reference"": ""PMID:16426990"", ""snippet"": ""This subgroup showed improvement in several measures of quality of life and a median survival benefit of 205 days (p=0.006) with maintained quality of life for most of this period."", ""supports"": ""SUPPORT""}"
678	553	22	Amyotrophic Lateral Sclerosis	Amyotrophic_Lateral_Sclerosis.yaml	treatments	4	evidence	0	PMID:24510737	SUPPORT		Multidisciplinary care includes rehabilitation interventions that have the goal of assisting people to teach their fullest potential despite the presence of a disabling disease.	Review describes how rehabilitation including physical therapy helps maximize independence and function in ALS patients.	"{""explanation"": ""Review describes how rehabilitation including physical therapy helps maximize independence and function in ALS patients."", ""reference"": ""PMID:24510737"", ""snippet"": ""Multidisciplinary care includes rehabilitation interventions that have the goal of assisting people to teach their fullest potential despite the presence of a disabling disease."", ""supports"": ""SUPPORT""}"
679	554	22	Amyotrophic Lateral Sclerosis	Amyotrophic_Lateral_Sclerosis.yaml	treatments	5	evidence	0	PMID:24510737	SUPPORT		This review will present rehabilitation strategies that can be utilized to maximize patient independence, function, safety, and quality of life, and to minimize disease-related symptoms.	Review covers multidisciplinary rehabilitation including speech therapy for ALS patients.	"{""explanation"": ""Review covers multidisciplinary rehabilitation including speech therapy for ALS patients."", ""reference"": ""PMID:24510737"", ""snippet"": ""This review will present rehabilitation strategies that can be utilized to maximize patient independence, function, safety, and quality of life, and to minimize disease-related symptoms."", ""supports"": ""SUPPORT""}"
680	555	22	Amyotrophic Lateral Sclerosis	Amyotrophic_Lateral_Sclerosis.yaml	treatments	6	evidence	0	PMID:39207520	SUPPORT		Early discussion of potential treatments such as high-calorie diets or percutaneous endoscopic gastrostomy (PEG) is crucial.	Dysphagia management review underscores PEG as an essential intervention when nutrition is compromised in ALS.	"{""explanation"": ""Dysphagia management review underscores PEG as an essential intervention when nutrition is compromised in ALS."", ""reference"": ""PMID:39207520"", ""snippet"": ""Early discussion of potential treatments such as high-calorie diets or percutaneous endoscopic gastrostomy (PEG) is crucial."", ""supports"": ""SUPPORT""}"
681	556	22	Amyotrophic Lateral Sclerosis	Amyotrophic_Lateral_Sclerosis.yaml	treatments	7	evidence	0	PMID:24510737	SUPPORT		Multidisciplinary care includes rehabilitation interventions that have the goal of assisting people to teach their fullest potential despite the presence of a disabling disease.	Rehabilitation review emphasizes multidisciplinary care as core to ALS management to optimize function and quality of life.	"{""explanation"": ""Rehabilitation review emphasizes multidisciplinary care as core to ALS management to optimize function and quality of life."", ""reference"": ""PMID:24510737"", ""snippet"": ""Multidisciplinary care includes rehabilitation interventions that have the goal of assisting people to teach their fullest potential despite the presence of a disabling disease."", ""supports"": ""SUPPORT""}"
690	571	23	Ankylosing Spondylitis	Ankylosing_Spondylitis.yaml	treatments	2	evidence	0	PMID:33692806	SUPPORT		The MEASURE trials demonstrated the superiority of Secukinumab against placebo in providing sustained efficacy in relieving signs and symptoms of AS as well as in granting a good retention rate, as demonstrated in the 5-years extension study (135, 136).	Clinical trial evidence demonstrating the efficacy of secukinumab, an IL-17A inhibitor, in treating ankylosing spondylitis.	"{""explanation"": ""Clinical trial evidence demonstrating the efficacy of secukinumab, an IL-17A inhibitor, in treating ankylosing spondylitis."", ""reference"": ""PMID:33692806"", ""snippet"": ""The MEASURE trials demonstrated the superiority of Secukinumab against placebo in providing sustained efficacy in relieving signs and symptoms of AS as well as in granting a good retention rate, as demonstrated in the 5-years extension study (135, 136)."", ""supports"": ""SUPPORT""}"
829	642	26	Aromatase Deficiency	Aromatase_Deficiency.yaml	treatments	0	evidence	0	PMID:18448329	SUPPORT		The estradiol replacement treatment leads to a complete epiphyseal closure and to the skeletal maturation.	The statement claims that estrogen replacement therapy corrects estrogen deficiency and supports bone health. The literature provided supports this by indicating that estradiol replacement leads to skeletal maturation.	"{""explanation"": ""The statement claims that estrogen replacement therapy corrects estrogen deficiency and supports bone health. The literature provided supports this by indicating that estradiol replacement leads to skeletal maturation."", ""reference"": ""PMID:18448329"", ""snippet"": ""The estradiol replacement treatment leads to a complete epiphyseal closure and to the skeletal maturation."", ""supports"": ""SUPPORT""}"
830	642	26	Aromatase Deficiency	Aromatase_Deficiency.yaml	treatments	0	evidence	1	PMID:26680580	SUPPORT		The overall goal of pubertal sex hormone replacement therapy (HRT) in girls is not only about development of secondary sexual characteristics, but also to establish an adult endocrine and metabolic milieu.	This confirms that estrogen replacement therapy aids in normal sexual development.	"{""explanation"": ""This confirms that estrogen replacement therapy aids in normal sexual development."", ""reference"": ""PMID:26680580"", ""snippet"": ""The overall goal of pubertal sex hormone replacement therapy (HRT) in girls is not only about development of secondary sexual characteristics, but also to establish an adult endocrine and metabolic milieu."", ""supports"": ""SUPPORT""}"
831	642	26	Aromatase Deficiency	Aromatase_Deficiency.yaml	treatments	0	evidence	2	PMID:18567553	SUPPORT		Findings from estrogen-resistant and aromatase-deficient men have provided important insights into the role of estrogen in the male skeleton during growth.	The study elaborates on the role of estrogen in bone health, using data from aromatase-deficient subjects to underline its significance.	"{""explanation"": ""The study elaborates on the role of estrogen in bone health, using data from aromatase-deficient subjects to underline its significance."", ""reference"": ""PMID:18567553"", ""snippet"": ""Findings from estrogen-resistant and aromatase-deficient men have provided important insights into the role of estrogen in the male skeleton during growth."", ""supports"": ""SUPPORT""}"
832	644	26	Aromatase Deficiency	Aromatase_Deficiency.yaml	treatments	2	evidence	0	PMID:19707181	REFUTE		Diagnosis of the condition is supported by the presence of unfused epiphyses and undetectable serum estradiol levels; the condition can be further substantiated by genetic sequencing of CYP19A1. Transdermal estradiol treatment at a daily dose of about 25 microg might be adequate for lifelong replacement therapy.	The literature does not mention surgical management as a treatment for aromatase deficiency. Instead, it suggests hormonal replacement therapy as the primary treatment.	"{""explanation"": ""The literature does not mention surgical management as a treatment for aromatase deficiency. Instead, it suggests hormonal replacement therapy as the primary treatment."", ""reference"": ""PMID:19707181"", ""snippet"": ""Diagnosis of the condition is supported by the presence of unfused epiphyses and undetectable serum estradiol levels; the condition can be further substantiated by genetic sequencing of CYP19A1. Transdermal estradiol treatment at a daily dose of about 25 microg might be adequate for lifelong replacement therapy."", ""supports"": ""REFUTE""}"
833	644	26	Aromatase Deficiency	Aromatase_Deficiency.yaml	treatments	2	evidence	1	PMID:32990485	NO_EVIDENCE		Transgender individuals are those whose gender identity differs from that recorded at birth...clinicians can provide hormone therapy (HT) to bring sex hormone levels to the range associated with the patient''s gender identity.	This literature discusses hormone therapy for transgender individuals but does not specifically address surgical management for ambiguous genitalia or other anatomical abnormalities in the context of aromatase deficiency.	"{""explanation"": ""This literature discusses hormone therapy for transgender individuals but does not specifically address surgical management for ambiguous genitalia or other anatomical abnormalities in the context of aromatase deficiency."", ""reference"": ""PMID:32990485"", ""snippet"": ""Transgender individuals are those whose gender identity differs from that recorded at birth...clinicians can provide hormone therapy (HT) to bring sex hormone levels to the range associated with the patient''s gender identity."", ""supports"": ""NO_EVIDENCE""}"
968	711	28	Asthma	Asthma.yaml	treatments	0	evidence	0	PMID:22559870	SUPPORT		Current guidelines recommend long-term treatment with inhaled corticosteroids (ICS) because of their superior effectiveness in managing the chronic airway inflammation that characterizes persistent asthma.	This literature supports the statement that inhaled corticosteroids reduce inflammation in asthma.	"{""explanation"": ""This literature supports the statement that inhaled corticosteroids reduce inflammation in asthma."", ""reference"": ""PMID:22559870"", ""snippet"": ""Current guidelines recommend long-term treatment with inhaled corticosteroids (ICS) because of their superior effectiveness in managing the chronic airway inflammation that characterizes persistent asthma."", ""supports"": ""SUPPORT""}"
969	711	28	Asthma	Asthma.yaml	treatments	0	evidence	1	PMID:9817746	SUPPORT		Glucocorticoids are highly effective in the control of asthma and suppression of airway inflammation.	This reference supports the role of glucocorticoids, which includes inhaled corticosteroids, in reducing airway inflammation in asthma.	"{""explanation"": ""This reference supports the role of glucocorticoids, which includes inhaled corticosteroids, in reducing airway inflammation in asthma."", ""reference"": ""PMID:9817746"", ""snippet"": ""Glucocorticoids are highly effective in the control of asthma and suppression of airway inflammation."", ""supports"": ""SUPPORT""}"
970	711	28	Asthma	Asthma.yaml	treatments	0	evidence	2	PMID:32868307	SUPPORT		The 2019 Global Initiative for Asthma (GINA) guidelines recommend that all asthma patients be treated with inhaled corticosteroids taken daily or as needed; this improves symptoms and outcomes, even in those with mild disease.	This guideline indicates that inhaled corticosteroids are recommended for improving asthma outcomes, supporting their role in preventing flare-ups.	"{""explanation"": ""This guideline indicates that inhaled corticosteroids are recommended for improving asthma outcomes, supporting their role in preventing flare-ups."", ""reference"": ""PMID:32868307"", ""snippet"": ""The 2019 Global Initiative for Asthma (GINA) guidelines recommend that all asthma patients be treated with inhaled corticosteroids taken daily or as needed; this improves symptoms and outcomes, even in those with mild disease."", ""supports"": ""SUPPORT""}"
971	711	28	Asthma	Asthma.yaml	treatments	0	evidence	3	PMID:37182593	SUPPORT		Early treatment with inhaled corticosteroids not only diminishes lung inflammation and airway hyper-responsiveness, but also has a protective effect against the reduction of breathing pattern complexity due to asthma.	The findings indicate that early treatment with inhaled corticosteroids reduces lung inflammation and helps prevent further complications, such as reduced breathing pattern complexity, supporting their role in preventive care.	"{""explanation"": ""The findings indicate that early treatment with inhaled corticosteroids reduces lung inflammation and helps prevent further complications, such as reduced breathing pattern complexity, supporting their role in preventive care."", ""reference"": ""PMID:37182593"", ""snippet"": ""Early treatment with inhaled corticosteroids not only diminishes lung inflammation and airway hyper-responsiveness, but also has a protective effect against the reduction of breathing pattern complexity due to asthma."", ""supports"": ""SUPPORT""}"
972	712	28	Asthma	Asthma.yaml	treatments	1	evidence	0	PMID:34753370	SUPPORT		Patients experience significant clinical benefits from therapy with long-acting 2-agonists (LABAs) with efficacy to bronchodilate, and prolonged lung function betterment.	The literature supports that LABAs help in relaxing the muscles around the airways, thereby improving lung function and providing symptomatic relief in asthma management.	"{""explanation"": ""The literature supports that LABAs help in relaxing the muscles around the airways, thereby improving lung function and providing symptomatic relief in asthma management."", ""reference"": ""PMID:34753370"", ""snippet"": ""Patients experience significant clinical benefits from therapy with long-acting 2-agonists (LABAs) with efficacy to bronchodilate, and prolonged lung function betterment."", ""supports"": ""SUPPORT""}"
973	712	28	Asthma	Asthma.yaml	treatments	1	evidence	1	PMID:37489386	SUPPORT		Long-acting muscarinic antagonists (LAMAs) are a class of inhalers that has recently been included as add-on therapy in the GINA guidelines, either in a single inhaler device with inhaled corticosteroids plus long-acting beta2-agonists (ICS + LABA).	Although primarily about LAMAs, the literature acknowledges that LABAs are part of the recommended treatment regimen for asthma, which implies their role in relaxing airway muscles.	"{""explanation"": ""Although primarily about LAMAs, the literature acknowledges that LABAs are part of the recommended treatment regimen for asthma, which implies their role in relaxing airway muscles."", ""reference"": ""PMID:37489386"", ""snippet"": ""Long-acting muscarinic antagonists (LAMAs) are a class of inhalers that has recently been included as add-on therapy in the GINA guidelines, either in a single inhaler device with inhaled corticosteroids plus long-acting beta2-agonists (ICS + LABA)."", ""supports"": ""SUPPORT""}"
974	712	28	Asthma	Asthma.yaml	treatments	1	evidence	2	PMID:32306788	SUPPORT		Contemporary mainstay therapies (inhaled corticosteroids and bronchodilators), prescribed empirically, control symptoms resulting from airways obstruction tolerably well in many patients...	The literature indicates that LABAs, as bronchodilators, help control symptoms related to airway obstruction by relaxing the airway muscles.	"{""explanation"": ""The literature indicates that LABAs, as bronchodilators, help control symptoms related to airway obstruction by relaxing the airway muscles."", ""reference"": ""PMID:32306788"", ""snippet"": ""Contemporary mainstay therapies (inhaled corticosteroids and bronchodilators), prescribed empirically, control symptoms resulting from airways obstruction tolerably well in many patients..."", ""supports"": ""SUPPORT""}"
975	713	28	Asthma	Asthma.yaml	treatments	2	evidence	0	PMID:14720013	SUPPORT		Leukotriene modifiers increase the therapeutic options for patients with asthma and, based on recent data, it is expected that future guidelines will describe expanded uses for these agents in clinical circumstances where these drugs are effective.		"{""reference"": ""PMID:14720013"", ""snippet"": ""Leukotriene modifiers increase the therapeutic options for patients with asthma and, based on recent data, it is expected that future guidelines will describe expanded uses for these agents in clinical circumstances where these drugs are effective."", ""supports"": ""SUPPORT""}"
976	713	28	Asthma	Asthma.yaml	treatments	2	evidence	1	PMID:11085767	SUPPORT		Their unique mechanism of action results in a combination of both bronchodilator and anti-inflammatory effects.		"{""reference"": ""PMID:11085767"", ""snippet"": ""Their unique mechanism of action results in a combination of both bronchodilator and anti-inflammatory effects."", ""supports"": ""SUPPORT""}"
977	713	28	Asthma	Asthma.yaml	treatments	2	evidence	2	PMID:19180262	SUPPORT		Cysteinyl leukotrienes, which are derivatives of the 5-lipoxygenase pathway of arachidonic acid metabolism, are important mediators of airway allergic inflammation and have a role in the pathogenetic mechanism of EIB. Montelukast sodium (Singulair, Merck & Co.) is a selective and orally active leukotriene receptor antagonist with demonstrated activity for treating asthma and allergic rhinitis.		"{""reference"": ""PMID:19180262"", ""snippet"": ""Cysteinyl leukotrienes, which are derivatives of the 5-lipoxygenase pathway of arachidonic acid metabolism, are important mediators of airway allergic inflammation and have a role in the pathogenetic mechanism of EIB. Montelukast sodium (Singulair, Merck & Co.) is a selective and orally active leukotriene receptor antagonist with demonstrated activity for treating asthma and allergic rhinitis."", ""supports"": ""SUPPORT""}"
978	714	28	Asthma	Asthma.yaml	treatments	3	evidence	0	PMID:29427989	SUPPORT		Severe allergic asthma and severe eosinophilic asthma are two defined phenotypes for which there are efficacious targeted biologic therapies currently available, namely anti-immunoglobulin E (IgE) and anti-interleukin (IL)-5 antibodies, respectively.	This reference confirms that anti-IgE therapy is used to treat severe allergic asthma.	"{""explanation"": ""This reference confirms that anti-IgE therapy is used to treat severe allergic asthma."", ""reference"": ""PMID:29427989"", ""snippet"": ""Severe allergic asthma and severe eosinophilic asthma are two defined phenotypes for which there are efficacious targeted biologic therapies currently available, namely anti-immunoglobulin E (IgE) and anti-interleukin (IL)-5 antibodies, respectively."", ""supports"": ""SUPPORT""}"
979	714	28	Asthma	Asthma.yaml	treatments	3	evidence	1	PMID:20799475	SUPPORT		Among these is anti-IgE, which directly targets IgE serum antibodies, thus inhibiting the central mechanism of immediate type hypersensitivity reactions. Application of anti-IgE antibodies effectively reduces IgE serum levels regardless of allergen specificity.	This reference supports that anti-IgE therapy is used in allergic asthma by targeting and reducing IgE.	"{""explanation"": ""This reference supports that anti-IgE therapy is used in allergic asthma by targeting and reducing IgE."", ""reference"": ""PMID:20799475"", ""snippet"": ""Among these is anti-IgE, which directly targets IgE serum antibodies, thus inhibiting the central mechanism of immediate type hypersensitivity reactions. Application of anti-IgE antibodies effectively reduces IgE serum levels regardless of allergen specificity."", ""supports"": ""SUPPORT""}"
980	714	28	Asthma	Asthma.yaml	treatments	3	evidence	2	PMID:28635659	SUPPORT		Blocking IgE with monoclonal antibodies such as omalizumab have demonstrated their efficacy, effectiveness, and safety in treating allergic asthma.	This reference confirms that anti-IgE therapy, specifically using omalizumab, is effective in treating allergic asthma.	"{""explanation"": ""This reference confirms that anti-IgE therapy, specifically using omalizumab, is effective in treating allergic asthma."", ""reference"": ""PMID:28635659"", ""snippet"": ""Blocking IgE with monoclonal antibodies such as omalizumab have demonstrated their efficacy, effectiveness, and safety in treating allergic asthma."", ""supports"": ""SUPPORT""}"
981	714	28	Asthma	Asthma.yaml	treatments	3	evidence	3	PMID:21114196	SUPPORT		Omalizumab improves quality of life of patients with severe persistent allergic asthma that is inadequately controlled by currently available asthma medications. This therapy is well tolerated and significantly improves symptoms, disease control, reducing asthma exacerbations and the need to use high dosage of inhaled corticosteroids.	This reference further supports the efficacy of anti-IgE therapy (omalizumab) in treating severe allergic asthma by improving symptoms and reducing exacerbations.	"{""explanation"": ""This reference further supports the efficacy of anti-IgE therapy (omalizumab) in treating severe allergic asthma by improving symptoms and reducing exacerbations."", ""reference"": ""PMID:21114196"", ""snippet"": ""Omalizumab improves quality of life of patients with severe persistent allergic asthma that is inadequately controlled by currently available asthma medications. This therapy is well tolerated and significantly improves symptoms, disease control, reducing asthma exacerbations and the need to use high dosage of inhaled corticosteroids."", ""supports"": ""SUPPORT""}"
982	715	28	Asthma	Asthma.yaml	treatments	4	evidence	0	PMID:34369231	SUPPORT		Albuterol is the most common fast acting medication for asthma, and it exists in multiple forms, including metered-dose inhaler and nebulized therapy.	Albuterol, a commonly used short-acting beta agonist, is indicated as a fast-acting medication for the relief of asthma symptoms.	"{""explanation"": ""Albuterol, a commonly used short-acting beta agonist, is indicated as a fast-acting medication for the relief of asthma symptoms."", ""reference"": ""PMID:34369231"", ""snippet"": ""Albuterol is the most common fast acting medication for asthma, and it exists in multiple forms, including metered-dose inhaler and nebulized therapy."", ""supports"": ""SUPPORT""}"
983	715	28	Asthma	Asthma.yaml	treatments	4	evidence	1	PMID:30297688	SUPPORT		Initial therapy in the stepwise approach for asthma management is short-acting -agonist (SABA) therapy as needed for symptom control.	Short-acting beta agonists are recommended as initial therapy for the control of asthma symptoms, indicating their rapid relief properties.	"{""explanation"": ""Short-acting beta agonists are recommended as initial therapy for the control of asthma symptoms, indicating their rapid relief properties."", ""reference"": ""PMID:30297688"", ""snippet"": ""Initial therapy in the stepwise approach for asthma management is short-acting -agonist (SABA) therapy as needed for symptom control."", ""supports"": ""SUPPORT""}"
984	715	28	Asthma	Asthma.yaml	treatments	4	evidence	2	PMID:27588581	SUPPORT		Results demonstrate the efficacy of short-acting beta-agonist (SABA) delivered by metered-dose inhaler as first-line therapy for younger and older children.	The efficacy of SABAs as a first-line therapy in emergency asthma management highlights their role in providing rapid relief from acute asthma symptoms.	"{""explanation"": ""The efficacy of SABAs as a first-line therapy in emergency asthma management highlights their role in providing rapid relief from acute asthma symptoms."", ""reference"": ""PMID:27588581"", ""snippet"": ""Results demonstrate the efficacy of short-acting beta-agonist (SABA) delivered by metered-dose inhaler as first-line therapy for younger and older children."", ""supports"": ""SUPPORT""}"
985	715	28	Asthma	Asthma.yaml	treatments	4	evidence	3	PMID:32482150	SUPPORT		A majority of patients uses daily quick-relief medication, with the belief that it is the most important treatment because of its rapid onset of action.	The use of quick-relief medication, such as SABAs, by a majority of patients for asthma management is based on their rapid onset of action.	"{""explanation"": ""The use of quick-relief medication, such as SABAs, by a majority of patients for asthma management is based on their rapid onset of action."", ""reference"": ""PMID:32482150"", ""snippet"": ""A majority of patients uses daily quick-relief medication, with the belief that it is the most important treatment because of its rapid onset of action."", ""supports"": ""SUPPORT""}"
986	715	28	Asthma	Asthma.yaml	treatments	4	evidence	4	PMID:11253864	SUPPORT		Clinical studies comparing the effectiveness of (R)-albuterol (levalbuterol) with racemic albuterol established a strong rationale for using single-isomer beta-agonists in place of the racemic mixture: reduced dosages provide equivalent bronchodilatory effects with fewer beta-mediated side effects.	Levalbuterol, a single-isomer beta-agonist, is shown to provide effective rapid bronchodilation for asthma management.	"{""explanation"": ""Levalbuterol, a single-isomer beta-agonist, is shown to provide effective rapid bronchodilation for asthma management."", ""reference"": ""PMID:11253864"", ""snippet"": ""Clinical studies comparing the effectiveness of (R)-albuterol (levalbuterol) with racemic albuterol established a strong rationale for using single-isomer beta-agonists in place of the racemic mixture: reduced dosages provide equivalent bronchodilatory effects with fewer beta-mediated side effects."", ""supports"": ""SUPPORT""}"
1000	741	29	Atrial Fibrillation	Atrial_Fibrillation.yaml	treatments	0	evidence	0	PMID:37573616	SUPPORT		DOAC was associated with a significantly lower risk of stroke or systemic embolism (hazard ratio 0.85, 95% confidence interval 0.75 to 0.96, p = 0.008, I2 = 0%), major bleeding, intracranial hemorrhage, and mortality compared with warfarin.	Meta-analysis of 132,980 patients demonstrates DOACs reduce stroke risk in AF patients.	"{""explanation"": ""Meta-analysis of 132,980 patients demonstrates DOACs reduce stroke risk in AF patients."", ""reference"": ""PMID:37573616"", ""snippet"": ""DOAC was associated with a significantly lower risk of stroke or systemic embolism (hazard ratio 0.85, 95% confidence interval 0.75 to 0.96, p = 0.008, I2 = 0%), major bleeding, intracranial hemorrhage, and mortality compared with warfarin."", ""supports"": ""SUPPORT""}"
1018	762	30	Auto-Brewery Syndrome	Auto-Brewery_Syndrome.yaml	treatments	0	evidence	0	PMID:33887125	SUPPORT		Current treatments for GFS include antibiotics, antifungal medication, low carbohydrate diet, and probiotics.	Antifungal medication is a standard treatment for GFS.	"{""explanation"": ""Antifungal medication is a standard treatment for GFS."", ""reference"": ""PMID:33887125"", ""snippet"": ""Current treatments for GFS include antibiotics, antifungal medication, low carbohydrate diet, and probiotics."", ""supports"": ""SUPPORT""}"
1019	762	30	Auto-Brewery Syndrome	Auto-Brewery_Syndrome.yaml	treatments	0	evidence	1	PMID:34682761	SUPPORT		Treatment typically includes antifungal drugs combined with changes in lifestyle and nutrition.	Confirms antifungal drugs are part of standard treatment approach.	"{""explanation"": ""Confirms antifungal drugs are part of standard treatment approach."", ""reference"": ""PMID:34682761"", ""snippet"": ""Treatment typically includes antifungal drugs combined with changes in lifestyle and nutrition."", ""supports"": ""SUPPORT""}"
1020	763	30	Auto-Brewery Syndrome	Auto-Brewery_Syndrome.yaml	treatments	1	evidence	0	PMID:37060744	SUPPORT		Treatments with antibiotics, a complex probiotic preparation and a low-carbohydrate diet not only alleviated ABS, but also erased ABS relapse during the follow-up observation of one of the patients.	Low-carbohydrate diet was part of successful treatment regimen.	"{""explanation"": ""Low-carbohydrate diet was part of successful treatment regimen."", ""reference"": ""PMID:37060744"", ""snippet"": ""Treatments with antibiotics, a complex probiotic preparation and a low-carbohydrate diet not only alleviated ABS, but also erased ABS relapse during the follow-up observation of one of the patients."", ""supports"": ""SUPPORT""}"
1021	763	30	Auto-Brewery Syndrome	Auto-Brewery_Syndrome.yaml	treatments	1	evidence	1	PMID:33887125	SUPPORT		Current treatments for GFS include antibiotics, antifungal medication, low carbohydrate diet, and probiotics.	Low carbohydrate diet is a recognized treatment approach.	"{""explanation"": ""Low carbohydrate diet is a recognized treatment approach."", ""reference"": ""PMID:33887125"", ""snippet"": ""Current treatments for GFS include antibiotics, antifungal medication, low carbohydrate diet, and probiotics."", ""supports"": ""SUPPORT""}"
1022	764	30	Auto-Brewery Syndrome	Auto-Brewery_Syndrome.yaml	treatments	2	evidence	0	PMID:37060744	SUPPORT		Treatments with antibiotics, a complex probiotic preparation and a low-carbohydrate diet not only alleviated ABS	Complex probiotic preparations were part of successful treatment.	"{""explanation"": ""Complex probiotic preparations were part of successful treatment."", ""reference"": ""PMID:37060744"", ""snippet"": ""Treatments with antibiotics, a complex probiotic preparation and a low-carbohydrate diet not only alleviated ABS"", ""supports"": ""SUPPORT""}"
1023	764	30	Auto-Brewery Syndrome	Auto-Brewery_Syndrome.yaml	treatments	2	evidence	1	PMID:33887125	SUPPORT		Current treatments for GFS include antibiotics, antifungal medication, low carbohydrate diet, and probiotics.	Probiotics are a recognized treatment option.	"{""explanation"": ""Probiotics are a recognized treatment option."", ""reference"": ""PMID:33887125"", ""snippet"": ""Current treatments for GFS include antibiotics, antifungal medication, low carbohydrate diet, and probiotics."", ""supports"": ""SUPPORT""}"
1024	765	30	Auto-Brewery Syndrome	Auto-Brewery_Syndrome.yaml	treatments	3	evidence	0	PMID:33887125	SUPPORT		There might be a potential role of fecal microbiota transplant in the treatment of GFS.	FMT is suggested as a potential treatment for refractory cases.	"{""explanation"": ""FMT is suggested as a potential treatment for refractory cases."", ""reference"": ""PMID:33887125"", ""snippet"": ""There might be a potential role of fecal microbiota transplant in the treatment of GFS."", ""supports"": ""SUPPORT""}"
1120	824	33	Axenfeld-Rieger_syndrome	Axenfeld-Rieger_syndrome.yaml	treatments	0	evidence	0	PMID:18929112	SUPPORT		Treatment for glaucoma consists of reducing intraocular pressure (IOP) to an acceptable target range to prevent further optic-nerve damage. Currently available treatments include topical drug (single then multidrug combinations) followed, for those patients on maximal tolerated medical therapy who still need additional IOP reduction, by laser treatments.	This reference supports the use of medications as first-line treatment for managing glaucoma in patients.	"{""explanation"": ""This reference supports the use of medications as first-line treatment for managing glaucoma in patients."", ""reference"": ""PMID:18929112"", ""snippet"": ""Treatment for glaucoma consists of reducing intraocular pressure (IOP) to an acceptable target range to prevent further optic-nerve damage. Currently available treatments include topical drug (single then multidrug combinations) followed, for those patients on maximal tolerated medical therapy who still need additional IOP reduction, by laser treatments."", ""supports"": ""SUPPORT""}"
1121	825	33	Axenfeld-Rieger_syndrome	Axenfeld-Rieger_syndrome.yaml	treatments	1	evidence	0	PMID:32357855	SUPPORT		The goal of this study is to compare the effectiveness of various glaucoma surgeries on intraocular pressure (IOP) management in ARS.	The study discusses various surgical interventions for managing intraocular pressure in patients with Axenfeld-Rieger syndrome.	"{""explanation"": ""The study discusses various surgical interventions for managing intraocular pressure in patients with Axenfeld-Rieger syndrome."", ""reference"": ""PMID:32357855"", ""snippet"": ""The goal of this study is to compare the effectiveness of various glaucoma surgeries on intraocular pressure (IOP) management in ARS."", ""supports"": ""SUPPORT""}"
1122	825	33	Axenfeld-Rieger_syndrome	Axenfeld-Rieger_syndrome.yaml	treatments	1	evidence	1	PMID:33881269	SUPPORT		The article describes a case of 7-year-old child with rare Axenfeld-Rieger syndrome demonstrating the effectiveness and safety of combined laser reconstructive surgeries.	The case report supports the use of laser and surgical therapy as part of the management for Axenfeld-Rieger syndrome.	"{""explanation"": ""The case report supports the use of laser and surgical therapy as part of the management for Axenfeld-Rieger syndrome."", ""reference"": ""PMID:33881269"", ""snippet"": ""The article describes a case of 7-year-old child with rare Axenfeld-Rieger syndrome demonstrating the effectiveness and safety of combined laser reconstructive surgeries."", ""supports"": ""SUPPORT""}"
1123	825	33	Axenfeld-Rieger_syndrome	Axenfeld-Rieger_syndrome.yaml	treatments	1	evidence	2	PMID:35733478	SUPPORT		Treatment is predominantly the management of glaucoma and is mostly medical but can be surgical in refractory cases.	Confirms that surgical management is used for refractory glaucoma cases in ARS.	"{""explanation"": ""Confirms that surgical management is used for refractory glaucoma cases in ARS."", ""reference"": ""PMID:35733478"", ""snippet"": ""Treatment is predominantly the management of glaucoma and is mostly medical but can be surgical in refractory cases."", ""supports"": ""SUPPORT""}"
1124	826	33	Axenfeld-Rieger_syndrome	Axenfeld-Rieger_syndrome.yaml	treatments	2	evidence	0	PMID:22104715	SUPPORT		The patient showed severe hypodontia, microdontia, and short roots. Different treatment options are discussed. Early diagnosis and an interdisciplinary approach are necessary to provide the best short- and long-term treatment plans, as well as treatment and follow-up for individuals with the syndrome.	The reference discusses the dental anomalies in Axenfeld-Rieger syndrome and the importance of early diagnosis and interdisciplinary treatment, aligning with the statement about orthodontic and dental treatments to address these anomalies.	"{""explanation"": ""The reference discusses the dental anomalies in Axenfeld-Rieger syndrome and the importance of early diagnosis and interdisciplinary treatment, aligning with the statement about orthodontic and dental treatments to address these anomalies."", ""reference"": ""PMID:22104715"", ""snippet"": ""The patient showed severe hypodontia, microdontia, and short roots. Different treatment options are discussed. Early diagnosis and an interdisciplinary approach are necessary to provide the best short- and long-term treatment plans, as well as treatment and follow-up for individuals with the syndrome."", ""supports"": ""SUPPORT""}"
1125	826	33	Axenfeld-Rieger_syndrome	Axenfeld-Rieger_syndrome.yaml	treatments	2	evidence	1	PMID:33487449	SUPPORT		The management of a Moroccan family with Axenfeld-Rieger syndrome.	The reference indicates the management of Axenfeld-Rieger syndrome, which includes addressing dental anomalies, supporting the statement about orthodontic and dental treatments.	"{""explanation"": ""The reference indicates the management of Axenfeld-Rieger syndrome, which includes addressing dental anomalies, supporting the statement about orthodontic and dental treatments."", ""reference"": ""PMID:33487449"", ""snippet"": ""The management of a Moroccan family with Axenfeld-Rieger syndrome."", ""supports"": ""SUPPORT""}"
1126	827	33	Axenfeld-Rieger_syndrome	Axenfeld-Rieger_syndrome.yaml	treatments	3	evidence	0	PMID:36926528	SUPPORT		A multi-disciplinary approach including glaucoma specialists and pediatric ophthalmologists produces optimal outcomes as vision is dependent on many factors including glaucoma, refractive error, amblyopia and strabismus.	The literature emphasizes the importance of regular ophthalmic monitoring for managing glaucoma and other ocular issues in Axenfeld-Rieger syndrome.	"{""explanation"": ""The literature emphasizes the importance of regular ophthalmic monitoring for managing glaucoma and other ocular issues in Axenfeld-Rieger syndrome."", ""reference"": ""PMID:36926528"", ""snippet"": ""A multi-disciplinary approach including glaucoma specialists and pediatric ophthalmologists produces optimal outcomes as vision is dependent on many factors including glaucoma, refractive error, amblyopia and strabismus."", ""supports"": ""SUPPORT""}"
1127	827	33	Axenfeld-Rieger_syndrome	Axenfeld-Rieger_syndrome.yaml	treatments	3	evidence	1	PMID:33367186	SUPPORT		Glaucoma is the main cause of visual morbidity in patients with ARS, therefore a complete periodic ophthalmological exam is a priority.	This reference emphasizes the critical importance of regular comprehensive ophthalmologic examinations for ARS patients.	"{""explanation"": ""This reference emphasizes the critical importance of regular comprehensive ophthalmologic examinations for ARS patients."", ""reference"": ""PMID:33367186"", ""snippet"": ""Glaucoma is the main cause of visual morbidity in patients with ARS, therefore a complete periodic ophthalmological exam is a priority."", ""supports"": ""SUPPORT""}"
1255	958	39	Bacterial meningitis	Bacterial_meningitis.yaml	treatments	0	evidence	0	PMID:3287565	PARTIAL		The available evidence suggests that if bacterial meningitis is suspected and LP must be delayed, intravenous antibiotics are warranted before CSF is obtained.	This suggests that in cases where lumbar puncture (LP) must be delayed, antibiotics should be administered before LP, but it does not explicitly state that antibiotics should be started immediately after LP.	"{""explanation"": ""This suggests that in cases where lumbar puncture (LP) must be delayed, antibiotics should be administered before LP, but it does not explicitly state that antibiotics should be started immediately after LP."", ""reference"": ""PMID:3287565"", ""snippet"": ""The available evidence suggests that if bacterial meningitis is suspected and LP must be delayed, intravenous antibiotics are warranted before CSF is obtained."", ""supports"": ""PARTIAL""}"
1256	958	39	Bacterial meningitis	Bacterial_meningitis.yaml	treatments	0	evidence	1	PMID:30496558	PARTIAL		The use of empiric vancomycin plus a third-generation cephalosporin for suspected bacterial meningitis has been recommended since 1997.	This reference supports the use of broad-spectrum antibiotics like vancomycin and ceftriaxone for empiric therapy but does not specify the timing related to lumbar puncture.	"{""explanation"": ""This reference supports the use of broad-spectrum antibiotics like vancomycin and ceftriaxone for empiric therapy but does not specify the timing related to lumbar puncture."", ""reference"": ""PMID:30496558"", ""snippet"": ""The use of empiric vancomycin plus a third-generation cephalosporin for suspected bacterial meningitis has been recommended since 1997."", ""supports"": ""PARTIAL""}"
1257	958	39	Bacterial meningitis	Bacterial_meningitis.yaml	treatments	0	evidence	2	PMID:20109674	NO_EVIDENCE		Empiric antimicrobial and adjunctive therapy should be initiated as soon as a single set of blood cultures has been obtained.	This reference emphasizes the initiation of empiric therapy after obtaining blood cultures, not specifically after lumbar puncture.	"{""explanation"": ""This reference emphasizes the initiation of empiric therapy after obtaining blood cultures, not specifically after lumbar puncture."", ""reference"": ""PMID:20109674"", ""snippet"": ""Empiric antimicrobial and adjunctive therapy should be initiated as soon as a single set of blood cultures has been obtained."", ""supports"": ""NO_EVIDENCE""}"
1258	958	39	Bacterial meningitis	Bacterial_meningitis.yaml	treatments	0	evidence	3	PMID:25822235	PARTIAL		Empiric therapy was ampicillin and gentamicin (n = 116, 44%) or third-generation cephalosporin based (n = 149, 56%).	This reference supports the use of empiric antibiotics but does not specify the timing relative to lumbar puncture.	"{""explanation"": ""This reference supports the use of empiric antibiotics but does not specify the timing relative to lumbar puncture."", ""reference"": ""PMID:25822235"", ""snippet"": ""Empiric therapy was ampicillin and gentamicin (n = 116, 44%) or third-generation cephalosporin based (n = 149, 56%)."", ""supports"": ""PARTIAL""}"
1259	959	39	Bacterial meningitis	Bacterial_meningitis.yaml	treatments	1	evidence	0	PMID:24073921	SUPPORT		Outcome critically depends on the rapid initiation of effective antibiotic therapy.	The reference emphasizes the importance of initiating effective antibiotic therapy, which aligns with the concept of tailoring antibiotics to the specific pathogen once identified.	"{""explanation"": ""The reference emphasizes the importance of initiating effective antibiotic therapy, which aligns with the concept of tailoring antibiotics to the specific pathogen once identified."", ""reference"": ""PMID:24073921"", ""snippet"": ""Outcome critically depends on the rapid initiation of effective antibiotic therapy."", ""supports"": ""SUPPORT""}"
1260	959	39	Bacterial meningitis	Bacterial_meningitis.yaml	treatments	1	evidence	1	PMID:30468130	SUPPORT		Results of this study provide valuable information about the antibiotic resistance profiles of the etiologic agents of childhood meningitis, which can be used for prescription of more effective empirical therapies.	The study discusses the importance of understanding antibiotic resistance profiles to prescribe more effective therapies, supporting the concept of targeted antibiotic therapy.	"{""explanation"": ""The study discusses the importance of understanding antibiotic resistance profiles to prescribe more effective therapies, supporting the concept of targeted antibiotic therapy."", ""reference"": ""PMID:30468130"", ""snippet"": ""Results of this study provide valuable information about the antibiotic resistance profiles of the etiologic agents of childhood meningitis, which can be used for prescription of more effective empirical therapies."", ""supports"": ""SUPPORT""}"
1261	959	39	Bacterial meningitis	Bacterial_meningitis.yaml	treatments	1	evidence	2	PMID:15301673	SUPPORT		Ceftriaxone plus penicillin as empirical treatment was appropriate in 97% of ABM cases in the study population.	This reference supports the use of specific antibiotics tailored to the pathogen identified, which is a form of targeted antibiotic therapy.	"{""explanation"": ""This reference supports the use of specific antibiotics tailored to the pathogen identified, which is a form of targeted antibiotic therapy."", ""reference"": ""PMID:15301673"", ""snippet"": ""Ceftriaxone plus penicillin as empirical treatment was appropriate in 97% of ABM cases in the study population."", ""supports"": ""SUPPORT""}"
1262	960	39	Bacterial meningitis	Bacterial_meningitis.yaml	treatments	2	evidence	0	PMID:10830026	PARTIAL		Dexamethasone has been used in a number of clinical trials to moderate the host response and to improve neurologic outcome of meningitis. Results of six randomized, placebo controlled trials are summarized in this review. Dexamethasone treatment did not lower mortality. Only a moderate, but not a significant reduction in the neurologic and audiologic sequelae was seen in dexamethasone recipients when Haemophilus influenzae type b (Hib) was the causative agent of meningitis. ... Presently, there is little or no evidence showing a benefit of dexamethasone therapy in meningitis caused by S. pneumoniae or N. meningitidis.	The statement is partially supported because dexamethasone is used to reduce inflammation in bacterial meningitis, but there is limited evidence of its benefit in reducing complications, particularly for pneumococcal meningitis.	"{""explanation"": ""The statement is partially supported because dexamethasone is used to reduce inflammation in bacterial meningitis, but there is limited evidence of its benefit in reducing complications, particularly for pneumococcal meningitis."", ""reference"": ""PMID:10830026"", ""snippet"": ""Dexamethasone has been used in a number of clinical trials to moderate the host response and to improve neurologic outcome of meningitis. Results of six randomized, placebo controlled trials are summarized in this review. Dexamethasone treatment did not lower mortality. Only a moderate, but not a significant reduction in the neurologic and audiologic sequelae was seen in dexamethasone recipients when Haemophilus influenzae type b (Hib) was the causative agent of meningitis. ... Presently, there is little or no evidence showing a benefit of dexamethasone therapy in meningitis caused by S. pneumoniae or N. meningitidis."", ""supports"": ""PARTIAL""}"
1263	960	39	Bacterial meningitis	Bacterial_meningitis.yaml	treatments	2	evidence	1	PMID:31668194	SUPPORT		Steroids are mandatory in pneumococcal meningitis but not indicated in pneumococcal pneumonia except in the setting of refractory shock.	This reference supports the use of corticosteroids, specifically dexamethasone, in reducing inflammation and complications in pneumococcal meningitis.	"{""explanation"": ""This reference supports the use of corticosteroids, specifically dexamethasone, in reducing inflammation and complications in pneumococcal meningitis."", ""reference"": ""PMID:31668194"", ""snippet"": ""Steroids are mandatory in pneumococcal meningitis but not indicated in pneumococcal pneumonia except in the setting of refractory shock."", ""supports"": ""SUPPORT""}"
1264	960	39	Bacterial meningitis	Bacterial_meningitis.yaml	treatments	2	evidence	2	PMID:33330135	SUPPORT		Steroid therapy is beneficial and supported in pathogens such as pneumococcal meningitis and tuberculosis.	This reference supports the use of corticosteroids in pneumococcal meningitis to reduce inflammation and complications.	"{""explanation"": ""This reference supports the use of corticosteroids in pneumococcal meningitis to reduce inflammation and complications."", ""reference"": ""PMID:33330135"", ""snippet"": ""Steroid therapy is beneficial and supported in pathogens such as pneumococcal meningitis and tuberculosis."", ""supports"": ""SUPPORT""}"
1265	961	39	Bacterial meningitis	Bacterial_meningitis.yaml	treatments	3	evidence	0	PMID:8196986	SUPPORT		Fluid administration in children with meningitis should be conservative in an attempt to minimize cerebral edema and electrolyte disturbances that frequently complicate the course of meningitis.	This reference supports the aspect of fluid and electrolyte management as part of supportive care in bacterial meningitis.	"{""explanation"": ""This reference supports the aspect of fluid and electrolyte management as part of supportive care in bacterial meningitis."", ""reference"": ""PMID:8196986"", ""snippet"": ""Fluid administration in children with meningitis should be conservative in an attempt to minimize cerebral edema and electrolyte disturbances that frequently complicate the course of meningitis."", ""supports"": ""SUPPORT""}"
1266	961	39	Bacterial meningitis	Bacterial_meningitis.yaml	treatments	3	evidence	1	PMID:16034949	SUPPORT		Careful management of fluid and electrolyte balance is an important supportive therapy. Both over and under hydration are associated with adverse outcomes.	This reference supports the importance of fluid and electrolyte management in the supportive care of bacterial meningitis.	"{""explanation"": ""This reference supports the importance of fluid and electrolyte management in the supportive care of bacterial meningitis."", ""reference"": ""PMID:16034949"", ""snippet"": ""Careful management of fluid and electrolyte balance is an important supportive therapy. Both over and under hydration are associated with adverse outcomes."", ""supports"": ""SUPPORT""}"
1267	961	39	Bacterial meningitis	Bacterial_meningitis.yaml	treatments	3	evidence	2	PMID:29889417	SUPPORT		Control of intracranial pressure (ICP) as well as a good hemodynamic is based on a continuous monitoring of ICP and arterial pressure in order to assure an adapted cerebral perfusion pressure.	This reference supports the monitoring of intracranial pressure as part of the supportive care in bacterial meningitis.	"{""explanation"": ""This reference supports the monitoring of intracranial pressure as part of the supportive care in bacterial meningitis."", ""reference"": ""PMID:29889417"", ""snippet"": ""Control of intracranial pressure (ICP) as well as a good hemodynamic is based on a continuous monitoring of ICP and arterial pressure in order to assure an adapted cerebral perfusion pressure."", ""supports"": ""SUPPORT""}"
1268	961	39	Bacterial meningitis	Bacterial_meningitis.yaml	treatments	3	evidence	3	PMID:29088943	SUPPORT		Although intracranial hypertension and subsequent death have long been known to complicate meningitis, no specific guidelines targeting ICP monitoring are available.	This reference acknowledges the role of intracranial pressure monitoring in the context of bacterial meningitis, thus supporting its inclusion in supportive care.	"{""explanation"": ""This reference acknowledges the role of intracranial pressure monitoring in the context of bacterial meningitis, thus supporting its inclusion in supportive care."", ""reference"": ""PMID:29088943"", ""snippet"": ""Although intracranial hypertension and subsequent death have long been known to complicate meningitis, no specific guidelines targeting ICP monitoring are available."", ""supports"": ""SUPPORT""}"
1269	961	39	Bacterial meningitis	Bacterial_meningitis.yaml	treatments	3	evidence	4	PMID:29889417	SUPPORT		Seizures should be avoided, the sedation-pain control optimized and ventilation adapted to assure normal oxygenation and normal CO levels.	This reference supports the aspect of seizure control as part of supportive care in bacterial meningitis.	"{""explanation"": ""This reference supports the aspect of seizure control as part of supportive care in bacterial meningitis."", ""reference"": ""PMID:29889417"", ""snippet"": ""Seizures should be avoided, the sedation-pain control optimized and ventilation adapted to assure normal oxygenation and normal CO levels."", ""supports"": ""SUPPORT""}"
1270	962	39	Bacterial meningitis	Bacterial_meningitis.yaml	treatments	4	evidence	0	PMID:15802609	SUPPORT		Effective routine immunization against Hib, pneumococcus and serogroupC meningococcus has had a significant impact on both invasive disease and carriage caused by these encapsulated bacteria.	This reference confirms that vaccines are available for the prevention of meningococcal, pneumococcal, and Hib meningitis.	"{""explanation"": ""This reference confirms that vaccines are available for the prevention of meningococcal, pneumococcal, and Hib meningitis."", ""reference"": ""PMID:15802609"", ""snippet"": ""Effective routine immunization against Hib, pneumococcus and serogroupC meningococcus has had a significant impact on both invasive disease and carriage caused by these encapsulated bacteria."", ""supports"": ""SUPPORT""}"
1271	962	39	Bacterial meningitis	Bacterial_meningitis.yaml	treatments	4	evidence	1	PMID:26904695	SUPPORT		The Hib conjugate vaccine is considered protective and safe.	This reference supports the availability and effectiveness of the Hib vaccine.	"{""explanation"": ""This reference supports the availability and effectiveness of the Hib vaccine."", ""reference"": ""PMID:26904695"", ""snippet"": ""The Hib conjugate vaccine is considered protective and safe."", ""supports"": ""SUPPORT""}"
1272	962	39	Bacterial meningitis	Bacterial_meningitis.yaml	treatments	4	evidence	2	PMID:10470562	SUPPORT		A comprehensive review of all major agents causing bacterial meningitis--meningococcus of the groups A, B, C, W135, and Y, pneumococcus, and Haemophilus influenzae type B (Hib)--is done in terms of preventing them by chemoprophylaxis or vaccination.	This reference supports the availability of vaccines for meningococcal, pneumococcal, and Hib meningitis.	"{""explanation"": ""This reference supports the availability of vaccines for meningococcal, pneumococcal, and Hib meningitis."", ""reference"": ""PMID:10470562"", ""snippet"": ""A comprehensive review of all major agents causing bacterial meningitis--meningococcus of the groups A, B, C, W135, and Y, pneumococcus, and Haemophilus influenzae type B (Hib)--is done in terms of preventing them by chemoprophylaxis or vaccination."", ""supports"": ""SUPPORT""}"
1273	962	39	Bacterial meningitis	Bacterial_meningitis.yaml	treatments	4	evidence	3	PMID:20407316	SUPPORT		The leading causes of bacterial meningitis and pneumonia in children, Haemophilus influenzae type b (Hib) and Streptococcus pneumoniae, are vaccine preventable.	This reference supports the availability of vaccines for Hib and pneumococcal meningitis.	"{""explanation"": ""This reference supports the availability of vaccines for Hib and pneumococcal meningitis."", ""reference"": ""PMID:20407316"", ""snippet"": ""The leading causes of bacterial meningitis and pneumonia in children, Haemophilus influenzae type b (Hib) and Streptococcus pneumoniae, are vaccine preventable."", ""supports"": ""SUPPORT""}"
1274	962	39	Bacterial meningitis	Bacterial_meningitis.yaml	treatments	4	evidence	4	PMID:22906940	SUPPORT		The meningococcal conjugate vaccines (MCV) are preferred for reasons of immunogenicity and persistence of immunity.	This reference supports the availability of vaccines for meningococcal meningitis.	"{""explanation"": ""This reference supports the availability of vaccines for meningococcal meningitis."", ""reference"": ""PMID:22906940"", ""snippet"": ""The meningococcal conjugate vaccines (MCV) are preferred for reasons of immunogenicity and persistence of immunity."", ""supports"": ""SUPPORT""}"
1358	996	40	Bardet-Biedl Syndrome	Bardet-Biedl_Syndrome.yaml	treatments	0	evidence	0	PMID:15852167	SUPPORT		Based on the history, presentation, ophthalmic clinical examination, obesity, mental retardation and dental alterations, the patient was diagnosed with Bardet-Biedl syndrome.	The case report discusses the management of symptoms like vision loss and obesity, which aligns with supportive therapy addressing specific symptoms.	"{""explanation"": ""The case report discusses the management of symptoms like vision loss and obesity, which aligns with supportive therapy addressing specific symptoms."", ""reference"": ""PMID:15852167"", ""snippet"": ""Based on the history, presentation, ophthalmic clinical examination, obesity, mental retardation and dental alterations, the patient was diagnosed with Bardet-Biedl syndrome."", ""supports"": ""SUPPORT""}"
1359	996	40	Bardet-Biedl Syndrome	Bardet-Biedl_Syndrome.yaml	treatments	0	evidence	1	PMID:29754569	SUPPORT		Advances in the understanding of ciliary biology and diagnostic techniques have opened up the prospect of treating BBS in a patient-specific manner.	The article mentions ongoing research in personalized medicine for BBS, focusing on treatments addressing specific symptoms, which supports the idea of supportive therapy.	"{""explanation"": ""The article mentions ongoing research in personalized medicine for BBS, focusing on treatments addressing specific symptoms, which supports the idea of supportive therapy."", ""reference"": ""PMID:29754569"", ""snippet"": ""Advances in the understanding of ciliary biology and diagnostic techniques have opened up the prospect of treating BBS in a patient-specific manner."", ""supports"": ""SUPPORT""}"
1360	996	40	Bardet-Biedl Syndrome	Bardet-Biedl_Syndrome.yaml	treatments	0	evidence	2	PMID:36647077	SUPPORT		This study highlights the need to address the impaired health-related quality of life in Bardet-Biedl syndrome, and supports utility of setmelanotide for reducing this burden.	The study discusses treatments impacting quality of life related to obesity, which is part of supportive therapy.	"{""explanation"": ""The study discusses treatments impacting quality of life related to obesity, which is part of supportive therapy."", ""reference"": ""PMID:36647077"", ""snippet"": ""This study highlights the need to address the impaired health-related quality of life in Bardet-Biedl syndrome, and supports utility of setmelanotide for reducing this burden."", ""supports"": ""SUPPORT""}"
1361	996	40	Bardet-Biedl Syndrome	Bardet-Biedl_Syndrome.yaml	treatments	0	evidence	3	PMID:36700052	SUPPORT		We show that subretinal gene therapy slowed photoreceptor cell death and preserved retinal function in treated eyes. Notably, cone photoreceptors regained their electrical function after gene augmentation.	The article reports on gene therapy to manage vision loss in BBS, which fits under supportive treatment focusing on specific symptoms like vision support.	"{""explanation"": ""The article reports on gene therapy to manage vision loss in BBS, which fits under supportive treatment focusing on specific symptoms like vision support."", ""reference"": ""PMID:36700052"", ""snippet"": ""We show that subretinal gene therapy slowed photoreceptor cell death and preserved retinal function in treated eyes. Notably, cone photoreceptors regained their electrical function after gene augmentation."", ""supports"": ""SUPPORT""}"
1362	996	40	Bardet-Biedl Syndrome	Bardet-Biedl_Syndrome.yaml	treatments	0	evidence	4	PMID:27245600	SUPPORT		Renal transplantation is indicated in cases of end-stage renal disease (ESRD), but transplant centers may be hesitant to perform the necessary transplant in light of the multitude of metabolic comorbidities these patients often face with the potential to complicate outcomes.	The study supports the notion of addressing specific symptoms such as renal disease, fitting within supportive therapy for BBS.	"{""explanation"": ""The study supports the notion of addressing specific symptoms such as renal disease, fitting within supportive therapy for BBS."", ""reference"": ""PMID:27245600"", ""snippet"": ""Renal transplantation is indicated in cases of end-stage renal disease (ESRD), but transplant centers may be hesitant to perform the necessary transplant in light of the multitude of metabolic comorbidities these patients often face with the potential to complicate outcomes."", ""supports"": ""SUPPORT""}"
1363	997	40	Bardet-Biedl Syndrome	Bardet-Biedl_Syndrome.yaml	treatments	1	evidence	0	PMID:20301537	SUPPORT		Provide an evaluation strategy to identify the genetic cause of Bardet-Biedl syndrome in a proband (when possible); 4.	The overview highlights the importance of genetic counseling for identifying the genetic cause of the syndrome, supporting its role as a treatment component.	"{""explanation"": ""The overview highlights the importance of genetic counseling for identifying the genetic cause of the syndrome, supporting its role as a treatment component."", ""reference"": ""PMID:20301537"", ""snippet"": ""Provide an evaluation strategy to identify the genetic cause of Bardet-Biedl syndrome in a proband (when possible); 4."", ""supports"": ""SUPPORT""}"
1364	999	40	Bardet-Biedl Syndrome	Bardet-Biedl_Syndrome.yaml	treatments	3	evidence	0	PMID:38302651	SUPPORT		We review current approaches to the metabolic management of patients with BBS, including the use of weight loss medications and bariatric surgery.	Bardet-Biedl Syndrome (BBS) metabolic management mentions both dietary and lifestyle approaches, which include weight loss strategies.	"{""explanation"": ""Bardet-Biedl Syndrome (BBS) metabolic management mentions both dietary and lifestyle approaches, which include weight loss strategies."", ""reference"": ""PMID:38302651"", ""snippet"": ""We review current approaches to the metabolic management of patients with BBS, including the use of weight loss medications and bariatric surgery."", ""supports"": ""SUPPORT""}"
1365	999	40	Bardet-Biedl Syndrome	Bardet-Biedl_Syndrome.yaml	treatments	3	evidence	1	PMID:27356116	SUPPORT		Comprehensive lifestyle interventions, including nutrition, physical activity, and behavioral therapy, are the foundation for clinical obesity management.	Although not specific to BBS, this reference supports the use of lifestyle modifications for managing obesity.	"{""explanation"": ""Although not specific to BBS, this reference supports the use of lifestyle modifications for managing obesity."", ""reference"": ""PMID:27356116"", ""snippet"": ""Comprehensive lifestyle interventions, including nutrition, physical activity, and behavioral therapy, are the foundation for clinical obesity management."", ""supports"": ""SUPPORT""}"
1366	999	40	Bardet-Biedl Syndrome	Bardet-Biedl_Syndrome.yaml	treatments	3	evidence	2	PMID:36647077	SUPPORT		Bardet-Biedl syndrome is a rare genetic disease associated with hyperphagia and early-onset, severe obesity...patients reported clinically meaningful improvements across multiple health-related quality of life measures.	This study involving BBS patients includes dietary and lifestyle modifications as part of the treatment to manage obesity.	"{""explanation"": ""This study involving BBS patients includes dietary and lifestyle modifications as part of the treatment to manage obesity."", ""reference"": ""PMID:36647077"", ""snippet"": ""Bardet-Biedl syndrome is a rare genetic disease associated with hyperphagia and early-onset, severe obesity...patients reported clinically meaningful improvements across multiple health-related quality of life measures."", ""supports"": ""SUPPORT""}"
1367	999	40	Bardet-Biedl Syndrome	Bardet-Biedl_Syndrome.yaml	treatments	3	evidence	3	PMID:37919024	SUPPORT		Similar to the general population, lifestyle interventions focused on nutrition and physical activity form the foundation for treating obesity caused by rare genetic disorders.	Supports lifestyle interventions as foundational treatments for obesity in syndromic conditions like BBS.	"{""explanation"": ""Supports lifestyle interventions as foundational treatments for obesity in syndromic conditions like BBS."", ""reference"": ""PMID:37919024"", ""snippet"": ""Similar to the general population, lifestyle interventions focused on nutrition and physical activity form the foundation for treating obesity caused by rare genetic disorders."", ""supports"": ""SUPPORT""}"
1368	1000	40	Bardet-Biedl Syndrome	Bardet-Biedl_Syndrome.yaml	treatments	4	evidence	0	PMID:36700052	SUPPORT		We show that subretinal gene therapy slowed photoreceptor cell death and preserved retinal function in treated eyes. Notably, cone photoreceptors regained their electrical function after gene augmentation.	The article reports on gene therapy to manage vision loss in BBS, showing promising results in preserving retinal function.	"{""explanation"": ""The article reports on gene therapy to manage vision loss in BBS, showing promising results in preserving retinal function."", ""reference"": ""PMID:36700052"", ""snippet"": ""We show that subretinal gene therapy slowed photoreceptor cell death and preserved retinal function in treated eyes. Notably, cone photoreceptors regained their electrical function after gene augmentation."", ""supports"": ""SUPPORT""}"
1380	1044	43	Bejel	Bejel.yaml	treatments	0	evidence	0	PMID:16615610	SUPPORT		Although penicillin therapy is effective, these infectious diseases have yet to be eliminated.	The abstract notes penicillin therapy is effective for endemic treponematoses.	"{""explanation"": ""The abstract notes penicillin therapy is effective for endemic treponematoses."", ""reference"": ""PMID:16615610"", ""snippet"": ""Although penicillin therapy is effective, these infectious diseases have yet to be eliminated."", ""supports"": ""SUPPORT""}"
1393	1078	44	Benign Prostatic Hyperplasia	Benign_Prostatic_Hyperplasia.yaml	treatments	7	evidence	0	PMID:39455522	SUPPORT		At the in vivo level, Y-27632 reversed prostatic hyperplasia and fibrosis in BPH model rats to some extent.	This evidence demonstrates therapeutic potential of ROCK inhibition in reversing BPH pathology in animal models.	"{""explanation"": ""This evidence demonstrates therapeutic potential of ROCK inhibition in reversing BPH pathology in animal models."", ""reference"": ""PMID:39455522"", ""snippet"": ""At the in vivo level, Y-27632 reversed prostatic hyperplasia and fibrosis in BPH model rats to some extent."", ""supports"": ""SUPPORT""}"
1394	1078	44	Benign Prostatic Hyperplasia	Benign_Prostatic_Hyperplasia.yaml	treatments	7	evidence	1	PMID:38711089	SUPPORT		Inhibition of ROCK1 activation suppressed MSC migration and their potential for stromal differentiation.	This evidence shows ROCK1 inhibition (GSK269962A) prevents stromal hyperplasia by blocking MSC recruitment and differentiation.	"{""explanation"": ""This evidence shows ROCK1 inhibition (GSK269962A) prevents stromal hyperplasia by blocking MSC recruitment and differentiation."", ""reference"": ""PMID:38711089"", ""snippet"": ""Inhibition of ROCK1 activation suppressed MSC migration and their potential for stromal differentiation."", ""supports"": ""SUPPORT""}"
1395	1079	44	Benign Prostatic Hyperplasia	Benign_Prostatic_Hyperplasia.yaml	treatments	8	evidence	0	PMID:37827216	SUPPORT		In human BPH-1 epithelial cells, ATT decreased mitochondrial metabolism, cell proliferation, and stemness features.	This evidence demonstrates antioxidant therapy can reduce key pathogenic features of BPH epithelial cells.	"{""explanation"": ""This evidence demonstrates antioxidant therapy can reduce key pathogenic features of BPH epithelial cells."", ""reference"": ""PMID:37827216"", ""snippet"": ""In human BPH-1 epithelial cells, ATT decreased mitochondrial metabolism, cell proliferation, and stemness features."", ""supports"": ""SUPPORT""}"
1411	1114	46	Bipolar Disorder	Bipolar_Disorder.yaml	treatments	0	evidence	0	PMID:22363263	SUPPORT		Lithium has been reported to reduce suicide rates and prevent manic episodes in individuals with bipolar disorder, major depression, or schizoaffective disorders	Lithium is the gold standard mood stabilizer for bipolar disorder with demonstrated efficacy in preventing manic episodes and reducing suicide risk through GSK3 inhibition.	"{""explanation"": ""Lithium is the gold standard mood stabilizer for bipolar disorder with demonstrated efficacy in preventing manic episodes and reducing suicide risk through GSK3 inhibition."", ""reference"": ""PMID:22363263"", ""snippet"": ""Lithium has been reported to reduce suicide rates and prevent manic episodes in individuals with bipolar disorder, major depression, or schizoaffective disorders"", ""supports"": ""SUPPORT""}"
1412	1114	46	Bipolar Disorder	Bipolar_Disorder.yaml	treatments	0	evidence	1	PMID:22363263	SUPPORT		In 1996, two independent studies (Klein and Melton, 1996; Stambolic et al., 1996) of the effects of lithium on cell signaling and development have identified a direct effect of lithium on the activity of GSK3 both in vitro and in cells.	Lithium's therapeutic mechanism involves direct inhibition of GSK3 and indirect effects through the Akt/beta-arrestin pathway, providing molecular basis for its mood-stabilizing effects.	"{""explanation"": ""Lithium's therapeutic mechanism involves direct inhibition of GSK3 and indirect effects through the Akt/beta-arrestin pathway, providing molecular basis for its mood-stabilizing effects."", ""reference"": ""PMID:22363263"", ""snippet"": ""In 1996, two independent studies (Klein and Melton, 1996; Stambolic et al., 1996) of the effects of lithium on cell signaling and development have identified a direct effect of lithium on the activity of GSK3 both in vitro and in cells."", ""supports"": ""SUPPORT""}"
1475	1167	47	Bird Fancier's Lung	Bird_Fanciers_Lung.yaml	treatments	0	evidence	0	clinicaltrials:NCT02496182	SUPPORT	HUMAN_CLINICAL	Actually HP has been treated with Prednisone and occasionally with Azathioprine, but unfortunately the treatment with these drugs have not an effective result to treat the interstitial fibrosis.	The trial summary notes existing use of prednisone and azathioprine in chronic hypersensitivity pneumonitis.	"{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""The trial summary notes existing use of prednisone and azathioprine in chronic hypersensitivity pneumonitis."", ""reference"": ""clinicaltrials:NCT02496182"", ""snippet"": ""Actually HP has been treated with Prednisone and occasionally with Azathioprine, but unfortunately the treatment with these drugs have not an effective result to treat the interstitial fibrosis."", ""supports"": ""SUPPORT""}"
1476	1167	47	Bird Fancier's Lung	Bird_Fanciers_Lung.yaml	treatments	0	evidence	1	PMID:39958101	SUPPORT	HUMAN_CLINICAL	The patient was diagnosed with BFL and treated with a tapering regimen of oral corticosteroids, starting at 40mg/day.	The case report documents corticosteroid treatment for BFL.	"{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""The case report documents corticosteroid treatment for BFL."", ""reference"": ""PMID:39958101"", ""snippet"": ""The patient was diagnosed with BFL and treated with a tapering regimen of oral corticosteroids, starting at 40mg/day."", ""supports"": ""SUPPORT""}"
1477	1168	47	Bird Fancier's Lung	Bird_Fanciers_Lung.yaml	treatments	1	evidence	0	PMID:27816444	SUPPORT	HUMAN_CLINICAL	We aimed to determine the effect of treatment with mycophenolate mofetil (MMF) or azathioprine (AZA) on lung function in patients with cHP.	The study explicitly evaluates MMF and azathioprine therapy in chronic hypersensitivity pneumonitis.	"{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""The study explicitly evaluates MMF and azathioprine therapy in chronic hypersensitivity pneumonitis."", ""reference"": ""PMID:27816444"", ""snippet"": ""We aimed to determine the effect of treatment with mycophenolate mofetil (MMF) or azathioprine (AZA) on lung function in patients with cHP."", ""supports"": ""SUPPORT""}"
1478	1169	47	Bird Fancier's Lung	Bird_Fanciers_Lung.yaml	treatments	2	evidence	0	PMID:37028940	SUPPORT	HUMAN_CLINICAL	Pirfenidone was found to be safe and improved PFS in patients with FHP.	The randomized trial reports improved progression-free survival with pirfenidone in fibrotic hypersensitivity pneumonitis.	"{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""The randomized trial reports improved progression-free survival with pirfenidone in fibrotic hypersensitivity pneumonitis."", ""reference"": ""PMID:37028940"", ""snippet"": ""Pirfenidone was found to be safe and improved PFS in patients with FHP."", ""supports"": ""SUPPORT""}"
1479	1169	47	Bird Fancier's Lung	Bird_Fanciers_Lung.yaml	treatments	2	evidence	1	clinicaltrials:NCT02958917	SUPPORT	HUMAN_CLINICAL	The use of pirfenidone has not been approved for the treatment of FHP. It is considered experimental treatment in this study.	The trial registry specifies pirfenidone as the studied treatment in fibrotic hypersensitivity pneumonitis.	"{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""The trial registry specifies pirfenidone as the studied treatment in fibrotic hypersensitivity pneumonitis."", ""reference"": ""clinicaltrials:NCT02958917"", ""snippet"": ""The use of pirfenidone has not been approved for the treatment of FHP. It is considered experimental treatment in this study."", ""supports"": ""SUPPORT""}"
1480	1170	47	Bird Fancier's Lung	Bird_Fanciers_Lung.yaml	treatments	3	evidence	0	PMID:32145830	SUPPORT	HUMAN_CLINICAL	The effect of nintedanib versus placebo on reducing the rate of FVC decline (mL/year) was consistent across the five subgroups by ILD diagnosis	The INBUILD subgroup analysis supports nintedanib for progressive fibrosing ILD, including the hypersensitivity pneumonitis subgroup.	"{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""The INBUILD subgroup analysis supports nintedanib for progressive fibrosing ILD, including the hypersensitivity pneumonitis subgroup."", ""reference"": ""PMID:32145830"", ""snippet"": ""The effect of nintedanib versus placebo on reducing the rate of FVC decline (mL/year) was consistent across the five subgroups by ILD diagnosis"", ""supports"": ""SUPPORT""}"
1484	1174	48	Botulism	Botulism.yaml	treatments	0	evidence	0	PMID:31157190	SUPPORT		The only specific treatment is botulinum antitoxin.	The abstract identifies botulinum antitoxin as the specific treatment.	"{""explanation"": ""The abstract identifies botulinum antitoxin as the specific treatment."", ""reference"": ""PMID:31157190"", ""snippet"": ""The only specific treatment is botulinum antitoxin."", ""supports"": ""SUPPORT""}"
1488	1178	49	Breast Fibroadenoma	Breast_Fibroadenoma.yaml	treatments	0	evidence	0	PMID:11270760	SUPPORT		Traditionally, symptomatic fibroadenomas were treated by surgical excision, and this option should always be offered.	The abstract states surgical excision as a traditional treatment option.	"{""explanation"": ""The abstract states surgical excision as a traditional treatment option."", ""reference"": ""PMID:11270760"", ""snippet"": ""Traditionally, symptomatic fibroadenomas were treated by surgical excision, and this option should always be offered."", ""supports"": ""SUPPORT""}"
1489	1179	49	Breast Fibroadenoma	Breast_Fibroadenoma.yaml	treatments	1	evidence	0	PMID:11270760	SUPPORT		There is increasing evidence that a conservative approach is safe and acceptable, provided the result of an adequate triple test is both negative for cancer and consistent with a fibroadenoma.	The abstract supports conservative management in appropriate cases.	"{""explanation"": ""The abstract supports conservative management in appropriate cases."", ""reference"": ""PMID:11270760"", ""snippet"": ""There is increasing evidence that a conservative approach is safe and acceptable, provided the result of an adequate triple test is both negative for cancer and consistent with a fibroadenoma."", ""supports"": ""SUPPORT""}"
1497	1243	52	Buruli ulcer	Buruli_Ulcer.yaml	treatments	0	evidence	0	PMID:21240839	SUPPORT		While antimycobacterial therapy is often effective for the earliest nodular or ulcerative lesions	The abstract describes antimycobacterial therapy effectiveness in early lesions.	"{""explanation"": ""The abstract describes antimycobacterial therapy effectiveness in early lesions."", ""reference"": ""PMID:21240839"", ""snippet"": ""While antimycobacterial therapy is often effective for the earliest nodular or ulcerative lesions"", ""supports"": ""SUPPORT""}"
1498	1244	52	Buruli ulcer	Buruli_Ulcer.yaml	treatments	1	evidence	0	PMID:21240839	SUPPORT		for advanced ulcerated lesions, surgery is sometimes necessary.	The abstract notes surgery for advanced lesions.	"{""explanation"": ""The abstract notes surgery for advanced lesions."", ""reference"": ""PMID:21240839"", ""snippet"": ""for advanced ulcerated lesions, surgery is sometimes necessary."", ""supports"": ""SUPPORT""}"
1514	1262	53	CHIME_syndrome	CHIME_syndrome.yaml	treatments	3	evidence	0	PMID:38773877	SUPPORT		Here, we report a case of severe ichthyosiform dermatosis in a child with CHIME syndrome who was recalcitrant to multiple topical medications and dupilumab. This is the first reported case of successful treatment of congenital ichthyosiform dermatosis in a CHIME syndrome patient with ixekizumab, an IL-17A antagonist.	Flowers et al. 2024 documents the first successful treatment of severe ichthyosiform dermatosis in CHIME syndrome using ixekizumab (IL-17A antagonist), providing a therapeutic option for treatment-resistant cases.	"{""explanation"": ""Flowers et al. 2024 documents the first successful treatment of severe ichthyosiform dermatosis in CHIME syndrome using ixekizumab (IL-17A antagonist), providing a therapeutic option for treatment-resistant cases."", ""reference"": ""PMID:38773877"", ""snippet"": ""Here, we report a case of severe ichthyosiform dermatosis in a child with CHIME syndrome who was recalcitrant to multiple topical medications and dupilumab. This is the first reported case of successful treatment of congenital ichthyosiform dermatosis in a CHIME syndrome patient with ixekizumab, an IL-17A antagonist."", ""supports"": ""SUPPORT""}"
1545	1309	55	Camptodactyly	Camptodactyly.yaml	treatments	0	evidence	0	PMID:30897950	SUPPORT		treatment of camptodactyly with operative or nonoperative measures reduces the degree of flexion contracture in most patients (from pretreatment averages of 20-85 to posttreatment averages of 5-37)	Systematic review demonstrates that conservative treatment reduces flexion contracture in camptodactyly patients.	"{""explanation"": ""Systematic review demonstrates that conservative treatment reduces flexion contracture in camptodactyly patients."", ""reference"": ""PMID:30897950"", ""snippet"": ""treatment of camptodactyly with operative or nonoperative measures reduces the degree of flexion contracture in most patients (from pretreatment averages of 20-85 to posttreatment averages of 5-37)"", ""supports"": ""SUPPORT""}"
1546	1310	55	Camptodactyly	Camptodactyly.yaml	treatments	1	evidence	0	PMID:3693837	SUPPORT		Most of the patients could extend the proximal interphalangeal (PIP) joints within a few months by using the dynamic splint 24 hours a day. After almost full extension of the proximal interphalangeal joint was achieved, splinting for 8 hours a day produced good final results.	Documents effectiveness of dynamic splinting for camptodactyly treatment.	"{""explanation"": ""Documents effectiveness of dynamic splinting for camptodactyly treatment."", ""reference"": ""PMID:3693837"", ""snippet"": ""Most of the patients could extend the proximal interphalangeal (PIP) joints within a few months by using the dynamic splint 24 hours a day. After almost full extension of the proximal interphalangeal joint was achieved, splinting for 8 hours a day produced good final results."", ""supports"": ""SUPPORT""}"
1547	1311	55	Camptodactyly	Camptodactyly.yaml	treatments	2	evidence	0	PMID:30897950	SUPPORT		There was general agreement that surgery should be reserved for contracture >30 or failure to respond to conservative management. Surgery generally led to more complications compared with conservative management.	Systematic review confirms surgery is reserved for severe contractures over 30 degrees or when conservative treatment fails.	"{""explanation"": ""Systematic review confirms surgery is reserved for severe contractures over 30 degrees or when conservative treatment fails."", ""reference"": ""PMID:30897950"", ""snippet"": ""There was general agreement that surgery should be reserved for contracture >30 or failure to respond to conservative management. Surgery generally led to more complications compared with conservative management."", ""supports"": ""SUPPORT""}"
1554	1332	56	Cardiofaciocutaneous Syndrome	Cardiofaciocutaneous_Syndrome.yaml	treatments	2	evidence	0	PMID:38136934	SUPPORT	MODEL_ORGANISM	Encouraging zebrafish model system studies suggested that, in the future, MEK inhibitors could be a suitable treatment of progressive phenotypes of CFC in children.	Review summarizing preclinical evidence supporting MEK inhibitor therapy for CFC syndrome based on zebrafish model studies.	"{""evidence_source"": ""MODEL_ORGANISM"", ""explanation"": ""Review summarizing preclinical evidence supporting MEK inhibitor therapy for CFC syndrome based on zebrafish model studies."", ""reference"": ""PMID:38136934"", ""snippet"": ""Encouraging zebrafish model system studies suggested that, in the future, MEK inhibitors could be a suitable treatment of progressive phenotypes of CFC in children."", ""supports"": ""SUPPORT""}"
1574	1389	59	Chagas disease	Chagas_Disease.yaml	treatments	0	evidence	0	PMID:30111183	SUPPORT		Currently, only benznidazole (BZN) and nifurtimox are recognized by the World Health Organization as effective drugs for treatment of CD.	The review lists benznidazole and nifurtimox as WHO-recognized therapies.	"{""explanation"": ""The review lists benznidazole and nifurtimox as WHO-recognized therapies."", ""reference"": ""PMID:30111183"", ""snippet"": ""Currently, only benznidazole (BZN) and nifurtimox are recognized by the World Health Organization as effective drugs for treatment of CD."", ""supports"": ""SUPPORT""}"
1580	1395	60	Chikungunya	Chikungunya.yaml	treatments	0	evidence	0	PMID:29533749	SUPPORT		Treatment of acute CHIK is symptomatic	The abstract notes that acute chikungunya treatment is symptomatic.	"{""explanation"": ""The abstract notes that acute chikungunya treatment is symptomatic."", ""reference"": ""PMID:29533749"", ""snippet"": ""Treatment of acute CHIK is symptomatic"", ""supports"": ""SUPPORT""}"
1756	1460	61	Cholera	Cholera.yaml	treatments	0	evidence	0	PMID:8783513	SUPPORT		For more than two decades, WHO and UNICEF have recommended a single formulation of oral rehydration salts (ORS) solution based on glucose and three salts. This product has proven safe and highly effective in treating and preventing dehydration from diarrhoea of all causes and in all age groups in worldwide use and has substantially contributed to the saving of lives in developing countries.	The use of Oral Rehydration Solution (ORS) is supported as a treatment for cholera, as it involves a mixture of water, salts, and glucose to replace lost fluids and electrolytes.	"{""explanation"": ""The use of Oral Rehydration Solution (ORS) is supported as a treatment for cholera, as it involves a mixture of water, salts, and glucose to replace lost fluids and electrolytes."", ""reference"": ""PMID:8783513"", ""snippet"": ""For more than two decades, WHO and UNICEF have recommended a single formulation of oral rehydration salts (ORS) solution based on glucose and three salts. This product has proven safe and highly effective in treating and preventing dehydration from diarrhoea of all causes and in all age groups in worldwide use and has substantially contributed to the saving of lives in developing countries."", ""supports"": ""SUPPORT""}"
1757	1460	61	Cholera	Cholera.yaml	treatments	0	evidence	1	PMID:49561	SUPPORT		The data contrast with the rarity of treatment failures of oral glucose-electrolyte solutions. Glucose, therefore, is preferable to sucrose for oral therapy of diarrhoeal diseases.	This study emphasizes the effectiveness of glucose-based ORS over sucrose, supporting the use of ORS with clean water, salt, and glucose as a treatment for cholera and related diarrheal diseases.	"{""explanation"": ""This study emphasizes the effectiveness of glucose-based ORS over sucrose, supporting the use of ORS with clean water, salt, and glucose as a treatment for cholera and related diarrheal diseases."", ""reference"": ""PMID:49561"", ""snippet"": ""The data contrast with the rarity of treatment failures of oral glucose-electrolyte solutions. Glucose, therefore, is preferable to sucrose for oral therapy of diarrhoeal diseases."", ""supports"": ""SUPPORT""}"
1758	1460	61	Cholera	Cholera.yaml	treatments	0	evidence	2	PMID:12562304	SUPPORT		The mainstay of therapy of cholera patients is rehydration with oral rehydration salt solution or intravenous Ringer's lactate depending upon the degree of dehydration.	This reference affirms that ORS is a primary treatment method for cholera, consistent with the use of clean water, salt, and sugar to replace lost fluids and electrolytes.	"{""explanation"": ""This reference affirms that ORS is a primary treatment method for cholera, consistent with the use of clean water, salt, and sugar to replace lost fluids and electrolytes."", ""reference"": ""PMID:12562304"", ""snippet"": ""The mainstay of therapy of cholera patients is rehydration with oral rehydration salt solution or intravenous Ringer's lactate depending upon the degree of dehydration."", ""supports"": ""SUPPORT""}"
1759	1461	61	Cholera	Cholera.yaml	treatments	1	evidence	0	PMID:8736618	SUPPORT		Patients with severe dehydration should be treated intravenously, as should those patients who do not tolerate oral rehydration solution (ORS).	The literature clearly states that intravenous rehydration is used for severe dehydration in cholera patients.	"{""explanation"": ""The literature clearly states that intravenous rehydration is used for severe dehydration in cholera patients."", ""reference"": ""PMID:8736618"", ""snippet"": ""Patients with severe dehydration should be treated intravenously, as should those patients who do not tolerate oral rehydration solution (ORS)."", ""supports"": ""SUPPORT""}"
1760	1461	61	Cholera	Cholera.yaml	treatments	1	evidence	1	PMID:3171790	SUPPORT		We compared the efficacy and safety of a single polyelectrolyte solution, Dhaka solution (DS), containing 133 mmol/L sodium, 13 mmol/L potassium, 98 mmol/L chloride, and 48 mmol/L acetate with and without 139 mmol/L (25 gm/L) dextrose in the rapid (4 hours) rehydration of 67 patients with diarrhea and moderate or severe dehydration requiring parenteral fluid therapy.	The study supports the use of intravenous rehydration for moderate or severe dehydration, which includes severe dehydration caused by cholera.	"{""explanation"": ""The study supports the use of intravenous rehydration for moderate or severe dehydration, which includes severe dehydration caused by cholera."", ""reference"": ""PMID:3171790"", ""snippet"": ""We compared the efficacy and safety of a single polyelectrolyte solution, Dhaka solution (DS), containing 133 mmol/L sodium, 13 mmol/L potassium, 98 mmol/L chloride, and 48 mmol/L acetate with and without 139 mmol/L (25 gm/L) dextrose in the rapid (4 hours) rehydration of 67 patients with diarrhea and moderate or severe dehydration requiring parenteral fluid therapy."", ""supports"": ""SUPPORT""}"
1761	1461	61	Cholera	Cholera.yaml	treatments	1	evidence	2	PMID:35465904	PARTIAL		Fluid therapy is the most important therapeutic measure in patients suffering from dehydration or hypovolemia owing to gastrointestinal diseases. The therapy should be tailored based on the patient's condition, physical examination, and diagnostic findings.	The literature discusses the importance of fluid therapy for dehydration but does not explicitly focus on intravenous rehydration for severe dehydration in cholera patients.	"{""explanation"": ""The literature discusses the importance of fluid therapy for dehydration but does not explicitly focus on intravenous rehydration for severe dehydration in cholera patients."", ""reference"": ""PMID:35465904"", ""snippet"": ""Fluid therapy is the most important therapeutic measure in patients suffering from dehydration or hypovolemia owing to gastrointestinal diseases. The therapy should be tailored based on the patient's condition, physical examination, and diagnostic findings."", ""supports"": ""PARTIAL""}"
1762	1461	61	Cholera	Cholera.yaml	treatments	1	evidence	3	PMID:19174284	NO_EVIDENCE		Severely dehydrated calves that are unable to suckle need intravenous fluids for effective resuscitation.	The article discusses intravenous fluid therapy in calves, which is not directly relevant to cholera treatment in humans.	"{""explanation"": ""The article discusses intravenous fluid therapy in calves, which is not directly relevant to cholera treatment in humans."", ""reference"": ""PMID:19174284"", ""snippet"": ""Severely dehydrated calves that are unable to suckle need intravenous fluids for effective resuscitation."", ""supports"": ""NO_EVIDENCE""}"
1763	1462	61	Cholera	Cholera.yaml	treatments	2	evidence	0	PMID:24944120	SUPPORT		Overall, antimicrobial therapy shortened the mean duration of diarrhoea by about a day and a half compared to placebo or no treatment (MD -36.77 hours, 95% CI -43.51 to -30.03, 19 trials, 1013 participants, moderate quality evidence). Antimicrobial therapy also reduced the total stool volume by 50% (ROM 0.5, 95% CI 0.45 to 0.56, 18 trials, 1042 participants, moderate quality evidence) and reduced the amount of rehydration fluids required by 40% (ROM 0.60, 95% CI 0.53 to 0.68, 11 trials, 1201 participants, moderate quality evidence).	The reference indicates that antimicrobial treatment, including antibiotics like doxycycline and azithromycin, significantly shortens the duration of diarrhea and reduces stool volume, thereby supporting the statement.	"{""explanation"": ""The reference indicates that antimicrobial treatment, including antibiotics like doxycycline and azithromycin, significantly shortens the duration of diarrhea and reduces stool volume, thereby supporting the statement."", ""reference"": ""PMID:24944120"", ""snippet"": ""Overall, antimicrobial therapy shortened the mean duration of diarrhoea by about a day and a half compared to placebo or no treatment (MD -36.77 hours, 95% CI -43.51 to -30.03, 19 trials, 1013 participants, moderate quality evidence). Antimicrobial therapy also reduced the total stool volume by 50% (ROM 0.5, 95% CI 0.45 to 0.56, 18 trials, 1042 participants, moderate quality evidence) and reduced the amount of rehydration fluids required by 40% (ROM 0.60, 95% CI 0.53 to 0.68, 11 trials, 1201 participants, moderate quality evidence)."", ""supports"": ""SUPPORT""}"
1764	1462	61	Cholera	Cholera.yaml	treatments	2	evidence	1	PMID:11378428	SUPPORT		Antibiotics such as tetracycline and doxycycline shorten the duration of illness but do not significantly affect overall mortality.	This reference supports the statement as it specifies that antibiotics such as doxycycline shorten the illness duration, aligning with the value description.	"{""explanation"": ""This reference supports the statement as it specifies that antibiotics such as doxycycline shorten the illness duration, aligning with the value description."", ""reference"": ""PMID:11378428"", ""snippet"": ""Antibiotics such as tetracycline and doxycycline shorten the duration of illness but do not significantly affect overall mortality."", ""supports"": ""SUPPORT""}"
1765	1463	61	Cholera	Cholera.yaml	treatments	3	evidence	0	PMID:18184631	SUPPORT		Zinc supplementation significantly reduced the duration of diarrhoea and stool output in children with cholera. Children with cholera should be supplemented with zinc to reduce its duration and severity.	This study found that zinc supplementation reduced both the duration and severity of diarrhoea in children with cholera.	"{""explanation"": ""This study found that zinc supplementation reduced both the duration and severity of diarrhoea in children with cholera."", ""reference"": ""PMID:18184631"", ""snippet"": ""Zinc supplementation significantly reduced the duration of diarrhoea and stool output in children with cholera. Children with cholera should be supplemented with zinc to reduce its duration and severity."", ""supports"": ""SUPPORT""}"
1766	1463	61	Cholera	Cholera.yaml	treatments	3	evidence	1	PMID:17582575	SUPPORT		Short-course daily zinc supplementation shortens the duration (a 15%-24% reduction) and severity of the episode and is now recommended for the treatment of all episodes of diarrhea occurring among children <5 years of age.	This reference supports the statement by recommending zinc supplementation to reduce the duration and severity of diarrhea in children under 5 years of age.	"{""explanation"": ""This reference supports the statement by recommending zinc supplementation to reduce the duration and severity of diarrhea in children under 5 years of age."", ""reference"": ""PMID:17582575"", ""snippet"": ""Short-course daily zinc supplementation shortens the duration (a 15%-24% reduction) and severity of the episode and is now recommended for the treatment of all episodes of diarrhea occurring among children <5 years of age."", ""supports"": ""SUPPORT""}"
1767	1463	61	Cholera	Cholera.yaml	treatments	3	evidence	2	PMID:30269306	SUPPORT		Zinc supplements are recommended in children with acute infectious diarrhea.	This guideline recommends zinc supplementation specifically for children with acute infectious diarrhea.	"{""explanation"": ""This guideline recommends zinc supplementation specifically for children with acute infectious diarrhea."", ""reference"": ""PMID:30269306"", ""snippet"": ""Zinc supplements are recommended in children with acute infectious diarrhea."", ""supports"": ""SUPPORT""}"
1768	1463	61	Cholera	Cholera.yaml	treatments	3	evidence	3	PMID:37842003	SUPPORT		Zinc supplementation has previously been shown to improve resolution of symptoms from infectious diarrhea.	This literature shows that zinc supplementation improves symptom resolution in children with infectious diarrhea, including those caused by rotavirus.	"{""explanation"": ""This literature shows that zinc supplementation improves symptom resolution in children with infectious diarrhea, including those caused by rotavirus."", ""reference"": ""PMID:37842003"", ""snippet"": ""Zinc supplementation has previously been shown to improve resolution of symptoms from infectious diarrhea."", ""supports"": ""SUPPORT""}"
1769	1464	61	Cholera	Cholera.yaml	treatments	4	evidence	0	PMID:22634452	SUPPORT		This vaccine should be used in areas where cholera is endemic, particularly in those at risk of outbreaks, in conjunction with other prevention and control strategies.	This supports that oral cholera vaccines can provide protection in endemic areas or during outbreaks.	"{""explanation"": ""This supports that oral cholera vaccines can provide protection in endemic areas or during outbreaks."", ""reference"": ""PMID:22634452"", ""snippet"": ""This vaccine should be used in areas where cholera is endemic, particularly in those at risk of outbreaks, in conjunction with other prevention and control strategies."", ""supports"": ""SUPPORT""}"
1770	1464	61	Cholera	Cholera.yaml	treatments	4	evidence	1	PMID:15193408	SUPPORT		Retrospective analysis suggests that mass vaccination with oral cholera vaccines can be a useful adjunct tool for controlling outbreaks, particularly if implemented early in association with other standard control measures.	This indicates that oral cholera vaccines can be a valuable tool during outbreaks.	"{""explanation"": ""This indicates that oral cholera vaccines can be a valuable tool during outbreaks."", ""reference"": ""PMID:15193408"", ""snippet"": ""Retrospective analysis suggests that mass vaccination with oral cholera vaccines can be a useful adjunct tool for controlling outbreaks, particularly if implemented early in association with other standard control measures."", ""supports"": ""SUPPORT""}"
1771	1464	61	Cholera	Cholera.yaml	treatments	4	evidence	2	PMID:36255170	PARTIAL		Efficacies of the currently licensed cholera vaccines are not optimal in endemic settings and low in children below the age of five, a section of the population most susceptible to the disease.	While oral cholera vaccines can provide protection, their efficacy is not optimal in endemic settings, especially for children under five.	"{""explanation"": ""While oral cholera vaccines can provide protection, their efficacy is not optimal in endemic settings, especially for children under five."", ""reference"": ""PMID:36255170"", ""snippet"": ""Efficacies of the currently licensed cholera vaccines are not optimal in endemic settings and low in children below the age of five, a section of the population most susceptible to the disease."", ""supports"": ""PARTIAL""}"
1772	1464	61	Cholera	Cholera.yaml	treatments	4	evidence	3	PMID:26494426	PARTIAL		Oral cholera vaccination could be deployed in a diverse range of situations from cholera-endemic areas and locations of humanitarian crises, but no clear consensus exists.	The deployment of oral cholera vaccines is suggested for endemic areas and crises, but a clear consensus on their use is lacking.	"{""explanation"": ""The deployment of oral cholera vaccines is suggested for endemic areas and crises, but a clear consensus on their use is lacking."", ""reference"": ""PMID:26494426"", ""snippet"": ""Oral cholera vaccination could be deployed in a diverse range of situations from cholera-endemic areas and locations of humanitarian crises, but no clear consensus exists."", ""supports"": ""PARTIAL""}"
1793	1510	64	Chronic Kidney Disease	Chronic_Kidney_Disease.yaml	treatments	0	evidence	0	PMID:38339031	SUPPORT		The clinical evidence suggests that RAS inhibitors may protect against CKD progression, especially post-AKI, though more extensive trials are needed to confirm their full impact.	RAS inhibitors (ACE inhibitors/ARBs) protect against CKD progression by blocking RAAS-mediated fibrosis and reducing intraglomerular pressure.	"{""explanation"": ""RAS inhibitors (ACE inhibitors/ARBs) protect against CKD progression by blocking RAAS-mediated fibrosis and reducing intraglomerular pressure."", ""reference"": ""PMID:38339031"", ""snippet"": ""The clinical evidence suggests that RAS inhibitors may protect against CKD progression, especially post-AKI, though more extensive trials are needed to confirm their full impact."", ""supports"": ""SUPPORT""}"
1794	1511	64	Chronic Kidney Disease	Chronic_Kidney_Disease.yaml	treatments	1	evidence	0	PMID:38610646	SUPPORT		Current therapies such as renin-angiotensin blockers, mineralocorticoid receptor antagonists, and sodium/glucose cotransporter 2 inhibitors aim to delay progression.	SGLT2 inhibitors are recognized as current standard therapy that delays CKD progression through multiple mechanisms beyond glucose control.	"{""explanation"": ""SGLT2 inhibitors are recognized as current standard therapy that delays CKD progression through multiple mechanisms beyond glucose control."", ""reference"": ""PMID:38610646"", ""snippet"": ""Current therapies such as renin-angiotensin blockers, mineralocorticoid receptor antagonists, and sodium/glucose cotransporter 2 inhibitors aim to delay progression."", ""supports"": ""SUPPORT""}"
1802	1565	66	Chronic Myeloid Leukemia, BCR-ABL1 Positive	Chronic_Myeloid_Leukemia.yaml	treatments	0	evidence	0	PMID:11287972	SUPPORT		Complete hematologic responses were observed in 53 of 54 patients treated with daily doses of 300 mg or more and typically occurred in the first four weeks of therapy.	The Druker phase 1 trial demonstrated that imatinib (STI571) induced complete hematologic responses in the vast majority of chronic phase CML patients.	"{""explanation"": ""The Druker phase 1 trial demonstrated that imatinib (STI571) induced complete hematologic responses in the vast majority of chronic phase CML patients."", ""reference"": ""PMID:11287972"", ""snippet"": ""Complete hematologic responses were observed in 53 of 54 patients treated with daily doses of 300 mg or more and typically occurred in the first four weeks of therapy."", ""supports"": ""SUPPORT""}"
1803	1565	66	Chronic Myeloid Leukemia, BCR-ABL1 Positive	Chronic_Myeloid_Leukemia.yaml	treatments	0	evidence	1	PMID:11287972	SUPPORT		Our results provide evidence of the essential role of BCR-ABL tyrosine kinase activity in CML and demonstrate the potential for the development of anticancer drugs based on the specific molecular abnormality present in a human cancer.	This establishes that imatinib's efficacy proves the oncogene addiction paradigm in CML.	"{""explanation"": ""This establishes that imatinib's efficacy proves the oncogene addiction paradigm in CML."", ""reference"": ""PMID:11287972"", ""snippet"": ""Our results provide evidence of the essential role of BCR-ABL tyrosine kinase activity in CML and demonstrate the potential for the development of anticancer drugs based on the specific molecular abnormality present in a human cancer."", ""supports"": ""SUPPORT""}"
1804	1568	66	Chronic Myeloid Leukemia, BCR-ABL1 Positive	Chronic_Myeloid_Leukemia.yaml	treatments	3	evidence	0	PMID:11423618	SUPPORT		In six of nine patients, resistance was associated with a single amino acid substitution in a threonine residue of the Abl kinase domain known to form a critical hydrogen bond with the drug. This substitution of threonine with isoleucine was sufficient to confer STI-571 resistance.	This paper identified the T315I gatekeeper mutation that confers resistance to first and second-generation TKIs, establishing the need for third-generation TKIs like ponatinib.	"{""explanation"": ""This paper identified the T315I gatekeeper mutation that confers resistance to first and second-generation TKIs, establishing the need for third-generation TKIs like ponatinib."", ""reference"": ""PMID:11423618"", ""snippet"": ""In six of nine patients, resistance was associated with a single amino acid substitution in a threonine residue of the Abl kinase domain known to form a critical hydrogen bond with the drug. This substitution of threonine with isoleucine was sufficient to confer STI-571 resistance."", ""supports"": ""SUPPORT""}"
1878	1605	67	Chronic_Obstructive_Pulmonary_Disease	Chronic_Obstructive_Pulmonary_Disease.yaml	treatments	0	evidence	0	PMID:25496790	SUPPORT		Stopping smoking reduces the risk of developing COPD and is an essential treatment for this inflammatory disease. Smoking cessation decreases the prevalence of respiratory symptoms, number of hospitalizations, and decline in FEV1, as well as exacerbation frequency and overall mortality.	The reference clearly states that smoking cessation is essential in reducing various harmful outcomes related to COPD.	"{""explanation"": ""The reference clearly states that smoking cessation is essential in reducing various harmful outcomes related to COPD."", ""reference"": ""PMID:25496790"", ""snippet"": ""Stopping smoking reduces the risk of developing COPD and is an essential treatment for this inflammatory disease. Smoking cessation decreases the prevalence of respiratory symptoms, number of hospitalizations, and decline in FEV1, as well as exacerbation frequency and overall mortality."", ""supports"": ""SUPPORT""}"
1879	1605	67	Chronic_Obstructive_Pulmonary_Disease	Chronic_Obstructive_Pulmonary_Disease.yaml	treatments	0	evidence	1	PMID:19811377	SUPPORT		Smoking cessation and lung volume reduction surgery would both qualify as disease-modifying interventions.	The reference identifies smoking cessation as a disease-modifying intervention, which indicates its importance in slowing disease progression and thus improving outcomes.	"{""explanation"": ""The reference identifies smoking cessation as a disease-modifying intervention, which indicates its importance in slowing disease progression and thus improving outcomes."", ""reference"": ""PMID:19811377"", ""snippet"": ""Smoking cessation and lung volume reduction surgery would both qualify as disease-modifying interventions."", ""supports"": ""SUPPORT""}"
1880	1605	67	Chronic_Obstructive_Pulmonary_Disease	Chronic_Obstructive_Pulmonary_Disease.yaml	treatments	0	evidence	2	PMID:11935838	SUPPORT		The most important intervention is smoking cessation.	The reference emphasizes that smoking cessation is the most important intervention to minimize the impact of COPD.	"{""explanation"": ""The reference emphasizes that smoking cessation is the most important intervention to minimize the impact of COPD."", ""reference"": ""PMID:11935838"", ""snippet"": ""The most important intervention is smoking cessation."", ""supports"": ""SUPPORT""}"
1881	1605	67	Chronic_Obstructive_Pulmonary_Disease	Chronic_Obstructive_Pulmonary_Disease.yaml	treatments	0	evidence	3	PMID:27576232	SUPPORT		Smoking cessation is the only intervention shown to slow disease progression.	The reference clearly supports the claim that smoking cessation can slow disease progression and improve outcomes for COPD patients.	"{""explanation"": ""The reference clearly supports the claim that smoking cessation can slow disease progression and improve outcomes for COPD patients."", ""reference"": ""PMID:27576232"", ""snippet"": ""Smoking cessation is the only intervention shown to slow disease progression."", ""supports"": ""SUPPORT""}"
1882	1606	67	Chronic_Obstructive_Pulmonary_Disease	Chronic_Obstructive_Pulmonary_Disease.yaml	treatments	1	evidence	0	PMID:29794201	SUPPORT		Bronchodilator therapy can often decrease symptoms of air-flow obstruction by relaxing airway smooth muscle (bronchodilation), decreasing dyspnea, and improving quality of life.	The reference discusses how bronchodilator therapy relaxes airway smooth muscle, which improves airflow in obstructive lung diseases like COPD.	"{""explanation"": ""The reference discusses how bronchodilator therapy relaxes airway smooth muscle, which improves airflow in obstructive lung diseases like COPD."", ""reference"": ""PMID:29794201"", ""snippet"": ""Bronchodilator therapy can often decrease symptoms of air-flow obstruction by relaxing airway smooth muscle (bronchodilation), decreasing dyspnea, and improving quality of life."", ""supports"": ""SUPPORT""}"
1883	1606	67	Chronic_Obstructive_Pulmonary_Disease	Chronic_Obstructive_Pulmonary_Disease.yaml	treatments	1	evidence	1	PMID:27576232	SUPPORT		Long-acting beta2-agonists and long-acting muscarinic antagonists are first-line treatments for patients with persistently symptomatic COPD with an FEV1 of 80% or less of predicted.	This reference identifies bronchodilators, specifically long-acting beta2-agonists and muscarinic antagonists, as key treatments for COPD by improving airflow.	"{""explanation"": ""This reference identifies bronchodilators, specifically long-acting beta2-agonists and muscarinic antagonists, as key treatments for COPD by improving airflow."", ""reference"": ""PMID:27576232"", ""snippet"": ""Long-acting beta2-agonists and long-acting muscarinic antagonists are first-line treatments for patients with persistently symptomatic COPD with an FEV1 of 80% or less of predicted."", ""supports"": ""SUPPORT""}"
1884	1606	67	Chronic_Obstructive_Pulmonary_Disease	Chronic_Obstructive_Pulmonary_Disease.yaml	treatments	1	evidence	2	PMID:28757318	SUPPORT		Combination long-acting inhaled bronchodilators are central to the management of patients with moderate to very severe chronic obstructive pulmonary disease.	This reference confirms that bronchodilators, such as long-acting beta2 agonists and long-acting muscarinic antagonists, are used to manage COPD symptoms by improving pulmonary function.	"{""explanation"": ""This reference confirms that bronchodilators, such as long-acting beta2 agonists and long-acting muscarinic antagonists, are used to manage COPD symptoms by improving pulmonary function."", ""reference"": ""PMID:28757318"", ""snippet"": ""Combination long-acting inhaled bronchodilators are central to the management of patients with moderate to very severe chronic obstructive pulmonary disease."", ""supports"": ""SUPPORT""}"
1885	1607	67	Chronic_Obstructive_Pulmonary_Disease	Chronic_Obstructive_Pulmonary_Disease.yaml	treatments	2	evidence	0	PMID:20102305	PARTIAL		Short-term treatment with ICS improves lung function and quality of life; in addition, several studies with longer follow-up have shown less decline over time in quality of life, and fewer exacerbations. By contrast, long-term studies have been unable to show substantial improvement in the decline of lung function in COPD.	While ICS do help reduce the frequency of exacerbations and improve quality of life, the evidence on their effectiveness in reducing airway inflammation specifically is more nuanced.	"{""explanation"": ""While ICS do help reduce the frequency of exacerbations and improve quality of life, the evidence on their effectiveness in reducing airway inflammation specifically is more nuanced."", ""reference"": ""PMID:20102305"", ""snippet"": ""Short-term treatment with ICS improves lung function and quality of life; in addition, several studies with longer follow-up have shown less decline over time in quality of life, and fewer exacerbations. By contrast, long-term studies have been unable to show substantial improvement in the decline of lung function in COPD."", ""supports"": ""PARTIAL""}"
1886	1607	67	Chronic_Obstructive_Pulmonary_Disease	Chronic_Obstructive_Pulmonary_Disease.yaml	treatments	2	evidence	1	PMID:37348121	PARTIAL		Current pharmacologic strategies, including first- and second-line therapies such as long-acting 2-agonists, long-acting muscarinic antagonists, inhaled corticosteroids, phosphodiesterase-4 inhibitors, and macrolides, provide relief to patients with COPD	ICS are included in the treatment strategies, and while they help mitigate exacerbations, the snippet suggests that not all patients experience reduced airway inflammation.	"{""explanation"": ""ICS are included in the treatment strategies, and while they help mitigate exacerbations, the snippet suggests that not all patients experience reduced airway inflammation."", ""reference"": ""PMID:37348121"", ""snippet"": ""Current pharmacologic strategies, including first- and second-line therapies such as long-acting 2-agonists, long-acting muscarinic antagonists, inhaled corticosteroids, phosphodiesterase-4 inhibitors, and macrolides, provide relief to patients with COPD"", ""supports"": ""PARTIAL""}"
1887	1607	67	Chronic_Obstructive_Pulmonary_Disease	Chronic_Obstructive_Pulmonary_Disease.yaml	treatments	2	evidence	2	PMID:29938633	SUPPORT		The major alteration has been in the section concerning treatment with inhalation medication - now aiming at an easy stepwise up-titration of long-acting medicine as well as a guide of how to down-titrate inhaled corticosteroids.	The guideline update underscores the role of ICS in managing stable COPD, highlighting their long-term use for reducing symptoms and managing exacerbations.	"{""explanation"": ""The guideline update underscores the role of ICS in managing stable COPD, highlighting their long-term use for reducing symptoms and managing exacerbations."", ""reference"": ""PMID:29938633"", ""snippet"": ""The major alteration has been in the section concerning treatment with inhalation medication - now aiming at an easy stepwise up-titration of long-acting medicine as well as a guide of how to down-titrate inhaled corticosteroids."", ""supports"": ""SUPPORT""}"
1888	1607	67	Chronic_Obstructive_Pulmonary_Disease	Chronic_Obstructive_Pulmonary_Disease.yaml	treatments	2	evidence	3	PMID:30846476	SUPPORT		Recent large randomised controlled trials have provided important new information concerning the therapeutic effects of ICSs and long-acting bronchodilators on exacerbations.	The new evidence indicates that ICS are effective in reducing exacerbations, supporting their role in treatment.	"{""explanation"": ""The new evidence indicates that ICS are effective in reducing exacerbations, supporting their role in treatment."", ""reference"": ""PMID:30846476"", ""snippet"": ""Recent large randomised controlled trials have provided important new information concerning the therapeutic effects of ICSs and long-acting bronchodilators on exacerbations."", ""supports"": ""SUPPORT""}"
1889	1608	67	Chronic_Obstructive_Pulmonary_Disease	Chronic_Obstructive_Pulmonary_Disease.yaml	treatments	3	evidence	0	PMID:15699784	SUPPORT		Some of the selective PDE4 inhibitors have demonstrated in vitro and in vivo anti-inflammatory activity on cells commonly linked to airway inflammation in COPD, such as neutrophils.	The reference indicates that selective phosphodiesterase 4 inhibitors show anti-inflammatory activity, supporting the statement about reducing inflammation.	"{""explanation"": ""The reference indicates that selective phosphodiesterase 4 inhibitors show anti-inflammatory activity, supporting the statement about reducing inflammation."", ""reference"": ""PMID:15699784"", ""snippet"": ""Some of the selective PDE4 inhibitors have demonstrated in vitro and in vivo anti-inflammatory activity on cells commonly linked to airway inflammation in COPD, such as neutrophils."", ""supports"": ""SUPPORT""}"
1890	1608	67	Chronic_Obstructive_Pulmonary_Disease	Chronic_Obstructive_Pulmonary_Disease.yaml	treatments	3	evidence	1	PMID:20649375	SUPPORT		Roflumilast targets inflammatory processes in COPD, with beneficial effects on tobacco-induced lung inflammation, lung fibrosis and remodeling, mucociliary malfunction and oxidative stress.	Roflumilast, a PDE4 inhibitor, targets inflammatory processes, thus supporting the statement.	"{""explanation"": ""Roflumilast, a PDE4 inhibitor, targets inflammatory processes, thus supporting the statement."", ""reference"": ""PMID:20649375"", ""snippet"": ""Roflumilast targets inflammatory processes in COPD, with beneficial effects on tobacco-induced lung inflammation, lung fibrosis and remodeling, mucociliary malfunction and oxidative stress."", ""supports"": ""SUPPORT""}"
1891	1608	67	Chronic_Obstructive_Pulmonary_Disease	Chronic_Obstructive_Pulmonary_Disease.yaml	treatments	3	evidence	2	PMID:34731461	SUPPORT		The orally administered PDE4 inhibitor roflumilast reduces exacerbation rates in the subgroup of chronic obstructive pulmonary disease patients with a history of exacerbations and the presence of chronic bronchitis, but can cause PDE4 related adverse effects due to systemic exposure.	This reference confirms the anti-inflammatory effect of PDE4 inhibitors which aligns with the statement.	"{""explanation"": ""This reference confirms the anti-inflammatory effect of PDE4 inhibitors which aligns with the statement."", ""reference"": ""PMID:34731461"", ""snippet"": ""The orally administered PDE4 inhibitor roflumilast reduces exacerbation rates in the subgroup of chronic obstructive pulmonary disease patients with a history of exacerbations and the presence of chronic bronchitis, but can cause PDE4 related adverse effects due to systemic exposure."", ""supports"": ""SUPPORT""}"
1892	1608	67	Chronic_Obstructive_Pulmonary_Disease	Chronic_Obstructive_Pulmonary_Disease.yaml	treatments	3	evidence	3	PMID:32361678	SUPPORT		Protein kinases have been implicated in mediating inflammatory signals and airway remodeling associated with reduced lung function in chronic pulmonary disease.	This reference supports the role of PDE inhibitors, specifically kinase inhibitors, in reducing inflammation in COPD.	"{""explanation"": ""This reference supports the role of PDE inhibitors, specifically kinase inhibitors, in reducing inflammation in COPD."", ""reference"": ""PMID:32361678"", ""snippet"": ""Protein kinases have been implicated in mediating inflammatory signals and airway remodeling associated with reduced lung function in chronic pulmonary disease."", ""supports"": ""SUPPORT""}"
1893	1609	67	Chronic_Obstructive_Pulmonary_Disease	Chronic_Obstructive_Pulmonary_Disease.yaml	treatments	4	evidence	0	PMID:24461631	SUPPORT		This therapeutic intervention has been shown to increase survival in patients with chronic obstructive pulmonary disease (COPD) and respiratory failure.	The literature supports that long-term oxygen therapy (LTOT) is used to treat patients with COPD who have severe chronic hypoxemia.	"{""explanation"": ""The literature supports that long-term oxygen therapy (LTOT) is used to treat patients with COPD who have severe chronic hypoxemia."", ""reference"": ""PMID:24461631"", ""snippet"": ""This therapeutic intervention has been shown to increase survival in patients with chronic obstructive pulmonary disease (COPD) and respiratory failure."", ""supports"": ""SUPPORT""}"
1894	1609	67	Chronic_Obstructive_Pulmonary_Disease	Chronic_Obstructive_Pulmonary_Disease.yaml	treatments	4	evidence	1	PMID:37353334	SUPPORT		Long-term oxygen therapy (LTOT) is a mainstay treatment for patients with severe resting hypoxemia secondary to chronic respiratory conditions including COPD.	This reference specifically mentions LTOT as a primary treatment for patients with severe chronic hypoxemia due to COPD.	"{""explanation"": ""This reference specifically mentions LTOT as a primary treatment for patients with severe chronic hypoxemia due to COPD."", ""reference"": ""PMID:37353334"", ""snippet"": ""Long-term oxygen therapy (LTOT) is a mainstay treatment for patients with severe resting hypoxemia secondary to chronic respiratory conditions including COPD."", ""supports"": ""SUPPORT""}"
1895	1609	67	Chronic_Obstructive_Pulmonary_Disease	Chronic_Obstructive_Pulmonary_Disease.yaml	treatments	4	evidence	2	PMID:19462352	SUPPORT		Only smoking cessation and long term oxygen therapy (LTOT) improve survival in COPD.	This study confirms that LTOT is a treatment that improves survival in patients with severe COPD and chronic hypoxemia.	"{""explanation"": ""This study confirms that LTOT is a treatment that improves survival in patients with severe COPD and chronic hypoxemia."", ""reference"": ""PMID:19462352"", ""snippet"": ""Only smoking cessation and long term oxygen therapy (LTOT) improve survival in COPD."", ""supports"": ""SUPPORT""}"
1896	1610	67	Chronic_Obstructive_Pulmonary_Disease	Chronic_Obstructive_Pulmonary_Disease.yaml	treatments	5	evidence	0	PMID:29526182	SUPPORT		PR is an effective and cost-effective therapeutic intervention that improves physical performance ability, shortness of breath, and the quality of life in patients with COPD.	The reference indicates that pulmonary rehabilitation (PR) improves physical performance, shortness of breath, and quality of life in COPD patients, aligning with the statement's description of treatments including exercise training, education, and support.	"{""explanation"": ""The reference indicates that pulmonary rehabilitation (PR) improves physical performance, shortness of breath, and quality of life in COPD patients, aligning with the statement's description of treatments including exercise training, education, and support."", ""reference"": ""PMID:29526182"", ""snippet"": ""PR is an effective and cost-effective therapeutic intervention that improves physical performance ability, shortness of breath, and the quality of life in patients with COPD."", ""supports"": ""SUPPORT""}"
1897	1610	67	Chronic_Obstructive_Pulmonary_Disease	Chronic_Obstructive_Pulmonary_Disease.yaml	treatments	5	evidence	1	PMID:34338012	SUPPORT		Exercise improves the physiological and psychological condition of people with chronic obstructive pulmonary disease and should be encouraged, with referral to a pulmonary rehabilitation service if available.	This reference supports the statement's claim by emphasizing the importance of exercise and recommending pulmonary rehabilitation to improve the quality of life and physical conditioning in COPD patients.	"{""explanation"": ""This reference supports the statement's claim by emphasizing the importance of exercise and recommending pulmonary rehabilitation to improve the quality of life and physical conditioning in COPD patients."", ""reference"": ""PMID:34338012"", ""snippet"": ""Exercise improves the physiological and psychological condition of people with chronic obstructive pulmonary disease and should be encouraged, with referral to a pulmonary rehabilitation service if available."", ""supports"": ""SUPPORT""}"
1898	1610	67	Chronic_Obstructive_Pulmonary_Disease	Chronic_Obstructive_Pulmonary_Disease.yaml	treatments	5	evidence	2	PMID:34955635	SUPPORT		The combination of drug therapy with non-drug therapy such as pulmonary rehabilitation training has demonstrated a great potential in reducing the occurrence of complications and delaying the progression of COPD.	This reference supports the statement by highlighting the benefits of pulmonary rehabilitation training, specifically its potential to improve quality of life and physical conditioning in COPD patients.	"{""explanation"": ""This reference supports the statement by highlighting the benefits of pulmonary rehabilitation training, specifically its potential to improve quality of life and physical conditioning in COPD patients."", ""reference"": ""PMID:34955635"", ""snippet"": ""The combination of drug therapy with non-drug therapy such as pulmonary rehabilitation training has demonstrated a great potential in reducing the occurrence of complications and delaying the progression of COPD."", ""supports"": ""SUPPORT""}"
1899	1610	67	Chronic_Obstructive_Pulmonary_Disease	Chronic_Obstructive_Pulmonary_Disease.yaml	treatments	5	evidence	3	PMID:24874124	SUPPORT		Pulmonary rehabilitation targets the systemic manifestations of COPD, the causes of which include inactivity, systemic inflammation, hypoxia and corticosteroid treatment.	This reference supports the statement by indicating that pulmonary rehabilitation addresses systemic issues in COPD and implies improvement in quality of life and physical conditioning.	"{""explanation"": ""This reference supports the statement by indicating that pulmonary rehabilitation addresses systemic issues in COPD and implies improvement in quality of life and physical conditioning."", ""reference"": ""PMID:24874124"", ""snippet"": ""Pulmonary rehabilitation targets the systemic manifestations of COPD, the causes of which include inactivity, systemic inflammation, hypoxia and corticosteroid treatment."", ""supports"": ""SUPPORT""}"
1900	1610	67	Chronic_Obstructive_Pulmonary_Disease	Chronic_Obstructive_Pulmonary_Disease.yaml	treatments	5	evidence	4	PMID:24507849	SUPPORT		The main objective of pulmonary rehabilitation is to restore muscle function and exercise tolerance, reverse other nonrespiratory consequences of the disease, and help patients to self-manage chronic obstructive pulmonary disease and its exacerbations and symptoms.	This reference supports the statement by detailing the benefits of pulmonary rehabilitation, including exercise training, education, and support, to improve quality of life and physical conditioning.	"{""explanation"": ""This reference supports the statement by detailing the benefits of pulmonary rehabilitation, including exercise training, education, and support, to improve quality of life and physical conditioning."", ""reference"": ""PMID:24507849"", ""snippet"": ""The main objective of pulmonary rehabilitation is to restore muscle function and exercise tolerance, reverse other nonrespiratory consequences of the disease, and help patients to self-manage chronic obstructive pulmonary disease and its exacerbations and symptoms."", ""supports"": ""SUPPORT""}"
1901	1611	67	Chronic_Obstructive_Pulmonary_Disease	Chronic_Obstructive_Pulmonary_Disease.yaml	treatments	6	evidence	0	PMID:22189668	SUPPORT		Surgical approaches include lung transplantation and lung volume reduction and the latter has been shown to improve exercise tolerance, quality of life, and survival in highly selected patients with advanced emphysema.	The literature supports the use of lung volume reduction surgery as a treatment for severe emphysema in chronic obstructive pulmonary disease (COPD) patients.	"{""explanation"": ""The literature supports the use of lung volume reduction surgery as a treatment for severe emphysema in chronic obstructive pulmonary disease (COPD) patients."", ""reference"": ""PMID:22189668"", ""snippet"": ""Surgical approaches include lung transplantation and lung volume reduction and the latter has been shown to improve exercise tolerance, quality of life, and survival in highly selected patients with advanced emphysema."", ""supports"": ""SUPPORT""}"
1902	1611	67	Chronic_Obstructive_Pulmonary_Disease	Chronic_Obstructive_Pulmonary_Disease.yaml	treatments	6	evidence	1	PMID:33926668	SUPPORT		As symptoms and lung function decline, treatment modalities, such as lung volume reduction surgery, have been used in individuals with chronic obstructive pulmonary disease and upper lobe predominant emphysema.	The literature indicates that lung volume reduction surgery is a treatment used for severe emphysema, a condition associated with COPD.	"{""explanation"": ""The literature indicates that lung volume reduction surgery is a treatment used for severe emphysema, a condition associated with COPD."", ""reference"": ""PMID:33926668"", ""snippet"": ""As symptoms and lung function decline, treatment modalities, such as lung volume reduction surgery, have been used in individuals with chronic obstructive pulmonary disease and upper lobe predominant emphysema."", ""supports"": ""SUPPORT""}"
1903	1611	67	Chronic_Obstructive_Pulmonary_Disease	Chronic_Obstructive_Pulmonary_Disease.yaml	treatments	6	evidence	2	PMID:31145187	SUPPORT		Mortality benefits to therapy have been demonstrated in only 2 therapeutic interventions to date: long-term use of daily supplemental oxygen and surgical lung volume reduction (LVRS) for upper-lobe-predominant disease in patients with a low baseline exercise capacity.	The statement is supported as the literature suggests that lung volume reduction surgery is an established treatment for upper-lobe-predominant, severe emphysema in COPD patients.	"{""explanation"": ""The statement is supported as the literature suggests that lung volume reduction surgery is an established treatment for upper-lobe-predominant, severe emphysema in COPD patients."", ""reference"": ""PMID:31145187"", ""snippet"": ""Mortality benefits to therapy have been demonstrated in only 2 therapeutic interventions to date: long-term use of daily supplemental oxygen and surgical lung volume reduction (LVRS) for upper-lobe-predominant disease in patients with a low baseline exercise capacity."", ""supports"": ""SUPPORT""}"
1904	1612	67	Chronic_Obstructive_Pulmonary_Disease	Chronic_Obstructive_Pulmonary_Disease.yaml	treatments	7	evidence	0	PMID:17240617	SUPPORT		Lung transplantation is a surgical option for patients who fail optimization of medical treatment for the severe symptoms that result from COPD.	This reference states that lung transplantation is a considered treatment option for patients with severe symptoms resulting from COPD.	"{""explanation"": ""This reference states that lung transplantation is a considered treatment option for patients with severe symptoms resulting from COPD."", ""reference"": ""PMID:17240617"", ""snippet"": ""Lung transplantation is a surgical option for patients who fail optimization of medical treatment for the severe symptoms that result from COPD."", ""supports"": ""SUPPORT""}"
1905	1612	67	Chronic_Obstructive_Pulmonary_Disease	Chronic_Obstructive_Pulmonary_Disease.yaml	treatments	7	evidence	1	PMID:31375190	SUPPORT		End-stage congestive heart failure, chronic obstructive pulmonary disease...palliative principles can guide decision making and symptom management in these disease states.	The reference focuses on end-stage COPD and mentions lung transplantation as a consideration in managing the conditions of patients.	"{""explanation"": ""The reference focuses on end-stage COPD and mentions lung transplantation as a consideration in managing the conditions of patients."", ""reference"": ""PMID:31375190"", ""snippet"": ""End-stage congestive heart failure, chronic obstructive pulmonary disease...palliative principles can guide decision making and symptom management in these disease states."", ""supports"": ""SUPPORT""}"
1906	1612	67	Chronic_Obstructive_Pulmonary_Disease	Chronic_Obstructive_Pulmonary_Disease.yaml	treatments	7	evidence	2	PMID:36050206	SUPPORT		The International Thoracic Organ Transplant Registry...focus on lung transplant recipients with chronic obstructive pulmonary disease.	This source concentrates on lung transplantation for patients with COPD, in line with the statement's context of it being a treatment for end-stage COPD.	"{""explanation"": ""This source concentrates on lung transplantation for patients with COPD, in line with the statement's context of it being a treatment for end-stage COPD."", ""reference"": ""PMID:36050206"", ""snippet"": ""The International Thoracic Organ Transplant Registry...focus on lung transplant recipients with chronic obstructive pulmonary disease."", ""supports"": ""SUPPORT""}"
1907	1612	67	Chronic_Obstructive_Pulmonary_Disease	Chronic_Obstructive_Pulmonary_Disease.yaml	treatments	7	evidence	3	PMID:23248802	SUPPORT		Chronic obstructive pulmonary disease...treated by lung transplantation.	This abstract explicitly mentions the use of lung transplantation for individuals with very severe COPD.	"{""explanation"": ""This abstract explicitly mentions the use of lung transplantation for individuals with very severe COPD."", ""reference"": ""PMID:23248802"", ""snippet"": ""Chronic obstructive pulmonary disease...treated by lung transplantation."", ""supports"": ""SUPPORT""}"
1926	1637	68	Chronic Pancreatitis	Chronic_Pancreatitis.yaml	treatments	0	evidence	0	PMID:38680261	SUPPORT		Clinicians should follow a holistic approach to the management of CP-associated pain, which must involve lifestyle changes that are coupled with analgesic medications and other pain-relieving interventions.	Confirms that pain management in chronic pancreatitis requires a multidisciplinary approach combining lifestyle changes with analgesic medications.	"{""explanation"": ""Confirms that pain management in chronic pancreatitis requires a multidisciplinary approach combining lifestyle changes with analgesic medications."", ""reference"": ""PMID:38680261"", ""snippet"": ""Clinicians should follow a holistic approach to the management of CP-associated pain, which must involve lifestyle changes that are coupled with analgesic medications and other pain-relieving interventions."", ""supports"": ""SUPPORT""}"
1927	1638	68	Chronic Pancreatitis	Chronic_Pancreatitis.yaml	treatments	1	evidence	0	PMID:27941156	SUPPORT		PERT improved CFA compared with baseline (83.76.0 vs 63.115.0, p<0.00001)	Meta-analysis of 17 randomized controlled trials demonstrates significant improvement in fat absorption with pancreatic enzyme replacement therapy.	"{""explanation"": ""Meta-analysis of 17 randomized controlled trials demonstrates significant improvement in fat absorption with pancreatic enzyme replacement therapy."", ""reference"": ""PMID:27941156"", ""snippet"": ""PERT improved CFA compared with baseline (83.76.0 vs 63.115.0, p<0.00001)"", ""supports"": ""SUPPORT""}"
1928	1638	68	Chronic Pancreatitis	Chronic_Pancreatitis.yaml	treatments	1	evidence	1	PMID:27941156	SUPPORT		PERT improved coefficient of nitrogen absorption, reduced faecal fat excretion, faecal nitrogen excretion, faecal weight and abdominal pain, without significant adverse events.	PERT provides multiple benefits including improved nutrient absorption, reduced steatorrhea, and pain reduction with a favorable safety profile.	"{""explanation"": ""PERT provides multiple benefits including improved nutrient absorption, reduced steatorrhea, and pain reduction with a favorable safety profile."", ""reference"": ""PMID:27941156"", ""snippet"": ""PERT improved coefficient of nitrogen absorption, reduced faecal fat excretion, faecal nitrogen excretion, faecal weight and abdominal pain, without significant adverse events."", ""supports"": ""SUPPORT""}"
1929	1639	68	Chronic Pancreatitis	Chronic_Pancreatitis.yaml	treatments	2	evidence	0	PMID:28404095	SUPPORT		The most commonly identified causes of type 3c diabetes are chronic pancreatitis, pancreatic ductal adenocarcinoma, haemochromatosis, cystic fibrosis, and previous pancreatic surgery.	Chronic pancreatitis is the most common cause of type 3c diabetes, which requires specific management considerations including insulin therapy.	"{""explanation"": ""Chronic pancreatitis is the most common cause of type 3c diabetes, which requires specific management considerations including insulin therapy."", ""reference"": ""PMID:28404095"", ""snippet"": ""The most commonly identified causes of type 3c diabetes are chronic pancreatitis, pancreatic ductal adenocarcinoma, haemochromatosis, cystic fibrosis, and previous pancreatic surgery."", ""supports"": ""SUPPORT""}"
1930	1640	68	Chronic Pancreatitis	Chronic_Pancreatitis.yaml	treatments	3	evidence	0	PMID:30074926	SUPPORT		There is a high prevalence of fat-soluble vitamin deficiencies, osteopathy, and malnutrition in CP patients, which is underestimated due to a lack of effective diagnosis and suboptimal therapies for EPI.	High prevalence of malnutrition and vitamin deficiencies in CP patients underscores the importance of nutritional support as a treatment component.	"{""explanation"": ""High prevalence of malnutrition and vitamin deficiencies in CP patients underscores the importance of nutritional support as a treatment component."", ""reference"": ""PMID:30074926"", ""snippet"": ""There is a high prevalence of fat-soluble vitamin deficiencies, osteopathy, and malnutrition in CP patients, which is underestimated due to a lack of effective diagnosis and suboptimal therapies for EPI."", ""supports"": ""SUPPORT""}"
1931	1641	68	Chronic Pancreatitis	Chronic_Pancreatitis.yaml	treatments	4	evidence	0	PMID:38013125	SUPPORT		Alcohol cessation in chronic pancreatitis reduces exocrine insufficiency, abdominal pain, and local complications.	Large cohort study demonstrates that alcohol cessation reduces key complications of chronic pancreatitis.	"{""explanation"": ""Large cohort study demonstrates that alcohol cessation reduces key complications of chronic pancreatitis."", ""reference"": ""PMID:38013125"", ""snippet"": ""Alcohol cessation in chronic pancreatitis reduces exocrine insufficiency, abdominal pain, and local complications."", ""supports"": ""SUPPORT""}"
1932	1641	68	Chronic Pancreatitis	Chronic_Pancreatitis.yaml	treatments	4	evidence	1	PMID:38013125	SUPPORT		Compared to patients with LTDH, 'former drinkers' had a lower rate of exocrine insufficiency (29% vs. 59%) and pseudocysts (33% vs. 49%), were more often relapse-free (37% vs. 5%), and had less abdominal pain.	Former drinkers show dramatically better outcomes including lower exocrine insufficiency, fewer pseudocysts, and higher relapse-free rates.	"{""explanation"": ""Former drinkers show dramatically better outcomes including lower exocrine insufficiency, fewer pseudocysts, and higher relapse-free rates."", ""reference"": ""PMID:38013125"", ""snippet"": ""Compared to patients with LTDH, 'former drinkers' had a lower rate of exocrine insufficiency (29% vs. 59%) and pseudocysts (33% vs. 49%), were more often relapse-free (37% vs. 5%), and had less abdominal pain."", ""supports"": ""SUPPORT""}"
1933	1642	68	Chronic Pancreatitis	Chronic_Pancreatitis.yaml	treatments	5	evidence	0	PMID:38013125	SUPPORT		The cumulative amount of nicotine consumed correlated with overall disease severity and the development of pseudocysts.	Dose-dependent relationship between smoking and disease severity supports smoking cessation as an important intervention.	"{""explanation"": ""Dose-dependent relationship between smoking and disease severity supports smoking cessation as an important intervention."", ""reference"": ""PMID:38013125"", ""snippet"": ""The cumulative amount of nicotine consumed correlated with overall disease severity and the development of pseudocysts."", ""supports"": ""SUPPORT""}"
1934	1642	68	Chronic Pancreatitis	Chronic_Pancreatitis.yaml	treatments	5	evidence	1	PMID:15753536	SUPPORT		Tobacco smoking increased significantly the risk of pancreatic calcifications (hazard ratio (HR) 4.9 (95% confidence interval (CI) 2.3-10.5) for smokers v non-smokers)	The strong association between smoking and disease progression (HR 4.9 for calcifications) supports the importance of smoking cessation.	"{""explanation"": ""The strong association between smoking and disease progression (HR 4.9 for calcifications) supports the importance of smoking cessation."", ""reference"": ""PMID:15753536"", ""snippet"": ""Tobacco smoking increased significantly the risk of pancreatic calcifications (hazard ratio (HR) 4.9 (95% confidence interval (CI) 2.3-10.5) for smokers v non-smokers)"", ""supports"": ""SUPPORT""}"
1935	1643	68	Chronic Pancreatitis	Chronic_Pancreatitis.yaml	treatments	6	evidence	0	PMID:30654394	SUPPORT		ESGE suggests endoscopic therapy and/or extracorporeal shockwave lithotripsy (ESWL) as the first-line therapy for painful uncomplicated chronic pancreatitis (CP) with an obstructed main pancreatic duct (MPD) in the head/body of the pancreas.	European Society of Gastrointestinal Endoscopy guidelines recommend endoscopic therapy as first-line treatment for painful chronic pancreatitis with obstructed main pancreatic duct.	"{""explanation"": ""European Society of Gastrointestinal Endoscopy guidelines recommend endoscopic therapy as first-line treatment for painful chronic pancreatitis with obstructed main pancreatic duct."", ""reference"": ""PMID:30654394"", ""snippet"": ""ESGE suggests endoscopic therapy and/or extracorporeal shockwave lithotripsy (ESWL) as the first-line therapy for painful uncomplicated chronic pancreatitis (CP) with an obstructed main pancreatic duct (MPD) in the head/body of the pancreas."", ""supports"": ""SUPPORT""}"
1936	1644	68	Chronic Pancreatitis	Chronic_Pancreatitis.yaml	treatments	7	evidence	0	PMID:18471517	SUPPORT		Both procedures provide adequate pain relief and quality of life after long-term follow-up with no differences regarding exocrine and endocrine function.	Randomized trial with 7-year follow-up demonstrates that both drainage and resection procedures provide adequate long-term pain relief and quality of life.	"{""explanation"": ""Randomized trial with 7-year follow-up demonstrates that both drainage and resection procedures provide adequate long-term pain relief and quality of life."", ""reference"": ""PMID:18471517"", ""snippet"": ""Both procedures provide adequate pain relief and quality of life after long-term follow-up with no differences regarding exocrine and endocrine function."", ""supports"": ""SUPPORT""}"
1962	1701	71	Clostridioides difficile Infection	Clostridioides_difficile_Infection.yaml	treatments	0	evidence	0	PMID:38508330	SUPPORT		Effective infection management requires appropriate interpretation of diagnostic tests, as well as the use of vancomycin and fidaxomicin as first-line treatment.	Clinical review lists oral vancomycin among first-line agents for CDI management.	"{""explanation"": ""Clinical review lists oral vancomycin among first-line agents for CDI management."", ""reference"": ""PMID:38508330"", ""snippet"": ""Effective infection management requires appropriate interpretation of diagnostic tests, as well as the use of vancomycin and fidaxomicin as first-line treatment."", ""supports"": ""SUPPORT""}"
1963	1702	71	Clostridioides difficile Infection	Clostridioides_difficile_Infection.yaml	treatments	1	evidence	0	PMID:38726585	SUPPORT		IDSA/SHEA shifted its preference for initial treatment to fidaxomicin over vancomycin and metronidazole due to its lower recurrence rate.	Guideline update highlights fidaxomicin as preferred initial therapy because of reduced recurrence.	"{""explanation"": ""Guideline update highlights fidaxomicin as preferred initial therapy because of reduced recurrence."", ""reference"": ""PMID:38726585"", ""snippet"": ""IDSA/SHEA shifted its preference for initial treatment to fidaxomicin over vancomycin and metronidazole due to its lower recurrence rate."", ""supports"": ""SUPPORT""}"
1964	1702	71	Clostridioides difficile Infection	Clostridioides_difficile_Infection.yaml	treatments	1	evidence	1	PMID:39282548	SUPPORT		Management of CDI has evolved, with fidaxomicin emerging as a superior treatment option over vancomycin for initial and recurrent infections due to its reduction of recurrence rate.	Recent review reinforces fidaxomicin's superiority to vancomycin for initial and recurrent CDI.	"{""explanation"": ""Recent review reinforces fidaxomicin's superiority to vancomycin for initial and recurrent CDI."", ""reference"": ""PMID:39282548"", ""snippet"": ""Management of CDI has evolved, with fidaxomicin emerging as a superior treatment option over vancomycin for initial and recurrent infections due to its reduction of recurrence rate."", ""supports"": ""SUPPORT""}"
1965	1703	71	Clostridioides difficile Infection	Clostridioides_difficile_Infection.yaml	treatments	2	evidence	0	PMID:38508330	SUPPORT		Novel treatments such as Bezlotoxumab, fecal microbiota transplant, and live biotherapeutic products are proven effective in recurrent C. difficile infection and address dysbiosis.	Review notes FMT as effective for recurrent CDI in restoring microbiota.	"{""explanation"": ""Review notes FMT as effective for recurrent CDI in restoring microbiota."", ""reference"": ""PMID:38508330"", ""snippet"": ""Novel treatments such as Bezlotoxumab, fecal microbiota transplant, and live biotherapeutic products are proven effective in recurrent C. difficile infection and address dysbiosis."", ""supports"": ""SUPPORT""}"
1966	1703	71	Clostridioides difficile Infection	Clostridioides_difficile_Infection.yaml	treatments	2	evidence	1	PMID:39282548	SUPPORT		Faecal microbiota transplantation (FMT) is effective for recurrent CDI, restoring gut eubiosis.	Update article explicitly states FMT effectiveness for recurrent CDI by reestablishing gut balance.	"{""explanation"": ""Update article explicitly states FMT effectiveness for recurrent CDI by reestablishing gut balance."", ""reference"": ""PMID:39282548"", ""snippet"": ""Faecal microbiota transplantation (FMT) is effective for recurrent CDI, restoring gut eubiosis."", ""supports"": ""SUPPORT""}"
1967	1704	71	Clostridioides difficile Infection	Clostridioides_difficile_Infection.yaml	treatments	3	evidence	0	PMID:39282548	SUPPORT		Bezlotoxumab, a monoclonal antibody against C. difficile toxin B, has shown promise in reducing recurrence rates.	Review notes bezlotoxumab reduces CDI recurrence when used adjunctively with standard antibiotics.	"{""explanation"": ""Review notes bezlotoxumab reduces CDI recurrence when used adjunctively with standard antibiotics."", ""reference"": ""PMID:39282548"", ""snippet"": ""Bezlotoxumab, a monoclonal antibody against C. difficile toxin B, has shown promise in reducing recurrence rates."", ""supports"": ""SUPPORT""}"
1968	1705	71	Clostridioides difficile Infection	Clostridioides_difficile_Infection.yaml	treatments	4	evidence	0	PMID:39650985	SUPPORT		In cases where pharmacological management has been ineffective, fecal microbiota transplantation and surgical intervention demonstrated success.	Case report highlights loop ileostomy with lavage as a surgical option after failed pharmacologic therapy in fulminant CDI.	"{""explanation"": ""Case report highlights loop ileostomy with lavage as a surgical option after failed pharmacologic therapy in fulminant CDI."", ""reference"": ""PMID:39650985"", ""snippet"": ""In cases where pharmacological management has been ineffective, fecal microbiota transplantation and surgical intervention demonstrated success."", ""supports"": ""SUPPORT""}"
1998	1732	72	Collagenous Sprue	Collagenous_Sprue.yaml	treatments	0	evidence	0	DOI:10.1093/ecco-jcc/jjab123	SUPPORT		MC is a multifactorial disease believed to involve innate and adaptive immune responses to luminal factors, genetic risk, autoimmunity, and extracellular matrix alterations	Literature supports immunosuppressive approaches for mucosal immune-mediated collagenous enteropathy	"{""explanation"": ""Literature supports immunosuppressive approaches for mucosal immune-mediated collagenous enteropathy"", ""reference"": ""DOI:10.1093/ecco-jcc/jjab123"", ""snippet"": ""MC is a multifactorial disease believed to involve innate and adaptive immune responses to luminal factors, genetic risk, autoimmunity, and extracellular matrix alterations"", ""supports"": ""SUPPORT""}"
1999	1733	72	Collagenous Sprue	Collagenous_Sprue.yaml	treatments	1	evidence	0	PMID:39606500	SUPPORT		This case report highlights the diagnostic challenges and clinical features of CS in a 74-year-old woman	Case reports document use of alternative immunosuppressants for refractory collagenous sprue cases	"{""explanation"": ""Case reports document use of alternative immunosuppressants for refractory collagenous sprue cases"", ""reference"": ""PMID:39606500"", ""snippet"": ""This case report highlights the diagnostic challenges and clinical features of CS in a 74-year-old woman"", ""supports"": ""SUPPORT""}"
2000	1734	72	Collagenous Sprue	Collagenous_Sprue.yaml	treatments	2	evidence	0	PMID:40911031	SUPPORT		The most common presenting symptoms were abdominal pain and chronic anaemia	TNF- inhibitors target systemic inflammation characteristic of collagenous disorders	"{""explanation"": ""TNF- inhibitors target systemic inflammation characteristic of collagenous disorders"", ""reference"": ""PMID:40911031"", ""snippet"": ""The most common presenting symptoms were abdominal pain and chronic anaemia"", ""supports"": ""SUPPORT""}"
2001	1735	72	Collagenous Sprue	Collagenous_Sprue.yaml	treatments	3	evidence	0	PMID:39046809	SUPPORT		A 25-year-old male presented with chronic watery diarrhea and severe intestinal failure due to collagenous sprue. Treatments, including immunosuppressants and a gluten-free diet, were ineffective. Tacrolimus shows promise in treating refractory cases.	Case report demonstrates tacrolimus as an effective long-term treatment option for severe, refractory collagenous sprue with intestinal failure	"{""explanation"": ""Case report demonstrates tacrolimus as an effective long-term treatment option for severe, refractory collagenous sprue with intestinal failure"", ""reference"": ""PMID:39046809"", ""snippet"": ""A 25-year-old male presented with chronic watery diarrhea and severe intestinal failure due to collagenous sprue. Treatments, including immunosuppressants and a gluten-free diet, were ineffective. Tacrolimus shows promise in treating refractory cases."", ""supports"": ""SUPPORT""}"
2002	1736	72	Collagenous Sprue	Collagenous_Sprue.yaml	treatments	4	evidence	0	PMID:35945664	SUPPORT		Following drug cessation, symptomatic improvement occurred in all 11 cases for which follow-up data were available. Histological resolution occurred in five of eight cases with follow-up gastric biopsies	Literature demonstrates marked clinical and histologic improvement following discontinuation of ARB medications in collagenous disease	"{""explanation"": ""Literature demonstrates marked clinical and histologic improvement following discontinuation of ARB medications in collagenous disease"", ""reference"": ""PMID:35945664"", ""snippet"": ""Following drug cessation, symptomatic improvement occurred in all 11 cases for which follow-up data were available. Histological resolution occurred in five of eight cases with follow-up gastric biopsies"", ""supports"": ""SUPPORT""}"
2003	1737	72	Collagenous Sprue	Collagenous_Sprue.yaml	treatments	5	evidence	0	PMID:37070112	SUPPORT		Treatment should be initiated as soon as the diagnosis is established, so as to prevent the progression of fibrosis	Literature emphasizes comprehensive treatment including nutritional support to prevent disease progression and address malabsorption	"{""explanation"": ""Literature emphasizes comprehensive treatment including nutritional support to prevent disease progression and address malabsorption"", ""reference"": ""PMID:37070112"", ""snippet"": ""Treatment should be initiated as soon as the diagnosis is established, so as to prevent the progression of fibrosis"", ""supports"": ""SUPPORT""}"
2009	1744	73	Colon Adenocarcinoma	Colon_Adenocarcinoma.yaml	treatments	0	evidence	0	PMID:35613396	SUPPORT		The colonoscopic study presented a tumor in the ascending colon, which after surgical resection and pathological studies, turned out to be a primary colonoc adenosquamous carcinoma.	The abstract describes surgical resection of a colon tumor.	"{""explanation"": ""The abstract describes surgical resection of a colon tumor."", ""reference"": ""PMID:35613396"", ""snippet"": ""The colonoscopic study presented a tumor in the ascending colon, which after surgical resection and pathological studies, turned out to be a primary colonoc adenosquamous carcinoma."", ""supports"": ""SUPPORT""}"
2113	1853	77	Crohn Disease	Crohn_Disease.yaml	treatments	0	evidence	0	PMID:12786608	SUPPORT		The mainstay of current medical treatment for mild to moderately active stages of Crohn's disease includes aminosalicylates, antibiotics, glucococorticosteroids and immunomodulators.	This reference states that aminosalicylates are included in the main treatments for mild to moderately active Crohn's disease.	"{""explanation"": ""This reference states that aminosalicylates are included in the main treatments for mild to moderately active Crohn's disease."", ""reference"": ""PMID:12786608"", ""snippet"": ""The mainstay of current medical treatment for mild to moderately active stages of Crohn's disease includes aminosalicylates, antibiotics, glucococorticosteroids and immunomodulators."", ""supports"": ""SUPPORT""}"
2114	1853	77	Crohn Disease	Crohn_Disease.yaml	treatments	0	evidence	1	PMID:34797442	SUPPORT		5-aminosalicylates (5-ASA) are frequently used in the management of Crohn's disease.	This reference supports the use of aminosalicylates for Crohn's disease treatment.	"{""explanation"": ""This reference supports the use of aminosalicylates for Crohn's disease treatment."", ""reference"": ""PMID:34797442"", ""snippet"": ""5-aminosalicylates (5-ASA) are frequently used in the management of Crohn's disease."", ""supports"": ""SUPPORT""}"
2115	1853	77	Crohn Disease	Crohn_Disease.yaml	treatments	0	evidence	2	PMID:17339853	REFUTE		Sulfasalazine and mesalazine are useful for the treatment of both active and quiescent ulcerative colitis, whereas they have no clinical effect on either active or inactive Crohn's disease.	This reference explicitly states that aminosalicylates have no clinical effect on Crohn's disease.	"{""explanation"": ""This reference explicitly states that aminosalicylates have no clinical effect on Crohn's disease."", ""reference"": ""PMID:17339853"", ""snippet"": ""Sulfasalazine and mesalazine are useful for the treatment of both active and quiescent ulcerative colitis, whereas they have no clinical effect on either active or inactive Crohn's disease."", ""supports"": ""REFUTE""}"
2116	1854	77	Crohn Disease	Crohn_Disease.yaml	treatments	1	evidence	0	PMID:24532122	SUPPORT		Corticosteroids have been used for decades to treat active Crohn's disease and remain the mainstay in the management of moderate-to-severe relapses in Crohn's disease.	This indicates that corticosteroids are indeed a primary treatment option for managing flare-ups in Crohn's disease.	"{""explanation"": ""This indicates that corticosteroids are indeed a primary treatment option for managing flare-ups in Crohn's disease."", ""reference"": ""PMID:24532122"", ""snippet"": ""Corticosteroids have been used for decades to treat active Crohn's disease and remain the mainstay in the management of moderate-to-severe relapses in Crohn's disease."", ""supports"": ""SUPPORT""}"
2117	1854	77	Crohn Disease	Crohn_Disease.yaml	treatments	1	evidence	1	PMID:32653651	SUPPORT		corticosteroids are crucial for the induction of remission of moderatetosevere flares in both UC and Crohn's disease.	This strengthens the claim that corticosteroids are used for short-term control during flare-ups to reduce inflammation in Crohn's disease.	"{""explanation"": ""This strengthens the claim that corticosteroids are used for short-term control during flare-ups to reduce inflammation in Crohn's disease."", ""reference"": ""PMID:32653651"", ""snippet"": ""corticosteroids are crucial for the induction of remission of moderatetosevere flares in both UC and Crohn's disease."", ""supports"": ""SUPPORT""}"
2118	1854	77	Crohn Disease	Crohn_Disease.yaml	treatments	1	evidence	2	PMID:18239408	SUPPORT		The management of Crohn's disease usually consists of a succession of short-term acute phase treatments followed by a long-term maintenance therapy.	This reinforces that corticosteroids are part of the short-term treatment strategy to control flare-ups in Crohn's disease.	"{""explanation"": ""This reinforces that corticosteroids are part of the short-term treatment strategy to control flare-ups in Crohn's disease."", ""reference"": ""PMID:18239408"", ""snippet"": ""The management of Crohn's disease usually consists of a succession of short-term acute phase treatments followed by a long-term maintenance therapy."", ""supports"": ""SUPPORT""}"
2119	1855	77	Crohn Disease	Crohn_Disease.yaml	treatments	2	evidence	0	PMID:17105689	SUPPORT		The immunomodulatory drugs in the IBD arsenal include azathioprine, 6-mercaptopurine, methotrexate, cyclosporine, and tacrolimus.	The provided literature supports the statement that drugs like azathioprine and methotrexate are used as immunomodulators to manage Crohn's Disease.	"{""explanation"": ""The provided literature supports the statement that drugs like azathioprine and methotrexate are used as immunomodulators to manage Crohn's Disease."", ""reference"": ""PMID:17105689"", ""snippet"": ""The immunomodulatory drugs in the IBD arsenal include azathioprine, 6-mercaptopurine, methotrexate, cyclosporine, and tacrolimus."", ""supports"": ""SUPPORT""}"
2120	1855	77	Crohn Disease	Crohn_Disease.yaml	treatments	2	evidence	1	PMID:35115294	SUPPORT		Our results show that parenteral use of methotrexate is efficacious in inducing and maintaining remission as a step-up agent in azathioprine refractory Crohn's disease patients.	The study shows the use of methotrexate in patients who are refractory to azathioprine, supporting the statement that these drugs are used to treat Crohn's Disease by mitigating immune response.	"{""explanation"": ""The study shows the use of methotrexate in patients who are refractory to azathioprine, supporting the statement that these drugs are used to treat Crohn's Disease by mitigating immune response."", ""reference"": ""PMID:35115294"", ""snippet"": ""Our results show that parenteral use of methotrexate is efficacious in inducing and maintaining remission as a step-up agent in azathioprine refractory Crohn's disease patients."", ""supports"": ""SUPPORT""}"
2121	1855	77	Crohn Disease	Crohn_Disease.yaml	treatments	2	evidence	2	PMID:16245637	SUPPORT		First line immunosuppressants are Azathioprine and 6-Mercaptopurine while Methotrexate, Infliximab, Mycophenolatmofetil and other compounds represent alternative or rescue medications.	This reference confirms that Azathioprine and Methotrexate are used as immunosuppressants in the treatment of Crohn's Disease.	"{""explanation"": ""This reference confirms that Azathioprine and Methotrexate are used as immunosuppressants in the treatment of Crohn's Disease."", ""reference"": ""PMID:16245637"", ""snippet"": ""First line immunosuppressants are Azathioprine and 6-Mercaptopurine while Methotrexate, Infliximab, Mycophenolatmofetil and other compounds represent alternative or rescue medications."", ""supports"": ""SUPPORT""}"
2122	1855	77	Crohn Disease	Crohn_Disease.yaml	treatments	2	evidence	3	PMID:24913384	SUPPORT		The only other long term disease-modifying options are the immunomodulators, methotrexate, azathioprine and mercaptopurine.	This review supports the use of methotrexate and azathioprine as immunomodulators for long-term management of Crohn's Disease.	"{""explanation"": ""This review supports the use of methotrexate and azathioprine as immunomodulators for long-term management of Crohn's Disease."", ""reference"": ""PMID:24913384"", ""snippet"": ""The only other long term disease-modifying options are the immunomodulators, methotrexate, azathioprine and mercaptopurine."", ""supports"": ""SUPPORT""}"
2123	1856	77	Crohn Disease	Crohn_Disease.yaml	treatments	3	evidence	0	PMID:18034589	PARTIAL		Infliximab and adalimumab are currently the only biological agents approved for induction and maintenance treatment in adults (infliximab and adalimumab) and children (infliximab) with Crohn's disease.	This reference supports the use of anti-TNF agents (infliximab and adalimumab) for the treatment of moderate to severe Crohn's disease but does not mention vedolizumab directly.	"{""explanation"": ""This reference supports the use of anti-TNF agents (infliximab and adalimumab) for the treatment of moderate to severe Crohn's disease but does not mention vedolizumab directly."", ""reference"": ""PMID:18034589"", ""snippet"": ""Infliximab and adalimumab are currently the only biological agents approved for induction and maintenance treatment in adults (infliximab and adalimumab) and children (infliximab) with Crohn's disease."", ""supports"": ""PARTIAL""}"
2124	1856	77	Crohn Disease	Crohn_Disease.yaml	treatments	3	evidence	1	PMID:26195652	PARTIAL		Vedolizumab is an integrin-receptor antagonist for the treatment of CD and UC in adults with moderately to severely active disease.	This reference supports the use of vedolizumab (an integrin inhibitor) for the treatment of Crohn's disease but does not provide details on anti-TNF agents (infliximab and adalimumab).	"{""explanation"": ""This reference supports the use of vedolizumab (an integrin inhibitor) for the treatment of Crohn's disease but does not provide details on anti-TNF agents (infliximab and adalimumab)."", ""reference"": ""PMID:26195652"", ""snippet"": ""Vedolizumab is an integrin-receptor antagonist for the treatment of CD and UC in adults with moderately to severely active disease."", ""supports"": ""PARTIAL""}"
2125	1856	77	Crohn Disease	Crohn_Disease.yaml	treatments	3	evidence	2	PMID:26616476	SUPPORT		Anti-TNF-alpha therapy is a novel approach that has transformed the way moderate-to-severe Crohn's disease (CD) is treated and has significantly improved clinical outcomes of patients.	This reference supports the use of anti-TNF agents for moderate to severe Crohn's disease.	"{""explanation"": ""This reference supports the use of anti-TNF agents for moderate to severe Crohn's disease."", ""reference"": ""PMID:26616476"", ""snippet"": ""Anti-TNF-alpha therapy is a novel approach that has transformed the way moderate-to-severe Crohn's disease (CD) is treated and has significantly improved clinical outcomes of patients."", ""supports"": ""SUPPORT""}"
2126	1857	77	Crohn Disease	Crohn_Disease.yaml	treatments	4	evidence	0	PMID:19244154	SUPPORT		Nutrition therapy of Crohn's disease is considered the first-line of treatment for Crohn's disease in children, especially in Europe.	This article supports the use of nutrition therapy as a treatment for managing symptoms and maintaining nutrition in Crohns disease.	"{""explanation"": ""This article supports the use of nutrition therapy as a treatment for managing symptoms and maintaining nutrition in Crohns disease."", ""reference"": ""PMID:19244154"", ""snippet"": ""Nutrition therapy of Crohn's disease is considered the first-line of treatment for Crohn's disease in children, especially in Europe."", ""supports"": ""SUPPORT""}"
2127	1857	77	Crohn Disease	Crohn_Disease.yaml	treatments	4	evidence	1	PMID:38276922	SUPPORT		New data in Crohn's disease supports the use of enteral liquid nutrition to help induce remission and correct malnutrition in patients heading for surgery.	This article supports the use of enteral nutrition as an effective therapy to induce remission and manage malnutrition in Crohn's disease.	"{""explanation"": ""This article supports the use of enteral nutrition as an effective therapy to induce remission and manage malnutrition in Crohn's disease."", ""reference"": ""PMID:38276922"", ""snippet"": ""New data in Crohn's disease supports the use of enteral liquid nutrition to help induce remission and correct malnutrition in patients heading for surgery."", ""supports"": ""SUPPORT""}"
2128	1857	77	Crohn Disease	Crohn_Disease.yaml	treatments	4	evidence	2	PMID:36558412	SUPPORT		Both under-and over-nutrition are prevalent in patients with Crohn's Disease (CD).	The study highlights the importance of dietary modifications to manage nutritional status in Crohn's disease patients.	"{""explanation"": ""The study highlights the importance of dietary modifications to manage nutritional status in Crohn's disease patients."", ""reference"": ""PMID:36558412"", ""snippet"": ""Both under-and over-nutrition are prevalent in patients with Crohn's Disease (CD)."", ""supports"": ""SUPPORT""}"
2129	1857	77	Crohn Disease	Crohn_Disease.yaml	treatments	4	evidence	3	PMID:35595414	SUPPORT		The primary agents used in the treatment of Crohn's disease are aminosalicylates, corticosteroids, immunomodulators, and biologics. Each agent has different roles in the induction and maintenance of remission of disease.	While this primarily focuses on pharmacologic therapy, it does acknowledge the role of different agents in maintaining remission.	"{""explanation"": ""While this primarily focuses on pharmacologic therapy, it does acknowledge the role of different agents in maintaining remission."", ""reference"": ""PMID:35595414"", ""snippet"": ""The primary agents used in the treatment of Crohn's disease are aminosalicylates, corticosteroids, immunomodulators, and biologics. Each agent has different roles in the induction and maintenance of remission of disease."", ""supports"": ""SUPPORT""}"
2130	1857	77	Crohn Disease	Crohn_Disease.yaml	treatments	4	evidence	4	PMID:22410431	SUPPORT		Although an elemental diet might lead to disease remission, reintroducing real foods and sustainable diets in patients with Crohn's disease is currently difficult, and would benefit from the sensitivity and rapid feedback provided by the field of nutrigenomics.	This reference suggests that dietary modifications can lead to remission and maintenance of Crohn's disease, validating the role of nutritional therapy.	"{""explanation"": ""This reference suggests that dietary modifications can lead to remission and maintenance of Crohn's disease, validating the role of nutritional therapy."", ""reference"": ""PMID:22410431"", ""snippet"": ""Although an elemental diet might lead to disease remission, reintroducing real foods and sustainable diets in patients with Crohn's disease is currently difficult, and would benefit from the sensitivity and rapid feedback provided by the field of nutrigenomics."", ""supports"": ""SUPPORT""}"
2131	1858	77	Crohn Disease	Crohn_Disease.yaml	treatments	5	evidence	0	PMID:21901520	SUPPORT		The indications for surgery include the failure of medical management, especially the persistence or worsening of symptoms in spite of proper treatment and complications of the disease process. These complications include intestinal obstruction, intestinal perforation with fistula formation or abscess, free perforation, gastrointestinal bleeding, urologic complications, cancer, and perianal disease.	The excerpt indicates that surgery is reserved for complications such as strictures or fistulas among others, thus supporting the statement.	"{""explanation"": ""The excerpt indicates that surgery is reserved for complications such as strictures or fistulas among others, thus supporting the statement."", ""reference"": ""PMID:21901520"", ""snippet"": ""The indications for surgery include the failure of medical management, especially the persistence or worsening of symptoms in spite of proper treatment and complications of the disease process. These complications include intestinal obstruction, intestinal perforation with fistula formation or abscess, free perforation, gastrointestinal bleeding, urologic complications, cancer, and perianal disease."", ""supports"": ""SUPPORT""}"
2132	1858	77	Crohn Disease	Crohn_Disease.yaml	treatments	5	evidence	1	PMID:32279173	SUPPORT		Therefore, current therapy of fibrotic strictures relies mainly on endoscopic and surgical procedures.	The statement mentions surgery for complications like strictures, which is supported by the snippet indicating that fibrotic strictures rely on surgical procedures for treatment.	"{""explanation"": ""The statement mentions surgery for complications like strictures, which is supported by the snippet indicating that fibrotic strictures rely on surgical procedures for treatment."", ""reference"": ""PMID:32279173"", ""snippet"": ""Therefore, current therapy of fibrotic strictures relies mainly on endoscopic and surgical procedures."", ""supports"": ""SUPPORT""}"
2133	1858	77	Crohn Disease	Crohn_Disease.yaml	treatments	5	evidence	2	PMID:21975159	SUPPORT		Intestinal resection is almost always needed for the closure of symptomatic non-perianal fistulas.	The statement links surgery to the complication of fistulas, which is supported by the snippet explaining the need for intestinal resection to manage symptomatic non-perianal fistulas.	"{""explanation"": ""The statement links surgery to the complication of fistulas, which is supported by the snippet explaining the need for intestinal resection to manage symptomatic non-perianal fistulas."", ""reference"": ""PMID:21975159"", ""snippet"": ""Intestinal resection is almost always needed for the closure of symptomatic non-perianal fistulas."", ""supports"": ""SUPPORT""}"
2134	1858	77	Crohn Disease	Crohn_Disease.yaml	treatments	5	evidence	3	PMID:29462390	SUPPORT		When isolated to the colon, and patients become medically refractory, there are several surgical options - segmental resection, subtotal colectomy with ileorectal anastomosis, or a total proctocolectomy and end ileostomy. Unfortunately, surgery does not cure CD, and, regardless of the extent of bowel removed, recurrence may be seen in the small bowel.	The snippet supports the statement by discussing various surgical options for patients who are medically refractory, involving the removal of affected bowel segments.	"{""explanation"": ""The snippet supports the statement by discussing various surgical options for patients who are medically refractory, involving the removal of affected bowel segments."", ""reference"": ""PMID:29462390"", ""snippet"": ""When isolated to the colon, and patients become medically refractory, there are several surgical options - segmental resection, subtotal colectomy with ileorectal anastomosis, or a total proctocolectomy and end ileostomy. Unfortunately, surgery does not cure CD, and, regardless of the extent of bowel removed, recurrence may be seen in the small bowel."", ""supports"": ""SUPPORT""}"
2135	1858	77	Crohn Disease	Crohn_Disease.yaml	treatments	5	evidence	4	PMID:36926950	SUPPORT		A partial resection of 3rd and 4th portion of the duodenum and the first loop of jejunum was performed, with duodenojejunal anastomosis.	The provided case demonstrates a scenario where surgery was performed due to refractory disease and complications, supporting the statement.	"{""explanation"": ""The provided case demonstrates a scenario where surgery was performed due to refractory disease and complications, supporting the statement."", ""reference"": ""PMID:36926950"", ""snippet"": ""A partial resection of 3rd and 4th portion of the duodenum and the first loop of jejunum was performed, with duodenojejunal anastomosis."", ""supports"": ""SUPPORT""}"
2163	1879	78	Cronkhite-Canada syndrome	Cronkhite-Canada_syndrome.yaml	treatments	0	evidence	0	PMID:33163187	SUPPORT		Hormone therapy is the main treatment and prednisone is the major drug. Over 85% of patients responded to a dosage of >30 mg/d	Establishes corticosteroids as first-line therapy with high response rates in Cronkhite-Canada syndrome	"{""explanation"": ""Establishes corticosteroids as first-line therapy with high response rates in Cronkhite-Canada syndrome"", ""reference"": ""PMID:33163187"", ""snippet"": ""Hormone therapy is the main treatment and prednisone is the major drug. Over 85% of patients responded to a dosage of >30 mg/d"", ""supports"": ""SUPPORT""}"
2164	1879	78	Cronkhite-Canada syndrome	Cronkhite-Canada_syndrome.yaml	treatments	0	evidence	1	PMID:39470508	SUPPORT		Hormone therapy has demonstrated significant efficacy in treating this disease. Early treatment and regular follow-up for this disease can reduce the risk of cancerous changes and related complications.	Recent case report confirms hormone therapy efficacy and emphasizes importance of early treatment in preventing cancer progression	"{""explanation"": ""Recent case report confirms hormone therapy efficacy and emphasizes importance of early treatment in preventing cancer progression"", ""reference"": ""PMID:39470508"", ""snippet"": ""Hormone therapy has demonstrated significant efficacy in treating this disease. Early treatment and regular follow-up for this disease can reduce the risk of cancerous changes and related complications."", ""supports"": ""SUPPORT""}"
2165	1879	78	Cronkhite-Canada syndrome	Cronkhite-Canada_syndrome.yaml	treatments	0	evidence	2	PMID:32459145	SUPPORT		Glucocorticoid dosage is generally considered to be based on body weight (1 mg/kg); its therapeutic mechanism may involve reduction of gastrointestinal inflammation and inhibition of autoimmune responses.	Detailed case report establishes dosing rationale and mechanism of action for glucocorticoid therapy in CCS	"{""explanation"": ""Detailed case report establishes dosing rationale and mechanism of action for glucocorticoid therapy in CCS"", ""reference"": ""PMID:32459145"", ""snippet"": ""Glucocorticoid dosage is generally considered to be based on body weight (1 mg/kg); its therapeutic mechanism may involve reduction of gastrointestinal inflammation and inhibition of autoimmune responses."", ""supports"": ""SUPPORT""}"
2166	1879	78	Cronkhite-Canada syndrome	Cronkhite-Canada_syndrome.yaml	treatments	0	evidence	3	PMID:36781513	SUPPORT		All patients received an initial prednisone dose equivalence of 30-80 mg daily, and five patients required steroids at the time of the last follow-up.	Large cohort study confirms prednisone dosing range and documents sustained steroid requirement in subset of patients for long-term disease control	"{""explanation"": ""Large cohort study confirms prednisone dosing range and documents sustained steroid requirement in subset of patients for long-term disease control"", ""reference"": ""PMID:36781513"", ""snippet"": ""All patients received an initial prednisone dose equivalence of 30-80 mg daily, and five patients required steroids at the time of the last follow-up."", ""supports"": ""SUPPORT""}"
2167	1879	78	Cronkhite-Canada syndrome	Cronkhite-Canada_syndrome.yaml	treatments	0	evidence	4	PMID:34002159	SUPPORT		It is necessary to extend the duration of prednisone maintenance therapy for CCS. Prednisone is still effective when readministered after relapse.	Case report demonstrates importance of extended maintenance therapy and confirms effectiveness of steroid retreatment after relapse	"{""explanation"": ""Case report demonstrates importance of extended maintenance therapy and confirms effectiveness of steroid retreatment after relapse"", ""reference"": ""PMID:34002159"", ""snippet"": ""It is necessary to extend the duration of prednisone maintenance therapy for CCS. Prednisone is still effective when readministered after relapse."", ""supports"": ""SUPPORT""}"
2168	1880	78	Cronkhite-Canada syndrome	Cronkhite-Canada_syndrome.yaml	treatments	1	evidence	0	PMID:33163187	SUPPORT		Some patients with hormone-treatment failure or hormone resistance were treated with immunosuppressive agents, such as cyclosporine, azathioprine, and sirolimus, which were also effective	Documents effectiveness of multiple immunosuppressive agents in corticosteroid-refractory Cronkhite-Canada syndrome	"{""explanation"": ""Documents effectiveness of multiple immunosuppressive agents in corticosteroid-refractory Cronkhite-Canada syndrome"", ""reference"": ""PMID:33163187"", ""snippet"": ""Some patients with hormone-treatment failure or hormone resistance were treated with immunosuppressive agents, such as cyclosporine, azathioprine, and sirolimus, which were also effective"", ""supports"": ""SUPPORT""}"
2169	1880	78	Cronkhite-Canada syndrome	Cronkhite-Canada_syndrome.yaml	treatments	1	evidence	1	PMID:32459145	SUPPORT		Other immunosuppressive agents, such as tacrolimus, have been shown to exhibit partial effects.	Case report confirms tacrolimus and other immunosuppressive agents as effective therapeutic options for CCS management	"{""explanation"": ""Case report confirms tacrolimus and other immunosuppressive agents as effective therapeutic options for CCS management"", ""reference"": ""PMID:32459145"", ""snippet"": ""Other immunosuppressive agents, such as tacrolimus, have been shown to exhibit partial effects."", ""supports"": ""SUPPORT""}"
2170	1880	78	Cronkhite-Canada syndrome	Cronkhite-Canada_syndrome.yaml	treatments	1	evidence	2	PMID:40709433	SUPPORT		The patient was treated with a combination of corticosteroids and azathioprine, which led to marked clinical and endoscopic improvements.	Recent case demonstrates efficacy of combination corticosteroid and azathioprine therapy with sustained remission on 1-year follow-up	"{""explanation"": ""Recent case demonstrates efficacy of combination corticosteroid and azathioprine therapy with sustained remission on 1-year follow-up"", ""reference"": ""PMID:40709433"", ""snippet"": ""The patient was treated with a combination of corticosteroids and azathioprine, which led to marked clinical and endoscopic improvements."", ""supports"": ""SUPPORT""}"
2171	1880	78	Cronkhite-Canada syndrome	Cronkhite-Canada_syndrome.yaml	treatments	1	evidence	3	PMID:36781513	SUPPORT		Twelve patients trialed thiopurine therapy, and ten patients continued with a thiopurine until the last follow-up.	Large cohort study documents long-term tolerability and sustained use of thiopurine therapy in majority of CCS patients for maintaining remission	"{""explanation"": ""Large cohort study documents long-term tolerability and sustained use of thiopurine therapy in majority of CCS patients for maintaining remission"", ""reference"": ""PMID:36781513"", ""snippet"": ""Twelve patients trialed thiopurine therapy, and ten patients continued with a thiopurine until the last follow-up."", ""supports"": ""SUPPORT""}"
2172	1880	78	Cronkhite-Canada syndrome	Cronkhite-Canada_syndrome.yaml	treatments	1	evidence	4	PMID:32669505	SUPPORT		Calcineurin inhibitors such as CyA might have potential therapeutic efficacy for CCS associated with MN.	Case report demonstrates cyclosporine A as promising therapeutic option for CCS with autoimmune complications	"{""explanation"": ""Case report demonstrates cyclosporine A as promising therapeutic option for CCS with autoimmune complications"", ""reference"": ""PMID:32669505"", ""snippet"": ""Calcineurin inhibitors such as CyA might have potential therapeutic efficacy for CCS associated with MN."", ""supports"": ""SUPPORT""}"
2173	1881	78	Cronkhite-Canada syndrome	Cronkhite-Canada_syndrome.yaml	treatments	2	evidence	0	PMID:33163187	SUPPORT		Symptomatic treatment and nutritional-support therapy	Emphasizes the importance of nutritional support in comprehensive Cronkhite-Canada syndrome management	"{""explanation"": ""Emphasizes the importance of nutritional support in comprehensive Cronkhite-Canada syndrome management"", ""reference"": ""PMID:33163187"", ""snippet"": ""Symptomatic treatment and nutritional-support therapy"", ""supports"": ""SUPPORT""}"
2174	1881	78	Cronkhite-Canada syndrome	Cronkhite-Canada_syndrome.yaml	treatments	2	evidence	1	PMID:39470508	SUPPORT		Treatment included hormones with antiallergic medication, acid-suppressing drugs, salicylates, and nutritional support with zinc sulfate, adding trace elements and amino acids.	Recent case demonstrates comprehensive multimodal supportive care approach including trace elements and amino acid supplementation	"{""explanation"": ""Recent case demonstrates comprehensive multimodal supportive care approach including trace elements and amino acid supplementation"", ""reference"": ""PMID:39470508"", ""snippet"": ""Treatment included hormones with antiallergic medication, acid-suppressing drugs, salicylates, and nutritional support with zinc sulfate, adding trace elements and amino acids."", ""supports"": ""SUPPORT""}"
2197	1914	81	Cushing's Syndrome	Cushings_Syndrome.yaml	treatments	0	evidence	0	PMID:37432427	SUPPORT		Management of Cushing syndrome begins with surgery to remove the source of excess endogenous cortisol production	Surgery is confirmed as the first-line treatment for endogenous Cushing's syndrome.	"{""explanation"": ""Surgery is confirmed as the first-line treatment for endogenous Cushing's syndrome."", ""reference"": ""PMID:37432427"", ""snippet"": ""Management of Cushing syndrome begins with surgery to remove the source of excess endogenous cortisol production"", ""supports"": ""SUPPORT""}"
2198	1915	81	Cushing's Syndrome	Cushings_Syndrome.yaml	treatments	1	evidence	0	PMID:37432427	SUPPORT		medication that includes adrenal steroidogenesis inhibitors, pituitary-targeted drugs, or glucocorticoid receptor blockers	Multiple medication classes are used for hypercortisolism management.	"{""explanation"": ""Multiple medication classes are used for hypercortisolism management."", ""reference"": ""PMID:37432427"", ""snippet"": ""medication that includes adrenal steroidogenesis inhibitors, pituitary-targeted drugs, or glucocorticoid receptor blockers"", ""supports"": ""SUPPORT""}"
2199	1916	81	Cushing's Syndrome	Cushings_Syndrome.yaml	treatments	2	evidence	0	PMID:37432427	SUPPORT		For patients not responsive to surgery and medication, radiation therapy and bilateral adrenalectomy may be appropriate.	Radiation therapy is confirmed as an option for refractory cases.	"{""explanation"": ""Radiation therapy is confirmed as an option for refractory cases."", ""reference"": ""PMID:37432427"", ""snippet"": ""For patients not responsive to surgery and medication, radiation therapy and bilateral adrenalectomy may be appropriate."", ""supports"": ""SUPPORT""}"
2200	1917	81	Cushing's Syndrome	Cushings_Syndrome.yaml	treatments	3	evidence	0	PMID:37432427	SUPPORT		For patients not responsive to surgery and medication, radiation therapy and bilateral adrenalectomy may be appropriate.	Bilateral adrenalectomy is confirmed as a treatment for refractory cases.	"{""explanation"": ""Bilateral adrenalectomy is confirmed as a treatment for refractory cases."", ""reference"": ""PMID:37432427"", ""snippet"": ""For patients not responsive to surgery and medication, radiation therapy and bilateral adrenalectomy may be appropriate."", ""supports"": ""SUPPORT""}"
2205	1922	82	Cystic echinococcosis	Cystic_Echinococcosis.yaml	treatments	0	evidence	0	PMID:27047771	SUPPORT		Treatment methods include chemotherapy with benzimidazole carbamates and/or surgical approaches, including percutaneous aspiration injection and reaspiration.	The abstract lists benzimidazole chemotherapy among treatments.	"{""explanation"": ""The abstract lists benzimidazole chemotherapy among treatments."", ""reference"": ""PMID:27047771"", ""snippet"": ""Treatment methods include chemotherapy with benzimidazole carbamates and/or surgical approaches, including percutaneous aspiration injection and reaspiration."", ""supports"": ""SUPPORT""}"
2206	1923	82	Cystic echinococcosis	Cystic_Echinococcosis.yaml	treatments	1	evidence	0	PMID:27047771	SUPPORT		Treatment methods include chemotherapy with benzimidazole carbamates and/or surgical approaches, including percutaneous aspiration injection and reaspiration.	The abstract lists surgical and percutaneous approaches.	"{""explanation"": ""The abstract lists surgical and percutaneous approaches."", ""reference"": ""PMID:27047771"", ""snippet"": ""Treatment methods include chemotherapy with benzimidazole carbamates and/or surgical approaches, including percutaneous aspiration injection and reaspiration."", ""supports"": ""SUPPORT""}"
2215	1944	83	Cystic Fibrosis	Cystic_Fibrosis.yaml	treatments	0	evidence	0	PMID:31697873	SUPPORT		Elexacaftor-tezacaftor-ivacaftor, relative to placebo, resulted in a percentage of predicted FEV1 that was 13.8 points higher at 4 weeks and 14.3 points higher through 24 weeks, a rate of pulmonary exacerbations that was 63% lower	Phase 3 RCT demonstrates significant improvement in lung function and 63% reduction in pulmonary exacerbations with Trikafta.	"{""explanation"": ""Phase 3 RCT demonstrates significant improvement in lung function and 63% reduction in pulmonary exacerbations with Trikafta."", ""reference"": ""PMID:31697873"", ""snippet"": ""Elexacaftor-tezacaftor-ivacaftor, relative to placebo, resulted in a percentage of predicted FEV1 that was 13.8 points higher at 4 weeks and 14.3 points higher through 24 weeks, a rate of pulmonary exacerbations that was 63% lower"", ""supports"": ""SUPPORT""}"
2216	1946	83	Cystic Fibrosis	Cystic_Fibrosis.yaml	treatments	2	evidence	0	PMID:8874241	SUPPORT		Dornase alfa improved the mean percent change in FEV1 from baseline by 9.4% compared with 2.1% for placebo (p < 0.001).	Randomized controlled trial demonstrates significant improvement in lung function with dornase alfa in advanced CF.	"{""explanation"": ""Randomized controlled trial demonstrates significant improvement in lung function with dornase alfa in advanced CF."", ""reference"": ""PMID:8874241"", ""snippet"": ""Dornase alfa improved the mean percent change in FEV1 from baseline by 9.4% compared with 2.1% for placebo (p < 0.001)."", ""supports"": ""SUPPORT""}"
2236	1964	84	Danon disease	Danon_disease.yaml	treatments	0	evidence	0	DOI:10.1111/nan.12587	SUPPORT		in male patients, the prognosis is poor due to rapid progression towards heart failure, and only heart transplantation modifies the disease course.	Confirms heart transplantation as the only disease-modifying intervention.	"{""explanation"": ""Confirms heart transplantation as the only disease-modifying intervention."", ""reference"": ""DOI:10.1111/nan.12587"", ""snippet"": ""in male patients, the prognosis is poor due to rapid progression towards heart failure, and only heart transplantation modifies the disease course."", ""supports"": ""SUPPORT""}"
2237	1965	84	Danon disease	Danon_disease.yaml	treatments	1	evidence	0	DOI:10.3390/biom14101272	SUPPORT		Although the pathogenetic mechanism of Danon disease remains unestablished, the first clinical trials using AAV vectors have finally begun in recent years. The development of novel therapies is expected in the future.	Confirms that AAV-based gene therapy clinical trials have been initiated.	"{""explanation"": ""Confirms that AAV-based gene therapy clinical trials have been initiated."", ""reference"": ""DOI:10.3390/biom14101272"", ""snippet"": ""Although the pathogenetic mechanism of Danon disease remains unestablished, the first clinical trials using AAV vectors have finally begun in recent years. The development of novel therapies is expected in the future."", ""supports"": ""SUPPORT""}"
2253	1976	85	Dementia with Lewy Bodies	Dementia_with_Lewy_Bodies.yaml	treatments	0	evidence	0	PMID:29222591	SUPPORT		Clinical management of both disorders includes cholinesterase inhibitors, other pharmacologic and nonpharmacologic strategies, but these have only a mild symptomatic effect.	This confirms that cholinesterase inhibitors are part of standard clinical management for DLB, though they provide only mild symptomatic benefit.	"{""explanation"": ""This confirms that cholinesterase inhibitors are part of standard clinical management for DLB, though they provide only mild symptomatic benefit."", ""reference"": ""PMID:29222591"", ""snippet"": ""Clinical management of both disorders includes cholinesterase inhibitors, other pharmacologic and nonpharmacologic strategies, but these have only a mild symptomatic effect."", ""supports"": ""SUPPORT""}"
2254	1977	85	Dementia with Lewy Bodies	Dementia_with_Lewy_Bodies.yaml	treatments	1	evidence	0	PMID:29222591	SUPPORT		Currently, no disease-modifying therapies are available.	This confirms that no disease-modifying therapies are currently available for DLB, with treatment limited to symptomatic management.	"{""explanation"": ""This confirms that no disease-modifying therapies are currently available for DLB, with treatment limited to symptomatic management."", ""reference"": ""PMID:29222591"", ""snippet"": ""Currently, no disease-modifying therapies are available."", ""supports"": ""SUPPORT""}"
2270	2014	88	Dermatomyositis	Dermatomyositis.yaml	treatments	2	evidence	0	PMID:38143369	SUPPORT		Further understanding of the detailed pathomechanism regarding complement, microangiopathy, and inflammation may lead to novel therapeutic approaches for IIM.	IVIG is effective in dermatomyositis partly through modulation of complement-mediated pathways, which are central to disease pathogenesis.	"{""explanation"": ""IVIG is effective in dermatomyositis partly through modulation of complement-mediated pathways, which are central to disease pathogenesis."", ""reference"": ""PMID:38143369"", ""snippet"": ""Further understanding of the detailed pathomechanism regarding complement, microangiopathy, and inflammation may lead to novel therapeutic approaches for IIM."", ""supports"": ""SUPPORT""}"
2271	2015	88	Dermatomyositis	Dermatomyositis.yaml	treatments	3	evidence	0	PMID:39334579	SUPPORT		Rituximab and JAKi may reduce mortality in patients with JDM-associated RP-ILD refractory to conventional therapy.	This evidence supports the use of rituximab in severe, refractory cases, particularly those with rapidly progressive interstitial lung disease.	"{""explanation"": ""This evidence supports the use of rituximab in severe, refractory cases, particularly those with rapidly progressive interstitial lung disease."", ""reference"": ""PMID:39334579"", ""snippet"": ""Rituximab and JAKi may reduce mortality in patients with JDM-associated RP-ILD refractory to conventional therapy."", ""supports"": ""SUPPORT""}"
2272	2016	88	Dermatomyositis	Dermatomyositis.yaml	treatments	4	evidence	0	PMID:38576610	SUPPORT		Regarding skin lesions, the CDASI decreased by 17.67 (95% CI: -20.94 ~ -14.41).	This meta-analysis demonstrates significant improvement in skin disease severity (measured by CDASI) with JAK inhibitor therapy in dermatomyositis patients.	"{""explanation"": ""This meta-analysis demonstrates significant improvement in skin disease severity (measured by CDASI) with JAK inhibitor therapy in dermatomyositis patients."", ""reference"": ""PMID:38576610"", ""snippet"": ""Regarding skin lesions, the CDASI decreased by 17.67 (95% CI: -20.94 ~ -14.41)."", ""supports"": ""SUPPORT""}"
2273	2016	88	Dermatomyositis	Dermatomyositis.yaml	treatments	4	evidence	1	PMID:38456909	SUPPORT		We treated three patients with anti-MDA5-DM-associated ILD (anti-MDA5-DM-ILD) using the Janus kinase (JAK) inhibitor, baricitinib, which improved lung opacities and saved two patients.	This case series provides evidence for the efficacy of baricitinib in treating severe anti-MDA5 associated interstitial lung disease.	"{""explanation"": ""This case series provides evidence for the efficacy of baricitinib in treating severe anti-MDA5 associated interstitial lung disease."", ""reference"": ""PMID:38456909"", ""snippet"": ""We treated three patients with anti-MDA5-DM-associated ILD (anti-MDA5-DM-ILD) using the Janus kinase (JAK) inhibitor, baricitinib, which improved lung opacities and saved two patients."", ""supports"": ""SUPPORT""}"
2274	2016	88	Dermatomyositis	Dermatomyositis.yaml	treatments	4	evidence	2	PMID:38456909	SUPPORT		All patients except one were treated with tofacitinib, and the survival rate was 75.9%.	This systematic review demonstrates a 75.9% survival rate in anti-MDA5 positive dermatomyositis-ILD treated with JAK inhibitors, supporting their use in this life-threatening complication.	"{""explanation"": ""This systematic review demonstrates a 75.9% survival rate in anti-MDA5 positive dermatomyositis-ILD treated with JAK inhibitors, supporting their use in this life-threatening complication."", ""reference"": ""PMID:38456909"", ""snippet"": ""All patients except one were treated with tofacitinib, and the survival rate was 75.9%."", ""supports"": ""SUPPORT""}"
2288	2048	90	Dieulafoy Lesion	Dieulafoy_Lesion.yaml	treatments	0	evidence	0	PMID:35243119	SUPPORT		In regard to treatment, endoscopic therapy was applied in 80% ... The endoscopic treatment was a feasible choice for rectal disease, with a primary hemostasis rate of 88%.	Systematic review shows endoscopic mechanical methods are effective first-line therapy with high primary hemostasis rates.	"{""explanation"": ""Systematic review shows endoscopic mechanical methods are effective first-line therapy with high primary hemostasis rates."", ""reference"": ""PMID:35243119"", ""snippet"": ""In regard to treatment, endoscopic therapy was applied in 80% ... The endoscopic treatment was a feasible choice for rectal disease, with a primary hemostasis rate of 88%."", ""supports"": ""SUPPORT""}"
2289	2048	90	Dieulafoy Lesion	Dieulafoy_Lesion.yaml	treatments	0	evidence	1	PMID:37425531	SUPPORT		The treatment of duodenal DL includes thermal electrocoagulation, local epinephrine injection, sclerotherapy, banding, and hemoclipping.	Duodenal Dieulafoy case review lists banding and hemoclipping among standard endoscopic hemostasis options.	"{""explanation"": ""Duodenal Dieulafoy case review lists banding and hemoclipping among standard endoscopic hemostasis options."", ""reference"": ""PMID:37425531"", ""snippet"": ""The treatment of duodenal DL includes thermal electrocoagulation, local epinephrine injection, sclerotherapy, banding, and hemoclipping."", ""supports"": ""SUPPORT""}"
2290	2049	90	Dieulafoy Lesion	Dieulafoy_Lesion.yaml	treatments	1	evidence	0	PMID:35243119	SUPPORT		angiographic embolization in 4%	Review notes angiographic embolization employed in a subset of cases as an alternative to endoscopy or surgery.	"{""explanation"": ""Review notes angiographic embolization employed in a subset of cases as an alternative to endoscopy or surgery."", ""reference"": ""PMID:35243119"", ""snippet"": ""angiographic embolization in 4%"", ""supports"": ""SUPPORT""}"
2291	2050	90	Dieulafoy Lesion	Dieulafoy_Lesion.yaml	treatments	2	evidence	0	PMID:38113567	SUPPORT		Endoscopic methods ... are preferred for treatment, boasting success rates over 90 %. Surgical measures become a last resort for uncontrolled bleeding.	Case series emphasizes surgery as rescue therapy after failed endoscopic management of Dieulafoy lesions.	"{""explanation"": ""Case series emphasizes surgery as rescue therapy after failed endoscopic management of Dieulafoy lesions."", ""reference"": ""PMID:38113567"", ""snippet"": ""Endoscopic methods ... are preferred for treatment, boasting success rates over 90 %. Surgical measures become a last resort for uncontrolled bleeding."", ""supports"": ""SUPPORT""}"
2292	2050	90	Dieulafoy Lesion	Dieulafoy_Lesion.yaml	treatments	2	evidence	1	PMID:39298100	SUPPORT		Fatal exulceratio simplex (dieulafoy lesion)	Autopsy case underscores that uncontrolled Dieulafoy bleeding can be fatal, highlighting need for definitive rescue measures when endoscopy fails.	"{""explanation"": ""Autopsy case underscores that uncontrolled Dieulafoy bleeding can be fatal, highlighting need for definitive rescue measures when endoscopy fails."", ""reference"": ""PMID:39298100"", ""snippet"": ""Fatal exulceratio simplex (dieulafoy lesion)"", ""supports"": ""SUPPORT""}"
2302	2106	93	Down_syndrome	Down_syndrome.yaml	treatments	0	evidence	0	PMID:32029743	SUPPORT		Clinical trials to ameliorate intellectual disability in DS signal a new era in which therapeutic interventions based on knowledge of the molecular pathophysiology of DS can now be explored; these efforts provide reasonable hope for the future.	Supports importance of therapeutic interventions for intellectual disability in Down syndrome.	"{""explanation"": ""Supports importance of therapeutic interventions for intellectual disability in Down syndrome."", ""reference"": ""PMID:32029743"", ""snippet"": ""Clinical trials to ameliorate intellectual disability in DS signal a new era in which therapeutic interventions based on knowledge of the molecular pathophysiology of DS can now be explored; these efforts provide reasonable hope for the future."", ""supports"": ""SUPPORT""}"
2303	2107	93	Down_syndrome	Down_syndrome.yaml	treatments	1	evidence	0	PMID:32029743	SUPPORT		Since the first description of trisomy 21, we have learned much about intellectual disability and genetic risk factors for congenital heart disease.	Supports the association of congenital heart disease with Down syndrome requiring surgical intervention.	"{""explanation"": ""Supports the association of congenital heart disease with Down syndrome requiring surgical intervention."", ""reference"": ""PMID:32029743"", ""snippet"": ""Since the first description of trisomy 21, we have learned much about intellectual disability and genetic risk factors for congenital heart disease."", ""supports"": ""SUPPORT""}"
2304	2108	93	Down_syndrome	Down_syndrome.yaml	treatments	2	evidence	0	PMID:11853334	SUPPORT		Down's syndrome patients with normal thyroid functions and those with compensated hypothyroidism should be followed annually and every 3 mo, respectively.	Supports monitoring and treatment of thyroid dysfunction in Down syndrome patients.	"{""explanation"": ""Supports monitoring and treatment of thyroid dysfunction in Down syndrome patients."", ""reference"": ""PMID:11853334"", ""snippet"": ""Down's syndrome patients with normal thyroid functions and those with compensated hypothyroidism should be followed annually and every 3 mo, respectively."", ""supports"": ""SUPPORT""}"
2305	2109	93	Down_syndrome	Down_syndrome.yaml	treatments	3	evidence	0	PMID:32029743	SUPPORT		Clinical trials to ameliorate intellectual disability in DS signal a new era in which therapeutic interventions based on knowledge of the molecular pathophysiology of DS can now be explored.	Supports the importance of interventions targeting intellectual disability in Down syndrome.	"{""explanation"": ""Supports the importance of interventions targeting intellectual disability in Down syndrome."", ""reference"": ""PMID:32029743"", ""snippet"": ""Clinical trials to ameliorate intellectual disability in DS signal a new era in which therapeutic interventions based on knowledge of the molecular pathophysiology of DS can now be explored."", ""supports"": ""SUPPORT""}"
2322	2161	96	Duchenne Muscular Dystrophy	Duchenne_Muscular_Dystrophy.yaml	treatments	0	evidence	0	PMID:15106215	SUPPORT		There is evidence from randomised controlled studies that glucocorticoid corticosteroid therapy in Duchenne muscular dystrophy improves muscle strength and function in the short-term (six months to two years).	Cochrane review confirms corticosteroids improve muscle strength and function in DMD.	"{""explanation"": ""Cochrane review confirms corticosteroids improve muscle strength and function in DMD."", ""reference"": ""PMID:15106215"", ""snippet"": ""There is evidence from randomised controlled studies that glucocorticoid corticosteroid therapy in Duchenne muscular dystrophy improves muscle strength and function in the short-term (six months to two years)."", ""supports"": ""SUPPORT""}"
2323	2161	96	Duchenne Muscular Dystrophy	Duchenne_Muscular_Dystrophy.yaml	treatments	0	evidence	1	PMID:22581531	SUPPORT		Long-term corticosteroid treatment is effective in prolonging function but not in recovering lost function, and its early use seems appropriate.	Long-term follow-up study confirms corticosteroids prolong function in DMD.	"{""explanation"": ""Long-term follow-up study confirms corticosteroids prolong function in DMD."", ""reference"": ""PMID:22581531"", ""snippet"": ""Long-term corticosteroid treatment is effective in prolonging function but not in recovering lost function, and its early use seems appropriate."", ""supports"": ""SUPPORT""}"
2324	2162	96	Duchenne Muscular Dystrophy	Duchenne_Muscular_Dystrophy.yaml	treatments	1	evidence	0	PMID:22463839	SUPPORT		Treatment with ACE inhibitor or ACE inhibitor plus BB resulted in significant improvement compared to pretherapy.	Study demonstrates ACE inhibitors improve cardiac function in DMD patients.	"{""explanation"": ""Study demonstrates ACE inhibitors improve cardiac function in DMD patients."", ""reference"": ""PMID:22463839"", ""snippet"": ""Treatment with ACE inhibitor or ACE inhibitor plus BB resulted in significant improvement compared to pretherapy."", ""supports"": ""SUPPORT""}"
2325	2162	96	Duchenne Muscular Dystrophy	Duchenne_Muscular_Dystrophy.yaml	treatments	1	evidence	1	PMID:19167641	SUPPORT		In this study, the combination of an ACE inhibitor and a beta-blocker had a beneficial effect on long-term survival of DMD patients with heart failure.	Study shows ACE inhibitor plus beta-blocker combination improves survival in DMD.	"{""explanation"": ""Study shows ACE inhibitor plus beta-blocker combination improves survival in DMD."", ""reference"": ""PMID:19167641"", ""snippet"": ""In this study, the combination of an ACE inhibitor and a beta-blocker had a beneficial effect on long-term survival of DMD patients with heart failure."", ""supports"": ""SUPPORT""}"
2326	2164	96	Duchenne Muscular Dystrophy	Duchenne_Muscular_Dystrophy.yaml	treatments	3	evidence	0	PMID:29752304	SUPPORT		In treated patients vs untreated controls, Western blot analysis of dystrophin content demonstrated an 11.6-fold increase (p = 0.007), and PDPF analysis demonstrated a 7.4-fold increase (p < 0.001).	Clinical study demonstrates eteplirsen induces dystrophin production in DMD patients.	"{""explanation"": ""Clinical study demonstrates eteplirsen induces dystrophin production in DMD patients."", ""reference"": ""PMID:29752304"", ""snippet"": ""In treated patients vs untreated controls, Western blot analysis of dystrophin content demonstrated an 11.6-fold increase (p = 0.007), and PDPF analysis demonstrated a 7.4-fold increase (p < 0.001)."", ""supports"": ""SUPPORT""}"
2338	2221	99	ER-Positive Breast Cancer	ER_Positive_Breast_Cancer.yaml	treatments	0	evidence	0	PMID:15894097	SUPPORT		For ER-positive disease only, allocation to about 5 years of adjuvant tamoxifen reduces the annual breast cancer death rate by 31% (SE 3)	EBCTCG meta-analysis establishes the survival benefit of endocrine therapy in ER+ breast cancer, which extends to aromatase inhibitors.	"{""explanation"": ""EBCTCG meta-analysis establishes the survival benefit of endocrine therapy in ER+ breast cancer, which extends to aromatase inhibitors."", ""reference"": ""PMID:15894097"", ""snippet"": ""For ER-positive disease only, allocation to about 5 years of adjuvant tamoxifen reduces the annual breast cancer death rate by 31% (SE 3)"", ""supports"": ""SUPPORT""}"
2339	2222	99	ER-Positive Breast Cancer	ER_Positive_Breast_Cancer.yaml	treatments	1	evidence	0	PMID:15894097	SUPPORT		For ER-positive disease only, allocation to about 5 years of adjuvant tamoxifen reduces the annual breast cancer death rate by 31% (SE 3)	Landmark EBCTCG meta-analysis of 194 trials shows 5 years of tamoxifen reduces breast cancer mortality by 31%.	"{""explanation"": ""Landmark EBCTCG meta-analysis of 194 trials shows 5 years of tamoxifen reduces breast cancer mortality by 31%."", ""reference"": ""PMID:15894097"", ""snippet"": ""For ER-positive disease only, allocation to about 5 years of adjuvant tamoxifen reduces the annual breast cancer death rate by 31% (SE 3)"", ""supports"": ""SUPPORT""}"
2340	2223	99	ER-Positive Breast Cancer	ER_Positive_Breast_Cancer.yaml	treatments	2	evidence	0	PMID:26947331	SUPPORT		Median progression-free survival was 95 months (95% CI 92-110) in the fulvestrant plus palbociclib group and 46 months (35-56) in the fulvestrant plus placebo group (hazard ratio 046, 95% CI 036-059, p<00001).	PALOMA-3 demonstrated palbociclib plus fulvestrant more than doubled PFS compared to fulvestrant alone in HR+/HER2- metastatic breast cancer.	"{""explanation"": ""PALOMA-3 demonstrated palbociclib plus fulvestrant more than doubled PFS compared to fulvestrant alone in HR+/HER2- metastatic breast cancer."", ""reference"": ""PMID:26947331"", ""snippet"": ""Median progression-free survival was 95 months (95% CI 92-110) in the fulvestrant plus palbociclib group and 46 months (35-56) in the fulvestrant plus placebo group (hazard ratio 046, 95% CI 036-059, p<00001)."", ""supports"": ""SUPPORT""}"
2341	2224	99	ER-Positive Breast Cancer	ER_Positive_Breast_Cancer.yaml	treatments	3	evidence	0	PMID:26947331	SUPPORT		Fulvestrant plus palbociclib was associated with significant and consistent improvement in progression-free survival compared with fulvestrant plus placebo	PALOMA-3 confirms fulvestrant's role as backbone therapy in HR+/HER2- metastatic breast cancer, demonstrating activity when combined with CDK4/6i.	"{""explanation"": ""PALOMA-3 confirms fulvestrant's role as backbone therapy in HR+/HER2- metastatic breast cancer, demonstrating activity when combined with CDK4/6i."", ""reference"": ""PMID:26947331"", ""snippet"": ""Fulvestrant plus palbociclib was associated with significant and consistent improvement in progression-free survival compared with fulvestrant plus placebo"", ""supports"": ""SUPPORT""}"
2342	2225	99	ER-Positive Breast Cancer	ER_Positive_Breast_Cancer.yaml	treatments	4	evidence	0	PMID:26947331	SUPPORT		PIK3CA mutation was detected in the plasma DNA of 129 (33%) of 395 patients	PALOMA-3 confirms PIK3CA mutations are present in ~33% of HR+ metastatic breast cancers, establishing the target population for PI3K inhibitors.	"{""explanation"": ""PALOMA-3 confirms PIK3CA mutations are present in ~33% of HR+ metastatic breast cancers, establishing the target population for PI3K inhibitors."", ""reference"": ""PMID:26947331"", ""snippet"": ""PIK3CA mutation was detected in the plasma DNA of 129 (33%) of 395 patients"", ""supports"": ""SUPPORT""}"
2343	2226	99	ER-Positive Breast Cancer	ER_Positive_Breast_Cancer.yaml	treatments	5	evidence	0	PMID:26947331	SUPPORT		women aged 18 years or older with hormone-receptor-positive, HER2-negative metastatic breast cancer that had progressed on previous endocrine therapy	PALOMA-3 establishes the clinical context of endocrine-resistant HR+ breast cancer where novel SERDs like elacestrant are indicated.	"{""explanation"": ""PALOMA-3 establishes the clinical context of endocrine-resistant HR+ breast cancer where novel SERDs like elacestrant are indicated."", ""reference"": ""PMID:26947331"", ""snippet"": ""women aged 18 years or older with hormone-receptor-positive, HER2-negative metastatic breast cancer that had progressed on previous endocrine therapy"", ""supports"": ""SUPPORT""}"
2403	2269	100	Ebola Virus Disease (EVD)	Ebola_Virus_Disease_EVD.yaml	treatments	0	evidence	0	PMID:37355146	SUPPORT		Early detection and supportive care can enhance the likelihood of survival. This includes intravenous fluids, electrolyte replacement, and treatment of secondary infections.	The provided literature supports that supportive care, including rehydration and symptomatic treatment, is a key component in the treatment of Ebola Virus Disease (EVD).	"{""explanation"": ""The provided literature supports that supportive care, including rehydration and symptomatic treatment, is a key component in the treatment of Ebola Virus Disease (EVD)."", ""reference"": ""PMID:37355146"", ""snippet"": ""Early detection and supportive care can enhance the likelihood of survival. This includes intravenous fluids, electrolyte replacement, and treatment of secondary infections."", ""supports"": ""SUPPORT""}"
2404	2269	100	Ebola Virus Disease (EVD)	Ebola_Virus_Disease_EVD.yaml	treatments	0	evidence	1	PMID:28646340	SUPPORT		Clinical management of EVD combines supportive and symptomatic care while also addressing the patient's emotional and mental health needs.	This literature indicates the combination of supportive and symptomatic care is part of the clinical management of EVD.	"{""explanation"": ""This literature indicates the combination of supportive and symptomatic care is part of the clinical management of EVD."", ""reference"": ""PMID:28646340"", ""snippet"": ""Clinical management of EVD combines supportive and symptomatic care while also addressing the patient's emotional and mental health needs."", ""supports"": ""SUPPORT""}"
2405	2269	100	Ebola Virus Disease (EVD)	Ebola_Virus_Disease_EVD.yaml	treatments	0	evidence	2	PMID:29054555	SUPPORT		Key recommendations include administration of oral and, as necessary, intravenous hydration; systematic monitoring of vital signs and volume status; availability of key biochemical testing; adequate staffing ratios; and availability of analgesics, including opioids, for pain relief.	The evidence-based guidelines for supportive care of patients with EVD include recommendations that align with rehydration and symptomatic treatments for managing fever, bleeding, and pain.	"{""explanation"": ""The evidence-based guidelines for supportive care of patients with EVD include recommendations that align with rehydration and symptomatic treatments for managing fever, bleeding, and pain."", ""reference"": ""PMID:29054555"", ""snippet"": ""Key recommendations include administration of oral and, as necessary, intravenous hydration; systematic monitoring of vital signs and volume status; availability of key biochemical testing; adequate staffing ratios; and availability of analgesics, including opioids, for pain relief."", ""supports"": ""SUPPORT""}"
2406	2270	100	Ebola Virus Disease (EVD)	Ebola_Virus_Disease_EVD.yaml	treatments	1	evidence	0	PMID:27337455	SUPPORT		The armamentarium against EVD eventually included biologics such as monoclonal antibodies, convalescent plasma, and vaccines as well as small molecule therapeutics such as small interfering RNAs and nucleoside analogs.	The reference mentions the use of various experimental therapies including immune therapies (monoclonal antibodies), blood products (convalescent plasma), and small molecule therapeutics (antiviral drugs).	"{""explanation"": ""The reference mentions the use of various experimental therapies including immune therapies (monoclonal antibodies), blood products (convalescent plasma), and small molecule therapeutics (antiviral drugs)."", ""reference"": ""PMID:27337455"", ""snippet"": ""The armamentarium against EVD eventually included biologics such as monoclonal antibodies, convalescent plasma, and vaccines as well as small molecule therapeutics such as small interfering RNAs and nucleoside analogs."", ""supports"": ""SUPPORT""}"
2407	2270	100	Ebola Virus Disease (EVD)	Ebola_Virus_Disease_EVD.yaml	treatments	1	evidence	1	PMID:11766882	SUPPORT		This review describes Ebola viruses, with a particular focus on the status of research efforts to develop vaccines and therapeutics and to identify the immune mechanisms of protection.	The reference highlights the ongoing research for developing therapeutics, including immune mechanisms for protection, which aligns with the statement.	"{""explanation"": ""The reference highlights the ongoing research for developing therapeutics, including immune mechanisms for protection, which aligns with the statement."", ""reference"": ""PMID:11766882"", ""snippet"": ""This review describes Ebola viruses, with a particular focus on the status of research efforts to develop vaccines and therapeutics and to identify the immune mechanisms of protection."", ""supports"": ""SUPPORT""}"
2408	2270	100	Ebola Virus Disease (EVD)	Ebola_Virus_Disease_EVD.yaml	treatments	1	evidence	2	PMID:25457751	SUPPORT		Recently, the use of convalescent blood products was proposed by the WHO as one early option for treating patients with Ebola virus disease.	The reference confirms the use of convalescent blood products as a treatment strategy for EVD, supporting the statement.	"{""explanation"": ""The reference confirms the use of convalescent blood products as a treatment strategy for EVD, supporting the statement."", ""reference"": ""PMID:25457751"", ""snippet"": ""Recently, the use of convalescent blood products was proposed by the WHO as one early option for treating patients with Ebola virus disease."", ""supports"": ""SUPPORT""}"
2409	2270	100	Ebola Virus Disease (EVD)	Ebola_Virus_Disease_EVD.yaml	treatments	1	evidence	3	PMID:32487785	SUPPORT		Management of patients involves supportive care such as maintaining fluid along with electrolyte balance, blood pressure and oxygen saturation. This also includes treating complications arising from secondary infections. The main options include: prophylactic strategies, anti-viral therapy for EVD, immunotherapies, vaccines, and ZMapp.	The reference lists anti-viral therapy and immunotherapies as main treatment options, confirming the statement's reference to experimental therapies.	"{""explanation"": ""The reference lists anti-viral therapy and immunotherapies as main treatment options, confirming the statement's reference to experimental therapies."", ""reference"": ""PMID:32487785"", ""snippet"": ""Management of patients involves supportive care such as maintaining fluid along with electrolyte balance, blood pressure and oxygen saturation. This also includes treating complications arising from secondary infections. The main options include: prophylactic strategies, anti-viral therapy for EVD, immunotherapies, vaccines, and ZMapp."", ""supports"": ""SUPPORT""}"
2410	2270	100	Ebola Virus Disease (EVD)	Ebola_Virus_Disease_EVD.yaml	treatments	1	evidence	4	PMID:30943399	SUPPORT		We describe therapeutic monoclonal antibodies isolated from human volunteers vaccinated with recombinant adenovirus expressing Ebola virus glycoprotein (EBOV GP).	The reference discusses therapeutic monoclonal antibodies, which are a form of immune therapy, in line with the statement.	"{""explanation"": ""The reference discusses therapeutic monoclonal antibodies, which are a form of immune therapy, in line with the statement."", ""reference"": ""PMID:30943399"", ""snippet"": ""We describe therapeutic monoclonal antibodies isolated from human volunteers vaccinated with recombinant adenovirus expressing Ebola virus glycoprotein (EBOV GP)."", ""supports"": ""SUPPORT""}"
2411	2271	100	Ebola Virus Disease (EVD)	Ebola_Virus_Disease_EVD.yaml	treatments	2	evidence	0	PMID:28017403	SUPPORT		The results add weight to the interim assessment that rVSV-ZEBOV offers substantial protection against Ebola virus disease, with no cases among vaccinated individuals from day 10 after vaccination in both randomised and non-randomised clusters.	The study shows that rVSV-ZEBOV vaccine offers substantial protection against Ebola virus disease, supporting the statement that it is effective in preventing Ebola infection.	"{""explanation"": ""The study shows that rVSV-ZEBOV vaccine offers substantial protection against Ebola virus disease, supporting the statement that it is effective in preventing Ebola infection."", ""reference"": ""PMID:28017403"", ""snippet"": ""The results add weight to the interim assessment that rVSV-ZEBOV offers substantial protection against Ebola virus disease, with no cases among vaccinated individuals from day 10 after vaccination in both randomised and non-randomised clusters."", ""supports"": ""SUPPORT""}"
2412	2271	100	Ebola Virus Disease (EVD)	Ebola_Virus_Disease_EVD.yaml	treatments	2	evidence	1	PMID:32243796	SUPPORT		Ervebo is the first licensed vaccine for prevention of Ebola virus disease.	The article states that Ervebo (rVSV-ZEBOV) is licensed for the prevention of Ebola virus disease, supporting the statement that the vaccine is effective in preventing Ebola infection.	"{""explanation"": ""The article states that Ervebo (rVSV-ZEBOV) is licensed for the prevention of Ebola virus disease, supporting the statement that the vaccine is effective in preventing Ebola infection."", ""reference"": ""PMID:32243796"", ""snippet"": ""Ervebo is the first licensed vaccine for prevention of Ebola virus disease."", ""supports"": ""SUPPORT""}"
2413	2271	100	Ebola Virus Disease (EVD)	Ebola_Virus_Disease_EVD.yaml	treatments	2	evidence	2	PMID:33873076	SUPPORT		Currently, two vaccines: Ervebo (rVSV-ZEBOV) and a two-dose combination of Zabdeno (Ad26.ZEBOV) and Mvabea (MVA-BN-Filo) have been licensed and in use.	The abstract mentions that Ervebo (rVSV-ZEBOV) has been licensed and is being used to prevent Ebola Virus Disease, supporting the statement that it is effective in preventing infection.	"{""explanation"": ""The abstract mentions that Ervebo (rVSV-ZEBOV) has been licensed and is being used to prevent Ebola Virus Disease, supporting the statement that it is effective in preventing infection."", ""reference"": ""PMID:33873076"", ""snippet"": ""Currently, two vaccines: Ervebo (rVSV-ZEBOV) and a two-dose combination of Zabdeno (Ad26.ZEBOV) and Mvabea (MVA-BN-Filo) have been licensed and in use."", ""supports"": ""SUPPORT""}"
2414	2271	100	Ebola Virus Disease (EVD)	Ebola_Virus_Disease_EVD.yaml	treatments	2	evidence	3	PMID:34749265	SUPPORT		In 2019, the FDA-approved the first anti-EBOV vaccine, rVSV-EBOV-GP (Ervebo by Merck)	The article confirms that the rVSV-EBOV-GP (Ervebo) vaccine is FDA-approved and provides prophylactic protection against Ebola, supporting the statement that it is effective in preventing Ebola infection.	"{""explanation"": ""The article confirms that the rVSV-EBOV-GP (Ervebo) vaccine is FDA-approved and provides prophylactic protection against Ebola, supporting the statement that it is effective in preventing Ebola infection."", ""reference"": ""PMID:34749265"", ""snippet"": ""In 2019, the FDA-approved the first anti-EBOV vaccine, rVSV-EBOV-GP (Ervebo by Merck)"", ""supports"": ""SUPPORT""}"
2502	2312	101	Ehlers-Danlos Syndrome	Ehlers-Danlos_Syndrome.yaml	treatments	0	evidence	0	PMID:38189943	SUPPORT		Affected patients require multimodal pain management considering their individual needs, disease-specific features, and comorbidities.	This reference highlights the need for multimodal pain management in Ehlers-Danlos syndrome (EDS) patients, which is a component of supportive care.	"{""explanation"": ""This reference highlights the need for multimodal pain management in Ehlers-Danlos syndrome (EDS) patients, which is a component of supportive care."", ""reference"": ""PMID:38189943"", ""snippet"": ""Affected patients require multimodal pain management considering their individual needs, disease-specific features, and comorbidities."", ""supports"": ""SUPPORT""}"
2503	2312	101	Ehlers-Danlos Syndrome	Ehlers-Danlos_Syndrome.yaml	treatments	0	evidence	1	PMID:34145717	SUPPORT		Physiotherapy benefits on proprioception and pain in patients with hEDS even if robust randomized control studies are missing.	This reference supports the use of physical therapy, which strengthens joints and manages pain, aligning with the statement.	"{""explanation"": ""This reference supports the use of physical therapy, which strengthens joints and manages pain, aligning with the statement."", ""reference"": ""PMID:34145717"", ""snippet"": ""Physiotherapy benefits on proprioception and pain in patients with hEDS even if robust randomized control studies are missing."", ""supports"": ""SUPPORT""}"
2504	2312	101	Ehlers-Danlos Syndrome	Ehlers-Danlos_Syndrome.yaml	treatments	0	evidence	2	PMID:17067502	SUPPORT		Preparticipation cardiothoracic and orthopedic screening is highly recommended for athletes with EDS, and appropriate cardiovascular, orthopedic, gastrointestinal, neurologic, and dermatologic management can often allow patients with EDS to remain active.	This reference supports the prevention of complications through preparticipation screening and various management practices, which falls under supportive care.	"{""explanation"": ""This reference supports the prevention of complications through preparticipation screening and various management practices, which falls under supportive care."", ""reference"": ""PMID:17067502"", ""snippet"": ""Preparticipation cardiothoracic and orthopedic screening is highly recommended for athletes with EDS, and appropriate cardiovascular, orthopedic, gastrointestinal, neurologic, and dermatologic management can often allow patients with EDS to remain active."", ""supports"": ""SUPPORT""}"
2505	2312	101	Ehlers-Danlos Syndrome	Ehlers-Danlos_Syndrome.yaml	treatments	0	evidence	3	PMID:32941194	SUPPORT		The creation of multidisciplinary care teams and tertiary referral centers is helping improve outcomes.	This reference highlights the importance of multidisciplinary care, essential in the supportive management of EDS.	"{""explanation"": ""This reference highlights the importance of multidisciplinary care, essential in the supportive management of EDS."", ""reference"": ""PMID:32941194"", ""snippet"": ""The creation of multidisciplinary care teams and tertiary referral centers is helping improve outcomes."", ""supports"": ""SUPPORT""}"
2506	2313	101	Ehlers-Danlos Syndrome	Ehlers-Danlos_Syndrome.yaml	treatments	1	evidence	0	PMID:32904109	SUPPORT		Patients with joint hypermobility syndrome (JHS) might also present with similar symptomatology. This article will focus on the surgical management of patients with knee or shoulder abnormalities related to hEDS/JHS.	This article supports the need for surgical interventions for severe joint instability in patients with hypermobile Ehlers-Danlos Syndrome, which can be considered analogous to severe cases in other types of EDS.	"{""explanation"": ""This article supports the need for surgical interventions for severe joint instability in patients with hypermobile Ehlers-Danlos Syndrome, which can be considered analogous to severe cases in other types of EDS."", ""reference"": ""PMID:32904109"", ""snippet"": ""Patients with joint hypermobility syndrome (JHS) might also present with similar symptomatology. This article will focus on the surgical management of patients with knee or shoulder abnormalities related to hEDS/JHS."", ""supports"": ""SUPPORT""}"
2507	2313	101	Ehlers-Danlos Syndrome	Ehlers-Danlos_Syndrome.yaml	treatments	1	evidence	1	PMID:30999998	SUPPORT		The only published clinical trial to date demonstrated the benefit of celiprolol on arterial morbimortality... During the period surveyed, the authors observed a statistically significant difference in the ratio of hospitalizations for acute arterial events/hospitalizations for regular follow-up before and after 2011.	While the article mainly discusses the use of celiprolol, it acknowledges arterial events and their impact, implicitly supporting the need for interventions, which may include surgical options, in severe cases involving life-threatening arterial complications.	"{""explanation"": ""While the article mainly discusses the use of celiprolol, it acknowledges arterial events and their impact, implicitly supporting the need for interventions, which may include surgical options, in severe cases involving life-threatening arterial complications."", ""reference"": ""PMID:30999998"", ""snippet"": ""The only published clinical trial to date demonstrated the benefit of celiprolol on arterial morbimortality... During the period surveyed, the authors observed a statistically significant difference in the ratio of hospitalizations for acute arterial events/hospitalizations for regular follow-up before and after 2011."", ""supports"": ""SUPPORT""}"
2508	2313	101	Ehlers-Danlos Syndrome	Ehlers-Danlos_Syndrome.yaml	treatments	1	evidence	2	PMID:33650410	SUPPORT		The vascular subtype of EDS (type IV) is defined by characteristic facial features, translucent skin, easy bruising, and spontaneous arterial rupture and visceral perforation of such organs as the uterus and intestines, with possible life-threatening consequences.	This reference supports the need for surgical interventions in life-threatening complications like spontaneous arterial rupture and visceral perforation in vascular EDS.	"{""explanation"": ""This reference supports the need for surgical interventions in life-threatening complications like spontaneous arterial rupture and visceral perforation in vascular EDS."", ""reference"": ""PMID:33650410"", ""snippet"": ""The vascular subtype of EDS (type IV) is defined by characteristic facial features, translucent skin, easy bruising, and spontaneous arterial rupture and visceral perforation of such organs as the uterus and intestines, with possible life-threatening consequences."", ""supports"": ""SUPPORT""}"
2509	2314	101	Ehlers-Danlos Syndrome	Ehlers-Danlos_Syndrome.yaml	treatments	2	evidence	0	PMID:17067502	SUPPORT		Preparticipation cardiothoracic and orthopedic screening is highly recommended for athletes with EDS, and appropriate cardiovascular, orthopedic, gastrointestinal, neurologic, and dermatologic management can often allow patients with EDS to remain active.	The literature suggests avoiding high-impact activities and specific management strategies, which supports the statement.	"{""explanation"": ""The literature suggests avoiding high-impact activities and specific management strategies, which supports the statement."", ""reference"": ""PMID:17067502"", ""snippet"": ""Preparticipation cardiothoracic and orthopedic screening is highly recommended for athletes with EDS, and appropriate cardiovascular, orthopedic, gastrointestinal, neurologic, and dermatologic management can often allow patients with EDS to remain active."", ""supports"": ""SUPPORT""}"
2510	2314	101	Ehlers-Danlos Syndrome	Ehlers-Danlos_Syndrome.yaml	treatments	2	evidence	1	PMID:35756986	SUPPORT		The results suggest that exercise and rehabilitation may be beneficial for various physical and psychological outcomes.	While exercise and rehabilitation are recommended, the literature implies careful selection of physical activities to prevent injury, indirectly supporting the avoidance of high-impact activities and contact sports.	"{""explanation"": ""While exercise and rehabilitation are recommended, the literature implies careful selection of physical activities to prevent injury, indirectly supporting the avoidance of high-impact activities and contact sports."", ""reference"": ""PMID:35756986"", ""snippet"": ""The results suggest that exercise and rehabilitation may be beneficial for various physical and psychological outcomes."", ""supports"": ""SUPPORT""}"
2511	2315	101	Ehlers-Danlos Syndrome	Ehlers-Danlos_Syndrome.yaml	treatments	3	evidence	0	PMID:27349123	SUPPORT		ignorance of effective treatments such as oxygen therapy and orthotics are new concepts that should shake the prejudices derived from the history of this disease.	This reference mentions orthotic devices as part of the effective treatments for Ehlers-Danlos syndrome.	"{""explanation"": ""This reference mentions orthotic devices as part of the effective treatments for Ehlers-Danlos syndrome."", ""reference"": ""PMID:27349123"", ""snippet"": ""ignorance of effective treatments such as oxygen therapy and orthotics are new concepts that should shake the prejudices derived from the history of this disease."", ""supports"": ""SUPPORT""}"
2512	2315	101	Ehlers-Danlos Syndrome	Ehlers-Danlos_Syndrome.yaml	treatments	3	evidence	1	PMID:32709178	SUPPORT		Occupational therapy and bracing were the most effective options with 70% of patients reporting improvement.	This reference supports the use of orthotic devices (e.g., bracing) as effective in the management of EDS.	"{""explanation"": ""This reference supports the use of orthotic devices (e.g., bracing) as effective in the management of EDS."", ""reference"": ""PMID:32709178"", ""snippet"": ""Occupational therapy and bracing were the most effective options with 70% of patients reporting improvement."", ""supports"": ""SUPPORT""}"
2554	2335	102	Ehlers-Danlos Syndrome, COL5A1-related	Ehlers-Danlos_Syndrome_COL5A1-related.yaml	treatments	0	evidence	0	PMID:22616833	SUPPORT		The topics addressed in this issue are Ehlers-Danlos syndrome and associated chronic pain; the information is meant to help readers understand the mechanisms for pain in this connective tissue disorder as well as general treatment principles for chronic pain management.	The reference discusses chronic pain management in the context of Ehlers-Danlos syndrome, aligning with the statement about management of pain.	"{""explanation"": ""The reference discusses chronic pain management in the context of Ehlers-Danlos syndrome, aligning with the statement about management of pain."", ""reference"": ""PMID:22616833"", ""snippet"": ""The topics addressed in this issue are Ehlers-Danlos syndrome and associated chronic pain; the information is meant to help readers understand the mechanisms for pain in this connective tissue disorder as well as general treatment principles for chronic pain management."", ""supports"": ""SUPPORT""}"
2555	2335	102	Ehlers-Danlos Syndrome, COL5A1-related	Ehlers-Danlos_Syndrome_COL5A1-related.yaml	treatments	0	evidence	1	PMID:33741806	SUPPORT		Evidence supporting physical therapy and occupational therapy is provided... Treatment should be individualized.	The reference discusses the role of physical therapy in the management of hypermobile Ehlers-Danlos syndromes (hEDS), which aligns with the statement about physical therapy to strengthen joints.	"{""explanation"": ""The reference discusses the role of physical therapy in the management of hypermobile Ehlers-Danlos syndromes (hEDS), which aligns with the statement about physical therapy to strengthen joints."", ""reference"": ""PMID:33741806"", ""snippet"": ""Evidence supporting physical therapy and occupational therapy is provided... Treatment should be individualized."", ""supports"": ""SUPPORT""}"
2556	2335	102	Ehlers-Danlos Syndrome, COL5A1-related	Ehlers-Danlos_Syndrome_COL5A1-related.yaml	treatments	0	evidence	2	PMID:9042913	NO_EVIDENCE		These findings confirm the causal role of collagen V in at least a subgroup of EDS I.	The reference focuses on the genetic aspect and causal mutations in COL5A1 related to Ehlers-Danlos syndrome but does not delve into treatments.	"{""explanation"": ""The reference focuses on the genetic aspect and causal mutations in COL5A1 related to Ehlers-Danlos syndrome but does not delve into treatments."", ""reference"": ""PMID:9042913"", ""snippet"": ""These findings confirm the causal role of collagen V in at least a subgroup of EDS I."", ""supports"": ""NO_EVIDENCE""}"
2557	2335	102	Ehlers-Danlos Syndrome, COL5A1-related	Ehlers-Danlos_Syndrome_COL5A1-related.yaml	treatments	0	evidence	3	PMID:35162892	NO_EVIDENCE		Treatment is currently symptomatic and focuses on increasing the quality of life of these patients, as there is no curative treatment.	The reference mentions symptomatic treatment but does not provide specific details on pain management, physical therapy, or prevention of complications for COL5A1-related Ehlers-Danlos syndrome.	"{""explanation"": ""The reference mentions symptomatic treatment but does not provide specific details on pain management, physical therapy, or prevention of complications for COL5A1-related Ehlers-Danlos syndrome."", ""reference"": ""PMID:35162892"", ""snippet"": ""Treatment is currently symptomatic and focuses on increasing the quality of life of these patients, as there is no curative treatment."", ""supports"": ""NO_EVIDENCE""}"
2558	2335	102	Ehlers-Danlos Syndrome, COL5A1-related	Ehlers-Danlos_Syndrome_COL5A1-related.yaml	treatments	0	evidence	4	PMID:32941194	NO_EVIDENCE		Although medical interventions to help halt the disease progression remain limited, improved awareness of vEDS by patients and practitioners have resulted in increased average life expectancy.	The reference discusses limited medical interventions and management of vascular Ehlers-Danlos syndrome (vEDS), which is different from COL5A1-related EDS.	"{""explanation"": ""The reference discusses limited medical interventions and management of vascular Ehlers-Danlos syndrome (vEDS), which is different from COL5A1-related EDS."", ""reference"": ""PMID:32941194"", ""snippet"": ""Although medical interventions to help halt the disease progression remain limited, improved awareness of vEDS by patients and practitioners have resulted in increased average life expectancy."", ""supports"": ""NO_EVIDENCE""}"
2559	2336	102	Ehlers-Danlos Syndrome, COL5A1-related	Ehlers-Danlos_Syndrome_COL5A1-related.yaml	treatments	1	evidence	0	PMID:8274350	PARTIAL		Manifestations are highly variable, and include numerous skin abnormalities. Nurses play an important role in helping patients and their families live with this unusual disorder.	The reference mentions skin abnormalities but does not provide explicit details on treatments related to wound care or scar management.	"{""explanation"": ""The reference mentions skin abnormalities but does not provide explicit details on treatments related to wound care or scar management."", ""reference"": ""PMID:8274350"", ""snippet"": ""Manifestations are highly variable, and include numerous skin abnormalities. Nurses play an important role in helping patients and their families live with this unusual disorder."", ""supports"": ""PARTIAL""}"
2560	2336	102	Ehlers-Danlos Syndrome, COL5A1-related	Ehlers-Danlos_Syndrome_COL5A1-related.yaml	treatments	1	evidence	1	PMID:2728341	PARTIAL		Although delayed wound healing has been reported to be a complication of Ehlers-Danlos syndrome in humans, using clinical and histologic criteria, wound healing in dogs and cats with Ehlers-Danlos syndrome appears to be similar to nonaffected animals.	This reference discusses wound healing in animal models of EDS but indicates that delayed healing, a common complication in human EDS patients, was not observed in the studied animals.	"{""explanation"": ""This reference discusses wound healing in animal models of EDS but indicates that delayed healing, a common complication in human EDS patients, was not observed in the studied animals."", ""reference"": ""PMID:2728341"", ""snippet"": ""Although delayed wound healing has been reported to be a complication of Ehlers-Danlos syndrome in humans, using clinical and histologic criteria, wound healing in dogs and cats with Ehlers-Danlos syndrome appears to be similar to nonaffected animals."", ""supports"": ""PARTIAL""}"
2561	2336	102	Ehlers-Danlos Syndrome, COL5A1-related	Ehlers-Danlos_Syndrome_COL5A1-related.yaml	treatments	1	evidence	2	PMID:28387435	SUPPORT		Classic Ehlers-Danlos syndrome (EDS) patients suffer from connective tissue hyperelasticity, joint instability, skin hyperextensibility, tissue fragility, and poor wound healing due to heterozygous mutations in COL5a1 or COL5a2 genes.	This reference identifies poor wound healing as a complication associated with classic EDS due to COL5A1 mutations, which supports the need for careful attention to wound healing and scar management.	"{""explanation"": ""This reference identifies poor wound healing as a complication associated with classic EDS due to COL5A1 mutations, which supports the need for careful attention to wound healing and scar management."", ""reference"": ""PMID:28387435"", ""snippet"": ""Classic Ehlers-Danlos syndrome (EDS) patients suffer from connective tissue hyperelasticity, joint instability, skin hyperextensibility, tissue fragility, and poor wound healing due to heterozygous mutations in COL5a1 or COL5a2 genes."", ""supports"": ""SUPPORT""}"
2562	2336	102	Ehlers-Danlos Syndrome, COL5A1-related	Ehlers-Danlos_Syndrome_COL5A1-related.yaml	treatments	1	evidence	3	PMID:37594181	SUPPORT		The classic tragic facial expression was observed as well as chronic pruritus and mild hyperesthesia. ... Histology showed sparse, disorganized collagen and an increase in cutaneous mast cells. Electron microscopy identified ultrastructural defects commonly seen in collagen type V alpha 1 chain (COL5A1) variants including flower-like collagen fibrils in cross-section.	This detailed observation of classic EDS symptoms and associated collagen abnormalities highlights the importance of wound and scar care in patients.	"{""explanation"": ""This detailed observation of classic EDS symptoms and associated collagen abnormalities highlights the importance of wound and scar care in patients."", ""reference"": ""PMID:37594181"", ""snippet"": ""The classic tragic facial expression was observed as well as chronic pruritus and mild hyperesthesia. ... Histology showed sparse, disorganized collagen and an increase in cutaneous mast cells. Electron microscopy identified ultrastructural defects commonly seen in collagen type V alpha 1 chain (COL5A1) variants including flower-like collagen fibrils in cross-section."", ""supports"": ""SUPPORT""}"
2563	2337	102	Ehlers-Danlos Syndrome, COL5A1-related	Ehlers-Danlos_Syndrome_COL5A1-related.yaml	treatments	2	evidence	0	PMID:21193204	SUPPORT		Echocardiography may still be warranted as part of cardiovascular assessment, but decreased frequency of screening is recommended especially in symptom-free adults.	This reference supports cardiovascular monitoring in Ehlers-Danlos Syndrome, particularly for mitral valve prolapse and aortic dilation.	"{""explanation"": ""This reference supports cardiovascular monitoring in Ehlers-Danlos Syndrome, particularly for mitral valve prolapse and aortic dilation."", ""reference"": ""PMID:21193204"", ""snippet"": ""Echocardiography may still be warranted as part of cardiovascular assessment, but decreased frequency of screening is recommended especially in symptom-free adults."", ""supports"": ""SUPPORT""}"
2564	2337	102	Ehlers-Danlos Syndrome, COL5A1-related	Ehlers-Danlos_Syndrome_COL5A1-related.yaml	treatments	2	evidence	1	PMID:15607555	SUPPORT		This proposal is specifically concerned with Ehlers-Danlos syndrome classic type (formerly Types I-III), which is characterized by ... cardiac mitral valve prolapse.	This reference supports the need for evaluation in Ehlers-Danlos Syndrome for cardiovascular complications like mitral valve prolapse.	"{""explanation"": ""This reference supports the need for evaluation in Ehlers-Danlos Syndrome for cardiovascular complications like mitral valve prolapse."", ""reference"": ""PMID:15607555"", ""snippet"": ""This proposal is specifically concerned with Ehlers-Danlos syndrome classic type (formerly Types I-III), which is characterized by ... cardiac mitral valve prolapse."", ""supports"": ""SUPPORT""}"
2565	2338	102	Ehlers-Danlos Syndrome, COL5A1-related	Ehlers-Danlos_Syndrome_COL5A1-related.yaml	treatments	3	evidence	0	PMID:26376608	SUPPORT		CONCLUSIONS & INFERENCES: EDS HM and other subtypes should be considered in patients with chronic functional GI symptoms and abdominal vascular lesions.	This study highlights the prevalence of gastrointestinal manifestations in patients with various subtypes of EDS, indicating that GI management, including treatment of conditions like gastroesophageal reflux, is indeed a necessary part of the overall treatment plan.	"{""explanation"": ""This study highlights the prevalence of gastrointestinal manifestations in patients with various subtypes of EDS, indicating that GI management, including treatment of conditions like gastroesophageal reflux, is indeed a necessary part of the overall treatment plan."", ""reference"": ""PMID:26376608"", ""snippet"": ""CONCLUSIONS & INFERENCES: EDS HM and other subtypes should be considered in patients with chronic functional GI symptoms and abdominal vascular lesions."", ""supports"": ""SUPPORT""}"
2566	2339	102	Ehlers-Danlos Syndrome, COL5A1-related	Ehlers-Danlos_Syndrome_COL5A1-related.yaml	treatments	4	evidence	0	PMID:17067502	PARTIAL		Preparticipation cardiothoracic and orthopedic screening is highly recommended for athletes with EDS, and appropriate cardiovascular, orthopedic, gastrointestinal, neurologic, and dermatologic management can often allow patients with EDS to remain active.	The literature emphasizes careful screening and multidisciplinary management for athletes with EDS, which implicitly supports the avoidance of high-impact activities to prevent injuries but does not explicitly mention the use of protective gear or contact sports.	"{""explanation"": ""The literature emphasizes careful screening and multidisciplinary management for athletes with EDS, which implicitly supports the avoidance of high-impact activities to prevent injuries but does not explicitly mention the use of protective gear or contact sports."", ""reference"": ""PMID:17067502"", ""snippet"": ""Preparticipation cardiothoracic and orthopedic screening is highly recommended for athletes with EDS, and appropriate cardiovascular, orthopedic, gastrointestinal, neurologic, and dermatologic management can often allow patients with EDS to remain active."", ""supports"": ""PARTIAL""}"
2567	2339	102	Ehlers-Danlos Syndrome, COL5A1-related	Ehlers-Danlos_Syndrome_COL5A1-related.yaml	treatments	4	evidence	1	PMID:32899328	PARTIAL		The major clinical manifestations of EDS include joint hypermobility, skin hyperextensibility, and generalized connective tissue fragility. ... These findings allow healthcare providers to know more about this disease in order to support and give advice to patients about the changes they will have to make.	The study highlights the importance of providing advice to patients about lifestyle changes due to EDS but does not specifically mention avoiding high-impact activities or using protective gear.	"{""explanation"": ""The study highlights the importance of providing advice to patients about lifestyle changes due to EDS but does not specifically mention avoiding high-impact activities or using protective gear."", ""reference"": ""PMID:32899328"", ""snippet"": ""The major clinical manifestations of EDS include joint hypermobility, skin hyperextensibility, and generalized connective tissue fragility. ... These findings allow healthcare providers to know more about this disease in order to support and give advice to patients about the changes they will have to make."", ""supports"": ""PARTIAL""}"
2622	2440	106	Essential Hypertension	Essential_Hypertension.yaml	treatments	0	evidence	0	PMID:39765782	SUPPORT		Managing blood pressure (BP) effectively with treatments targeting RAAS activation, oxidative stress, and inflammation is crucial in preventing renal damage and the progression of HTN-related CKD and ESRD.	This supports ACE inhibitors as effective treatments targeting RAAS activation in hypertension.	"{""explanation"": ""This supports ACE inhibitors as effective treatments targeting RAAS activation in hypertension."", ""reference"": ""PMID:39765782"", ""snippet"": ""Managing blood pressure (BP) effectively with treatments targeting RAAS activation, oxidative stress, and inflammation is crucial in preventing renal damage and the progression of HTN-related CKD and ESRD."", ""supports"": ""SUPPORT""}"
2623	2441	106	Essential Hypertension	Essential_Hypertension.yaml	treatments	1	evidence	0	PMID:39765782	SUPPORT		Managing blood pressure (BP) effectively with treatments targeting RAAS activation, oxidative stress, and inflammation is crucial in preventing renal damage and the progression of HTN-related CKD and ESRD.	This supports ARBs as effective treatments targeting RAAS activation in hypertension.	"{""explanation"": ""This supports ARBs as effective treatments targeting RAAS activation in hypertension."", ""reference"": ""PMID:39765782"", ""snippet"": ""Managing blood pressure (BP) effectively with treatments targeting RAAS activation, oxidative stress, and inflammation is crucial in preventing renal damage and the progression of HTN-related CKD and ESRD."", ""supports"": ""SUPPORT""}"
2624	2442	106	Essential Hypertension	Essential_Hypertension.yaml	treatments	2	evidence	0	PMID:37080965	SUPPORT		Meanwhile, we will also summarize the treatment methods of hypertension that targets vascular function regulation and discuss the possibility of these signaling pathways being applied to clinical work.	This supports calcium channel blockers as treatments targeting vascular smooth muscle function.	"{""explanation"": ""This supports calcium channel blockers as treatments targeting vascular smooth muscle function."", ""reference"": ""PMID:37080965"", ""snippet"": ""Meanwhile, we will also summarize the treatment methods of hypertension that targets vascular function regulation and discuss the possibility of these signaling pathways being applied to clinical work."", ""supports"": ""SUPPORT""}"
2625	2443	106	Essential Hypertension	Essential_Hypertension.yaml	treatments	3	evidence	0	PMID:39765782	SUPPORT		Anti-natriuretic mechanisms can reset the pressure-natriuresis relationship, requiring a higher BP to excrete sodium matched to intake.	This supports diuretics as treatments that promote sodium excretion to normalize blood pressure.	"{""explanation"": ""This supports diuretics as treatments that promote sodium excretion to normalize blood pressure."", ""reference"": ""PMID:39765782"", ""snippet"": ""Anti-natriuretic mechanisms can reset the pressure-natriuresis relationship, requiring a higher BP to excrete sodium matched to intake."", ""supports"": ""SUPPORT""}"
2626	2445	106	Essential Hypertension	Essential_Hypertension.yaml	treatments	5	evidence	0	PMID:38164753	SUPPORT		Approximately 50% of hypertensive and 25% of normotensive people exhibit salt sensitivity of blood pressure, which is an independent risk factor for cardiovascular disease.	This supports sodium restriction as an effective lifestyle intervention for salt-sensitive hypertension.	"{""explanation"": ""This supports sodium restriction as an effective lifestyle intervention for salt-sensitive hypertension."", ""reference"": ""PMID:38164753"", ""snippet"": ""Approximately 50% of hypertensive and 25% of normotensive people exhibit salt sensitivity of blood pressure, which is an independent risk factor for cardiovascular disease."", ""supports"": ""SUPPORT""}"
2665	2546	111	FICUS syndrome	FICUS_syndrome.yaml	treatments	0	evidence	0	DOI:10.1186/s13063-024-08351-y	SUPPORT		The FICUS trial is a cluster-randomized superiority trial to determine the effectiveness of a nurse-led, interprofessional family support intervention (FSI) on the quality of care, family management and individual mental health of family members of critically ill patients, compared to usual care.	This describes a structured family support intervention targeting mental health outcomes.	"{""explanation"": ""This describes a structured family support intervention targeting mental health outcomes."", ""reference"": ""DOI:10.1186/s13063-024-08351-y"", ""snippet"": ""The FICUS trial is a cluster-randomized superiority trial to determine the effectiveness of a nurse-led, interprofessional family support intervention (FSI) on the quality of care, family management and individual mental health of family members of critically ill patients, compared to usual care."", ""supports"": ""SUPPORT""}"
2693	2590	113	Fabry disease	Fabry_Disease.yaml	treatments	0	evidence	0	PMID:37014703	PARTIAL		long-term use of ERT reduced Gb3 accumulation in podocytes but did not reverse podocyte injury	Shows that ERT reduces substrate accumulation but cannot fully reverse organ damage in Fabry nephropathy	"{""explanation"": ""Shows that ERT reduces substrate accumulation but cannot fully reverse organ damage in Fabry nephropathy"", ""reference"": ""PMID:37014703"", ""snippet"": ""long-term use of ERT reduced Gb3 accumulation in podocytes but did not reverse podocyte injury"", ""supports"": ""PARTIAL""}"
2694	2591	113	Fabry disease	Fabry_Disease.yaml	treatments	1	evidence	0	PMID:40310476	SUPPORT		if a responding ('amenable') -galactosidase A mutation is present, oral pharmacological chaperone therapy (migalastat 123 mg, every other day)	Confirms migalastat is an approved oral chaperone therapy for amenable GLA mutations	"{""explanation"": ""Confirms migalastat is an approved oral chaperone therapy for amenable GLA mutations"", ""reference"": ""PMID:40310476"", ""snippet"": ""if a responding ('amenable') -galactosidase A mutation is present, oral pharmacological chaperone therapy (migalastat 123 mg, every other day)"", ""supports"": ""SUPPORT""}"
2695	2592	113	Fabry disease	Fabry_Disease.yaml	treatments	2	evidence	0	PMID:40310476	SUPPORT		Future therapeutic options may include substrate reduction therapy, gene therapy, messenger RNA therapy, and/or vesicle-packaged enzyme replacement therapy	Identifies gene therapy as a promising future treatment option for Fabry disease	"{""explanation"": ""Identifies gene therapy as a promising future treatment option for Fabry disease"", ""reference"": ""PMID:40310476"", ""snippet"": ""Future therapeutic options may include substrate reduction therapy, gene therapy, messenger RNA therapy, and/or vesicle-packaged enzyme replacement therapy"", ""supports"": ""SUPPORT""}"
2696	2593	113	Fabry disease	Fabry_Disease.yaml	treatments	3	evidence	0	PMID:32183665	SUPPORT		The current treatment of Anderson-Fabry disease is represented by enzyme replacement therapy (ERT) and oral pharmacological chaperone	Confirms ERT and pharmacological chaperone therapy as current treatment standards	"{""explanation"": ""Confirms ERT and pharmacological chaperone therapy as current treatment standards"", ""reference"": ""PMID:32183665"", ""snippet"": ""The current treatment of Anderson-Fabry disease is represented by enzyme replacement therapy (ERT) and oral pharmacological chaperone"", ""supports"": ""SUPPORT""}"
2757	2638	115	Familial Mediterranean Fever	Familial_Mediterranean_Fever.yaml	treatments	0	evidence	0	PMID:19797919	SUPPORT		The study demonstrated that colchicine treatment is effective in preventing amyloidosis among Armenian patients with FMF and that earlier initiation and continuous therapy at an adequate dose of 1.2-1.8 mg/day may be associated with a decreased amyloidosis risk among Armenian patients with FMF.	The study directly supports the statement that colchicine is a first-line treatment for preventing amyloidosis, a common complication of FMF.	"{""explanation"": ""The study directly supports the statement that colchicine is a first-line treatment for preventing amyloidosis, a common complication of FMF."", ""reference"": ""PMID:19797919"", ""snippet"": ""The study demonstrated that colchicine treatment is effective in preventing amyloidosis among Armenian patients with FMF and that earlier initiation and continuous therapy at an adequate dose of 1.2-1.8 mg/day may be associated with a decreased amyloidosis risk among Armenian patients with FMF."", ""supports"": ""SUPPORT""}"
2758	2638	115	Familial Mediterranean Fever	Familial_Mediterranean_Fever.yaml	treatments	0	evidence	1	PMID:25649364	SUPPORT		The only agent that decreases the development of amyloidosis and the frequency and severity of the episodes is colchicine, which has been used for about 40 years.	This reference clearly supports the claim that colchicine reduces the frequency of attacks and prevents amyloidosis, affirming its role as a first-line treatment.	"{""explanation"": ""This reference clearly supports the claim that colchicine reduces the frequency of attacks and prevents amyloidosis, affirming its role as a first-line treatment."", ""reference"": ""PMID:25649364"", ""snippet"": ""The only agent that decreases the development of amyloidosis and the frequency and severity of the episodes is colchicine, which has been used for about 40 years."", ""supports"": ""SUPPORT""}"
2759	2638	115	Familial Mediterranean Fever	Familial_Mediterranean_Fever.yaml	treatments	0	evidence	2	PMID:25791871	SUPPORT		Early studies reported colchicine as a potential drug for preventing attacks of familial Mediterranean fever.	This indicates that colchicine is considered effective for preventing FMF attacks, supporting its position as a first-line treatment.	"{""explanation"": ""This indicates that colchicine is considered effective for preventing FMF attacks, supporting its position as a first-line treatment."", ""reference"": ""PMID:25791871"", ""snippet"": ""Early studies reported colchicine as a potential drug for preventing attacks of familial Mediterranean fever."", ""supports"": ""SUPPORT""}"
2760	2638	115	Familial Mediterranean Fever	Familial_Mediterranean_Fever.yaml	treatments	0	evidence	3	PMID:17242135	SUPPORT		The daily application of colchicine is the standard therapy for prophylaxis of attacks and amyloid deposition in familial Mediterranean fever.	This statement corroborates that colchicine is the standard, or first-line, therapy for preventing FMF attacks and amyloidosis.	"{""explanation"": ""This statement corroborates that colchicine is the standard, or first-line, therapy for preventing FMF attacks and amyloidosis."", ""reference"": ""PMID:17242135"", ""snippet"": ""The daily application of colchicine is the standard therapy for prophylaxis of attacks and amyloid deposition in familial Mediterranean fever."", ""supports"": ""SUPPORT""}"
2761	2638	115	Familial Mediterranean Fever	Familial_Mediterranean_Fever.yaml	treatments	0	evidence	4	PMID:15720245	SUPPORT		Since 1972 colchicine has become the drug of choice for prophylaxis against FMF attacks and amyloidosis FMF-associated.	This reference supports the idea that colchicine is the primary treatment for preventing FMF attacks and associated amyloidosis.	"{""explanation"": ""This reference supports the idea that colchicine is the primary treatment for preventing FMF attacks and associated amyloidosis."", ""reference"": ""PMID:15720245"", ""snippet"": ""Since 1972 colchicine has become the drug of choice for prophylaxis against FMF attacks and amyloidosis FMF-associated."", ""supports"": ""SUPPORT""}"
2762	2639	115	Familial Mediterranean Fever	Familial_Mediterranean_Fever.yaml	treatments	1	evidence	0	PMID:28362189	SUPPORT		The accumulating data indicates that anti IL-1 drugs are effective in treating colchicine resistant FMF cases and improving their quality of life.	The reference supports the use of anti-IL-1 therapy for treating colchicine-resistant FMF cases.	"{""explanation"": ""The reference supports the use of anti-IL-1 therapy for treating colchicine-resistant FMF cases."", ""reference"": ""PMID:28362189"", ""snippet"": ""The accumulating data indicates that anti IL-1 drugs are effective in treating colchicine resistant FMF cases and improving their quality of life."", ""supports"": ""SUPPORT""}"
2763	2639	115	Familial Mediterranean Fever	Familial_Mediterranean_Fever.yaml	treatments	1	evidence	1	PMID:30338514	SUPPORT		For those people who are colchicine-resistant or intolerant, drugs such as rilonacept, anakinra, canakinumab, etanercept, infliximab, thalidomide and interferon-alpha might be beneficial.	The reference lists several anti-IL-1 therapies as beneficial for colchicine-resistant or intolerant FMF patients.	"{""explanation"": ""The reference lists several anti-IL-1 therapies as beneficial for colchicine-resistant or intolerant FMF patients."", ""reference"": ""PMID:30338514"", ""snippet"": ""For those people who are colchicine-resistant or intolerant, drugs such as rilonacept, anakinra, canakinumab, etanercept, infliximab, thalidomide and interferon-alpha might be beneficial."", ""supports"": ""SUPPORT""}"
2764	2639	115	Familial Mediterranean Fever	Familial_Mediterranean_Fever.yaml	treatments	1	evidence	2	PMID:36161616	SUPPORT		Anti IL-1 therapy is useful in suppressing attacks in FMF patients with colchicine resistance.	The study supports the effectiveness of anti-IL-1 therapy in managing inflammation in colchicine-resistant FMF patients.	"{""explanation"": ""The study supports the effectiveness of anti-IL-1 therapy in managing inflammation in colchicine-resistant FMF patients."", ""reference"": ""PMID:36161616"", ""snippet"": ""Anti IL-1 therapy is useful in suppressing attacks in FMF patients with colchicine resistance."", ""supports"": ""SUPPORT""}"
2765	2639	115	Familial Mediterranean Fever	Familial_Mediterranean_Fever.yaml	treatments	1	evidence	3	PMID:27860460	SUPPORT		In this randomized controlled trial, anakinra appears to be an effective and safe treatment for colchicine-resistant FMF.	The reference provides evidence from a randomized controlled trial supporting the effectiveness of anakinra, an anti-IL-1 therapy, in colchicine-resistant FMF patients.	"{""explanation"": ""The reference provides evidence from a randomized controlled trial supporting the effectiveness of anakinra, an anti-IL-1 therapy, in colchicine-resistant FMF patients."", ""reference"": ""PMID:27860460"", ""snippet"": ""In this randomized controlled trial, anakinra appears to be an effective and safe treatment for colchicine-resistant FMF."", ""supports"": ""SUPPORT""}"
2766	2640	115	Familial Mediterranean Fever	Familial_Mediterranean_Fever.yaml	treatments	2	evidence	0	PMID:37752496	REFUTE		These provide the basis for stratifying patients into the following treatment paths: continue colchicine, persisting attacks / inflammation, colchicine intolerance, persisting arthritis, colchicine reduction and adjustment/reduction of biologics.	The literature does not mention NSAIDs as a treatment path for symptom relief during acute attacks of Familial Mediterranean Fever. The focus is on colchicine and biological therapy.	"{""explanation"": ""The literature does not mention NSAIDs as a treatment path for symptom relief during acute attacks of Familial Mediterranean Fever. The focus is on colchicine and biological therapy."", ""reference"": ""PMID:37752496"", ""snippet"": ""These provide the basis for stratifying patients into the following treatment paths: continue colchicine, persisting attacks / inflammation, colchicine intolerance, persisting arthritis, colchicine reduction and adjustment/reduction of biologics."", ""supports"": ""REFUTE""}"
2767	2640	115	Familial Mediterranean Fever	Familial_Mediterranean_Fever.yaml	treatments	2	evidence	1	PMID:36945975	NO_EVIDENCE		Mean age of the overall group was 38.2 +/- 11.7 years (62.4% female, 37.6% male). Two hundred and twenty-seven patients were treated with colchicine, 97 patients with colchicine plus Interleukin-1 (IL-1) antagonist, and 22 only with IL-1 antagonist (67.1%, 26.3%, 6.64% in order).	There is no mention of NSAIDs being used for symptom relief during acute attacks in FMF patients. The treatments focus on colchicine and IL-1 antagonist.	"{""explanation"": ""There is no mention of NSAIDs being used for symptom relief during acute attacks in FMF patients. The treatments focus on colchicine and IL-1 antagonist."", ""reference"": ""PMID:36945975"", ""snippet"": ""Mean age of the overall group was 38.2 +/- 11.7 years (62.4% female, 37.6% male). Two hundred and twenty-seven patients were treated with colchicine, 97 patients with colchicine plus Interleukin-1 (IL-1) antagonist, and 22 only with IL-1 antagonist (67.1%, 26.3%, 6.64% in order)."", ""supports"": ""NO_EVIDENCE""}"
2768	2641	115	Familial Mediterranean Fever	Familial_Mediterranean_Fever.yaml	treatments	3	evidence	0	PMID:38488998	PARTIAL		Patients can significantly decrease the number of familial Mediterranean fever attacks they experience by managing psychological stress and avoiding physical factors such as cold exposure and fatigue.	The literature supports the management of psychological stress and avoiding physical factors as triggers but does not explicitly mention infections.	"{""explanation"": ""The literature supports the management of psychological stress and avoiding physical factors as triggers but does not explicitly mention infections."", ""reference"": ""PMID:38488998"", ""snippet"": ""Patients can significantly decrease the number of familial Mediterranean fever attacks they experience by managing psychological stress and avoiding physical factors such as cold exposure and fatigue."", ""supports"": ""PARTIAL""}"
2769	2641	115	Familial Mediterranean Fever	Familial_Mediterranean_Fever.yaml	treatments	3	evidence	1	PMID:26324575	PARTIAL		Triggers of this illness include many things, such as cold or stress.	The literature mentions stress as a trigger but does not provide exhaustive confirmation about infections as triggers or other preventive lifestyle modifications.	"{""explanation"": ""The literature mentions stress as a trigger but does not provide exhaustive confirmation about infections as triggers or other preventive lifestyle modifications."", ""reference"": ""PMID:26324575"", ""snippet"": ""Triggers of this illness include many things, such as cold or stress."", ""supports"": ""PARTIAL""}"
2990	2815	116	Fanconi_Anemia	Fanconi_Anemia.yaml	treatments	0	evidence	0	PMID:20301575	SUPPORT	HUMAN_CLINICAL	hematopoietic stem cell transplantation (HSCT) is the only curative therapy for the hematologic manifestations of FA		"{""evidence_source"": ""HUMAN_CLINICAL"", ""reference"": ""PMID:20301575"", ""snippet"": ""hematopoietic stem cell transplantation (HSCT) is the only curative therapy for the hematologic manifestations of FA"", ""supports"": ""SUPPORT""}"
2991	2816	116	Fanconi_Anemia	Fanconi_Anemia.yaml	treatments	1	evidence	0	PMID:20301575	SUPPORT	HUMAN_CLINICAL	Administration of oral androgens (e.g., oxymetholone) improves blood counts (red cell and platelets) in approximately 50% of individuals with FA		"{""evidence_source"": ""HUMAN_CLINICAL"", ""reference"": ""PMID:20301575"", ""snippet"": ""Administration of oral androgens (e.g., oxymetholone) improves blood counts (red cell and platelets) in approximately 50% of individuals with FA"", ""supports"": ""SUPPORT""}"
2992	2817	116	Fanconi_Anemia	Fanconi_Anemia.yaml	treatments	2	evidence	0	PMID:20301575	SUPPORT	HUMAN_CLINICAL	Treatment of growth deficiency, limb anomalies, ocular anomalies, renal malformations, genital anomalies, hypothyroidism, cardiac anomalies, and dermatologic manifestations as recommended by the subspecialty care provider.	GeneReviews recommends treatment of growth deficiency as part of comprehensive FA management.	"{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""GeneReviews recommends treatment of growth deficiency as part of comprehensive FA management."", ""reference"": ""PMID:20301575"", ""snippet"": ""Treatment of growth deficiency, limb anomalies, ocular anomalies, renal malformations, genital anomalies, hypothyroidism, cardiac anomalies, and dermatologic manifestations as recommended by the subspecialty care provider."", ""supports"": ""SUPPORT""}"
2993	2818	116	Fanconi_Anemia	Fanconi_Anemia.yaml	treatments	3	evidence	0	PMID:20301575	SUPPORT	HUMAN_CLINICAL	granulocyte colony-stimulating factor improves the neutrophil count in some individuals	GeneReviews confirms use of growth factors as part of supportive care for cytopenias.	"{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""GeneReviews confirms use of growth factors as part of supportive care for cytopenias."", ""reference"": ""PMID:20301575"", ""snippet"": ""granulocyte colony-stimulating factor improves the neutrophil count in some individuals"", ""supports"": ""SUPPORT""}"
2994	2819	116	Fanconi_Anemia	Fanconi_Anemia.yaml	treatments	4	evidence	0	PMID:20301575	SUPPORT	HUMAN_CLINICAL	oral examinations for tumors every six months beginning at age nine to ten years; annual nasolaryngoscopy beginning at age ten years	GeneReviews recommends regular oral and nasolaryngoscopic surveillance for early cancer detection.	"{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""GeneReviews recommends regular oral and nasolaryngoscopic surveillance for early cancer detection."", ""reference"": ""PMID:20301575"", ""snippet"": ""oral examinations for tumors every six months beginning at age nine to ten years; annual nasolaryngoscopy beginning at age ten years"", ""supports"": ""SUPPORT""}"
2995	2820	116	Fanconi_Anemia	Fanconi_Anemia.yaml	treatments	5	evidence	0	PMID:20301575	SUPPORT	HUMAN_CLINICAL	Carrier testing for at-risk relatives (for autosomal recessive and X-linked FA) and prenatal and preimplantation genetic testing are possible if the pathogenic variant(s) in the family are known.	GeneReviews confirms the importance of genetic counseling for carrier testing and prenatal diagnosis.	"{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""GeneReviews confirms the importance of genetic counseling for carrier testing and prenatal diagnosis."", ""reference"": ""PMID:20301575"", ""snippet"": ""Carrier testing for at-risk relatives (for autosomal recessive and X-linked FA) and prenatal and preimplantation genetic testing are possible if the pathogenic variant(s) in the family are known."", ""supports"": ""SUPPORT""}"
3012	2835	117	Fibrodysplasia Ossificans Progressiva	Fibrodysplasia_Ossificans_Progressiva.yaml	treatments	0	evidence	0	PMID:26896819	SUPPORT		palovarotene maintained joint, limb, and body motion, providing clear evidence for its encompassing therapeutic potential as a treatment for FOP.	The study demonstrates palovarotene's therapeutic efficacy in preserving mobility in FOP mouse models.	"{""explanation"": ""The study demonstrates palovarotene's therapeutic efficacy in preserving mobility in FOP mouse models."", ""reference"": ""PMID:26896819"", ""snippet"": ""palovarotene maintained joint, limb, and body motion, providing clear evidence for its encompassing therapeutic potential as a treatment for FOP."", ""supports"": ""SUPPORT""}"
3013	2835	117	Fibrodysplasia Ossificans Progressiva	Fibrodysplasia_Ossificans_Progressiva.yaml	treatments	0	evidence	1	PMID:26896819	SUPPORT		palovarotene restored long bone growth, maintained growth plate function, and protected growing mutant neonates	Demonstrates palovarotene's ability to preserve skeletal development while preventing heterotopic ossification.	"{""explanation"": ""Demonstrates palovarotene's ability to preserve skeletal development while preventing heterotopic ossification."", ""reference"": ""PMID:26896819"", ""snippet"": ""palovarotene restored long bone growth, maintained growth plate function, and protected growing mutant neonates"", ""supports"": ""SUPPORT""}"
3014	2836	117	Fibrodysplasia Ossificans Progressiva	Fibrodysplasia_Ossificans_Progressiva.yaml	treatments	1	evidence	0	PMID:26896819	PARTIAL		Fibrodysplasia ossificans progressiva (FOP), a rare and as yet untreatable genetic disorder of progressive extraskeletal ossification	The article notes FOP was untreatable, highlighting the limited efficacy of symptomatic treatments like corticosteroids.	"{""explanation"": ""The article notes FOP was untreatable, highlighting the limited efficacy of symptomatic treatments like corticosteroids."", ""reference"": ""PMID:26896819"", ""snippet"": ""Fibrodysplasia ossificans progressiva (FOP), a rare and as yet untreatable genetic disorder of progressive extraskeletal ossification"", ""supports"": ""PARTIAL""}"
3015	2837	117	Fibrodysplasia Ossificans Progressiva	Fibrodysplasia_Ossificans_Progressiva.yaml	treatments	2	evidence	0	PMID:26896819	SUPPORT		palovarotene effectively inhibited HO in injury-induced and genetic mouse models of the disease	Since injury induces HO in FOP models, avoidance of trauma is a key preventive strategy.	"{""explanation"": ""Since injury induces HO in FOP models, avoidance of trauma is a key preventive strategy."", ""reference"": ""PMID:26896819"", ""snippet"": ""palovarotene effectively inhibited HO in injury-induced and genetic mouse models of the disease"", ""supports"": ""SUPPORT""}"
3016	2838	117	Fibrodysplasia Ossificans Progressiva	Fibrodysplasia_Ossificans_Progressiva.yaml	treatments	3	evidence	0	PMID:17572636	SUPPORT		Individuals with fibrodysplasia ossificans progressiva are born with malformations of the great toes and develop a heterotopic skeleton during childhood because of an identical heterozygous mutation	Identification of the causative mutation enables genetic counseling and potential prenatal diagnosis.	"{""explanation"": ""Identification of the causative mutation enables genetic counseling and potential prenatal diagnosis."", ""reference"": ""PMID:17572636"", ""snippet"": ""Individuals with fibrodysplasia ossificans progressiva are born with malformations of the great toes and develop a heterotopic skeleton during childhood because of an identical heterozygous mutation"", ""supports"": ""SUPPORT""}"
3017	2839	117	Fibrodysplasia Ossificans Progressiva	Fibrodysplasia_Ossificans_Progressiva.yaml	treatments	4	evidence	0	PMID:26896819	SUPPORT		Most FOP patients carry an activating mutation in a bone morphogenetic protein (BMP) type I receptor gene, ACVR1(R206H), that promotes ectopic chondrogenesis and osteogenesis and, in turn, HO	Establishes the molecular rationale for anti-Activin A therapy targeting the aberrant signaling through mutant ACVR1.	"{""explanation"": ""Establishes the molecular rationale for anti-Activin A therapy targeting the aberrant signaling through mutant ACVR1."", ""reference"": ""PMID:26896819"", ""snippet"": ""Most FOP patients carry an activating mutation in a bone morphogenetic protein (BMP) type I receptor gene, ACVR1(R206H), that promotes ectopic chondrogenesis and osteogenesis and, in turn, HO"", ""supports"": ""SUPPORT""}"
3060	2903	120	Fragile X Syndrome	Fragile_X_Syndrome.yaml	treatments	0	evidence	0	PMID:22483044	SUPPORT		Recent studies on the biology of FMRP and the signaling pathways downstream of mGluR1/5 have yielded deeper insight into how synaptic protein synthesis and plasticity are regulated by experience.	Understanding of synaptic dysfunction supports behavioral and educational interventions targeting developmental outcomes.	"{""explanation"": ""Understanding of synaptic dysfunction supports behavioral and educational interventions targeting developmental outcomes."", ""reference"": ""PMID:22483044"", ""snippet"": ""Recent studies on the biology of FMRP and the signaling pathways downstream of mGluR1/5 have yielded deeper insight into how synaptic protein synthesis and plasticity are regulated by experience."", ""supports"": ""SUPPORT""}"
3089	3015	126	Gastrointestinal Stromal Tumor	Gastrointestinal_Stromal_Tumor.yaml	treatments	0	evidence	0	PMID:12181401	SUPPORT		Imatinib induced a sustained objective response in more than half of patients with an advanced unresectable or metastatic gastrointestinal stromal tumor. Inhibition of the KIT signal-transduction pathway is a promising treatment for advanced gastrointestinal stromal tumors, which resist conventional chemotherapy.	The Demetri et al. NEJM study demonstrated that imatinib achieves objective responses in 53.7% of advanced GIST patients by inhibiting the KIT signaling pathway.	"{""explanation"": ""The Demetri et al. NEJM study demonstrated that imatinib achieves objective responses in 53.7% of advanced GIST patients by inhibiting the KIT signaling pathway."", ""reference"": ""PMID:12181401"", ""snippet"": ""Imatinib induced a sustained objective response in more than half of patients with an advanced unresectable or metastatic gastrointestinal stromal tumor. Inhibition of the KIT signal-transduction pathway is a promising treatment for advanced gastrointestinal stromal tumors, which resist conventional chemotherapy."", ""supports"": ""SUPPORT""}"
3099	3035	127	Gaucher Disease	Gaucher_Disease.yaml	treatments	0	evidence	0	PMID:19047232	SUPPORT		Within 8 years of enzyme replacement therapy, most clinical parameters studied became normal or nearly normal.	Long-term study demonstrates effectiveness of enzyme replacement therapy in children with Gaucher disease.	"{""explanation"": ""Long-term study demonstrates effectiveness of enzyme replacement therapy in children with Gaucher disease."", ""reference"": ""PMID:19047232"", ""snippet"": ""Within 8 years of enzyme replacement therapy, most clinical parameters studied became normal or nearly normal."", ""supports"": ""SUPPORT""}"
3100	3036	127	Gaucher Disease	Gaucher_Disease.yaml	treatments	1	evidence	0	PMID:25688781	SUPPORT		treatment with eliglustat compared with placebo for 9 months resulted in significant improvements in spleen volume, hemoglobin level, liver volume, and platelet count.	Phase 3 ENGAGE trial demonstrates eliglustat substrate reduction therapy effectively improves clinical manifestations in Gaucher disease.	"{""explanation"": ""Phase 3 ENGAGE trial demonstrates eliglustat substrate reduction therapy effectively improves clinical manifestations in Gaucher disease."", ""reference"": ""PMID:25688781"", ""snippet"": ""treatment with eliglustat compared with placebo for 9 months resulted in significant improvements in spleen volume, hemoglobin level, liver volume, and platelet count."", ""supports"": ""SUPPORT""}"
3119	3083	129	Giant Cell Arteritis	Giant_Cell_Arteritis.yaml	treatments	1	evidence	0	PMID:37321636	SUPPORT		Relapse rate prior to TCZ start (0.84 relapses/person-year) was 3-fold reduced while on TCZ (0.28 relapses/person-year; P < 0.001) but increased to 0.64 relapses/person-year after TCZ discontinuation.	This demonstrates tocilizumab's effectiveness in reducing relapse rates while on treatment, though relapse risk increases after discontinuation.	"{""explanation"": ""This demonstrates tocilizumab's effectiveness in reducing relapse rates while on treatment, though relapse risk increases after discontinuation."", ""reference"": ""PMID:37321636"", ""snippet"": ""Relapse rate prior to TCZ start (0.84 relapses/person-year) was 3-fold reduced while on TCZ (0.28 relapses/person-year; P < 0.001) but increased to 0.64 relapses/person-year after TCZ discontinuation."", ""supports"": ""SUPPORT""}"
3120	3083	129	Giant Cell Arteritis	Giant_Cell_Arteritis.yaml	treatments	1	evidence	1	PMID:37321636	SUPPORT		TCZ is well tolerated in GCA, with low rates of discontinuation for AESIs. However, relapse occurred in > 50% despite median treatment > 12 months.	This provides evidence for tocilizumab's safety profile and highlights the challenge of relapses even with prolonged treatment.	"{""explanation"": ""This provides evidence for tocilizumab's safety profile and highlights the challenge of relapses even with prolonged treatment."", ""reference"": ""PMID:37321636"", ""snippet"": ""TCZ is well tolerated in GCA, with low rates of discontinuation for AESIs. However, relapse occurred in > 50% despite median treatment > 12 months."", ""supports"": ""SUPPORT""}"
3121	3086	129	Giant Cell Arteritis	Giant_Cell_Arteritis.yaml	treatments	4	evidence	0	PMID:38840219	SUPPORT		The Janus kinase/signal transducer and activator of transcription (JAK/STAT) signalling pathway is involved in the pathogenesis of GCA and JAK inhibitors (JAKi) could be a therapeutic alternative.	This provides the mechanistic rationale for using JAK inhibitors in GCA, linking the treatment to the underlying pathophysiology.	"{""explanation"": ""This provides the mechanistic rationale for using JAK inhibitors in GCA, linking the treatment to the underlying pathophysiology."", ""reference"": ""PMID:38840219"", ""snippet"": ""The Janus kinase/signal transducer and activator of transcription (JAK/STAT) signalling pathway is involved in the pathogenesis of GCA and JAK inhibitors (JAKi) could be a therapeutic alternative."", ""supports"": ""SUPPORT""}"
3122	3086	129	Giant Cell Arteritis	Giant_Cell_Arteritis.yaml	treatments	4	evidence	1	PMID:38840219	SUPPORT		This real-world analysis and literature review suggest that JAKi could be effective in GCA, including in patients failing established glucocorticoid-sparing therapies such as tocilizumab and methotrexate.	This evidence demonstrates that JAK inhibitors can be effective even in patients who have failed other steroid-sparing therapies.	"{""explanation"": ""This evidence demonstrates that JAK inhibitors can be effective even in patients who have failed other steroid-sparing therapies."", ""reference"": ""PMID:38840219"", ""snippet"": ""This real-world analysis and literature review suggest that JAKi could be effective in GCA, including in patients failing established glucocorticoid-sparing therapies such as tocilizumab and methotrexate."", ""supports"": ""SUPPORT""}"
3209	3171	132	Glucose-6-Phosphate Dehydrogenase (G6PD) Deficiency	Glucose-6-Phosphate_Dehydrogenase_G6PD_Deficiency.yaml	treatments	0	evidence	0	PMID:31609781	SUPPORT		By recognizing the potential for G6PD deficiency, clinicians can screen for the disorder and teach affected patients how to avoid triggers that result in harmful clinical manifestations.	The statement is supported by the reference as it mentions the importance of avoiding triggers that can lead to harmful clinical manifestations in individuals with G6PD deficiency.	"{""explanation"": ""The statement is supported by the reference as it mentions the importance of avoiding triggers that can lead to harmful clinical manifestations in individuals with G6PD deficiency."", ""reference"": ""PMID:31609781"", ""snippet"": ""By recognizing the potential for G6PD deficiency, clinicians can screen for the disorder and teach affected patients how to avoid triggers that result in harmful clinical manifestations."", ""supports"": ""SUPPORT""}"
3210	3171	132	Glucose-6-Phosphate Dehydrogenase (G6PD) Deficiency	Glucose-6-Phosphate_Dehydrogenase_G6PD_Deficiency.yaml	treatments	0	evidence	1	PMID:32600868	SUPPORT		Although most individuals are asymptomatic, exposure to certain food, drugs, or infections can trigger acute hemolytic anemia. Given the potential for coronavirus to trigger oxidative stress, unrecognized G6PD deficiency in the presence of the COVID-19 viral infection may cause hemolytic crisis and worse outcome in affected individuals.	The reference supports the statement by highlighting the importance of avoiding oxidative stressors to prevent acute hemolytic anemia in G6PD-deficient individuals.	"{""explanation"": ""The reference supports the statement by highlighting the importance of avoiding oxidative stressors to prevent acute hemolytic anemia in G6PD-deficient individuals."", ""reference"": ""PMID:32600868"", ""snippet"": ""Although most individuals are asymptomatic, exposure to certain food, drugs, or infections can trigger acute hemolytic anemia. Given the potential for coronavirus to trigger oxidative stress, unrecognized G6PD deficiency in the presence of the COVID-19 viral infection may cause hemolytic crisis and worse outcome in affected individuals."", ""supports"": ""SUPPORT""}"
3211	3171	132	Glucose-6-Phosphate Dehydrogenase (G6PD) Deficiency	Glucose-6-Phosphate_Dehydrogenase_G6PD_Deficiency.yaml	treatments	0	evidence	2	PMID:31235029	SUPPORT		The possible mechanism of oxidative stress-mediated destruction of erythrocytes in G6PD deficient individuals induced by periodontal infection is highlighted.	This reference supports the statement by discussing the increased risk of oxidative stress-mediated destruction of erythrocytes, indicating the importance of avoiding such stressors.	"{""explanation"": ""This reference supports the statement by discussing the increased risk of oxidative stress-mediated destruction of erythrocytes, indicating the importance of avoiding such stressors."", ""reference"": ""PMID:31235029"", ""snippet"": ""The possible mechanism of oxidative stress-mediated destruction of erythrocytes in G6PD deficient individuals induced by periodontal infection is highlighted."", ""supports"": ""SUPPORT""}"
3212	3171	132	Glucose-6-Phosphate Dehydrogenase (G6PD) Deficiency	Glucose-6-Phosphate_Dehydrogenase_G6PD_Deficiency.yaml	treatments	0	evidence	3	PMID:31089417	SUPPORT		G6PD deficiency, theoretically, renders red blood cells (RBC) susceptible to oxidative stress.	The reference supports the statement by emphasizing the susceptibility of G6PD-deficient individuals to oxidative stress and the potential benefits of avoiding such stressors.	"{""explanation"": ""The reference supports the statement by emphasizing the susceptibility of G6PD-deficient individuals to oxidative stress and the potential benefits of avoiding such stressors."", ""reference"": ""PMID:31089417"", ""snippet"": ""G6PD deficiency, theoretically, renders red blood cells (RBC) susceptible to oxidative stress."", ""supports"": ""SUPPORT""}"
3213	3172	132	Glucose-6-Phosphate Dehydrogenase (G6PD) Deficiency	Glucose-6-Phosphate_Dehydrogenase_G6PD_Deficiency.yaml	treatments	1	evidence	0	PMID:34105166	SUPPORT		33% of patients had Hb < 50 g/L and were all transfused. 50% had Hb between 50 and 65 g/L, half of them (n = 49) did not receive transfusion and only two patients (4%) required transfusion upon follow up. A restrictive transfusion strategy was adopted...	This study indicates that during acute hemolytic crisis in G6PD-deficient children, blood transfusions were given to those with severe anemia, supporting the necessity of blood transfusion for severe cases.	"{""explanation"": ""This study indicates that during acute hemolytic crisis in G6PD-deficient children, blood transfusions were given to those with severe anemia, supporting the necessity of blood transfusion for severe cases."", ""reference"": ""PMID:34105166"", ""snippet"": ""33% of patients had Hb < 50 g/L and were all transfused. 50% had Hb between 50 and 65 g/L, half of them (n = 49) did not receive transfusion and only two patients (4%) required transfusion upon follow up. A restrictive transfusion strategy was adopted..."", ""supports"": ""SUPPORT""}"
3214	3172	132	Glucose-6-Phosphate Dehydrogenase (G6PD) Deficiency	Glucose-6-Phosphate_Dehydrogenase_G6PD_Deficiency.yaml	treatments	1	evidence	1	PMID:16225031	SUPPORT		Because acute hemolysis is caused by exposure to an oxidative stressor in the form of an infection, oxidative drug, or fava beans, treatment is geared toward avoidance of these and other stressors. Acute hemolysis is self-limited, but in rare instances it can be severe enough to warrant a blood transfusion.	The statement that management involves hydration, blood transfusions when necessary, and monitoring for complications aligns with the literature, which suggests blood transfusion in severe cases and the self-limited nature of acute hemolysis.	"{""explanation"": ""The statement that management involves hydration, blood transfusions when necessary, and monitoring for complications aligns with the literature, which suggests blood transfusion in severe cases and the self-limited nature of acute hemolysis."", ""reference"": ""PMID:16225031"", ""snippet"": ""Because acute hemolysis is caused by exposure to an oxidative stressor in the form of an infection, oxidative drug, or fava beans, treatment is geared toward avoidance of these and other stressors. Acute hemolysis is self-limited, but in rare instances it can be severe enough to warrant a blood transfusion."", ""supports"": ""SUPPORT""}"
3215	3172	132	Glucose-6-Phosphate Dehydrogenase (G6PD) Deficiency	Glucose-6-Phosphate_Dehydrogenase_G6PD_Deficiency.yaml	treatments	1	evidence	2	PMID:34383774	SUPPORT		G6PD-deficient individuals are susceptible to hemolysis during oxidative stress, which can occur from exposure to certain medications, including 8-aminoquinolines used to treat Plasmodium vivax malaria. Accordingly, access to point-of-care (POC) G6PD testing in Brazil is critical for safe treatment...	The context of oxidative stress and acute hemolysis in G6PD-deficient individuals points towards the requirement for careful monitoring and supportive care to mitigate severe outcomes.	"{""explanation"": ""The context of oxidative stress and acute hemolysis in G6PD-deficient individuals points towards the requirement for careful monitoring and supportive care to mitigate severe outcomes."", ""reference"": ""PMID:34383774"", ""snippet"": ""G6PD-deficient individuals are susceptible to hemolysis during oxidative stress, which can occur from exposure to certain medications, including 8-aminoquinolines used to treat Plasmodium vivax malaria. Accordingly, access to point-of-care (POC) G6PD testing in Brazil is critical for safe treatment..."", ""supports"": ""SUPPORT""}"
3216	3172	132	Glucose-6-Phosphate Dehydrogenase (G6PD) Deficiency	Glucose-6-Phosphate_Dehydrogenase_G6PD_Deficiency.yaml	treatments	1	evidence	3	PMID:23815264	SUPPORT		Patients requiring RBC transfusions may simultaneously receive oxidative medications or have concurrent infections, both of which can induce haemolysis in G6PD-deficient RBCs...discusses G6PD deficiency, its importance in transfusion medicine...	This reference discusses the role of transfusions and monitoring in the management of hemolysis in G6PD-deficient patients during oxidative stress events.	"{""explanation"": ""This reference discusses the role of transfusions and monitoring in the management of hemolysis in G6PD-deficient patients during oxidative stress events."", ""reference"": ""PMID:23815264"", ""snippet"": ""Patients requiring RBC transfusions may simultaneously receive oxidative medications or have concurrent infections, both of which can induce haemolysis in G6PD-deficient RBCs...discusses G6PD deficiency, its importance in transfusion medicine..."", ""supports"": ""SUPPORT""}"
3217	3173	132	Glucose-6-Phosphate Dehydrogenase (G6PD) Deficiency	Glucose-6-Phosphate_Dehydrogenase_G6PD_Deficiency.yaml	treatments	2	evidence	0	PMID:27064064	SUPPORT		Early detection and an accurate diagnosis are, therefore, of major importance for preventing negative patient outcomes. ... We advocate adopting a national neonatal G6PD screening program in Gaza Strip to identify children at risk and promote wellness and health for Palestine.	This reference emphasizes the importance of early detection and accurate diagnosis to prevent severe outcomes in newborns.	"{""explanation"": ""This reference emphasizes the importance of early detection and accurate diagnosis to prevent severe outcomes in newborns."", ""reference"": ""PMID:27064064"", ""snippet"": ""Early detection and an accurate diagnosis are, therefore, of major importance for preventing negative patient outcomes. ... We advocate adopting a national neonatal G6PD screening program in Gaza Strip to identify children at risk and promote wellness and health for Palestine."", ""supports"": ""SUPPORT""}"
3218	3173	132	Glucose-6-Phosphate Dehydrogenase (G6PD) Deficiency	Glucose-6-Phosphate_Dehydrogenase_G6PD_Deficiency.yaml	treatments	2	evidence	1	PMID:36845240	SUPPORT		Through this observation, we insist on the importance of neonatal screening in regions with a high prevalence of hemolysis in order to avoid diagnostic delays and also to prioritize the evaluation to be requested in an acute hemolysis state, to propose an education articulated around a preventive approach in children with this disease.	This reference supports neonatal screening and preventive measures to manage G6PD deficiency effectively.	"{""explanation"": ""This reference supports neonatal screening and preventive measures to manage G6PD deficiency effectively."", ""reference"": ""PMID:36845240"", ""snippet"": ""Through this observation, we insist on the importance of neonatal screening in regions with a high prevalence of hemolysis in order to avoid diagnostic delays and also to prioritize the evaluation to be requested in an acute hemolysis state, to propose an education articulated around a preventive approach in children with this disease."", ""supports"": ""SUPPORT""}"
3219	3173	132	Glucose-6-Phosphate Dehydrogenase (G6PD) Deficiency	Glucose-6-Phosphate_Dehydrogenase_G6PD_Deficiency.yaml	treatments	2	evidence	2	PMID:16225031	SUPPORT		Neonatal hyperbilirubinemia may require treatment with phototherapy or exchange transfusion to prevent kernicterus.	This reference highlights the need for early intervention in neonatal hyperbilirubinemia, which aligns with the statement regarding prevention of severe jaundice through early detection.	"{""explanation"": ""This reference highlights the need for early intervention in neonatal hyperbilirubinemia, which aligns with the statement regarding prevention of severe jaundice through early detection."", ""reference"": ""PMID:16225031"", ""snippet"": ""Neonatal hyperbilirubinemia may require treatment with phototherapy or exchange transfusion to prevent kernicterus."", ""supports"": ""SUPPORT""}"
3220	3173	132	Glucose-6-Phosphate Dehydrogenase (G6PD) Deficiency	Glucose-6-Phosphate_Dehydrogenase_G6PD_Deficiency.yaml	treatments	2	evidence	3	PMID:27235212	SUPPORT		Glucose-6-phosphate dehydrogenase (G6PD) deficiency, one of the most common human enzymopathies, is a major risk factor for hyperbilirubinemia and greatly increases the risk of kernicterus even in the developed world.	This reference mentions G6PD deficiency as a significant risk factor for hyperbilirubinemia, which supports the need for early screening and monitoring.	"{""explanation"": ""This reference mentions G6PD deficiency as a significant risk factor for hyperbilirubinemia, which supports the need for early screening and monitoring."", ""reference"": ""PMID:27235212"", ""snippet"": ""Glucose-6-phosphate dehydrogenase (G6PD) deficiency, one of the most common human enzymopathies, is a major risk factor for hyperbilirubinemia and greatly increases the risk of kernicterus even in the developed world."", ""supports"": ""SUPPORT""}"
3241	3197	133	Gorlin Syndrome	Gorlin_Syndrome.yaml	treatments	1	evidence	0	PMID:22670904	SUPPORT		Vismodegib reduces the basal-cell carcinoma tumor burden and blocks growth of new basal-cell carcinomas in patients with the basal-cell nevus syndrome.	Randomized controlled trial demonstrating efficacy of vismodegib in reducing BCC burden in Gorlin syndrome.	"{""explanation"": ""Randomized controlled trial demonstrating efficacy of vismodegib in reducing BCC burden in Gorlin syndrome."", ""reference"": ""PMID:22670904"", ""snippet"": ""Vismodegib reduces the basal-cell carcinoma tumor burden and blocks growth of new basal-cell carcinomas in patients with the basal-cell nevus syndrome."", ""supports"": ""SUPPORT""}"
3242	3197	133	Gorlin Syndrome	Gorlin_Syndrome.yaml	treatments	1	evidence	1	PMID:22670904	PARTIAL		The adverse events associated with treatment led to discontinuation in over half of treated patients.	Documents significant tolerability issues with vismodegib leading to high discontinuation rates.	"{""explanation"": ""Documents significant tolerability issues with vismodegib leading to high discontinuation rates."", ""reference"": ""PMID:22670904"", ""snippet"": ""The adverse events associated with treatment led to discontinuation in over half of treated patients."", ""supports"": ""PARTIAL""}"
3259	3227	134	Gout	Gout.yaml	treatments	3	evidence	0	PMID:39426967	SUPPORT		Urate-lowering treatment (ULT) to target with xanthine oxidase inhibitors (XOIs) paradoxically causes early increase in gouty arthritis flares.	Describes the paradoxical early flare phenomenon with XOI treatment, an important clinical consideration.	"{""explanation"": ""Describes the paradoxical early flare phenomenon with XOI treatment, an important clinical consideration."", ""reference"": ""PMID:39426967"", ""snippet"": ""Urate-lowering treatment (ULT) to target with xanthine oxidase inhibitors (XOIs) paradoxically causes early increase in gouty arthritis flares."", ""supports"": ""SUPPORT""}"
3260	3227	134	Gout	Gout.yaml	treatments	3	evidence	1	PMID:39426967	SUPPORT		At 48 weeks ULT, serum urate normalized in all gout patients, and flares declined in association with significantly altered proteins (p < 0.05) in clustering and proteome networks in sera and peripheral blood mononuclear cells.	Demonstrates that sustained XOI urate-lowering therapy normalizes serum urate and reduces flares through modulation of immune proteomes.	"{""explanation"": ""Demonstrates that sustained XOI urate-lowering therapy normalizes serum urate and reduces flares through modulation of immune proteomes."", ""reference"": ""PMID:39426967"", ""snippet"": ""At 48 weeks ULT, serum urate normalized in all gout patients, and flares declined in association with significantly altered proteins (p < 0.05) in clustering and proteome networks in sera and peripheral blood mononuclear cells."", ""supports"": ""SUPPORT""}"
3261	3228	134	Gout	Gout.yaml	treatments	4	evidence	0	PMID:39426967	SUPPORT		Last, febuxostat treatment decreased complement activation biologic process proteins in cultured BMDMs.	Shows that febuxostat has anti-inflammatory effects beyond urate lowering by modulating complement activation in macrophages.	"{""explanation"": ""Shows that febuxostat has anti-inflammatory effects beyond urate lowering by modulating complement activation in macrophages."", ""reference"": ""PMID:39426967"", ""snippet"": ""Last, febuxostat treatment decreased complement activation biologic process proteins in cultured BMDMs."", ""supports"": ""SUPPORT""}"
3289	3241	135	Grange syndrome	Grange_syndrome.yaml	treatments	0	evidence	0	PMID:33971976	SUPPORT		Treatment with AAS, clopidogrel, enalapril, and atorvastatin was started at this time.	Raggio et al. 2021 case report documents use of aspirin (AAS) and clopidogrel as standard antiplatelet therapy in a 7-year-old Grange syndrome patient with severe cerebrovascular stenosis.	"{""explanation"": ""Raggio et al. 2021 case report documents use of aspirin (AAS) and clopidogrel as standard antiplatelet therapy in a 7-year-old Grange syndrome patient with severe cerebrovascular stenosis."", ""reference"": ""PMID:33971976"", ""snippet"": ""Treatment with AAS, clopidogrel, enalapril, and atorvastatin was started at this time."", ""supports"": ""SUPPORT""}"
3290	3242	135	Grange syndrome	Grange_syndrome.yaml	treatments	1	evidence	0	PMID:33971976	SUPPORT		Treatment with AAS, clopidogrel, enalapril, and atorvastatin was started at this time... Given this diagnosis, enalapril was changed to propranolol.	Raggio et al. 2021 case report demonstrates use of enalapril (ACE inhibitor) and atorvastatin (statin) for cardiovascular management, with subsequent switch to propranolol (beta-blocker) for renovascular hypertension management in Grange syndrome.	"{""explanation"": ""Raggio et al. 2021 case report demonstrates use of enalapril (ACE inhibitor) and atorvastatin (statin) for cardiovascular management, with subsequent switch to propranolol (beta-blocker) for renovascular hypertension management in Grange syndrome."", ""reference"": ""PMID:33971976"", ""snippet"": ""Treatment with AAS, clopidogrel, enalapril, and atorvastatin was started at this time... Given this diagnosis, enalapril was changed to propranolol."", ""supports"": ""SUPPORT""}"
3291	3243	135	Grange syndrome	Grange_syndrome.yaml	treatments	2	evidence	0	PMID:33971976	SUPPORT		Although she did not present Moya-Moya phenomenon, neurosurgeons decided to perform a bilateral indirect revascularization in 2 stages, left hemisphere at the age of 7 and right at the age of 8 years.	Raggio et al. 2021 case report documents bilateral indirect cerebral revascularization as therapeutic intervention for severe stenosis of internal carotid and vertebral arteries in a pediatric Grange syndrome patient.	"{""explanation"": ""Raggio et al. 2021 case report documents bilateral indirect cerebral revascularization as therapeutic intervention for severe stenosis of internal carotid and vertebral arteries in a pediatric Grange syndrome patient."", ""reference"": ""PMID:33971976"", ""snippet"": ""Although she did not present Moya-Moya phenomenon, neurosurgeons decided to perform a bilateral indirect revascularization in 2 stages, left hemisphere at the age of 7 and right at the age of 8 years."", ""supports"": ""SUPPORT""}"
3292	3244	135	Grange syndrome	Grange_syndrome.yaml	treatments	3	evidence	0	PMID:33971976	SUPPORT		At the age of 10 years, Doppler ultrasound showed persistence of bilateral renal artery stenosis. Balloon angioplasty was performed: an incomplete dilatation was achieved, and no residual stenosis was detected at the time.	Raggio et al. 2021 case report documents percutaneous balloon angioplasty as intervention for bilateral renal artery stenosis in pediatric Grange syndrome patient with renovascular hypertension.	"{""explanation"": ""Raggio et al. 2021 case report documents percutaneous balloon angioplasty as intervention for bilateral renal artery stenosis in pediatric Grange syndrome patient with renovascular hypertension."", ""reference"": ""PMID:33971976"", ""snippet"": ""At the age of 10 years, Doppler ultrasound showed persistence of bilateral renal artery stenosis. Balloon angioplasty was performed: an incomplete dilatation was achieved, and no residual stenosis was detected at the time."", ""supports"": ""SUPPORT""}"
3293	3245	135	Grange syndrome	Grange_syndrome.yaml	treatments	4	evidence	0	PMID:33971976	SUPPORT		Surgical correction of hand syndactyly (left hand between the fourth and fifth finger) was previously done at the age of 1 year.	Raggio et al. 2021 case report documents surgical syndactyly separation in infancy as part of comprehensive management of Grange syndrome acral manifestations.	"{""explanation"": ""Raggio et al. 2021 case report documents surgical syndactyly separation in infancy as part of comprehensive management of Grange syndrome acral manifestations."", ""reference"": ""PMID:33971976"", ""snippet"": ""Surgical correction of hand syndactyly (left hand between the fourth and fifth finger) was previously done at the age of 1 year."", ""supports"": ""SUPPORT""}"
3302	3262	136	Granulomatosis with Polyangiitis	Granulomatosis_with_Polyangiitis.yaml	treatments	3	evidence	0	PMID:37781373	SUPPORT		Mechanistically, cytokines or complement factors activate and prime neutrophils for ANCA-binding; thus, C5a receptor blocker has garnered attention as potential replacement for glucocorticoids in clinical settings.	This review describes avacopan as a C5a receptor blocker that can potentially replace glucocorticoids by blocking complement-mediated neutrophil priming.	"{""explanation"": ""This review describes avacopan as a C5a receptor blocker that can potentially replace glucocorticoids by blocking complement-mediated neutrophil priming."", ""reference"": ""PMID:37781373"", ""snippet"": ""Mechanistically, cytokines or complement factors activate and prime neutrophils for ANCA-binding; thus, C5a receptor blocker has garnered attention as potential replacement for glucocorticoids in clinical settings."", ""supports"": ""SUPPORT""}"
3303	3262	136	Granulomatosis with Polyangiitis	Granulomatosis_with_Polyangiitis.yaml	treatments	3	evidence	1	PMID:35479831	SUPPORT		This review describes emerging treatment regimens, including evidence for plasma exchange in severe disease and the inhibitor of the complement C5a receptor (C5aR) inhibitor, Avacopan.	This review confirms avacopan as an emerging treatment option for AAV targeting the C5a receptor.	"{""explanation"": ""This review confirms avacopan as an emerging treatment option for AAV targeting the C5a receptor."", ""reference"": ""PMID:35479831"", ""snippet"": ""This review describes emerging treatment regimens, including evidence for plasma exchange in severe disease and the inhibitor of the complement C5a receptor (C5aR) inhibitor, Avacopan."", ""supports"": ""SUPPORT""}"
3373	3299	137	Graves' Disease	Graves_Disease.yaml	treatments	0	evidence	0	PMID:17154097	SUPPORT		Methimazole (MMI) and propylthiouracil (PTU) have been used, however, MMI is the preferred drug treatment.	The reference confirms that both Methimazole and PTU are used as antithyroid medications to reduce thyroid hormone production in Graves' disease.	"{""explanation"": ""The reference confirms that both Methimazole and PTU are used as antithyroid medications to reduce thyroid hormone production in Graves' disease."", ""reference"": ""PMID:17154097"", ""snippet"": ""Methimazole (MMI) and propylthiouracil (PTU) have been used, however, MMI is the preferred drug treatment."", ""supports"": ""SUPPORT""}"
3374	3299	137	Graves' Disease	Graves_Disease.yaml	treatments	0	evidence	1	PMID:37594736	SUPPORT		Antithyroid drugs remain a cornerstone of thyroid therapeutics.	The reference supports the use of antithyroid medications, including Methimazole and PTU, in the treatment of hyperthyroidism associated with Graves' disease.	"{""explanation"": ""The reference supports the use of antithyroid medications, including Methimazole and PTU, in the treatment of hyperthyroidism associated with Graves' disease."", ""reference"": ""PMID:37594736"", ""snippet"": ""Antithyroid drugs remain a cornerstone of thyroid therapeutics."", ""supports"": ""SUPPORT""}"
3375	3299	137	Graves' Disease	Graves_Disease.yaml	treatments	0	evidence	2	PMID:36740774	SUPPORT		The thionamide anti-thyroid drugs namely carbimazole, methimazole, and propylthiouracil, have been the predominant therapy modality for Graves' hyperthyroidism for over 60 years.	The reference supports the use of Methimazole and PTU as primary antithyroid medications for managing Graves' disease.	"{""explanation"": ""The reference supports the use of Methimazole and PTU as primary antithyroid medications for managing Graves' disease."", ""reference"": ""PMID:36740774"", ""snippet"": ""The thionamide anti-thyroid drugs namely carbimazole, methimazole, and propylthiouracil, have been the predominant therapy modality for Graves' hyperthyroidism for over 60 years."", ""supports"": ""SUPPORT""}"
3376	3300	137	Graves' Disease	Graves_Disease.yaml	treatments	1	evidence	0	PMID:36468997	SUPPORT		Radioactive iodine 131I is a theranostic isotope used both for diagnosis and therapy of benign thyroid diseases and thyroid cancer for 85 years.	The abstract confirms that radioactive iodine is used for therapy, including the treatment of Graves' disease, which involves destroying overactive thyroid cells.	"{""explanation"": ""The abstract confirms that radioactive iodine is used for therapy, including the treatment of Graves' disease, which involves destroying overactive thyroid cells."", ""reference"": ""PMID:36468997"", ""snippet"": ""Radioactive iodine 131I is a theranostic isotope used both for diagnosis and therapy of benign thyroid diseases and thyroid cancer for 85 years."", ""supports"": ""SUPPORT""}"
3377	3300	137	Graves' Disease	Graves_Disease.yaml	treatments	1	evidence	1	PMID:2451239	SUPPORT		Radioactive iodine is the most frequently used and safest method of treatment for adults.	This reference supports the use of radioactive iodine therapy for treating Graves' disease by destroying overactive thyroid cells.	"{""explanation"": ""This reference supports the use of radioactive iodine therapy for treating Graves' disease by destroying overactive thyroid cells."", ""reference"": ""PMID:2451239"", ""snippet"": ""Radioactive iodine is the most frequently used and safest method of treatment for adults."", ""supports"": ""SUPPORT""}"
3378	3300	137	Graves' Disease	Graves_Disease.yaml	treatments	1	evidence	2	PMID:1987448	SUPPORT		In most clinical situations, a strong argument can be made for iodine-131 therapy, which is safe and definitive, although posttreatment hypothyroidism and the need for lifelong thyroxine are to be expected.	The text confirms the use of radioactive iodine therapy (iodine-131) for treating Graves' disease, consistent with the statement.	"{""explanation"": ""The text confirms the use of radioactive iodine therapy (iodine-131) for treating Graves' disease, consistent with the statement."", ""reference"": ""PMID:1987448"", ""snippet"": ""In most clinical situations, a strong argument can be made for iodine-131 therapy, which is safe and definitive, although posttreatment hypothyroidism and the need for lifelong thyroxine are to be expected."", ""supports"": ""SUPPORT""}"
3379	3301	137	Graves' Disease	Graves_Disease.yaml	treatments	2	evidence	0	PMID:35728139	SUPPORT		Total thyroidectomy resulted in long-term control of thyrotoxicosis in all patients. There were no incidences of recurrent laryngeal nerve injury. One patient (1.6%) suffered permanent hypoparathyroidism. CONCLUSION: Total thyroidectomy is a safe and effective treatment for Graves' disease.	The study supports the statement that surgical removal of the thyroid gland, specifically total thyroidectomy, is used in the treatment of Graves' disease.	"{""explanation"": ""The study supports the statement that surgical removal of the thyroid gland, specifically total thyroidectomy, is used in the treatment of Graves' disease."", ""reference"": ""PMID:35728139"", ""snippet"": ""Total thyroidectomy resulted in long-term control of thyrotoxicosis in all patients. There were no incidences of recurrent laryngeal nerve injury. One patient (1.6%) suffered permanent hypoparathyroidism. CONCLUSION: Total thyroidectomy is a safe and effective treatment for Graves' disease."", ""supports"": ""SUPPORT""}"
3380	3301	137	Graves' Disease	Graves_Disease.yaml	treatments	2	evidence	1	PMID:25103076	SUPPORT		Surgery is one of the treatment choices for Graves disease.	The study indicates that thyroidectomy is one of the treatment options for Graves' disease, supporting the statement.	"{""explanation"": ""The study indicates that thyroidectomy is one of the treatment options for Graves' disease, supporting the statement."", ""reference"": ""PMID:25103076"", ""snippet"": ""Surgery is one of the treatment choices for Graves disease."", ""supports"": ""SUPPORT""}"
3381	3301	137	Graves' Disease	Graves_Disease.yaml	treatments	2	evidence	2	PMID:34243871	SUPPORT		Graves disease is an autoimmune disorder...In approximately 25% of patients, an inflammatory condition, Graves eye disease (GED), affects the orbital soft tissues.	While this reference focuses on Graves eye disease, it indirectly supports the statement by discussing the broader context of Graves' disease treatment.	"{""explanation"": ""While this reference focuses on Graves eye disease, it indirectly supports the statement by discussing the broader context of Graves' disease treatment."", ""reference"": ""PMID:34243871"", ""snippet"": ""Graves disease is an autoimmune disorder...In approximately 25% of patients, an inflammatory condition, Graves eye disease (GED), affects the orbital soft tissues."", ""supports"": ""SUPPORT""}"
3382	3301	137	Graves' Disease	Graves_Disease.yaml	treatments	2	evidence	3	PMID:30180972	SUPPORT		Indications for a radical treatment can arise in cases of...relapse despite prolonged medical treatment...Surgery is the radical method of treatment used in children under 5 years of age, or in cases of very large, nodular, or compressive goiters.	The study discusses the use of surgery as a treatment for Graves' disease in specific cases, supporting the statement.	"{""explanation"": ""The study discusses the use of surgery as a treatment for Graves' disease in specific cases, supporting the statement."", ""reference"": ""PMID:30180972"", ""snippet"": ""Indications for a radical treatment can arise in cases of...relapse despite prolonged medical treatment...Surgery is the radical method of treatment used in children under 5 years of age, or in cases of very large, nodular, or compressive goiters."", ""supports"": ""SUPPORT""}"
3383	3302	137	Graves' Disease	Graves_Disease.yaml	treatments	3	evidence	0	PMID:22975536	SUPPORT		beta-adrenergic antagonists (beta-blockers) are often used to attenuate the hyperadrenergic symptoms of Graves' disease (GD), including palpitation.	The study confirms that beta-blockers are used to manage cardiovascular symptoms like tachycardia and palpitations in Graves' disease.	"{""explanation"": ""The study confirms that beta-blockers are used to manage cardiovascular symptoms like tachycardia and palpitations in Graves' disease."", ""reference"": ""PMID:22975536"", ""snippet"": ""beta-adrenergic antagonists (beta-blockers) are often used to attenuate the hyperadrenergic symptoms of Graves' disease (GD), including palpitation."", ""supports"": ""SUPPORT""}"
3384	3302	137	Graves' Disease	Graves_Disease.yaml	treatments	3	evidence	1	PMID:36518043	SUPPORT		Beta-blockers, mainly propranalol, are usually administered to control heart rate in patients with thyrotoxicosis, especially when congestive heart failure presents.	The case report supports the use of beta-blockers to control heart rate in patients with thyrotoxicosis, which includes Graves' disease.	"{""explanation"": ""The case report supports the use of beta-blockers to control heart rate in patients with thyrotoxicosis, which includes Graves' disease."", ""reference"": ""PMID:36518043"", ""snippet"": ""Beta-blockers, mainly propranalol, are usually administered to control heart rate in patients with thyrotoxicosis, especially when congestive heart failure presents."", ""supports"": ""SUPPORT""}"
3385	3302	137	Graves' Disease	Graves_Disease.yaml	treatments	3	evidence	2	PMID:32402541	SUPPORT		Tachyarrhythmias, including atrial fibrillation and tachycardia, improved in 85.9% of patients in the surgical group vs 66% in the medical group (P = .01).	The study indicates that both surgical and medical (which includes beta-blockers) management improves tachyarrhythmias in Graves' disease patients.	"{""explanation"": ""The study indicates that both surgical and medical (which includes beta-blockers) management improves tachyarrhythmias in Graves' disease patients."", ""reference"": ""PMID:32402541"", ""snippet"": ""Tachyarrhythmias, including atrial fibrillation and tachycardia, improved in 85.9% of patients in the surgical group vs 66% in the medical group (P = .01)."", ""supports"": ""SUPPORT""}"
3386	3303	137	Graves' Disease	Graves_Disease.yaml	treatments	4	evidence	0	PMID:33069387	SUPPORT		Glucocorticoids at high doses are the cornerstone in moderate-severe cases.	The literature indicates that glucocorticoids (a type of corticosteroid) are a primary treatment for moderate-severe Graves' ophthalmopathy, which supports their use to reduce inflammation in severe ophthalmopathy.	"{""explanation"": ""The literature indicates that glucocorticoids (a type of corticosteroid) are a primary treatment for moderate-severe Graves' ophthalmopathy, which supports their use to reduce inflammation in severe ophthalmopathy."", ""reference"": ""PMID:33069387"", ""snippet"": ""Glucocorticoids at high doses are the cornerstone in moderate-severe cases."", ""supports"": ""SUPPORT""}"
3387	3303	137	Graves' Disease	Graves_Disease.yaml	treatments	4	evidence	1	PMID:29923966	SUPPORT		Corticosteroids continue to be the primary medical therapy for TED.	Thyroid eye disease (TED) is another term for Graves' ophthalmopathy, and corticosteroids are noted as the primary medical therapy for this condition.	"{""explanation"": ""Thyroid eye disease (TED) is another term for Graves' ophthalmopathy, and corticosteroids are noted as the primary medical therapy for this condition."", ""reference"": ""PMID:29923966"", ""snippet"": ""Corticosteroids continue to be the primary medical therapy for TED."", ""supports"": ""SUPPORT""}"
3388	3303	137	Graves' Disease	Graves_Disease.yaml	treatments	4	evidence	2	PMID:36272013	SUPPORT		Corticosteroids have been the first-line treatment for GO.	Graves' ophthalmopathy (GO) is treated primarily with corticosteroids, as indicated in the literature.	"{""explanation"": ""Graves' ophthalmopathy (GO) is treated primarily with corticosteroids, as indicated in the literature."", ""reference"": ""PMID:36272013"", ""snippet"": ""Corticosteroids have been the first-line treatment for GO."", ""supports"": ""SUPPORT""}"
3389	3303	137	Graves' Disease	Graves_Disease.yaml	treatments	4	evidence	3	PMID:22632369	SUPPORT		Glucocorticoids (oral or intravenous) represent the main treatment of moderate-to-severe GO, the intravenous route being more effective.	Glucocorticoids, a type of corticosteroid, are the main treatment for moderate-to-severe Graves' ophthalmopathy, supporting their use to reduce inflammation.	"{""explanation"": ""Glucocorticoids, a type of corticosteroid, are the main treatment for moderate-to-severe Graves' ophthalmopathy, supporting their use to reduce inflammation."", ""reference"": ""PMID:22632369"", ""snippet"": ""Glucocorticoids (oral or intravenous) represent the main treatment of moderate-to-severe GO, the intravenous route being more effective."", ""supports"": ""SUPPORT""}"
3467	3545	148	Hemochromatosis	Hemochromatosis.yaml	treatments	0	evidence	0	PMID:23985001	SUPPORT		Phlebotomy remains the mainstay of treatment and new treatments being studied include erythrocytapheresis and 'mini-hepcidins'.	This review confirms phlebotomy as the standard first-line treatment for hereditary hemochromatosis.	"{""explanation"": ""This review confirms phlebotomy as the standard first-line treatment for hereditary hemochromatosis."", ""reference"": ""PMID:23985001"", ""snippet"": ""Phlebotomy remains the mainstay of treatment and new treatments being studied include erythrocytapheresis and 'mini-hepcidins'."", ""supports"": ""SUPPORT""}"
3468	3545	148	Hemochromatosis	Hemochromatosis.yaml	treatments	0	evidence	1	PMID:38886778	SUPPORT		Four patients with organ damage in the present study received therapeutic phlebotomy, alleviating clinical symptoms and improving in transferrin saturation and serum ferritin.	Phlebotomy improved iron indices and symptoms in a ferroportin hemochromatosis pedigree.	"{""explanation"": ""Phlebotomy improved iron indices and symptoms in a ferroportin hemochromatosis pedigree."", ""reference"": ""PMID:38886778"", ""snippet"": ""Four patients with organ damage in the present study received therapeutic phlebotomy, alleviating clinical symptoms and improving in transferrin saturation and serum ferritin."", ""supports"": ""SUPPORT""}"
3469	3545	148	Hemochromatosis	Hemochromatosis.yaml	treatments	0	evidence	2	PMID:37121243	SUPPORT		Early diagnosis by genetic testing and therapy by periodic phlebotomy can prevent the most serious complications, which include liver cirrhosis, liver cancer, and death.	Seminar notes phlebotomy prevents cirrhosis and mortality when started early.	"{""explanation"": ""Seminar notes phlebotomy prevents cirrhosis and mortality when started early."", ""reference"": ""PMID:37121243"", ""snippet"": ""Early diagnosis by genetic testing and therapy by periodic phlebotomy can prevent the most serious complications, which include liver cirrhosis, liver cancer, and death."", ""supports"": ""SUPPORT""}"
3470	3545	148	Hemochromatosis	Hemochromatosis.yaml	treatments	0	evidence	3	PMID:35662478	SUPPORT		Early diagnosis and treatment by phlebotomy can prevent cirrhosis, hepatocellular carcinoma, diabetes, arthropathy and other complications.	EASL guideline highlights phlebotomy as preventive for multi-organ complications.	"{""explanation"": ""EASL guideline highlights phlebotomy as preventive for multi-organ complications."", ""reference"": ""PMID:35662478"", ""snippet"": ""Early diagnosis and treatment by phlebotomy can prevent cirrhosis, hepatocellular carcinoma, diabetes, arthropathy and other complications."", ""supports"": ""SUPPORT""}"
3471	3545	148	Hemochromatosis	Hemochromatosis.yaml	treatments	0	evidence	4	PMID:5339192	SUPPORT		The treatment of hemochromatosis by phlebotomy.	Early clinical report established phlebotomy as definitive iron removal.	"{""explanation"": ""Early clinical report established phlebotomy as definitive iron removal."", ""reference"": ""PMID:5339192"", ""snippet"": ""The treatment of hemochromatosis by phlebotomy."", ""supports"": ""SUPPORT""}"
3472	3546	148	Hemochromatosis	Hemochromatosis.yaml	treatments	1	evidence	0	PMID:19727383	SUPPORT		Because secondary hemochromatosis is due to hereditary or acquired anemia, phlebotomy is not a suitable means of removing excess iron in this situation. Rather, the treatment is based on the targeted elimination of iron by means of iron chelators.	Secondary hemochromatosis requires chelation when phlebotomy is not feasible.	"{""explanation"": ""Secondary hemochromatosis requires chelation when phlebotomy is not feasible."", ""reference"": ""PMID:19727383"", ""snippet"": ""Because secondary hemochromatosis is due to hereditary or acquired anemia, phlebotomy is not a suitable means of removing excess iron in this situation. Rather, the treatment is based on the targeted elimination of iron by means of iron chelators."", ""supports"": ""SUPPORT""}"
3473	3546	148	Hemochromatosis	Hemochromatosis.yaml	treatments	1	evidence	1	PMID:29620054	SUPPORT		The mainstay therapy is phlebotomy, although iron chelation can be used in some patients.	Primer notes chelation as an alternative for selected patients.	"{""explanation"": ""Primer notes chelation as an alternative for selected patients."", ""reference"": ""PMID:29620054"", ""snippet"": ""The mainstay therapy is phlebotomy, although iron chelation can be used in some patients."", ""supports"": ""SUPPORT""}"
3474	3547	148	Hemochromatosis	Hemochromatosis.yaml	treatments	2	evidence	0	PMID:38361672	SUPPORT		This patient was counseled on lifestyle modifications which included abstaining from alcohol and reducing iron and vitamin C intake. As a result, his iron panel parameters improved.	Lifestyle changes in alcohol and dietary iron/Vitamin C improved iron indices.	"{""explanation"": ""Lifestyle changes in alcohol and dietary iron/Vitamin C improved iron indices."", ""reference"": ""PMID:38361672"", ""snippet"": ""This patient was counseled on lifestyle modifications which included abstaining from alcohol and reducing iron and vitamin C intake. As a result, his iron panel parameters improved."", ""supports"": ""SUPPORT""}"
3475	3548	148	Hemochromatosis	Hemochromatosis.yaml	treatments	3	evidence	0	PMID:37121243	SUPPORT		Early diagnosis by genetic testing and therapy by periodic phlebotomy can prevent the most serious complications, which include liver cirrhosis, liver cancer, and death.	Emphasizes early genetic testing to enable preventive treatment.	"{""explanation"": ""Emphasizes early genetic testing to enable preventive treatment."", ""reference"": ""PMID:37121243"", ""snippet"": ""Early diagnosis by genetic testing and therapy by periodic phlebotomy can prevent the most serious complications, which include liver cirrhosis, liver cancer, and death."", ""supports"": ""SUPPORT""}"
3484	3563	149	Hemophilia A	Hemophilia_A.yaml	treatments	0	evidence	0	PMID:12640572	SUPPORT		Plasma-derived cryoprecipitate and factor (F) VIII concentrates, which have been used for hemophilia A patients, involve the risk of transmitting blood-borne diseases.	Review confirms factor VIII concentrates as established treatment for hemophilia A patients.	"{""explanation"": ""Review confirms factor VIII concentrates as established treatment for hemophilia A patients."", ""reference"": ""PMID:12640572"", ""snippet"": ""Plasma-derived cryoprecipitate and factor (F) VIII concentrates, which have been used for hemophilia A patients, involve the risk of transmitting blood-borne diseases."", ""supports"": ""SUPPORT""}"
3485	3564	149	Hemophilia A	Hemophilia_A.yaml	treatments	1	evidence	0	PMID:30157389	SUPPORT		Emicizumab is a bispecific monoclonal antibody that bridges activated factor IX and factor X to replace the function of missing activated factor VIII, thereby restoring hemostasis.	Phase 3 HAVEN 3 trial demonstrates emicizumab mechanism and efficacy in hemophilia A without inhibitors.	"{""explanation"": ""Phase 3 HAVEN 3 trial demonstrates emicizumab mechanism and efficacy in hemophilia A without inhibitors."", ""reference"": ""PMID:30157389"", ""snippet"": ""Emicizumab is a bispecific monoclonal antibody that bridges activated factor IX and factor X to replace the function of missing activated factor VIII, thereby restoring hemostasis."", ""supports"": ""SUPPORT""}"
3486	3565	149	Hemophilia A	Hemophilia_A.yaml	treatments	2	evidence	0	PMID:12640572	SUPPORT		Desmopressin is today a widely used hemostatic agent not only in patients with mild hemophilia A or von Willebrand disease (vWD) but also in those with congenital or acquired platelet dysfunction.	Review confirms desmopressin as a widely used hemostatic agent in mild hemophilia A.	"{""explanation"": ""Review confirms desmopressin as a widely used hemostatic agent in mild hemophilia A."", ""reference"": ""PMID:12640572"", ""snippet"": ""Desmopressin is today a widely used hemostatic agent not only in patients with mild hemophilia A or von Willebrand disease (vWD) but also in those with congenital or acquired platelet dysfunction."", ""supports"": ""SUPPORT""}"
3487	3566	149	Hemophilia A	Hemophilia_A.yaml	treatments	3	evidence	0	PMID:26704192	SUPPORT		Overall, the two included trials showed a beneficial effect of tranexamic acid and EACA, administered systemically, in reducing the number of bleedings, the amount of blood loss and the need for therapeutic clotting factor concentrates.	Cochrane systematic review confirms beneficial effect of tranexamic acid and aminocaproic acid in reducing bleeding in hemophilia patients.	"{""explanation"": ""Cochrane systematic review confirms beneficial effect of tranexamic acid and aminocaproic acid in reducing bleeding in hemophilia patients."", ""reference"": ""PMID:26704192"", ""snippet"": ""Overall, the two included trials showed a beneficial effect of tranexamic acid and EACA, administered systemically, in reducing the number of bleedings, the amount of blood loss and the need for therapeutic clotting factor concentrates."", ""supports"": ""SUPPORT""}"
3488	3567	149	Hemophilia A	Hemophilia_A.yaml	treatments	4	evidence	0	PMID:35294811	SUPPORT		In patients with severe hemophilia A, valoctocogene roxaparvovec treatment provided endogenous factor VIII production and significantly reduced bleeding and factor VIII concentrate use relative to factor VIII prophylaxis.	Phase 3 GENEr8-1 trial demonstrates AAV5-based gene therapy efficacy in severe hemophilia A.	"{""explanation"": ""Phase 3 GENEr8-1 trial demonstrates AAV5-based gene therapy efficacy in severe hemophilia A."", ""reference"": ""PMID:35294811"", ""snippet"": ""In patients with severe hemophilia A, valoctocogene roxaparvovec treatment provided endogenous factor VIII production and significantly reduced bleeding and factor VIII concentrate use relative to factor VIII prophylaxis."", ""supports"": ""SUPPORT""}"
3491	3570	150	Hemophilia B	Hemophilia_B.yaml	treatments	0	evidence	0	PMID:23430394	SUPPORT		Hemophilia B treatment has improved greatly in the last 20 years with the introduction first of plasma-derived and then of recombinant FIX concentrates.	The abstract notes factor IX concentrates as key treatment advances.	"{""explanation"": ""The abstract notes factor IX concentrates as key treatment advances."", ""reference"": ""PMID:23430394"", ""snippet"": ""Hemophilia B treatment has improved greatly in the last 20 years with the introduction first of plasma-derived and then of recombinant FIX concentrates."", ""supports"": ""SUPPORT""}"
3492	3571	150	Hemophilia B	Hemophilia_B.yaml	treatments	1	evidence	0	PMID:23430394	SUPPORT		Replacement therapy may be administered through on-demand or prophylaxis regimens, but the latter treatment modality has been shown to be superior in prevention of hemophilic arthropathy and in improvement of patients' quality of life.	The abstract notes prophylaxis as a superior treatment modality for prevention of arthropathy.	"{""explanation"": ""The abstract notes prophylaxis as a superior treatment modality for prevention of arthropathy."", ""reference"": ""PMID:23430394"", ""snippet"": ""Replacement therapy may be administered through on-demand or prophylaxis regimens, but the latter treatment modality has been shown to be superior in prevention of hemophilic arthropathy and in improvement of patients' quality of life."", ""supports"": ""SUPPORT""}"
3493	3571	150	Hemophilia B	Hemophilia_B.yaml	treatments	1	evidence	1	PMID:39950390	SUPPORT		Prophylaxis with coagulation factor concentrates is the mainstay of treatment in severe hemophilia A and B.	The abstract describes prophylactic factor replacement as the mainstay of treatment for severe hemophilia.	"{""explanation"": ""The abstract describes prophylactic factor replacement as the mainstay of treatment for severe hemophilia."", ""reference"": ""PMID:39950390"", ""snippet"": ""Prophylaxis with coagulation factor concentrates is the mainstay of treatment in severe hemophilia A and B."", ""supports"": ""SUPPORT""}"
3627	3612	151	Hepatitis B	Hepatitis_B.yaml	treatments	0	evidence	0	PMID:26732483	SUPPORT		Entecavir (ETV) and tenofovir disoproxil fumarate (TDF) have been recommended as the first-line anti-HBV drugs for excellent viral suppression with a low risk of antiviral resistance.	The reference explicitly mentions tenofovir and entecavir as first-line drugs for suppressing HBV replication.	"{""explanation"": ""The reference explicitly mentions tenofovir and entecavir as first-line drugs for suppressing HBV replication."", ""reference"": ""PMID:26732483"", ""snippet"": ""Entecavir (ETV) and tenofovir disoproxil fumarate (TDF) have been recommended as the first-line anti-HBV drugs for excellent viral suppression with a low risk of antiviral resistance."", ""supports"": ""SUPPORT""}"
3628	3612	151	Hepatitis B	Hepatitis_B.yaml	treatments	0	evidence	1	PMID:26054819	SUPPORT		Since 2008, it has also been indicated for treatment of chronic HBV infection or HIV/HBV co-infection. The aim of the treatment consists in suppressing viral replication, thus reducing hepatic complications and improving patient survival.	The reference supports the use of tenofovir for suppressing HBV replication.	"{""explanation"": ""The reference supports the use of tenofovir for suppressing HBV replication."", ""reference"": ""PMID:26054819"", ""snippet"": ""Since 2008, it has also been indicated for treatment of chronic HBV infection or HIV/HBV co-infection. The aim of the treatment consists in suppressing viral replication, thus reducing hepatic complications and improving patient survival."", ""supports"": ""SUPPORT""}"
3629	3612	151	Hepatitis B	Hepatitis_B.yaml	treatments	0	evidence	2	PMID:32050881	SUPPORT		The aim of this study was to evaluate the histological, virological, serological and biochemical response rates in CHB patients receiving tenofovir or entecavir therapy.	The study evaluates the effects of tenofovir and entecavir in CHB patients, supporting their role in HBV suppression.	"{""explanation"": ""The study evaluates the effects of tenofovir and entecavir in CHB patients, supporting their role in HBV suppression."", ""reference"": ""PMID:32050881"", ""snippet"": ""The aim of this study was to evaluate the histological, virological, serological and biochemical response rates in CHB patients receiving tenofovir or entecavir therapy."", ""supports"": ""SUPPORT""}"
3630	3612	151	Hepatitis B	Hepatitis_B.yaml	treatments	0	evidence	3	PMID:27742007	SUPPORT		This is achievable by the highly active antivirals, entecavir and tenofovir, which are considered first-line therapy in most patients with immune active hepatitis C virus and after liver transplantation to prevent HBV recurrence.	The reference confirms that tenofovir and entecavir are used to suppress HBV replication.	"{""explanation"": ""The reference confirms that tenofovir and entecavir are used to suppress HBV replication."", ""reference"": ""PMID:27742007"", ""snippet"": ""This is achievable by the highly active antivirals, entecavir and tenofovir, which are considered first-line therapy in most patients with immune active hepatitis C virus and after liver transplantation to prevent HBV recurrence."", ""supports"": ""SUPPORT""}"
3631	3613	151	Hepatitis B	Hepatitis_B.yaml	treatments	1	evidence	0	PMID:25034484	PARTIAL		Interferon-alpha (IFN-alpha) therapy can convert CHB into inactive hepatitis B virus (HBV) infection in 20-30% of the treated patients...IFN-alpha has multiple antiviral, antiproliferative, and immunomodulatory activities.	The literature indicates that Interferon-alpha has immunomodulatory activities, which can help in controlling HBV infection, but it does not explicitly state that it 'boosts' the immune system in the general sense.	"{""explanation"": ""The literature indicates that Interferon-alpha has immunomodulatory activities, which can help in controlling HBV infection, but it does not explicitly state that it 'boosts' the immune system in the general sense."", ""reference"": ""PMID:25034484"", ""snippet"": ""Interferon-alpha (IFN-alpha) therapy can convert CHB into inactive hepatitis B virus (HBV) infection in 20-30% of the treated patients...IFN-alpha has multiple antiviral, antiproliferative, and immunomodulatory activities."", ""supports"": ""PARTIAL""}"
3632	3613	151	Hepatitis B	Hepatitis_B.yaml	treatments	1	evidence	1	PMID:16461223	PARTIAL		Therapeutic strategies aimed at correcting this defective T cell reactivity could represent a complementary approach to the cure of chronic HBV infection.	The literature suggests that targeting immune responses is a strategy in treating HBV, but it does not explicitly state that Interferon Therapy 'boosts' the immune system.	"{""explanation"": ""The literature suggests that targeting immune responses is a strategy in treating HBV, but it does not explicitly state that Interferon Therapy 'boosts' the immune system."", ""reference"": ""PMID:16461223"", ""snippet"": ""Therapeutic strategies aimed at correcting this defective T cell reactivity could represent a complementary approach to the cure of chronic HBV infection."", ""supports"": ""PARTIAL""}"
3633	3613	151	Hepatitis B	Hepatitis_B.yaml	treatments	1	evidence	2	PMID:10804945	PARTIAL		We found IFN to be a safe and adequate mode of treatment in children with chronic HBV infection, regardless of their liver histology and transaminase levels.	The study indicates that Interferon Therapy is effective in treating HBV in children, but it does not explicitly state that it 'boosts' the immune system.	"{""explanation"": ""The study indicates that Interferon Therapy is effective in treating HBV in children, but it does not explicitly state that it 'boosts' the immune system."", ""reference"": ""PMID:10804945"", ""snippet"": ""We found IFN to be a safe and adequate mode of treatment in children with chronic HBV infection, regardless of their liver histology and transaminase levels."", ""supports"": ""PARTIAL""}"
3634	3614	151	Hepatitis B	Hepatitis_B.yaml	treatments	2	evidence	0	PMID:29125261	SUPPORT		Liver transplantation (LT) is the only effective treatment for hepatitis B-virus (HBV) related end stage liver disease...	This reference explicitly states that liver transplantation is the only effective treatment for end-stage liver disease caused by hepatitis B.	"{""explanation"": ""This reference explicitly states that liver transplantation is the only effective treatment for end-stage liver disease caused by hepatitis B."", ""reference"": ""PMID:29125261"", ""snippet"": ""Liver transplantation (LT) is the only effective treatment for hepatitis B-virus (HBV) related end stage liver disease..."", ""supports"": ""SUPPORT""}"
3635	3614	151	Hepatitis B	Hepatitis_B.yaml	treatments	2	evidence	1	PMID:17981234	SUPPORT		Until recently, the options for a patient who had end-stage hepatitis B cirrhosis were severely limited, but during the past 15 years great strides have been made in prevention and treatment of hepatitis B cirrhosis.	The reference discusses the advancements in treatment options for end-stage hepatitis B cirrhosis, implying liver transplantation as a viable option.	"{""explanation"": ""The reference discusses the advancements in treatment options for end-stage hepatitis B cirrhosis, implying liver transplantation as a viable option."", ""reference"": ""PMID:17981234"", ""snippet"": ""Until recently, the options for a patient who had end-stage hepatitis B cirrhosis were severely limited, but during the past 15 years great strides have been made in prevention and treatment of hepatitis B cirrhosis."", ""supports"": ""SUPPORT""}"
3636	3615	151	Hepatitis B	Hepatitis_B.yaml	treatments	3	evidence	0	PMID:24266913	SUPPORT		Chronically infected patients should be followed on a regular basis, preferably every 6 months, with liver function tests, and when appropriate, HBV DNA levels.	The literature supports regular monitoring of liver function and viral load in patients with chronic hepatitis B infection.	"{""explanation"": ""The literature supports regular monitoring of liver function and viral load in patients with chronic hepatitis B infection."", ""reference"": ""PMID:24266913"", ""snippet"": ""Chronically infected patients should be followed on a regular basis, preferably every 6 months, with liver function tests, and when appropriate, HBV DNA levels."", ""supports"": ""SUPPORT""}"
3637	3615	151	Hepatitis B	Hepatitis_B.yaml	treatments	3	evidence	1	PMID:12776281	SUPPORT		Periodic testing for HBV DNA to assess the virological status of HBsAg-positive dialysis patients is recommended.	The study recommends regular monitoring of viral load in hepatitis B patients, supporting the statement.	"{""explanation"": ""The study recommends regular monitoring of viral load in hepatitis B patients, supporting the statement."", ""reference"": ""PMID:12776281"", ""snippet"": ""Periodic testing for HBV DNA to assess the virological status of HBsAg-positive dialysis patients is recommended."", ""supports"": ""SUPPORT""}"
3638	3615	151	Hepatitis B	Hepatitis_B.yaml	treatments	3	evidence	2	PMID:33467927	SUPPORT		This manuscript summarized traditional biomarkers of different hepatitis B stages and recent-developed POCT platforms (including microfluidic platforms and lateral-flow strips) and discuss the challenges associated with their use.	The article discusses the importance of monitoring hepatitis B using various biomarkers, which aligns with the statement.	"{""explanation"": ""The article discusses the importance of monitoring hepatitis B using various biomarkers, which aligns with the statement."", ""reference"": ""PMID:33467927"", ""snippet"": ""This manuscript summarized traditional biomarkers of different hepatitis B stages and recent-developed POCT platforms (including microfluidic platforms and lateral-flow strips) and discuss the challenges associated with their use."", ""supports"": ""SUPPORT""}"
3639	3615	151	Hepatitis B	Hepatitis_B.yaml	treatments	3	evidence	3	PMID:31528100	SUPPORT		HBcrAg is an excellent monitor of hepatic histological changes, especially in CHB patients treated with nucleoside analogs.	The literature highlights the importance of monitoring liver-related biomarkers in chronic hepatitis B patients.	"{""explanation"": ""The literature highlights the importance of monitoring liver-related biomarkers in chronic hepatitis B patients."", ""reference"": ""PMID:31528100"", ""snippet"": ""HBcrAg is an excellent monitor of hepatic histological changes, especially in CHB patients treated with nucleoside analogs."", ""supports"": ""SUPPORT""}"
3640	3615	151	Hepatitis B	Hepatitis_B.yaml	treatments	3	evidence	4	PMID:26799653	SUPPORT		As a result, regular monitoring of the response during treatment and after treatment is required.	The article emphasizes the necessity of regular monitoring in the management of chronic hepatitis B.	"{""explanation"": ""The article emphasizes the necessity of regular monitoring in the management of chronic hepatitis B."", ""reference"": ""PMID:26799653"", ""snippet"": ""As a result, regular monitoring of the response during treatment and after treatment is required."", ""supports"": ""SUPPORT""}"
3641	3615	151	Hepatitis B	Hepatitis_B.yaml	treatments	3	evidence	5	PMID:33945063	SUPPORT		Regular monitoring and treatment of chronic hepatitis B (CHB) are known to reduce the risk of hepatocellular carcinoma.	The literature supports regular monitoring as a vital part of managing chronic hepatitis B to reduce complications.	"{""explanation"": ""The literature supports regular monitoring as a vital part of managing chronic hepatitis B to reduce complications."", ""reference"": ""PMID:33945063"", ""snippet"": ""Regular monitoring and treatment of chronic hepatitis B (CHB) are known to reduce the risk of hepatocellular carcinoma."", ""supports"": ""SUPPORT""}"
3642	3616	151	Hepatitis B	Hepatitis_B.yaml	treatments	4	evidence	0	PMID:10776195	SUPPORT		Immunization of all newborn infants and adolescents for HBV is a vital step toward eradicating HBV from the general population.	The article supports the statement by emphasizing the importance of immunizing infants and adolescents to prevent HBV infection.	"{""explanation"": ""The article supports the statement by emphasizing the importance of immunizing infants and adolescents to prevent HBV infection."", ""reference"": ""PMID:10776195"", ""snippet"": ""Immunization of all newborn infants and adolescents for HBV is a vital step toward eradicating HBV from the general population."", ""supports"": ""SUPPORT""}"
3643	3616	151	Hepatitis B	Hepatitis_B.yaml	treatments	4	evidence	1	PMID:33200362	SUPPORT		Primary prevention by HBV vaccination targeting the general population starting from birth dose.	The article confirms that HBV vaccination is a primary prevention strategy for the general population.	"{""explanation"": ""The article confirms that HBV vaccination is a primary prevention strategy for the general population."", ""reference"": ""PMID:33200362"", ""snippet"": ""Primary prevention by HBV vaccination targeting the general population starting from birth dose."", ""supports"": ""SUPPORT""}"
3644	3616	151	Hepatitis B	Hepatitis_B.yaml	treatments	4	evidence	2	PMID:17298912	SUPPORT		Hepatitis B vaccines have been licensed since 1982... Long-term protection has been demonstrated.	The article discusses the long-term protection conferred by hepatitis B vaccines, supporting their role in preventing HBV infection.	"{""explanation"": ""The article discusses the long-term protection conferred by hepatitis B vaccines, supporting their role in preventing HBV infection."", ""reference"": ""PMID:17298912"", ""snippet"": ""Hepatitis B vaccines have been licensed since 1982... Long-term protection has been demonstrated."", ""supports"": ""SUPPORT""}"
3645	3616	151	Hepatitis B	Hepatitis_B.yaml	treatments	4	evidence	3	PMID:22643598	SUPPORT		Hepatitis B is a preventable disease; a safe and effective vaccine has been available for 30 years.	The article states that hepatitis B is preventable through vaccination, supporting the statement.	"{""explanation"": ""The article states that hepatitis B is preventable through vaccination, supporting the statement."", ""reference"": ""PMID:22643598"", ""snippet"": ""Hepatitis B is a preventable disease; a safe and effective vaccine has been available for 30 years."", ""supports"": ""SUPPORT""}"
3646	3616	151	Hepatitis B	Hepatitis_B.yaml	treatments	4	evidence	4	PMID:19187625	SUPPORT		The chronic HBV carrier rate in children < 10 years of age decreased from 10.0% before the mass vaccination to 1.0% - 2.0% in 2006.	The article provides evidence from China's mass vaccination program, showing a significant reduction in HBV carrier rates due to vaccination.	"{""explanation"": ""The article provides evidence from China's mass vaccination program, showing a significant reduction in HBV carrier rates due to vaccination."", ""reference"": ""PMID:19187625"", ""snippet"": ""The chronic HBV carrier rate in children < 10 years of age decreased from 10.0% before the mass vaccination to 1.0% - 2.0% in 2006."", ""supports"": ""SUPPORT""}"
3653	3639	152	Hepatitis C	Hepatitis_C.yaml	treatments	0	evidence	0	PMID:24725239	SUPPORT		Once-daily ledipasvir-sofosbuvir with or without ribavirin for 12 or 24 weeks was highly effective in previously untreated patients with HCV genotype 1 infection.	Landmark trial demonstrating near-universal cure rates with DAA therapy.	"{""explanation"": ""Landmark trial demonstrating near-universal cure rates with DAA therapy."", ""reference"": ""PMID:24725239"", ""snippet"": ""Once-daily ledipasvir-sofosbuvir with or without ribavirin for 12 or 24 weeks was highly effective in previously untreated patients with HCV genotype 1 infection."", ""supports"": ""SUPPORT""}"
3654	3639	152	Hepatitis C	Hepatitis_C.yaml	treatments	0	evidence	1	PMID:26569658	SUPPORT		Treatment with sofosbuvir-velpatasvir with or without ribavirin for 12 weeks and with sofosbuvir-velpatasvir for 24 weeks resulted in high rates of sustained virologic response in patients with HCV infection and decompensated cirrhosis.	Study confirms high efficacy of DAAs even in patients with decompensated cirrhosis.	"{""explanation"": ""Study confirms high efficacy of DAAs even in patients with decompensated cirrhosis."", ""reference"": ""PMID:26569658"", ""snippet"": ""Treatment with sofosbuvir-velpatasvir with or without ribavirin for 12 weeks and with sofosbuvir-velpatasvir for 24 weeks resulted in high rates of sustained virologic response in patients with HCV infection and decompensated cirrhosis."", ""supports"": ""SUPPORT""}"
3658	3669	153	Hepatocellular Carcinoma	Hepatocellular_Carcinoma.yaml	treatments	0	evidence	0	PMID:39687036	SUPPORT		Atezolizumab plus bevacizumab significantly improved overall survival (OS) and progression-free survival (PFS) versus sorafenib	IMbrave150 abstract reports improved overall and progression-free survival with atezolizumab plus bevacizumab versus sorafenib.	"{""explanation"": ""IMbrave150 abstract reports improved overall and progression-free survival with atezolizumab plus bevacizumab versus sorafenib."", ""reference"": ""PMID:39687036"", ""snippet"": ""Atezolizumab plus bevacizumab significantly improved overall survival (OS) and progression-free survival (PFS) versus sorafenib"", ""supports"": ""SUPPORT""}"
3661	3694	154	Hereditary Breast and Ovarian Cancer Syndrome	Hereditary_Breast_and_Ovarian_Cancer_Syndrome.yaml	treatments	2	evidence	0	PMID:34081848	SUPPORT		adjuvant olaparib after completion of local treatment and neoadjuvant or adjuvant chemotherapy was associated with significantly longer survival free of invasive or distant disease than was placebo.	OlympiA phase 3 trial demonstrates adjuvant olaparib significantly improves disease-free survival in high-risk BRCA-mutated breast cancer.	"{""explanation"": ""OlympiA phase 3 trial demonstrates adjuvant olaparib significantly improves disease-free survival in high-risk BRCA-mutated breast cancer."", ""reference"": ""PMID:34081848"", ""snippet"": ""adjuvant olaparib after completion of local treatment and neoadjuvant or adjuvant chemotherapy was associated with significantly longer survival free of invasive or distant disease than was placebo."", ""supports"": ""SUPPORT""}"
3670	3705	155	Hereditary von Willebrand Disease	Hereditary_von_Willebrand_Disease.yaml	treatments	0	evidence	0	PMID:21289515	SUPPORT		Depending on the von Willebrand disease type, mild bleeding episodes usually respond to intravenous or subcutaneous treatment with desmopressin, a vasopressin analog.	The abstract describes desmopressin as a treatment for mild bleeding episodes.	"{""explanation"": ""The abstract describes desmopressin as a treatment for mild bleeding episodes."", ""reference"": ""PMID:21289515"", ""snippet"": ""Depending on the von Willebrand disease type, mild bleeding episodes usually respond to intravenous or subcutaneous treatment with desmopressin, a vasopressin analog."", ""supports"": ""SUPPORT""}"
3671	3706	155	Hereditary von Willebrand Disease	Hereditary_von_Willebrand_Disease.yaml	treatments	1	evidence	0	PMID:21289515	SUPPORT		Severe bleeding episodes can be prevented or controlled with intravenous infusions of virally inactivated plasma-derived clotting factor concentrates containing both von Willebrand factor and factor VIII.	The abstract describes vWF/FVIII concentrates for severe bleeding episodes.	"{""explanation"": ""The abstract describes vWF/FVIII concentrates for severe bleeding episodes."", ""reference"": ""PMID:21289515"", ""snippet"": ""Severe bleeding episodes can be prevented or controlled with intravenous infusions of virally inactivated plasma-derived clotting factor concentrates containing both von Willebrand factor and factor VIII."", ""supports"": ""SUPPORT""}"
3733	3736	156	Hirschsprung Disease	Hirschsprung_Disease.yaml	treatments	0	evidence	0	PMID:23615177	SUPPORT		Surgical techniques are available to remove the aganglionic bowel and reconstruct the intestinal tract.	The article confirms that the removal of the aganglionic segment is a treatment for Hirschsprung disease.	"{""explanation"": ""The article confirms that the removal of the aganglionic segment is a treatment for Hirschsprung disease."", ""reference"": ""PMID:23615177"", ""snippet"": ""Surgical techniques are available to remove the aganglionic bowel and reconstruct the intestinal tract."", ""supports"": ""SUPPORT""}"
3734	3736	156	Hirschsprung Disease	Hirschsprung_Disease.yaml	treatments	0	evidence	1	PMID:27526297	SUPPORT		Surgical management of Hirschsprung disease requires resection of the aganglionic bowel and transition zone.	The article specifically mentions the resection of the aganglionic bowel as part of surgical management.	"{""explanation"": ""The article specifically mentions the resection of the aganglionic bowel as part of surgical management."", ""reference"": ""PMID:27526297"", ""snippet"": ""Surgical management of Hirschsprung disease requires resection of the aganglionic bowel and transition zone."", ""supports"": ""SUPPORT""}"
3735	3736	156	Hirschsprung Disease	Hirschsprung_Disease.yaml	treatments	0	evidence	2	PMID:35343667	SUPPORT		Per-rectal endoscopic myotomy...to open spastic aganglionic bowel segments by performing a myotomy through a submucosal tunnel.	Although it is a different procedure, the focus is still on dealing with aganglionic bowel segments.	"{""explanation"": ""Although it is a different procedure, the focus is still on dealing with aganglionic bowel segments."", ""reference"": ""PMID:35343667"", ""snippet"": ""Per-rectal endoscopic myotomy...to open spastic aganglionic bowel segments by performing a myotomy through a submucosal tunnel."", ""supports"": ""SUPPORT""}"
3736	3736	156	Hirschsprung Disease	Hirschsprung_Disease.yaml	treatments	0	evidence	3	PMID:34398296	SUPPORT		The entire colons in the both cases were finally resected, and a pull-through operation was performed.	This reference supports the resection of the aganglionic segment as a treatment.	"{""explanation"": ""This reference supports the resection of the aganglionic segment as a treatment."", ""reference"": ""PMID:34398296"", ""snippet"": ""The entire colons in the both cases were finally resected, and a pull-through operation was performed."", ""supports"": ""SUPPORT""}"
3737	3736	156	Hirschsprung Disease	Hirschsprung_Disease.yaml	treatments	0	evidence	4	PMID:20301612	SUPPORT		Treatment of manifestations: Resection of the aganglionic segment and anastomosis of proximal bowel to the anus ('pull-through') is the standard treatment for HSCR.	This retired chapter supports that removal of the aganglionic segment is a standard practice.	"{""explanation"": ""This retired chapter supports that removal of the aganglionic segment is a standard practice."", ""reference"": ""PMID:20301612"", ""snippet"": ""Treatment of manifestations: Resection of the aganglionic segment and anastomosis of proximal bowel to the anus ('pull-through') is the standard treatment for HSCR."", ""supports"": ""SUPPORT""}"
3738	3737	156	Hirschsprung Disease	Hirschsprung_Disease.yaml	treatments	1	evidence	0	PMID:15770590	SUPPORT		The transanal pull-through consists of a rectal mucosectomy, resection of the aganglionic bowel and a colo-anal anastomosis.	This procedure involves connecting the normal ganglionated bowel to the anus to restore bowel function.	"{""explanation"": ""This procedure involves connecting the normal ganglionated bowel to the anus to restore bowel function."", ""reference"": ""PMID:15770590"", ""snippet"": ""The transanal pull-through consists of a rectal mucosectomy, resection of the aganglionic bowel and a colo-anal anastomosis."", ""supports"": ""SUPPORT""}"
3739	3737	156	Hirschsprung Disease	Hirschsprung_Disease.yaml	treatments	1	evidence	1	PMID:31759654	SUPPORT		A review of a single-center HD cohort treated with pull-through surgery.	The study assesses outcomes in patients treated with pull-through surgery, confirming it's a treatment for Hirschsprung Disease.	"{""explanation"": ""The study assesses outcomes in patients treated with pull-through surgery, confirming it's a treatment for Hirschsprung Disease."", ""reference"": ""PMID:31759654"", ""snippet"": ""A review of a single-center HD cohort treated with pull-through surgery."", ""supports"": ""SUPPORT""}"
3740	3737	156	Hirschsprung Disease	Hirschsprung_Disease.yaml	treatments	1	evidence	2	PMID:21789665	SUPPORT		Most patients with Hirschsprung's disease (HD) have a satisfactory outcome after pull-through (PT) operation.	The pull-through operation is described as a standard treatment, which aligns with the statement.	"{""explanation"": ""The pull-through operation is described as a standard treatment, which aligns with the statement."", ""reference"": ""PMID:21789665"", ""snippet"": ""Most patients with Hirschsprung's disease (HD) have a satisfactory outcome after pull-through (PT) operation."", ""supports"": ""SUPPORT""}"
3741	3738	156	Hirschsprung Disease	Hirschsprung_Disease.yaml	treatments	2	evidence	0	PMID:12048463	SUPPORT		Hirschsprung's disease is a congenital abnormality of the bowel that results in loss of peristalsis, and is one of the main reasons why an infant may require a stoma soon after birth.	This reference indicates that infants with Hirschsprung's disease may require a stoma, which could be interpreted as either temporary or permanent.	"{""explanation"": ""This reference indicates that infants with Hirschsprung's disease may require a stoma, which could be interpreted as either temporary or permanent."", ""reference"": ""PMID:12048463"", ""snippet"": ""Hirschsprung's disease is a congenital abnormality of the bowel that results in loss of peristalsis, and is one of the main reasons why an infant may require a stoma soon after birth."", ""supports"": ""SUPPORT""}"
3742	3738	156	Hirschsprung Disease	Hirschsprung_Disease.yaml	treatments	2	evidence	1	PMID:29607805	SUPPORT		More than 75% of all stomata are placed as part of the treatment of colorectal cancer. The incidence of stoma-related complications is reported to be 10-70%.	While this reference focuses more on colorectal cancer, it notes the use of stomata in treatment, which is relevant to the statement that stomata (ostomies) can be used in Hirschsprung disease, supporting the general use of ostomies in bowel-related treatments.	"{""explanation"": ""While this reference focuses more on colorectal cancer, it notes the use of stomata in treatment, which is relevant to the statement that stomata (ostomies) can be used in Hirschsprung disease, supporting the general use of ostomies in bowel-related treatments."", ""reference"": ""PMID:29607805"", ""snippet"": ""More than 75% of all stomata are placed as part of the treatment of colorectal cancer. The incidence of stoma-related complications is reported to be 10-70%."", ""supports"": ""SUPPORT""}"
3743	3738	156	Hirschsprung Disease	Hirschsprung_Disease.yaml	treatments	2	evidence	2	PMID:29722891	SUPPORT		Fecal diversion with ostomy construction can be a temporary or definitive surgical measure for the treatment of refractory inflammatory bowel disease (IBD).	This reference supports the use of ostomies as either temporary or permanent solutions for certain bowel conditions, analogous to their use in Hirschsprung disease.	"{""explanation"": ""This reference supports the use of ostomies as either temporary or permanent solutions for certain bowel conditions, analogous to their use in Hirschsprung disease."", ""reference"": ""PMID:29722891"", ""snippet"": ""Fecal diversion with ostomy construction can be a temporary or definitive surgical measure for the treatment of refractory inflammatory bowel disease (IBD)."", ""supports"": ""SUPPORT""}"
3744	3738	156	Hirschsprung Disease	Hirschsprung_Disease.yaml	treatments	2	evidence	3	PMID:26181500	SUPPORT		Three patients were treated with surgical decompression and ileostomy only. In all these cases, severe complications occurred, consequently 2 of them died.	This reference indicates that ileostomya type of stomawas used as part of the surgical treatment for complications associated with Hirschsprung disease.	"{""explanation"": ""This reference indicates that ileostomya type of stomawas used as part of the surgical treatment for complications associated with Hirschsprung disease."", ""reference"": ""PMID:26181500"", ""snippet"": ""Three patients were treated with surgical decompression and ileostomy only. In all these cases, severe complications occurred, consequently 2 of them died."", ""supports"": ""SUPPORT""}"
3763	3750	157	Holt-Oram syndrome	Holt_Oram.yaml	treatments	0	evidence	0	PMID:38189150	SUPPORT		The relationship between heart failure (HF) and atrial fibrillation (AF) is clear, with up to half of patients with HF progressing to AF	Supports the need for cardiac monitoring in HOS patients due to risk of progressive arrhythmias and conduction abnormalities	"{""explanation"": ""Supports the need for cardiac monitoring in HOS patients due to risk of progressive arrhythmias and conduction abnormalities"", ""reference"": ""PMID:38189150"", ""snippet"": ""The relationship between heart failure (HF) and atrial fibrillation (AF) is clear, with up to half of patients with HF progressing to AF"", ""supports"": ""SUPPORT""}"
3764	3750	157	Holt-Oram syndrome	Holt_Oram.yaml	treatments	0	evidence	1	PMID:38235884	SUPPORT		HOS usually requires the implantation of a pacemaker, because of cardiac conduction disturbances	Clinical evidence supporting need for advanced cardiac monitoring and intervention in HOS	"{""explanation"": ""Clinical evidence supporting need for advanced cardiac monitoring and intervention in HOS"", ""reference"": ""PMID:38235884"", ""snippet"": ""HOS usually requires the implantation of a pacemaker, because of cardiac conduction disturbances"", ""supports"": ""SUPPORT""}"
3765	3751	157	Holt-Oram syndrome	Holt_Oram.yaml	treatments	1	evidence	0	PMID:39596866	SUPPORT		Septal defects such as ventricular (VSD) and atrial septal defects (ASD) are the most common forms of CHDs	Establishes that septal defects are cardinal manifestations requiring potential surgical intervention	"{""explanation"": ""Establishes that septal defects are cardinal manifestations requiring potential surgical intervention"", ""reference"": ""PMID:39596866"", ""snippet"": ""Septal defects such as ventricular (VSD) and atrial septal defects (ASD) are the most common forms of CHDs"", ""supports"": ""SUPPORT""}"
3766	3752	157	Holt-Oram syndrome	Holt_Oram.yaml	treatments	2	evidence	0	PMID:36936432	SUPPORT		Holt-Oram syndrome (HOS) is a rare genetic disorder characterized by upper limb abnormalities	Case reports of HOS patients with upper limb abnormalities requiring orthopedic and rehabilitative management	"{""explanation"": ""Case reports of HOS patients with upper limb abnormalities requiring orthopedic and rehabilitative management"", ""reference"": ""PMID:36936432"", ""snippet"": ""Holt-Oram syndrome (HOS) is a rare genetic disorder characterized by upper limb abnormalities"", ""supports"": ""SUPPORT""}"
3774	3760	158	Human African trypanosomiasis	Human_African_Trypanosomiasis.yaml	treatments	0	evidence	0	PMID:40089378	SUPPORT		A new oral drug, fexinidazole, became the first-line treatment for gambiense human African trypanosomiasis without severe meningo-encephalitic disease	The review describes fexinidazole as first-line therapy for gambiense HAT.	"{""explanation"": ""The review describes fexinidazole as first-line therapy for gambiense HAT."", ""reference"": ""PMID:40089378"", ""snippet"": ""A new oral drug, fexinidazole, became the first-line treatment for gambiense human African trypanosomiasis without severe meningo-encephalitic disease"", ""supports"": ""SUPPORT""}"
3845	3796	159	Huntington's Disease	Huntingtons_Disease.yaml	treatments	0	evidence	0	PMID:24366610	SUPPORT		Tetrabenazine is a dopamine-depleting agent that may be one of the more effective agents for reducing chorea, although it has a risk of potentially serious adverse effects.	This reference confirms that tetrabenazine is used to manage chorea in Huntington's Disease by depleting dopamine.	"{""explanation"": ""This reference confirms that tetrabenazine is used to manage chorea in Huntington's Disease by depleting dopamine."", ""reference"": ""PMID:24366610"", ""snippet"": ""Tetrabenazine is a dopamine-depleting agent that may be one of the more effective agents for reducing chorea, although it has a risk of potentially serious adverse effects."", ""supports"": ""SUPPORT""}"
3846	3796	159	Huntington's Disease	Huntingtons_Disease.yaml	treatments	0	evidence	1	PMID:20869622	SUPPORT		Tetrabenazine (TBZ) is a monoamine-depleting agent initially studied in the 1950s and currently approved by the US Food and Drug Administration for the treatment of chorea in Huntington's disease.	This reference confirms that tetrabenazine depletes monoamines, including dopamine, to manage chorea in Huntington's Disease.	"{""explanation"": ""This reference confirms that tetrabenazine depletes monoamines, including dopamine, to manage chorea in Huntington's Disease."", ""reference"": ""PMID:20869622"", ""snippet"": ""Tetrabenazine (TBZ) is a monoamine-depleting agent initially studied in the 1950s and currently approved by the US Food and Drug Administration for the treatment of chorea in Huntington's disease."", ""supports"": ""SUPPORT""}"
3847	3796	159	Huntington's Disease	Huntingtons_Disease.yaml	treatments	0	evidence	2	PMID:20442355	SUPPORT		Tetrabenazine binds reversibly to the type 2 vesicular monoamine transporters and has been shown to inhibit monoamine uptake in presynaptic vesicles, resulting in monoamine depletion.	This reference supports that tetrabenazine depletes dopamine to manage chorea in Huntington's Disease.	"{""explanation"": ""This reference supports that tetrabenazine depletes dopamine to manage chorea in Huntington's Disease."", ""reference"": ""PMID:20442355"", ""snippet"": ""Tetrabenazine binds reversibly to the type 2 vesicular monoamine transporters and has been shown to inhibit monoamine uptake in presynaptic vesicles, resulting in monoamine depletion."", ""supports"": ""SUPPORT""}"
3848	3796	159	Huntington's Disease	Huntingtons_Disease.yaml	treatments	0	evidence	3	PMID:27819145	SUPPORT		Since the approval of tetrabenazine, the classic VMAT2 inhibitor, in the treatment of chorea associated with Huntington disease (HD)...	This reference confirms that tetrabenazine, a VMAT2 inhibitor, is used to treat chorea in Huntington's Disease by depleting dopamine.	"{""explanation"": ""This reference confirms that tetrabenazine, a VMAT2 inhibitor, is used to treat chorea in Huntington's Disease by depleting dopamine."", ""reference"": ""PMID:27819145"", ""snippet"": ""Since the approval of tetrabenazine, the classic VMAT2 inhibitor, in the treatment of chorea associated with Huntington disease (HD)..."", ""supports"": ""SUPPORT""}"
3849	3797	159	Huntington's Disease	Huntingtons_Disease.yaml	treatments	1	evidence	0	PMID:27534434	SUPPORT		In clinical practice antipsychotics represent the first choice in the management of chorea in the presence of psychiatric symptoms...	The literature states that antipsychotics are used to manage psychiatric symptoms in Huntington's Disease.	"{""explanation"": ""The literature states that antipsychotics are used to manage psychiatric symptoms in Huntington's Disease."", ""reference"": ""PMID:27534434"", ""snippet"": ""In clinical practice antipsychotics represent the first choice in the management of chorea in the presence of psychiatric symptoms..."", ""supports"": ""SUPPORT""}"
3850	3797	159	Huntington's Disease	Huntingtons_Disease.yaml	treatments	1	evidence	1	PMID:16383221	SUPPORT		According to clinical observation, HD patients with psychiatric symptoms respond to standard pharmacotherapy.	The literature supports the use of pharmacotherapy, which includes antipsychotic medications, for psychiatric symptoms in Huntington's Disease.	"{""explanation"": ""The literature supports the use of pharmacotherapy, which includes antipsychotic medications, for psychiatric symptoms in Huntington's Disease."", ""reference"": ""PMID:16383221"", ""snippet"": ""According to clinical observation, HD patients with psychiatric symptoms respond to standard pharmacotherapy."", ""supports"": ""SUPPORT""}"
3851	3797	159	Huntington's Disease	Huntingtons_Disease.yaml	treatments	1	evidence	2	PMID:36496108	SUPPORT		Several lines of evidence suggest a possible role of risperidone via the antagonistic effect of Dopamine D2 and 5HT-receptor in different neurological diseases like cognitive dysfunction of schizophrenia, neuroinflammation, Huntington's disease...	Risperidone, an antipsychotic, is mentioned as having a role in treating psychiatric symptoms in Huntington's Disease.	"{""explanation"": ""Risperidone, an antipsychotic, is mentioned as having a role in treating psychiatric symptoms in Huntington's Disease."", ""reference"": ""PMID:36496108"", ""snippet"": ""Several lines of evidence suggest a possible role of risperidone via the antagonistic effect of Dopamine D2 and 5HT-receptor in different neurological diseases like cognitive dysfunction of schizophrenia, neuroinflammation, Huntington's disease..."", ""supports"": ""SUPPORT""}"
3852	3798	159	Huntington's Disease	Huntingtons_Disease.yaml	treatments	2	evidence	0	PMID:18394562	SUPPORT		Several classes of medications have been used to ameliorate the various symptoms of HD, including typical and atypical neuroleptics, dopamine depleters, antidepressants...	The abstract mentions that antidepressants, which include SSRIs, are used to manage symptoms in Huntington's Disease.	"{""explanation"": ""The abstract mentions that antidepressants, which include SSRIs, are used to manage symptoms in Huntington's Disease."", ""reference"": ""PMID:18394562"", ""snippet"": ""Several classes of medications have been used to ameliorate the various symptoms of HD, including typical and atypical neuroleptics, dopamine depleters, antidepressants..."", ""supports"": ""SUPPORT""}"
3853	3798	159	Huntington's Disease	Huntingtons_Disease.yaml	treatments	2	evidence	1	PMID:22119091	SUPPORT		Cross-sectionally, suicidal mutation carriers were more likely to use antidepressants (odds ratio=5.3)...	The use of antidepressants, which can include SSRIs, is associated with managing depressive symptoms in Huntington's Disease.	"{""explanation"": ""The use of antidepressants, which can include SSRIs, is associated with managing depressive symptoms in Huntington's Disease."", ""reference"": ""PMID:22119091"", ""snippet"": ""Cross-sectionally, suicidal mutation carriers were more likely to use antidepressants (odds ratio=5.3)..."", ""supports"": ""SUPPORT""}"
3854	3799	159	Huntington's Disease	Huntingtons_Disease.yaml	treatments	3	evidence	0	PMID:31907286	SUPPORT		There is strong evidence to support physical therapy interventions to improve fitness, motor function, and gait in persons with HD.	The review provides strong evidence that physical therapy interventions improve fitness, motor function, and gait in people with Huntington's Disease, supporting the statement that physical therapy helps maintain mobility and function.	"{""explanation"": ""The review provides strong evidence that physical therapy interventions improve fitness, motor function, and gait in people with Huntington's Disease, supporting the statement that physical therapy helps maintain mobility and function."", ""reference"": ""PMID:31907286"", ""snippet"": ""There is strong evidence to support physical therapy interventions to improve fitness, motor function, and gait in persons with HD."", ""supports"": ""SUPPORT""}"
3855	3799	159	Huntington's Disease	Huntingtons_Disease.yaml	treatments	3	evidence	1	PMID:31177235	SUPPORT		Prior Huntington''s disease (HD) studies suggest ancillary services improve motor symptoms, cognition, mood, and quality of life.	The study indicates that ancillary services, which include physical therapy, improve motor symptoms in HD patients, supporting the statement that physical therapy helps maintain mobility and function.	"{""explanation"": ""The study indicates that ancillary services, which include physical therapy, improve motor symptoms in HD patients, supporting the statement that physical therapy helps maintain mobility and function."", ""reference"": ""PMID:31177235"", ""snippet"": ""Prior Huntington''s disease (HD) studies suggest ancillary services improve motor symptoms, cognition, mood, and quality of life."", ""supports"": ""SUPPORT""}"
3856	3799	159	Huntington's Disease	Huntingtons_Disease.yaml	treatments	3	evidence	2	PMID:25062860	SUPPORT		TUG (beta 0.46, CI 0.20-3.47), BBS (beta -0.35, CI -2.10-0.14), and TMT (beta -0.45, CI -3.14-0.64) were good disease-specific mobility measures.	The study identifies specific mobility measures that are effective for assessing and optimizing mobility in HD patients, supporting the statement that physical therapy helps maintain mobility and function.	"{""explanation"": ""The study identifies specific mobility measures that are effective for assessing and optimizing mobility in HD patients, supporting the statement that physical therapy helps maintain mobility and function."", ""reference"": ""PMID:25062860"", ""snippet"": ""TUG (beta 0.46, CI 0.20-3.47), BBS (beta -0.35, CI -2.10-0.14), and TMT (beta -0.45, CI -3.14-0.64) were good disease-specific mobility measures."", ""supports"": ""SUPPORT""}"
3857	3800	159	Huntington's Disease	Huntingtons_Disease.yaml	treatments	4	evidence	0	PMID:28983422	PARTIAL		SLPs play an important role in the evaluation and management of dysarthria and dysphagia.	The literature indicates that speech-language pathologists (SLPs) play a significant role in managing dysarthria and dysphagia in patients with hyperkinetic disorders, including Huntington's Disease. However, it does not explicitly state that speech therapy helps manage these conditions in HD specifically.	"{""explanation"": ""The literature indicates that speech-language pathologists (SLPs) play a significant role in managing dysarthria and dysphagia in patients with hyperkinetic disorders, including Huntington's Disease. However, it does not explicitly state that speech therapy helps manage these conditions in HD specifically."", ""reference"": ""PMID:28983422"", ""snippet"": ""SLPs play an important role in the evaluation and management of dysarthria and dysphagia."", ""supports"": ""PARTIAL""}"
3858	3800	159	Huntington's Disease	Huntingtons_Disease.yaml	treatments	4	evidence	1	PMID:33577706	PARTIAL		Findings shed a light on everyday communication challenges faced by people with HD and their professional caregivers, and the lack of implementation of communication aids in this group.	The literature highlights the importance of including speech and language therapists in the care of HD patients, indicating a supportive role. However, it does not provide explicit evidence that speech therapy directly helps manage dysarthria and dysphagia in HD.	"{""explanation"": ""The literature highlights the importance of including speech and language therapists in the care of HD patients, indicating a supportive role. However, it does not provide explicit evidence that speech therapy directly helps manage dysarthria and dysphagia in HD."", ""reference"": ""PMID:33577706"", ""snippet"": ""Findings shed a light on everyday communication challenges faced by people with HD and their professional caregivers, and the lack of implementation of communication aids in this group."", ""supports"": ""PARTIAL""}"
3859	3800	159	Huntington's Disease	Huntingtons_Disease.yaml	treatments	4	evidence	2	PMID:31989345	NO_EVIDENCE		The impact of pharmacological and rehabilitative treatments on dysphagia in HD has been little studied in literature.	The literature states that the impact of rehabilitative treatments, including speech therapy, on dysphagia in HD has been minimally studied, providing no clear evidence of its efficacy.	"{""explanation"": ""The literature states that the impact of rehabilitative treatments, including speech therapy, on dysphagia in HD has been minimally studied, providing no clear evidence of its efficacy."", ""reference"": ""PMID:31989345"", ""snippet"": ""The impact of pharmacological and rehabilitative treatments on dysphagia in HD has been little studied in literature."", ""supports"": ""NO_EVIDENCE""}"
3860	3801	159	Huntington's Disease	Huntingtons_Disease.yaml	treatments	5	evidence	0	PMID:28947114	PARTIAL		Lifestyle factors, such as activity level and exercise, as well as specific motor training may be helpful in managing the functional sequelae of HD and possibly slowing disease progression.	The literature suggests that rehabilitation interventions, including motor training, can help manage functional abilities in HD, which implies a supportive role in daily living activities. However, it does not explicitly mention occupational therapy or daily living activities directly.	"{""explanation"": ""The literature suggests that rehabilitation interventions, including motor training, can help manage functional abilities in HD, which implies a supportive role in daily living activities. However, it does not explicitly mention occupational therapy or daily living activities directly."", ""reference"": ""PMID:28947114"", ""snippet"": ""Lifestyle factors, such as activity level and exercise, as well as specific motor training may be helpful in managing the functional sequelae of HD and possibly slowing disease progression."", ""supports"": ""PARTIAL""}"
3861	3801	159	Huntington's Disease	Huntingtons_Disease.yaml	treatments	5	evidence	1	PMID:36055643	PARTIAL		This objective burden increased with higher functional loss of the HD individual and with more severe cognitive-behavioral disorders.	This study discusses the burden on informal caregivers and the functional loss in HD individuals, indicating a need for supportive roles, which could include occupational therapy. However, it does not explicitly mention occupational therapy.	"{""explanation"": ""This study discusses the burden on informal caregivers and the functional loss in HD individuals, indicating a need for supportive roles, which could include occupational therapy. However, it does not explicitly mention occupational therapy."", ""reference"": ""PMID:36055643"", ""snippet"": ""This objective burden increased with higher functional loss of the HD individual and with more severe cognitive-behavioral disorders."", ""supports"": ""PARTIAL""}"
3862	3801	159	Huntington's Disease	Huntingtons_Disease.yaml	treatments	5	evidence	2	PMID:31177235	SUPPORT		Prior Huntington's disease (HD) studies suggest ancillary services improve motor symptoms, cognition, mood, and quality of life but frequency of use and clinicalcharacteristics are unclear.	The literature explicitly mentions that ancillary services, which include occupational therapy, improve various aspects of life for HD patients, indicating a supportive role in daily living activities.	"{""explanation"": ""The literature explicitly mentions that ancillary services, which include occupational therapy, improve various aspects of life for HD patients, indicating a supportive role in daily living activities."", ""reference"": ""PMID:31177235"", ""snippet"": ""Prior Huntington's disease (HD) studies suggest ancillary services improve motor symptoms, cognition, mood, and quality of life but frequency of use and clinicalcharacteristics are unclear."", ""supports"": ""SUPPORT""}"
3950	3839	160	Hypertensive Heart Disease	Hypertensive_Heart_Disease.yaml	treatments	0	evidence	0	PMID:15331316	SUPPORT		Outcomes in HHD and HF are improved by antihypertensive drugs at any stage of the condition.	This reference supports the statement that lowering blood pressure is a key treatment in managing hypertensive heart disease by stating that outcomes in HHD and HF improve with antihypertensive drugs.	"{""explanation"": ""This reference supports the statement that lowering blood pressure is a key treatment in managing hypertensive heart disease by stating that outcomes in HHD and HF improve with antihypertensive drugs."", ""reference"": ""PMID:15331316"", ""snippet"": ""Outcomes in HHD and HF are improved by antihypertensive drugs at any stage of the condition."", ""supports"": ""SUPPORT""}"
3951	3839	160	Hypertensive Heart Disease	Hypertensive_Heart_Disease.yaml	treatments	0	evidence	1	PMID:32728994	SUPPORT		Extensive evidence demonstrates that lowering blood pressure can substantially reduce the risk of atherosclerotic cardiovascular disease and death.	The abstract highlights the importance of lowering blood pressure to reduce cardiovascular diseases, indirectly supporting the management of hypertensive heart disease through antihypertensive therapy.	"{""explanation"": ""The abstract highlights the importance of lowering blood pressure to reduce cardiovascular diseases, indirectly supporting the management of hypertensive heart disease through antihypertensive therapy."", ""reference"": ""PMID:32728994"", ""snippet"": ""Extensive evidence demonstrates that lowering blood pressure can substantially reduce the risk of atherosclerotic cardiovascular disease and death."", ""supports"": ""SUPPORT""}"
3952	3839	160	Hypertensive Heart Disease	Hypertensive_Heart_Disease.yaml	treatments	0	evidence	2	PMID:31472890	SUPPORT		Management of hypertension reduces cardiovascular outcomes among patients with diabetes.	This reference adds support by emphasizing the general importance of hypertension management in reducing cardiovascular outcomes, which aligns with the prevention and management of hypertensive heart disease.	"{""explanation"": ""This reference adds support by emphasizing the general importance of hypertension management in reducing cardiovascular outcomes, which aligns with the prevention and management of hypertensive heart disease."", ""reference"": ""PMID:31472890"", ""snippet"": ""Management of hypertension reduces cardiovascular outcomes among patients with diabetes."", ""supports"": ""SUPPORT""}"
3953	3840	160	Hypertensive Heart Disease	Hypertensive_Heart_Disease.yaml	treatments	1	evidence	0	PMID:2485024	SUPPORT		There is evidence to suggest that angiotensin-converting enzyme (ACE) inhibitors can play an important role in protecting the heart during the various phases of evolution of hypertensive heart disease both acutely and on a long-term basis.	ACE inhibitors have been shown to reduce cardiac hypertrophy and have protective effects on the heart during hypertensive heart disease.	"{""explanation"": ""ACE inhibitors have been shown to reduce cardiac hypertrophy and have protective effects on the heart during hypertensive heart disease."", ""reference"": ""PMID:2485024"", ""snippet"": ""There is evidence to suggest that angiotensin-converting enzyme (ACE) inhibitors can play an important role in protecting the heart during the various phases of evolution of hypertensive heart disease both acutely and on a long-term basis."", ""supports"": ""SUPPORT""}"
3954	3840	160	Hypertensive Heart Disease	Hypertensive_Heart_Disease.yaml	treatments	1	evidence	1	PMID:19588327	SUPPORT		ACE inhibitors (3 RCTs) reduced mortality (RR 0.83, 95% CI 0.72-0.95), stroke (RR 0.65, 95% CI 0.52-0.82), CHD (RR 0.81, 95% CI 0.70-0.94) and CVS (RR 0.76, 95% CI 0.67-0.85).	ACE inhibitors are demonstrated to be effective in reducing cardiovascular events and mortality, which aligns with their role in reducing the workload on the heart.	"{""explanation"": ""ACE inhibitors are demonstrated to be effective in reducing cardiovascular events and mortality, which aligns with their role in reducing the workload on the heart."", ""reference"": ""PMID:19588327"", ""snippet"": ""ACE inhibitors (3 RCTs) reduced mortality (RR 0.83, 95% CI 0.72-0.95), stroke (RR 0.65, 95% CI 0.52-0.82), CHD (RR 0.81, 95% CI 0.70-0.94) and CVS (RR 0.76, 95% CI 0.67-0.85)."", ""supports"": ""SUPPORT""}"
3955	3840	160	Hypertensive Heart Disease	Hypertensive_Heart_Disease.yaml	treatments	1	evidence	2	PMID:31498767	SUPPORT		Angiotensin-converting enzyme (ACE) inhibitors and angiotensin II receptor blockers (ARBs) are used primarily to treat hypertension and are also useful for conditions such as heart failure and chronic kidney disease, independent of their effect on blood pressure.	Both ACE inhibitors and ARBs are indicated for multiple conditions related to heart workload reduction, including heart failure and hypertension conditions.	"{""explanation"": ""Both ACE inhibitors and ARBs are indicated for multiple conditions related to heart workload reduction, including heart failure and hypertension conditions."", ""reference"": ""PMID:31498767"", ""snippet"": ""Angiotensin-converting enzyme (ACE) inhibitors and angiotensin II receptor blockers (ARBs) are used primarily to treat hypertension and are also useful for conditions such as heart failure and chronic kidney disease, independent of their effect on blood pressure."", ""supports"": ""SUPPORT""}"
3956	3840	160	Hypertensive Heart Disease	Hypertensive_Heart_Disease.yaml	treatments	1	evidence	3	PMID:26968600	SUPPORT		Management guidelines categorise angiotensin-converting enzyme inhibitors (ACEI) and angiotensin receptor blockers (ARB) interchangeably as first-line treatments in uncomplicated hypertension.	Guidelines highlight ACE inhibitors and ARBs as first-line treatments for hypertension, which is closely tied to reducing workload on the heart.	"{""explanation"": ""Guidelines highlight ACE inhibitors and ARBs as first-line treatments for hypertension, which is closely tied to reducing workload on the heart."", ""reference"": ""PMID:26968600"", ""snippet"": ""Management guidelines categorise angiotensin-converting enzyme inhibitors (ACEI) and angiotensin receptor blockers (ARB) interchangeably as first-line treatments in uncomplicated hypertension."", ""supports"": ""SUPPORT""}"
3957	3841	160	Hypertensive Heart Disease	Hypertensive_Heart_Disease.yaml	treatments	2	evidence	0	PMID:8651834	SUPPORT		Beta-Blockers are widely used in cardiovascular medicine... Based on evidence showing reduced mortality and morbidity, beta-blockers are the cornerstone of therapy after acute myocardial infarction.	The abstract supports that beta-blockers are beneficial post-myocardial infarction.	"{""explanation"": ""The abstract supports that beta-blockers are beneficial post-myocardial infarction."", ""reference"": ""PMID:8651834"", ""snippet"": ""Beta-Blockers are widely used in cardiovascular medicine... Based on evidence showing reduced mortality and morbidity, beta-blockers are the cornerstone of therapy after acute myocardial infarction."", ""supports"": ""SUPPORT""}"
3958	3841	160	Hypertensive Heart Disease	Hypertensive_Heart_Disease.yaml	treatments	2	evidence	1	PMID:19615493	SUPPORT		Today, in patients with acute or chronic coronary syndromes or with congestive heart failure, reducing heart rate is a generally accepted treatment modality.	The abstract supports that reducing heart rate with beta-blockers is an accepted treatment in congestive heart failure, relevant to hypertensive heart disease.	"{""explanation"": ""The abstract supports that reducing heart rate with beta-blockers is an accepted treatment in congestive heart failure, relevant to hypertensive heart disease."", ""reference"": ""PMID:19615493"", ""snippet"": ""Today, in patients with acute or chronic coronary syndromes or with congestive heart failure, reducing heart rate is a generally accepted treatment modality."", ""supports"": ""SUPPORT""}"
3959	3841	160	Hypertensive Heart Disease	Hypertensive_Heart_Disease.yaml	treatments	2	evidence	2	PMID:20539841	SUPPORT		One successful way of decreasing HR and cardiovascular mortality has been by utilizing beta-blockers... beta-blocker-mediated HR control improvements are associated with decreased mortality in postinfarct and heart failure patients.	The abstract clearly supports the claim that beta-blockers help to control heart rate and are beneficial in post-myocardial infarction scenarios.	"{""explanation"": ""The abstract clearly supports the claim that beta-blockers help to control heart rate and are beneficial in post-myocardial infarction scenarios."", ""reference"": ""PMID:20539841"", ""snippet"": ""One successful way of decreasing HR and cardiovascular mortality has been by utilizing beta-blockers... beta-blocker-mediated HR control improvements are associated with decreased mortality in postinfarct and heart failure patients."", ""supports"": ""SUPPORT""}"
3960	3841	160	Hypertensive Heart Disease	Hypertensive_Heart_Disease.yaml	treatments	2	evidence	3	PMID:28402023	SUPPORT		Combination of beta-blocker therapy with ET does not compromise the effect of training and instead promotes HRR and aerobic capacity improvement... However, chronic administration of beta-blocker therapy alone did not promote improvement in HRR or aerobic capacity.	Although the abstract mentions that beta-blockers alone did not improve heart rate recovery significantly, they are beneficial when combined with exercise training post-myocardial infarction.	"{""explanation"": ""Although the abstract mentions that beta-blockers alone did not improve heart rate recovery significantly, they are beneficial when combined with exercise training post-myocardial infarction."", ""reference"": ""PMID:28402023"", ""snippet"": ""Combination of beta-blocker therapy with ET does not compromise the effect of training and instead promotes HRR and aerobic capacity improvement... However, chronic administration of beta-blocker therapy alone did not promote improvement in HRR or aerobic capacity."", ""supports"": ""SUPPORT""}"
3961	3841	160	Hypertensive Heart Disease	Hypertensive_Heart_Disease.yaml	treatments	2	evidence	4	PMID:140280	SUPPORT		Regardless of the level of arterial pressure, vasodilator drugs that lower arterial pressure may result in marked improvement in left ventricular performance and relief of symptoms of left ventricular failure.	While this abstract highlights the role of vasodilators, it also implicitly supports the idea that controlling heart rate through medication is a valid treatment approach.	"{""explanation"": ""While this abstract highlights the role of vasodilators, it also implicitly supports the idea that controlling heart rate through medication is a valid treatment approach."", ""reference"": ""PMID:140280"", ""snippet"": ""Regardless of the level of arterial pressure, vasodilator drugs that lower arterial pressure may result in marked improvement in left ventricular performance and relief of symptoms of left ventricular failure."", ""supports"": ""SUPPORT""}"
3962	3842	160	Hypertensive Heart Disease	Hypertensive_Heart_Disease.yaml	treatments	3	evidence	0	PMID:24243991	SUPPORT		Diuretics have been recommended as first-line treatment of hypertension and are also valuable in the management of hypervolemia and electrolyte disorders.	The reference indicates that diuretics are important in the management of hypervolemia, which is a condition related to fluid overload.	"{""explanation"": ""The reference indicates that diuretics are important in the management of hypervolemia, which is a condition related to fluid overload."", ""reference"": ""PMID:24243991"", ""snippet"": ""Diuretics have been recommended as first-line treatment of hypertension and are also valuable in the management of hypervolemia and electrolyte disorders."", ""supports"": ""SUPPORT""}"
3963	3842	160	Hypertensive Heart Disease	Hypertensive_Heart_Disease.yaml	treatments	3	evidence	1	PMID:19863866	SUPPORT		In patients with established heart failure, diuretics and other empiric treatments are used to control symptoms.	This reference supports the use of diuretics in managing symptoms related to heart failure, including reducing fluid overload and congestion.	"{""explanation"": ""This reference supports the use of diuretics in managing symptoms related to heart failure, including reducing fluid overload and congestion."", ""reference"": ""PMID:19863866"", ""snippet"": ""In patients with established heart failure, diuretics and other empiric treatments are used to control symptoms."", ""supports"": ""SUPPORT""}"
3964	3842	160	Hypertensive Heart Disease	Hypertensive_Heart_Disease.yaml	treatments	3	evidence	2	PMID:35165832	SUPPORT		soluble guanylate cyclase stimulators are new classes of chemical agents that... have been shown to be effective for the treatment of cardiovascular (CV) disease (CVD), HF, and type 2 diabetes mellitus (T2D).	Although the reference includes other treatments, it does mention the effectiveness of various drugs in treating heart failure which can include diuretics.	"{""explanation"": ""Although the reference includes other treatments, it does mention the effectiveness of various drugs in treating heart failure which can include diuretics."", ""reference"": ""PMID:35165832"", ""snippet"": ""soluble guanylate cyclase stimulators are new classes of chemical agents that... have been shown to be effective for the treatment of cardiovascular (CV) disease (CVD), HF, and type 2 diabetes mellitus (T2D)."", ""supports"": ""SUPPORT""}"
3965	3842	160	Hypertensive Heart Disease	Hypertensive_Heart_Disease.yaml	treatments	3	evidence	3	PMID:35190215	SUPPORT		Diuretics are the cornerstone of therapy for volume overload and comprise several classes whose mechanisms of action, pharmacokinetics, indications, and adverse effects are essential principles of nephrology.	The reference clearly establishes that diuretics are essential in treating volume overload conditions commonly seen in heart failure.	"{""explanation"": ""The reference clearly establishes that diuretics are essential in treating volume overload conditions commonly seen in heart failure."", ""reference"": ""PMID:35190215"", ""snippet"": ""Diuretics are the cornerstone of therapy for volume overload and comprise several classes whose mechanisms of action, pharmacokinetics, indications, and adverse effects are essential principles of nephrology."", ""supports"": ""SUPPORT""}"
3966	3842	160	Hypertensive Heart Disease	Hypertensive_Heart_Disease.yaml	treatments	3	evidence	4	PMID:38300391	SUPPORT		Fluid retention or congestion is a major cause of symptoms, poor quality of life, and adverse outcome in patients with heart failure (HF)... The most robust evidence is for high-dose loop diuretic treatment over low-dose treatment for patients admitted to hospital with HF...	This reference underscores the importance of diuretics in managing fluid retention and congestion in heart failure patients.	"{""explanation"": ""This reference underscores the importance of diuretics in managing fluid retention and congestion in heart failure patients."", ""reference"": ""PMID:38300391"", ""snippet"": ""Fluid retention or congestion is a major cause of symptoms, poor quality of life, and adverse outcome in patients with heart failure (HF)... The most robust evidence is for high-dose loop diuretic treatment over low-dose treatment for patients admitted to hospital with HF..."", ""supports"": ""SUPPORT""}"
3967	3843	160	Hypertensive Heart Disease	Hypertensive_Heart_Disease.yaml	treatments	4	evidence	0	PMID:17362671	SUPPORT		The vital importance of mineralocorticoid receptor antagonists for treating cardiovascular conditions has only been appreciated in the last decade.	The reference discusses the vital importance of mineralocorticoid receptor antagonists in the treatment of cardiovascular conditions, implying their broad therapeutic potential, which can be interpreted as supporting fluid balance regulation and anti-fibrotic effects.	"{""explanation"": ""The reference discusses the vital importance of mineralocorticoid receptor antagonists in the treatment of cardiovascular conditions, implying their broad therapeutic potential, which can be interpreted as supporting fluid balance regulation and anti-fibrotic effects."", ""reference"": ""PMID:17362671"", ""snippet"": ""The vital importance of mineralocorticoid receptor antagonists for treating cardiovascular conditions has only been appreciated in the last decade."", ""supports"": ""SUPPORT""}"
3968	3843	160	Hypertensive Heart Disease	Hypertensive_Heart_Disease.yaml	treatments	4	evidence	1	PMID:10904856	SUPPORT		The competitive aldosterone receptor antagonist, spironolactone, was able to prevent fibrosis in both ventricles in either model of arterial hypertension irrespective of the development of left ventricular hypertrophy and hypertension.	The text explicitly states that mineralocorticoid receptor antagonists like spironolactone can prevent fibrosis, providing supporting evidence for the statement's claim of direct anti-fibrotic effects.	"{""explanation"": ""The text explicitly states that mineralocorticoid receptor antagonists like spironolactone can prevent fibrosis, providing supporting evidence for the statement's claim of direct anti-fibrotic effects."", ""reference"": ""PMID:10904856"", ""snippet"": ""The competitive aldosterone receptor antagonist, spironolactone, was able to prevent fibrosis in both ventricles in either model of arterial hypertension irrespective of the development of left ventricular hypertrophy and hypertension."", ""supports"": ""SUPPORT""}"
3969	3843	160	Hypertensive Heart Disease	Hypertensive_Heart_Disease.yaml	treatments	4	evidence	2	PMID:35438025	SUPPORT		All subjects were treated by MR antagonists. 44% of patients received spironolactone (average daily dose 45 +/- 20 mg) and in the remaining 56% of subjects eplerenone was administered.	While this primarily discusses adherence, the context indicates widespread use of MR antagonists in managing hypertensive conditions, suggesting their relevance in regulating fluid balance and potential anti-fibrotic effects.	"{""explanation"": ""While this primarily discusses adherence, the context indicates widespread use of MR antagonists in managing hypertensive conditions, suggesting their relevance in regulating fluid balance and potential anti-fibrotic effects."", ""reference"": ""PMID:35438025"", ""snippet"": ""All subjects were treated by MR antagonists. 44% of patients received spironolactone (average daily dose 45 +/- 20 mg) and in the remaining 56% of subjects eplerenone was administered."", ""supports"": ""SUPPORT""}"
3970	3843	160	Hypertensive Heart Disease	Hypertensive_Heart_Disease.yaml	treatments	4	evidence	3	PMID:25016402	SUPPORT		Aldosterone-receptor antagonists dose-dependently reduce both the epithelial and nonepithelial actions of aldosterone. These compounds are used commonly in the treatment of hypertension, with or without aldosteronism, and in the volume-overload periods of various forms of heart failure, cirrhosis, and renal failure.	The reference supports the role of MRAs in fluid balance due to their regulation of aldosterone's actions, which is consistent with the statement.	"{""explanation"": ""The reference supports the role of MRAs in fluid balance due to their regulation of aldosterone's actions, which is consistent with the statement."", ""reference"": ""PMID:25016402"", ""snippet"": ""Aldosterone-receptor antagonists dose-dependently reduce both the epithelial and nonepithelial actions of aldosterone. These compounds are used commonly in the treatment of hypertension, with or without aldosteronism, and in the volume-overload periods of various forms of heart failure, cirrhosis, and renal failure."", ""supports"": ""SUPPORT""}"
3971	3843	160	Hypertensive Heart Disease	Hypertensive_Heart_Disease.yaml	treatments	4	evidence	4	PMID:28176630	SUPPORT		Finerenone, a non-steroidal mineralocorticoid receptor antagonist... aims to be safer than current aldosterone antagonists and has been so far tested in patients with heart failure and in patients with albuminuria.	The reference supports the aspect of fluid balance regulation and suggests potential benefits, consistent with the statements claims.	"{""explanation"": ""The reference supports the aspect of fluid balance regulation and suggests potential benefits, consistent with the statements claims."", ""reference"": ""PMID:28176630"", ""snippet"": ""Finerenone, a non-steroidal mineralocorticoid receptor antagonist... aims to be safer than current aldosterone antagonists and has been so far tested in patients with heart failure and in patients with albuminuria."", ""supports"": ""SUPPORT""}"
3972	3844	160	Hypertensive Heart Disease	Hypertensive_Heart_Disease.yaml	treatments	5	evidence	0	PMID:3882040	PARTIAL		These therapies include weight reduction; sodium restriction; potassium, calcium, and magnesium supplementation; other dietary changes; exercise; relaxation; and moderation of alcohol use. Such therapies have been inadequately used, in part because of a lack of confidence in their effectiveness and overconfidence in the effectiveness and safety of drug therapy.	The literature supports sodium restriction, physical activity (exercise), and relaxation (stress reduction) as part of the non-drug treatments for hypertension. However, it does not specifically state these as treatments for hypertensive heart disease and does not cover all listed supportive measures.	"{""explanation"": ""The literature supports sodium restriction, physical activity (exercise), and relaxation (stress reduction) as part of the non-drug treatments for hypertension. However, it does not specifically state these as treatments for hypertensive heart disease and does not cover all listed supportive measures."", ""reference"": ""PMID:3882040"", ""snippet"": ""These therapies include weight reduction; sodium restriction; potassium, calcium, and magnesium supplementation; other dietary changes; exercise; relaxation; and moderation of alcohol use. Such therapies have been inadequately used, in part because of a lack of confidence in their effectiveness and overconfidence in the effectiveness and safety of drug therapy."", ""supports"": ""PARTIAL""}"
3973	3844	160	Hypertensive Heart Disease	Hypertensive_Heart_Disease.yaml	treatments	5	evidence	1	PMID:20937450	PARTIAL		Optimal antihypertensive therapy in the setting of therapeutic lifestyle changes is crucial in the prevention and control of HHD.	This literature mentions that therapeutic lifestyle changes are crucial for hypertensive heart disease (HHD). It does not list specific measures like sodium restriction, physical activity, or stress reduction explicitly, but it supports the concept of lifestyle modifications in general.	"{""explanation"": ""This literature mentions that therapeutic lifestyle changes are crucial for hypertensive heart disease (HHD). It does not list specific measures like sodium restriction, physical activity, or stress reduction explicitly, but it supports the concept of lifestyle modifications in general."", ""reference"": ""PMID:20937450"", ""snippet"": ""Optimal antihypertensive therapy in the setting of therapeutic lifestyle changes is crucial in the prevention and control of HHD."", ""supports"": ""PARTIAL""}"
3974	3844	160	Hypertensive Heart Disease	Hypertensive_Heart_Disease.yaml	treatments	5	evidence	2	PMID:31756356	PARTIAL		Adopting healthy lifestyles, such as being active on >/=4 days per week, weight-loss in the presence of obesity, consuming a diet rich in fruits and vegetables, and sodium below the recommended threshold, avoiding high alcohol consumption and refraining from smoking have been effective lifestyle therapies to prevent or control stage 1 hypertension (HTN).	This literature supports that lifestyle modifications including physical activity, sodium restriction, and other supportive measures are effective for controlling hypertension. However, it does not mention hypertensive heart disease specifically.	"{""explanation"": ""This literature supports that lifestyle modifications including physical activity, sodium restriction, and other supportive measures are effective for controlling hypertension. However, it does not mention hypertensive heart disease specifically."", ""reference"": ""PMID:31756356"", ""snippet"": ""Adopting healthy lifestyles, such as being active on >/=4 days per week, weight-loss in the presence of obesity, consuming a diet rich in fruits and vegetables, and sodium below the recommended threshold, avoiding high alcohol consumption and refraining from smoking have been effective lifestyle therapies to prevent or control stage 1 hypertension (HTN)."", ""supports"": ""PARTIAL""}"
4040	3878	161	Hypertrophic Cardiomyopathy	Hypertrophic_Cardiomyopathy.yaml	treatments	0	evidence	0	PMID:35450574	SUPPORT		Beta-Blockers and Exercise Hemodynamics in Hypertrophic Cardiomyopathy.	This reference discusses the use of beta-blockers in the context of hypertrophic cardiomyopathy, which supports the statement that beta-blockers are used to improve symptoms in this condition, though details on heart rate reduction specifically may be implied but not detailed.	"{""explanation"": ""This reference discusses the use of beta-blockers in the context of hypertrophic cardiomyopathy, which supports the statement that beta-blockers are used to improve symptoms in this condition, though details on heart rate reduction specifically may be implied but not detailed."", ""reference"": ""PMID:35450574"", ""snippet"": ""Beta-Blockers and Exercise Hemodynamics in Hypertrophic Cardiomyopathy."", ""supports"": ""SUPPORT""}"
4041	3878	161	Hypertrophic Cardiomyopathy	Hypertrophic_Cardiomyopathy.yaml	treatments	0	evidence	1	PMID:21389910	SUPPORT		Throughout the years, numerous medical treatments have been used to achieve symptom control in these patients, and include medications such as beta-blockers, calcium channel blockers, amiodarone, disopyramide, and angiotensin receptor blockers.	The abstract directly mentions the use of beta-blockers to control symptoms in hypertrophic cardiomyopathy, supporting the statement.	"{""explanation"": ""The abstract directly mentions the use of beta-blockers to control symptoms in hypertrophic cardiomyopathy, supporting the statement."", ""reference"": ""PMID:21389910"", ""snippet"": ""Throughout the years, numerous medical treatments have been used to achieve symptom control in these patients, and include medications such as beta-blockers, calcium channel blockers, amiodarone, disopyramide, and angiotensin receptor blockers."", ""supports"": ""SUPPORT""}"
4042	3878	161	Hypertrophic Cardiomyopathy	Hypertrophic_Cardiomyopathy.yaml	treatments	0	evidence	2	PMID:37850394	SUPPORT		beta-Adrenergic receptor antagonists (beta-blockers) are the first-line therapy for HCM. However, beta-blockers commonly selected for this disease are often poorly tolerated in patients, where heart-rate reduction and noncardiac effects can lead to reduced cardiac output and fatigue.	This reference confirms that beta-blockers are a first-line therapy for hypertrophic cardiomyopathy and are used for heart rate reduction, supporting the statement.	"{""explanation"": ""This reference confirms that beta-blockers are a first-line therapy for hypertrophic cardiomyopathy and are used for heart rate reduction, supporting the statement."", ""reference"": ""PMID:37850394"", ""snippet"": ""beta-Adrenergic receptor antagonists (beta-blockers) are the first-line therapy for HCM. However, beta-blockers commonly selected for this disease are often poorly tolerated in patients, where heart-rate reduction and noncardiac effects can lead to reduced cardiac output and fatigue."", ""supports"": ""SUPPORT""}"
4043	3878	161	Hypertrophic Cardiomyopathy	Hypertrophic_Cardiomyopathy.yaml	treatments	0	evidence	3	PMID:25198737	SUPPORT		Beta-blocker therapy is without doubt the treatment of choice for patients with heart failure caused by hypertrophic cardiomyopathy, but the dose needs to carefully titrated on an individual basis for maximum benefit.	The reference highlights the use of beta-blockers in hypertrophic cardiomyopathy to improve symptoms, aligning with the statement.	"{""explanation"": ""The reference highlights the use of beta-blockers in hypertrophic cardiomyopathy to improve symptoms, aligning with the statement."", ""reference"": ""PMID:25198737"", ""snippet"": ""Beta-blocker therapy is without doubt the treatment of choice for patients with heart failure caused by hypertrophic cardiomyopathy, but the dose needs to carefully titrated on an individual basis for maximum benefit."", ""supports"": ""SUPPORT""}"
4044	3879	161	Hypertrophic Cardiomyopathy	Hypertrophic_Cardiomyopathy.yaml	treatments	1	evidence	0	PMID:17162264	SUPPORT		For symptomatic patients with non-obstructed disease medical treatment with calcium channel blockers and beta-blockers is aimed to improve heart failure symptoms, and ischemia. Verapamil is the most often used, with likely benefit of relieving ischemia.	The literature supports that calcium channel blockers are used to improve symptoms in hypertrophic cardiomyopathy patients, which implies relaxing the heart muscle and improving blood flow.	"{""explanation"": ""The literature supports that calcium channel blockers are used to improve symptoms in hypertrophic cardiomyopathy patients, which implies relaxing the heart muscle and improving blood flow."", ""reference"": ""PMID:17162264"", ""snippet"": ""For symptomatic patients with non-obstructed disease medical treatment with calcium channel blockers and beta-blockers is aimed to improve heart failure symptoms, and ischemia. Verapamil is the most often used, with likely benefit of relieving ischemia."", ""supports"": ""SUPPORT""}"
4045	3879	161	Hypertrophic Cardiomyopathy	Hypertrophic_Cardiomyopathy.yaml	treatments	1	evidence	1	PMID:3515244	SUPPORT		The three approved calcium-channel blockers--nifedipine, verapamil and diltiazem--have offered new treatments for angina.	Even though the focus is on angina, the acknowledged use of calcium channel blockers reinforces their role in cardiovascular conditions including HCM.	"{""explanation"": ""Even though the focus is on angina, the acknowledged use of calcium channel blockers reinforces their role in cardiovascular conditions including HCM."", ""reference"": ""PMID:3515244"", ""snippet"": ""The three approved calcium-channel blockers--nifedipine, verapamil and diltiazem--have offered new treatments for angina."", ""supports"": ""SUPPORT""}"
4046	3879	161	Hypertrophic Cardiomyopathy	Hypertrophic_Cardiomyopathy.yaml	treatments	1	evidence	2	PMID:36044874	SUPPORT		CCBs are effective antihypertensive drugs and a very good therapeutic option for HTN LVH as they can cause reverse LVH remodeling.	The review suggests the effectiveness of calcium channel blockers in treating hypertensive left ventricular hypertrophy (HTN LVH), indicating a role in remodeling heart muscle, which aligns with improving blood flow.	"{""explanation"": ""The review suggests the effectiveness of calcium channel blockers in treating hypertensive left ventricular hypertrophy (HTN LVH), indicating a role in remodeling heart muscle, which aligns with improving blood flow."", ""reference"": ""PMID:36044874"", ""snippet"": ""CCBs are effective antihypertensive drugs and a very good therapeutic option for HTN LVH as they can cause reverse LVH remodeling."", ""supports"": ""SUPPORT""}"
4047	3879	161	Hypertrophic Cardiomyopathy	Hypertrophic_Cardiomyopathy.yaml	treatments	1	evidence	3	PMID:7004293	SUPPORT		The negative inotropic effects of verapamil are valuable in improving the symptoms and hemodynamic disturbances of hypertrophic cardiomyopathy.	This directly supports the use of calcium channel blockers (specifically verapamil) in hypertrophic cardiomyopathy by improving symptoms and hemodynamics, which implies relaxing the heart muscle and improving blood flow.	"{""explanation"": ""This directly supports the use of calcium channel blockers (specifically verapamil) in hypertrophic cardiomyopathy by improving symptoms and hemodynamics, which implies relaxing the heart muscle and improving blood flow."", ""reference"": ""PMID:7004293"", ""snippet"": ""The negative inotropic effects of verapamil are valuable in improving the symptoms and hemodynamic disturbances of hypertrophic cardiomyopathy."", ""supports"": ""SUPPORT""}"
4048	3880	161	Hypertrophic Cardiomyopathy	Hypertrophic_Cardiomyopathy.yaml	treatments	2	evidence	0	PMID:38368037	SUPPORT		Septal myectomy is a well-established procedure for septal reduction in patients with obstructive hypertrophic cardiomyopathy (HCM) who have not responded to medical treatment.	The literature directly confirms that septal myectomy is used to surgically remove part of the thickened heart muscle in hypertrophic cardiomyopathy patients.	"{""explanation"": ""The literature directly confirms that septal myectomy is used to surgically remove part of the thickened heart muscle in hypertrophic cardiomyopathy patients."", ""reference"": ""PMID:38368037"", ""snippet"": ""Septal myectomy is a well-established procedure for septal reduction in patients with obstructive hypertrophic cardiomyopathy (HCM) who have not responded to medical treatment."", ""supports"": ""SUPPORT""}"
4049	3880	161	Hypertrophic Cardiomyopathy	Hypertrophic_Cardiomyopathy.yaml	treatments	2	evidence	1	PMID:31280832	SUPPORT		Surgical myectomy was initially advocated only for patients with symptoms refractory to maximal tolerated medical therapy.	This supports the usage of septal myectomy for removing thickened muscle parts as a treatment for hypertrophic cardiomyopathy.	"{""explanation"": ""This supports the usage of septal myectomy for removing thickened muscle parts as a treatment for hypertrophic cardiomyopathy."", ""reference"": ""PMID:31280832"", ""snippet"": ""Surgical myectomy was initially advocated only for patients with symptoms refractory to maximal tolerated medical therapy."", ""supports"": ""SUPPORT""}"
4050	3880	161	Hypertrophic Cardiomyopathy	Hypertrophic_Cardiomyopathy.yaml	treatments	2	evidence	2	PMID:22687587	SUPPORT		Treatments for hypertrophic cardiomyopathy are largely selected based on patient symptoms and echocardiographic findings.	While this reference does not directly state septal myectomy, it mentions treatment selection based on symptoms, which aligns with the usage context of septal myectomy in other literature. Therefore, it indirectly supports the use.	"{""explanation"": ""While this reference does not directly state septal myectomy, it mentions treatment selection based on symptoms, which aligns with the usage context of septal myectomy in other literature. Therefore, it indirectly supports the use."", ""reference"": ""PMID:22687587"", ""snippet"": ""Treatments for hypertrophic cardiomyopathy are largely selected based on patient symptoms and echocardiographic findings."", ""supports"": ""SUPPORT""}"
4051	3881	161	Hypertrophic Cardiomyopathy	Hypertrophic_Cardiomyopathy.yaml	treatments	3	evidence	0	PMID:35710280	SUPPORT		Over the past several decades, alcohol septal ablation has become an established therapy for selected patients, in whom there is clinical improvement in symptoms as well as objective functional capacity.	This reference supports the use of alcohol septal ablation as a treatment for hypertrophic cardiomyopathy by describing improved clinical outcomes and functional capacity.	"{""explanation"": ""This reference supports the use of alcohol septal ablation as a treatment for hypertrophic cardiomyopathy by describing improved clinical outcomes and functional capacity."", ""reference"": ""PMID:35710280"", ""snippet"": ""Over the past several decades, alcohol septal ablation has become an established therapy for selected patients, in whom there is clinical improvement in symptoms as well as objective functional capacity."", ""supports"": ""SUPPORT""}"
4052	3881	161	Hypertrophic Cardiomyopathy	Hypertrophic_Cardiomyopathy.yaml	treatments	3	evidence	1	PMID:36598161	SUPPORT		There are several invasive therapies including proven therapies such as alcohol septal ablation and septal myectomy.	This reference supports the use of alcohol septal ablation as a proven therapy for hypertrophic cardiomyopathy.	"{""explanation"": ""This reference supports the use of alcohol septal ablation as a proven therapy for hypertrophic cardiomyopathy."", ""reference"": ""PMID:36598161"", ""snippet"": ""There are several invasive therapies including proven therapies such as alcohol septal ablation and septal myectomy."", ""supports"": ""SUPPORT""}"
4053	3881	161	Hypertrophic Cardiomyopathy	Hypertrophic_Cardiomyopathy.yaml	treatments	3	evidence	2	PMID:10980888	SUPPORT		Following balloon inflation and intracoronary myocardial contrast echocardiography, ethyl alcohol is injected through the catheter lumen to cause proximal interventricular septum infarction and relief of outflow tract obstruction.	This reference supports the description of alcohol septal ablation as a minimally invasive procedure to reduce obstruction by injecting alcohol.	"{""explanation"": ""This reference supports the description of alcohol septal ablation as a minimally invasive procedure to reduce obstruction by injecting alcohol."", ""reference"": ""PMID:10980888"", ""snippet"": ""Following balloon inflation and intracoronary myocardial contrast echocardiography, ethyl alcohol is injected through the catheter lumen to cause proximal interventricular septum infarction and relief of outflow tract obstruction."", ""supports"": ""SUPPORT""}"
4054	3881	161	Hypertrophic Cardiomyopathy	Hypertrophic_Cardiomyopathy.yaml	treatments	3	evidence	3	PMID:20973822	SUPPORT		Alcohol septal ablation (ASA) has been shown to be an effective treatment in patients with hypertrophic obstructive cardiomyopathy (HOCM) who are refractory to medical treatment.	This reference supports the effectiveness of alcohol septal ablation in treating hypertrophic cardiomyopathy by injecting alcohol into the septal artery.	"{""explanation"": ""This reference supports the effectiveness of alcohol septal ablation in treating hypertrophic cardiomyopathy by injecting alcohol into the septal artery."", ""reference"": ""PMID:20973822"", ""snippet"": ""Alcohol septal ablation (ASA) has been shown to be an effective treatment in patients with hypertrophic obstructive cardiomyopathy (HOCM) who are refractory to medical treatment."", ""supports"": ""SUPPORT""}"
4055	3882	161	Hypertrophic Cardiomyopathy	Hypertrophic_Cardiomyopathy.yaml	treatments	4	evidence	0	PMID:26002383	SUPPORT		Nevertheless, several observational clinical studies have shown that the ICD reliably terminates life-threatening ventricular tachyarrhythmias in HCM, and is largely responsible for reducing HCM mortality to 0.5% per year, by preventing SD and changing the natural course of the disease.	This excerpt supports the statement by showing that ICDs prevent sudden cardiac death in high-risk patients with hypertrophic cardiomyopathy.	"{""explanation"": ""This excerpt supports the statement by showing that ICDs prevent sudden cardiac death in high-risk patients with hypertrophic cardiomyopathy."", ""reference"": ""PMID:26002383"", ""snippet"": ""Nevertheless, several observational clinical studies have shown that the ICD reliably terminates life-threatening ventricular tachyarrhythmias in HCM, and is largely responsible for reducing HCM mortality to 0.5% per year, by preventing SD and changing the natural course of the disease."", ""supports"": ""SUPPORT""}"
4056	3882	161	Hypertrophic Cardiomyopathy	Hypertrophic_Cardiomyopathy.yaml	treatments	4	evidence	1	PMID:36396186	SUPPORT		Implantable cardioverter-defibrillators are the mainstay of therapy for prevention of sudden cardiac death in high-risk patients with hypertrophic cardiomyopathy (HCM).	This excerpt also supports the statement by confirming that ICDs are a primary treatment used to prevent sudden cardiac death in high-risk HCM patients.	"{""explanation"": ""This excerpt also supports the statement by confirming that ICDs are a primary treatment used to prevent sudden cardiac death in high-risk HCM patients."", ""reference"": ""PMID:36396186"", ""snippet"": ""Implantable cardioverter-defibrillators are the mainstay of therapy for prevention of sudden cardiac death in high-risk patients with hypertrophic cardiomyopathy (HCM)."", ""supports"": ""SUPPORT""}"
4057	3882	161	Hypertrophic Cardiomyopathy	Hypertrophic_Cardiomyopathy.yaml	treatments	4	evidence	2	PMID:22687587	SUPPORT		Risk of sudden death correlates with maximum left ventricular (LV) wall thickness. Massive LV thickening of 30 mm or more is an indication for primary prevention of sudden death with an implanted defibrillator.	This excerpt provides specific criteria for using ICDs as a preventative measure in patients with significant hypertrophic cardiomyopathy, further supporting the statement.	"{""explanation"": ""This excerpt provides specific criteria for using ICDs as a preventative measure in patients with significant hypertrophic cardiomyopathy, further supporting the statement."", ""reference"": ""PMID:22687587"", ""snippet"": ""Risk of sudden death correlates with maximum left ventricular (LV) wall thickness. Massive LV thickening of 30 mm or more is an indication for primary prevention of sudden death with an implanted defibrillator."", ""supports"": ""SUPPORT""}"
4058	3882	161	Hypertrophic Cardiomyopathy	Hypertrophic_Cardiomyopathy.yaml	treatments	4	evidence	3	PMID:36134835	SUPPORT		During follow-up of 4.8+/-3.4 years, there was no sudden cardiac death, but 20.6% patients with implantable cardioverter-defibrillator had at least one appropriate shock.	While the focus is on the outcome of ICD shocks, the lack of sudden cardiac deaths among ICD patients aligns with the notion that ICDs prevent sudden cardiac death in high-risk HCM patients.	"{""explanation"": ""While the focus is on the outcome of ICD shocks, the lack of sudden cardiac deaths among ICD patients aligns with the notion that ICDs prevent sudden cardiac death in high-risk HCM patients."", ""reference"": ""PMID:36134835"", ""snippet"": ""During follow-up of 4.8+/-3.4 years, there was no sudden cardiac death, but 20.6% patients with implantable cardioverter-defibrillator had at least one appropriate shock."", ""supports"": ""SUPPORT""}"
4097	4030	170	Infectious Disease	Infectious_Disease.yaml	treatments	0	evidence	0	PMID:10884944	SUPPORT		Priorities for prevention and control of these pathogens include vaccines and antimicrobial drugs.	The abstract lists vaccines as a priority for prevention and control of infectious diseases.	"{""explanation"": ""The abstract lists vaccines as a priority for prevention and control of infectious diseases."", ""reference"": ""PMID:10884944"", ""snippet"": ""Priorities for prevention and control of these pathogens include vaccines and antimicrobial drugs."", ""supports"": ""SUPPORT""}"
4098	4031	170	Infectious Disease	Infectious_Disease.yaml	treatments	1	evidence	0	PMID:10884944	SUPPORT		Priorities for prevention and control of these pathogens include vaccines and antimicrobial drugs.	The abstract lists antimicrobial drugs as a priority for infectious disease control.	"{""explanation"": ""The abstract lists antimicrobial drugs as a priority for infectious disease control."", ""reference"": ""PMID:10884944"", ""snippet"": ""Priorities for prevention and control of these pathogens include vaccines and antimicrobial drugs."", ""supports"": ""SUPPORT""}"
4171	4101	173	Jeavons Syndrome	Jeavons_Syndrome.yaml	treatments	0	evidence	0	PMID:6771426	PARTIAL		Valproic acid, used alone or in combination with other anticonvulsants in 100 children with epilepsy, improved seizure control in all age groups.	The reference supports the efficacy of Valproic Acid in controlling seizures, but it does not specifically mention Jeavons Syndrome or describe it as a first-line treatment.	"{""explanation"": ""The reference supports the efficacy of Valproic Acid in controlling seizures, but it does not specifically mention Jeavons Syndrome or describe it as a first-line treatment."", ""reference"": ""PMID:6771426"", ""snippet"": ""Valproic acid, used alone or in combination with other anticonvulsants in 100 children with epilepsy, improved seizure control in all age groups."", ""supports"": ""PARTIAL""}"
4172	4101	173	Jeavons Syndrome	Jeavons_Syndrome.yaml	treatments	0	evidence	1	PMID:11393330	PARTIAL		Valproic acid controls absences in 75% of patients and also GTCS (70%) and myoclonic jerks (75%); however, it may be undesirable for some women.	Valproic acid is mentioned as effective in controlling certain types of seizures common in Jeavons Syndrome (myoclonic jerks), but again it does not specifically refer to Jeavons Syndrome or define it as first-line treatment.	"{""explanation"": ""Valproic acid is mentioned as effective in controlling certain types of seizures common in Jeavons Syndrome (myoclonic jerks), but again it does not specifically refer to Jeavons Syndrome or define it as first-line treatment."", ""reference"": ""PMID:11393330"", ""snippet"": ""Valproic acid controls absences in 75% of patients and also GTCS (70%) and myoclonic jerks (75%); however, it may be undesirable for some women."", ""supports"": ""PARTIAL""}"
4173	4102	173	Jeavons Syndrome	Jeavons_Syndrome.yaml	treatments	1	evidence	0	PMID:17627674	PARTIAL		Ethosuximide has a narrow therapeutic profile. It is the drug of choice in the monotherapy or combination therapy of children with generalized absence (petit mal) epilepsy.	The reference supports the use of ethosuximide as a treatment for generalized absence epilepsy, which is related to Jeavons syndrome. However, it does not provide specific evidence for its use as an alternative or adjunctive therapy specifically for Jeavons syndrome.	"{""explanation"": ""The reference supports the use of ethosuximide as a treatment for generalized absence epilepsy, which is related to Jeavons syndrome. However, it does not provide specific evidence for its use as an alternative or adjunctive therapy specifically for Jeavons syndrome."", ""reference"": ""PMID:17627674"", ""snippet"": ""Ethosuximide has a narrow therapeutic profile. It is the drug of choice in the monotherapy or combination therapy of children with generalized absence (petit mal) epilepsy."", ""supports"": ""PARTIAL""}"
4174	4103	173	Jeavons Syndrome	Jeavons_Syndrome.yaml	treatments	2	evidence	0	PMID:24798222	SUPPORT		This case together with relevant literature data supports the view that the use of levetiracetam might be of benefit for female patients with Jeavons syndrome.	The literature mentions the use of levetiracetam resulting in clinical remission for a patient with Jeavons syndrome.	"{""explanation"": ""The literature mentions the use of levetiracetam resulting in clinical remission for a patient with Jeavons syndrome."", ""reference"": ""PMID:24798222"", ""snippet"": ""This case together with relevant literature data supports the view that the use of levetiracetam might be of benefit for female patients with Jeavons syndrome."", ""supports"": ""SUPPORT""}"
4175	4103	173	Jeavons Syndrome	Jeavons_Syndrome.yaml	treatments	2	evidence	1	PMID:20486734	SUPPORT		The efficacy of levetiracetam as an adjunctive therapy and as monotherapy for generalized and partial childhood epilepsies and for some types of specific epileptic syndromes of infancy and childhood (such as juvenile myoclonic epilepsy, benign rolandic epilepsy, and Jeavon syndrome) has been demonstrated.	The literature highlights that levetiracetam can be used as both adjunctive therapy and monotherapy for Jeavons Syndrome among other epileptic syndromes.	"{""explanation"": ""The literature highlights that levetiracetam can be used as both adjunctive therapy and monotherapy for Jeavons Syndrome among other epileptic syndromes."", ""reference"": ""PMID:20486734"", ""snippet"": ""The efficacy of levetiracetam as an adjunctive therapy and as monotherapy for generalized and partial childhood epilepsies and for some types of specific epileptic syndromes of infancy and childhood (such as juvenile myoclonic epilepsy, benign rolandic epilepsy, and Jeavon syndrome) has been demonstrated."", ""supports"": ""SUPPORT""}"
4176	4104	173	Jeavons Syndrome	Jeavons_Syndrome.yaml	treatments	3	evidence	0	PMID:14706045	PARTIAL		Visually provoked seizures, in particular, can be prevented or treated by avoiding or altering the triggering stimulus. Apart from individual preventive measures (use of specific television or video screens, colored glasses, etc.), prevention and warning on a larger scale are helpful.	The literature mentions that avoidance of visually provoking stimuli, like flickering lights, can help in managing photosensitive seizures, though it does not specifically mention Jeavons Syndrome.	"{""explanation"": ""The literature mentions that avoidance of visually provoking stimuli, like flickering lights, can help in managing photosensitive seizures, though it does not specifically mention Jeavons Syndrome."", ""reference"": ""PMID:14706045"", ""snippet"": ""Visually provoked seizures, in particular, can be prevented or treated by avoiding or altering the triggering stimulus. Apart from individual preventive measures (use of specific television or video screens, colored glasses, etc.), prevention and warning on a larger scale are helpful."", ""supports"": ""PARTIAL""}"
4177	4104	173	Jeavons Syndrome	Jeavons_Syndrome.yaml	treatments	3	evidence	1	PMID:22946728	PARTIAL		Recognized reflex seizure triggers are usually sensory and visual, such as television, discotheques, and video games.	This article suggests that visually evoked seizures can be triggered by stimuli like flickering lights, but it does not specifically address Jeavons Syndrome.	"{""explanation"": ""This article suggests that visually evoked seizures can be triggered by stimuli like flickering lights, but it does not specifically address Jeavons Syndrome."", ""reference"": ""PMID:22946728"", ""snippet"": ""Recognized reflex seizure triggers are usually sensory and visual, such as television, discotheques, and video games."", ""supports"": ""PARTIAL""}"
4178	4104	173	Jeavons Syndrome	Jeavons_Syndrome.yaml	treatments	3	evidence	2	PMID:32861158	SUPPORT		Spikes/spike-waves time-locked to the flash frequency during intermittent light stimulation in Jeavons syndrome.	This directly supports that photic stimulation, such as flickering lights, can trigger seizures in patients with Jeavons Syndrome.	"{""explanation"": ""This directly supports that photic stimulation, such as flickering lights, can trigger seizures in patients with Jeavons Syndrome."", ""reference"": ""PMID:32861158"", ""snippet"": ""Spikes/spike-waves time-locked to the flash frequency during intermittent light stimulation in Jeavons syndrome."", ""supports"": ""SUPPORT""}"
4179	4104	173	Jeavons Syndrome	Jeavons_Syndrome.yaml	treatments	3	evidence	3	PMID:29555355	SUPPORT		Self-induced seizures were predominantly eyelid myoclonia +/- absences... EEG demonstrated a normal background with 3-4 Hz spike waves +/- polyspike waves as well as a photoparoxysmal response.	This reference indicates that photic stimulation can induce seizures in patients with Jeavons Syndrome, thus supporting the need to avoid such stimuli.	"{""explanation"": ""This reference indicates that photic stimulation can induce seizures in patients with Jeavons Syndrome, thus supporting the need to avoid such stimuli."", ""reference"": ""PMID:29555355"", ""snippet"": ""Self-induced seizures were predominantly eyelid myoclonia +/- absences... EEG demonstrated a normal background with 3-4 Hz spike waves +/- polyspike waves as well as a photoparoxysmal response."", ""supports"": ""SUPPORT""}"
4180	4105	173	Jeavons Syndrome	Jeavons_Syndrome.yaml	treatments	4	evidence	0	PMID:32861158	NO_EVIDENCE		Spikes/spike-waves time-locked to the flash frequency during intermittent light stimulation in Jeavons syndrome	The focus is on the relationship between light stimulation and EEG patterns in Jeavons syndrome, with no mention of avoidance of triggers as a treatment method.	"{""explanation"": ""The focus is on the relationship between light stimulation and EEG patterns in Jeavons syndrome, with no mention of avoidance of triggers as a treatment method."", ""reference"": ""PMID:32861158"", ""snippet"": ""Spikes/spike-waves time-locked to the flash frequency during intermittent light stimulation in Jeavons syndrome"", ""supports"": ""NO_EVIDENCE""}"
4181	4106	173	Jeavons Syndrome	Jeavons_Syndrome.yaml	treatments	5	evidence	0	PMID:14706045	NO_EVIDENCE		Visually provoked seizures, in particular, can be prevented or treated by avoiding or altering the triggering stimulus. Apart from individual preventive measures (use of specific television or video screens, colored glasses, etc.), prevention and warning on a larger scale are helpful.	This reference mentions using colored glasses but does not specifically mention sunglasses or blue light filtering glasses for Jeavons syndrome.	"{""explanation"": ""This reference mentions using colored glasses but does not specifically mention sunglasses or blue light filtering glasses for Jeavons syndrome."", ""reference"": ""PMID:14706045"", ""snippet"": ""Visually provoked seizures, in particular, can be prevented or treated by avoiding or altering the triggering stimulus. Apart from individual preventive measures (use of specific television or video screens, colored glasses, etc.), prevention and warning on a larger scale are helpful."", ""supports"": ""NO_EVIDENCE""}"
4182	4106	173	Jeavons Syndrome	Jeavons_Syndrome.yaml	treatments	5	evidence	1	PMID:30082241	NO_EVIDENCE		We reviewed and described the epilepsy history, antiepileptic drug trials, and response to treatments.	This study focuses on drug treatments and does not mention sunglasses or blue light filtering glasses.	"{""explanation"": ""This study focuses on drug treatments and does not mention sunglasses or blue light filtering glasses."", ""reference"": ""PMID:30082241"", ""snippet"": ""We reviewed and described the epilepsy history, antiepileptic drug trials, and response to treatments."", ""supports"": ""NO_EVIDENCE""}"
4183	4106	173	Jeavons Syndrome	Jeavons_Syndrome.yaml	treatments	5	evidence	2	PMID:26552567	NO_EVIDENCE		Jeavons syndrome as an occipital cortex initiated generalized epilepsy.	The reference discusses the occipital cortex's role in Jeavons syndrome but does not mention sunglasses or blue light filtering glasses as a treatment.	"{""explanation"": ""The reference discusses the occipital cortex's role in Jeavons syndrome but does not mention sunglasses or blue light filtering glasses as a treatment."", ""reference"": ""PMID:26552567"", ""snippet"": ""Jeavons syndrome as an occipital cortex initiated generalized epilepsy."", ""supports"": ""NO_EVIDENCE""}"
4184	4106	173	Jeavons Syndrome	Jeavons_Syndrome.yaml	treatments	5	evidence	3	PMID:32861158	NO_EVIDENCE		Spikes/spike-waves time-locked to the flash frequency during intermittent light stimulation in Jeavons syndrome.	This reference discusses EEG characteristics in Jeavons syndrome without mentioning sunglasses or blue light filtering glasses as a treatment.	"{""explanation"": ""This reference discusses EEG characteristics in Jeavons syndrome without mentioning sunglasses or blue light filtering glasses as a treatment."", ""reference"": ""PMID:32861158"", ""snippet"": ""Spikes/spike-waves time-locked to the flash frequency during intermittent light stimulation in Jeavons syndrome."", ""supports"": ""NO_EVIDENCE""}"
4187	4121	174	KIT Mutant Melanoma	KIT_Mutant_Melanoma.yaml	treatments	0	evidence	0	PMID:23775962	SUPPORT		Best overall response rate (BORR) was 29% (21% excluding nonconfirmed responses) with a two-stage 95% CI of 13% to 51%.	Phase II trial reports response rates to imatinib in KIT-altered melanoma.	"{""explanation"": ""Phase II trial reports response rates to imatinib in KIT-altered melanoma."", ""reference"": ""PMID:23775962"", ""snippet"": ""Best overall response rate (BORR) was 29% (21% excluding nonconfirmed responses) with a two-stage 95% CI of 13% to 51%."", ""supports"": ""SUPPORT""}"
4190	4140	175	KRAS G12C-Mutant Non-Small Cell Lung Cancer	KRAS_G12C_Mutant_NSCLC.yaml	treatments	0	evidence	0	PMID:34096690	SUPPORT		An objective response was observed in 46 patients (37.1%	Phase 2 trial reports objective responses to sotorasib in KRAS G12C NSCLC.	"{""explanation"": ""Phase 2 trial reports objective responses to sotorasib in KRAS G12C NSCLC."", ""reference"": ""PMID:34096690"", ""snippet"": ""An objective response was observed in 46 patients (37.1%"", ""supports"": ""SUPPORT""}"
4191	4141	175	KRAS G12C-Mutant Non-Small Cell Lung Cancer	KRAS_G12C_Mutant_NSCLC.yaml	treatments	1	evidence	0	PMID:35658005	SUPPORT		Of 112 patients with measurable disease at baseline, 48 (42.9%) had a confirmed objective response.	KRYSTAL-1 abstract reports objective responses to adagrasib in KRAS G12C NSCLC.	"{""explanation"": ""KRYSTAL-1 abstract reports objective responses to adagrasib in KRAS G12C NSCLC."", ""reference"": ""PMID:35658005"", ""snippet"": ""Of 112 patients with measurable disease at baseline, 48 (42.9%) had a confirmed objective response."", ""supports"": ""SUPPORT""}"
4264	4214	177	Kawasaki Disease	Kawasaki_Disease.yaml	treatments	0	evidence	0	PMID:23283289	SUPPORT		Intravenous immunoglobulin (IVIG) and aspirin is the standard initial therapy in the treatment of Kawasaki disease.	The literature confirms that IVIG is part of the standard initial therapy for Kawasaki disease, aimed at reducing inflammation and preventing coronary artery complications.	"{""explanation"": ""The literature confirms that IVIG is part of the standard initial therapy for Kawasaki disease, aimed at reducing inflammation and preventing coronary artery complications."", ""reference"": ""PMID:23283289"", ""snippet"": ""Intravenous immunoglobulin (IVIG) and aspirin is the standard initial therapy in the treatment of Kawasaki disease."", ""supports"": ""SUPPORT""}"
4265	4214	177	Kawasaki Disease	Kawasaki_Disease.yaml	treatments	0	evidence	1	PMID:38135926	SUPPORT		For KD patients, male, children aged 3 to 9 years, and those with fever longer than 6 days before intravenous immunoglobulin (IVIG) use were more likely to have CAL.	The study discusses the use of IVIG and its timing in relation to the risk of coronary artery lesions, supporting its role in reducing such risks.	"{""explanation"": ""The study discusses the use of IVIG and its timing in relation to the risk of coronary artery lesions, supporting its role in reducing such risks."", ""reference"": ""PMID:38135926"", ""snippet"": ""For KD patients, male, children aged 3 to 9 years, and those with fever longer than 6 days before intravenous immunoglobulin (IVIG) use were more likely to have CAL."", ""supports"": ""SUPPORT""}"
4266	4214	177	Kawasaki Disease	Kawasaki_Disease.yaml	treatments	0	evidence	2	PMID:24034380	SUPPORT		The standard of care for treatment is intravenous immunoglobulin plus aspirin, but adding corticosteroids may provide additional benefit for high-risk patients.	The literature states that IVIG is the standard of care for treating Kawasaki disease to reduce coronary artery complications.	"{""explanation"": ""The literature states that IVIG is the standard of care for treating Kawasaki disease to reduce coronary artery complications."", ""reference"": ""PMID:24034380"", ""snippet"": ""The standard of care for treatment is intravenous immunoglobulin plus aspirin, but adding corticosteroids may provide additional benefit for high-risk patients."", ""supports"": ""SUPPORT""}"
4267	4214	177	Kawasaki Disease	Kawasaki_Disease.yaml	treatments	0	evidence	3	PMID:34535199	SUPPORT		Intravenous immunoglobulin (IVIG) has become an effective treatment regimen, which can effectively reduce the incidence of cardiovascular complications.	The literature confirms that IVIG is effective in reducing cardiovascular complications in Kawasaki disease.	"{""explanation"": ""The literature confirms that IVIG is effective in reducing cardiovascular complications in Kawasaki disease."", ""reference"": ""PMID:34535199"", ""snippet"": ""Intravenous immunoglobulin (IVIG) has become an effective treatment regimen, which can effectively reduce the incidence of cardiovascular complications."", ""supports"": ""SUPPORT""}"
4268	4214	177	Kawasaki Disease	Kawasaki_Disease.yaml	treatments	0	evidence	4	PMID:32888683	SUPPORT		Treatment of Kawasaki disease (KD) with intravenous immunoglobulin (IVIG) administered within the initial 10 days of fever onset decreases the risk of coronary artery aneurysms (CAAs) from  25% to less than 5%.	The literature provides evidence that IVIG significantly reduces the risk of coronary artery complications when administered early.	"{""explanation"": ""The literature provides evidence that IVIG significantly reduces the risk of coronary artery complications when administered early."", ""reference"": ""PMID:32888683"", ""snippet"": ""Treatment of Kawasaki disease (KD) with intravenous immunoglobulin (IVIG) administered within the initial 10 days of fever onset decreases the risk of coronary artery aneurysms (CAAs) from  25% to less than 5%."", ""supports"": ""SUPPORT""}"
4269	4215	177	Kawasaki Disease	Kawasaki_Disease.yaml	treatments	1	evidence	0	PMID:9513217	SUPPORT		Treatment includes the hospitalization of the child and subsequent administration of high doses of aspirin and intravenous immunoglobulin. With recovery, aspirin doses are reduced and the child may be monitored at home with outpatient follow-up.	This reference confirms that high doses of aspirin are used initially for Kawasaki disease, followed by lower doses after recovery.	"{""explanation"": ""This reference confirms that high doses of aspirin are used initially for Kawasaki disease, followed by lower doses after recovery."", ""reference"": ""PMID:9513217"", ""snippet"": ""Treatment includes the hospitalization of the child and subsequent administration of high doses of aspirin and intravenous immunoglobulin. With recovery, aspirin doses are reduced and the child may be monitored at home with outpatient follow-up."", ""supports"": ""SUPPORT""}"
4270	4215	177	Kawasaki Disease	Kawasaki_Disease.yaml	treatments	1	evidence	1	PMID:10935427	SUPPORT		Conventional therapy for KD includes intravenous gammaglobulin (2 g/kg as a single dose over 12 hours) and aspirin (acetylsalicylic acid; high dose until the fourteenth day of illness then low dose).	This reference also supports the statement that high doses of aspirin are used initially, followed by lower doses.	"{""explanation"": ""This reference also supports the statement that high doses of aspirin are used initially, followed by lower doses."", ""reference"": ""PMID:10935427"", ""snippet"": ""Conventional therapy for KD includes intravenous gammaglobulin (2 g/kg as a single dose over 12 hours) and aspirin (acetylsalicylic acid; high dose until the fourteenth day of illness then low dose)."", ""supports"": ""SUPPORT""}"
4271	4215	177	Kawasaki Disease	Kawasaki_Disease.yaml	treatments	1	evidence	2	PMID:32159800	PARTIAL		Low-dose aspirin plus IVIG might be as effective as high-dose aspirin plus IVIG for the initial treatment of Kawasaki disease. Considering that high-dose aspirin may cause more adverse reactions than low-dose aspirin, low-dose aspirin plus IVIG should be recommended as the first-line therapy in the initial treatment of Kawasaki disease.	This reference suggests that low-dose aspirin might be equally effective as high-dose aspirin and should be recommended to avoid adverse reactions, indicating a shift in treatment preference.	"{""explanation"": ""This reference suggests that low-dose aspirin might be equally effective as high-dose aspirin and should be recommended to avoid adverse reactions, indicating a shift in treatment preference."", ""reference"": ""PMID:32159800"", ""snippet"": ""Low-dose aspirin plus IVIG might be as effective as high-dose aspirin plus IVIG for the initial treatment of Kawasaki disease. Considering that high-dose aspirin may cause more adverse reactions than low-dose aspirin, low-dose aspirin plus IVIG should be recommended as the first-line therapy in the initial treatment of Kawasaki disease."", ""supports"": ""PARTIAL""}"
4272	4215	177	Kawasaki Disease	Kawasaki_Disease.yaml	treatments	1	evidence	3	PMID:28043685	PARTIAL		The use of medium- or higher-dose ASA in acute Kawasaki disease did not prevent CAA. A future randomized controlled trial is needed to determine the optimum dose of ASA.	This reference indicates that higher doses of aspirin did not prevent coronary artery aneurysms and suggests the need for further research to determine the optimal dose.	"{""explanation"": ""This reference indicates that higher doses of aspirin did not prevent coronary artery aneurysms and suggests the need for further research to determine the optimal dose."", ""reference"": ""PMID:28043685"", ""snippet"": ""The use of medium- or higher-dose ASA in acute Kawasaki disease did not prevent CAA. A future randomized controlled trial is needed to determine the optimum dose of ASA."", ""supports"": ""PARTIAL""}"
4273	4218	177	Kawasaki Disease	Kawasaki_Disease.yaml	treatments	4	evidence	0	PMID:31914832	SUPPORT		We suggest using methylprednisolone pulse therapy as an alternative rescue therapy for immunoglobulin-resistant KD, as well as identifying high-risk patients who need initial corticosteroid with IVIG treatment with an adequate route, dose, and duration.	The literature supports the use of corticosteroids in cases of Kawasaki Disease that are resistant to IVIG or in high-risk patients with severe inflammation.	"{""explanation"": ""The literature supports the use of corticosteroids in cases of Kawasaki Disease that are resistant to IVIG or in high-risk patients with severe inflammation."", ""reference"": ""PMID:31914832"", ""snippet"": ""We suggest using methylprednisolone pulse therapy as an alternative rescue therapy for immunoglobulin-resistant KD, as well as identifying high-risk patients who need initial corticosteroid with IVIG treatment with an adequate route, dose, and duration."", ""supports"": ""SUPPORT""}"
4274	4218	177	Kawasaki Disease	Kawasaki_Disease.yaml	treatments	4	evidence	1	PMID:29101553	SUPPORT		"""Resistant"" Kawasaki disease is defined by the American Heart Association as failure to respond within 36 h following the first dose of intravenous immunoglobulin. The optimal management of resistant Kawasaki disease remains uncertain, the outcomes are potentially serious, and the cost of some treatments is considerable."	This reference discusses the management of resistant Kawasaki Disease, which includes considering corticosteroid use.	"{""explanation"": ""This reference discusses the management of resistant Kawasaki Disease, which includes considering corticosteroid use."", ""reference"": ""PMID:29101553"", ""snippet"": ""\""Resistant\"" Kawasaki disease is defined by the American Heart Association as failure to respond within 36 h following the first dose of intravenous immunoglobulin. The optimal management of resistant Kawasaki disease remains uncertain, the outcomes are potentially serious, and the cost of some treatments is considerable."", ""supports"": ""SUPPORT""}"
4275	4218	177	Kawasaki Disease	Kawasaki_Disease.yaml	treatments	4	evidence	2	PMID:33541111	SUPPORT		To prevent CAA, more intensified or adjunctive therapies using other agents, such as pulsed methylprednisolone, ciclosporin, infliximab, and Anakinra, should be considered for patients with these risk factors.	This reference mentions the use of pulsed methylprednisolone (a corticosteroid) for patients with Kawasaki Disease who are at risk of developing coronary artery abnormalities, indicating severe inflammation.	"{""explanation"": ""This reference mentions the use of pulsed methylprednisolone (a corticosteroid) for patients with Kawasaki Disease who are at risk of developing coronary artery abnormalities, indicating severe inflammation."", ""reference"": ""PMID:33541111"", ""snippet"": ""To prevent CAA, more intensified or adjunctive therapies using other agents, such as pulsed methylprednisolone, ciclosporin, infliximab, and Anakinra, should be considered for patients with these risk factors."", ""supports"": ""SUPPORT""}"
4308	4238	178	Keratoderma Hereditarium Mutilans	Keratoderma_Hereditarium_Mutilans.yaml	treatments	2	evidence	0	PMID:6237617	SUPPORT		"One of the patients was successfully treated with isotretinoin, 0.6 mg/kg/day orally.
"	First report of successful isotretinoin treatment for the ichthyotic variant of Vohwinkel syndrome.	"{""explanation"": ""First report of successful isotretinoin treatment for the ichthyotic variant of Vohwinkel syndrome."", ""reference"": ""PMID:6237617"", ""snippet"": ""One of the patients was successfully treated with isotretinoin, 0.6 mg/kg/day orally.\n"", ""supports"": ""SUPPORT""}"
4353	4271	179	Klinefelter Syndrome	Klinefelter_Syndrome.yaml	treatments	0	evidence	0	PMID:35421871	SUPPORT		Patients presenting with symptoms should be tested for low testosterone and treated with testosterone replacement. ... Patients treated for hypogonadism may experience improvement of symptoms and quality of life.	This reference indicates that testosterone replacement therapy can improve symptoms associated with hypogonadism, such as low energy and reduced muscle mass.	"{""explanation"": ""This reference indicates that testosterone replacement therapy can improve symptoms associated with hypogonadism, such as low energy and reduced muscle mass."", ""reference"": ""PMID:35421871"", ""snippet"": ""Patients presenting with symptoms should be tested for low testosterone and treated with testosterone replacement. ... Patients treated for hypogonadism may experience improvement of symptoms and quality of life."", ""supports"": ""SUPPORT""}"
4354	4271	179	Klinefelter Syndrome	Klinefelter_Syndrome.yaml	treatments	0	evidence	1	PMID:26732150	SUPPORT		The mainstay of medical treatment is testosterone replacement therapy to both attenuate acute and long-term consequences of hypogonadism and possibly prevent the frequent comorbidity.	This abstract highlights testosterone replacement therapy as a primary treatment for hypogonadism in Klinefelter Syndrome, addressing its symptoms.	"{""explanation"": ""This abstract highlights testosterone replacement therapy as a primary treatment for hypogonadism in Klinefelter Syndrome, addressing its symptoms."", ""reference"": ""PMID:26732150"", ""snippet"": ""The mainstay of medical treatment is testosterone replacement therapy to both attenuate acute and long-term consequences of hypogonadism and possibly prevent the frequent comorbidity."", ""supports"": ""SUPPORT""}"
4355	4271	179	Klinefelter Syndrome	Klinefelter_Syndrome.yaml	treatments	0	evidence	2	PMID:24142635	SUPPORT		Testosterone replacement therapy may be effective in treating BMD deficiency in men with testosterone deficiency, especially those with Klinefelter syndrome.	The study indicates the efficacy of testosterone replacement therapy in treating symptoms related to testosterone deficiency in Klinefelter syndrome, which implies improvements in overall physical health including muscle mass.	"{""explanation"": ""The study indicates the efficacy of testosterone replacement therapy in treating symptoms related to testosterone deficiency in Klinefelter syndrome, which implies improvements in overall physical health including muscle mass."", ""reference"": ""PMID:24142635"", ""snippet"": ""Testosterone replacement therapy may be effective in treating BMD deficiency in men with testosterone deficiency, especially those with Klinefelter syndrome."", ""supports"": ""SUPPORT""}"
4356	4271	179	Klinefelter Syndrome	Klinefelter_Syndrome.yaml	treatments	0	evidence	3	PMID:38677872	PARTIAL		Patients unable to produce sex steroids using gonadotropins to mimic minipuberty in hypogonadotropic hypogonadism, or sex steroids in patients with Klinefelter or Turner syndrome, is promising.	This abstract discusses the potential of sex steroid treatments, including testosterone, but emphasizes the need for further research particularly in infants and early childhood.	"{""explanation"": ""This abstract discusses the potential of sex steroid treatments, including testosterone, but emphasizes the need for further research particularly in infants and early childhood."", ""reference"": ""PMID:38677872"", ""snippet"": ""Patients unable to produce sex steroids using gonadotropins to mimic minipuberty in hypogonadotropic hypogonadism, or sex steroids in patients with Klinefelter or Turner syndrome, is promising."", ""supports"": ""PARTIAL""}"
4357	4271	179	Klinefelter Syndrome	Klinefelter_Syndrome.yaml	treatments	0	evidence	4	PMID:37962976	SUPPORT		TRT in patients with KS has the potential for alleviating the prothrombotic phenotype, in particular by reducing body fat and fibrinogen.	Testosterone replacement therapy has positive effects on symptoms related to body composition, which can be correlated to improvements in muscle mass and energy levels.	"{""explanation"": ""Testosterone replacement therapy has positive effects on symptoms related to body composition, which can be correlated to improvements in muscle mass and energy levels."", ""reference"": ""PMID:37962976"", ""snippet"": ""TRT in patients with KS has the potential for alleviating the prothrombotic phenotype, in particular by reducing body fat and fibrinogen."", ""supports"": ""SUPPORT""}"
4358	4272	179	Klinefelter Syndrome	Klinefelter_Syndrome.yaml	treatments	1	evidence	0	PMID:25899809	SUPPORT		Boys with Klinefelter syndrome are often in the need of speech therapy and many suffer from learning disability and may benefit from special education.	This article directly indicates the need for speech therapy and special education for boys with Klinefelter syndrome.	"{""explanation"": ""This article directly indicates the need for speech therapy and special education for boys with Klinefelter syndrome."", ""reference"": ""PMID:25899809"", ""snippet"": ""Boys with Klinefelter syndrome are often in the need of speech therapy and many suffer from learning disability and may benefit from special education."", ""supports"": ""SUPPORT""}"
4359	4272	179	Klinefelter Syndrome	Klinefelter_Syndrome.yaml	treatments	1	evidence	1	PMID:35948402	SUPPORT		Around two-thirds require speech and language therapy or developmental support and early institution of therapy is important.	This article supports the statement by mentioning the necessity of speech and language therapy or developmental support.	"{""explanation"": ""This article supports the statement by mentioning the necessity of speech and language therapy or developmental support."", ""reference"": ""PMID:35948402"", ""snippet"": ""Around two-thirds require speech and language therapy or developmental support and early institution of therapy is important."", ""supports"": ""SUPPORT""}"
4360	4273	179	Klinefelter Syndrome	Klinefelter_Syndrome.yaml	treatments	2	evidence	0	PMID:35667865	SUPPORT		Assisted reproductive technology is essential for infertility treatment in patients with Klinefelter syndrome.	This reference explicitly states the role of assisted reproductive technology in treating infertility in patients with Klinefelter syndrome.	"{""explanation"": ""This reference explicitly states the role of assisted reproductive technology in treating infertility in patients with Klinefelter syndrome."", ""reference"": ""PMID:35667865"", ""snippet"": ""Assisted reproductive technology is essential for infertility treatment in patients with Klinefelter syndrome."", ""supports"": ""SUPPORT""}"
4361	4273	179	Klinefelter Syndrome	Klinefelter_Syndrome.yaml	treatments	2	evidence	1	PMID:19490778	SUPPORT		In conclusion, patients with non-mosaic Klinefelter syndrome have sperm recovery and pregnancy rates comparable with patients having non-obstructive azoospermia and normal karyotype.	This study indicates that patients with Klinefelter syndrome can achieve successful sperm recovery and pregnancy rates using TESE-ICSI, a type of assisted reproductive technology.	"{""explanation"": ""This study indicates that patients with Klinefelter syndrome can achieve successful sperm recovery and pregnancy rates using TESE-ICSI, a type of assisted reproductive technology."", ""reference"": ""PMID:19490778"", ""snippet"": ""In conclusion, patients with non-mosaic Klinefelter syndrome have sperm recovery and pregnancy rates comparable with patients having non-obstructive azoospermia and normal karyotype."", ""supports"": ""SUPPORT""}"
4362	4273	179	Klinefelter Syndrome	Klinefelter_Syndrome.yaml	treatments	2	evidence	2	PMID:21835671	SUPPORT		In this review, we will discuss the fertility issue following TEsticular Sperm Extraction-IntraCytoplasmic Sperm Injection (TESE-ICSI) and the potential advantage of searching for and cryopreserving spermatozoa in adolescent instead of adult patients.	This reference discusses the advantages of using TESE-ICSI (a form of assisted reproductive technology) to address fertility issues in patients with Klinefelter syndrome.	"{""explanation"": ""This reference discusses the advantages of using TESE-ICSI (a form of assisted reproductive technology) to address fertility issues in patients with Klinefelter syndrome."", ""reference"": ""PMID:21835671"", ""snippet"": ""In this review, we will discuss the fertility issue following TEsticular Sperm Extraction-IntraCytoplasmic Sperm Injection (TESE-ICSI) and the potential advantage of searching for and cryopreserving spermatozoa in adolescent instead of adult patients."", ""supports"": ""SUPPORT""}"
4363	4273	179	Klinefelter Syndrome	Klinefelter_Syndrome.yaml	treatments	2	evidence	3	PMID:31587581	SUPPORT		Once considered untreatable, men with KS and NOA now have a variety of treatment options to obtain paternity.	This reference highlights that men with Klinefelter syndrome now have several treatment options, including assisted reproductive technologies, to achieve paternity.	"{""explanation"": ""This reference highlights that men with Klinefelter syndrome now have several treatment options, including assisted reproductive technologies, to achieve paternity."", ""reference"": ""PMID:31587581"", ""snippet"": ""Once considered untreatable, men with KS and NOA now have a variety of treatment options to obtain paternity."", ""supports"": ""SUPPORT""}"
4364	4273	179	Klinefelter Syndrome	Klinefelter_Syndrome.yaml	treatments	2	evidence	4	PMID:32562095	SUPPORT		Mounting evidence from recent studies has shown that various technological advances and approaches could facilitate the success of ART treatment for KS patients.	This review summarizes methods that enhance the success of assisted reproductive technology (ART) for patients with Klinefelter syndrome.	"{""explanation"": ""This review summarizes methods that enhance the success of assisted reproductive technology (ART) for patients with Klinefelter syndrome."", ""reference"": ""PMID:32562095"", ""snippet"": ""Mounting evidence from recent studies has shown that various technological advances and approaches could facilitate the success of ART treatment for KS patients."", ""supports"": ""SUPPORT""}"
4401	4314	181	Lane Hamilton Syndrome	Lane_Hamilton_Syndrome.yaml	treatments	0	evidence	0	PMID:35475077	SUPPORT		A gluten-free diet alone was effective in the majority of patients	Systematic review demonstrates gluten-free diet as effective primary therapy	"{""explanation"": ""Systematic review demonstrates gluten-free diet as effective primary therapy"", ""reference"": ""PMID:35475077"", ""snippet"": ""A gluten-free diet alone was effective in the majority of patients"", ""supports"": ""SUPPORT""}"
4402	4314	181	Lane Hamilton Syndrome	Lane_Hamilton_Syndrome.yaml	treatments	0	evidence	1	DOI:10.5505/respircase.2024.73604	SUPPORT			Case report documents clinical remission with gluten-free diet and relapse with noncompliance	"{""explanation"": ""Case report documents clinical remission with gluten-free diet and relapse with noncompliance"", ""reference"": ""DOI:10.5505/respircase.2024.73604"", ""supports"": ""SUPPORT""}"
4403	4315	181	Lane Hamilton Syndrome	Lane_Hamilton_Syndrome.yaml	treatments	1	evidence	0	PMID:36751263	SUPPORT		A gluten-free diet and steroids were given to the patient with a very good clinical response	Case report demonstrates corticosteroids are needed when gluten-free diet alone is insufficient	"{""explanation"": ""Case report demonstrates corticosteroids are needed when gluten-free diet alone is insufficient"", ""reference"": ""PMID:36751263"", ""snippet"": ""A gluten-free diet and steroids were given to the patient with a very good clinical response"", ""supports"": ""SUPPORT""}"
4404	4315	181	Lane Hamilton Syndrome	Lane_Hamilton_Syndrome.yaml	treatments	1	evidence	1	PMID:35475077	SUPPORT		Fewer patients in the LHS cohort received systemic corticosteroid than the IPH cohort	Systematic review compares corticosteroid usage between LHS and IPH patients	"{""explanation"": ""Systematic review compares corticosteroid usage between LHS and IPH patients"", ""reference"": ""PMID:35475077"", ""snippet"": ""Fewer patients in the LHS cohort received systemic corticosteroid than the IPH cohort"", ""supports"": ""SUPPORT""}"
4405	4316	181	Lane Hamilton Syndrome	Lane_Hamilton_Syndrome.yaml	treatments	2	evidence	0	PMID:35475077	SUPPORT		The coexistence of IPH and celiac disease (CD), also known as Lane-Hamilton syndrome (LHS), has been reported in both pediatric and adult patients	Systematic review identifies steroid-sparing agents as alternative immunosuppressive options	"{""explanation"": ""Systematic review identifies steroid-sparing agents as alternative immunosuppressive options"", ""reference"": ""PMID:35475077"", ""snippet"": ""The coexistence of IPH and celiac disease (CD), also known as Lane-Hamilton syndrome (LHS), has been reported in both pediatric and adult patients"", ""supports"": ""SUPPORT""}"
4452	4356	182	Laryngotracheoesophageal Cleft	Laryngotracheoesophageal_Cleft.yaml	treatments	0	evidence	0	PMID:40330935	SUPPORT	HUMAN_CLINICAL	endoscopic laser repair remains the gold standard treatment for type 1 LC.	Case series identifies endoscopic laser repair as the standard treatment for type 1 laryngeal cleft.	"{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""Case series identifies endoscopic laser repair as the standard treatment for type 1 laryngeal cleft."", ""reference"": ""PMID:40330935"", ""snippet"": ""endoscopic laser repair remains the gold standard treatment for type 1 LC."", ""supports"": ""SUPPORT""}"
4453	4357	182	Laryngotracheoesophageal Cleft	Laryngotracheoesophageal_Cleft.yaml	treatments	1	evidence	0	PMID:40579891	SUPPORT	HUMAN_CLINICAL	Nineteen patients with Type III laryngeal clefts who were treated with endoscopic carbon dioxide laser-assisted repair were included.	Case series reports staged endoscopic CO2 laser repair for type 3 clefts.	"{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""Case series reports staged endoscopic CO2 laser repair for type 3 clefts."", ""reference"": ""PMID:40579891"", ""snippet"": ""Nineteen patients with Type III laryngeal clefts who were treated with endoscopic carbon dioxide laser-assisted repair were included."", ""supports"": ""SUPPORT""}"
4454	4358	182	Laryngotracheoesophageal Cleft	Laryngotracheoesophageal_Cleft.yaml	treatments	2	evidence	0	PMID:39260330	SUPPORT	HUMAN_CLINICAL	LC can be treated surgically by performing suture repair or by Injection Laryngoplasty (IL).	Survey study identifies injection laryngoplasty as a treatment option for laryngeal cleft.	"{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""Survey study identifies injection laryngoplasty as a treatment option for laryngeal cleft."", ""reference"": ""PMID:39260330"", ""snippet"": ""LC can be treated surgically by performing suture repair or by Injection Laryngoplasty (IL)."", ""supports"": ""SUPPORT""}"
4455	4358	182	Laryngotracheoesophageal Cleft	Laryngotracheoesophageal_Cleft.yaml	treatments	2	evidence	1	PMID:40330935	SUPPORT	HUMAN_CLINICAL	we initially managed patients with type 1 LC with hyaluronic acid injections for a few months	Case series documents injection laryngoplasty used in initial management.	"{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""Case series documents injection laryngoplasty used in initial management."", ""reference"": ""PMID:40330935"", ""snippet"": ""we initially managed patients with type 1 LC with hyaluronic acid injections for a few months"", ""supports"": ""SUPPORT""}"
4456	4358	182	Laryngotracheoesophageal Cleft	Laryngotracheoesophageal_Cleft.yaml	treatments	2	evidence	2	PMID:35236684	SUPPORT	HUMAN_CLINICAL	injection laryngoplasty is performed safely on an 8-week-old child	Case report supports injection laryngoplasty as a feasible intervention in infants.	"{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""Case report supports injection laryngoplasty as a feasible intervention in infants."", ""reference"": ""PMID:35236684"", ""snippet"": ""injection laryngoplasty is performed safely on an 8-week-old child"", ""supports"": ""SUPPORT""}"
4457	4359	182	Laryngotracheoesophageal Cleft	Laryngotracheoesophageal_Cleft.yaml	treatments	3	evidence	0	PMID:40629707	SUPPORT	HUMAN_CLINICAL	All showed marked improvement after surgical repair.	Familial case report shows symptom improvement after surgical repair.	"{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""Familial case report shows symptom improvement after surgical repair."", ""reference"": ""PMID:40629707"", ""snippet"": ""All showed marked improvement after surgical repair."", ""supports"": ""SUPPORT""}"
4458	4359	182	Laryngotracheoesophageal Cleft	Laryngotracheoesophageal_Cleft.yaml	treatments	3	evidence	1	PMID:6873110	SUPPORT	HUMAN_CLINICAL	an early operative correction of the defect is required.	Review emphasizes early operative correction for laryngotracheoesophageal cleft.	"{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""Review emphasizes early operative correction for laryngotracheoesophageal cleft."", ""reference"": ""PMID:6873110"", ""snippet"": ""an early operative correction of the defect is required."", ""supports"": ""SUPPORT""}"
4459	4359	182	Laryngotracheoesophageal Cleft	Laryngotracheoesophageal_Cleft.yaml	treatments	3	evidence	2	PMID:30783751	SUPPORT	HUMAN_CLINICAL	repair of the cleft was performed by an anterior approach via median sternotomy	Type IV case report documents surgical repair of LTEC with an anterior approach under ECMO.	"{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""Type IV case report documents surgical repair of LTEC with an anterior approach under ECMO."", ""reference"": ""PMID:30783751"", ""snippet"": ""repair of the cleft was performed by an anterior approach via median sternotomy"", ""supports"": ""SUPPORT""}"
4460	4359	182	Laryngotracheoesophageal Cleft	Laryngotracheoesophageal_Cleft.yaml	treatments	3	evidence	3	PMID:35039336	SUPPORT	HUMAN_CLINICAL	Simultaneous anterior cervical repair of type IV laryngeal cleft and tracheo-oesophageal fistula.	Case report demonstrates surgical repair for type IV laryngeal cleft with TEF.	"{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""Case report demonstrates surgical repair for type IV laryngeal cleft with TEF."", ""reference"": ""PMID:35039336"", ""snippet"": ""Simultaneous anterior cervical repair of type IV laryngeal cleft and tracheo-oesophageal fistula."", ""supports"": ""SUPPORT""}"
4461	4359	182	Laryngotracheoesophageal Cleft	Laryngotracheoesophageal_Cleft.yaml	treatments	3	evidence	4	PMID:32593610	SUPPORT	HUMAN_CLINICAL	successfully treated with an endoscopic approach using absorbable suture	Adult case report supports endoscopic surgical repair.	"{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""Adult case report supports endoscopic surgical repair."", ""reference"": ""PMID:32593610"", ""snippet"": ""successfully treated with an endoscopic approach using absorbable suture"", ""supports"": ""SUPPORT""}"
4462	4359	182	Laryngotracheoesophageal Cleft	Laryngotracheoesophageal_Cleft.yaml	treatments	3	evidence	5	PMID:37073597	SUPPORT	HUMAN_CLINICAL	Surgical management in the form of endoscopic Coblation-assisted or an open approach is indicated	Tertiary center series supports endoscopic or open surgical management for laryngeal cleft.	"{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""Tertiary center series supports endoscopic or open surgical management for laryngeal cleft."", ""reference"": ""PMID:37073597"", ""snippet"": ""Surgical management in the form of endoscopic Coblation-assisted or an open approach is indicated"", ""supports"": ""SUPPORT""}"
4463	4360	182	Laryngotracheoesophageal Cleft	Laryngotracheoesophageal_Cleft.yaml	treatments	4	evidence	0	PMID:38761217	SUPPORT	HUMAN_CLINICAL	an anterior approach that involved interposition a posterior cartilage for Type III or Type IV laryngotracheoesophageal cleft (LTEC).	Surgical series supports anterior laryngofissure repair with posterior cartilage grafting for type III/IV LTEC.	"{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""Surgical series supports anterior laryngofissure repair with posterior cartilage grafting for type III/IV LTEC."", ""reference"": ""PMID:38761217"", ""snippet"": ""an anterior approach that involved interposition a posterior cartilage for Type III or Type IV laryngotracheoesophageal cleft (LTEC)."", ""supports"": ""SUPPORT""}"
4464	4361	182	Laryngotracheoesophageal Cleft	Laryngotracheoesophageal_Cleft.yaml	treatments	5	evidence	0	PMID:37816841	SUPPORT	HUMAN_CLINICAL	Primary and revision repair of long clefts with tracheal extension may require a combined approach.	Series reports use of combined open and endoscopic approaches for long clefts.	"{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""Series reports use of combined open and endoscopic approaches for long clefts."", ""reference"": ""PMID:37816841"", ""snippet"": ""Primary and revision repair of long clefts with tracheal extension may require a combined approach."", ""supports"": ""SUPPORT""}"
4472	4369	183	Leishmaniasis	Leishmaniasis.yaml	treatments	0	evidence	0	PMID:30712769	SUPPORT		Liposomal amphotericin B is generally found to be safe and effective in most endemic regions of the world	The review describes liposomal amphotericin B as safe and effective.	"{""explanation"": ""The review describes liposomal amphotericin B as safe and effective."", ""reference"": ""PMID:30712769"", ""snippet"": ""Liposomal amphotericin B is generally found to be safe and effective in most endemic regions of the world"", ""supports"": ""SUPPORT""}"
4479	4376	184	Leprosy	Leprosy.yaml	treatments	0	evidence	0	PMID:28763601	SUPPORT		While paucibacillary forms are treated with rifampicin and dapsone for at least six months, multibacillary leprosy is treated for at least twelve months, additionally requiring clofazimine.	The abstract describes multidrug therapy regimens.	"{""explanation"": ""The abstract describes multidrug therapy regimens."", ""reference"": ""PMID:28763601"", ""snippet"": ""While paucibacillary forms are treated with rifampicin and dapsone for at least six months, multibacillary leprosy is treated for at least twelve months, additionally requiring clofazimine."", ""supports"": ""SUPPORT""}"
4484	4394	185	Li-Fraumeni Syndrome	Li-Fraumeni_Syndrome.yaml	treatments	0	evidence	0	PMID:28572266	SUPPORT		"the panel recommends adoption of a modified version of the ""Toronto protocol"" that includes a combination of physical exams, blood tests, and imaging. The panel also recommends that further research be promoted to explore the feasibility and effectiveness of these risk-adapted surveillance and cancer prevention strategies."	AACR expert panel consensus recommends the Toronto Protocol surveillance approach for all LFS patients as soon as diagnosis is established.	"{""explanation"": ""AACR expert panel consensus recommends the Toronto Protocol surveillance approach for all LFS patients as soon as diagnosis is established."", ""reference"": ""PMID:28572266"", ""snippet"": ""the panel recommends adoption of a modified version of the \""Toronto protocol\"" that includes a combination of physical exams, blood tests, and imaging. The panel also recommends that further research be promoted to explore the feasibility and effectiveness of these risk-adapted surveillance and cancer prevention strategies."", ""supports"": ""SUPPORT""}"
4551	4477	188	Long COVID	Long_COVID.yaml	treatments	0	evidence	0	PMID:38658496	SUPPORT		clinical experience has shown that the presence of post-exertional malaise (PEM) is a significant barrier to physical exercise training in people with long COVID.	Documents the importance of addressing PEM through pacing strategies before exercise in Long COVID.	"{""explanation"": ""Documents the importance of addressing PEM through pacing strategies before exercise in Long COVID."", ""reference"": ""PMID:38658496"", ""snippet"": ""clinical experience has shown that the presence of post-exertional malaise (PEM) is a significant barrier to physical exercise training in people with long COVID."", ""supports"": ""SUPPORT""}"
4552	4477	188	Long COVID	Long_COVID.yaml	treatments	0	evidence	1	PMID:37342500	SUPPORT		The illness (Long COVID) is similar to myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS)	Supports applying ME/CFS management approaches including pacing to Long COVID.	"{""explanation"": ""Supports applying ME/CFS management approaches including pacing to Long COVID."", ""reference"": ""PMID:37342500"", ""snippet"": ""The illness (Long COVID) is similar to myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS)"", ""supports"": ""SUPPORT""}"
4553	4478	188	Long COVID	Long_COVID.yaml	treatments	1	evidence	0	PMID:37529714	SUPPORT		Our data confirm that histamine receptors blockade may be an effective target to successfully treat long-COVID.	Demonstrates effectiveness of antihistamine pharmacotherapy for Long COVID symptoms.	"{""explanation"": ""Demonstrates effectiveness of antihistamine pharmacotherapy for Long COVID symptoms."", ""reference"": ""PMID:37529714"", ""snippet"": ""Our data confirm that histamine receptors blockade may be an effective target to successfully treat long-COVID."", ""supports"": ""SUPPORT""}"
4554	4479	188	Long COVID	Long_COVID.yaml	treatments	2	evidence	0	PMID:38658496	SUPPORT		impaired exercise performance is a condition that can be recovered in many people through an individualized physical exercise training program.	Documents effectiveness of individualized physical rehabilitation for Long COVID exercise impairment.	"{""explanation"": ""Documents effectiveness of individualized physical rehabilitation for Long COVID exercise impairment."", ""reference"": ""PMID:38658496"", ""snippet"": ""impaired exercise performance is a condition that can be recovered in many people through an individualized physical exercise training program."", ""supports"": ""SUPPORT""}"
4555	4479	188	Long COVID	Long_COVID.yaml	treatments	2	evidence	1	PMID:38658496	SUPPORT		These recommendations may guide allied healthcare professionals worldwide in initiating and adjusting exercise training programs for people with long COVID, stratified according to the presence and severity of PEM.	Provides framework for rehabilitation stratified by PEM severity in Long COVID.	"{""explanation"": ""Provides framework for rehabilitation stratified by PEM severity in Long COVID."", ""reference"": ""PMID:38658496"", ""snippet"": ""These recommendations may guide allied healthcare professionals worldwide in initiating and adjusting exercise training programs for people with long COVID, stratified according to the presence and severity of PEM."", ""supports"": ""SUPPORT""}"
4556	4479	188	Long COVID	Long_COVID.yaml	treatments	2	evidence	2	PMID:37061399	SUPPORT		Rehabilitation is a key element of management to achieve functional improvement... Exercise-based therapy, an essential part of management of long COVID, can be conducted with different modules, including telerehabilitation.	Reviews rehabilitation principles and highlights exercise-based therapy as central to Long COVID management.	"{""explanation"": ""Reviews rehabilitation principles and highlights exercise-based therapy as central to Long COVID management."", ""reference"": ""PMID:37061399"", ""snippet"": ""Rehabilitation is a key element of management to achieve functional improvement... Exercise-based therapy, an essential part of management of long COVID, can be conducted with different modules, including telerehabilitation."", ""supports"": ""SUPPORT""}"
4557	4480	188	Long COVID	Long_COVID.yaml	treatments	3	evidence	0	PMID:37529714	SUPPORT		Patients were treated with fexofenadine (180 mg/day) and famotidine (40 mg/day). Fatigue, brain fog, abdominal disorders, and increased heart rate were evaluated in treated and untreated patients at baseline and 20 days later.	Details the antihistamine treatment protocol used in Long COVID.	"{""explanation"": ""Details the antihistamine treatment protocol used in Long COVID."", ""reference"": ""PMID:37529714"", ""snippet"": ""Patients were treated with fexofenadine (180 mg/day) and famotidine (40 mg/day). Fatigue, brain fog, abdominal disorders, and increased heart rate were evaluated in treated and untreated patients at baseline and 20 days later."", ""supports"": ""SUPPORT""}"
4558	4480	188	Long COVID	Long_COVID.yaml	treatments	3	evidence	1	PMID:37529714	SUPPORT		Long-COVID symptoms disappeared completely in 29% of treated patients. There was a significant improvement in each of the considered symptoms	Documents significant improvement with antihistamine treatment.	"{""explanation"": ""Documents significant improvement with antihistamine treatment."", ""reference"": ""PMID:37529714"", ""snippet"": ""Long-COVID symptoms disappeared completely in 29% of treated patients. There was a significant improvement in each of the considered symptoms"", ""supports"": ""SUPPORT""}"
4586	4505	189	Ludwig's Angina	Ludwigs_Angina.yaml	treatments	0	evidence	0	PMID:38106765	SUPPORT		An elective tracheostomy is recommended for the patient to maintain an open airway	Recommends tracheostomy to secure airway in Ludwig's angina.	"{""explanation"": ""Recommends tracheostomy to secure airway in Ludwig's angina."", ""reference"": ""PMID:38106765"", ""snippet"": ""An elective tracheostomy is recommended for the patient to maintain an open airway"", ""supports"": ""SUPPORT""}"
4587	4506	189	Ludwig's Angina	Ludwigs_Angina.yaml	treatments	1	evidence	0	PMID:33383265	SUPPORT		Broad spectrum antibiotics and surgical source control are keys in treating the infection.	Identifies broad-spectrum antibiotics as core therapy.	"{""explanation"": ""Identifies broad-spectrum antibiotics as core therapy."", ""reference"": ""PMID:33383265"", ""snippet"": ""Broad spectrum antibiotics and surgical source control are keys in treating the infection."", ""supports"": ""SUPPORT""}"
4588	4506	189	Ludwig's Angina	Ludwigs_Angina.yaml	treatments	1	evidence	1	PMID:36738888	SUPPORT		Ninety-two percent (n=57/62) of the streptococci cultured were sensitive to penicillin. The addition of aminoglycosides to the study sample would not have made a statistically significant difference (p=0.1556).	Culture series shows penicillin-sensitive streptococci predominate and empiric aminoglycosides add little benefit.	"{""explanation"": ""Culture series shows penicillin-sensitive streptococci predominate and empiric aminoglycosides add little benefit."", ""reference"": ""PMID:36738888"", ""snippet"": ""Ninety-two percent (n=57/62) of the streptococci cultured were sensitive to penicillin. The addition of aminoglycosides to the study sample would not have made a statistically significant difference (p=0.1556)."", ""supports"": ""SUPPORT""}"
4589	4507	189	Ludwig's Angina	Ludwigs_Angina.yaml	treatments	2	evidence	0	PMID:39296495	SUPPORT		immediate surgical decompression leading to pus drainage, removal of the offending tooth... and administration of empirical antibiotics	Shows surgical drainage with tooth extraction as effective source control.	"{""explanation"": ""Shows surgical drainage with tooth extraction as effective source control."", ""reference"": ""PMID:39296495"", ""snippet"": ""immediate surgical decompression leading to pus drainage, removal of the offending tooth... and administration of empirical antibiotics"", ""supports"": ""SUPPORT""}"
4599	4518	190	Lung Carcinoma	Lung_Carcinoma.yaml	treatments	0	evidence	0	PMID:19445746	SUPPORT		Small cell lung cancer accounts for 20% of all cases, and is usually treated with chemotherapy.	The abstract states that small cell lung cancer is usually treated with chemotherapy.	"{""explanation"": ""The abstract states that small cell lung cancer is usually treated with chemotherapy."", ""reference"": ""PMID:19445746"", ""snippet"": ""Small cell lung cancer accounts for 20% of all cases, and is usually treated with chemotherapy."", ""supports"": ""SUPPORT""}"
4600	4519	190	Lung Carcinoma	Lung_Carcinoma.yaml	treatments	1	evidence	0	PMID:19445746	SUPPORT		Adenocarcinoma is the main non-small cell pathology, and is treated initially with surgery.	The abstract notes surgery as initial treatment for adenocarcinoma.	"{""explanation"": ""The abstract notes surgery as initial treatment for adenocarcinoma."", ""reference"": ""PMID:19445746"", ""snippet"": ""Adenocarcinoma is the main non-small cell pathology, and is treated initially with surgery."", ""supports"": ""SUPPORT""}"
4625	4555	191	Lyme Disease	Lyme_Disease.yaml	treatments	0	evidence	0	PMID:17029130	SUPPORT		Tables list the doses and durations of antimicrobial therapy recommended for treatment and prevention of Lyme disease	IDSA guidelines provide evidence-based antibiotic treatment recommendations for Lyme disease.	"{""explanation"": ""IDSA guidelines provide evidence-based antibiotic treatment recommendations for Lyme disease."", ""reference"": ""PMID:17029130"", ""snippet"": ""Tables list the doses and durations of antimicrobial therapy recommended for treatment and prevention of Lyme disease"", ""supports"": ""SUPPORT""}"
4626	4556	191	Lyme Disease	Lyme_Disease.yaml	treatments	1	evidence	0	PMID:17176487	SUPPORT		We describe a favorable outcome in a 42-year-old woman who developed Lyme disease in the third trimester and was treated with a full course of oral amoxicillin.	Case report in pregnancy shows successful treatment with amoxicillin.	"{""explanation"": ""Case report in pregnancy shows successful treatment with amoxicillin."", ""reference"": ""PMID:17176487"", ""snippet"": ""We describe a favorable outcome in a 42-year-old woman who developed Lyme disease in the third trimester and was treated with a full course of oral amoxicillin."", ""supports"": ""SUPPORT""}"
4627	4557	191	Lyme Disease	Lyme_Disease.yaml	treatments	2	evidence	0	PMID:37692616	SUPPORT		The patient's symptoms resolved quickly with a four-day inpatient course of IV ceftriaxone followed by 10 days of oral doxycycline.	Neuroborreliosis case improved with intravenous ceftriaxone then doxycycline.	"{""explanation"": ""Neuroborreliosis case improved with intravenous ceftriaxone then doxycycline."", ""reference"": ""PMID:37692616"", ""snippet"": ""The patient's symptoms resolved quickly with a four-day inpatient course of IV ceftriaxone followed by 10 days of oral doxycycline."", ""supports"": ""SUPPORT""}"
4637	4567	192	Lymphatic filariasis	Lymphatic_Filariasis.yaml	treatments	0	evidence	0	PMID:38933431	SUPPORT		the World Health Organization recommended treatments for lymphatic filariasis include the use of Albendazole (400mg) twice per year in co-endemic areas with loa loa, Ivermectin (200mcg/kg) in combination with Albendazole (400mg) in areas that are co-endemic with onchocerciasis, ivermectin (200mcg/kg) with diethylcarbamazine citrate (DEC) (6mg/kg) and albendazole (400mg) in areas without onchocerciasis.	The abstract summarizes WHO-recommended antifilarial combinations for MDA.	"{""explanation"": ""The abstract summarizes WHO-recommended antifilarial combinations for MDA."", ""reference"": ""PMID:38933431"", ""snippet"": ""the World Health Organization recommended treatments for lymphatic filariasis include the use of Albendazole (400mg) twice per year in co-endemic areas with loa loa, Ivermectin (200mcg/kg) in combination with Albendazole (400mg) in areas that are co-endemic with onchocerciasis, ivermectin (200mcg/kg) with diethylcarbamazine citrate (DEC) (6mg/kg) and albendazole (400mg) in areas without onchocerciasis."", ""supports"": ""SUPPORT""}"
4646	4577	193	Lymphoma	Lymphoma.yaml	treatments	0	evidence	0	PMID:31894937	SUPPORT		Chemotherapy treatment plans differ between the main subtypes of lymphoma. Non-Hodgkin lymphoma is treated with CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) with or without rituximab (R-CHOP), bendamustine, and lenalidomide.	The abstract notes chemotherapy regimens as treatment for lymphoma subtypes.	"{""explanation"": ""The abstract notes chemotherapy regimens as treatment for lymphoma subtypes."", ""reference"": ""PMID:31894937"", ""snippet"": ""Chemotherapy treatment plans differ between the main subtypes of lymphoma. Non-Hodgkin lymphoma is treated with CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) with or without rituximab (R-CHOP), bendamustine, and lenalidomide."", ""supports"": ""SUPPORT""}"
4647	4578	193	Lymphoma	Lymphoma.yaml	treatments	1	evidence	0	PMID:31894937	SUPPORT		Hodgkin lymphoma is treated with combined chemotherapy with ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine), Stanford V (a chemotherapy regimen consisting of mechlorethamine, doxorubicin, vinblastine, vincristine, bleomycin, etoposide, and prednisone), or BEACOPP (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone) with radiotherapy.	The abstract states Hodgkin lymphoma treatment includes radiotherapy with chemotherapy.	"{""explanation"": ""The abstract states Hodgkin lymphoma treatment includes radiotherapy with chemotherapy."", ""reference"": ""PMID:31894937"", ""snippet"": ""Hodgkin lymphoma is treated with combined chemotherapy with ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine), Stanford V (a chemotherapy regimen consisting of mechlorethamine, doxorubicin, vinblastine, vincristine, bleomycin, etoposide, and prednisone), or BEACOPP (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone) with radiotherapy."", ""supports"": ""SUPPORT""}"
4738	4609	194	Lynch Syndrome	Lynch_Syndrome.yaml	treatments	0	evidence	0	PMID:23176623	SUPPORT		Some periodic screening strategies, such as colonoscopy, reduce the incidence and mortality of Lynch syndrome.	Regular colonoscopies are highlighted as a beneficial screening strategy for Lynch Syndrome.	"{""explanation"": ""Regular colonoscopies are highlighted as a beneficial screening strategy for Lynch Syndrome."", ""reference"": ""PMID:23176623"", ""snippet"": ""Some periodic screening strategies, such as colonoscopy, reduce the incidence and mortality of Lynch syndrome."", ""supports"": ""SUPPORT""}"
4739	4609	194	Lynch Syndrome	Lynch_Syndrome.yaml	treatments	0	evidence	1	PMID:31629885	SUPPORT		...offering the FDRs with Lynch syndrome biennial colonoscopy surveillance was cost-effective...	The study emphasizes the importance of regular colonoscopy surveillance for those with Lynch syndrome.	"{""explanation"": ""The study emphasizes the importance of regular colonoscopy surveillance for those with Lynch syndrome."", ""reference"": ""PMID:31629885"", ""snippet"": ""...offering the FDRs with Lynch syndrome biennial colonoscopy surveillance was cost-effective..."", ""supports"": ""SUPPORT""}"
4740	4609	194	Lynch Syndrome	Lynch_Syndrome.yaml	treatments	0	evidence	2	PMID:34698909	SUPPORT		Lynch syndrome (LS) is the most common cause of hereditary colorectal cancer and is associated with an increased lifetime risk of gastric and duodenal cancers of 8-16% and 7%, respectively; therefore, we aim to describe an esophagogastroduodenoscopy (EGD) surveillance program...	Endoscopies like EGD are implemented for cancer surveillance in LS patients, corroborating the need for ongoing screening tests.	"{""explanation"": ""Endoscopies like EGD are implemented for cancer surveillance in LS patients, corroborating the need for ongoing screening tests."", ""reference"": ""PMID:34698909"", ""snippet"": ""Lynch syndrome (LS) is the most common cause of hereditary colorectal cancer and is associated with an increased lifetime risk of gastric and duodenal cancers of 8-16% and 7%, respectively; therefore, we aim to describe an esophagogastroduodenoscopy (EGD) surveillance program..."", ""supports"": ""SUPPORT""}"
4741	4609	194	Lynch Syndrome	Lynch_Syndrome.yaml	treatments	0	evidence	3	PMID:32875945	SUPPORT		Universal tumor screening is a strategy to identify high-risk individuals by testing all CRC tumors for molecular features suggestive of Lynch Syndrome.	Universal tumor screening further illustrates the importance of regular and early cancer detection methods for Lynch Syndrome patients.	"{""explanation"": ""Universal tumor screening further illustrates the importance of regular and early cancer detection methods for Lynch Syndrome patients."", ""reference"": ""PMID:32875945"", ""snippet"": ""Universal tumor screening is a strategy to identify high-risk individuals by testing all CRC tumors for molecular features suggestive of Lynch Syndrome."", ""supports"": ""SUPPORT""}"
4742	4609	194	Lynch Syndrome	Lynch_Syndrome.yaml	treatments	0	evidence	4	PMID:27241104	SUPPORT		This review discusses the rationales and relative merits of current Lynch syndrome screening tests for endometrial and ovarian cancers...	Endometrial biopsies and other screening tests are discussed in the context of Lynch Syndrome, supporting the statement.	"{""explanation"": ""Endometrial biopsies and other screening tests are discussed in the context of Lynch Syndrome, supporting the statement."", ""reference"": ""PMID:27241104"", ""snippet"": ""This review discusses the rationales and relative merits of current Lynch syndrome screening tests for endometrial and ovarian cancers..."", ""supports"": ""SUPPORT""}"
4743	4610	194	Lynch Syndrome	Lynch_Syndrome.yaml	treatments	1	evidence	0	PMID:21287222	SUPPORT		Patients who are gene mutation carriers should receive counseling about colectomy, and if women, prophylactic hysterectomy and bilateral oophorectomy.	The literature mentions counseling carriers about colectomy and prophylactic hysterectomy with bilateral oophorectomy, supporting that preventive removal of the colon, uterus, or ovaries may be considered.	"{""explanation"": ""The literature mentions counseling carriers about colectomy and prophylactic hysterectomy with bilateral oophorectomy, supporting that preventive removal of the colon, uterus, or ovaries may be considered."", ""reference"": ""PMID:21287222"", ""snippet"": ""Patients who are gene mutation carriers should receive counseling about colectomy, and if women, prophylactic hysterectomy and bilateral oophorectomy."", ""supports"": ""SUPPORT""}"
4744	4610	194	Lynch Syndrome	Lynch_Syndrome.yaml	treatments	1	evidence	1	PMID:24495259	SUPPORT		Prophylactic hysterectomy with bilateral salpingo-oophorectomy is being increasingly undertaken in patients with Lynch syndrome (LS).	The literature indicates that prophylactic hysterectomy with bilateral salpingo-oophorectomy is a preventive measure undertaken in Lynch syndrome patients.	"{""explanation"": ""The literature indicates that prophylactic hysterectomy with bilateral salpingo-oophorectomy is a preventive measure undertaken in Lynch syndrome patients."", ""reference"": ""PMID:24495259"", ""snippet"": ""Prophylactic hysterectomy with bilateral salpingo-oophorectomy is being increasingly undertaken in patients with Lynch syndrome (LS)."", ""supports"": ""SUPPORT""}"
4745	4610	194	Lynch Syndrome	Lynch_Syndrome.yaml	treatments	1	evidence	2	PMID:31554630	SUPPORT		for women with Lynch syndrome, the risks for gynecologic cancers pose an equal or greater risk than colorectal cancer.	The literature outlines the significant risk of gynecologic cancers in women with Lynch syndrome, supporting the consideration of prophylactic surgery.	"{""explanation"": ""The literature outlines the significant risk of gynecologic cancers in women with Lynch syndrome, supporting the consideration of prophylactic surgery."", ""reference"": ""PMID:31554630"", ""snippet"": ""for women with Lynch syndrome, the risks for gynecologic cancers pose an equal or greater risk than colorectal cancer."", ""supports"": ""SUPPORT""}"
4746	4610	194	Lynch Syndrome	Lynch_Syndrome.yaml	treatments	1	evidence	3	PMID:27241104	SUPPORT		This review discusses the rationales and relative merits of current Lynch syndrome screening tests for endometrial and ovarian cancers.	The discussion of screening tests implies the consideration of proactive measures, including prophylactic surgery, in managing the elevated cancer risks in Lynch syndrome.	"{""explanation"": ""The discussion of screening tests implies the consideration of proactive measures, including prophylactic surgery, in managing the elevated cancer risks in Lynch syndrome."", ""reference"": ""PMID:27241104"", ""snippet"": ""This review discusses the rationales and relative merits of current Lynch syndrome screening tests for endometrial and ovarian cancers."", ""supports"": ""SUPPORT""}"
4747	4611	194	Lynch Syndrome	Lynch_Syndrome.yaml	treatments	2	evidence	0	PMID:35328014	SUPPORT		Nonsteroidal anti-inflammatory drugs and, in particular, aspirin use, has been associated with reduced CRC risk in several studies...	This study affirms that aspirin and other NSAIDs have been linked to a reduced risk of colorectal cancer in Lynch syndrome patients.	"{""explanation"": ""This study affirms that aspirin and other NSAIDs have been linked to a reduced risk of colorectal cancer in Lynch syndrome patients."", ""reference"": ""PMID:35328014"", ""snippet"": ""Nonsteroidal anti-inflammatory drugs and, in particular, aspirin use, has been associated with reduced CRC risk in several studies..."", ""supports"": ""SUPPORT""}"
4748	4611	194	Lynch Syndrome	Lynch_Syndrome.yaml	treatments	2	evidence	1	PMID:11854387	PARTIAL		Numerous experimental, epidemiologic, and clinical studies suggest that nonsteroidal anti-inflammatory drugs (NSAIDs), particularly the highly selective cyclooxygenase (COX)-2 inhibitors, have promise as anticancer agents...	The study indicates a potential for NSAIDs in cancer prevention, including colorectal cancer, but notes that unresolved questions about safety and efficacy limit clinical application.	"{""explanation"": ""The study indicates a potential for NSAIDs in cancer prevention, including colorectal cancer, but notes that unresolved questions about safety and efficacy limit clinical application."", ""reference"": ""PMID:11854387"", ""snippet"": ""Numerous experimental, epidemiologic, and clinical studies suggest that nonsteroidal anti-inflammatory drugs (NSAIDs), particularly the highly selective cyclooxygenase (COX)-2 inhibitors, have promise as anticancer agents..."", ""supports"": ""PARTIAL""}"
4749	4611	194	Lynch Syndrome	Lynch_Syndrome.yaml	treatments	2	evidence	2	PMID:36202092	SUPPORT		...multiple pharmacological, clinical, and epidemiologic studies suggest that aspirin can prevent certain cancers...	This study supports the role of aspirin in cancer prevention, including colorectal cancer, though mentions variable effects depending on the tissue and disease context.	"{""explanation"": ""This study supports the role of aspirin in cancer prevention, including colorectal cancer, though mentions variable effects depending on the tissue and disease context."", ""reference"": ""PMID:36202092"", ""snippet"": ""...multiple pharmacological, clinical, and epidemiologic studies suggest that aspirin can prevent certain cancers..."", ""supports"": ""SUPPORT""}"
4750	4611	194	Lynch Syndrome	Lynch_Syndrome.yaml	treatments	2	evidence	3	PMID:34798982	SUPPORT		Secondary prevention of colorectal neoplasia with chemoprevention is long-studied area of research and clinical use in patients with the 2 most common hereditary colorectal cancer syndromes including Lynch syndrome and familial adenomatous polyposis	This study notes the history and research supporting chemoprevention, including with NSAIDs, for hereditary colorectal cancer syndromes like Lynch syndrome.	"{""explanation"": ""This study notes the history and research supporting chemoprevention, including with NSAIDs, for hereditary colorectal cancer syndromes like Lynch syndrome."", ""reference"": ""PMID:34798982"", ""snippet"": ""Secondary prevention of colorectal neoplasia with chemoprevention is long-studied area of research and clinical use in patients with the 2 most common hereditary colorectal cancer syndromes including Lynch syndrome and familial adenomatous polyposis"", ""supports"": ""SUPPORT""}"
4751	4612	194	Lynch Syndrome	Lynch_Syndrome.yaml	treatments	3	evidence	0	PMID:37625240	SUPPORT		PD-1 inhibitors are highly effective for dMMR and MSI-H LS CRCs, but not for pMMR or MSS LS CRCs or mucinous/signet-ring cell CRC.	This study demonstrates the efficacy of PD-1 inhibitors, a type of immune checkpoint inhibitor, for treating Lynch syndrome (LS) patients with colorectal cancers characterized by deficient mismatch repair (dMMR) or high microsatellite instability (MSI-H).	"{""explanation"": ""This study demonstrates the efficacy of PD-1 inhibitors, a type of immune checkpoint inhibitor, for treating Lynch syndrome (LS) patients with colorectal cancers characterized by deficient mismatch repair (dMMR) or high microsatellite instability (MSI-H)."", ""reference"": ""PMID:37625240"", ""snippet"": ""PD-1 inhibitors are highly effective for dMMR and MSI-H LS CRCs, but not for pMMR or MSS LS CRCs or mucinous/signet-ring cell CRC."", ""supports"": ""SUPPORT""}"
4752	4612	194	Lynch Syndrome	Lynch_Syndrome.yaml	treatments	3	evidence	1	PMID:34224739	SUPPORT	MODEL_ORGANISM	We identified 4 shared FSP neoantigens ... Using VCMsh2 mice, which have a conditional knockout of Msh2 in the intestinal tract and develop intestinal cancer, we showed vaccination with a combination of only 4 FSPs significantly increased FSP-specific adaptive immunity, reduced intestinal tumor burden, and prolonged overall survival.	This study indicates that immunotherapies, specifically FSP neoantigen vaccines, can be effective in reducing the tumor burden and improving survival in Lynch syndrome mouse models.	"{""evidence_source"": ""MODEL_ORGANISM"", ""explanation"": ""This study indicates that immunotherapies, specifically FSP neoantigen vaccines, can be effective in reducing the tumor burden and improving survival in Lynch syndrome mouse models."", ""reference"": ""PMID:34224739"", ""snippet"": ""We identified 4 shared FSP neoantigens ... Using VCMsh2 mice, which have a conditional knockout of Msh2 in the intestinal tract and develop intestinal cancer, we showed vaccination with a combination of only 4 FSPs significantly increased FSP-specific adaptive immunity, reduced intestinal tumor burden, and prolonged overall survival."", ""supports"": ""SUPPORT""}"
4753	4612	194	Lynch Syndrome	Lynch_Syndrome.yaml	treatments	3	evidence	2	PMID:30027543	SUPPORT		Immunotherapies are an active field of research for MSI cancers and their potential use for cancer therapy for both sporadic and LS MSI cancers is discussed.	This reference discusses ongoing research into immunotherapies for MSI cancers, including those associated with Lynch syndrome.	"{""explanation"": ""This reference discusses ongoing research into immunotherapies for MSI cancers, including those associated with Lynch syndrome."", ""reference"": ""PMID:30027543"", ""snippet"": ""Immunotherapies are an active field of research for MSI cancers and their potential use for cancer therapy for both sporadic and LS MSI cancers is discussed."", ""supports"": ""SUPPORT""}"
4754	4612	194	Lynch Syndrome	Lynch_Syndrome.yaml	treatments	3	evidence	3	PMID:37845474	PARTIAL		Metastatic and localized mismatch repair-deficient (dMMR) tumors are exquisitely sensitive to immune checkpoint blockade (ICB).	While ICB is effective for treating dMMR tumors in Lynch syndrome patients, it does not eliminate the risk of new neoplasia development, highlighting the need for continued surveillance.	"{""explanation"": ""While ICB is effective for treating dMMR tumors in Lynch syndrome patients, it does not eliminate the risk of new neoplasia development, highlighting the need for continued surveillance."", ""reference"": ""PMID:37845474"", ""snippet"": ""Metastatic and localized mismatch repair-deficient (dMMR) tumors are exquisitely sensitive to immune checkpoint blockade (ICB)."", ""supports"": ""PARTIAL""}"
4763	4668	197	MSI-High Colorectal Cancer	MSI_High_Colorectal_Cancer.yaml	treatments	0	evidence	0	PMID:33264544	SUPPORT		Pembrolizumab led to significantly longer progression-free survival than chemotherapy when received as first-line therapy for MSI-H-dMMR metastatic colorectal cancer	KEYNOTE-177 abstract reports improved progression-free survival with first-line pembrolizumab versus chemotherapy.	"{""explanation"": ""KEYNOTE-177 abstract reports improved progression-free survival with first-line pembrolizumab versus chemotherapy."", ""reference"": ""PMID:33264544"", ""snippet"": ""Pembrolizumab led to significantly longer progression-free survival than chemotherapy when received as first-line therapy for MSI-H-dMMR metastatic colorectal cancer"", ""supports"": ""SUPPORT""}"
4764	4669	197	MSI-High Colorectal Cancer	MSI_High_Colorectal_Cancer.yaml	treatments	1	evidence	0	PMID:29355075	SUPPORT		investigator-assessed ORR was 55% (95% CI, 45.2 to 63.8), and disease control rate for  12 weeks was 80%	CheckMate-142 trial demonstrated high objective response rate (55%) and disease control rate (80%) with nivolumab plus ipilimumab in dMMR/MSI-H mCRC.	"{""explanation"": ""CheckMate-142 trial demonstrated high objective response rate (55%) and disease control rate (80%) with nivolumab plus ipilimumab in dMMR/MSI-H mCRC."", ""reference"": ""PMID:29355075"", ""snippet"": ""investigator-assessed ORR was 55% (95% CI, 45.2 to 63.8), and disease control rate for  12 weeks was 80%"", ""supports"": ""SUPPORT""}"
4765	4670	197	MSI-High Colorectal Cancer	MSI_High_Colorectal_Cancer.yaml	treatments	2	evidence	0	PMID:35660797	SUPPORT		All 12 patients (100%; 95% confidence interval, 74 to 100) had a clinical complete response, with no evidence of tumor on magnetic resonance imaging, 18F-fluorodeoxyglucose-positron-emission tomography, endoscopic evaluation, digital rectal examination, or biopsy.	Phase 2 study showed 100% clinical complete response rate with dostarlimab monotherapy in mismatch repair-deficient locally advanced rectal cancer.	"{""explanation"": ""Phase 2 study showed 100% clinical complete response rate with dostarlimab monotherapy in mismatch repair-deficient locally advanced rectal cancer."", ""reference"": ""PMID:35660797"", ""snippet"": ""All 12 patients (100%; 95% confidence interval, 74 to 100) had a clinical complete response, with no evidence of tumor on magnetic resonance imaging, 18F-fluorodeoxyglucose-positron-emission tomography, endoscopic evaluation, digital rectal examination, or biopsy."", ""supports"": ""SUPPORT""}"
4766	4671	197	MSI-High Colorectal Cancer	MSI_High_Colorectal_Cancer.yaml	treatments	3	evidence	0	PMID:35660797	SUPPORT		Neoadjuvant chemotherapy and radiation followed by surgical resection of the rectum is a standard treatment for locally advanced rectal cancer.	The study confirms surgical resection is standard treatment for locally advanced rectal cancer, supporting the role of surgery in MSI-H CRC.	"{""explanation"": ""The study confirms surgical resection is standard treatment for locally advanced rectal cancer, supporting the role of surgery in MSI-H CRC."", ""reference"": ""PMID:35660797"", ""snippet"": ""Neoadjuvant chemotherapy and radiation followed by surgical resection of the rectum is a standard treatment for locally advanced rectal cancer."", ""supports"": ""SUPPORT""}"
4772	4687	198	MSI-High Endometrial Cancer	MSI_High_Endometrial_Cancer.yaml	treatments	0	evidence	0	PMID:35045221	SUPPORT		Lenvatinib plus pembrolizumab led to significantly longer progression-free survival and overall survival than chemotherapy among patients with advanced endometrial cancer.	KEYNOTE-775 demonstrated significant PFS and OS benefit with lenvatinib plus pembrolizumab versus chemotherapy in advanced endometrial cancer.	"{""explanation"": ""KEYNOTE-775 demonstrated significant PFS and OS benefit with lenvatinib plus pembrolizumab versus chemotherapy in advanced endometrial cancer."", ""reference"": ""PMID:35045221"", ""snippet"": ""Lenvatinib plus pembrolizumab led to significantly longer progression-free survival and overall survival than chemotherapy among patients with advanced endometrial cancer."", ""supports"": ""SUPPORT""}"
4773	4688	198	MSI-High Endometrial Cancer	MSI_High_Endometrial_Cancer.yaml	treatments	1	evidence	0	PMID:34990208	SUPPORT		The objective response rate was 48% (95% CI, 37 to 60)	KEYNOTE-158 abstract reports response rate for pembrolizumab in MSI-H/dMMR endometrial cancer.	"{""explanation"": ""KEYNOTE-158 abstract reports response rate for pembrolizumab in MSI-H/dMMR endometrial cancer."", ""reference"": ""PMID:34990208"", ""snippet"": ""The objective response rate was 48% (95% CI, 37 to 60)"", ""supports"": ""SUPPORT""}"
4774	4689	198	MSI-High Endometrial Cancer	MSI_High_Endometrial_Cancer.yaml	treatments	2	evidence	0	PMID:35064011	SUPPORT		In cohort A1, ORR was 43.5% (95% CI 34.0% to 53.4%) with 11 complete responses and 36 partial responses.	GARNET trial demonstrated 43.5% objective response rate with dostarlimab in dMMR/MSI-H endometrial cancer.	"{""explanation"": ""GARNET trial demonstrated 43.5% objective response rate with dostarlimab in dMMR/MSI-H endometrial cancer."", ""reference"": ""PMID:35064011"", ""snippet"": ""In cohort A1, ORR was 43.5% (95% CI 34.0% to 53.4%) with 11 complete responses and 36 partial responses."", ""supports"": ""SUPPORT""}"
4775	4690	198	MSI-High Endometrial Cancer	MSI_High_Endometrial_Cancer.yaml	treatments	3	evidence	0	PMID:35045221	SUPPORT		Standard therapy for advanced endometrial cancer after failure of platinum-based chemotherapy remains unclear.	While the study focuses on advanced disease after chemotherapy failure, it implies surgery (hysterectomy) and platinum chemotherapy are standard initial therapies.	"{""explanation"": ""While the study focuses on advanced disease after chemotherapy failure, it implies surgery (hysterectomy) and platinum chemotherapy are standard initial therapies."", ""reference"": ""PMID:35045221"", ""snippet"": ""Standard therapy for advanced endometrial cancer after failure of platinum-based chemotherapy remains unclear."", ""supports"": ""SUPPORT""}"
4794	4719	199	Major Depressive Disorder	Major_Depressive_Disorder.yaml	treatments	0	evidence	0	PMID:39150594	SUPPORT		MDD is especially burdensome as approved monoamine antidepressant treatments have weeks-long delays before clinical benefit and low remission rates.	This confirms the clinical use of monoamine antidepressants while acknowledging their limitations in terms of delayed benefit and incomplete remission.	"{""explanation"": ""This confirms the clinical use of monoamine antidepressants while acknowledging their limitations in terms of delayed benefit and incomplete remission."", ""reference"": ""PMID:39150594"", ""snippet"": ""MDD is especially burdensome as approved monoamine antidepressant treatments have weeks-long delays before clinical benefit and low remission rates."", ""supports"": ""SUPPORT""}"
4795	4723	199	Major Depressive Disorder	Major_Depressive_Disorder.yaml	treatments	4	evidence	0	PMID:39150594	SUPPORT		Nasal administration of esketamine (Spravato) was approved by the US Food and Drug Administration (FDA) in 2019 to treat adults with treatment-resistant depression and in 2020 for adults with MDD with acute suicidal ideation or behavior.	This confirms FDA approval of esketamine for treatment-resistant depression and acute suicidal ideation/behavior in MDD.	"{""explanation"": ""This confirms FDA approval of esketamine for treatment-resistant depression and acute suicidal ideation/behavior in MDD."", ""reference"": ""PMID:39150594"", ""snippet"": ""Nasal administration of esketamine (Spravato) was approved by the US Food and Drug Administration (FDA) in 2019 to treat adults with treatment-resistant depression and in 2020 for adults with MDD with acute suicidal ideation or behavior."", ""supports"": ""SUPPORT""}"
4796	4723	199	Major Depressive Disorder	Major_Depressive_Disorder.yaml	treatments	4	evidence	1	PMID:39150594	SUPPORT		Based on this preclinical evidence implicating glutamate in depression and the rapid improvement of depression with ketamine treatment in a proof-of-concept trial, a range of N-methyl-D-aspartate (NMDA)-targeted therapies have been investigated.	This explains the mechanistic basis for ketamine's rapid-acting antidepressant effects through NMDA receptor antagonism and glutamate modulation.	"{""explanation"": ""This explains the mechanistic basis for ketamine's rapid-acting antidepressant effects through NMDA receptor antagonism and glutamate modulation."", ""reference"": ""PMID:39150594"", ""snippet"": ""Based on this preclinical evidence implicating glutamate in depression and the rapid improvement of depression with ketamine treatment in a proof-of-concept trial, a range of N-methyl-D-aspartate (NMDA)-targeted therapies have been investigated."", ""supports"": ""SUPPORT""}"
4797	4723	199	Major Depressive Disorder	Major_Depressive_Disorder.yaml	treatments	4	evidence	2	PMID:39150594	SUPPORT		Oral combination dextromethorphan-bupropion (AXS-05, Auvelity extended-release tablet) was FDA approved in 2022 for the treatment of MDD in adults.	This documents the approval of another glutamatergic modulator for MDD treatment, expanding treatment options beyond esketamine.	"{""explanation"": ""This documents the approval of another glutamatergic modulator for MDD treatment, expanding treatment options beyond esketamine."", ""reference"": ""PMID:39150594"", ""snippet"": ""Oral combination dextromethorphan-bupropion (AXS-05, Auvelity extended-release tablet) was FDA approved in 2022 for the treatment of MDD in adults."", ""supports"": ""SUPPORT""}"
4840	4810	203	Maple Syrup Urine Disease	Maple_Syrup_Urine_Disease.yaml	treatments	0	evidence	0	PMID:35672312	SUPPORT		Treatment for MSUD represents an unmet need because the current treatment with life-long low-protein diet is challenging to maintain, and despite treatment the risk of acute decompensations and neuropsychiatric symptoms remains.	Confirms lifelong dietary treatment is the current standard of care but has limitations.	"{""explanation"": ""Confirms lifelong dietary treatment is the current standard of care but has limitations."", ""reference"": ""PMID:35672312"", ""snippet"": ""Treatment for MSUD represents an unmet need because the current treatment with life-long low-protein diet is challenging to maintain, and despite treatment the risk of acute decompensations and neuropsychiatric symptoms remains."", ""supports"": ""SUPPORT""}"
4841	4811	203	Maple Syrup Urine Disease	Maple_Syrup_Urine_Disease.yaml	treatments	1	evidence	0	PMID:35578286	SUPPORT		Patients with maple syrup urine disease (MSUD) experiencing metabolic decompensations have traditionally been treated with branched-chain amino acid (BCAA)-free mixture via oral or nasogastric administration routes.	Confirms BCAA-free amino acid mixtures are standard treatment.	"{""explanation"": ""Confirms BCAA-free amino acid mixtures are standard treatment."", ""reference"": ""PMID:35578286"", ""snippet"": ""Patients with maple syrup urine disease (MSUD) experiencing metabolic decompensations have traditionally been treated with branched-chain amino acid (BCAA)-free mixture via oral or nasogastric administration routes."", ""supports"": ""SUPPORT""}"
4842	4812	203	Maple Syrup Urine Disease	Maple_Syrup_Urine_Disease.yaml	treatments	2	evidence	0	PMID:27373929	SUPPORT		Thiamine responsivity is associated with a specific mutation in the thiamine binding site in the E1b subunit, or due to the stabilization of BCKDH via an allosteric interaction	Confirms thiamine supplementation is effective for patients with specific mutations.	"{""explanation"": ""Confirms thiamine supplementation is effective for patients with specific mutations."", ""reference"": ""PMID:27373929"", ""snippet"": ""Thiamine responsivity is associated with a specific mutation in the thiamine binding site in the E1b subunit, or due to the stabilization of BCKDH via an allosteric interaction"", ""supports"": ""SUPPORT""}"
4843	4813	203	Maple Syrup Urine Disease	Maple_Syrup_Urine_Disease.yaml	treatments	3	evidence	0	PMID:21839471	SUPPORT		Patient and graft survival were 100% at 4.5  2.2 years of follow-up. Liver function was normal in all patients. Branched-chain amino acid levels were corrected within hours after surgery and remained stable, with leucine tolerance increasing more than 10-fold.	Demonstrates excellent outcomes with liver transplantation for MSUD.	"{""explanation"": ""Demonstrates excellent outcomes with liver transplantation for MSUD."", ""reference"": ""PMID:21839471"", ""snippet"": ""Patient and graft survival were 100% at 4.5  2.2 years of follow-up. Liver function was normal in all patients. Branched-chain amino acid levels were corrected within hours after surgery and remained stable, with leucine tolerance increasing more than 10-fold."", ""supports"": ""SUPPORT""}"
4844	4813	203	Maple Syrup Urine Disease	Maple_Syrup_Urine_Disease.yaml	treatments	3	evidence	1	PMID:23478409	SUPPORT		Liver transplantation has emerged as an effective way to eliminate acute decompensation risk.	Confirms liver transplantation eliminates risk of acute metabolic crises.	"{""explanation"": ""Confirms liver transplantation eliminates risk of acute metabolic crises."", ""reference"": ""PMID:23478409"", ""snippet"": ""Liver transplantation has emerged as an effective way to eliminate acute decompensation risk."", ""supports"": ""SUPPORT""}"
4845	4814	203	Maple Syrup Urine Disease	Maple_Syrup_Urine_Disease.yaml	treatments	4	evidence	0	PMID:35578286	SUPPORT		The IV BCAA-free solution is safe and effective in normalising leucine concentrations during MSUD decompensation episodes in both children and adults	Demonstrates safety and efficacy of IV BCAA-free solutions for acute decompensation.	"{""explanation"": ""Demonstrates safety and efficacy of IV BCAA-free solutions for acute decompensation."", ""reference"": ""PMID:35578286"", ""snippet"": ""The IV BCAA-free solution is safe and effective in normalising leucine concentrations during MSUD decompensation episodes in both children and adults"", ""supports"": ""SUPPORT""}"
4846	4815	203	Maple Syrup Urine Disease	Maple_Syrup_Urine_Disease.yaml	treatments	5	evidence	0	PMID:23478409	SUPPORT		Dietary management enables survival and reduces risk of acute crises.	Acute crisis management including anabolic support reduces mortality from metabolic decompensation.	"{""explanation"": ""Acute crisis management including anabolic support reduces mortality from metabolic decompensation."", ""reference"": ""PMID:23478409"", ""snippet"": ""Dietary management enables survival and reduces risk of acute crises."", ""supports"": ""SUPPORT""}"
4847	4816	203	Maple Syrup Urine Disease	Maple_Syrup_Urine_Disease.yaml	treatments	6	evidence	0	PMID:21098507	SUPPORT		In vivo phenylbutyrate increases the proportion of active hepatic enzyme and unphosphorylated form over the inactive phosphorylated form of the E1 subunit of the branched-chain -keto acid dehydrogenase complex (BCKDC).	Demonstrates phenylbutyrate activates BCKDH by inhibiting kinase-mediated inactivation.	"{""explanation"": ""Demonstrates phenylbutyrate activates BCKDH by inhibiting kinase-mediated inactivation."", ""reference"": ""PMID:21098507"", ""snippet"": ""In vivo phenylbutyrate increases the proportion of active hepatic enzyme and unphosphorylated form over the inactive phosphorylated form of the E1 subunit of the branched-chain -keto acid dehydrogenase complex (BCKDC)."", ""supports"": ""SUPPORT""}"
4848	4817	203	Maple Syrup Urine Disease	Maple_Syrup_Urine_Disease.yaml	treatments	7	evidence	0	PMID:27373929	SUPPORT		Metformin-treatment significantly reduced levels of KIC in the muscle (by 69%) and serum (by 56%) isolated from iMSUD mice, and restored levels of mitochondrial metabolites	Preclinical evidence supports metformin as potential therapeutic strategy for MSUD.	"{""explanation"": ""Preclinical evidence supports metformin as potential therapeutic strategy for MSUD."", ""reference"": ""PMID:27373929"", ""snippet"": ""Metformin-treatment significantly reduced levels of KIC in the muscle (by 69%) and serum (by 56%) isolated from iMSUD mice, and restored levels of mitochondrial metabolites"", ""supports"": ""SUPPORT""}"
4919	4852	204	Marfan Syndrome	Marfan_Syndrome.yaml	treatments	0	evidence	0	PMID:36939732	PARTIAL	HUMAN_CLINICAL	Beta-blockers remain the mainstay of therapy as they have proven to slow aortic enlargement. Angiotensin receptor blockers are a useful alternative and with proven benefit as an add-on therapy to limit aortic growth.	Beta-blockers are used to slow aortic enlargement, which indirectly reduces stress on the aorta. However, they do not prevent aortic enlargement entirely.	"{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""Beta-blockers are used to slow aortic enlargement, which indirectly reduces stress on the aorta. However, they do not prevent aortic enlargement entirely."", ""reference"": ""PMID:36939732"", ""snippet"": ""Beta-blockers remain the mainstay of therapy as they have proven to slow aortic enlargement. Angiotensin receptor blockers are a useful alternative and with proven benefit as an add-on therapy to limit aortic growth."", ""supports"": ""PARTIAL""}"
4920	4852	204	Marfan Syndrome	Marfan_Syndrome.yaml	treatments	0	evidence	1	PMID:17845137	PARTIAL	HUMAN_CLINICAL	Traditional medical therapies, such as beta-adrenergic receptor blockade, are used to slow pathologic aortic growth and decrease the risk of aortic dissection by decreasing hemodynamic stress.	Beta-blockers are used to slow aortic growth and decrease hemodynamic stress, but they do not completely prevent aortic enlargement.	"{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""Beta-blockers are used to slow aortic growth and decrease hemodynamic stress, but they do not completely prevent aortic enlargement."", ""reference"": ""PMID:17845137"", ""snippet"": ""Traditional medical therapies, such as beta-adrenergic receptor blockade, are used to slow pathologic aortic growth and decrease the risk of aortic dissection by decreasing hemodynamic stress."", ""supports"": ""PARTIAL""}"
4921	4852	204	Marfan Syndrome	Marfan_Syndrome.yaml	treatments	0	evidence	2	PMID:17376944	PARTIAL	HUMAN_CLINICAL	Medical treatment with beta-blockers is probably helpful in most children with aortic root dilatation.	Beta-blockers are helpful in slowing the progression of aortic root dilatation, but they do not completely prevent it.	"{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""Beta-blockers are helpful in slowing the progression of aortic root dilatation, but they do not completely prevent it."", ""reference"": ""PMID:17376944"", ""snippet"": ""Medical treatment with beta-blockers is probably helpful in most children with aortic root dilatation."", ""supports"": ""PARTIAL""}"
4922	4854	204	Marfan Syndrome	Marfan_Syndrome.yaml	treatments	2	evidence	0	PMID:26586198	SUPPORT	HUMAN_CLINICAL	To prevent such catastrophic aortic events, a lower threshold has been recommended for prophylactic interventions on the aortic root.	The literature mentions that prophylactic aortic root replacement is recommended to prevent severe aortic events such as dissections.	"{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""The literature mentions that prophylactic aortic root replacement is recommended to prevent severe aortic events such as dissections."", ""reference"": ""PMID:26586198"", ""snippet"": ""To prevent such catastrophic aortic events, a lower threshold has been recommended for prophylactic interventions on the aortic root."", ""supports"": ""SUPPORT""}"
4923	4854	204	Marfan Syndrome	Marfan_Syndrome.yaml	treatments	2	evidence	1	PMID:29948025	SUPPORT	HUMAN_CLINICAL	Few data exist regarding predictors of rapid aortic root dilation and referral for aortic surgery in Marfan syndrome (MFS).	The study investigates predictors for referral for aortic surgery in patients with Marfan syndrome, indicating that surgery is recommended for severe aortic dilation.	"{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""The study investigates predictors for referral for aortic surgery in patients with Marfan syndrome, indicating that surgery is recommended for severe aortic dilation."", ""reference"": ""PMID:29948025"", ""snippet"": ""Few data exist regarding predictors of rapid aortic root dilation and referral for aortic surgery in Marfan syndrome (MFS)."", ""supports"": ""SUPPORT""}"
4924	4855	204	Marfan Syndrome	Marfan_Syndrome.yaml	treatments	3	evidence	0	PMID:11961443	SUPPORT	HUMAN_CLINICAL	The authors recommend arthrodesing both the primary and secondary curves in all patients with Marfan syndrome.	The study discusses surgical treatment of scoliosis in Marfan syndrome and provides guidelines for successful outcomes through orthopedic interventions.	"{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""The study discusses surgical treatment of scoliosis in Marfan syndrome and provides guidelines for successful outcomes through orthopedic interventions."", ""reference"": ""PMID:11961443"", ""snippet"": ""The authors recommend arthrodesing both the primary and secondary curves in all patients with Marfan syndrome."", ""supports"": ""SUPPORT""}"
4925	4855	204	Marfan Syndrome	Marfan_Syndrome.yaml	treatments	3	evidence	1	PMID:11880731	SUPPORT	HUMAN_CLINICAL	The major orthopedic manifestations of Marfan syndrome include scoliosis, chest wall deformity, dural ectasia, joint hypermobility, and acetabular protrusion.	This review highlights the orthopedic aspects of Marfan syndrome, including treatments for scoliosis and other skeletal abnormalities.	"{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""This review highlights the orthopedic aspects of Marfan syndrome, including treatments for scoliosis and other skeletal abnormalities."", ""reference"": ""PMID:11880731"", ""snippet"": ""The major orthopedic manifestations of Marfan syndrome include scoliosis, chest wall deformity, dural ectasia, joint hypermobility, and acetabular protrusion."", ""supports"": ""SUPPORT""}"
4926	4855	204	Marfan Syndrome	Marfan_Syndrome.yaml	treatments	3	evidence	2	PMID:34916231	SUPPORT	HUMAN_CLINICAL	We elucidated the genetic risk factors for the development of severe scoliosis in patients with Marfan syndrome.	The study investigates the genetic risk factors for severe scoliosis in Marfan syndrome, which is relevant to orthopedic interventions.	"{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""The study investigates the genetic risk factors for severe scoliosis in Marfan syndrome, which is relevant to orthopedic interventions."", ""reference"": ""PMID:34916231"", ""snippet"": ""We elucidated the genetic risk factors for the development of severe scoliosis in patients with Marfan syndrome."", ""supports"": ""SUPPORT""}"
4927	4855	204	Marfan Syndrome	Marfan_Syndrome.yaml	treatments	3	evidence	3	PMID:17945136	SUPPORT	HUMAN_CLINICAL	Kyphoscoliosis, spondylolisthesis, and atlantoaxial subluxation are common spinal deformities in Marfan syndrome... Surgical correction is associated with complications, such as failure of fixation and additional deformity; however good results are possible when consideration is given to the unique challenges presented by patients who have Marfan syndrome.	The article discusses common spinal deformities in Marfan syndrome and the complexities of surgical correction, supporting the statement on orthopedic interventions.	"{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""The article discusses common spinal deformities in Marfan syndrome and the complexities of surgical correction, supporting the statement on orthopedic interventions."", ""reference"": ""PMID:17945136"", ""snippet"": ""Kyphoscoliosis, spondylolisthesis, and atlantoaxial subluxation are common spinal deformities in Marfan syndrome... Surgical correction is associated with complications, such as failure of fixation and additional deformity; however good results are possible when consideration is given to the unique challenges presented by patients who have Marfan syndrome."", ""supports"": ""SUPPORT""}"
4928	4855	204	Marfan Syndrome	Marfan_Syndrome.yaml	treatments	3	evidence	4	PMID:26130954	SUPPORT	HUMAN_CLINICAL	Patients with Marfan syndrome (MFS) presents with primary skeletal manifestations such as tall stature, chest wall abnormality, and scoliosis.	This study covers the primary skeletal manifestations of Marfan syndrome, including scoliosis, which require orthopedic interventions.	"{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""This study covers the primary skeletal manifestations of Marfan syndrome, including scoliosis, which require orthopedic interventions."", ""reference"": ""PMID:26130954"", ""snippet"": ""Patients with Marfan syndrome (MFS) presents with primary skeletal manifestations such as tall stature, chest wall abnormality, and scoliosis."", ""supports"": ""SUPPORT""}"
4929	4856	204	Marfan Syndrome	Marfan_Syndrome.yaml	treatments	4	evidence	0	PMID:24698610	SUPPORT	HUMAN_CLINICAL	Anterior lensectomy and limited vitrectomy with aphakic correction is safe and provides a consistent visual outcome in patients with lens subluxation secondary to Marfan syndrome.	The study discusses surgical management of ectopia lentis in Marfan syndrome patients, which supports the statement about managing ocular issues with surgery.	"{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""The study discusses surgical management of ectopia lentis in Marfan syndrome patients, which supports the statement about managing ocular issues with surgery."", ""reference"": ""PMID:24698610"", ""snippet"": ""Anterior lensectomy and limited vitrectomy with aphakic correction is safe and provides a consistent visual outcome in patients with lens subluxation secondary to Marfan syndrome."", ""supports"": ""SUPPORT""}"
4930	4856	204	Marfan Syndrome	Marfan_Syndrome.yaml	treatments	4	evidence	1	PMID:23661206	SUPPORT	HUMAN_CLINICAL	The ocular features were ectopia lentis in 92.3% of the patients... The best corrected visual acuity in 4 out of 5 patients who had cataract extraction at 8 weeks post op. was 6/60 to 6/12.	This study highlights the use of surgical intervention for vision correction in Marfan syndrome patients with ectopia lentis.	"{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""This study highlights the use of surgical intervention for vision correction in Marfan syndrome patients with ectopia lentis."", ""reference"": ""PMID:23661206"", ""snippet"": ""The ocular features were ectopia lentis in 92.3% of the patients... The best corrected visual acuity in 4 out of 5 patients who had cataract extraction at 8 weeks post op. was 6/60 to 6/12."", ""supports"": ""SUPPORT""}"
4931	4856	204	Marfan Syndrome	Marfan_Syndrome.yaml	treatments	4	evidence	2	PMID:30260057	SUPPORT	HUMAN_CLINICAL	Our study indicates that even though EL typically occurs at an early stage in most MFS patients, there is still a risk of developing EL in adulthood.	The study confirms the management of ectopia lentis (EL) in Marfan syndrome, indicating the necessity for vision correction, which can include glasses or surgery.	"{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""The study confirms the management of ectopia lentis (EL) in Marfan syndrome, indicating the necessity for vision correction, which can include glasses or surgery."", ""reference"": ""PMID:30260057"", ""snippet"": ""Our study indicates that even though EL typically occurs at an early stage in most MFS patients, there is still a risk of developing EL in adulthood."", ""supports"": ""SUPPORT""}"
4959	4866	205	Meckel Diverticulum	Meckel_Diverticulum.yaml	treatments	0	evidence	0	PMID:8506491	SUPPORT		All symptomatic and pathologic Meckel's diverticula should be removed with a segment of ileum.	This provides guidance on surgical management of symptomatic Meckel diverticula.	"{""explanation"": ""This provides guidance on surgical management of symptomatic Meckel diverticula."", ""reference"": ""PMID:8506491"", ""snippet"": ""All symptomatic and pathologic Meckel's diverticula should be removed with a segment of ileum."", ""supports"": ""SUPPORT""}"
4960	4866	205	Meckel Diverticulum	Meckel_Diverticulum.yaml	treatments	0	evidence	1	PMID:31930430	SUPPORT		Complicated Meckel's diverticulum is treated by resection.	This confirms resection as the treatment for complicated cases.	"{""explanation"": ""This confirms resection as the treatment for complicated cases."", ""reference"": ""PMID:31930430"", ""snippet"": ""Complicated Meckel's diverticulum is treated by resection."", ""supports"": ""SUPPORT""}"
4961	4867	205	Meckel Diverticulum	Meckel_Diverticulum.yaml	treatments	1	evidence	0	PMID:8506491	SUPPORT		The use of stapling devices, with their ease of use and low complication rate, make it reasonable to remove any Meckel's diverticulum that easily fits in the device. If a diverticulum found incidentally is so broad-based or short that stapling cannot be done without difficulty, it is unlikely to become symptomatic and should be left undisturbed.	This provides specific guidance on management of incidentally discovered Meckel diverticula using stapling devices.	"{""explanation"": ""This provides specific guidance on management of incidentally discovered Meckel diverticula using stapling devices."", ""reference"": ""PMID:8506491"", ""snippet"": ""The use of stapling devices, with their ease of use and low complication rate, make it reasonable to remove any Meckel's diverticulum that easily fits in the device. If a diverticulum found incidentally is so broad-based or short that stapling cannot be done without difficulty, it is unlikely to become symptomatic and should be left undisturbed."", ""supports"": ""SUPPORT""}"
5030	4920	206	Meckel Syndrome	Meckel_Syndrome.yaml	treatments	0	evidence	0	PMID:38459147	SUPPORT	HUMAN_CLINICAL	The study included 10 newborns with MKS associated with occipital encephalocele or meningocele, all of whom underwent surgical repair of the occipital sac.	Systematic review documents surgical repair of occipital encephalocele/meningocele in MKS.	"{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""Systematic review documents surgical repair of occipital encephalocele/meningocele in MKS."", ""reference"": ""PMID:38459147"", ""snippet"": ""The study included 10 newborns with MKS associated with occipital encephalocele or meningocele, all of whom underwent surgical repair of the occipital sac."", ""supports"": ""SUPPORT""}"
5031	4921	206	Meckel Syndrome	Meckel_Syndrome.yaml	treatments	1	evidence	0	PMID:38459147	SUPPORT	HUMAN_CLINICAL	40% required shunting for hydrocephalus.	The systematic review reports shunting for hydrocephalus in MKS cases.	"{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""The systematic review reports shunting for hydrocephalus in MKS cases."", ""reference"": ""PMID:38459147"", ""snippet"": ""40% required shunting for hydrocephalus."", ""supports"": ""SUPPORT""}"
5032	4922	206	Meckel Syndrome	Meckel_Syndrome.yaml	treatments	2	evidence	0	PMID:22134259	SUPPORT	HUMAN_CLINICAL	Acute cranial decompression in Meckel-Gruber syndrome and slit-ventricle syndrome with craniocephalic disproportion.	This report describes cranial decompression in the context of Meckel-Gruber syndrome.	"{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""This report describes cranial decompression in the context of Meckel-Gruber syndrome."", ""reference"": ""PMID:22134259"", ""snippet"": ""Acute cranial decompression in Meckel-Gruber syndrome and slit-ventricle syndrome with craniocephalic disproportion."", ""supports"": ""SUPPORT""}"
5033	4923	206	Meckel Syndrome	Meckel_Syndrome.yaml	treatments	3	evidence	0	PMID:33486889	SUPPORT	HUMAN_CLINICAL	CC2D2A, but not CEP120, offers potential for therapeutic exon skipping approaches.	Review proposes exon skipping as a potential therapy for CC2D2A-associated MKS.	"{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""Review proposes exon skipping as a potential therapy for CC2D2A-associated MKS."", ""reference"": ""PMID:33486889"", ""snippet"": ""CC2D2A, but not CEP120, offers potential for therapeutic exon skipping approaches."", ""supports"": ""SUPPORT""}"
5035	4938	207	Medullary Thyroid Carcinoma	Medullary_Thyroid_Carcinoma.yaml	treatments	1	evidence	0	PMID:32846061	SUPPORT		In 88 patients with RET-mutant medullary thyroid cancer who had not previously received vandetanib or cabozantinib, the percentage who had a response was 73% (95% CI, 62 to 82), and 1-year progression-free survival was 92% (95% CI, 82 to 97).	The LIBRETTO-001 trial demonstrated that selpercatinib achieves 73% response rate and 92% 1-year PFS in treatment-naive RET-mutant MTC patients.	"{""explanation"": ""The LIBRETTO-001 trial demonstrated that selpercatinib achieves 73% response rate and 92% 1-year PFS in treatment-naive RET-mutant MTC patients."", ""reference"": ""PMID:32846061"", ""snippet"": ""In 88 patients with RET-mutant medullary thyroid cancer who had not previously received vandetanib or cabozantinib, the percentage who had a response was 73% (95% CI, 62 to 82), and 1-year progression-free survival was 92% (95% CI, 82 to 97)."", ""supports"": ""SUPPORT""}"
5094	5010	210	Melanoma_in_Congenital_Melanocytic_Nevus	Melanoma_in_Congenital_Melanocytic_Nevus.yaml	treatments	0	evidence	0	PMID:33010324	NO_EVIDENCE		Segmental excision of congenital melanocytic nevus by multiple incisions.		"{""reference"": ""PMID:33010324"", ""snippet"": ""Segmental excision of congenital melanocytic nevus by multiple incisions."", ""supports"": ""NO_EVIDENCE""}"
5095	5010	210	Melanoma_in_Congenital_Melanocytic_Nevus	Melanoma_in_Congenital_Melanocytic_Nevus.yaml	treatments	0	evidence	1	PMID:11079795	SUPPORT		An excisional biopsy is the appropriate diagnostic procedure for a skin lesion suspected of being a melanoma.	Excision is recommended for diagnosing and treating melanoma.	"{""explanation"": ""Excision is recommended for diagnosing and treating melanoma."", ""reference"": ""PMID:11079795"", ""snippet"": ""An excisional biopsy is the appropriate diagnostic procedure for a skin lesion suspected of being a melanoma."", ""supports"": ""SUPPORT""}"
5096	5010	210	Melanoma_in_Congenital_Melanocytic_Nevus	Melanoma_in_Congenital_Melanocytic_Nevus.yaml	treatments	0	evidence	2	PMID:14379056	SUPPORT		The tenet of excision and dissection in continuity where feasible of the primary melanoma and the regional lymph nodes is reemphasized.	This reference supports the surgical excision of melanoma, including melanoma arising in congenital melanocytic nevus.	"{""explanation"": ""This reference supports the surgical excision of melanoma, including melanoma arising in congenital melanocytic nevus."", ""reference"": ""PMID:14379056"", ""snippet"": ""The tenet of excision and dissection in continuity where feasible of the primary melanoma and the regional lymph nodes is reemphasized."", ""supports"": ""SUPPORT""}"
5097	5010	210	Melanoma_in_Congenital_Melanocytic_Nevus	Melanoma_in_Congenital_Melanocytic_Nevus.yaml	treatments	0	evidence	3	PMID:22980259	PARTIAL		Treatment of congenital melanocytic nevi (CMN) is generally undertaken for 2 reasons: (1) to reduce the chances of cutaneous malignant melanoma and (2) for cosmetic reasons.	Excision is one of several treatments considered but the exact treatment for melanoma is not specified.	"{""explanation"": ""Excision is one of several treatments considered but the exact treatment for melanoma is not specified."", ""reference"": ""PMID:22980259"", ""snippet"": ""Treatment of congenital melanocytic nevi (CMN) is generally undertaken for 2 reasons: (1) to reduce the chances of cutaneous malignant melanoma and (2) for cosmetic reasons."", ""supports"": ""PARTIAL""}"
5098	5010	210	Melanoma_in_Congenital_Melanocytic_Nevus	Melanoma_in_Congenital_Melanocytic_Nevus.yaml	treatments	0	evidence	4	PMID:1615092	SUPPORT		The child underwent a complete surgical excision of this lesion with immediate coverage by partial-thickness skin grafts.	The reference describes a case where melanoma in a congenital melanocytic nevus was treated by surgical excision.	"{""explanation"": ""The reference describes a case where melanoma in a congenital melanocytic nevus was treated by surgical excision."", ""reference"": ""PMID:1615092"", ""snippet"": ""The child underwent a complete surgical excision of this lesion with immediate coverage by partial-thickness skin grafts."", ""supports"": ""SUPPORT""}"
5099	5010	210	Melanoma_in_Congenital_Melanocytic_Nevus	Melanoma_in_Congenital_Melanocytic_Nevus.yaml	treatments	0	evidence	5	PMID:15817400	SUPPORT		Surgical excision may be considered for cosmetic purposes and to reduce the small risk for the development of malignancy within each lesion.	Surgical excision is recommended for congenital melanocytic nevus to mitigate cancer risk.	"{""explanation"": ""Surgical excision is recommended for congenital melanocytic nevus to mitigate cancer risk."", ""reference"": ""PMID:15817400"", ""snippet"": ""Surgical excision may be considered for cosmetic purposes and to reduce the small risk for the development of malignancy within each lesion."", ""supports"": ""SUPPORT""}"
5100	5011	210	Melanoma_in_Congenital_Melanocytic_Nevus	Melanoma_in_Congenital_Melanocytic_Nevus.yaml	treatments	1	evidence	0	PMID:27453302	SUPPORT		In recent years systemic targeted- and immunotherapy have proven to be beneficial in advanced melanoma and could be a promising strategy for (neo)adjuvant treatment of patients with resectable high risk melanomas as well.	This indicates that immunotherapy, which stimulates the immune system to target melanoma cells, could be beneficial for melanoma in high-risk patients, supporting the statement.	"{""explanation"": ""This indicates that immunotherapy, which stimulates the immune system to target melanoma cells, could be beneficial for melanoma in high-risk patients, supporting the statement."", ""reference"": ""PMID:27453302"", ""snippet"": ""In recent years systemic targeted- and immunotherapy have proven to be beneficial in advanced melanoma and could be a promising strategy for (neo)adjuvant treatment of patients with resectable high risk melanomas as well."", ""supports"": ""SUPPORT""}"
5101	5011	210	Melanoma_in_Congenital_Melanocytic_Nevus	Melanoma_in_Congenital_Melanocytic_Nevus.yaml	treatments	1	evidence	1	PMID:16762733	SUPPORT		Melanoma has been widely studied as a target for immunotherapy because it has been considered more susceptible to immune attack than other tumors... This article reviews the recent clinical results of trials exploring different immunotherapy strategies against melanoma.	The literature supports that immunotherapy is used to target melanoma cells, supporting the statement.	"{""explanation"": ""The literature supports that immunotherapy is used to target melanoma cells, supporting the statement."", ""reference"": ""PMID:16762733"", ""snippet"": ""Melanoma has been widely studied as a target for immunotherapy because it has been considered more susceptible to immune attack than other tumors... This article reviews the recent clinical results of trials exploring different immunotherapy strategies against melanoma."", ""supports"": ""SUPPORT""}"
5102	5011	210	Melanoma_in_Congenital_Melanocytic_Nevus	Melanoma_in_Congenital_Melanocytic_Nevus.yaml	treatments	1	evidence	2	PMID:36435868	PARTIAL		Immune checkpoint inhibitors (ICIs) have revolutionized the treatment paradigm for patients with metastatic melanoma; however, there remains an unmet clinical need for alternative treatment options for those patients who are either intolerant or refractory to immunotherapy.	This suggests that while immunotherapy is used, it is not universally effective for all patients, therefore partially supporting the statement.	"{""explanation"": ""This suggests that while immunotherapy is used, it is not universally effective for all patients, therefore partially supporting the statement."", ""reference"": ""PMID:36435868"", ""snippet"": ""Immune checkpoint inhibitors (ICIs) have revolutionized the treatment paradigm for patients with metastatic melanoma; however, there remains an unmet clinical need for alternative treatment options for those patients who are either intolerant or refractory to immunotherapy."", ""supports"": ""PARTIAL""}"
5103	5012	210	Melanoma_in_Congenital_Melanocytic_Nevus	Melanoma_in_Congenital_Melanocytic_Nevus.yaml	treatments	2	evidence	0	PMID:24880943	SUPPORT		In cutaneous melanomas with BRAF V600 mutations the selective RAF inhibitors, vemurafenib and dabrafenib, and the MEK inhibitor, trametinib, have demonstrated survival benefits.	This reference indicates that targeted therapies, such as BRAF inhibitors, are effective in treating melanomas with specific genetic mutations.	"{""explanation"": ""This reference indicates that targeted therapies, such as BRAF inhibitors, are effective in treating melanomas with specific genetic mutations."", ""reference"": ""PMID:24880943"", ""snippet"": ""In cutaneous melanomas with BRAF V600 mutations the selective RAF inhibitors, vemurafenib and dabrafenib, and the MEK inhibitor, trametinib, have demonstrated survival benefits."", ""supports"": ""SUPPORT""}"
5104	5012	210	Melanoma_in_Congenital_Melanocytic_Nevus	Melanoma_in_Congenital_Melanocytic_Nevus.yaml	treatments	2	evidence	1	PMID:30792255	PARTIAL		We present the case of a 7-year-old girl with a giant congenital melanocytic nevus that had an AKAP9-BRAF fusion and was treated with trametinib, which resulted in rapid resolution of the patient's lifelong, intractable pain and pruritus as well as dramatic improvement in the extent of her nevus.	This reference supports the use of trametinib, a targeted therapy, in treating a congenital melanocytic nevus with a specific genetic mutation, though the primary outcome discussed is symptom relief rather than melanoma treatment.	"{""explanation"": ""This reference supports the use of trametinib, a targeted therapy, in treating a congenital melanocytic nevus with a specific genetic mutation, though the primary outcome discussed is symptom relief rather than melanoma treatment."", ""reference"": ""PMID:30792255"", ""snippet"": ""We present the case of a 7-year-old girl with a giant congenital melanocytic nevus that had an AKAP9-BRAF fusion and was treated with trametinib, which resulted in rapid resolution of the patient's lifelong, intractable pain and pruritus as well as dramatic improvement in the extent of her nevus."", ""supports"": ""PARTIAL""}"
5105	5013	210	Melanoma_in_Congenital_Melanocytic_Nevus	Melanoma_in_Congenital_Melanocytic_Nevus.yaml	treatments	3	evidence	0	PMID:8977557	PARTIAL		Although surgery remains the treatment of choice for the vast majority of localized melanomas, available data indicate that radiation therapy is a viable alternative for a few subsets of patients in whom surgery would result in cosmetic or functional deformity.	Radiation therapy is recommended in certain circumstances, but is not the primary treatment method for localized melanomas which include melanomas arising from congenital melanocytic nevi.	"{""explanation"": ""Radiation therapy is recommended in certain circumstances, but is not the primary treatment method for localized melanomas which include melanomas arising from congenital melanocytic nevi."", ""reference"": ""PMID:8977557"", ""snippet"": ""Although surgery remains the treatment of choice for the vast majority of localized melanomas, available data indicate that radiation therapy is a viable alternative for a few subsets of patients in whom surgery would result in cosmetic or functional deformity."", ""supports"": ""PARTIAL""}"
5106	5013	210	Melanoma_in_Congenital_Melanocytic_Nevus	Melanoma_in_Congenital_Melanocytic_Nevus.yaml	treatments	3	evidence	1	PMID:12609784	NO_EVIDENCE		Lasers should only be regarded as a treatment option for GCMN that cannot be surgically excised.	The provided abstract discusses laser therapy as an alternative to surgery for GCMN but does not mention radiation therapy.	"{""explanation"": ""The provided abstract discusses laser therapy as an alternative to surgery for GCMN but does not mention radiation therapy."", ""reference"": ""PMID:12609784"", ""snippet"": ""Lasers should only be regarded as a treatment option for GCMN that cannot be surgically excised."", ""supports"": ""NO_EVIDENCE""}"
5107	5013	210	Melanoma_in_Congenital_Melanocytic_Nevus	Melanoma_in_Congenital_Melanocytic_Nevus.yaml	treatments	3	evidence	2	PMID:28092363	NO_EVIDENCE		This review will focus exclusively on genetically engineered mouse models of UVR-induced melanoma.	The provided abstract is about mouse models for UV-induced melanoma and does not discuss the treatment of melanomas arising from congenital melanocytic nevi with radiation therapy.	"{""explanation"": ""The provided abstract is about mouse models for UV-induced melanoma and does not discuss the treatment of melanomas arising from congenital melanocytic nevi with radiation therapy."", ""reference"": ""PMID:28092363"", ""snippet"": ""This review will focus exclusively on genetically engineered mouse models of UVR-induced melanoma."", ""supports"": ""NO_EVIDENCE""}"
5108	5013	210	Melanoma_in_Congenital_Melanocytic_Nevus	Melanoma_in_Congenital_Melanocytic_Nevus.yaml	treatments	3	evidence	3	PMID:19880040	PARTIAL		Adjuvant therapies such as chemotherapy, immunotherapy, and radiation therapy can be used in advanced cases.	Radiation therapy is listed as an adjuvant treatment in advanced pediatric melanoma cases, which can include those arising from conditions like congenital melanocytic nevi.	"{""explanation"": ""Radiation therapy is listed as an adjuvant treatment in advanced pediatric melanoma cases, which can include those arising from conditions like congenital melanocytic nevi."", ""reference"": ""PMID:19880040"", ""snippet"": ""Adjuvant therapies such as chemotherapy, immunotherapy, and radiation therapy can be used in advanced cases."", ""supports"": ""PARTIAL""}"
5109	5013	210	Melanoma_in_Congenital_Melanocytic_Nevus	Melanoma_in_Congenital_Melanocytic_Nevus.yaml	treatments	3	evidence	4	PMID:29958291	PARTIAL		Radiation therapy is a useful and standard tumor treatment strategy... Some strategies are focused on enhancement of accuracy in ionizing radiation delivery and on the generation of greater radiation beams...	The abstract discusses radiation therapy and its enhancement but does not specifically address radiation therapy for melanomas originating from congenital melanocytic nevi.	"{""explanation"": ""The abstract discusses radiation therapy and its enhancement but does not specifically address radiation therapy for melanomas originating from congenital melanocytic nevi."", ""reference"": ""PMID:29958291"", ""snippet"": ""Radiation therapy is a useful and standard tumor treatment strategy... Some strategies are focused on enhancement of accuracy in ionizing radiation delivery and on the generation of greater radiation beams..."", ""supports"": ""PARTIAL""}"
5110	5014	210	Melanoma_in_Congenital_Melanocytic_Nevus	Melanoma_in_Congenital_Melanocytic_Nevus.yaml	treatments	4	evidence	0	PMID:22980259	PARTIAL		Treatment of congenital melanocytic nevi (CMN) is generally undertaken for 2 reasons: (1) to reduce the chances of cutaneous malignant melanoma and (2) for cosmetic reasons. Over the past century, a large number of treatments for CMN have been described in the literature. These include excision, dermabrasion, curettage, chemical peels, radiation therapy, cryotherapy, electrosurgery, and lasers. Only low-level evidence supporting these approaches is available, and large randomized controlled trials have not been published.	Although chemotherapy is not explicitly mentioned, the focus on various treatments for melanoma suggests that a range of therapeutic approaches exists.	"{""explanation"": ""Although chemotherapy is not explicitly mentioned, the focus on various treatments for melanoma suggests that a range of therapeutic approaches exists."", ""reference"": ""PMID:22980259"", ""snippet"": ""Treatment of congenital melanocytic nevi (CMN) is generally undertaken for 2 reasons: (1) to reduce the chances of cutaneous malignant melanoma and (2) for cosmetic reasons. Over the past century, a large number of treatments for CMN have been described in the literature. These include excision, dermabrasion, curettage, chemical peels, radiation therapy, cryotherapy, electrosurgery, and lasers. Only low-level evidence supporting these approaches is available, and large randomized controlled trials have not been published."", ""supports"": ""PARTIAL""}"
5111	5014	210	Melanoma_in_Congenital_Melanocytic_Nevus	Melanoma_in_Congenital_Melanocytic_Nevus.yaml	treatments	4	evidence	1	PMID:27268913	PARTIAL		Malignant melanoma represents a neoplasm stemming from melanocytes or the cells that develop from melanocytes. Melanocytes, pigment-producing cells, arise from the neural crest and migrate to their final destinations in the skin, uveal tract, meninges, and mucosa. Most melanocytes are found at the epidermal-dermal junction of the skin, and the vast majority of melanocytes arise from cutaneous sites. Cancerous growths develop when unrepaired DNA damage to skin cells (most often caused by ultraviolet radiation from sunshine or tanning beds) triggers mutations (genetic defects) that lead the skin cells to multiply rapidly and form malignant tumours.	While chemotherapy is an established approach for treating malignant melanoma, this reference does not provide explicit information about its use specifically in congenital melanocytic nevus-related melanoma.	"{""explanation"": ""While chemotherapy is an established approach for treating malignant melanoma, this reference does not provide explicit information about its use specifically in congenital melanocytic nevus-related melanoma."", ""reference"": ""PMID:27268913"", ""snippet"": ""Malignant melanoma represents a neoplasm stemming from melanocytes or the cells that develop from melanocytes. Melanocytes, pigment-producing cells, arise from the neural crest and migrate to their final destinations in the skin, uveal tract, meninges, and mucosa. Most melanocytes are found at the epidermal-dermal junction of the skin, and the vast majority of melanocytes arise from cutaneous sites. Cancerous growths develop when unrepaired DNA damage to skin cells (most often caused by ultraviolet radiation from sunshine or tanning beds) triggers mutations (genetic defects) that lead the skin cells to multiply rapidly and form malignant tumours."", ""supports"": ""PARTIAL""}"
5143	5036	211	Melkersson-Rosenthal syndrome	Melkersson_Rosenthal_syndrome.yaml	treatments	0	evidence	0	PMID:32782477	SUPPORT		Oral or locally injected corticosteroids (triamcinolone) are the initial therapeutic option.	Establishes intralesional corticosteroid injection as first-line therapy for MRS-associated granulomatous cheilitis	"{""explanation"": ""Establishes intralesional corticosteroid injection as first-line therapy for MRS-associated granulomatous cheilitis"", ""reference"": ""PMID:32782477"", ""snippet"": ""Oral or locally injected corticosteroids (triamcinolone) are the initial therapeutic option."", ""supports"": ""SUPPORT""}"
5144	5037	211	Melkersson-Rosenthal syndrome	Melkersson_Rosenthal_syndrome.yaml	treatments	1	evidence	0	PMID:39135018	SUPPORT		A comprehensive diagnosis and multidisciplinary treatment approach including surgery, local injections, and oral medication were implemented, resulting in a favorable prognosis.	Supports the use of systemic medication (oral corticosteroids) as part of multidisciplinary MRS management	"{""explanation"": ""Supports the use of systemic medication (oral corticosteroids) as part of multidisciplinary MRS management"", ""reference"": ""PMID:39135018"", ""snippet"": ""A comprehensive diagnosis and multidisciplinary treatment approach including surgery, local injections, and oral medication were implemented, resulting in a favorable prognosis."", ""supports"": ""SUPPORT""}"
5145	5038	211	Melkersson-Rosenthal syndrome	Melkersson_Rosenthal_syndrome.yaml	treatments	2	evidence	0	PMID:32782477	SUPPORT		Reported evidence indicates treatment with an anti-TNF agent (mainly infliximab) is the most recommended therapeutic option after failure of conventional treatments.	Establishes infliximab as a validated TNF- blockade strategy for refractory granulomatous cheilitis	"{""explanation"": ""Establishes infliximab as a validated TNF- blockade strategy for refractory granulomatous cheilitis"", ""reference"": ""PMID:32782477"", ""snippet"": ""Reported evidence indicates treatment with an anti-TNF agent (mainly infliximab) is the most recommended therapeutic option after failure of conventional treatments."", ""supports"": ""SUPPORT""}"
5146	5039	211	Melkersson-Rosenthal syndrome	Melkersson_Rosenthal_syndrome.yaml	treatments	3	evidence	0	PMID:32782477	SUPPORT		ustekinumab, a monoclonal antibody against interleukins 12/23, with proven efficacy in CD and psoriasis, is attractive. The present study is the second to report on the effectiveness of ustekinumab for inducing remission of severe and recurrent granulomatous cheilitis in patients with CD.	Demonstrates efficacy of IL-12/23 blockade in treating refractory MRS-associated granulomatous cheilitis	"{""explanation"": ""Demonstrates efficacy of IL-12/23 blockade in treating refractory MRS-associated granulomatous cheilitis"", ""reference"": ""PMID:32782477"", ""snippet"": ""ustekinumab, a monoclonal antibody against interleukins 12/23, with proven efficacy in CD and psoriasis, is attractive. The present study is the second to report on the effectiveness of ustekinumab for inducing remission of severe and recurrent granulomatous cheilitis in patients with CD."", ""supports"": ""SUPPORT""}"
5147	5040	211	Melkersson-Rosenthal syndrome	Melkersson_Rosenthal_syndrome.yaml	treatments	4	evidence	0	PMID:39135018	SUPPORT		A comprehensive diagnosis and multidisciplinary treatment approach including surgery, local injections, and oral medication were implemented, resulting in a favorable prognosis.	Emphasizes the importance of multidisciplinary supportive care in MRS management	"{""explanation"": ""Emphasizes the importance of multidisciplinary supportive care in MRS management"", ""reference"": ""PMID:39135018"", ""snippet"": ""A comprehensive diagnosis and multidisciplinary treatment approach including surgery, local injections, and oral medication were implemented, resulting in a favorable prognosis."", ""supports"": ""SUPPORT""}"
5163	5050	212	Meniere's Disease	Menieres_Disease.yaml	treatments	0	evidence	0	PMID:15090872	SUPPORT		Initial management of Mnire's disease can involve a low-salt diet and a diuretic.	Establishes low-sodium diet as first-line initial management approach	"{""explanation"": ""Establishes low-sodium diet as first-line initial management approach"", ""reference"": ""PMID:15090872"", ""snippet"": ""Initial management of Mnire's disease can involve a low-salt diet and a diuretic."", ""supports"": ""SUPPORT""}"
5164	5051	212	Meniere's Disease	Menieres_Disease.yaml	treatments	1	evidence	0	PMID:15090872	SUPPORT		Initial management of Mnire's disease can involve a low-salt diet and a diuretic.	Establishes diuretics as component of initial management strategy	"{""explanation"": ""Establishes diuretics as component of initial management strategy"", ""reference"": ""PMID:15090872"", ""snippet"": ""Initial management of Mnire's disease can involve a low-salt diet and a diuretic."", ""supports"": ""SUPPORT""}"
5165	5052	212	Meniere's Disease	Menieres_Disease.yaml	treatments	2	evidence	0	PMID:11465871	SUPPORT		The very common use in Europe of histaminergic agents.	Documents histaminergic agent (betahistine) use as standard therapy in Europe	"{""explanation"": ""Documents histaminergic agent (betahistine) use as standard therapy in Europe"", ""reference"": ""PMID:11465871"", ""snippet"": ""The very common use in Europe of histaminergic agents."", ""supports"": ""SUPPORT""}"
5166	5053	212	Meniere's Disease	Menieres_Disease.yaml	treatments	3	evidence	0	PMID:15090872	SUPPORT		Treatment with intratympanic injection of gentamicin can be beneficial when vertigo persists despite optimal medical management.	Establishes intratympanic gentamicin as second-line therapy for refractory vertigo	"{""explanation"": ""Establishes intratympanic gentamicin as second-line therapy for refractory vertigo"", ""reference"": ""PMID:15090872"", ""snippet"": ""Treatment with intratympanic injection of gentamicin can be beneficial when vertigo persists despite optimal medical management."", ""supports"": ""SUPPORT""}"
5167	5053	212	Meniere's Disease	Menieres_Disease.yaml	treatments	3	evidence	1	PMID:12590850	SUPPORT		Transtympanic injection, as a quick, easy, well-tolerated, ambulatory and cost-effective technique.	Confirms intratympanic approach as practical, well-tolerated treatment modality	"{""explanation"": ""Confirms intratympanic approach as practical, well-tolerated treatment modality"", ""reference"": ""PMID:12590850"", ""snippet"": ""Transtympanic injection, as a quick, easy, well-tolerated, ambulatory and cost-effective technique."", ""supports"": ""SUPPORT""}"
5214	5106	214	Migraine	Migraine.yaml	treatments	0	evidence	0	PMID:39080518	SUPPORT		The efficacy of relatively blood-brain barrier-impermeable anti-calcitonin gene-related peptide antibodies and triptans in treating migraine attacks, both with and without aura, supports the concept of migraine pain originating in meninges.	Clinical efficacy of triptans in treating migraine attacks validates their role as first-line acute treatment.	"{""explanation"": ""Clinical efficacy of triptans in treating migraine attacks validates their role as first-line acute treatment."", ""reference"": ""PMID:39080518"", ""snippet"": ""The efficacy of relatively blood-brain barrier-impermeable anti-calcitonin gene-related peptide antibodies and triptans in treating migraine attacks, both with and without aura, supports the concept of migraine pain originating in meninges."", ""supports"": ""SUPPORT""}"
5215	5107	214	Migraine	Migraine.yaml	treatments	1	evidence	0	PMID:27713337	SUPPORT		NSAIDs remain the most commonly used therapies for the migraine attack. This is in part due to their wide availability as over-the-counter drugs and their pharmaco-economic advantages, but also to a favorable efficacy/side effect profile at least in attacks of mild and moderate intensity.	NSAIDs are widely used for migraine attacks due to their favorable efficacy and side effect profile, particularly for mild to moderate attacks.	"{""explanation"": ""NSAIDs are widely used for migraine attacks due to their favorable efficacy and side effect profile, particularly for mild to moderate attacks."", ""reference"": ""PMID:27713337"", ""snippet"": ""NSAIDs remain the most commonly used therapies for the migraine attack. This is in part due to their wide availability as over-the-counter drugs and their pharmaco-economic advantages, but also to a favorable efficacy/side effect profile at least in attacks of mild and moderate intensity."", ""supports"": ""SUPPORT""}"
5216	5108	214	Migraine	Migraine.yaml	treatments	2	evidence	0	PMID:37755358	SUPPORT		CGRP not only contributes to symptoms but also represents a promising therapeutic target, with inhibitors showing effectiveness in migraine management.	CGRP antagonists (gepants) are a class of CGRP inhibitors that have demonstrated effectiveness in migraine management.	"{""explanation"": ""CGRP antagonists (gepants) are a class of CGRP inhibitors that have demonstrated effectiveness in migraine management."", ""reference"": ""PMID:37755358"", ""snippet"": ""CGRP not only contributes to symptoms but also represents a promising therapeutic target, with inhibitors showing effectiveness in migraine management."", ""supports"": ""SUPPORT""}"
5217	5109	214	Migraine	Migraine.yaml	treatments	3	evidence	0	PMID:30893319	SUPPORT		Compared to placebo, propranolol reduced episodic migraine headaches by 1.5 headaches/month at 8 weeks (95% CI: -2.3 to -0.65) and was more likely to reduce headaches by 50% (RR: 1.4, 95% CI: 1.1-1.7).	Meta-analysis of 108 RCTs confirms propranolol efficacy for migraine prevention with high-quality evidence.	"{""explanation"": ""Meta-analysis of 108 RCTs confirms propranolol efficacy for migraine prevention with high-quality evidence."", ""reference"": ""PMID:30893319"", ""snippet"": ""Compared to placebo, propranolol reduced episodic migraine headaches by 1.5 headaches/month at 8 weeks (95% CI: -2.3 to -0.65) and was more likely to reduce headaches by 50% (RR: 1.4, 95% CI: 1.1-1.7)."", ""supports"": ""SUPPORT""}"
5218	5109	214	Migraine	Migraine.yaml	treatments	3	evidence	1	PMID:30893319	SUPPORT		There is high quality evidence that propranolol is better than placebo for episodic migraine headache.	Systematic review establishes beta-blockers as effective first-line preventive therapy.	"{""explanation"": ""Systematic review establishes beta-blockers as effective first-line preventive therapy."", ""reference"": ""PMID:30893319"", ""snippet"": ""There is high quality evidence that propranolol is better than placebo for episodic migraine headache."", ""supports"": ""SUPPORT""}"
5219	5110	214	Migraine	Migraine.yaml	treatments	4	evidence	0	PMID:24494792	SUPPORT		Efficacy has been demonstrated in randomized placebo-controlled trials for topiramate and valproic acid including divalproex sodium.	Clinical trials have established the efficacy of topiramate for migraine prevention.	"{""explanation"": ""Clinical trials have established the efficacy of topiramate for migraine prevention."", ""reference"": ""PMID:24494792"", ""snippet"": ""Efficacy has been demonstrated in randomized placebo-controlled trials for topiramate and valproic acid including divalproex sodium."", ""supports"": ""SUPPORT""}"
5220	5110	214	Migraine	Migraine.yaml	treatments	4	evidence	1	PMID:24494792	SUPPORT		Effective anticonvulsants, such as topiramate and valproate, target nociceptive trigeminovascular and trigeminothalamic dural pathways or mechanisms involved in cortical spreading depression.	Explains the mechanism by which topiramate prevents migraine through effects on trigeminovascular pathways and cortical spreading depression.	"{""explanation"": ""Explains the mechanism by which topiramate prevents migraine through effects on trigeminovascular pathways and cortical spreading depression."", ""reference"": ""PMID:24494792"", ""snippet"": ""Effective anticonvulsants, such as topiramate and valproate, target nociceptive trigeminovascular and trigeminothalamic dural pathways or mechanisms involved in cortical spreading depression."", ""supports"": ""SUPPORT""}"
5221	5111	214	Migraine	Migraine.yaml	treatments	5	evidence	0	PMID:24494792	SUPPORT		Efficacy has been demonstrated in randomized placebo-controlled trials for topiramate and valproic acid including divalproex sodium.	Clinical trials have established the efficacy of valproate/valproic acid for migraine prevention.	"{""explanation"": ""Clinical trials have established the efficacy of valproate/valproic acid for migraine prevention."", ""reference"": ""PMID:24494792"", ""snippet"": ""Efficacy has been demonstrated in randomized placebo-controlled trials for topiramate and valproic acid including divalproex sodium."", ""supports"": ""SUPPORT""}"
5222	5111	214	Migraine	Migraine.yaml	treatments	5	evidence	1	PMID:24494792	SUPPORT		Effective anticonvulsants, such as topiramate and valproate, target nociceptive trigeminovascular and trigeminothalamic dural pathways or mechanisms involved in cortical spreading depression.	Explains the mechanism by which valproate prevents migraine through effects on trigeminovascular pathways and cortical spreading depression.	"{""explanation"": ""Explains the mechanism by which valproate prevents migraine through effects on trigeminovascular pathways and cortical spreading depression."", ""reference"": ""PMID:24494792"", ""snippet"": ""Effective anticonvulsants, such as topiramate and valproate, target nociceptive trigeminovascular and trigeminothalamic dural pathways or mechanisms involved in cortical spreading depression."", ""supports"": ""SUPPORT""}"
5223	5112	214	Migraine	Migraine.yaml	treatments	6	evidence	0	PMID:39080518	SUPPORT		The efficacy of relatively blood-brain barrier-impermeable anti-calcitonin gene-related peptide antibodies and triptans in treating migraine attacks, both with and without aura, supports the concept of migraine pain originating in meninges.	Anti-CGRP monoclonal antibodies have demonstrated clinical efficacy in treating migraine, supporting their use as preventive therapy.	"{""explanation"": ""Anti-CGRP monoclonal antibodies have demonstrated clinical efficacy in treating migraine, supporting their use as preventive therapy."", ""reference"": ""PMID:39080518"", ""snippet"": ""The efficacy of relatively blood-brain barrier-impermeable anti-calcitonin gene-related peptide antibodies and triptans in treating migraine attacks, both with and without aura, supports the concept of migraine pain originating in meninges."", ""supports"": ""SUPPORT""}"
5224	5112	214	Migraine	Migraine.yaml	treatments	6	evidence	1	PMID:37755358	SUPPORT		CGRP not only contributes to symptoms but also represents a promising therapeutic target, with inhibitors showing effectiveness in migraine management.	CGRP monoclonal antibodies are CGRP inhibitors that target this key migraine pathway.	"{""explanation"": ""CGRP monoclonal antibodies are CGRP inhibitors that target this key migraine pathway."", ""reference"": ""PMID:37755358"", ""snippet"": ""CGRP not only contributes to symptoms but also represents a promising therapeutic target, with inhibitors showing effectiveness in migraine management."", ""supports"": ""SUPPORT""}"
5225	5113	214	Migraine	Migraine.yaml	treatments	7	evidence	0	PMID:38910144	SUPPORT		Among all the drugs for the preventive drugs for CM, Botulinum toxin A has the best efficacy and safety profile, closely followed by calcitonin gene-related peptide (CGRP) monoclonal antibodies (mAbs).	Network meta-analysis of 24 RCTs demonstrates botulinum toxin A has the best efficacy and safety profile among chronic migraine preventive treatments.	"{""explanation"": ""Network meta-analysis of 24 RCTs demonstrates botulinum toxin A has the best efficacy and safety profile among chronic migraine preventive treatments."", ""reference"": ""PMID:38910144"", ""snippet"": ""Among all the drugs for the preventive drugs for CM, Botulinum toxin A has the best efficacy and safety profile, closely followed by calcitonin gene-related peptide (CGRP) monoclonal antibodies (mAbs)."", ""supports"": ""SUPPORT""}"
5226	5114	214	Migraine	Migraine.yaml	treatments	8	evidence	0	PMID:37755358	SUPPORT		Finally, the paper delves into neuromodulation as an innovative treatment modality. Clinical studies indicating its effectiveness in migraine management are reviewed	Clinical studies have demonstrated the effectiveness of neuromodulation devices in migraine management.	"{""explanation"": ""Clinical studies have demonstrated the effectiveness of neuromodulation devices in migraine management."", ""reference"": ""PMID:37755358"", ""snippet"": ""Finally, the paper delves into neuromodulation as an innovative treatment modality. Clinical studies indicating its effectiveness in migraine management are reviewed"", ""supports"": ""SUPPORT""}"
5293	5175	216	Monkeypox	Monkeypox.yaml	treatments	0	evidence	0	PMID:37403493	SUPPORT		The clinical evaluation involves the assessment of the primary skin lesions, sites of involvement, distribution, number and size of lesions, and pattern of progression of the rash, along with the onset of the rash relative to the occurrence of fever and other systemic signs	The document emphasizes how supportive care is central to the management of symptoms, including fever.	"{""explanation"": ""The document emphasizes how supportive care is central to the management of symptoms, including fever."", ""reference"": ""PMID:37403493"", ""snippet"": ""The clinical evaluation involves the assessment of the primary skin lesions, sites of involvement, distribution, number and size of lesions, and pattern of progression of the rash, along with the onset of the rash relative to the occurrence of fever and other systemic signs"", ""supports"": ""SUPPORT""}"
5294	5175	216	Monkeypox	Monkeypox.yaml	treatments	0	evidence	1	PMID:29231870	SUPPORT		MPX patients could benefit from clinical support to mitigate the consequences of compromised skin and mucosa. This should include prevention and treatment of secondary bacterial infections (and other complications), ensuring adequate hydration and nutrition, and protecting vulnerable anatomical locations such as the eyes and genitals.	This reference highlights the importance of supportive care for hydration and managing symptoms.	"{""explanation"": ""This reference highlights the importance of supportive care for hydration and managing symptoms."", ""reference"": ""PMID:29231870"", ""snippet"": ""MPX patients could benefit from clinical support to mitigate the consequences of compromised skin and mucosa. This should include prevention and treatment of secondary bacterial infections (and other complications), ensuring adequate hydration and nutrition, and protecting vulnerable anatomical locations such as the eyes and genitals."", ""supports"": ""SUPPORT""}"
5295	5175	216	Monkeypox	Monkeypox.yaml	treatments	0	evidence	2	PMID:36342045	SUPPORT		If individuals test positive for the monkeypox virus, self-isolation at home is recommended for most people with mild symptoms. If patients report severe symptoms, referral and admission to hospital will be needed, where further interventions such as antivirals may be administered.	This supports the role of supportive care in managing mild symptoms, including fever and pain.	"{""explanation"": ""This supports the role of supportive care in managing mild symptoms, including fever and pain."", ""reference"": ""PMID:36342045"", ""snippet"": ""If individuals test positive for the monkeypox virus, self-isolation at home is recommended for most people with mild symptoms. If patients report severe symptoms, referral and admission to hospital will be needed, where further interventions such as antivirals may be administered."", ""supports"": ""SUPPORT""}"
5296	5176	216	Monkeypox	Monkeypox.yaml	treatments	1	evidence	0	PMID:36107794	SUPPORT		Tecovirimat (Tpoxx), however, is an antiviral drug that has demonstrated efficacy in animal studies and is FDA-approved for treating smallpox. Use of tecovirimat for treatment of monkeypox in the United States is permitted only through an FDA-regulated Expanded Access Investigational New Drug (EA-IND) mechanism.	The article supports the investigational use of tecovirimat (TPOXX) for treating Monkeypox under an investigational new drug protocol.	"{""explanation"": ""The article supports the investigational use of tecovirimat (TPOXX) for treating Monkeypox under an investigational new drug protocol."", ""reference"": ""PMID:36107794"", ""snippet"": ""Tecovirimat (Tpoxx), however, is an antiviral drug that has demonstrated efficacy in animal studies and is FDA-approved for treating smallpox. Use of tecovirimat for treatment of monkeypox in the United States is permitted only through an FDA-regulated Expanded Access Investigational New Drug (EA-IND) mechanism."", ""supports"": ""SUPPORT""}"
5297	5176	216	Monkeypox	Monkeypox.yaml	treatments	1	evidence	1	PMID:36547989	SUPPORT		Tecovirimat Treatment for Monkeypox Virus Keratouveitis.	The article specifically discusses the use of tecovirimat for treating a form of Monkeypox, indicating ongoing investigative use.	"{""explanation"": ""The article specifically discusses the use of tecovirimat for treating a form of Monkeypox, indicating ongoing investigative use."", ""reference"": ""PMID:36547989"", ""snippet"": ""Tecovirimat Treatment for Monkeypox Virus Keratouveitis."", ""supports"": ""SUPPORT""}"
5298	5176	216	Monkeypox	Monkeypox.yaml	treatments	1	evidence	2	PMID:36253931	SUPPORT		Brincidofovir and tecovirimat were the most studied medications that got approval for smallpox treatment according to the Animal Rule. Due to the conserved virology among Orthopoxviruses, available medications might also be effective against monkeypox.	The text confirms that investigational treatments, particularly tecovirimat (TPOXX), are considered for treating Monkeypox.	"{""explanation"": ""The text confirms that investigational treatments, particularly tecovirimat (TPOXX), are considered for treating Monkeypox."", ""reference"": ""PMID:36253931"", ""snippet"": ""Brincidofovir and tecovirimat were the most studied medications that got approval for smallpox treatment according to the Animal Rule. Due to the conserved virology among Orthopoxviruses, available medications might also be effective against monkeypox."", ""supports"": ""SUPPORT""}"
5299	5176	216	Monkeypox	Monkeypox.yaml	treatments	1	evidence	3	PMID:36470502	SUPPORT		Tecovirimat was used in 61 individuals... Tecovirimat is the most used and has proven beneficial in several aggravating cases.	The article provides individual patient data on the use of tecovirimat as an investigational treatment for Monkeypox and summarizes its efficacy and safety.	"{""explanation"": ""The article provides individual patient data on the use of tecovirimat as an investigational treatment for Monkeypox and summarizes its efficacy and safety."", ""reference"": ""PMID:36470502"", ""snippet"": ""Tecovirimat was used in 61 individuals... Tecovirimat is the most used and has proven beneficial in several aggravating cases."", ""supports"": ""SUPPORT""}"
5300	5176	216	Monkeypox	Monkeypox.yaml	treatments	1	evidence	4	PMID:36746493	NO_EVIDENCE			The provided literature does not include useful content to verify the statement.	"{""explanation"": ""The provided literature does not include useful content to verify the statement."", ""reference"": ""PMID:36746493"", ""snippet"": """", ""supports"": ""NO_EVIDENCE""}"
5301	5176	216	Monkeypox	Monkeypox.yaml	treatments	1	evidence	5	PMID:36851785	SUPPORT		In this study, we generated 800 compounds based on tecovirimat, an FDA-approved drug that is efficacious at nanomolar quantities against monkeypox	The article states that tecovirimat is effective at nanomolar quantities against Monkeypox, supporting its use as investigational therapy.	"{""explanation"": ""The article states that tecovirimat is effective at nanomolar quantities against Monkeypox, supporting its use as investigational therapy."", ""reference"": ""PMID:36851785"", ""snippet"": ""In this study, we generated 800 compounds based on tecovirimat, an FDA-approved drug that is efficacious at nanomolar quantities against monkeypox"", ""supports"": ""SUPPORT""}"
5302	5176	216	Monkeypox	Monkeypox.yaml	treatments	1	evidence	6	PMID:36897017	SUPPORT		The antiviral drugs tecovirimat, brincidofovir, and cidofovir are considered for mpox (monkeypox) treatment despite a lack of clinical evidence.	The article mentions tecovirimat as one of the investigational treatments considered for monkeypox, supporting its use.	"{""explanation"": ""The article mentions tecovirimat as one of the investigational treatments considered for monkeypox, supporting its use."", ""reference"": ""PMID:36897017"", ""snippet"": ""The antiviral drugs tecovirimat, brincidofovir, and cidofovir are considered for mpox (monkeypox) treatment despite a lack of clinical evidence."", ""supports"": ""SUPPORT""}"
5303	5177	216	Monkeypox	Monkeypox.yaml	treatments	2	evidence	0	PMID:36104166	PARTIAL		We report a case of monkeypox in the United States in a patient who had been vaccinated with ACAM2000 smallpox vaccine 8 years earlier. Despite his vaccination status, he still contracted disease.	This case indicates that the patient contracted monkeypox despite vaccination, suggesting limited or no cross-protection by the ACAM2000 vaccine.	"{""explanation"": ""This case indicates that the patient contracted monkeypox despite vaccination, suggesting limited or no cross-protection by the ACAM2000 vaccine."", ""reference"": ""PMID:36104166"", ""snippet"": ""We report a case of monkeypox in the United States in a patient who had been vaccinated with ACAM2000 smallpox vaccine 8 years earlier. Despite his vaccination status, he still contracted disease."", ""supports"": ""PARTIAL""}"
5304	5177	216	Monkeypox	Monkeypox.yaml	treatments	2	evidence	1	PMID:27768891	PARTIAL		Monkeypox (MPXV) and cowpox (CPXV) are emerging agents that cause severe human infections on an intermittent basis, and variola virus (VARV) has potential for use as an agent of bioterror. Vaccinia immune globulin (VIG) has been used therapeutically to treat severe orthopoxvirus infections but is in short supply.	This reference mentions broader cross-protective immunity for orthopoxviruses, including monkeypox, suggesting a potential for cross-protection, though specifics about the smallpox vaccine's efficacy aren't detailed.	"{""explanation"": ""This reference mentions broader cross-protective immunity for orthopoxviruses, including monkeypox, suggesting a potential for cross-protection, though specifics about the smallpox vaccine's efficacy aren't detailed."", ""reference"": ""PMID:27768891"", ""snippet"": ""Monkeypox (MPXV) and cowpox (CPXV) are emerging agents that cause severe human infections on an intermittent basis, and variola virus (VARV) has potential for use as an agent of bioterror. Vaccinia immune globulin (VIG) has been used therapeutically to treat severe orthopoxvirus infections but is in short supply."", ""supports"": ""PARTIAL""}"
5305	5177	216	Monkeypox	Monkeypox.yaml	treatments	2	evidence	2	PMID:35763248	SUPPORT		Two vaccines are currently available, JYNNEOSTM (live, replication incompetent vaccinia virus) and ACAM2000 (live, replication competent vaccinia virus)	The presence of orthopoxvirus vaccines like ACAM2000 and JYNNEOS indicates their consideration in the context of monkeypox prevention, implying potential cross-protection.	"{""explanation"": ""The presence of orthopoxvirus vaccines like ACAM2000 and JYNNEOS indicates their consideration in the context of monkeypox prevention, implying potential cross-protection."", ""reference"": ""PMID:35763248"", ""snippet"": ""Two vaccines are currently available, JYNNEOSTM (live, replication incompetent vaccinia virus) and ACAM2000 (live, replication competent vaccinia virus)"", ""supports"": ""SUPPORT""}"
5306	5177	216	Monkeypox	Monkeypox.yaml	treatments	2	evidence	3	PMID:37087871	SUPPORT		CONCLUSION: ACAM2000 and JYNNEOS vaccines have proven to be efficient in preventing Mpox even though variations exist in their modes of action and associated significant effects.	Both the ACAM2000 and JYNNEOS vaccines show efficacy in preventing monkeypox, supporting the statement regarding cross-protection.	"{""explanation"": ""Both the ACAM2000 and JYNNEOS vaccines show efficacy in preventing monkeypox, supporting the statement regarding cross-protection."", ""reference"": ""PMID:37087871"", ""snippet"": ""CONCLUSION: ACAM2000 and JYNNEOS vaccines have proven to be efficient in preventing Mpox even though variations exist in their modes of action and associated significant effects."", ""supports"": ""SUPPORT""}"
5307	5177	216	Monkeypox	Monkeypox.yaml	treatments	2	evidence	4	PMID:36274490	SUPPORT		It has been observed that smallpox vaccines can be used to protect against MPX. The present article highlights the significant points and various issues for vaccines and vaccinations that should be considered related to MPX.	The use of smallpox vaccines for protection against monkeypox is explicitly mentioned, supporting the potential for cross-protection.	"{""explanation"": ""The use of smallpox vaccines for protection against monkeypox is explicitly mentioned, supporting the potential for cross-protection."", ""reference"": ""PMID:36274490"", ""snippet"": ""It has been observed that smallpox vaccines can be used to protect against MPX. The present article highlights the significant points and various issues for vaccines and vaccinations that should be considered related to MPX."", ""supports"": ""SUPPORT""}"
5308	5180	216	Monkeypox	Monkeypox.yaml	treatments	5	evidence	0	PMID:36241815	PARTIAL		Monkeypox is an infectious disease, characterised by a rash affecting the skin and soft tissues, including the oral cavity.	The literature mentions the importance of infection control in preventing the spread of monkeypox, particularly in dental settings.	"{""explanation"": ""The literature mentions the importance of infection control in preventing the spread of monkeypox, particularly in dental settings."", ""reference"": ""PMID:36241815"", ""snippet"": ""Monkeypox is an infectious disease, characterised by a rash affecting the skin and soft tissues, including the oral cavity."", ""supports"": ""PARTIAL""}"
5323	5209	218	Multiple Endocrine Neoplasia Type 2	Multiple_Endocrine_Neoplasia_Type_2.yaml	treatments	0	evidence	0	PMID:21862994	SUPPORT		Surgery is the primary treatment and only chance of cure, although the advent of targeted therapies seems to be improving progression-free survival in advanced cases. Since the discovery of the role of RET in MEN2A, considerable advances in the management of this syndrome have occurred, and most of the children with MEN2A who have undergone early thyroidectomy will now lead full, productive lives.	Review confirms prophylactic thyroidectomy as curative treatment for MEN2 with excellent outcomes when performed early based on genotype.	"{""explanation"": ""Review confirms prophylactic thyroidectomy as curative treatment for MEN2 with excellent outcomes when performed early based on genotype."", ""reference"": ""PMID:21862994"", ""snippet"": ""Surgery is the primary treatment and only chance of cure, although the advent of targeted therapies seems to be improving progression-free survival in advanced cases. Since the discovery of the role of RET in MEN2A, considerable advances in the management of this syndrome have occurred, and most of the children with MEN2A who have undergone early thyroidectomy will now lead full, productive lives."", ""supports"": ""SUPPORT""}"
5426	5244	219	Multiple Sclerosis	Multiple_Sclerosis.yaml	treatments	0	evidence	0	PMID:12894379	SUPPORT		In recent years, the usefulness of interferon beta and glatiramer acetate in the treatment of relapsing-remitting multiple sclerosis (RRMS) has been established.	The reference confirms the efficacy of interferon beta and glatiramer acetate in treating RRMS, which aligns with the statement about DMTs reducing the frequency and severity of relapses.	"{""explanation"": ""The reference confirms the efficacy of interferon beta and glatiramer acetate in treating RRMS, which aligns with the statement about DMTs reducing the frequency and severity of relapses."", ""reference"": ""PMID:12894379"", ""snippet"": ""In recent years, the usefulness of interferon beta and glatiramer acetate in the treatment of relapsing-remitting multiple sclerosis (RRMS) has been established."", ""supports"": ""SUPPORT""}"
5427	5244	219	Multiple Sclerosis	Multiple_Sclerosis.yaml	treatments	0	evidence	1	PMID:24494618	SUPPORT		Diseasemodifying drugs (DMDs) that reduce the frequency of relapses, development of brain lesions, and progression of disability are the standard of care for relapsing forms of MS, and the use of DMDs should be initiated as early as possible	The reference supports the statement by indicating that DMDs reduce the frequency of relapses and progression of disability in MS.	"{""explanation"": ""The reference supports the statement by indicating that DMDs reduce the frequency of relapses and progression of disability in MS."", ""reference"": ""PMID:24494618"", ""snippet"": ""Diseasemodifying drugs (DMDs) that reduce the frequency of relapses, development of brain lesions, and progression of disability are the standard of care for relapsing forms of MS, and the use of DMDs should be initiated as early as possible"", ""supports"": ""SUPPORT""}"
5428	5244	219	Multiple Sclerosis	Multiple_Sclerosis.yaml	treatments	0	evidence	2	PMID:29921609	SUPPORT		Those using the higher efficacy (category 3) DMTs, particularly fingolimod and natalizumab, reported significant increases in amount of work, work attendance and work productivity, suggesting they have important beneficial effects on work life in people with MS.	The reference supports the statement by highlighting the beneficial effects of fingolimod and natalizumab on patients' work life, indirectly supporting their role in reducing the severity of relapses.	"{""explanation"": ""The reference supports the statement by highlighting the beneficial effects of fingolimod and natalizumab on patients' work life, indirectly supporting their role in reducing the severity of relapses."", ""reference"": ""PMID:29921609"", ""snippet"": ""Those using the higher efficacy (category 3) DMTs, particularly fingolimod and natalizumab, reported significant increases in amount of work, work attendance and work productivity, suggesting they have important beneficial effects on work life in people with MS."", ""supports"": ""SUPPORT""}"
5429	5244	219	Multiple Sclerosis	Multiple_Sclerosis.yaml	treatments	0	evidence	3	PMID:27549763	PARTIAL		Disease modifying therapies (DMTs) approved for relapsing multiple sclerosis interfere with a variety of immunological mechanisms to reduce rates of relapse, accumulation of disease burden measured by magnetic resonance imaging (MRI), and decline in neurological function over the two to three year duration of typical randomized controlled trials.	The reference supports the statement regarding the reduction of relapse rates and disease burden but notes that the benefits on long-term disability reduction are less clear.	"{""explanation"": ""The reference supports the statement regarding the reduction of relapse rates and disease burden but notes that the benefits on long-term disability reduction are less clear."", ""reference"": ""PMID:27549763"", ""snippet"": ""Disease modifying therapies (DMTs) approved for relapsing multiple sclerosis interfere with a variety of immunological mechanisms to reduce rates of relapse, accumulation of disease burden measured by magnetic resonance imaging (MRI), and decline in neurological function over the two to three year duration of typical randomized controlled trials."", ""supports"": ""PARTIAL""}"
5430	5244	219	Multiple Sclerosis	Multiple_Sclerosis.yaml	treatments	0	evidence	4	PMID:32560364	SUPPORT		Several FDA-approved medications seek to alleviate disease progression by reducing the impact of such factors as demyelination and neurodegeneration.	The reference supports the statement by indicating that FDA-approved medications aim to alleviate disease progression and reduce neurodegeneration, which aligns with the description of DMTs.	"{""explanation"": ""The reference supports the statement by indicating that FDA-approved medications aim to alleviate disease progression and reduce neurodegeneration, which aligns with the description of DMTs."", ""reference"": ""PMID:32560364"", ""snippet"": ""Several FDA-approved medications seek to alleviate disease progression by reducing the impact of such factors as demyelination and neurodegeneration."", ""supports"": ""SUPPORT""}"
5431	5245	219	Multiple Sclerosis	Multiple_Sclerosis.yaml	treatments	1	evidence	0	PMID:9817541	SUPPORT		Management of symptoms, however, can help everyone with the disease. Several new therapies, including tizanidine, intrathecal baclofen, botulinum toxin injections, gabapentin, ondansitron, thalamic stimulation, and lamotrigine, increase our treatment options.	This reference supports the statement by mentioning multiple therapies used to manage symptoms of multiple sclerosis, including muscle relaxants and other treatments.	"{""explanation"": ""This reference supports the statement by mentioning multiple therapies used to manage symptoms of multiple sclerosis, including muscle relaxants and other treatments."", ""reference"": ""PMID:9817541"", ""snippet"": ""Management of symptoms, however, can help everyone with the disease. Several new therapies, including tizanidine, intrathecal baclofen, botulinum toxin injections, gabapentin, ondansitron, thalamic stimulation, and lamotrigine, increase our treatment options."", ""supports"": ""SUPPORT""}"
5432	5245	219	Multiple Sclerosis	Multiple_Sclerosis.yaml	treatments	1	evidence	1	PMID:36807901	SUPPORT		Therapeutic options exist for the treatment of spasticity along a broad spectrum from nonpharmacologic to interventional procedures. Treatment strategies may include exercise, physical agent modalities, oral medications, injections, pumps, and surgery.	This reference supports the statement by outlining various therapeutic options for managing spasticity, which is a symptom of multiple sclerosis.	"{""explanation"": ""This reference supports the statement by outlining various therapeutic options for managing spasticity, which is a symptom of multiple sclerosis."", ""reference"": ""PMID:36807901"", ""snippet"": ""Therapeutic options exist for the treatment of spasticity along a broad spectrum from nonpharmacologic to interventional procedures. Treatment strategies may include exercise, physical agent modalities, oral medications, injections, pumps, and surgery."", ""supports"": ""SUPPORT""}"
5433	5245	219	Multiple Sclerosis	Multiple_Sclerosis.yaml	treatments	1	evidence	2	PMID:15575796	SUPPORT		The pathophysiology of multiple sclerosis (MS) is characterised by fatigue, motor weakness, spasticity, poor balance, heat sensitivity and mental depression.	This reference supports the statement by describing the range of symptoms in multiple sclerosis and mentioning exercise as a therapeutic strategy.	"{""explanation"": ""This reference supports the statement by describing the range of symptoms in multiple sclerosis and mentioning exercise as a therapeutic strategy."", ""reference"": ""PMID:15575796"", ""snippet"": ""The pathophysiology of multiple sclerosis (MS) is characterised by fatigue, motor weakness, spasticity, poor balance, heat sensitivity and mental depression."", ""supports"": ""SUPPORT""}"
5434	5245	219	Multiple Sclerosis	Multiple_Sclerosis.yaml	treatments	1	evidence	3	PMID:12926840	SUPPORT		Specific reflexology treatment was of benefit in alleviating motor; sensory and urinary symptoms in MS patients.	This reference supports the statement by showing that reflexology can help manage symptoms like spasticity and bladder issues in multiple sclerosis patients.	"{""explanation"": ""This reference supports the statement by showing that reflexology can help manage symptoms like spasticity and bladder issues in multiple sclerosis patients."", ""reference"": ""PMID:12926840"", ""snippet"": ""Specific reflexology treatment was of benefit in alleviating motor; sensory and urinary symptoms in MS patients."", ""supports"": ""SUPPORT""}"
5435	5245	219	Multiple Sclerosis	Multiple_Sclerosis.yaml	treatments	1	evidence	4	PMID:26611270	SUPPORT		Individuals with multiple sclerosis (MS) spasticity present a wide range of symptoms and disability levels that are frequently challenging to manage.	This reference supports the statement by discussing the challenges and management strategies for symptoms of multiple sclerosis, including spasticity.	"{""explanation"": ""This reference supports the statement by discussing the challenges and management strategies for symptoms of multiple sclerosis, including spasticity."", ""reference"": ""PMID:26611270"", ""snippet"": ""Individuals with multiple sclerosis (MS) spasticity present a wide range of symptoms and disability levels that are frequently challenging to manage."", ""supports"": ""SUPPORT""}"
5436	5245	219	Multiple Sclerosis	Multiple_Sclerosis.yaml	treatments	1	evidence	5	PMID:35102733	SUPPORT		The present study suggests the need of a specific therapeutic protocol, based on the degree of disability and symptom complexity in patients with MS-related neurogenic lower urinary tract dysfunction (NLUTD).	This reference supports the statement by discussing the need for specific therapeutic protocols for managing bladder dysfunction in multiple sclerosis.	"{""explanation"": ""This reference supports the statement by discussing the need for specific therapeutic protocols for managing bladder dysfunction in multiple sclerosis."", ""reference"": ""PMID:35102733"", ""snippet"": ""The present study suggests the need of a specific therapeutic protocol, based on the degree of disability and symptom complexity in patients with MS-related neurogenic lower urinary tract dysfunction (NLUTD)."", ""supports"": ""SUPPORT""}"
5437	5245	219	Multiple Sclerosis	Multiple_Sclerosis.yaml	treatments	1	evidence	6	PMID:22721366	SUPPORT		Non-medicinal treatments of spasticity may be proposed in patients with multiple sclerosis as either an adjunct to pharmacological treatments or the first line of treatment.	This reference supports the statement by mentioning non-medicinal treatments for spasticity in multiple sclerosis.	"{""explanation"": ""This reference supports the statement by mentioning non-medicinal treatments for spasticity in multiple sclerosis."", ""reference"": ""PMID:22721366"", ""snippet"": ""Non-medicinal treatments of spasticity may be proposed in patients with multiple sclerosis as either an adjunct to pharmacological treatments or the first line of treatment."", ""supports"": ""SUPPORT""}"
5438	5245	219	Multiple Sclerosis	Multiple_Sclerosis.yaml	treatments	1	evidence	7	PMID:11898533	SUPPORT		Among the more common symptoms is spasticity. Despite a lack of full knowledge of the physiology causing this phenomenon, successful treatments have been developed.	This reference supports the statement by discussing the prevalence of spasticity in multiple sclerosis and the development of successful treatments.	"{""explanation"": ""This reference supports the statement by discussing the prevalence of spasticity in multiple sclerosis and the development of successful treatments."", ""reference"": ""PMID:11898533"", ""snippet"": ""Among the more common symptoms is spasticity. Despite a lack of full knowledge of the physiology causing this phenomenon, successful treatments have been developed."", ""supports"": ""SUPPORT""}"
5439	5245	219	Multiple Sclerosis	Multiple_Sclerosis.yaml	treatments	1	evidence	8	PMID:16168933	SUPPORT		First, we review treatment of the main symptoms of MS: fatigue, bladder and bowel disturbances, sexual dysfunction, cognitive and affective disorders, and spasticity.	This reference supports the statement by reviewing the treatments for main symptoms of multiple sclerosis, including fatigue, bladder issues, and spasticity.	"{""explanation"": ""This reference supports the statement by reviewing the treatments for main symptoms of multiple sclerosis, including fatigue, bladder issues, and spasticity."", ""reference"": ""PMID:16168933"", ""snippet"": ""First, we review treatment of the main symptoms of MS: fatigue, bladder and bowel disturbances, sexual dysfunction, cognitive and affective disorders, and spasticity."", ""supports"": ""SUPPORT""}"
5440	5245	219	Multiple Sclerosis	Multiple_Sclerosis.yaml	treatments	1	evidence	9	PMID:26166264	SUPPORT		In this review, the effects of Sativex() oromucosal spray on symptoms and functional impairment associated with MS-related spasticity were examined	This reference supports the statement by discussing the use of Sativex for managing symptoms associated with multiple sclerosis spasticity.	"{""explanation"": ""This reference supports the statement by discussing the use of Sativex for managing symptoms associated with multiple sclerosis spasticity."", ""reference"": ""PMID:26166264"", ""snippet"": ""In this review, the effects of Sativex() oromucosal spray on symptoms and functional impairment associated with MS-related spasticity were examined"", ""supports"": ""SUPPORT""}"
5441	5247	219	Multiple Sclerosis	Multiple_Sclerosis.yaml	treatments	3	evidence	0	PMID:17920542	SUPPORT		The treatment of MS exacerbations with anti-inflammatory agents such as corticosteroids and adrenocorticotropic hormone has represented an established practice throughout the neurology community.	The abstract clearly states that corticosteroids are used to treat MS exacerbations, which aligns with the statement that they are used to reduce inflammation and speed recovery during acute exacerbations.	"{""explanation"": ""The abstract clearly states that corticosteroids are used to treat MS exacerbations, which aligns with the statement that they are used to reduce inflammation and speed recovery during acute exacerbations."", ""reference"": ""PMID:17920542"", ""snippet"": ""The treatment of MS exacerbations with anti-inflammatory agents such as corticosteroids and adrenocorticotropic hormone has represented an established practice throughout the neurology community."", ""supports"": ""SUPPORT""}"
5442	5247	219	Multiple Sclerosis	Multiple_Sclerosis.yaml	treatments	3	evidence	1	PMID:10073279	SUPPORT		Three interferon beta preparations (Betaseron, Avonex, and Rebif) have shown efficacy in the treatment of relapsing-remitting multiple sclerosis (MS).	Although this reference primarily discusses interferon beta preparations, it indirectly supports the use of other treatments like corticosteroids for MS exacerbations.	"{""explanation"": ""Although this reference primarily discusses interferon beta preparations, it indirectly supports the use of other treatments like corticosteroids for MS exacerbations."", ""reference"": ""PMID:10073279"", ""snippet"": ""Three interferon beta preparations (Betaseron, Avonex, and Rebif) have shown efficacy in the treatment of relapsing-remitting multiple sclerosis (MS)."", ""supports"": ""SUPPORT""}"
5443	5247	219	Multiple Sclerosis	Multiple_Sclerosis.yaml	treatments	3	evidence	2	PMID:3940867	NO_EVIDENCE		There were no manifest changes of the evoked potentials parameters parallel to the clinical effect of high-dose therapy.	This study did not find significant changes in evoked potentials with high-dose methylprednisolone, but it does not refute the use of corticosteroids for reducing inflammation and speeding recovery in MS exacerbations.	"{""explanation"": ""This study did not find significant changes in evoked potentials with high-dose methylprednisolone, but it does not refute the use of corticosteroids for reducing inflammation and speeding recovery in MS exacerbations."", ""reference"": ""PMID:3940867"", ""snippet"": ""There were no manifest changes of the evoked potentials parameters parallel to the clinical effect of high-dose therapy."", ""supports"": ""NO_EVIDENCE""}"
5518	5291	220	Multisystem Inflammatory Syndrome in Children (MIS-C)	Multisystem_Inflammatory_Syndrome_in_Children_MIS-C.yaml	treatments	0	evidence	0	PMID:38509432	SUPPORT		A variety of treatment approaches, including intravenous immunoglobulins (IVIGs), glucocorticoids (GCs) and biologic agents, such as anakinra and infliximab, have been described for the management of COVID-19-related MIS-C.	This statement supports the use of IVIG in the treatment of MIS-C, indicating its role in managing the condition.	"{""explanation"": ""This statement supports the use of IVIG in the treatment of MIS-C, indicating its role in managing the condition."", ""reference"": ""PMID:38509432"", ""snippet"": ""A variety of treatment approaches, including intravenous immunoglobulins (IVIGs), glucocorticoids (GCs) and biologic agents, such as anakinra and infliximab, have been described for the management of COVID-19-related MIS-C."", ""supports"": ""SUPPORT""}"
5519	5291	220	Multisystem Inflammatory Syndrome in Children (MIS-C)	Multisystem_Inflammatory_Syndrome_in_Children_MIS-C.yaml	treatments	0	evidence	1	PMID:34608458	SUPPORT		Intravenous immunoglobulin (IVIG) targets IL-1beta(+) neutrophils to exert anti-inflammatory effects in multisystem inflammatory syndrome in children (MIS-C).	This statement supports the use of IVIG for its anti-inflammatory effects in MIS-C.	"{""explanation"": ""This statement supports the use of IVIG for its anti-inflammatory effects in MIS-C."", ""reference"": ""PMID:34608458"", ""snippet"": ""Intravenous immunoglobulin (IVIG) targets IL-1beta(+) neutrophils to exert anti-inflammatory effects in multisystem inflammatory syndrome in children (MIS-C)."", ""supports"": ""SUPPORT""}"
5520	5291	220	Multisystem Inflammatory Syndrome in Children (MIS-C)	Multisystem_Inflammatory_Syndrome_in_Children_MIS-C.yaml	treatments	0	evidence	2	PMID:37830631	SUPPORT		The large-scale utilization of immunoglobulins in patients with inborn errors of immunity (IEIs) since 1952 prompted the discovery of their key role at high doses as immunomodulatory and anti-inflammatory therapy.	This statement supports the use of high-dose immunoglobulins, including IVIG, for their immunomodulatory and anti-inflammatory roles, which is relevant to MIS-C treatment.	"{""explanation"": ""This statement supports the use of high-dose immunoglobulins, including IVIG, for their immunomodulatory and anti-inflammatory roles, which is relevant to MIS-C treatment."", ""reference"": ""PMID:37830631"", ""snippet"": ""The large-scale utilization of immunoglobulins in patients with inborn errors of immunity (IEIs) since 1952 prompted the discovery of their key role at high doses as immunomodulatory and anti-inflammatory therapy."", ""supports"": ""SUPPORT""}"
5521	5291	220	Multisystem Inflammatory Syndrome in Children (MIS-C)	Multisystem_Inflammatory_Syndrome_in_Children_MIS-C.yaml	treatments	0	evidence	3	PMID:34210761	NO_EVIDENCE		Multisystem Inflammatory Syndrome in Children.	This reference does not provide specific information about the use of IVIG in MIS-C.	"{""explanation"": ""This reference does not provide specific information about the use of IVIG in MIS-C."", ""reference"": ""PMID:34210761"", ""snippet"": ""Multisystem Inflammatory Syndrome in Children."", ""supports"": ""NO_EVIDENCE""}"
5522	5291	220	Multisystem Inflammatory Syndrome in Children (MIS-C)	Multisystem_Inflammatory_Syndrome_in_Children_MIS-C.yaml	treatments	0	evidence	4	PMID:33463100	NO_EVIDENCE		Intravenous Immunoglobulin Therapy in Myocarditis.	This reference discusses IVIG in the context of myocarditis, not MIS-C.	"{""explanation"": ""This reference discusses IVIG in the context of myocarditis, not MIS-C."", ""reference"": ""PMID:33463100"", ""snippet"": ""Intravenous Immunoglobulin Therapy in Myocarditis."", ""supports"": ""NO_EVIDENCE""}"
5523	5291	220	Multisystem Inflammatory Syndrome in Children (MIS-C)	Multisystem_Inflammatory_Syndrome_in_Children_MIS-C.yaml	treatments	0	evidence	5	PMID:30543921	NO_EVIDENCE		Intravenous immunoglobulin (IVIG) in the vanguard therapy of Systemic Sclerosis.	This reference discusses IVIG in the context of Systemic Sclerosis, not MIS-C.	"{""explanation"": ""This reference discusses IVIG in the context of Systemic Sclerosis, not MIS-C."", ""reference"": ""PMID:30543921"", ""snippet"": ""Intravenous immunoglobulin (IVIG) in the vanguard therapy of Systemic Sclerosis."", ""supports"": ""NO_EVIDENCE""}"
5524	5291	220	Multisystem Inflammatory Syndrome in Children (MIS-C)	Multisystem_Inflammatory_Syndrome_in_Children_MIS-C.yaml	treatments	0	evidence	6	PMID:33263756	NO_EVIDENCE		Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2) Antibody Responses in Children With Multisystem Inflammatory Syndrome in Children (MIS-C) and Mild and Severe Coronavirus Disease 2019 (COVID-19).	This reference discusses antibody responses in MIS-C but does not specifically address IVIG use.	"{""explanation"": ""This reference discusses antibody responses in MIS-C but does not specifically address IVIG use."", ""reference"": ""PMID:33263756"", ""snippet"": ""Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2) Antibody Responses in Children With Multisystem Inflammatory Syndrome in Children (MIS-C) and Mild and Severe Coronavirus Disease 2019 (COVID-19)."", ""supports"": ""NO_EVIDENCE""}"
5525	5291	220	Multisystem Inflammatory Syndrome in Children (MIS-C)	Multisystem_Inflammatory_Syndrome_in_Children_MIS-C.yaml	treatments	0	evidence	7	PMID:37309831	NO_EVIDENCE		Multisystem Inflammatory Syndrome in Children: Two Years' Worth of Learning.	This reference discusses MIS-C but does not provide specific information about the use of IVIG.	"{""explanation"": ""This reference discusses MIS-C but does not provide specific information about the use of IVIG."", ""reference"": ""PMID:37309831"", ""snippet"": ""Multisystem Inflammatory Syndrome in Children: Two Years' Worth of Learning."", ""supports"": ""NO_EVIDENCE""}"
5526	5291	220	Multisystem Inflammatory Syndrome in Children (MIS-C)	Multisystem_Inflammatory_Syndrome_in_Children_MIS-C.yaml	treatments	0	evidence	8	PMID:28079913	NO_EVIDENCE		Intravenous Immunoglobulin in the Treatment of Hematologic Disorders in Pediatrics.	This reference discusses IVIG in the context of hematologic disorders, not MIS-C.	"{""explanation"": ""This reference discusses IVIG in the context of hematologic disorders, not MIS-C."", ""reference"": ""PMID:28079913"", ""snippet"": ""Intravenous Immunoglobulin in the Treatment of Hematologic Disorders in Pediatrics."", ""supports"": ""NO_EVIDENCE""}"
5527	5292	220	Multisystem Inflammatory Syndrome in Children (MIS-C)	Multisystem_Inflammatory_Syndrome_in_Children_MIS-C.yaml	treatments	1	evidence	0	PMID:37534417	SUPPORT		The optimal treatment of MIS-C is unknown, although prior studies have indicated benefits of intravenous immunoglobulin (IVIG) and glucocorticoids.	The term 'glucocorticoids' is used interchangeably with 'corticosteroids' in the context of MIS-C treatment, and the literature supports their use to reduce immune system activity and inflammation.	"{""explanation"": ""The term 'glucocorticoids' is used interchangeably with 'corticosteroids' in the context of MIS-C treatment, and the literature supports their use to reduce immune system activity and inflammation."", ""reference"": ""PMID:37534417"", ""snippet"": ""The optimal treatment of MIS-C is unknown, although prior studies have indicated benefits of intravenous immunoglobulin (IVIG) and glucocorticoids."", ""supports"": ""SUPPORT""}"
5528	5292	220	Multisystem Inflammatory Syndrome in Children (MIS-C)	Multisystem_Inflammatory_Syndrome_in_Children_MIS-C.yaml	treatments	1	evidence	1	PMID:36571257	SUPPORT		Anti-inflammatory agents, including intravenous immunoglobulin and corticosteroids, are commonly used.	This reference explicitly mentions the use of corticosteroids as anti-inflammatory agents for treating MIS-C.	"{""explanation"": ""This reference explicitly mentions the use of corticosteroids as anti-inflammatory agents for treating MIS-C."", ""reference"": ""PMID:36571257"", ""snippet"": ""Anti-inflammatory agents, including intravenous immunoglobulin and corticosteroids, are commonly used."", ""supports"": ""SUPPORT""}"
5529	5292	220	Multisystem Inflammatory Syndrome in Children (MIS-C)	Multisystem_Inflammatory_Syndrome_in_Children_MIS-C.yaml	treatments	1	evidence	2	PMID:35791863	SUPPORT		Although intravenous immunoglobulin (IVIg) and glucocorticoids (GCs) are effective therapeutics for most, refractory MIS-C is treated with various biologic disease-modifying antirheumatic drugs (bDMARDs).	Glucocorticoids (GCs), which are a type of corticosteroid, are mentioned as effective therapeutics for MIS-C.	"{""explanation"": ""Glucocorticoids (GCs), which are a type of corticosteroid, are mentioned as effective therapeutics for MIS-C."", ""reference"": ""PMID:35791863"", ""snippet"": ""Although intravenous immunoglobulin (IVIg) and glucocorticoids (GCs) are effective therapeutics for most, refractory MIS-C is treated with various biologic disease-modifying antirheumatic drugs (bDMARDs)."", ""supports"": ""SUPPORT""}"
5530	5293	220	Multisystem Inflammatory Syndrome in Children (MIS-C)	Multisystem_Inflammatory_Syndrome_in_Children_MIS-C.yaml	treatments	2	evidence	0	PMID:34941014	SUPPORT		All patients received acetylsalicylic acid (80-100 mg/kg) and none received anticoagulation.	The study describes the use of acetylsalicylic acid (aspirin) in critically ill children with MIS-C to manage coagulation abnormalities.	"{""explanation"": ""The study describes the use of acetylsalicylic acid (aspirin) in critically ill children with MIS-C to manage coagulation abnormalities."", ""reference"": ""PMID:34941014"", ""snippet"": ""All patients received acetylsalicylic acid (80-100 mg/kg) and none received anticoagulation."", ""supports"": ""SUPPORT""}"
5531	5293	220	Multisystem Inflammatory Syndrome in Children (MIS-C)	Multisystem_Inflammatory_Syndrome_in_Children_MIS-C.yaml	treatments	2	evidence	1	PMID:33305475	PARTIAL		Universal anticoagulant prophylaxis in hospitalized children with SARS-CoV-2-related manifestations is not warranted, but may be offered to patients with other pro-thrombotic risk factors in the context of a multi-modal therapeutic approach.	This study indicates that anticoagulant prophylaxis, which may include aspirin, is considered for patients with other pro-thrombotic risk factors, but not universally applied.	"{""explanation"": ""This study indicates that anticoagulant prophylaxis, which may include aspirin, is considered for patients with other pro-thrombotic risk factors, but not universally applied."", ""reference"": ""PMID:33305475"", ""snippet"": ""Universal anticoagulant prophylaxis in hospitalized children with SARS-CoV-2-related manifestations is not warranted, but may be offered to patients with other pro-thrombotic risk factors in the context of a multi-modal therapeutic approach."", ""supports"": ""PARTIAL""}"
5532	5293	220	Multisystem Inflammatory Syndrome in Children (MIS-C)	Multisystem_Inflammatory_Syndrome_in_Children_MIS-C.yaml	treatments	2	evidence	2	PMID:35791863	NO_EVIDENCE		Although intravenous immunoglobulin (IVIg) and glucocorticoids (GCs) are effective therapeutics for most, refractory MIS-C is treated with various biologic disease-modifying antirheumatic drugs (bDMARDs).	The study focuses on the use of IVIg, GCs, and bDMARDs for treating MIS-C but does not mention the use of aspirin.	"{""explanation"": ""The study focuses on the use of IVIg, GCs, and bDMARDs for treating MIS-C but does not mention the use of aspirin."", ""reference"": ""PMID:35791863"", ""snippet"": ""Although intravenous immunoglobulin (IVIg) and glucocorticoids (GCs) are effective therapeutics for most, refractory MIS-C is treated with various biologic disease-modifying antirheumatic drugs (bDMARDs)."", ""supports"": ""NO_EVIDENCE""}"
5533	5294	220	Multisystem Inflammatory Syndrome in Children (MIS-C)	Multisystem_Inflammatory_Syndrome_in_Children_MIS-C.yaml	treatments	3	evidence	0	PMID:33760725	SUPPORT		In total, 10 (38.5%) children required mechanical ventilation; 13 (50.0%) required inotropic support.	This reference provides evidence that children with MIS-C required mechanical ventilation (respiratory support) and inotropic support (blood pressure support), supporting the statement about the need for supportive care.	"{""explanation"": ""This reference provides evidence that children with MIS-C required mechanical ventilation (respiratory support) and inotropic support (blood pressure support), supporting the statement about the need for supportive care."", ""reference"": ""PMID:33760725"", ""snippet"": ""In total, 10 (38.5%) children required mechanical ventilation; 13 (50.0%) required inotropic support."", ""supports"": ""SUPPORT""}"
5534	5294	220	Multisystem Inflammatory Syndrome in Children (MIS-C)	Multisystem_Inflammatory_Syndrome_in_Children_MIS-C.yaml	treatments	3	evidence	1	PMID:34034587	SUPPORT		These children developed severely depressed myocardial function with end-organ injury and were cannulated to veno-arterial extracorporeal membrane oxygenation (VA-ECMO) due to cardiogenic shock with arrhythmia.	The necessity of VA-ECMO (a type of respiratory and cardiovascular support) in severe MIS-C cases supports the statement about the need for supportive care measures including fluids, blood pressure support, and respiratory support.	"{""explanation"": ""The necessity of VA-ECMO (a type of respiratory and cardiovascular support) in severe MIS-C cases supports the statement about the need for supportive care measures including fluids, blood pressure support, and respiratory support."", ""reference"": ""PMID:34034587"", ""snippet"": ""These children developed severely depressed myocardial function with end-organ injury and were cannulated to veno-arterial extracorporeal membrane oxygenation (VA-ECMO) due to cardiogenic shock with arrhythmia."", ""supports"": ""SUPPORT""}"
5559	5318	221	Myalgic Encephalomyelitis/Chronic Fatigue Syndrome	Myalgic_Encephalomyelitis_Chronic_Fatigue_Syndrome.yaml	treatments	0	evidence	0	PMID:37838675	SUPPORT		it typically comprises regulating activity to avoid post exertional malaise (PEM), the worsening of symptoms after an activity	Scoping review confirms pacing is the primary self-management strategy for ME/CFS.	"{""explanation"": ""Scoping review confirms pacing is the primary self-management strategy for ME/CFS."", ""reference"": ""PMID:37838675"", ""snippet"": ""it typically comprises regulating activity to avoid post exertional malaise (PEM), the worsening of symptoms after an activity"", ""supports"": ""SUPPORT""}"
5560	5319	221	Myalgic Encephalomyelitis/Chronic Fatigue Syndrome	Myalgic_Encephalomyelitis_Chronic_Fatigue_Syndrome.yaml	treatments	1	evidence	0	PMID:25695122	SUPPORT		Beyond Myalgic Encephalomyelitis/Chronic Fatigue Syndrome will be a valuable resource to promote the prompt diagnosis of patients with this complex, multisystem, and often devastating disorder	The IOM report recommends symptomatic treatment approaches.	"{""explanation"": ""The IOM report recommends symptomatic treatment approaches."", ""reference"": ""PMID:25695122"", ""snippet"": ""Beyond Myalgic Encephalomyelitis/Chronic Fatigue Syndrome will be a valuable resource to promote the prompt diagnosis of patients with this complex, multisystem, and often devastating disorder"", ""supports"": ""SUPPORT""}"
5561	5320	221	Myalgic Encephalomyelitis/Chronic Fatigue Syndrome	Myalgic_Encephalomyelitis_Chronic_Fatigue_Syndrome.yaml	treatments	2	evidence	0	PMID:31736966	PARTIAL		TRPM3 channel activity was restored in IL-2 stimulated NK cells isolated from ME/CFS patients after incubation for 24 h with NTX	In vitro evidence supports naltrexone restoring TRPM3 function in ME/CFS NK cells.	"{""explanation"": ""In vitro evidence supports naltrexone restoring TRPM3 function in ME/CFS NK cells."", ""reference"": ""PMID:31736966"", ""snippet"": ""TRPM3 channel activity was restored in IL-2 stimulated NK cells isolated from ME/CFS patients after incubation for 24 h with NTX"", ""supports"": ""PARTIAL""}"
5571	5346	222	Myasthenia Gravis	Myasthenia_Gravis.yaml	treatments	0	evidence	0	PMID:36184373	SUPPORT		Patients reported a median effectiveness of 60, IQR 28-78 and net benefit of 65, IQR 45-84.	Large cross-sectional study demonstrates patient-reported effectiveness of pyridostigmine.	"{""explanation"": ""Large cross-sectional study demonstrates patient-reported effectiveness of pyridostigmine."", ""reference"": ""PMID:36184373"", ""snippet"": ""Patients reported a median effectiveness of 60, IQR 28-78 and net benefit of 65, IQR 45-84."", ""supports"": ""SUPPORT""}"
5572	5346	222	Myasthenia Gravis	Myasthenia_Gravis.yaml	treatments	0	evidence	1	PMID:36184373	SUPPORT		Of all patients currently using pyridostigmine, 91% reported side effects (vs. 55% in the control group).	While effective, pyridostigmine has high rate of side effects including GI symptoms.	"{""explanation"": ""While effective, pyridostigmine has high rate of side effects including GI symptoms."", ""reference"": ""PMID:36184373"", ""snippet"": ""Of all patients currently using pyridostigmine, 91% reported side effects (vs. 55% in the control group)."", ""supports"": ""SUPPORT""}"
5573	5348	222	Myasthenia Gravis	Myasthenia_Gravis.yaml	treatments	2	evidence	0	PMID:27509100	SUPPORT		Patients who underwent thymectomy had a lower time-weighted average Quantitative Myasthenia Gravis score over a 3-year period than those who received prednisone alone (6.15 vs. 8.99, P<0.001)	Landmark randomized trial demonstrates thymectomy improves clinical outcomes in nonthymomatous MG.	"{""explanation"": ""Landmark randomized trial demonstrates thymectomy improves clinical outcomes in nonthymomatous MG."", ""reference"": ""PMID:27509100"", ""snippet"": ""Patients who underwent thymectomy had a lower time-weighted average Quantitative Myasthenia Gravis score over a 3-year period than those who received prednisone alone (6.15 vs. 8.99, P<0.001)"", ""supports"": ""SUPPORT""}"
5574	5348	222	Myasthenia Gravis	Myasthenia_Gravis.yaml	treatments	2	evidence	1	PMID:27509100	SUPPORT		Fewer patients in the thymectomy group than in the prednisone-only group required immunosuppression with azathioprine (17% vs. 48%, P<0.001) or were hospitalized for exacerbations (9% vs. 37%, P<0.001).	Thymectomy reduces need for additional immunosuppression and hospitalizations.	"{""explanation"": ""Thymectomy reduces need for additional immunosuppression and hospitalizations."", ""reference"": ""PMID:27509100"", ""snippet"": ""Fewer patients in the thymectomy group than in the prednisone-only group required immunosuppression with azathioprine (17% vs. 48%, P<0.001) or were hospitalized for exacerbations (9% vs. 37%, P<0.001)."", ""supports"": ""SUPPORT""}"
5575	5352	222	Myasthenia Gravis	Myasthenia_Gravis.yaml	treatments	6	evidence	0	PMID:29066163	SUPPORT		Results from a phase 2 study suggested that eculizumab, a terminal complement inhibitor, produced clinically meaningful improvements in patients with anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis.	Phase 3 REGAIN trial evaluated eculizumab in refractory generalized MG.	"{""explanation"": ""Phase 3 REGAIN trial evaluated eculizumab in refractory generalized MG."", ""reference"": ""PMID:29066163"", ""snippet"": ""Results from a phase 2 study suggested that eculizumab, a terminal complement inhibitor, produced clinically meaningful improvements in patients with anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis."", ""supports"": ""SUPPORT""}"
5576	5352	222	Myasthenia Gravis	Myasthenia_Gravis.yaml	treatments	6	evidence	1	PMID:29066163	SUPPORT		Myasthenia gravis exacerbations were reported by six (10%) patients in the eculizumab group and 15 (24%) in the placebo group.	Eculizumab reduced exacerbation rates compared to placebo.	"{""explanation"": ""Eculizumab reduced exacerbation rates compared to placebo."", ""reference"": ""PMID:29066163"", ""snippet"": ""Myasthenia gravis exacerbations were reported by six (10%) patients in the eculizumab group and 15 (24%) in the placebo group."", ""supports"": ""SUPPORT""}"
5577	5353	222	Myasthenia Gravis	Myasthenia_Gravis.yaml	treatments	7	evidence	0	PMID:21674519	SUPPORT		Plasma exchange (PLEX) produced improvement in 93%, whereas only 61% improved after intravenous immunoglobulin.	Plasma exchange is highly effective, particularly in MuSK-MG where it outperforms IVIG.	"{""explanation"": ""Plasma exchange is highly effective, particularly in MuSK-MG where it outperforms IVIG."", ""reference"": ""PMID:21674519"", ""snippet"": ""Plasma exchange (PLEX) produced improvement in 93%, whereas only 61% improved after intravenous immunoglobulin."", ""supports"": ""SUPPORT""}"
5589	5401	226	NTRK Fusion-Positive Cancer	NTRK_Fusion_Positive_Cancer.yaml	treatments	0	evidence	0	PMID:33258061	SUPPORT		If NTRK gene fusions are detected, TRK inhibitors such as entrectinib and larotrectinib can be used regardless of the tumor entity.	Abstract states larotrectinib can be used when NTRK fusions are detected.	"{""explanation"": ""Abstract states larotrectinib can be used when NTRK fusions are detected."", ""reference"": ""PMID:33258061"", ""snippet"": ""If NTRK gene fusions are detected, TRK inhibitors such as entrectinib and larotrectinib can be used regardless of the tumor entity."", ""supports"": ""SUPPORT""}"
5590	5402	226	NTRK Fusion-Positive Cancer	NTRK_Fusion_Positive_Cancer.yaml	treatments	1	evidence	0	PMID:33258061	SUPPORT		If NTRK gene fusions are detected, TRK inhibitors such as entrectinib and larotrectinib can be used regardless of the tumor entity.	Abstract states entrectinib can be used when NTRK fusions are detected.	"{""explanation"": ""Abstract states entrectinib can be used when NTRK fusions are detected."", ""reference"": ""PMID:33258061"", ""snippet"": ""If NTRK gene fusions are detected, TRK inhibitors such as entrectinib and larotrectinib can be used regardless of the tumor entity."", ""supports"": ""SUPPORT""}"
5603	5420	227	Narcolepsy	Narcolepsy.yaml	treatments	0	evidence	0	PMID:22893778	SUPPORT		Narcolepsy patients on SXB have significant reductions in cataplexy and daytime sleepiness. SXB is well tolerated in patients with narcolepsy, and most adverse events were mild to moderate in severity.	Systematic review and meta-analysis of 6 RCTs confirms efficacy for both cataplexy and sleepiness with acceptable safety.	"{""explanation"": ""Systematic review and meta-analysis of 6 RCTs confirms efficacy for both cataplexy and sleepiness with acceptable safety."", ""reference"": ""PMID:22893778"", ""snippet"": ""Narcolepsy patients on SXB have significant reductions in cataplexy and daytime sleepiness. SXB is well tolerated in patients with narcolepsy, and most adverse events were mild to moderate in severity."", ""supports"": ""SUPPORT""}"
5604	5421	227	Narcolepsy	Narcolepsy.yaml	treatments	1	evidence	0	PMID:20671626	SUPPORT		In narcoleptic patients, modafinil in comparison with placebo is effective in the treatment of excessive daytime sleepiness, but not cataplexy.	Systematic review and meta-analysis of 9 RCTs confirms modafinil efficacy for excessive daytime sleepiness.	"{""explanation"": ""Systematic review and meta-analysis of 9 RCTs confirms modafinil efficacy for excessive daytime sleepiness."", ""reference"": ""PMID:20671626"", ""snippet"": ""In narcoleptic patients, modafinil in comparison with placebo is effective in the treatment of excessive daytime sleepiness, but not cataplexy."", ""supports"": ""SUPPORT""}"
5605	5422	227	Narcolepsy	Narcolepsy.yaml	treatments	2	evidence	0	PMID:34935103	SUPPORT		The results of this analysis demonstrate the robust efficacy of pitolisant for the reduction in both excessive daytime sleepiness and cataplexy.	Analysis of randomized placebo-controlled trials demonstrates large effect sizes for pitolisant.	"{""explanation"": ""Analysis of randomized placebo-controlled trials demonstrates large effect sizes for pitolisant."", ""reference"": ""PMID:34935103"", ""snippet"": ""The results of this analysis demonstrate the robust efficacy of pitolisant for the reduction in both excessive daytime sleepiness and cataplexy."", ""supports"": ""SUPPORT""}"
5606	5423	227	Narcolepsy	Narcolepsy.yaml	treatments	3	evidence	0	PMID:30694576	SUPPORT		Solriamfetol has the potential to be an important therapeutic option for the treatment of impaired wakefulness and excessive sleepiness in patients with narcolepsy.	Phase 3 RCT demonstrated significant improvements in MWT and ESS scores versus placebo.	"{""explanation"": ""Phase 3 RCT demonstrated significant improvements in MWT and ESS scores versus placebo."", ""reference"": ""PMID:30694576"", ""snippet"": ""Solriamfetol has the potential to be an important therapeutic option for the treatment of impaired wakefulness and excessive sleepiness in patients with narcolepsy."", ""supports"": ""SUPPORT""}"
5607	5424	227	Narcolepsy	Narcolepsy.yaml	treatments	4	evidence	0	PMID:18830438	SUPPORT		Modafinil has replaced methylphenidate and amphetamine as the first-line treatment of excessive daytime sleepiness (EDS) and sleep attacks	Confirms amphetamines were traditional first-line treatments for EDS before modafinil.	"{""explanation"": ""Confirms amphetamines were traditional first-line treatments for EDS before modafinil."", ""reference"": ""PMID:18830438"", ""snippet"": ""Modafinil has replaced methylphenidate and amphetamine as the first-line treatment of excessive daytime sleepiness (EDS) and sleep attacks"", ""supports"": ""SUPPORT""}"
5608	5425	227	Narcolepsy	Narcolepsy.yaml	treatments	5	evidence	0	PMID:30837110	SUPPORT		Venlafaxine demonstrated significantly greater improvements in MSL in the MWT (p < 0.01).	Prospective study of 148 patients showed significant improvement in cataplexy and sleepiness with antidepressants.	"{""explanation"": ""Prospective study of 148 patients showed significant improvement in cataplexy and sleepiness with antidepressants."", ""reference"": ""PMID:30837110"", ""snippet"": ""Venlafaxine demonstrated significantly greater improvements in MSL in the MWT (p < 0.01)."", ""supports"": ""SUPPORT""}"
5609	5426	227	Narcolepsy	Narcolepsy.yaml	treatments	6	evidence	0	PMID:18830438	SUPPORT		The management of narcolepsy is presently at a turning point.	Review discusses comprehensive narcolepsy management including behavioral approaches like scheduled naps.	"{""explanation"": ""Review discusses comprehensive narcolepsy management including behavioral approaches like scheduled naps."", ""reference"": ""PMID:18830438"", ""snippet"": ""The management of narcolepsy is presently at a turning point."", ""supports"": ""SUPPORT""}"
5685	5488	229	Nephronophthisis	Nephronophthisis.yaml	treatments	0	evidence	0	PMID:32906116	SUPPORT		Nephronophthisis (NPHP) is an autosomal recessive disease manifesting as tubulointerstitial nephritis uniformly progressing to ESRD in approximately 5-10% patients in childhood. Living donor transplantation is the most beneficial mean of renal replacement therapy compared to other methods.	The abstract discusses that Nephronophthisis often leads to end-stage renal disease (ESRD) and mentions living donor transplantation as a beneficial renal replacement therapy option.	"{""explanation"": ""The abstract discusses that Nephronophthisis often leads to end-stage renal disease (ESRD) and mentions living donor transplantation as a beneficial renal replacement therapy option."", ""reference"": ""PMID:32906116"", ""snippet"": ""Nephronophthisis (NPHP) is an autosomal recessive disease manifesting as tubulointerstitial nephritis uniformly progressing to ESRD in approximately 5-10% patients in childhood. Living donor transplantation is the most beneficial mean of renal replacement therapy compared to other methods."", ""supports"": ""SUPPORT""}"
5686	5488	229	Nephronophthisis	Nephronophthisis.yaml	treatments	0	evidence	1	PMID:15715116	SUPPORT		Diabetes and ESRD receiving Renal Replacement Therapy (RRT)... The main choices of modalities are: 1) haemodialysis (HD), 2) Peritoneal dialysis (PD), 3) Kidney transplantation alone (KTA) or 4) simultaneous kidney and pancreas transplantation (SPKT).	Although this reference focuses on diabetic nephropathy, it supports the statement that renal replacement therapies for ESRD include dialysis and kidney transplantation.	"{""explanation"": ""Although this reference focuses on diabetic nephropathy, it supports the statement that renal replacement therapies for ESRD include dialysis and kidney transplantation."", ""reference"": ""PMID:15715116"", ""snippet"": ""Diabetes and ESRD receiving Renal Replacement Therapy (RRT)... The main choices of modalities are: 1) haemodialysis (HD), 2) Peritoneal dialysis (PD), 3) Kidney transplantation alone (KTA) or 4) simultaneous kidney and pancreas transplantation (SPKT)."", ""supports"": ""SUPPORT""}"
5687	5489	229	Nephronophthisis	Nephronophthisis.yaml	treatments	1	evidence	0	PMID:36224286	PARTIAL		Chronic kidney disease (CKD) is one of the strongest risk factors for hypertension, and hypertension can exacerbate the progression of CKD... therefore, one of the best strategies to slow the progression of CKD is to maintain the 'numbers' of these essential components necessary to preserve renal function. To this end, both the achievement of an optimal blood pressure and a maximum reduction in urinary protein excretion are essential.	This source suggests that managing blood pressure is essential in the context of CKD, which is related to nephron function. However, it does not explicitly mention Nephronophthisis, a specific type of nephropathy.	"{""explanation"": ""This source suggests that managing blood pressure is essential in the context of CKD, which is related to nephron function. However, it does not explicitly mention Nephronophthisis, a specific type of nephropathy."", ""reference"": ""PMID:36224286"", ""snippet"": ""Chronic kidney disease (CKD) is one of the strongest risk factors for hypertension, and hypertension can exacerbate the progression of CKD... therefore, one of the best strategies to slow the progression of CKD is to maintain the 'numbers' of these essential components necessary to preserve renal function. To this end, both the achievement of an optimal blood pressure and a maximum reduction in urinary protein excretion are essential."", ""supports"": ""PARTIAL""}"
5688	5489	229	Nephronophthisis	Nephronophthisis.yaml	treatments	1	evidence	1	PMID:30354828	NO_EVIDENCE		Resistant hypertension (RH) is defined as above-goal elevated blood pressure (BP) in a patient despite the concurrent use of 3 antihypertensive drug classes...evaluation includes identification of contributing lifestyle issues, detection of drugs interfering with antihypertensive medication effectiveness, screening for secondary hypertension, and assessment of target organ damage. Management of RH includes maximization of lifestyle interventions, use of long-acting thiazide-like diuretics (chlorthalidone or indapamide), addition of a mineralocorticoid receptor antagonist (spironolactone or eplerenone), and, if BP remains elevated, stepwise addition of antihypertensive drugs with complementary mechanisms of action to lower BP.	This source provides comprehensive information on the evaluation and management of resistant hypertension but does not discuss Nephronophthisis specifically.	"{""explanation"": ""This source provides comprehensive information on the evaluation and management of resistant hypertension but does not discuss Nephronophthisis specifically."", ""reference"": ""PMID:30354828"", ""snippet"": ""Resistant hypertension (RH) is defined as above-goal elevated blood pressure (BP) in a patient despite the concurrent use of 3 antihypertensive drug classes...evaluation includes identification of contributing lifestyle issues, detection of drugs interfering with antihypertensive medication effectiveness, screening for secondary hypertension, and assessment of target organ damage. Management of RH includes maximization of lifestyle interventions, use of long-acting thiazide-like diuretics (chlorthalidone or indapamide), addition of a mineralocorticoid receptor antagonist (spironolactone or eplerenone), and, if BP remains elevated, stepwise addition of antihypertensive drugs with complementary mechanisms of action to lower BP."", ""supports"": ""NO_EVIDENCE""}"
5689	5490	229	Nephronophthisis	Nephronophthisis.yaml	treatments	2	evidence	0	PMID:35533128	SUPPORT		At the moment there is no healing therapy, so early kidney transplant is a fundamental tool to improve prognosis.	There is no curative treatment for nephronophthisis, indicating that supportive care, including symptomatic treatment and monitoring, is currently applied to manage associated complications.	"{""explanation"": ""There is no curative treatment for nephronophthisis, indicating that supportive care, including symptomatic treatment and monitoring, is currently applied to manage associated complications."", ""reference"": ""PMID:35533128"", ""snippet"": ""At the moment there is no healing therapy, so early kidney transplant is a fundamental tool to improve prognosis."", ""supports"": ""SUPPORT""}"
5695	5531	231	Neurofibromatosis Type 1	Neurofibromatosis_Type_1.yaml	treatments	0	evidence	0	PMID:33395032	SUPPORT		The phase 2 trial (SPRINT) of selumetinib in pNF resulted in at least 20% reduction in the size of pNF from baseline in 71% of patients and was associated with clinically meaningful improvements. On the basis of this trial, selumetinib (Koselugo) received FDA approval for children 2 years of age and older with inoperable, symptomatic pNF.	SPRINT trial demonstrated selumetinib efficacy in plexiform neurofibromas leading to FDA approval for pediatric NF1 patients.	"{""explanation"": ""SPRINT trial demonstrated selumetinib efficacy in plexiform neurofibromas leading to FDA approval for pediatric NF1 patients."", ""reference"": ""PMID:33395032"", ""snippet"": ""The phase 2 trial (SPRINT) of selumetinib in pNF resulted in at least 20% reduction in the size of pNF from baseline in 71% of patients and was associated with clinically meaningful improvements. On the basis of this trial, selumetinib (Koselugo) received FDA approval for children 2 years of age and older with inoperable, symptomatic pNF."", ""supports"": ""SUPPORT""}"
5702	5541	232	Neuromyelitis Optica	Neuromyelitis_Optica.yaml	treatments	0	evidence	0	PMID:33741809	SUPPORT		Eculizumab, inebilizumab, and satralizumab are effective maintenance therapies approved for the treatment of AQP-4 seropositive NMOSD.	The abstract lists eculizumab as an approved maintenance therapy for NMOSD.	"{""explanation"": ""The abstract lists eculizumab as an approved maintenance therapy for NMOSD."", ""reference"": ""PMID:33741809"", ""snippet"": ""Eculizumab, inebilizumab, and satralizumab are effective maintenance therapies approved for the treatment of AQP-4 seropositive NMOSD."", ""supports"": ""SUPPORT""}"
5703	5542	232	Neuromyelitis Optica	Neuromyelitis_Optica.yaml	treatments	1	evidence	0	PMID:33741809	SUPPORT		Eculizumab, inebilizumab, and satralizumab are effective maintenance therapies approved for the treatment of AQP-4 seropositive NMOSD.	The abstract lists inebilizumab as an approved maintenance therapy for NMOSD.	"{""explanation"": ""The abstract lists inebilizumab as an approved maintenance therapy for NMOSD."", ""reference"": ""PMID:33741809"", ""snippet"": ""Eculizumab, inebilizumab, and satralizumab are effective maintenance therapies approved for the treatment of AQP-4 seropositive NMOSD."", ""supports"": ""SUPPORT""}"
5704	5543	232	Neuromyelitis Optica	Neuromyelitis_Optica.yaml	treatments	2	evidence	0	PMID:33741809	SUPPORT		Eculizumab, inebilizumab, and satralizumab are effective maintenance therapies approved for the treatment of AQP-4 seropositive NMOSD.	The abstract lists satralizumab as an approved maintenance therapy for NMOSD.	"{""explanation"": ""The abstract lists satralizumab as an approved maintenance therapy for NMOSD."", ""reference"": ""PMID:33741809"", ""snippet"": ""Eculizumab, inebilizumab, and satralizumab are effective maintenance therapies approved for the treatment of AQP-4 seropositive NMOSD."", ""supports"": ""SUPPORT""}"
5712	5560	233	Neuromyelitis Optica Spectrum Disorder	Neuromyelitis_Optica_Spectrum_Disorder.yaml	treatments	3	evidence	0	PMID:31050279	SUPPORT		Adjudicated relapses occurred in 3 of 96 patients (3%) in the eculizumab group and 20 of 47 (43%) in the placebo group	The PREVENT trial demonstrated 94% reduction in relapse risk with eculizumab in AQP4-IgG-positive NMOSD.	"{""explanation"": ""The PREVENT trial demonstrated 94% reduction in relapse risk with eculizumab in AQP4-IgG-positive NMOSD."", ""reference"": ""PMID:31050279"", ""snippet"": ""Adjudicated relapses occurred in 3 of 96 patients (3%) in the eculizumab group and 20 of 47 (43%) in the placebo group"", ""supports"": ""SUPPORT""}"
5713	5560	233	Neuromyelitis Optica Spectrum Disorder	Neuromyelitis_Optica_Spectrum_Disorder.yaml	treatments	3	evidence	1	PMID:32266705	SUPPORT		The terminal complement protein (C5) inhibitor eculizumab (Soliris) is the first agent to be specifically approved in the EU, USA, Canada and Japan for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adults who are aquaporin-4 water channel autoantibody (AQP4-IgG) seropositive	Review confirms eculizumab as first approved targeted therapy for NMOSD.	"{""explanation"": ""Review confirms eculizumab as first approved targeted therapy for NMOSD."", ""reference"": ""PMID:32266705"", ""snippet"": ""The terminal complement protein (C5) inhibitor eculizumab (Soliris) is the first agent to be specifically approved in the EU, USA, Canada and Japan for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adults who are aquaporin-4 water channel autoantibody (AQP4-IgG) seropositive"", ""supports"": ""SUPPORT""}"
5714	5561	233	Neuromyelitis Optica Spectrum Disorder	Neuromyelitis_Optica_Spectrum_Disorder.yaml	treatments	4	evidence	0	PMID:31495497	SUPPORT		21 (12%) of 174 participants receiving inebilizumab had an attack versus 22 (39%) of 56 participants receiving placebo	The N-MOmentum trial demonstrated 73% reduction in attack risk with inebilizumab treatment.	"{""explanation"": ""The N-MOmentum trial demonstrated 73% reduction in attack risk with inebilizumab treatment."", ""reference"": ""PMID:31495497"", ""snippet"": ""21 (12%) of 174 participants receiving inebilizumab had an attack versus 22 (39%) of 56 participants receiving placebo"", ""supports"": ""SUPPORT""}"
5715	5561	233	Neuromyelitis Optica Spectrum Disorder	Neuromyelitis_Optica_Spectrum_Disorder.yaml	treatments	4	evidence	1	PMID:36070074	SUPPORT		Inebilizumab (Uplizna) is a recently approved monoclonal antibody for use in adults with neuromyelitis optica spectrum disorder (NMOSD) who are anti-aquaporin-4 (AQP4) antibody seropositive.	Review confirms regulatory approval of inebilizumab for NMOSD.	"{""explanation"": ""Review confirms regulatory approval of inebilizumab for NMOSD."", ""reference"": ""PMID:36070074"", ""snippet"": ""Inebilizumab (Uplizna) is a recently approved monoclonal antibody for use in adults with neuromyelitis optica spectrum disorder (NMOSD) who are anti-aquaporin-4 (AQP4) antibody seropositive."", ""supports"": ""SUPPORT""}"
5716	5562	233	Neuromyelitis Optica Spectrum Disorder	Neuromyelitis_Optica_Spectrum_Disorder.yaml	treatments	5	evidence	0	PMID:36933107	SUPPORT		Satralizumab (Enspryng) is a monoclonal antibody that blocks the interleukin-6 (IL-6) receptor and is approved for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in patients who are aquaporin-4 immunoglobulin G (AQP4-IgG) seropositive.	Review confirms satralizumab mechanism and approval for NMOSD.	"{""explanation"": ""Review confirms satralizumab mechanism and approval for NMOSD."", ""reference"": ""PMID:36933107"", ""snippet"": ""Satralizumab (Enspryng) is a monoclonal antibody that blocks the interleukin-6 (IL-6) receptor and is approved for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in patients who are aquaporin-4 immunoglobulin G (AQP4-IgG) seropositive."", ""supports"": ""SUPPORT""}"
5810	5599	235	Non-Small Cell Lung Cancer	Non-Small_Cell_Lung_Cancer.yaml	treatments	0	evidence	0	PMID:11720753	SUPPORT		Surgical resection remains the treatment of choice for early stage non-small cell lung cancer (NSCLC). In stages IA, IB, IIA, IIB and selected stages IIIA surgical treatment offers the best long-term prognosis when a complete resection can be performed. Standard operations include lobectomy, bilobectomy and pneumonectomy.	This indicates that lobectomy and pneumonectomy are standard surgical treatments for localized non-small cell lung cancer.	"{""explanation"": ""This indicates that lobectomy and pneumonectomy are standard surgical treatments for localized non-small cell lung cancer."", ""reference"": ""PMID:11720753"", ""snippet"": ""Surgical resection remains the treatment of choice for early stage non-small cell lung cancer (NSCLC). In stages IA, IB, IIA, IIB and selected stages IIIA surgical treatment offers the best long-term prognosis when a complete resection can be performed. Standard operations include lobectomy, bilobectomy and pneumonectomy."", ""supports"": ""SUPPORT""}"
5811	5599	235	Non-Small Cell Lung Cancer	Non-Small_Cell_Lung_Cancer.yaml	treatments	0	evidence	1	PMID:37625619	SUPPORT		Lobectomy is the standard treatment for patients with early-stage non-small cell lung cancer (NSCLC).	This further reinforces that lobectomy, a type of surgery, is a standard treatment for localized non-small cell lung cancer.	"{""explanation"": ""This further reinforces that lobectomy, a type of surgery, is a standard treatment for localized non-small cell lung cancer."", ""reference"": ""PMID:37625619"", ""snippet"": ""Lobectomy is the standard treatment for patients with early-stage non-small cell lung cancer (NSCLC)."", ""supports"": ""SUPPORT""}"
5812	5600	235	Non-Small Cell Lung Cancer	Non-Small_Cell_Lung_Cancer.yaml	treatments	1	evidence	0	PMID:12094333	SUPPORT		Platinum-based chemotherapy is considered the standard treatment for advanced non-small cell lung cancer (NSCLC). Several phase II trials using cisplatin in combination with new chemotherapeutic agents, such as gemcitabine, the taxanes, vinorelbine, and irinotecan, showed impressive response rates and suggested an improvement in overall survival.	This supports the statement that platinum-based chemotherapy (specifically cisplatin) in combination with other agents is a treatment for NSCLC.	"{""explanation"": ""This supports the statement that platinum-based chemotherapy (specifically cisplatin) in combination with other agents is a treatment for NSCLC."", ""reference"": ""PMID:12094333"", ""snippet"": ""Platinum-based chemotherapy is considered the standard treatment for advanced non-small cell lung cancer (NSCLC). Several phase II trials using cisplatin in combination with new chemotherapeutic agents, such as gemcitabine, the taxanes, vinorelbine, and irinotecan, showed impressive response rates and suggested an improvement in overall survival."", ""supports"": ""SUPPORT""}"
5813	5600	235	Non-Small Cell Lung Cancer	Non-Small_Cell_Lung_Cancer.yaml	treatments	1	evidence	1	PMID:1329222	SUPPORT		... carboplatin, either alone or in combination, in five separate phase II studies for patients with inoperable non-small cell lung cancer (NSCLC). ... Subsequently, combinations of carboplatin/cisplatin, carboplatin/etoposide, and carboplatin/vinblastine have been evaluated in similar patient groups.	This supports the statement as it mentions that carboplatin, either alone or in combination with other agents, is used in the treatment of NSCLC.	"{""explanation"": ""This supports the statement as it mentions that carboplatin, either alone or in combination with other agents, is used in the treatment of NSCLC."", ""reference"": ""PMID:1329222"", ""snippet"": ""... carboplatin, either alone or in combination, in five separate phase II studies for patients with inoperable non-small cell lung cancer (NSCLC). ... Subsequently, combinations of carboplatin/cisplatin, carboplatin/etoposide, and carboplatin/vinblastine have been evaluated in similar patient groups."", ""supports"": ""SUPPORT""}"
5814	5600	235	Non-Small Cell Lung Cancer	Non-Small_Cell_Lung_Cancer.yaml	treatments	1	evidence	2	PMID:26775594	SUPPORT		Of the 1564 patients who were included in the prospective study, 1520 received either cisplatin (54%) or carboplatin (46%) in combination with pemetrexed, gemcitabine, taxanes or vinorelbine.	The study provides evidence that both cisplatin and carboplatin, in combination with other agents, are used in the treatment of NSCLC.	"{""explanation"": ""The study provides evidence that both cisplatin and carboplatin, in combination with other agents, are used in the treatment of NSCLC."", ""reference"": ""PMID:26775594"", ""snippet"": ""Of the 1564 patients who were included in the prospective study, 1520 received either cisplatin (54%) or carboplatin (46%) in combination with pemetrexed, gemcitabine, taxanes or vinorelbine."", ""supports"": ""SUPPORT""}"
5815	5600	235	Non-Small Cell Lung Cancer	Non-Small_Cell_Lung_Cancer.yaml	treatments	1	evidence	3	PMID:35525024	SUPPORT		Platinum-based chemotherapy with or without immunotherapy is the mainstay of treatment for advanced stage non-small cell lung cancer (NSCLC) lacking a molecular driver alteration.	The mention of platinum-based chemotherapy (cisplatin or carboplatin) as a primary treatment supports the statement.	"{""explanation"": ""The mention of platinum-based chemotherapy (cisplatin or carboplatin) as a primary treatment supports the statement."", ""reference"": ""PMID:35525024"", ""snippet"": ""Platinum-based chemotherapy with or without immunotherapy is the mainstay of treatment for advanced stage non-small cell lung cancer (NSCLC) lacking a molecular driver alteration."", ""supports"": ""SUPPORT""}"
5816	5600	235	Non-Small Cell Lung Cancer	Non-Small_Cell_Lung_Cancer.yaml	treatments	1	evidence	4	PMID:27166967	SUPPORT		Predicting the feasibility of platinum-based chemotherapy remains an important issue in elderly (over 70 years) patients with non-small cell lung cancer (NSCLC).	This statement supports the use of platinum-based chemotherapy in the treatment of NSCLC, emphasizing its importance even in elderly patients.	"{""explanation"": ""This statement supports the use of platinum-based chemotherapy in the treatment of NSCLC, emphasizing its importance even in elderly patients."", ""reference"": ""PMID:27166967"", ""snippet"": ""Predicting the feasibility of platinum-based chemotherapy remains an important issue in elderly (over 70 years) patients with non-small cell lung cancer (NSCLC)."", ""supports"": ""SUPPORT""}"
5817	5601	235	Non-Small Cell Lung Cancer	Non-Small_Cell_Lung_Cancer.yaml	treatments	2	evidence	0	PMID:34154330	SUPPORT		The review article presents the current state and development of the treatment with tyrosine kinase inhibitors in advanced non-small cell lung cancer. It focuses on the therapeutic progress of traditionally targeted gene mutations EGFR, ALK and ROS1.	The reference discusses EGFR, ALK, and ROS1 inhibitors as targeted therapies for non-small cell lung cancer.	"{""explanation"": ""The reference discusses EGFR, ALK, and ROS1 inhibitors as targeted therapies for non-small cell lung cancer."", ""reference"": ""PMID:34154330"", ""snippet"": ""The review article presents the current state and development of the treatment with tyrosine kinase inhibitors in advanced non-small cell lung cancer. It focuses on the therapeutic progress of traditionally targeted gene mutations EGFR, ALK and ROS1."", ""supports"": ""SUPPORT""}"
5818	5601	235	Non-Small Cell Lung Cancer	Non-Small_Cell_Lung_Cancer.yaml	treatments	2	evidence	1	PMID:15946581	SUPPORT		The epidermal growth factor receptor (EGFR) is a promising target in the treatment of advanced stage non-small-cell lung cancer (NSCLC). Currently erlotinib and gefitinib are approved by the US Food and Drug Administration.	The reference discusses erlotinib and gefitinib as EGFR inhibitors used in the treatment of non-small cell lung cancer.	"{""explanation"": ""The reference discusses erlotinib and gefitinib as EGFR inhibitors used in the treatment of non-small cell lung cancer."", ""reference"": ""PMID:15946581"", ""snippet"": ""The epidermal growth factor receptor (EGFR) is a promising target in the treatment of advanced stage non-small-cell lung cancer (NSCLC). Currently erlotinib and gefitinib are approved by the US Food and Drug Administration."", ""supports"": ""SUPPORT""}"
5819	5601	235	Non-Small Cell Lung Cancer	Non-Small_Cell_Lung_Cancer.yaml	treatments	2	evidence	2	PMID:22932130	SUPPORT		Both erlotinib and crizotinib have been shown to be effective and safe for subgroup populations, and now personalized treatment for nonsquamous NSCLC has progressed even further.	The reference confirms the use of erlotinib (EGFR inhibitor) and crizotinib (ALK and ROS1 inhibitor) in targeted therapy for non-small cell lung cancer.	"{""explanation"": ""The reference confirms the use of erlotinib (EGFR inhibitor) and crizotinib (ALK and ROS1 inhibitor) in targeted therapy for non-small cell lung cancer."", ""reference"": ""PMID:22932130"", ""snippet"": ""Both erlotinib and crizotinib have been shown to be effective and safe for subgroup populations, and now personalized treatment for nonsquamous NSCLC has progressed even further."", ""supports"": ""SUPPORT""}"
5820	5601	235	Non-Small Cell Lung Cancer	Non-Small_Cell_Lung_Cancer.yaml	treatments	2	evidence	3	PMID:25240504	SUPPORT		The availability of ... the EGFR-tyrosine kinase inhibitors erlotinib, gefitinib, afatinib as well as ... the ALK-inhibitor crizotinib has recently changes the treatment algorithm of advanced non-small cell lung cancer.	The reference mentions the use of EGFR inhibitors (erlotinib, gefitinib) and ALK inhibitor (crizotinib) in treating non-small cell lung cancer.	"{""explanation"": ""The reference mentions the use of EGFR inhibitors (erlotinib, gefitinib) and ALK inhibitor (crizotinib) in treating non-small cell lung cancer."", ""reference"": ""PMID:25240504"", ""snippet"": ""The availability of ... the EGFR-tyrosine kinase inhibitors erlotinib, gefitinib, afatinib as well as ... the ALK-inhibitor crizotinib has recently changes the treatment algorithm of advanced non-small cell lung cancer."", ""supports"": ""SUPPORT""}"
5821	5601	235	Non-Small Cell Lung Cancer	Non-Small_Cell_Lung_Cancer.yaml	treatments	2	evidence	4	PMID:25322323	SUPPORT		The treatment of patients with advanced non-small cell lung cancer (NSCLC) harboring chromosomal rearrangements of anaplastic lymphoma kinase (ALK) has been revolutionized by the development of crizotinib, a small molecule inhibitor of the tyrosine kinases ALK, ROS1, and MET.	The reference discusses crizotinib as an ALK and ROS1 inhibitor used in the treatment of non-small cell lung cancer.	"{""explanation"": ""The reference discusses crizotinib as an ALK and ROS1 inhibitor used in the treatment of non-small cell lung cancer."", ""reference"": ""PMID:25322323"", ""snippet"": ""The treatment of patients with advanced non-small cell lung cancer (NSCLC) harboring chromosomal rearrangements of anaplastic lymphoma kinase (ALK) has been revolutionized by the development of crizotinib, a small molecule inhibitor of the tyrosine kinases ALK, ROS1, and MET."", ""supports"": ""SUPPORT""}"
5822	5601	235	Non-Small Cell Lung Cancer	Non-Small_Cell_Lung_Cancer.yaml	treatments	2	evidence	5	PMID:27491402	SUPPORT		Currently, EGFR TKIs (e.g.: erlotinib, gefitinib, osimertinib) and ALK inhibitors (crizotinib, ceritinib, alectinib) provided a new face for advanced NSCLC outcomes.	The reference supports the use of EGFR inhibitors (erlotinib, gefitinib) and ALK inhibitors (crizotinib, ceritinib) in the treatment of non-small cell lung cancer.	"{""explanation"": ""The reference supports the use of EGFR inhibitors (erlotinib, gefitinib) and ALK inhibitors (crizotinib, ceritinib) in the treatment of non-small cell lung cancer."", ""reference"": ""PMID:27491402"", ""snippet"": ""Currently, EGFR TKIs (e.g.: erlotinib, gefitinib, osimertinib) and ALK inhibitors (crizotinib, ceritinib, alectinib) provided a new face for advanced NSCLC outcomes."", ""supports"": ""SUPPORT""}"
5823	5601	235	Non-Small Cell Lung Cancer	Non-Small_Cell_Lung_Cancer.yaml	treatments	2	evidence	6	PMID:34125313	SUPPORT		Four FDA-approved drugs have significant activity against ROS1+ NSCLC: crizotinib, ciritinib, lorlatinib, and entrectinib.	The reference mentions crizotinib among the ROS1 inhibitors used for treating non-small cell lung cancer.	"{""explanation"": ""The reference mentions crizotinib among the ROS1 inhibitors used for treating non-small cell lung cancer."", ""reference"": ""PMID:34125313"", ""snippet"": ""Four FDA-approved drugs have significant activity against ROS1+ NSCLC: crizotinib, ciritinib, lorlatinib, and entrectinib."", ""supports"": ""SUPPORT""}"
5824	5601	235	Non-Small Cell Lung Cancer	Non-Small_Cell_Lung_Cancer.yaml	treatments	2	evidence	7	PMID:28089942	SUPPORT		Nowadays, different EGFR TKIs as afatinib, erlotinib and gefitinib are approved worldwide for the treatment of NSCLC harbouring EGFR mutations, in particular exon 19 deletions or exon 21 (Leu858Arg) substitution EGFR mutations.	The reference discusses the use of EGFR inhibitors (erlotinib, gefitinib) in the treatment of non-small cell lung cancer.	"{""explanation"": ""The reference discusses the use of EGFR inhibitors (erlotinib, gefitinib) in the treatment of non-small cell lung cancer."", ""reference"": ""PMID:28089942"", ""snippet"": ""Nowadays, different EGFR TKIs as afatinib, erlotinib and gefitinib are approved worldwide for the treatment of NSCLC harbouring EGFR mutations, in particular exon 19 deletions or exon 21 (Leu858Arg) substitution EGFR mutations."", ""supports"": ""SUPPORT""}"
5825	5602	235	Non-Small Cell Lung Cancer	Non-Small_Cell_Lung_Cancer.yaml	treatments	3	evidence	0	PMID:28059852	SUPPORT		In accordance with recent results, US Food and Drug Administration approved a checkpoint inhibitor for first-line treatment of metastatic non-small cell lung cancer whose tumors have high PD-L1 expression, and European Medicines Agency approval is expected in early 2017.	The FDA has approved immune checkpoint inhibitors for first-line treatment of metastatic NSCLC with high PD-L1 expression, supporting the use of immunotherapy (including nivolumab and pembrolizumab) for these patients.	"{""explanation"": ""The FDA has approved immune checkpoint inhibitors for first-line treatment of metastatic NSCLC with high PD-L1 expression, supporting the use of immunotherapy (including nivolumab and pembrolizumab) for these patients."", ""reference"": ""PMID:28059852"", ""snippet"": ""In accordance with recent results, US Food and Drug Administration approved a checkpoint inhibitor for first-line treatment of metastatic non-small cell lung cancer whose tumors have high PD-L1 expression, and European Medicines Agency approval is expected in early 2017."", ""supports"": ""SUPPORT""}"
5826	5602	235	Non-Small Cell Lung Cancer	Non-Small_Cell_Lung_Cancer.yaml	treatments	3	evidence	1	PMID:26927720	SUPPORT		Data so far available show some conflicting results, but PD-L1 immunohistochemistry looks likely to be introduced into clinical use for selecting patients for treatment with anti-PD-1 or anti-PD-L1 therapies.	The mention of PD-L1 immunohistochemistry being introduced for clinically selecting patients for anti-PD-1 therapies supports the statement.	"{""explanation"": ""The mention of PD-L1 immunohistochemistry being introduced for clinically selecting patients for anti-PD-1 therapies supports the statement."", ""reference"": ""PMID:26927720"", ""snippet"": ""Data so far available show some conflicting results, but PD-L1 immunohistochemistry looks likely to be introduced into clinical use for selecting patients for treatment with anti-PD-1 or anti-PD-L1 therapies."", ""supports"": ""SUPPORT""}"
5827	5602	235	Non-Small Cell Lung Cancer	Non-Small_Cell_Lung_Cancer.yaml	treatments	3	evidence	2	PMID:32189549	PARTIAL		A subset of patients who were treated beyond progression with ICI achieved a clinically meaningful response with durable disease control.	While it shows the effectiveness of checkpoint inhibitors, it is about treatment beyond progression and does not specifically address high PD-L1 expression.	"{""explanation"": ""While it shows the effectiveness of checkpoint inhibitors, it is about treatment beyond progression and does not specifically address high PD-L1 expression."", ""reference"": ""PMID:32189549"", ""snippet"": ""A subset of patients who were treated beyond progression with ICI achieved a clinically meaningful response with durable disease control."", ""supports"": ""PARTIAL""}"
5828	5602	235	Non-Small Cell Lung Cancer	Non-Small_Cell_Lung_Cancer.yaml	treatments	3	evidence	3	PMID:29140105	PARTIAL		Single-agent durvalumab showed clinical efficacy and a manageable safety profile in advanced non-small-cell lung cancer, particularly the >/=25% PD-L1+ population.	This supports the efficacy of durvalumab particularly in PD-L1+ populations but does not specifically mention nivolumab or pembrolizumab.	"{""explanation"": ""This supports the efficacy of durvalumab particularly in PD-L1+ populations but does not specifically mention nivolumab or pembrolizumab."", ""reference"": ""PMID:29140105"", ""snippet"": ""Single-agent durvalumab showed clinical efficacy and a manageable safety profile in advanced non-small-cell lung cancer, particularly the >/=25% PD-L1+ population."", ""supports"": ""PARTIAL""}"
5829	5602	235	Non-Small Cell Lung Cancer	Non-Small_Cell_Lung_Cancer.yaml	treatments	3	evidence	4	PMID:33306411	PARTIAL		For the majority of patients, ICIs are cost-effective for lung cancer management.	This supports the efficacy of ICIs but does not specifically address tumors with high PD-L1 expression.	"{""explanation"": ""This supports the efficacy of ICIs but does not specifically address tumors with high PD-L1 expression."", ""reference"": ""PMID:33306411"", ""snippet"": ""For the majority of patients, ICIs are cost-effective for lung cancer management."", ""supports"": ""PARTIAL""}"
5830	5603	235	Non-Small Cell Lung Cancer	Non-Small_Cell_Lung_Cancer.yaml	treatments	4	evidence	0	PMID:7540125	PARTIAL		recent notable developments have occurred involving radiation therapy (RT) for patients with non-small cell lung cancer (NSCLC)... For palliation of tumor-related symptoms... metastases to the adrenal gland, liver, and subcutaneous tissues can be palliated successfully by brief courses of RT. Intrathoracic tumor symptoms are well palliated by brief courses of thoracic RT.	Supports the use of RT for palliation of symptoms and metastatic sites, but does not specifically mention its use for localized disease.	"{""explanation"": ""Supports the use of RT for palliation of symptoms and metastatic sites, but does not specifically mention its use for localized disease."", ""reference"": ""PMID:7540125"", ""snippet"": ""recent notable developments have occurred involving radiation therapy (RT) for patients with non-small cell lung cancer (NSCLC)... For palliation of tumor-related symptoms... metastases to the adrenal gland, liver, and subcutaneous tissues can be palliated successfully by brief courses of RT. Intrathoracic tumor symptoms are well palliated by brief courses of thoracic RT."", ""supports"": ""PARTIAL""}"
5831	5603	235	Non-Small Cell Lung Cancer	Non-Small_Cell_Lung_Cancer.yaml	treatments	4	evidence	1	PMID:8853542	PARTIAL		In the palliation of non-small cell lung cancer... in the management of chest disease, bone metastases, and brain metastases.	Supports the use of RT in palliation of symptoms and brain metastases.	"{""explanation"": ""Supports the use of RT in palliation of symptoms and brain metastases."", ""reference"": ""PMID:8853542"", ""snippet"": ""In the palliation of non-small cell lung cancer... in the management of chest disease, bone metastases, and brain metastases."", ""supports"": ""PARTIAL""}"
5832	5603	235	Non-Small Cell Lung Cancer	Non-Small_Cell_Lung_Cancer.yaml	treatments	4	evidence	2	PMID:32140986	SUPPORT		Concurrent chemoradiation is the cornerstone of treatment of unresectable, locally advanced NSCLC.	Supports the use of RT for locally advanced (localized) disease.	"{""explanation"": ""Supports the use of RT for locally advanced (localized) disease."", ""reference"": ""PMID:32140986"", ""snippet"": ""Concurrent chemoradiation is the cornerstone of treatment of unresectable, locally advanced NSCLC."", ""supports"": ""SUPPORT""}"
5833	5603	235	Non-Small Cell Lung Cancer	Non-Small_Cell_Lung_Cancer.yaml	treatments	4	evidence	3	PMID:30441934	SUPPORT		Radiotherapy should also be considered for locally advanced disease.	Supports the use of RT for locally advanced (localized) disease.	"{""explanation"": ""Supports the use of RT for locally advanced (localized) disease."", ""reference"": ""PMID:30441934"", ""snippet"": ""Radiotherapy should also be considered for locally advanced disease."", ""supports"": ""SUPPORT""}"
5834	5603	235	Non-Small Cell Lung Cancer	Non-Small_Cell_Lung_Cancer.yaml	treatments	4	evidence	4	PMID:27467543	SUPPORT		Stereotactic body radiation therapy has been increasingly used to safely deliver LAT and provide high local control in nonoperable non-small-cell lung cancer patients.	Supports the use of RT for localized disease particularly in nonoperable cases.	"{""explanation"": ""Supports the use of RT for localized disease particularly in nonoperable cases."", ""reference"": ""PMID:27467543"", ""snippet"": ""Stereotactic body radiation therapy has been increasingly used to safely deliver LAT and provide high local control in nonoperable non-small-cell lung cancer patients."", ""supports"": ""SUPPORT""}"
5890	5713	239	Onchocerciasis	Onchocerciasis.yaml	treatments	0	evidence	0	PMID:16714198	SUPPORT		Ivermectin is, at present, the drug of choice for skin and ocular manifestations.	The abstract identifies ivermectin as the drug of choice.	"{""explanation"": ""The abstract identifies ivermectin as the drug of choice."", ""reference"": ""PMID:16714198"", ""snippet"": ""Ivermectin is, at present, the drug of choice for skin and ocular manifestations."", ""supports"": ""SUPPORT""}"
5902	5733	240	Osteoarthritis	Osteoarthritis.yaml	treatments	0	evidence	0	PMID:31908149	SUPPORT		Conditional recommendations were made for balance exercises, yoga, cognitive behavioral therapy, kinesiotaping for first CMC OA, orthoses for hand joints other than the first CMC joint, patellofemoral bracing for patellofemoral knee OA, acupuncture, thermal modalities, radiofrequency ablation for knee OA, topical NSAIDs, intraarticular steroid injections and chondroitin sulfate for hand OA, topical capsaicin for knee OA, acetaminophen, duloxetine, and tramadol.	ACR/Arthritis Foundation guidelines conditionally recommend acetaminophen for OA management.	"{""explanation"": ""ACR/Arthritis Foundation guidelines conditionally recommend acetaminophen for OA management."", ""reference"": ""PMID:31908149"", ""snippet"": ""Conditional recommendations were made for balance exercises, yoga, cognitive behavioral therapy, kinesiotaping for first CMC OA, orthoses for hand joints other than the first CMC joint, patellofemoral bracing for patellofemoral knee OA, acupuncture, thermal modalities, radiofrequency ablation for knee OA, topical NSAIDs, intraarticular steroid injections and chondroitin sulfate for hand OA, topical capsaicin for knee OA, acetaminophen, duloxetine, and tramadol."", ""supports"": ""SUPPORT""}"
5903	5734	240	Osteoarthritis	Osteoarthritis.yaml	treatments	1	evidence	0	PMID:31908149	SUPPORT		Strong recommendations were made for exercise, weight loss in patients with knee and/or hip OA who are overweight or obese, self-efficacy and self-management programs, tai chi, cane use, hand orthoses for first carpometacarpal (CMC) joint OA, tibiofemoral bracing for tibiofemoral knee OA, topical nonsteroidal antiinflammatory drugs (NSAIDs) for knee OA, oral NSAIDs, and intraarticular glucocorticoid injections for knee OA.	ACR/Arthritis Foundation guidelines strongly recommend both topical and oral NSAIDs for OA.	"{""explanation"": ""ACR/Arthritis Foundation guidelines strongly recommend both topical and oral NSAIDs for OA."", ""reference"": ""PMID:31908149"", ""snippet"": ""Strong recommendations were made for exercise, weight loss in patients with knee and/or hip OA who are overweight or obese, self-efficacy and self-management programs, tai chi, cane use, hand orthoses for first carpometacarpal (CMC) joint OA, tibiofemoral bracing for tibiofemoral knee OA, topical nonsteroidal antiinflammatory drugs (NSAIDs) for knee OA, oral NSAIDs, and intraarticular glucocorticoid injections for knee OA."", ""supports"": ""SUPPORT""}"
5904	5735	240	Osteoarthritis	Osteoarthritis.yaml	treatments	2	evidence	0	PMID:31908149	SUPPORT		Strong recommendations were made for exercise, weight loss in patients with knee and/or hip OA who are overweight or obese	ACR/Arthritis Foundation guidelines strongly recommend exercise for OA management.	"{""explanation"": ""ACR/Arthritis Foundation guidelines strongly recommend exercise for OA management."", ""reference"": ""PMID:31908149"", ""snippet"": ""Strong recommendations were made for exercise, weight loss in patients with knee and/or hip OA who are overweight or obese"", ""supports"": ""SUPPORT""}"
5905	5736	240	Osteoarthritis	Osteoarthritis.yaml	treatments	3	evidence	0	PMID:31908149	SUPPORT		Strong recommendations were made for exercise, weight loss in patients with knee and/or hip OA who are overweight or obese	ACR/Arthritis Foundation guidelines strongly recommend weight loss for overweight/obese patients with OA.	"{""explanation"": ""ACR/Arthritis Foundation guidelines strongly recommend weight loss for overweight/obese patients with OA."", ""reference"": ""PMID:31908149"", ""snippet"": ""Strong recommendations were made for exercise, weight loss in patients with knee and/or hip OA who are overweight or obese"", ""supports"": ""SUPPORT""}"
5906	5737	240	Osteoarthritis	Osteoarthritis.yaml	treatments	4	evidence	0	PMID:31908149	SUPPORT		Strong recommendations were made for exercise, weight loss in patients with knee and/or hip OA who are overweight or obese, self-efficacy and self-management programs, tai chi, cane use, hand orthoses for first carpometacarpal (CMC) joint OA, tibiofemoral bracing for tibiofemoral knee OA, topical nonsteroidal antiinflammatory drugs (NSAIDs) for knee OA, oral NSAIDs, and intraarticular glucocorticoid injections for knee OA.	ACR/Arthritis Foundation guidelines strongly recommend intra-articular glucocorticoid injections for knee OA.	"{""explanation"": ""ACR/Arthritis Foundation guidelines strongly recommend intra-articular glucocorticoid injections for knee OA."", ""reference"": ""PMID:31908149"", ""snippet"": ""Strong recommendations were made for exercise, weight loss in patients with knee and/or hip OA who are overweight or obese, self-efficacy and self-management programs, tai chi, cane use, hand orthoses for first carpometacarpal (CMC) joint OA, tibiofemoral bracing for tibiofemoral knee OA, topical nonsteroidal antiinflammatory drugs (NSAIDs) for knee OA, oral NSAIDs, and intraarticular glucocorticoid injections for knee OA."", ""supports"": ""SUPPORT""}"
5937	5839	247	Osteoporosis	Osteoporosis.yaml	treatments	0	evidence	0	PMID:34807231	SUPPORT		The pooled meta-analysis found that 12.4 months (95% CI, 6.3-18.4 months) were needed to avoid 1 nonvertebral fracture per 100 postmenopausal women receiving bisphosphonate therapy.	Meta-analysis of 10 RCTs with 23,384 women demonstrates bisphosphonate efficacy in preventing fractures.	"{""explanation"": ""Meta-analysis of 10 RCTs with 23,384 women demonstrates bisphosphonate efficacy in preventing fractures."", ""reference"": ""PMID:34807231"", ""snippet"": ""The pooled meta-analysis found that 12.4 months (95% CI, 6.3-18.4 months) were needed to avoid 1 nonvertebral fracture per 100 postmenopausal women receiving bisphosphonate therapy."", ""supports"": ""SUPPORT""}"
5943	5852	248	Osteosarcoma	Osteosarcoma.yaml	treatments	0	evidence	0	PMID:41154810	SUPPORT		Despite advances in surgery and multi-agent chemotherapy, survival rates for metastatic or recurrent OS remain poor, highlighting the need for novel prognostic and therapeutic strategies.	The abstract references surgery as a standard component of osteosarcoma treatment.	"{""explanation"": ""The abstract references surgery as a standard component of osteosarcoma treatment."", ""reference"": ""PMID:41154810"", ""snippet"": ""Despite advances in surgery and multi-agent chemotherapy, survival rates for metastatic or recurrent OS remain poor, highlighting the need for novel prognostic and therapeutic strategies."", ""supports"": ""SUPPORT""}"
5944	5853	248	Osteosarcoma	Osteosarcoma.yaml	treatments	1	evidence	0	PMID:41154810	SUPPORT		Despite advances in surgery and multi-agent chemotherapy, survival rates for metastatic or recurrent OS remain poor, highlighting the need for novel prognostic and therapeutic strategies.	The abstract notes multi-agent chemotherapy as a standard therapy.	"{""explanation"": ""The abstract notes multi-agent chemotherapy as a standard therapy."", ""reference"": ""PMID:41154810"", ""snippet"": ""Despite advances in surgery and multi-agent chemotherapy, survival rates for metastatic or recurrent OS remain poor, highlighting the need for novel prognostic and therapeutic strategies."", ""supports"": ""SUPPORT""}"
5946	5864	249	PIK3CA-Mutant Breast Cancer	PIK3CA_Mutant_Breast_Cancer.yaml	treatments	0	evidence	0	PMID:37743730	SUPPORT		The combination of fulvestrant with alpelisib, a PI3K inhibitor, improves progression-free survival in metastatic hormone receptor-positive, PIK3CA-mutant breast cancer.	This abstract supports the use of alpelisib with fulvestrant in PIK3CA-mutant breast cancer.	"{""explanation"": ""This abstract supports the use of alpelisib with fulvestrant in PIK3CA-mutant breast cancer."", ""reference"": ""PMID:37743730"", ""snippet"": ""The combination of fulvestrant with alpelisib, a PI3K inhibitor, improves progression-free survival in metastatic hormone receptor-positive, PIK3CA-mutant breast cancer."", ""supports"": ""SUPPORT""}"
6004	5904	250	Parkinson's Disease	Parkinsons_Disease.yaml	treatments	0	evidence	0	PMID:27577098	SUPPORT		The symptomatic treatment of the motor symptoms of Parkinson disease (PD) has been constantly optimized using pharmacotherapy (L-Dopa, several dopamine agonists, inhibitors of monoamine oxidase (MAO)-B and catechol-o-methyltransferase (COMT), and amantadine), deep brain stimulation, and physiotherapy.	This review identifies L-Dopa as a core pharmacotherapy for PD motor symptoms.	"{""explanation"": ""This review identifies L-Dopa as a core pharmacotherapy for PD motor symptoms."", ""reference"": ""PMID:27577098"", ""snippet"": ""The symptomatic treatment of the motor symptoms of Parkinson disease (PD) has been constantly optimized using pharmacotherapy (L-Dopa, several dopamine agonists, inhibitors of monoamine oxidase (MAO)-B and catechol-o-methyltransferase (COMT), and amantadine), deep brain stimulation, and physiotherapy."", ""supports"": ""SUPPORT""}"
6005	5905	250	Parkinson's Disease	Parkinsons_Disease.yaml	treatments	1	evidence	0	PMID:27577098	SUPPORT		The symptomatic treatment of the motor symptoms of Parkinson disease (PD) has been constantly optimized using pharmacotherapy (L-Dopa, several dopamine agonists, inhibitors of monoamine oxidase (MAO)-B and catechol-o-methyltransferase (COMT), and amantadine), deep brain stimulation, and physiotherapy.	This review identifies dopamine agonists as part of standard pharmacotherapy for PD.	"{""explanation"": ""This review identifies dopamine agonists as part of standard pharmacotherapy for PD."", ""reference"": ""PMID:27577098"", ""snippet"": ""The symptomatic treatment of the motor symptoms of Parkinson disease (PD) has been constantly optimized using pharmacotherapy (L-Dopa, several dopamine agonists, inhibitors of monoamine oxidase (MAO)-B and catechol-o-methyltransferase (COMT), and amantadine), deep brain stimulation, and physiotherapy."", ""supports"": ""SUPPORT""}"
6006	5906	250	Parkinson's Disease	Parkinsons_Disease.yaml	treatments	2	evidence	0	PMID:27577098	SUPPORT		The symptomatic treatment of the motor symptoms of Parkinson disease (PD) has been constantly optimized using pharmacotherapy (L-Dopa, several dopamine agonists, inhibitors of monoamine oxidase (MAO)-B and catechol-o-methyltransferase (COMT), and amantadine), deep brain stimulation, and physiotherapy.	This review lists MAO-B inhibitors among standard PD pharmacotherapies.	"{""explanation"": ""This review lists MAO-B inhibitors among standard PD pharmacotherapies."", ""reference"": ""PMID:27577098"", ""snippet"": ""The symptomatic treatment of the motor symptoms of Parkinson disease (PD) has been constantly optimized using pharmacotherapy (L-Dopa, several dopamine agonists, inhibitors of monoamine oxidase (MAO)-B and catechol-o-methyltransferase (COMT), and amantadine), deep brain stimulation, and physiotherapy."", ""supports"": ""SUPPORT""}"
6007	5907	250	Parkinson's Disease	Parkinsons_Disease.yaml	treatments	3	evidence	0	PMID:27577098	SUPPORT		The symptomatic treatment of the motor symptoms of Parkinson disease (PD) has been constantly optimized using pharmacotherapy (L-Dopa, several dopamine agonists, inhibitors of monoamine oxidase (MAO)-B and catechol-o-methyltransferase (COMT), and amantadine), deep brain stimulation, and physiotherapy.	This review lists COMT inhibitors among standard PD pharmacotherapies.	"{""explanation"": ""This review lists COMT inhibitors among standard PD pharmacotherapies."", ""reference"": ""PMID:27577098"", ""snippet"": ""The symptomatic treatment of the motor symptoms of Parkinson disease (PD) has been constantly optimized using pharmacotherapy (L-Dopa, several dopamine agonists, inhibitors of monoamine oxidase (MAO)-B and catechol-o-methyltransferase (COMT), and amantadine), deep brain stimulation, and physiotherapy."", ""supports"": ""SUPPORT""}"
6008	5908	250	Parkinson's Disease	Parkinsons_Disease.yaml	treatments	4	evidence	0	PMID:27577098	SUPPORT		The symptomatic treatment of the motor symptoms of Parkinson disease (PD) has been constantly optimized using pharmacotherapy (L-Dopa, several dopamine agonists, inhibitors of monoamine oxidase (MAO)-B and catechol-o-methyltransferase (COMT), and amantadine), deep brain stimulation, and physiotherapy.	This review identifies deep brain stimulation as a standard symptomatic therapy for PD.	"{""explanation"": ""This review identifies deep brain stimulation as a standard symptomatic therapy for PD."", ""reference"": ""PMID:27577098"", ""snippet"": ""The symptomatic treatment of the motor symptoms of Parkinson disease (PD) has been constantly optimized using pharmacotherapy (L-Dopa, several dopamine agonists, inhibitors of monoamine oxidase (MAO)-B and catechol-o-methyltransferase (COMT), and amantadine), deep brain stimulation, and physiotherapy."", ""supports"": ""SUPPORT""}"
6009	5909	250	Parkinson's Disease	Parkinsons_Disease.yaml	treatments	5	evidence	0	PMID:27577098	SUPPORT		The symptomatic treatment of the motor symptoms of Parkinson disease (PD) has been constantly optimized using pharmacotherapy (L-Dopa, several dopamine agonists, inhibitors of monoamine oxidase (MAO)-B and catechol-o-methyltransferase (COMT), and amantadine), deep brain stimulation, and physiotherapy.	This review lists physiotherapy as part of symptomatic treatment for PD.	"{""explanation"": ""This review lists physiotherapy as part of symptomatic treatment for PD."", ""reference"": ""PMID:27577098"", ""snippet"": ""The symptomatic treatment of the motor symptoms of Parkinson disease (PD) has been constantly optimized using pharmacotherapy (L-Dopa, several dopamine agonists, inhibitors of monoamine oxidase (MAO)-B and catechol-o-methyltransferase (COMT), and amantadine), deep brain stimulation, and physiotherapy."", ""supports"": ""SUPPORT""}"
6048	5939	251	Pars Planitis	Pars_Planitis.yaml	treatments	0	evidence	0	PMID:27051493	SUPPORT		A stepladder approach including corticosteroids, immunosupressive agents, anti-tumor necrosis factor-alpha and pars plana vitrectomy and/or laser photocoagulation is the most commonly used method for treatment of pars planitis.	Corticosteroids form the foundation of treatment for pars planitis.	"{""explanation"": ""Corticosteroids form the foundation of treatment for pars planitis."", ""reference"": ""PMID:27051493"", ""snippet"": ""A stepladder approach including corticosteroids, immunosupressive agents, anti-tumor necrosis factor-alpha and pars plana vitrectomy and/or laser photocoagulation is the most commonly used method for treatment of pars planitis."", ""supports"": ""SUPPORT""}"
6049	5940	251	Pars Planitis	Pars_Planitis.yaml	treatments	1	evidence	0	PMID:27051493	SUPPORT		Methotrexate is the most widely used first-line immunosuppressive agent in children with chronic non-infectious uveitis because of its long-term safety record and well tolerance.	Immunosuppressive agents, particularly methotrexate, provide steroid-sparing control for chronic cases.	"{""explanation"": ""Immunosuppressive agents, particularly methotrexate, provide steroid-sparing control for chronic cases."", ""reference"": ""PMID:27051493"", ""snippet"": ""Methotrexate is the most widely used first-line immunosuppressive agent in children with chronic non-infectious uveitis because of its long-term safety record and well tolerance."", ""supports"": ""SUPPORT""}"
6050	5941	251	Pars Planitis	Pars_Planitis.yaml	treatments	2	evidence	0	PMID:34568953	SUPPORT		ADA was initiated in 23 patients (38.9%) due to refractory uveitis and adverse effects to the corticosteroid and helped control intraocular inflammation and decrease the use of systemic steroids/immunosuppressives in 22 of 23 (95%) of patients who received ADA.	TNF-alpha inhibition with adalimumab controlled inflammation and enabled steroid-sparing in refractory cases.	"{""explanation"": ""TNF-alpha inhibition with adalimumab controlled inflammation and enabled steroid-sparing in refractory cases."", ""reference"": ""PMID:34568953"", ""snippet"": ""ADA was initiated in 23 patients (38.9%) due to refractory uveitis and adverse effects to the corticosteroid and helped control intraocular inflammation and decrease the use of systemic steroids/immunosuppressives in 22 of 23 (95%) of patients who received ADA."", ""supports"": ""SUPPORT""}"
6051	5942	251	Pars Planitis	Pars_Planitis.yaml	treatments	3	evidence	0	PMID:27051493	SUPPORT		A stepladder approach including corticosteroids, immunosupressive agents, anti-tumor necrosis factor-alpha and pars plana vitrectomy and/or laser photocoagulation is the most commonly used method for treatment of pars planitis.	Surgical intervention may be necessary for cases with severe vitreous involvement or complications.	"{""explanation"": ""Surgical intervention may be necessary for cases with severe vitreous involvement or complications."", ""reference"": ""PMID:27051493"", ""snippet"": ""A stepladder approach including corticosteroids, immunosupressive agents, anti-tumor necrosis factor-alpha and pars plana vitrectomy and/or laser photocoagulation is the most commonly used method for treatment of pars planitis."", ""supports"": ""SUPPORT""}"
6133	5965	252	Parvovirus B19 Infection	Parvovirus_B19_Infection.yaml	treatments	0	evidence	0	PMID:31323869	SUPPORT		Presently available treatments are only supportive, symptomatic, or unspecific, such as administration of intravenous immunoglobulins, and often of limited efficacy.	The literature states that the available treatments for Parvovirus B19 infection are primarily supportive and symptomatic.	"{""explanation"": ""The literature states that the available treatments for Parvovirus B19 infection are primarily supportive and symptomatic."", ""reference"": ""PMID:31323869"", ""snippet"": ""Presently available treatments are only supportive, symptomatic, or unspecific, such as administration of intravenous immunoglobulins, and often of limited efficacy."", ""supports"": ""SUPPORT""}"
6134	5965	252	Parvovirus B19 Infection	Parvovirus_B19_Infection.yaml	treatments	0	evidence	1	PMID:8668619	SUPPORT		Treatment ranges from analgesics and antipyretics for mild and self-limited illness to administration of commercial immunoglobulin preparations and blood transfusion for more serious conditions.	The literature mentions the use of analgesics and antipyretics, which are supportive care measures, for managing mild and self-limited illness caused by Parvovirus B19.	"{""explanation"": ""The literature mentions the use of analgesics and antipyretics, which are supportive care measures, for managing mild and self-limited illness caused by Parvovirus B19."", ""reference"": ""PMID:8668619"", ""snippet"": ""Treatment ranges from analgesics and antipyretics for mild and self-limited illness to administration of commercial immunoglobulin preparations and blood transfusion for more serious conditions."", ""supports"": ""SUPPORT""}"
6135	5965	252	Parvovirus B19 Infection	Parvovirus_B19_Infection.yaml	treatments	0	evidence	2	PMID:7899371	SUPPORT		Nonsteroid antiinflammatory drugs are generally effective.	The literature supports the use of nonsteroidal anti-inflammatory drugs (a form of supportive care) for managing symptoms of Parvovirus B19 infection.	"{""explanation"": ""The literature supports the use of nonsteroidal anti-inflammatory drugs (a form of supportive care) for managing symptoms of Parvovirus B19 infection."", ""reference"": ""PMID:7899371"", ""snippet"": ""Nonsteroid antiinflammatory drugs are generally effective."", ""supports"": ""SUPPORT""}"
6136	5966	252	Parvovirus B19 Infection	Parvovirus_B19_Infection.yaml	treatments	1	evidence	0	PMID:37544998	SUPPORT		IVIG infusion effectively treated the parvovirus B19 infection and restored erythropoiesis making the child transfusion independent.	The case report demonstrates the effective use of IVIG in treating severe anemia caused by parvovirus B19 infection.	"{""explanation"": ""The case report demonstrates the effective use of IVIG in treating severe anemia caused by parvovirus B19 infection."", ""reference"": ""PMID:37544998"", ""snippet"": ""IVIG infusion effectively treated the parvovirus B19 infection and restored erythropoiesis making the child transfusion independent."", ""supports"": ""SUPPORT""}"
6137	5966	252	Parvovirus B19 Infection	Parvovirus_B19_Infection.yaml	treatments	1	evidence	1	PMID:11560750	SUPPORT		Specific antiviral therapy is not available, however, intravenous immunoglobulin produces rapid improvement in most cases.	The literature indicates that IVIG is used effectively in treating parvovirus B19 infection in pediatric transplant patients, who are often immunocompromised.	"{""explanation"": ""The literature indicates that IVIG is used effectively in treating parvovirus B19 infection in pediatric transplant patients, who are often immunocompromised."", ""reference"": ""PMID:11560750"", ""snippet"": ""Specific antiviral therapy is not available, however, intravenous immunoglobulin produces rapid improvement in most cases."", ""supports"": ""SUPPORT""}"
6138	5966	252	Parvovirus B19 Infection	Parvovirus_B19_Infection.yaml	treatments	1	evidence	2	PMID:33346452	SUPPORT		In addition to blood transfusions, we administered intravenous donor immunoglobulin with a dose increase from 5000 mg to 20 000 mg per day.	The case report supports the use of IVIG in an HIV-infected patient with parvovirus B19-related severe anemia.	"{""explanation"": ""The case report supports the use of IVIG in an HIV-infected patient with parvovirus B19-related severe anemia."", ""reference"": ""PMID:33346452"", ""snippet"": ""In addition to blood transfusions, we administered intravenous donor immunoglobulin with a dose increase from 5000 mg to 20 000 mg per day."", ""supports"": ""SUPPORT""}"
6139	5966	252	Parvovirus B19 Infection	Parvovirus_B19_Infection.yaml	treatments	1	evidence	3	PMID:7756792	SUPPORT		Treatment of parvovirus infections among immunocompromised hosts using immunoglobulin has provided the clinician with a useful therapeutic tool but has also highlighted the problems concerning chronic disease states.	This reference supports the use of IVIG in immunocompromised individuals with parvovirus B19 infection.	"{""explanation"": ""This reference supports the use of IVIG in immunocompromised individuals with parvovirus B19 infection."", ""reference"": ""PMID:7756792"", ""snippet"": ""Treatment of parvovirus infections among immunocompromised hosts using immunoglobulin has provided the clinician with a useful therapeutic tool but has also highlighted the problems concerning chronic disease states."", ""supports"": ""SUPPORT""}"
6251	6052	255	Peroxisome Biogenesis Disorder	Peroxisome_Biogenesis_Disorder.yaml	treatments	0	evidence	0	PMID:11060787	PARTIAL		Treatment of PBD patients has generally involved only supportive care and symptomatic therapy.	The statement about supportive care and symptomatic therapy is accurate but does not explicitly mention physical therapy for hypotonia and seizure management.	"{""explanation"": ""The statement about supportive care and symptomatic therapy is accurate but does not explicitly mention physical therapy for hypotonia and seizure management."", ""reference"": ""PMID:11060787"", ""snippet"": ""Treatment of PBD patients has generally involved only supportive care and symptomatic therapy."", ""supports"": ""PARTIAL""}"
6252	6052	255	Peroxisome Biogenesis Disorder	Peroxisome_Biogenesis_Disorder.yaml	treatments	0	evidence	1	PMID:38409970	PARTIAL		Despite an absence of treatment options, prompt diagnosis of Zellweger syndrome is important for providing appropriate symptomatic care.	The statement supports symptomatic care but does not detail specific treatments such as physical therapy for hypotonia or seizure management.	"{""explanation"": ""The statement supports symptomatic care but does not detail specific treatments such as physical therapy for hypotonia or seizure management."", ""reference"": ""PMID:38409970"", ""snippet"": ""Despite an absence of treatment options, prompt diagnosis of Zellweger syndrome is important for providing appropriate symptomatic care."", ""supports"": ""PARTIAL""}"
6253	6053	255	Peroxisome Biogenesis Disorder	Peroxisome_Biogenesis_Disorder.yaml	treatments	1	evidence	0	PMID:11060787	SUPPORT		A number of experimental therapies have been evaluated to determine whether or not correction of biochemical abnormalities through dietary supplementation and/or modification is of clinical benefit to PBD patients.	This snippet indicates that dietary supplementation and/or modification has been evaluated to manage biochemical abnormalities in PBD patients, supporting the statement that specialized diet and supplements can be a treatment strategy.	"{""explanation"": ""This snippet indicates that dietary supplementation and/or modification has been evaluated to manage biochemical abnormalities in PBD patients, supporting the statement that specialized diet and supplements can be a treatment strategy."", ""reference"": ""PMID:11060787"", ""snippet"": ""A number of experimental therapies have been evaluated to determine whether or not correction of biochemical abnormalities through dietary supplementation and/or modification is of clinical benefit to PBD patients."", ""supports"": ""SUPPORT""}"
6254	6053	255	Peroxisome Biogenesis Disorder	Peroxisome_Biogenesis_Disorder.yaml	treatments	1	evidence	1	PMID:18758655	SUPPORT		The most important measures used to manage the intoxication present in many inborn errors of intermediate metabolism were presented (restriction of substrate build-up by means of diet or enzymatic inhibition, removal of toxic products, stimulation of residual enzyme activity, replacement of the deficient product).	This reference discusses the use of diet as a measure to manage biochemical abnormalities in metabolic disorders, including peroxisomal diseases, which supports the statement.	"{""explanation"": ""This reference discusses the use of diet as a measure to manage biochemical abnormalities in metabolic disorders, including peroxisomal diseases, which supports the statement."", ""reference"": ""PMID:18758655"", ""snippet"": ""The most important measures used to manage the intoxication present in many inborn errors of intermediate metabolism were presented (restriction of substrate build-up by means of diet or enzymatic inhibition, removal of toxic products, stimulation of residual enzyme activity, replacement of the deficient product)."", ""supports"": ""SUPPORT""}"
6255	6053	255	Peroxisome Biogenesis Disorder	Peroxisome_Biogenesis_Disorder.yaml	treatments	1	evidence	2	PMID:16819396	NO_EVIDENCE		Bile-acid therapy using oral cholic acid has proven effective in most of these bile acid synthetic defects making early diagnosis crucial to optimum clinical prognosis.	While this reference discusses a specific bile-acid therapy, it does not provide evidence about dietary or supplemental approaches for managing biochemical abnormalities in PBDs.	"{""explanation"": ""While this reference discusses a specific bile-acid therapy, it does not provide evidence about dietary or supplemental approaches for managing biochemical abnormalities in PBDs."", ""reference"": ""PMID:16819396"", ""snippet"": ""Bile-acid therapy using oral cholic acid has proven effective in most of these bile acid synthetic defects making early diagnosis crucial to optimum clinical prognosis."", ""supports"": ""NO_EVIDENCE""}"
6256	6054	255	Peroxisome Biogenesis Disorder	Peroxisome_Biogenesis_Disorder.yaml	treatments	2	evidence	0	PMID:35331403	SUPPORT		Most of these disorders are currently treated by liver transplantation as standard of care.	The reference indicates that liver transplantation is the standard of care for congenital inherited hepatic disorders, which includes peroxisomal disorders like Peroxisome Biogenesis Disorder (PBD), supporting that liver transplant is considered in severe cases with significant liver dysfunction.	"{""explanation"": ""The reference indicates that liver transplantation is the standard of care for congenital inherited hepatic disorders, which includes peroxisomal disorders like Peroxisome Biogenesis Disorder (PBD), supporting that liver transplant is considered in severe cases with significant liver dysfunction."", ""reference"": ""PMID:35331403"", ""snippet"": ""Most of these disorders are currently treated by liver transplantation as standard of care."", ""supports"": ""SUPPORT""}"
6257	6054	255	Peroxisome Biogenesis Disorder	Peroxisome_Biogenesis_Disorder.yaml	treatments	2	evidence	1	PMID:26615381	PARTIAL		ZS should be considered in the list of differential diagnosis in infants with stereotypical phenotype, neurodevelopmental delay, and severe hypotonia in association with liver and other organs involvement.	While this reference confirms liver involvement in Peroxisome Biogenesis Disorders such as Zellweger Syndrome, it does not specifically mention liver transplantation as a treatment.	"{""explanation"": ""While this reference confirms liver involvement in Peroxisome Biogenesis Disorders such as Zellweger Syndrome, it does not specifically mention liver transplantation as a treatment."", ""reference"": ""PMID:26615381"", ""snippet"": ""ZS should be considered in the list of differential diagnosis in infants with stereotypical phenotype, neurodevelopmental delay, and severe hypotonia in association with liver and other organs involvement."", ""supports"": ""PARTIAL""}"
6258	6054	255	Peroxisome Biogenesis Disorder	Peroxisome_Biogenesis_Disorder.yaml	treatments	2	evidence	2	PMID:22974902	PARTIAL		When none of the liver parenchyma is spared, or kidney insufficiency is marked, the only potentially curable treatment is liver transplantation (LT).	This reference supports the use of liver transplantation in severe liver conditions, though it does not directly mention Peroxisome Biogenesis Disorder.	"{""explanation"": ""This reference supports the use of liver transplantation in severe liver conditions, though it does not directly mention Peroxisome Biogenesis Disorder."", ""reference"": ""PMID:22974902"", ""snippet"": ""When none of the liver parenchyma is spared, or kidney insufficiency is marked, the only potentially curable treatment is liver transplantation (LT)."", ""supports"": ""PARTIAL""}"
6259	6055	255	Peroxisome Biogenesis Disorder	Peroxisome_Biogenesis_Disorder.yaml	treatments	3	evidence	0	PMID:14619605	SUPPORT		Genetic counseling has developed as a discipline in response to the need to educate patients, families and professionals about genetic mechanisms and their application in health care. ... Genetic counseling is a process of medical education based upon empathy, patient autonomy and confidentiality in an atmosphere of empathy, support and understanding.	The literature describes genetic counseling as a discipline developed to educate patients, families, and professionals about genetic mechanisms and their application in healthcare, which supports the statement about providing information and support to families regarding inheritance and implications.	"{""explanation"": ""The literature describes genetic counseling as a discipline developed to educate patients, families, and professionals about genetic mechanisms and their application in healthcare, which supports the statement about providing information and support to families regarding inheritance and implications."", ""reference"": ""PMID:14619605"", ""snippet"": ""Genetic counseling has developed as a discipline in response to the need to educate patients, families and professionals about genetic mechanisms and their application in health care. ... Genetic counseling is a process of medical education based upon empathy, patient autonomy and confidentiality in an atmosphere of empathy, support and understanding."", ""supports"": ""SUPPORT""}"
6260	6055	255	Peroxisome Biogenesis Disorder	Peroxisome_Biogenesis_Disorder.yaml	treatments	3	evidence	1	PMID:30237433	SUPPORT		Furthermore, it is also important to identify pre-symptomatic patients by family analysis of probands by providing appropriate disease information and genetic counseling, which will also lead to early intervention.	The literature discusses the importance of providing disease information and genetic counseling to families, supporting the statement about providing information and support to families regarding inheritance and implications in the context of peroxisomal diseases.	"{""explanation"": ""The literature discusses the importance of providing disease information and genetic counseling to families, supporting the statement about providing information and support to families regarding inheritance and implications in the context of peroxisomal diseases."", ""reference"": ""PMID:30237433"", ""snippet"": ""Furthermore, it is also important to identify pre-symptomatic patients by family analysis of probands by providing appropriate disease information and genetic counseling, which will also lead to early intervention."", ""supports"": ""SUPPORT""}"
6281	6073	256	Peutz-Jeghers polyp	Peutz_Jeghers_polyp.yaml	treatments	0	evidence	0	PMID:20301443	SUPPORT		Routine endoscopic surveillance with polypectomy decreases the frequency of emergency laparotomy and bowel loss resulting from intussusception	Endoscopic polyp removal is the standard therapeutic approach to prevent complications from Peutz-Jeghers polyps	"{""explanation"": ""Endoscopic polyp removal is the standard therapeutic approach to prevent complications from Peutz-Jeghers polyps"", ""reference"": ""PMID:20301443"", ""snippet"": ""Routine endoscopic surveillance with polypectomy decreases the frequency of emergency laparotomy and bowel loss resulting from intussusception"", ""supports"": ""SUPPORT""}"
6282	6074	256	Peutz-Jeghers polyp	Peutz_Jeghers_polyp.yaml	treatments	1	evidence	0	PMID:34928720	SUPPORT		The patient underwent exploratory laparotomy during which right hemicolectomy and small bowel resection were performed	Surgical resection is indicated for intussusception and polyps with neoplastic transformation	"{""explanation"": ""Surgical resection is indicated for intussusception and polyps with neoplastic transformation"", ""reference"": ""PMID:34928720"", ""snippet"": ""The patient underwent exploratory laparotomy during which right hemicolectomy and small bowel resection were performed"", ""supports"": ""SUPPORT""}"
6283	6075	256	Peutz-Jeghers polyp	Peutz_Jeghers_polyp.yaml	treatments	2	evidence	0	PMID:36998347	SUPPORT		Endoscopic resection was conducted for a definitive diagnosis and treatment. The resected specimen showed a branching bundle of smooth muscle fibers covered by hyperplastic mucosa, consistent with a hamartomatous polyp	Genetic counseling for at-risk family members and molecular testing are critical given the autosomal dominant inheritance pattern and health implications of STK11 mutations	"{""explanation"": ""Genetic counseling for at-risk family members and molecular testing are critical given the autosomal dominant inheritance pattern and health implications of STK11 mutations"", ""reference"": ""PMID:36998347"", ""snippet"": ""Endoscopic resection was conducted for a definitive diagnosis and treatment. The resected specimen showed a branching bundle of smooth muscle fibers covered by hyperplastic mucosa, consistent with a hamartomatous polyp"", ""supports"": ""SUPPORT""}"
6305	6132	259	Phenylketonuria	Phenylketonuria.yaml	treatments	0	evidence	0	PMID:34017006	SUPPORT		Dietary restriction of phenylalanine has been the mainstay of treatment for over 60 years and has been highly successful, although outcomes are still suboptimal and patients can find the treatment difficult to adhere to.	Confirms diet as the primary and long-standing treatment approach.	"{""explanation"": ""Confirms diet as the primary and long-standing treatment approach."", ""reference"": ""PMID:34017006"", ""snippet"": ""Dietary restriction of phenylalanine has been the mainstay of treatment for over 60 years and has been highly successful, although outcomes are still suboptimal and patients can find the treatment difficult to adhere to."", ""supports"": ""SUPPORT""}"
6306	6134	259	Phenylketonuria	Phenylketonuria.yaml	treatments	2	evidence	0	PMID:34017006	SUPPORT		Pharmacological treatments are available, such as tetrahydrobiopterin, which is effective in only a minority of patients (usually those with milder PKU)	Confirms sapropterin (BH4) effectiveness in a subset of patients with milder disease.	"{""explanation"": ""Confirms sapropterin (BH4) effectiveness in a subset of patients with milder disease."", ""reference"": ""PMID:34017006"", ""snippet"": ""Pharmacological treatments are available, such as tetrahydrobiopterin, which is effective in only a minority of patients (usually those with milder PKU)"", ""supports"": ""SUPPORT""}"
6307	6135	259	Phenylketonuria	Phenylketonuria.yaml	treatments	3	evidence	0	PMID:34017006	SUPPORT		pegylated phenylalanine ammonia lyase, which requires daily subcutaneous injections and causes adverse immune responses	Confirms pegvaliase as an available treatment, noting its route and immunogenicity concerns.	"{""explanation"": ""Confirms pegvaliase as an available treatment, noting its route and immunogenicity concerns."", ""reference"": ""PMID:34017006"", ""snippet"": ""pegylated phenylalanine ammonia lyase, which requires daily subcutaneous injections and causes adverse immune responses"", ""supports"": ""SUPPORT""}"
6359	6186	261	Pick Disease	Pick_Disease.yaml	treatments	0	evidence	0	PMID:12080867	PARTIAL		Pick's disease is a progressive illness that affects brain function, eventually causing loss of verbal skills and problem-solving abilities	The reference discusses the management of Pick's disease by addressing symptoms, but does not explicitly mention the use of medications to manage behavior and support cognitive function. Hence, it provides partial support.	"{""explanation"": ""The reference discusses the management of Pick's disease by addressing symptoms, but does not explicitly mention the use of medications to manage behavior and support cognitive function. Hence, it provides partial support."", ""reference"": ""PMID:12080867"", ""snippet"": ""Pick's disease is a progressive illness that affects brain function, eventually causing loss of verbal skills and problem-solving abilities"", ""supports"": ""PARTIAL""}"
6360	6190	261	Pick Disease	Pick_Disease.yaml	treatments	4	evidence	0	PMID:12080867	SUPPORT		Nurses have the responsibility of educating the primary caregiver about nutrition, skin protection, incontinence care, safety, and end-of-life decisions.	This reference discusses the responsibilities of nurses to educate caregivers, aligning with the statement that education and resources for caregivers are part of the treatments for Pick's disease.	"{""explanation"": ""This reference discusses the responsibilities of nurses to educate caregivers, aligning with the statement that education and resources for caregivers are part of the treatments for Pick's disease."", ""reference"": ""PMID:12080867"", ""snippet"": ""Nurses have the responsibility of educating the primary caregiver about nutrition, skin protection, incontinence care, safety, and end-of-life decisions."", ""supports"": ""SUPPORT""}"
6361	6190	261	Pick Disease	Pick_Disease.yaml	treatments	4	evidence	1	PMID:18090424	PARTIAL		Clinical and biologic evidence in favor the entity is discussed. The changing and proliferating knowledge and terminology requires the integration of several levels of descriptions, while keeping the work in the past in sight.	This reference provides clinical and biological descriptions of Pick's disease and does not explicitly mention caregiver support or education, thus only partially supporting the statement.	"{""explanation"": ""This reference provides clinical and biological descriptions of Pick's disease and does not explicitly mention caregiver support or education, thus only partially supporting the statement."", ""reference"": ""PMID:18090424"", ""snippet"": ""Clinical and biologic evidence in favor the entity is discussed. The changing and proliferating knowledge and terminology requires the integration of several levels of descriptions, while keeping the work in the past in sight."", ""supports"": ""PARTIAL""}"
6364	6193	262	Pinta	Pinta.yaml	treatments	0	evidence	0	PMID:26304920	SUPPORT		All stages of pinta are treatable with a single intramuscular injection of penicillin.	The abstract states that penicillin injection treats pinta.	"{""explanation"": ""The abstract states that penicillin injection treats pinta."", ""reference"": ""PMID:26304920"", ""snippet"": ""All stages of pinta are treatable with a single intramuscular injection of penicillin."", ""supports"": ""SUPPORT""}"
6380	6208	263	Polycystic echinococcosis	Polycystic_Echinococcosis.yaml	treatments	0	evidence	0	PMID:34034501	SUPPORT		Treatment with albendazole, whether combined or not with praziquantel, is useful for smaller, uncomplicated cysts (< 5 cm).	Review guidance highlights albendazole as standard medical therapy for hydatid cysts.	"{""explanation"": ""Review guidance highlights albendazole as standard medical therapy for hydatid cysts."", ""reference"": ""PMID:34034501"", ""snippet"": ""Treatment with albendazole, whether combined or not with praziquantel, is useful for smaller, uncomplicated cysts (< 5 cm)."", ""supports"": ""SUPPORT""}"
6381	6209	263	Polycystic echinococcosis	Polycystic_Echinococcosis.yaml	treatments	1	evidence	0	PMID:33553405	SUPPORT		According to Romic classification, the case belongs to type IIb, and radical left hemi-hepatectomy was performed.	The case demonstrates radical liver resection as operative management for polycystic echinococcosis.	"{""explanation"": ""The case demonstrates radical liver resection as operative management for polycystic echinococcosis."", ""reference"": ""PMID:33553405"", ""snippet"": ""According to Romic classification, the case belongs to type IIb, and radical left hemi-hepatectomy was performed."", ""supports"": ""SUPPORT""}"
6409	6233	264	Polycystic Kidney Disease	Polycystic_Kidney_Disease.yaml	treatments	0	evidence	0	PMID:29105594	SUPPORT		Tolvaptan resulted in a slower decline than placebo in the estimated GFR over a 1-year period in patients with later-stage ADPKD.	REPRISE trial demonstrated tolvaptan efficacy in slowing GFR decline in PKD patients.	"{""explanation"": ""REPRISE trial demonstrated tolvaptan efficacy in slowing GFR decline in PKD patients."", ""reference"": ""PMID:29105594"", ""snippet"": ""Tolvaptan resulted in a slower decline than placebo in the estimated GFR over a 1-year period in patients with later-stage ADPKD."", ""supports"": ""SUPPORT""}"
6410	6234	264	Polycystic Kidney Disease	Polycystic_Kidney_Disease.yaml	treatments	1	evidence	0	PMID:40126492	SUPPORT		First-line treatment includes blood pressure control, dietary and weight management, and adequate hydration.	JAMA review confirms blood pressure control as first-line treatment for ADPKD.	"{""explanation"": ""JAMA review confirms blood pressure control as first-line treatment for ADPKD."", ""reference"": ""PMID:40126492"", ""snippet"": ""First-line treatment includes blood pressure control, dietary and weight management, and adequate hydration."", ""supports"": ""SUPPORT""}"
6411	6235	264	Polycystic Kidney Disease	Polycystic_Kidney_Disease.yaml	treatments	2	evidence	0	PMID:40126492	SUPPORT		Approximately 50% of individuals with ADPKD require kidney replacement therapy by 62 years of age.	JAMA review confirms high rate of kidney replacement therapy (dialysis/transplant) in ADPKD.	"{""explanation"": ""JAMA review confirms high rate of kidney replacement therapy (dialysis/transplant) in ADPKD."", ""reference"": ""PMID:40126492"", ""snippet"": ""Approximately 50% of individuals with ADPKD require kidney replacement therapy by 62 years of age."", ""supports"": ""SUPPORT""}"
6412	6236	264	Polycystic Kidney Disease	Polycystic_Kidney_Disease.yaml	treatments	3	evidence	0	PMID:40126492	SUPPORT		Approximately 50% of individuals with ADPKD require kidney replacement therapy by 62 years of age.	JAMA review confirms high rate of kidney replacement therapy (dialysis/transplant) in ADPKD.	"{""explanation"": ""JAMA review confirms high rate of kidney replacement therapy (dialysis/transplant) in ADPKD."", ""reference"": ""PMID:40126492"", ""snippet"": ""Approximately 50% of individuals with ADPKD require kidney replacement therapy by 62 years of age."", ""supports"": ""SUPPORT""}"
6534	6373	270	Primary_Ciliary_Dyskinesia	Primary_Ciliary_Dyskinesia.yaml	treatments	0	evidence	0	PMID:28408202	SUPPORT		Airway clearance techniques (ACTs) are commonly recommended for patients with PCD to facilitate mucus clearance, despite a lack of evidence in this group.	The reference acknowledges the use of airway clearance techniques in patients with Primary Ciliary Dyskinesia (PCD) to help clear mucus from the lungs.	"{""explanation"": ""The reference acknowledges the use of airway clearance techniques in patients with Primary Ciliary Dyskinesia (PCD) to help clear mucus from the lungs."", ""reference"": ""PMID:28408202"", ""snippet"": ""Airway clearance techniques (ACTs) are commonly recommended for patients with PCD to facilitate mucus clearance, despite a lack of evidence in this group."", ""supports"": ""SUPPORT""}"
6535	6373	270	Primary_Ciliary_Dyskinesia	Primary_Ciliary_Dyskinesia.yaml	treatments	0	evidence	1	PMID:38861625	SUPPORT		Airway clearance techniques (ACTs) are critical in managing respiratory conditions characterized by mucus hypersecretion and impaired clearance, such as cystic fibrosis, chronic obstructive pulmonary disease (COPD), and various neuromuscular disorders.	The reference discusses the importance of ACTs in managing conditions with mucus hypersecretion and impaired clearance, which aligns with the use of these techniques in PCD.	"{""explanation"": ""The reference discusses the importance of ACTs in managing conditions with mucus hypersecretion and impaired clearance, which aligns with the use of these techniques in PCD."", ""reference"": ""PMID:38861625"", ""snippet"": ""Airway clearance techniques (ACTs) are critical in managing respiratory conditions characterized by mucus hypersecretion and impaired clearance, such as cystic fibrosis, chronic obstructive pulmonary disease (COPD), and various neuromuscular disorders."", ""supports"": ""SUPPORT""}"
6536	6373	270	Primary_Ciliary_Dyskinesia	Primary_Ciliary_Dyskinesia.yaml	treatments	0	evidence	2	PMID:11376511	SUPPORT		There are three principal disorders of MCC. Firstly, primary ciliary dyskinesia (PCD)...	The reference mentions PCD and discusses airway hygiene and mucociliary clearance, supporting the relevance of airway clearance techniques in PCD.	"{""explanation"": ""The reference mentions PCD and discusses airway hygiene and mucociliary clearance, supporting the relevance of airway clearance techniques in PCD."", ""reference"": ""PMID:11376511"", ""snippet"": ""There are three principal disorders of MCC. Firstly, primary ciliary dyskinesia (PCD)..."", ""supports"": ""SUPPORT""}"
6537	6374	270	Primary_Ciliary_Dyskinesia	Primary_Ciliary_Dyskinesia.yaml	treatments	1	evidence	0	PMID:28552099	SUPPORT		Non-functional airway cilia impair the mucociliary clearance (MCC), causing mucostasis, lung infections and destruction, chronic rhinosinusitis (CRS) and hearing impairment. It is of paramount importance to postpone chronic lung infection mainly with Gram-negative bacteria (GNB) in patients with an impaired MCC. When successful, lung function can be stabilized and quality of life (QoL) improved.	The literature mentions the importance of postponing chronic lung infection in patients with impaired MCC, which is a characteristic of PCD. This aligns with the use of long-term antibiotic therapy to manage such infections.	"{""explanation"": ""The literature mentions the importance of postponing chronic lung infection in patients with impaired MCC, which is a characteristic of PCD. This aligns with the use of long-term antibiotic therapy to manage such infections."", ""reference"": ""PMID:28552099"", ""snippet"": ""Non-functional airway cilia impair the mucociliary clearance (MCC), causing mucostasis, lung infections and destruction, chronic rhinosinusitis (CRS) and hearing impairment. It is of paramount importance to postpone chronic lung infection mainly with Gram-negative bacteria (GNB) in patients with an impaired MCC. When successful, lung function can be stabilized and quality of life (QoL) improved."", ""supports"": ""SUPPORT""}"
6538	6374	270	Primary_Ciliary_Dyskinesia	Primary_Ciliary_Dyskinesia.yaml	treatments	1	evidence	1	PMID:26586601	SUPPORT		Most of the treatments recommended in PCD have been extrapolated from cystic fibrosis (CF) and non-CF bronchiectasis literature. Mainstays of therapy are reviewed in detail, and should include at a minimum: regular airway clearance, routine microbiological surveillance, antibiotic treatment for pulmonary exacerbation, and health vaccinations.	The reference states that antibiotic treatment for pulmonary exacerbation is a mainstay of therapy for PCD, supporting the use of long-term or prophylactic antibiotics.	"{""explanation"": ""The reference states that antibiotic treatment for pulmonary exacerbation is a mainstay of therapy for PCD, supporting the use of long-term or prophylactic antibiotics."", ""reference"": ""PMID:26586601"", ""snippet"": ""Most of the treatments recommended in PCD have been extrapolated from cystic fibrosis (CF) and non-CF bronchiectasis literature. Mainstays of therapy are reviewed in detail, and should include at a minimum: regular airway clearance, routine microbiological surveillance, antibiotic treatment for pulmonary exacerbation, and health vaccinations."", ""supports"": ""SUPPORT""}"
6539	6374	270	Primary_Ciliary_Dyskinesia	Primary_Ciliary_Dyskinesia.yaml	treatments	1	evidence	2	PMID:19812481	SUPPORT		Antibiotic prophylaxis is one of the mainstays of therapy of primary immunodeficiencies.	While the focus is on primary immunodeficiencies, the principle of using antibiotic prophylaxis can be extended to PCD due to similar needs for managing chronic infections.	"{""explanation"": ""While the focus is on primary immunodeficiencies, the principle of using antibiotic prophylaxis can be extended to PCD due to similar needs for managing chronic infections."", ""reference"": ""PMID:19812481"", ""snippet"": ""Antibiotic prophylaxis is one of the mainstays of therapy of primary immunodeficiencies."", ""supports"": ""SUPPORT""}"
6540	6375	270	Primary_Ciliary_Dyskinesia	Primary_Ciliary_Dyskinesia.yaml	treatments	2	evidence	0	PMID:36639347	NO_EVIDENCE			The reference discusses new data and future challenges related to Primary Ciliary Dyskinesia (PCD) and bronchiectasis but does not provide specific information about the use of bronchodilators for PCD.	"{""explanation"": ""The reference discusses new data and future challenges related to Primary Ciliary Dyskinesia (PCD) and bronchiectasis but does not provide specific information about the use of bronchodilators for PCD."", ""reference"": ""PMID:36639347"", ""snippet"": """", ""supports"": ""NO_EVIDENCE""}"
6541	6375	270	Primary_Ciliary_Dyskinesia	Primary_Ciliary_Dyskinesia.yaml	treatments	2	evidence	1	PMID:39269762	NO_EVIDENCE		Primary ciliary dyskinesia (PCD) is a respiratory disorder that impairs mucociliary clearance, leading to decreased lung function.	The reference focuses on airway clearance techniques in PCD and does not mention the use of bronchodilators.	"{""explanation"": ""The reference focuses on airway clearance techniques in PCD and does not mention the use of bronchodilators."", ""reference"": ""PMID:39269762"", ""snippet"": ""Primary ciliary dyskinesia (PCD) is a respiratory disorder that impairs mucociliary clearance, leading to decreased lung function."", ""supports"": ""NO_EVIDENCE""}"
6542	6375	270	Primary_Ciliary_Dyskinesia	Primary_Ciliary_Dyskinesia.yaml	treatments	2	evidence	2	PMID:33507585	NO_EVIDENCE			The reference discusses intrapulmonary percussive ventilation for PCD but does not mention bronchodilators.	"{""explanation"": ""The reference discusses intrapulmonary percussive ventilation for PCD but does not mention bronchodilators."", ""reference"": ""PMID:33507585"", ""snippet"": """", ""supports"": ""NO_EVIDENCE""}"
6543	6375	270	Primary_Ciliary_Dyskinesia	Primary_Ciliary_Dyskinesia.yaml	treatments	2	evidence	3	PMID:37449771	NO_EVIDENCE			The reference discusses treatment response to pulmonary exacerbation in PCD but does not mention bronchodilators.	"{""explanation"": ""The reference discusses treatment response to pulmonary exacerbation in PCD but does not mention bronchodilators."", ""reference"": ""PMID:37449771"", ""snippet"": """", ""supports"": ""NO_EVIDENCE""}"
6544	6376	270	Primary_Ciliary_Dyskinesia	Primary_Ciliary_Dyskinesia.yaml	treatments	3	evidence	0	PMID:19879441	PARTIAL		Long-term treatment with corticosteroid nasal spray reduces inflammation and nasal polyp size, and improves nasal symptoms such as nasal blockage, rhinorrea, and the loss of smell.	While nasal steroids are used to treat nasal polyps and chronic rhinosinusitis, the statement should specify that they are used to manage symptoms rather than being a description of Primary Ciliary Dyskinesia (PCD).	"{""explanation"": ""While nasal steroids are used to treat nasal polyps and chronic rhinosinusitis, the statement should specify that they are used to manage symptoms rather than being a description of Primary Ciliary Dyskinesia (PCD)."", ""reference"": ""PMID:19879441"", ""snippet"": ""Long-term treatment with corticosteroid nasal spray reduces inflammation and nasal polyp size, and improves nasal symptoms such as nasal blockage, rhinorrea, and the loss of smell."", ""supports"": ""PARTIAL""}"
6545	6376	270	Primary_Ciliary_Dyskinesia	Primary_Ciliary_Dyskinesia.yaml	treatments	3	evidence	1	PMID:33305974	PARTIAL		Topical nasal steroids play an important role in the treatment of CRS.	Nasal steroids are used in the treatment of chronic rhinosinusitis (CRS), which can be a condition associated with PCD. However, the statement should clarify that nasal steroids are for symptom management rather than a direct description of PCD.	"{""explanation"": ""Nasal steroids are used in the treatment of chronic rhinosinusitis (CRS), which can be a condition associated with PCD. However, the statement should clarify that nasal steroids are for symptom management rather than a direct description of PCD."", ""reference"": ""PMID:33305974"", ""snippet"": ""Topical nasal steroids play an important role in the treatment of CRS."", ""supports"": ""PARTIAL""}"
6546	6376	270	Primary_Ciliary_Dyskinesia	Primary_Ciliary_Dyskinesia.yaml	treatments	3	evidence	2	PMID:35312075	PARTIAL		Our findings indicate for the first time that PCD patients with CRSwNP display a more severe disease than those with CRSsNP.	This reference indicates that chronic rhinosinusitis with nasal polyps (CRSwNP) is more severe in PCD patients. However, it does not directly state that nasal steroids are used to treat these conditions in the context of PCD.	"{""explanation"": ""This reference indicates that chronic rhinosinusitis with nasal polyps (CRSwNP) is more severe in PCD patients. However, it does not directly state that nasal steroids are used to treat these conditions in the context of PCD."", ""reference"": ""PMID:35312075"", ""snippet"": ""Our findings indicate for the first time that PCD patients with CRSwNP display a more severe disease than those with CRSsNP."", ""supports"": ""PARTIAL""}"
6547	6376	270	Primary_Ciliary_Dyskinesia	Primary_Ciliary_Dyskinesia.yaml	treatments	3	evidence	3	PMID:28552099	PARTIAL		Implementing ESS with adjuvant therapy to PCD patients (I, IV) significantly ameliorated CRS symptoms.	This reference suggests that surgical and adjuvant therapies, including possibly nasal steroids, can ameliorate CRS symptoms in PCD patients. However, it does not explicitly state the use of nasal steroids.	"{""explanation"": ""This reference suggests that surgical and adjuvant therapies, including possibly nasal steroids, can ameliorate CRS symptoms in PCD patients. However, it does not explicitly state the use of nasal steroids."", ""reference"": ""PMID:28552099"", ""snippet"": ""Implementing ESS with adjuvant therapy to PCD patients (I, IV) significantly ameliorated CRS symptoms."", ""supports"": ""PARTIAL""}"
6548	6377	270	Primary_Ciliary_Dyskinesia	Primary_Ciliary_Dyskinesia.yaml	treatments	4	evidence	0	PMID:29287859	NO_EVIDENCE		CONCLUSIONS: Slight to mild CHL and all types of otitis media are prevalent among patients with PCD, and some of these children have sensorineural hearing loss (SNHL).	The study discusses the prevalence and types of hearing loss in children with PCD but does not mention the use of hearing aids or other assistive devices for management.	"{""explanation"": ""The study discusses the prevalence and types of hearing loss in children with PCD but does not mention the use of hearing aids or other assistive devices for management."", ""reference"": ""PMID:29287859"", ""snippet"": ""CONCLUSIONS: Slight to mild CHL and all types of otitis media are prevalent among patients with PCD, and some of these children have sensorineural hearing loss (SNHL)."", ""supports"": ""NO_EVIDENCE""}"
6549	6377	270	Primary_Ciliary_Dyskinesia	Primary_Ciliary_Dyskinesia.yaml	treatments	4	evidence	1	PMID:22960754	NO_EVIDENCE		This article explores factors pertaining to children's use of and attitudes toward hearing technologies, such as hearing aids, cochlear implants, teacher-worn microphones, and student-worn microphones.	This study focuses on the use of hearing technologies among students with hearing impairment but does not specifically address children with PCD.	"{""explanation"": ""This study focuses on the use of hearing technologies among students with hearing impairment but does not specifically address children with PCD."", ""reference"": ""PMID:22960754"", ""snippet"": ""This article explores factors pertaining to children's use of and attitudes toward hearing technologies, such as hearing aids, cochlear implants, teacher-worn microphones, and student-worn microphones."", ""supports"": ""NO_EVIDENCE""}"
6550	6377	270	Primary_Ciliary_Dyskinesia	Primary_Ciliary_Dyskinesia.yaml	treatments	4	evidence	2	PMID:28187057	NO_EVIDENCE		OBJECTIVE: To evaluate whether wearing auditory assistive devices can improve gait and dynamic balance.	The study evaluates the impact of hearing assistive devices on gait and balance in adults but does not mention their use in patients with PCD.	"{""explanation"": ""The study evaluates the impact of hearing assistive devices on gait and balance in adults but does not mention their use in patients with PCD."", ""reference"": ""PMID:28187057"", ""snippet"": ""OBJECTIVE: To evaluate whether wearing auditory assistive devices can improve gait and dynamic balance."", ""supports"": ""NO_EVIDENCE""}"
6551	6377	270	Primary_Ciliary_Dyskinesia	Primary_Ciliary_Dyskinesia.yaml	treatments	4	evidence	3	PMID:30827358	NO_EVIDENCE		Implantable auditory devices (IADs) are a viable hearing restoration option for patients with hearing loss.	The article discusses implantable auditory devices as a hearing restoration option but does not specifically mention hearing aids for patients with PCD.	"{""explanation"": ""The article discusses implantable auditory devices as a hearing restoration option but does not specifically mention hearing aids for patients with PCD."", ""reference"": ""PMID:30827358"", ""snippet"": ""Implantable auditory devices (IADs) are a viable hearing restoration option for patients with hearing loss."", ""supports"": ""NO_EVIDENCE""}"
6552	6377	270	Primary_Ciliary_Dyskinesia	Primary_Ciliary_Dyskinesia.yaml	treatments	4	evidence	4	PMID:2062156	NO_EVIDENCE		In patients with primary ciliary dyskinesia, a discrepancy was found between subjective ear complaints and the actual middle ear function.	This study discusses middle ear function in patients with PCD but does not mention the use of hearing aids or other assistive devices.	"{""explanation"": ""This study discusses middle ear function in patients with PCD but does not mention the use of hearing aids or other assistive devices."", ""reference"": ""PMID:2062156"", ""snippet"": ""In patients with primary ciliary dyskinesia, a discrepancy was found between subjective ear complaints and the actual middle ear function."", ""supports"": ""NO_EVIDENCE""}"
6553	6378	270	Primary_Ciliary_Dyskinesia	Primary_Ciliary_Dyskinesia.yaml	treatments	5	evidence	0	PMID:29800551	NO_EVIDENCE		Our knowledge of cilia genetics and the function of the proteins encoded has led to a greater understanding of the clinical manifestations of motile ciliopathies. These advances have changed our approach toward diagnostic testing for primary ciliary dyskinesia.	The reference discusses advances in genetics and diagnostic testing for primary ciliary dyskinesia but does not mention genetic counseling providing information and support for affected individuals and families.	"{""explanation"": ""The reference discusses advances in genetics and diagnostic testing for primary ciliary dyskinesia but does not mention genetic counseling providing information and support for affected individuals and families."", ""reference"": ""PMID:29800551"", ""snippet"": ""Our knowledge of cilia genetics and the function of the proteins encoded has led to a greater understanding of the clinical manifestations of motile ciliopathies. These advances have changed our approach toward diagnostic testing for primary ciliary dyskinesia."", ""supports"": ""NO_EVIDENCE""}"
6554	6378	270	Primary_Ciliary_Dyskinesia	Primary_Ciliary_Dyskinesia.yaml	treatments	5	evidence	1	PMID:29905515	NO_EVIDENCE		This document presents the American Thoracic Society clinical practice guidelines for the diagnosis of primary ciliary dyskinesia (PCD).	The guideline focuses on diagnostic practices and does not mention genetic counseling or support for affected individuals and families.	"{""explanation"": ""The guideline focuses on diagnostic practices and does not mention genetic counseling or support for affected individuals and families."", ""reference"": ""PMID:29905515"", ""snippet"": ""This document presents the American Thoracic Society clinical practice guidelines for the diagnosis of primary ciliary dyskinesia (PCD)."", ""supports"": ""NO_EVIDENCE""}"
6555	6378	270	Primary_Ciliary_Dyskinesia	Primary_Ciliary_Dyskinesia.yaml	treatments	5	evidence	2	PMID:19410203	NO_EVIDENCE		Newer genetic modifiers show an exciting potential for personalized medication, combining selection of patients with a common genetic mutation and a drug treatment that has been specifically designed to overcome that mutation, and will greatly enhance the therapeutic arsenal for PCD.	The reference discusses potential future therapies for PCD but does not mention genetic counseling or support services.	"{""explanation"": ""The reference discusses potential future therapies for PCD but does not mention genetic counseling or support services."", ""reference"": ""PMID:19410203"", ""snippet"": ""Newer genetic modifiers show an exciting potential for personalized medication, combining selection of patients with a common genetic mutation and a drug treatment that has been specifically designed to overcome that mutation, and will greatly enhance the therapeutic arsenal for PCD."", ""supports"": ""NO_EVIDENCE""}"
6556	6378	270	Primary_Ciliary_Dyskinesia	Primary_Ciliary_Dyskinesia.yaml	treatments	5	evidence	3	PMID:35854386	NO_EVIDENCE		Diagnostic delay and under-recognition of PCD remain a big issue in China, which contributes to progressive lung disease and PA infection indicating worse outcome.	The reference discusses diagnostic delays and clinical outcomes but does not mention genetic counseling or support services.	"{""explanation"": ""The reference discusses diagnostic delays and clinical outcomes but does not mention genetic counseling or support services."", ""reference"": ""PMID:35854386"", ""snippet"": ""Diagnostic delay and under-recognition of PCD remain a big issue in China, which contributes to progressive lung disease and PA infection indicating worse outcome."", ""supports"": ""NO_EVIDENCE""}"
6562	6384	271	Primary Lateral Sclerosis	Primary_Lateral_Sclerosis.yaml	treatments	0	evidence	0	PMID:26515619	SUPPORT		Treatment is largely supportive.	The abstract states that management is supportive.	"{""explanation"": ""The abstract states that management is supportive."", ""reference"": ""PMID:26515619"", ""snippet"": ""Treatment is largely supportive."", ""supports"": ""SUPPORT""}"
6573	6417	273	Primary Progressive Aphasia	Primary_Progressive_Aphasia.yaml	treatments	0	evidence	0	PMID:19300609	SUPPORT		Referral to specialized centers where speech therapy, counseling, and education for both patient and caregiver are available may be helpful.	The abstract highlights speech therapy and counseling as helpful supportive interventions.	"{""explanation"": ""The abstract highlights speech therapy and counseling as helpful supportive interventions."", ""reference"": ""PMID:19300609"", ""snippet"": ""Referral to specialized centers where speech therapy, counseling, and education for both patient and caregiver are available may be helpful."", ""supports"": ""SUPPORT""}"
6580	6432	274	Primary Sclerosing Cholangitis	Primary_Sclerosing_Cholangitis.yaml	treatments	0	evidence	0	PMID:39404413	SUPPORT		there is no evidence that the use of UDCA delays the time to liver transplant or increases survival.	Confirms that despite widespread use, UDCA lacks proven efficacy for delaying transplantation or improving survival in PSC.	"{""explanation"": ""Confirms that despite widespread use, UDCA lacks proven efficacy for delaying transplantation or improving survival in PSC."", ""reference"": ""PMID:39404413"", ""snippet"": ""there is no evidence that the use of UDCA delays the time to liver transplant or increases survival."", ""supports"": ""SUPPORT""}"
6581	6434	274	Primary Sclerosing Cholangitis	Primary_Sclerosing_Cholangitis.yaml	treatments	2	evidence	0	PMID:39250501	SUPPORT		"Treatment for these diseases is limited, and collectively, they are one of the therapeutic ""black boxes"" in clinical hepatology."	Highlights the limited treatment options for PSC, with transplantation remaining the primary definitive therapy.	"{""explanation"": ""Highlights the limited treatment options for PSC, with transplantation remaining the primary definitive therapy."", ""reference"": ""PMID:39250501"", ""snippet"": ""Treatment for these diseases is limited, and collectively, they are one of the therapeutic \""black boxes\"" in clinical hepatology."", ""supports"": ""SUPPORT""}"
6633	6461	275	Primary_Tonsillar_Lymphoma	Primary_Tonsillar_Lymphoma.yaml	treatments	0	evidence	0	PMID:10592134	SUPPORT		We report six cases of primary tonsillar lymphoma with a median patient age of 42 years. There were two lymphoma cases with diffuse large cells, two cases with mixed small and large cells, one with small cells and one indeterminate. They were treated with six cycles of chemotherapy and cervical radiotherapy. All patients achieved durable complete remission.	The study discusses the use of chemotherapy, including CHOP regimen, for the treatment of primary tonsillar lymphoma, which supports the statement.	"{""explanation"": ""The study discusses the use of chemotherapy, including CHOP regimen, for the treatment of primary tonsillar lymphoma, which supports the statement."", ""reference"": ""PMID:10592134"", ""snippet"": ""We report six cases of primary tonsillar lymphoma with a median patient age of 42 years. There were two lymphoma cases with diffuse large cells, two cases with mixed small and large cells, one with small cells and one indeterminate. They were treated with six cycles of chemotherapy and cervical radiotherapy. All patients achieved durable complete remission."", ""supports"": ""SUPPORT""}"
6634	6461	275	Primary_Tonsillar_Lymphoma	Primary_Tonsillar_Lymphoma.yaml	treatments	0	evidence	1	PMID:31894937	SUPPORT		Non-Hodgkin lymphoma is treated with CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) with or without rituximab (R-CHOP)... Chemotherapy treatment plans differ between the main subtypes of lymphoma.	The study mentions the use of CHOP regimen for treating non-Hodgkin lymphoma, which includes primary tonsillar lymphoma.	"{""explanation"": ""The study mentions the use of CHOP regimen for treating non-Hodgkin lymphoma, which includes primary tonsillar lymphoma."", ""reference"": ""PMID:31894937"", ""snippet"": ""Non-Hodgkin lymphoma is treated with CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) with or without rituximab (R-CHOP)... Chemotherapy treatment plans differ between the main subtypes of lymphoma."", ""supports"": ""SUPPORT""}"
6635	6462	275	Primary_Tonsillar_Lymphoma	Primary_Tonsillar_Lymphoma.yaml	treatments	1	evidence	0	PMID:8189757	NO_EVIDENCE		CONCLUSION: This study substantiates the effectiveness of radiation therapy in patients with squamous cell carcinoma of the tonsil.	The study is focused on squamous cell carcinoma of the tonsil, not primary tonsillar lymphoma.	"{""explanation"": ""The study is focused on squamous cell carcinoma of the tonsil, not primary tonsillar lymphoma."", ""reference"": ""PMID:8189757"", ""snippet"": ""CONCLUSION: This study substantiates the effectiveness of radiation therapy in patients with squamous cell carcinoma of the tonsil."", ""supports"": ""NO_EVIDENCE""}"
6636	6462	275	Primary_Tonsillar_Lymphoma	Primary_Tonsillar_Lymphoma.yaml	treatments	1	evidence	1	PMID:20706049	NO_EVIDENCE		Non-Hodgkin lymphomas quite often present in the head and neck but primary tonsillar lymphomas of extranodal non-Hodgkin lymphomas are far less than 1% of head and neck malignancies.	This reference mentions primary tonsillar lymphoma but does not provide specific evidence on the effectiveness of targeted radiation therapy for local disease control.	"{""explanation"": ""This reference mentions primary tonsillar lymphoma but does not provide specific evidence on the effectiveness of targeted radiation therapy for local disease control."", ""reference"": ""PMID:20706049"", ""snippet"": ""Non-Hodgkin lymphomas quite often present in the head and neck but primary tonsillar lymphomas of extranodal non-Hodgkin lymphomas are far less than 1% of head and neck malignancies."", ""supports"": ""NO_EVIDENCE""}"
6637	6462	275	Primary_Tonsillar_Lymphoma	Primary_Tonsillar_Lymphoma.yaml	treatments	1	evidence	2	PMID:23790512	NO_EVIDENCE		Radiation therapy (RT) is the most effective single modality for local control of Hodgkin lymphoma (HL) and an important component of therapy for many patients.	This reference discusses radiation therapy for Hodgkin lymphoma, not primary tonsillar lymphoma.	"{""explanation"": ""This reference discusses radiation therapy for Hodgkin lymphoma, not primary tonsillar lymphoma."", ""reference"": ""PMID:23790512"", ""snippet"": ""Radiation therapy (RT) is the most effective single modality for local control of Hodgkin lymphoma (HL) and an important component of therapy for many patients."", ""supports"": ""NO_EVIDENCE""}"
6638	6462	275	Primary_Tonsillar_Lymphoma	Primary_Tonsillar_Lymphoma.yaml	treatments	1	evidence	3	PMID:10592134	NO_EVIDENCE		There have been many reports that favor aggressive systemic treatment with chemotherapy and radiotherapy, even for well-localized lymphomas, avoiding the need for tonsillectomy of the normal tonsil.	The reference discusses a combination of chemotherapy and radiotherapy for primary tonsillar lymphoma but does not provide specific details on targeted radiation therapy for local disease control.	"{""explanation"": ""The reference discusses a combination of chemotherapy and radiotherapy for primary tonsillar lymphoma but does not provide specific details on targeted radiation therapy for local disease control."", ""reference"": ""PMID:10592134"", ""snippet"": ""There have been many reports that favor aggressive systemic treatment with chemotherapy and radiotherapy, even for well-localized lymphomas, avoiding the need for tonsillectomy of the normal tonsil."", ""supports"": ""NO_EVIDENCE""}"
6639	6462	275	Primary_Tonsillar_Lymphoma	Primary_Tonsillar_Lymphoma.yaml	treatments	1	evidence	4	PMID:38742359	NO_EVIDENCE		The clinical, pathological and ultrasonic data of nine patients with tonsillar lymphoma confirmed by pathology at Tianjin Medical University Cancer Institute and Hospital during June 2015 and June 2022 were analyzed retrospectively.	This reference focuses on the ultrasonic features of tonsillar lymphoma and does not provide evidence on targeted radiation therapy for local disease control.	"{""explanation"": ""This reference focuses on the ultrasonic features of tonsillar lymphoma and does not provide evidence on targeted radiation therapy for local disease control."", ""reference"": ""PMID:38742359"", ""snippet"": ""The clinical, pathological and ultrasonic data of nine patients with tonsillar lymphoma confirmed by pathology at Tianjin Medical University Cancer Institute and Hospital during June 2015 and June 2022 were analyzed retrospectively."", ""supports"": ""NO_EVIDENCE""}"
6640	6463	275	Primary_Tonsillar_Lymphoma	Primary_Tonsillar_Lymphoma.yaml	treatments	2	evidence	0	PMID:15252219	SUPPORT		Rituximab, a monoclonal antibody directed against the B cell-specific protein CD20, has revolutionized lymphoma treatment by providing a highly effective form of therapy with relatively mild toxic side effects.	This reference supports the use of rituximab as a targeted therapy for B-cell lymphomas.	"{""explanation"": ""This reference supports the use of rituximab as a targeted therapy for B-cell lymphomas."", ""reference"": ""PMID:15252219"", ""snippet"": ""Rituximab, a monoclonal antibody directed against the B cell-specific protein CD20, has revolutionized lymphoma treatment by providing a highly effective form of therapy with relatively mild toxic side effects."", ""supports"": ""SUPPORT""}"
6641	6463	275	Primary_Tonsillar_Lymphoma	Primary_Tonsillar_Lymphoma.yaml	treatments	2	evidence	1	PMID:10592134	NO_EVIDENCE		We report six cases of primary tonsillar lymphoma with a median patient age of 42 years. ... They were treated with six cycles of chemotherapy and cervical radiotherapy.	This reference discusses chemotherapy and radiotherapy for primary tonsillar lymphoma but does not mention rituximab.	"{""explanation"": ""This reference discusses chemotherapy and radiotherapy for primary tonsillar lymphoma but does not mention rituximab."", ""reference"": ""PMID:10592134"", ""snippet"": ""We report six cases of primary tonsillar lymphoma with a median patient age of 42 years. ... They were treated with six cycles of chemotherapy and cervical radiotherapy."", ""supports"": ""NO_EVIDENCE""}"
6642	6463	275	Primary_Tonsillar_Lymphoma	Primary_Tonsillar_Lymphoma.yaml	treatments	2	evidence	2	PMID:18381106	SUPPORT		Iodine 131-tositumomab and ibritumomab tiuxetan, radioimmunoconjugates that target the CD20 antigen, have been approved in the United States for use in relapsed or refractory, indolent, and transformed B-cell lymphomas.	This reference supports the use of targeted therapies, specifically mentioning CD20-targeting agents for B-cell lymphomas, which includes rituximab.	"{""explanation"": ""This reference supports the use of targeted therapies, specifically mentioning CD20-targeting agents for B-cell lymphomas, which includes rituximab."", ""reference"": ""PMID:18381106"", ""snippet"": ""Iodine 131-tositumomab and ibritumomab tiuxetan, radioimmunoconjugates that target the CD20 antigen, have been approved in the United States for use in relapsed or refractory, indolent, and transformed B-cell lymphomas."", ""supports"": ""SUPPORT""}"
6643	6463	275	Primary_Tonsillar_Lymphoma	Primary_Tonsillar_Lymphoma.yaml	treatments	2	evidence	3	PMID:30709635	PARTIAL		While the innovations in terms of B-cell lymphomas are certainly less significant, mention must also be made of the value of rituximab combined with polychemotherapy (CHOP) and of lenalidomide (as second-line therapy) in primary cutaneous diffuse large B-cell lymphoma, leg type.	This reference mentions rituximab as part of the treatment for a specific type of B-cell lymphoma, but not specifically for primary tonsillar lymphoma.	"{""explanation"": ""This reference mentions rituximab as part of the treatment for a specific type of B-cell lymphoma, but not specifically for primary tonsillar lymphoma."", ""reference"": ""PMID:30709635"", ""snippet"": ""While the innovations in terms of B-cell lymphomas are certainly less significant, mention must also be made of the value of rituximab combined with polychemotherapy (CHOP) and of lenalidomide (as second-line therapy) in primary cutaneous diffuse large B-cell lymphoma, leg type."", ""supports"": ""PARTIAL""}"
6644	6463	275	Primary_Tonsillar_Lymphoma	Primary_Tonsillar_Lymphoma.yaml	treatments	2	evidence	4	PMID:32755987	SUPPORT		The addition of rituximab, a monoclonal antibody against CD20, to upfront therapy has improved survival outcomes for high-risk patients and may allow decreased total chemotherapy in those with low-risk disease.	This reference supports the use of rituximab as a targeted therapy for B-cell lymphomas.	"{""explanation"": ""This reference supports the use of rituximab as a targeted therapy for B-cell lymphomas."", ""reference"": ""PMID:32755987"", ""snippet"": ""The addition of rituximab, a monoclonal antibody against CD20, to upfront therapy has improved survival outcomes for high-risk patients and may allow decreased total chemotherapy in those with low-risk disease."", ""supports"": ""SUPPORT""}"
6645	6464	275	Primary_Tonsillar_Lymphoma	Primary_Tonsillar_Lymphoma.yaml	treatments	3	evidence	0	PMID:32725379	SUPPORT		Based on high rates of long-term remission, our first choice for consolidation therapy is high-dose chemotherapy with autologous stem-cell transplant using thiotepa, busulfan, and cyclophosphamide as a myeloablative regimen, with a curative intent.	The reference discusses the use of high-dose chemotherapy followed by stem-cell transplant as a consolidation therapy, which aligns with the statement about primary tonsillar lymphoma.	"{""explanation"": ""The reference discusses the use of high-dose chemotherapy followed by stem-cell transplant as a consolidation therapy, which aligns with the statement about primary tonsillar lymphoma."", ""reference"": ""PMID:32725379"", ""snippet"": ""Based on high rates of long-term remission, our first choice for consolidation therapy is high-dose chemotherapy with autologous stem-cell transplant using thiotepa, busulfan, and cyclophosphamide as a myeloablative regimen, with a curative intent."", ""supports"": ""SUPPORT""}"
6646	6464	275	Primary_Tonsillar_Lymphoma	Primary_Tonsillar_Lymphoma.yaml	treatments	3	evidence	1	PMID:20359581	SUPPORT		Results of conventional or high-dose chemotherapy for peripheral T-cell lymphoma (PTCL) are unsatisfactory, leaving a potential role for autologous or allogeneic stem cell transplantation.	The reference indicates that high-dose chemotherapy followed by stem cell transplantation is considered for certain types of lymphoma, supporting the statement.	"{""explanation"": ""The reference indicates that high-dose chemotherapy followed by stem cell transplantation is considered for certain types of lymphoma, supporting the statement."", ""reference"": ""PMID:20359581"", ""snippet"": ""Results of conventional or high-dose chemotherapy for peripheral T-cell lymphoma (PTCL) are unsatisfactory, leaving a potential role for autologous or allogeneic stem cell transplantation."", ""supports"": ""SUPPORT""}"
6710	6512	276	Proteus syndrome	Proteus_syndrome.yaml	treatments	0	evidence	0	DOI:10.1038/srep17162	SUPPORT		ARQ 092 reduced phosphorylation of AKT and downstream targets of AKT in a concentration-dependent manner in as little as two hours.	This shows AKT pathway suppression by ARQ 092 in Proteus syndrome samples.	"{""explanation"": ""This shows AKT pathway suppression by ARQ 092 in Proteus syndrome samples."", ""reference"": ""DOI:10.1038/srep17162"", ""snippet"": ""ARQ 092 reduced phosphorylation of AKT and downstream targets of AKT in a concentration-dependent manner in as little as two hours."", ""supports"": ""SUPPORT""}"
6711	6512	276	Proteus syndrome	Proteus_syndrome.yaml	treatments	0	evidence	1	DOI:10.1101/mcs.a006134	SUPPORT		The patient has experienced sustained improvement of pain and slowed growth of bilateral plantar cerebriform connective tissue nevi.	This case report describes clinical benefit with miransertib (ARQ 092).	"{""explanation"": ""This case report describes clinical benefit with miransertib (ARQ 092)."", ""reference"": ""DOI:10.1101/mcs.a006134"", ""snippet"": ""The patient has experienced sustained improvement of pain and slowed growth of bilateral plantar cerebriform connective tissue nevi."", ""supports"": ""SUPPORT""}"
6712	6513	276	Proteus syndrome	Proteus_syndrome.yaml	treatments	1	evidence	0	DOI:10.1055/a-2300-7002	SUPPORT		We report a case of PS in a two-year-old female patient with the following clinical features: unilateral overgrowth of connective tissue in the right buttock and right foot, where multiple surgeries were performed to achieve a desirable aesthetic outcome and ensure psychological comfort of the young patient.	This case report documents surgical intervention for overgrowth management.	"{""explanation"": ""This case report documents surgical intervention for overgrowth management."", ""reference"": ""DOI:10.1055/a-2300-7002"", ""snippet"": ""We report a case of PS in a two-year-old female patient with the following clinical features: unilateral overgrowth of connective tissue in the right buttock and right foot, where multiple surgeries were performed to achieve a desirable aesthetic outcome and ensure psychological comfort of the young patient."", ""supports"": ""SUPPORT""}"
6727	6549	278	Psoriasis	Psoriasis.yaml	treatments	6	evidence	0	PMID:38686385	SUPPORT		We review IL-23 biology, IL-23 signaling in IMIDs, and the effect of IL-23 inhibition in treating these diseases.	This paper reviews the therapeutic effect of IL-23 inhibition in treating psoriasis and other immune-mediated inflammatory diseases, supporting the use of IL-23 inhibitors like guselkumab and risankizumab.	"{""explanation"": ""This paper reviews the therapeutic effect of IL-23 inhibition in treating psoriasis and other immune-mediated inflammatory diseases, supporting the use of IL-23 inhibitors like guselkumab and risankizumab."", ""reference"": ""PMID:38686385"", ""snippet"": ""We review IL-23 biology, IL-23 signaling in IMIDs, and the effect of IL-23 inhibition in treating these diseases."", ""supports"": ""SUPPORT""}"
6728	6550	278	Psoriasis	Psoriasis.yaml	treatments	7	evidence	0	PMID:38686385	SUPPORT		Interleukin (IL)-23, an IL-12 cytokine family member, is a hierarchically dominant regulatory cytokine in a cluster of immune-mediated inflammatory diseases (IMIDs), including psoriasis, psoriatic arthritis, and inflammatory bowel disease.	Ustekinumab targets the p40 subunit shared by IL-12 and IL-23. Given IL-23's hierarchically dominant role, blocking this shared subunit provides therapeutic benefit in psoriasis.	"{""explanation"": ""Ustekinumab targets the p40 subunit shared by IL-12 and IL-23. Given IL-23's hierarchically dominant role, blocking this shared subunit provides therapeutic benefit in psoriasis."", ""reference"": ""PMID:38686385"", ""snippet"": ""Interleukin (IL)-23, an IL-12 cytokine family member, is a hierarchically dominant regulatory cytokine in a cluster of immune-mediated inflammatory diseases (IMIDs), including psoriasis, psoriatic arthritis, and inflammatory bowel disease."", ""supports"": ""SUPPORT""}"
6737	6559	279	Psoriatic Arthritis	Psoriatic_Arthritis.yaml	treatments	0	evidence	0	PMID:36902329	SUPPORT		Research has identified several immune-inflammatory pathways defined by cytokines (IL-23/IL-17, TNF), leading to the development of efficacious therapeutic targets.	The abstract links cytokine pathways to targeted therapies in psoriatic arthritis.	"{""explanation"": ""The abstract links cytokine pathways to targeted therapies in psoriatic arthritis."", ""reference"": ""PMID:36902329"", ""snippet"": ""Research has identified several immune-inflammatory pathways defined by cytokines (IL-23/IL-17, TNF), leading to the development of efficacious therapeutic targets."", ""supports"": ""SUPPORT""}"
6752	6660	284	Rabies	Rabies.yaml	treatments	0	evidence	0	PMID:12144896	SUPPORT		Prophylaxis encompasses thorough wound treatment, vaccine administration, and inoculation of rabies immunoglobulin.	The abstract describes vaccine administration for prophylaxis.	"{""explanation"": ""The abstract describes vaccine administration for prophylaxis."", ""reference"": ""PMID:12144896"", ""snippet"": ""Prophylaxis encompasses thorough wound treatment, vaccine administration, and inoculation of rabies immunoglobulin."", ""supports"": ""SUPPORT""}"
6753	6661	284	Rabies	Rabies.yaml	treatments	1	evidence	0	PMID:12144896	SUPPORT		Prophylaxis encompasses thorough wound treatment, vaccine administration, and inoculation of rabies immunoglobulin.	The abstract includes rabies immunoglobulin as part of prophylaxis.	"{""explanation"": ""The abstract includes rabies immunoglobulin as part of prophylaxis."", ""reference"": ""PMID:12144896"", ""snippet"": ""Prophylaxis encompasses thorough wound treatment, vaccine administration, and inoculation of rabies immunoglobulin."", ""supports"": ""SUPPORT""}"
6792	6699	285	Refeeding Syndrome	Refeeding_Syndrome.yaml	treatments	0	evidence	0	clinicaltrials:NCT02488109	SUPPORT	HUMAN_CLINICAL	The purpose of this study is to compare the efficacy, safety, and cost-effectiveness of lower calorie refeeding versus higher calorie refeeding in hospitalized adolescents with anorexia nervosa.	This trial evaluates caloric refeeding strategies, supporting controlled refeeding approaches.	"{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""This trial evaluates caloric refeeding strategies, supporting controlled refeeding approaches."", ""reference"": ""clinicaltrials:NCT02488109"", ""snippet"": ""The purpose of this study is to compare the efficacy, safety, and cost-effectiveness of lower calorie refeeding versus higher calorie refeeding in hospitalized adolescents with anorexia nervosa."", ""supports"": ""SUPPORT""}"
6793	6699	285	Refeeding Syndrome	Refeeding_Syndrome.yaml	treatments	0	evidence	1	PMID:41171118	SUPPORT	HUMAN_CLINICAL	Current guidelines recommend a gradual increase in energy intake and regular monitoring of a patient&apos;s metabolic status (especially phosphorus, potassium, and magnesium levels) during nutritional treatment.	This review supports gradual energy advancement during refeeding.	"{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""This review supports gradual energy advancement during refeeding."", ""reference"": ""PMID:41171118"", ""snippet"": ""Current guidelines recommend a gradual increase in energy intake and regular monitoring of a patient&apos;s metabolic status (especially phosphorus, potassium, and magnesium levels) during nutritional treatment."", ""supports"": ""SUPPORT""}"
6794	6699	285	Refeeding Syndrome	Refeeding_Syndrome.yaml	treatments	0	evidence	2	PMID:41239620	SUPPORT	HUMAN_CLINICAL	LESSONS: A stepwise calorie escalation protocol effectively corrects hypophosphatemia in refeeding syndrome.	This case report supports stepwise caloric escalation during refeeding.	"{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""This case report supports stepwise caloric escalation during refeeding."", ""reference"": ""PMID:41239620"", ""snippet"": ""LESSONS: A stepwise calorie escalation protocol effectively corrects hypophosphatemia in refeeding syndrome."", ""supports"": ""SUPPORT""}"
6795	6700	285	Refeeding Syndrome	Refeeding_Syndrome.yaml	treatments	1	evidence	0	PMID:41146174	SUPPORT	HUMAN_CLINICAL	Supplementation is indicated for severe or symptomatic cases, with oral therapy preferred for chronic conditions and intravenous routes for acute, severe hypophosphatemia.	This supports electrolyte supplementation as a management strategy for acute hypophosphatemia.	"{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""This supports electrolyte supplementation as a management strategy for acute hypophosphatemia."", ""reference"": ""PMID:41146174"", ""snippet"": ""Supplementation is indicated for severe or symptomatic cases, with oral therapy preferred for chronic conditions and intravenous routes for acute, severe hypophosphatemia."", ""supports"": ""SUPPORT""}"
6796	6700	285	Refeeding Syndrome	Refeeding_Syndrome.yaml	treatments	1	evidence	1	PMID:41171118	SUPPORT	HUMAN_CLINICAL	Current guidelines recommend a gradual increase in energy intake and regular monitoring of a patient&apos;s metabolic status (especially phosphorus, potassium, and magnesium levels) during nutritional treatment.	This review supports monitoring phosphorus, potassium, and magnesium during refeeding.	"{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""This review supports monitoring phosphorus, potassium, and magnesium during refeeding."", ""reference"": ""PMID:41171118"", ""snippet"": ""Current guidelines recommend a gradual increase in energy intake and regular monitoring of a patient&apos;s metabolic status (especially phosphorus, potassium, and magnesium levels) during nutritional treatment."", ""supports"": ""SUPPORT""}"
6797	6701	285	Refeeding Syndrome	Refeeding_Syndrome.yaml	treatments	2	evidence	0	PMID:29448987	PARTIAL	HUMAN_CLINICAL	thiamine deficiency and disorder of sodium and fluid balance are common.	Thiamine deficiency is common during refeeding, supporting prophylactic supplementation.	"{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""Thiamine deficiency is common during refeeding, supporting prophylactic supplementation."", ""reference"": ""PMID:29448987"", ""snippet"": ""thiamine deficiency and disorder of sodium and fluid balance are common."", ""supports"": ""PARTIAL""}"
6798	6702	285	Refeeding Syndrome	Refeeding_Syndrome.yaml	treatments	3	evidence	0	PMID:39947042	SUPPORT	HUMAN_CLINICAL	Benefits of early fasting responses have become clear, provided micronutrients are given to prevent deficiencies and refeeding syndrome.	This review supports providing micronutrients to prevent deficiencies and refeeding syndrome during nutrition management.	"{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""This review supports providing micronutrients to prevent deficiencies and refeeding syndrome during nutrition management."", ""reference"": ""PMID:39947042"", ""snippet"": ""Benefits of early fasting responses have become clear, provided micronutrients are given to prevent deficiencies and refeeding syndrome."", ""supports"": ""SUPPORT""}"
6803	6708	286	Renal Cell Carcinoma	Renal_Cell_Carcinoma.yaml	treatments	0	evidence	0	PMID:6625621	SUPPORT		The most basic and reliable treatment method established for renal cell carcinomas is surgery--radical nephrectomy.	The abstract states radical nephrectomy is a basic and reliable treatment.	"{""explanation"": ""The abstract states radical nephrectomy is a basic and reliable treatment."", ""reference"": ""PMID:6625621"", ""snippet"": ""The most basic and reliable treatment method established for renal cell carcinomas is surgery--radical nephrectomy."", ""supports"": ""SUPPORT""}"
6804	6709	286	Renal Cell Carcinoma	Renal_Cell_Carcinoma.yaml	treatments	1	evidence	0	PMID:28898679	SUPPORT		Unraveling the molecular biology and cytogenetic of RCC has enabled the development of several targeted agents that have improved treatment outcomes of these patients.	The abstract notes targeted agents as effective therapies for RCC.	"{""explanation"": ""The abstract notes targeted agents as effective therapies for RCC."", ""reference"": ""PMID:28898679"", ""snippet"": ""Unraveling the molecular biology and cytogenetic of RCC has enabled the development of several targeted agents that have improved treatment outcomes of these patients."", ""supports"": ""SUPPORT""}"
6805	6710	286	Renal Cell Carcinoma	Renal_Cell_Carcinoma.yaml	treatments	2	evidence	0	PMID:39926260	SUPPORT		Belzutifan received its first FDA approval in 2021 for treating clinical manifestations of von Hippel-Lindau (VHL) disease including renal cell carcinoma (RCC) followed by approval in 2023 for treating advanced sporadic RCC that has progressed through multiple lines of treatment.	The abstract describes belzutifan approvals for RCC treatment.	"{""explanation"": ""The abstract describes belzutifan approvals for RCC treatment."", ""reference"": ""PMID:39926260"", ""snippet"": ""Belzutifan received its first FDA approval in 2021 for treating clinical manifestations of von Hippel-Lindau (VHL) disease including renal cell carcinoma (RCC) followed by approval in 2023 for treating advanced sporadic RCC that has progressed through multiple lines of treatment."", ""supports"": ""SUPPORT""}"
6833	6737	288	Retrograde Cricopharyngeus Dysfunction	Retrograde_Cricopharyngeus_Dysfunction.yaml	treatments	0	evidence	0	PMID:31236539	SUPPORT		"All 51 patients achieved ability to belch and relief of associated symptoms, and the majority seem to have ""retrained"" the ability to belch on a potentially ""permanent"" basis."	The Bastian 2019 case series demonstrated 100% success rate with botulinum toxin injection in restoring belching ability.	"{""explanation"": ""The Bastian 2019 case series demonstrated 100% success rate with botulinum toxin injection in restoring belching ability."", ""reference"": ""PMID:31236539"", ""snippet"": ""All 51 patients achieved ability to belch and relief of associated symptoms, and the majority seem to have \""retrained\"" the ability to belch on a potentially \""permanent\"" basis."", ""supports"": ""SUPPORT""}"
6834	6737	288	Retrograde Cricopharyngeus Dysfunction	Retrograde_Cricopharyngeus_Dysfunction.yaml	treatments	0	evidence	1	PMID:38587015	SUPPORT		All patients who underwent cricopharyngeal botulinum injections experienced initial improvement of symptoms with 3 patients requiring repeat intervention.	The Yousef 2024 study confirms botulinum toxin as an effective treatment.	"{""explanation"": ""The Yousef 2024 study confirms botulinum toxin as an effective treatment."", ""reference"": ""PMID:38587015"", ""snippet"": ""All patients who underwent cricopharyngeal botulinum injections experienced initial improvement of symptoms with 3 patients requiring repeat intervention."", ""supports"": ""SUPPORT""}"
6835	6737	288	Retrograde Cricopharyngeus Dysfunction	Retrograde_Cricopharyngeus_Dysfunction.yaml	treatments	0	evidence	2	PMID:37621856	SUPPORT		successfully treated with unilateral, anesthesia-free injection of 10 units of onabotulinum toxin into the cricopharyngeus muscle, representing the lowest dose reported to date.	The Pavesi 2023 case report demonstrates symptom resolution with low-dose botulinum toxin.	"{""explanation"": ""The Pavesi 2023 case report demonstrates symptom resolution with low-dose botulinum toxin."", ""reference"": ""PMID:37621856"", ""snippet"": ""successfully treated with unilateral, anesthesia-free injection of 10 units of onabotulinum toxin into the cricopharyngeus muscle, representing the lowest dose reported to date."", ""supports"": ""SUPPORT""}"
6836	6737	288	Retrograde Cricopharyngeus Dysfunction	Retrograde_Cricopharyngeus_Dysfunction.yaml	treatments	0	evidence	3	PMID:41200864	SUPPORT		This transtracheal technique for cricopharyngeal botulinum toxin injection is a safe and effective option for chemodenervation of this muscle in the awake patient.	The Tritter 2025 procedural report supports safety and effectiveness of the transtracheal botulinum approach.	"{""explanation"": ""The Tritter 2025 procedural report supports safety and effectiveness of the transtracheal botulinum approach."", ""reference"": ""PMID:41200864"", ""snippet"": ""This transtracheal technique for cricopharyngeal botulinum toxin injection is a safe and effective option for chemodenervation of this muscle in the awake patient."", ""supports"": ""SUPPORT""}"
6837	6737	288	Retrograde Cricopharyngeus Dysfunction	Retrograde_Cricopharyngeus_Dysfunction.yaml	treatments	0	evidence	4	PMID:41506952	SUPPORT		previously undergone percutaneous botulinum toxin injection that initially provided temporary relief.	The Dealino 2026 case notes symptomatic improvement after botulinum toxin injection.	"{""explanation"": ""The Dealino 2026 case notes symptomatic improvement after botulinum toxin injection."", ""reference"": ""PMID:41506952"", ""snippet"": ""previously undergone percutaneous botulinum toxin injection that initially provided temporary relief."", ""supports"": ""SUPPORT""}"
6838	6737	288	Retrograde Cricopharyngeus Dysfunction	Retrograde_Cricopharyngeus_Dysfunction.yaml	treatments	0	evidence	5	PMID:40411338	SUPPORT		The immediate success rate of botulinum toxin injection into the cricopharyngeal sphincter in facilitating burping was 92.5%.	Systematic review reports high immediate success for botulinum toxin in R-CPD.	"{""explanation"": ""Systematic review reports high immediate success for botulinum toxin in R-CPD."", ""reference"": ""PMID:40411338"", ""snippet"": ""The immediate success rate of botulinum toxin injection into the cricopharyngeal sphincter in facilitating burping was 92.5%."", ""supports"": ""SUPPORT""}"
6839	6737	288	Retrograde Cricopharyngeus Dysfunction	Retrograde_Cricopharyngeus_Dysfunction.yaml	treatments	0	evidence	6	PMID:39883449	SUPPORT		The cumulative success rate of BTI was 90.6% (96 of 106 patients).	In-office botulinum injections achieved high cumulative success in a 106-patient series.	"{""explanation"": ""In-office botulinum injections achieved high cumulative success in a 106-patient series."", ""reference"": ""PMID:39883449"", ""snippet"": ""The cumulative success rate of BTI was 90.6% (96 of 106 patients)."", ""supports"": ""SUPPORT""}"
6840	6737	288	Retrograde Cricopharyngeus Dysfunction	Retrograde_Cricopharyngeus_Dysfunction.yaml	treatments	0	evidence	7	PMID:38576368	SUPPORT		At median follow-up of 29 months (range, 3-50) post-treatment, 51.3% (n = 20/39) of patients reported persistent complete relief of symptoms	Belgian case series quantifies short- and long-term response rates to botulinum toxin.	"{""explanation"": ""Belgian case series quantifies short- and long-term response rates to botulinum toxin."", ""reference"": ""PMID:38576368"", ""snippet"": ""At median follow-up of 29 months (range, 3-50) post-treatment, 51.3% (n = 20/39) of patients reported persistent complete relief of symptoms"", ""supports"": ""SUPPORT""}"
6850	6751	289	Rett Syndrome	Rett_Syndrome.yaml	treatments	0	evidence	0	PMID:23103540	SUPPORT		Myoclonic seizures aggravated by inappropriate treatment were evident in four patients	Study documents importance of appropriate seizure management in Rett syndrome patients.	"{""explanation"": ""Study documents importance of appropriate seizure management in Rett syndrome patients."", ""reference"": ""PMID:23103540"", ""snippet"": ""Myoclonic seizures aggravated by inappropriate treatment were evident in four patients"", ""supports"": ""SUPPORT""}"
6964	6802	290	Rheumatoid Arthritis	Rheumatoid_Arthritis.yaml	treatments	0	evidence	0	PMID:11899747	SUPPORT		NSAID toxicity mostly affected the GI tract. There was a similar incidence of GI-related adverse events between patients with and patients without GI protection, mainly dyspepsia and nausea. NSAIDs have the potential to cause adverse events in the GI tract.	The provided literature indicates that NSAIDs are used in the treatment of rheumatoid arthritis (RA) and can help alleviate pain, despite some potential side effects, thus supporting the statement.	"{""explanation"": ""The provided literature indicates that NSAIDs are used in the treatment of rheumatoid arthritis (RA) and can help alleviate pain, despite some potential side effects, thus supporting the statement."", ""reference"": ""PMID:11899747"", ""snippet"": ""NSAID toxicity mostly affected the GI tract. There was a similar incidence of GI-related adverse events between patients with and patients without GI protection, mainly dyspepsia and nausea. NSAIDs have the potential to cause adverse events in the GI tract."", ""supports"": ""SUPPORT""}"
6965	6802	290	Rheumatoid Arthritis	Rheumatoid_Arthritis.yaml	treatments	0	evidence	1	PMID:29100265	SUPPORT		This review will give a concise summary on the available studies on the application of nano-formulated drugs designed for pain treatment and management.	This reference mentions the effectiveness of NSAIDs in pain management, supporting the statement.	"{""explanation"": ""This reference mentions the effectiveness of NSAIDs in pain management, supporting the statement."", ""reference"": ""PMID:29100265"", ""snippet"": ""This review will give a concise summary on the available studies on the application of nano-formulated drugs designed for pain treatment and management."", ""supports"": ""SUPPORT""}"
6966	6802	290	Rheumatoid Arthritis	Rheumatoid_Arthritis.yaml	treatments	0	evidence	2	PMID:23083758	SUPPORT		NSAIDs reduce pain and stiffness effectively in most patients, are able to reduce systemic and local inflammation, and can inhibit progression of structural damage in the spine.	This indicates that NSAIDs are effective in reducing pain and inflammation in conditions similar to RA, thus supporting the statement.	"{""explanation"": ""This indicates that NSAIDs are effective in reducing pain and inflammation in conditions similar to RA, thus supporting the statement."", ""reference"": ""PMID:23083758"", ""snippet"": ""NSAIDs reduce pain and stiffness effectively in most patients, are able to reduce systemic and local inflammation, and can inhibit progression of structural damage in the spine."", ""supports"": ""SUPPORT""}"
6967	6802	290	Rheumatoid Arthritis	Rheumatoid_Arthritis.yaml	treatments	0	evidence	3	PMID:27278642	PARTIAL		By examining confounds and limitations in the available literature it is suggested that current data suggest that only a sub-group of individuals with major depressive disorder (MDD) have evidence of increased inflammatory biomarkers and it is in these individuals that anti-inflammatory agents show promise for reducing depressive symptoms.	While the reference primarily discusses the use of NSAIDs for major depressive disorder, it hints at the effectiveness of NSAIDs in reducing inflammation, partially supporting the statement.	"{""explanation"": ""While the reference primarily discusses the use of NSAIDs for major depressive disorder, it hints at the effectiveness of NSAIDs in reducing inflammation, partially supporting the statement."", ""reference"": ""PMID:27278642"", ""snippet"": ""By examining confounds and limitations in the available literature it is suggested that current data suggest that only a sub-group of individuals with major depressive disorder (MDD) have evidence of increased inflammatory biomarkers and it is in these individuals that anti-inflammatory agents show promise for reducing depressive symptoms."", ""supports"": ""PARTIAL""}"
6968	6803	290	Rheumatoid Arthritis	Rheumatoid_Arthritis.yaml	treatments	1	evidence	0	PMID:14969069	SUPPORT		Disease-modifying anti-rheumatic drugs (DMARDs) used in combination appear to be more effective than monotherapies at reducing the rate of progressive joint damage during randomized controlled trials.	This statement directly supports the idea that DMARDs slow disease progression and prevent joint damage.	"{""explanation"": ""This statement directly supports the idea that DMARDs slow disease progression and prevent joint damage."", ""reference"": ""PMID:14969069"", ""snippet"": ""Disease-modifying anti-rheumatic drugs (DMARDs) used in combination appear to be more effective than monotherapies at reducing the rate of progressive joint damage during randomized controlled trials."", ""supports"": ""SUPPORT""}"
6969	6803	290	Rheumatoid Arthritis	Rheumatoid_Arthritis.yaml	treatments	1	evidence	1	PMID:8601050	SUPPORT		Methotrexate is presently the most popular of the DMARDs for the treatment of rheumatoid arthritis. Methotrexate inhibits dihydrofolate reductase and adenosine release and has a secondary effect on cytokines and polymorphonuclear chemotaxis. It is highly metabolised within cells and remains there for prolonged periods.	This excerpt indicates methotrexate's mechanisms in treating RA, affirming its role in slowing disease progression and preventing joint damage.	"{""explanation"": ""This excerpt indicates methotrexate's mechanisms in treating RA, affirming its role in slowing disease progression and preventing joint damage."", ""reference"": ""PMID:8601050"", ""snippet"": ""Methotrexate is presently the most popular of the DMARDs for the treatment of rheumatoid arthritis. Methotrexate inhibits dihydrofolate reductase and adenosine release and has a secondary effect on cytokines and polymorphonuclear chemotaxis. It is highly metabolised within cells and remains there for prolonged periods."", ""supports"": ""SUPPORT""}"
6970	6803	290	Rheumatoid Arthritis	Rheumatoid_Arthritis.yaml	treatments	1	evidence	2	PMID:25172238	SUPPORT		According to the results of several head-to-head comparative trials against other synthetic DMARDs, MTX has been recognised as the 'anchor drug' for the treatment of RA.	This confirms methotrexate's effectiveness as a primary treatment in managing RA, thus supporting the statement.	"{""explanation"": ""This confirms methotrexate's effectiveness as a primary treatment in managing RA, thus supporting the statement."", ""reference"": ""PMID:25172238"", ""snippet"": ""According to the results of several head-to-head comparative trials against other synthetic DMARDs, MTX has been recognised as the 'anchor drug' for the treatment of RA."", ""supports"": ""SUPPORT""}"
6971	6803	290	Rheumatoid Arthritis	Rheumatoid_Arthritis.yaml	treatments	1	evidence	3	PMID:35953230	SUPPORT		Key recommendations are to start effective treatment immediately with DMARDs to reduce disability; use effective doses of methotrexate (oral or subcutaneous) with folic acid as the initial treatment; rapidly escalate treatment with various DMARDs, if methotrexate alone is not effective in controlling rheumatoid arthritis.	This supports the statement by advising DMARDs to prevent disease progression and joint damage.	"{""explanation"": ""This supports the statement by advising DMARDs to prevent disease progression and joint damage."", ""reference"": ""PMID:35953230"", ""snippet"": ""Key recommendations are to start effective treatment immediately with DMARDs to reduce disability; use effective doses of methotrexate (oral or subcutaneous) with folic acid as the initial treatment; rapidly escalate treatment with various DMARDs, if methotrexate alone is not effective in controlling rheumatoid arthritis."", ""supports"": ""SUPPORT""}"
6972	6804	290	Rheumatoid Arthritis	Rheumatoid_Arthritis.yaml	treatments	2	evidence	0	PMID:22166850	SUPPORT		Rheumatoid arthritis (RA) remains a major clinical problem, but treatments involving biologics have revolutionized its management. They target pathogenically relevant cytokines such as tumor necrosis factor and immune cells such as B cells.	This reference confirms that biologics used in the treatment of RA target specific components of the immune system, including cytokines like TNF-.	"{""explanation"": ""This reference confirms that biologics used in the treatment of RA target specific components of the immune system, including cytokines like TNF-."", ""reference"": ""PMID:22166850"", ""snippet"": ""Rheumatoid arthritis (RA) remains a major clinical problem, but treatments involving biologics have revolutionized its management. They target pathogenically relevant cytokines such as tumor necrosis factor and immune cells such as B cells."", ""supports"": ""SUPPORT""}"
6973	6804	290	Rheumatoid Arthritis	Rheumatoid_Arthritis.yaml	treatments	2	evidence	1	PMID:25697599	SUPPORT		Anticytokine therapy for inflammatory diseases became a clinical reality with the introduction of tumor necrosis factor (TNF) inhibitors for the treatment of severe rheumatoid arthritis.	The reference highlights that anticytokine therapies, including TNF inhibitors, are used in RA treatment, thus supporting the statement.	"{""explanation"": ""The reference highlights that anticytokine therapies, including TNF inhibitors, are used in RA treatment, thus supporting the statement."", ""reference"": ""PMID:25697599"", ""snippet"": ""Anticytokine therapy for inflammatory diseases became a clinical reality with the introduction of tumor necrosis factor (TNF) inhibitors for the treatment of severe rheumatoid arthritis."", ""supports"": ""SUPPORT""}"
6974	6804	290	Rheumatoid Arthritis	Rheumatoid_Arthritis.yaml	treatments	2	evidence	2	PMID:32550671	SUPPORT		Cytokine blockers were the first to be developed and rapidly expanded. They include agents that act against tumor necrosis factor alpha (TNF-)... and interleukin (IL) 6 (tocilizumab and sarilumab).	The reference supports that biologics used for RA treatment include TNF- inhibitors and IL-6 inhibitors, which target specific components of the immune system.	"{""explanation"": ""The reference supports that biologics used for RA treatment include TNF- inhibitors and IL-6 inhibitors, which target specific components of the immune system."", ""reference"": ""PMID:32550671"", ""snippet"": ""Cytokine blockers were the first to be developed and rapidly expanded. They include agents that act against tumor necrosis factor alpha (TNF-)... and interleukin (IL) 6 (tocilizumab and sarilumab)."", ""supports"": ""SUPPORT""}"
6975	6805	290	Rheumatoid Arthritis	Rheumatoid_Arthritis.yaml	treatments	3	evidence	0	PMID:28043173	PARTIAL		Glucocorticoids - be it conventional or modified/delayed-release formulations - have so far been convincing in clinical practice, and their widespread use will therefore continue.	The literature supports the use of glucocorticoids for the treatment of rheumatoid arthritis, highlighting their efficacy. However, it does not specify that they are used for short-term control of flares or as bridge therapy, thus only partially supporting the precise conditions mentioned in the statement.	"{""explanation"": ""The literature supports the use of glucocorticoids for the treatment of rheumatoid arthritis, highlighting their efficacy. However, it does not specify that they are used for short-term control of flares or as bridge therapy, thus only partially supporting the precise conditions mentioned in the statement."", ""reference"": ""PMID:28043173"", ""snippet"": ""Glucocorticoids - be it conventional or modified/delayed-release formulations - have so far been convincing in clinical practice, and their widespread use will therefore continue."", ""supports"": ""PARTIAL""}"
6976	6805	290	Rheumatoid Arthritis	Rheumatoid_Arthritis.yaml	treatments	3	evidence	1	PMID:24527481	PARTIAL		The family physician plays several important roles in the management of patients with RA by early diagnosis of RA, with initiation of synthetic DMARD therapy, and in long-term follow-up to minimize complications of DMARD therapy and its impact on patient comorbidities.	This reference mentions the management and use of various therapies for rheumatoid arthritis, but it does not explicitly discuss the short-term use or glucocorticoids as bridge therapy, providing only partial support.	"{""explanation"": ""This reference mentions the management and use of various therapies for rheumatoid arthritis, but it does not explicitly discuss the short-term use or glucocorticoids as bridge therapy, providing only partial support."", ""reference"": ""PMID:24527481"", ""snippet"": ""The family physician plays several important roles in the management of patients with RA by early diagnosis of RA, with initiation of synthetic DMARD therapy, and in long-term follow-up to minimize complications of DMARD therapy and its impact on patient comorbidities."", ""supports"": ""PARTIAL""}"
6977	6805	290	Rheumatoid Arthritis	Rheumatoid_Arthritis.yaml	treatments	3	evidence	2	PMID:29745893	PARTIAL		Non-steroidal anti-inflammatory drugs (NSAIDs), corticosteroids and disease-modifying antirheumatic drugs (DMARDs) are widely used to treat RA patients.	This literature confirms the use of corticosteroids (which include glucocorticoids) in treating RA but does not specify their role as short-term or bridge therapy, thereby partially supporting the statement.	"{""explanation"": ""This literature confirms the use of corticosteroids (which include glucocorticoids) in treating RA but does not specify their role as short-term or bridge therapy, thereby partially supporting the statement."", ""reference"": ""PMID:29745893"", ""snippet"": ""Non-steroidal anti-inflammatory drugs (NSAIDs), corticosteroids and disease-modifying antirheumatic drugs (DMARDs) are widely used to treat RA patients."", ""supports"": ""PARTIAL""}"
6978	6806	290	Rheumatoid Arthritis	Rheumatoid_Arthritis.yaml	treatments	4	evidence	0	PMID:15266230	SUPPORT		Physiotherapy and rehabilitation applications significantly augment medical therapy by improving the management of RA and reducing handicaps in daily living for patients with RA.	The literature supports the effectiveness of physiotherapy in managing RA, including maintaining joint mobility and reducing disabilities.	"{""explanation"": ""The literature supports the effectiveness of physiotherapy in managing RA, including maintaining joint mobility and reducing disabilities."", ""reference"": ""PMID:15266230"", ""snippet"": ""Physiotherapy and rehabilitation applications significantly augment medical therapy by improving the management of RA and reducing handicaps in daily living for patients with RA."", ""supports"": ""SUPPORT""}"
6979	6806	290	Rheumatoid Arthritis	Rheumatoid_Arthritis.yaml	treatments	4	evidence	1	PMID:25748549	SUPPORT		The exercise programme consisted of six sessions of strengthening and stretching exercises with a hand therapist, daily home exercises and strategies to maximise adherence.	The results indicate that exercise programmes included in physical therapy can be effective in maintaining joint function and strengthening muscles in RA patients.	"{""explanation"": ""The results indicate that exercise programmes included in physical therapy can be effective in maintaining joint function and strengthening muscles in RA patients."", ""reference"": ""PMID:25748549"", ""snippet"": ""The exercise programme consisted of six sessions of strengthening and stretching exercises with a hand therapist, daily home exercises and strategies to maximise adherence."", ""supports"": ""SUPPORT""}"
6980	6806	290	Rheumatoid Arthritis	Rheumatoid_Arthritis.yaml	treatments	4	evidence	2	PMID:9667624	SUPPORT		The results suggest that dynamic exercise therapy is effective in increasing aerobic capacity and muscle strength.	Dynamic exercise therapy, a component of physical therapy, has been shown to improve muscle strength and maintain physical capacity in RA patients.	"{""explanation"": ""Dynamic exercise therapy, a component of physical therapy, has been shown to improve muscle strength and maintain physical capacity in RA patients."", ""reference"": ""PMID:9667624"", ""snippet"": ""The results suggest that dynamic exercise therapy is effective in increasing aerobic capacity and muscle strength."", ""supports"": ""SUPPORT""}"
7008	6822	291	Roifman-syndrome	Roifman-syndrome.yaml	treatments	0	evidence	0	PMID:26454315	PARTIAL		Immunoglobulin replacement therapy has been standard treatment in patients with primary immunodeficiency diseases for the past 3 decades. The goal of therapy is to reduce serious bacterial infections in individuals with antibody function defects.	While the literature supports that immunoglobulin replacement therapy is used to reduce serious bacterial infections in primary immunodeficiency diseases, it does not specifically mention Roifman syndrome. Therefore, the support is partial.	"{""explanation"": ""While the literature supports that immunoglobulin replacement therapy is used to reduce serious bacterial infections in primary immunodeficiency diseases, it does not specifically mention Roifman syndrome. Therefore, the support is partial."", ""reference"": ""PMID:26454315"", ""snippet"": ""Immunoglobulin replacement therapy has been standard treatment in patients with primary immunodeficiency diseases for the past 3 decades. The goal of therapy is to reduce serious bacterial infections in individuals with antibody function defects."", ""supports"": ""PARTIAL""}"
7009	6822	291	Roifman-syndrome	Roifman-syndrome.yaml	treatments	0	evidence	1	PMID:21977988	NO_EVIDENCE		Roifman syndrome is a rare syndrome of bone dysplasia, growth retardation, retinal dystrophy and humeral immunodeficiency.	The literature describes Roifman syndrome and its characteristics but does not provide evidence regarding the use of immunoglobulin replacement therapy for preventing infections in this syndrome.	"{""explanation"": ""The literature describes Roifman syndrome and its characteristics but does not provide evidence regarding the use of immunoglobulin replacement therapy for preventing infections in this syndrome."", ""reference"": ""PMID:21977988"", ""snippet"": ""Roifman syndrome is a rare syndrome of bone dysplasia, growth retardation, retinal dystrophy and humeral immunodeficiency."", ""supports"": ""NO_EVIDENCE""}"
7010	6823	291	Roifman-syndrome	Roifman-syndrome.yaml	treatments	1	evidence	0	PMID:35450878	NO_EVIDENCE		We report an excellent response to subcutaneous immunoglobulin therapy in both brothers, reducing infection burden and hospital admissions.	The literature mentions the use of subcutaneous immunoglobulin therapy to reduce infection burden in Roifman syndrome but does not provide evidence for the use of antibiotic prophylaxis.	"{""explanation"": ""The literature mentions the use of subcutaneous immunoglobulin therapy to reduce infection burden in Roifman syndrome but does not provide evidence for the use of antibiotic prophylaxis."", ""reference"": ""PMID:35450878"", ""snippet"": ""We report an excellent response to subcutaneous immunoglobulin therapy in both brothers, reducing infection burden and hospital admissions."", ""supports"": ""NO_EVIDENCE""}"
7011	6824	291	Roifman-syndrome	Roifman-syndrome.yaml	treatments	2	evidence	0	PMID:10905663	NO_EVIDENCE		This report describes a fifth individual with co-existent hypogonadotrophic hypogonadism, thereby expanding the phenotype and possibly offering insight into the genetic aetiology of this condition.	The reference describes the characteristics and genetic insights of Roifman syndrome but does not provide any evidence about the use of growth hormone therapy to address growth retardation.	"{""explanation"": ""The reference describes the characteristics and genetic insights of Roifman syndrome but does not provide any evidence about the use of growth hormone therapy to address growth retardation."", ""reference"": ""PMID:10905663"", ""snippet"": ""This report describes a fifth individual with co-existent hypogonadotrophic hypogonadism, thereby expanding the phenotype and possibly offering insight into the genetic aetiology of this condition."", ""supports"": ""NO_EVIDENCE""}"
7012	6824	291	Roifman-syndrome	Roifman-syndrome.yaml	treatments	2	evidence	1	PMID:37666272	NO_EVIDENCE		Roifman syndrome is a rare congenital disorder characterized by growth retardation, cognitive delay, spondyloepiphyseal dysplasia, immunodeficiency, and retinal dystrophy.	While this reference describes the clinical manifestations of Roifman syndrome, it does not mention the use of growth hormone therapy for growth retardation.	"{""explanation"": ""While this reference describes the clinical manifestations of Roifman syndrome, it does not mention the use of growth hormone therapy for growth retardation."", ""reference"": ""PMID:37666272"", ""snippet"": ""Roifman syndrome is a rare congenital disorder characterized by growth retardation, cognitive delay, spondyloepiphyseal dysplasia, immunodeficiency, and retinal dystrophy."", ""supports"": ""NO_EVIDENCE""}"
7013	6825	291	Roifman-syndrome	Roifman-syndrome.yaml	treatments	3	evidence	0	PMID:21910238	PARTIAL		The results confirmed a stable pattern of intellectual disability, and indicated that Roifman syndrome may be associated with major structural neuro-anatomical abnormalities.	The reference confirms intellectual disability associated with Roifman syndrome but does not specifically mention supportive educational programs tailored for these needs.	"{""explanation"": ""The reference confirms intellectual disability associated with Roifman syndrome but does not specifically mention supportive educational programs tailored for these needs."", ""reference"": ""PMID:21910238"", ""snippet"": ""The results confirmed a stable pattern of intellectual disability, and indicated that Roifman syndrome may be associated with major structural neuro-anatomical abnormalities."", ""supports"": ""PARTIAL""}"
7014	6825	291	Roifman-syndrome	Roifman-syndrome.yaml	treatments	3	evidence	1	PMID:28623346	PARTIAL		Whole exome sequencing revealed KMT2A-associated Wiedemann-Steiner syndrome in one sibling pair and their mother. In the other sibling pair, targeted testing of the known disease gene for Roifman syndrome (RNU4ATAC) provided a definite diagnosis.	This reference discusses the genetic diagnosis of Roifman syndrome but does not provide details on supportive educational programs tailored for intellectual disability and developmental delays.	"{""explanation"": ""This reference discusses the genetic diagnosis of Roifman syndrome but does not provide details on supportive educational programs tailored for intellectual disability and developmental delays."", ""reference"": ""PMID:28623346"", ""snippet"": ""Whole exome sequencing revealed KMT2A-associated Wiedemann-Steiner syndrome in one sibling pair and their mother. In the other sibling pair, targeted testing of the known disease gene for Roifman syndrome (RNU4ATAC) provided a definite diagnosis."", ""supports"": ""PARTIAL""}"
7015	6826	291	Roifman-syndrome	Roifman-syndrome.yaml	treatments	4	evidence	0	PMID:35450878	REFUTE		Roifman syndrome is a rare autosomal recessive inherited syndromic immunodeficiency.	The literature describes Roifman syndrome primarily as an immunodeficiency syndrome, and does not mention severe skeletal or craniofacial abnormalities as part of its clinical features.	"{""explanation"": ""The literature describes Roifman syndrome primarily as an immunodeficiency syndrome, and does not mention severe skeletal or craniofacial abnormalities as part of its clinical features."", ""reference"": ""PMID:35450878"", ""snippet"": ""Roifman syndrome is a rare autosomal recessive inherited syndromic immunodeficiency."", ""supports"": ""REFUTE""}"
7032	6842	292	SADDAN	SADDAN.yaml	treatments	0	evidence	0	PMID:38993719	SUPPORT		We administered GH therapy for a markedly short stature.	Case report documents growth hormone therapy in a SADDAN patient with marked short stature.	"{""explanation"": ""Case report documents growth hormone therapy in a SADDAN patient with marked short stature."", ""reference"": ""PMID:38993719"", ""snippet"": ""We administered GH therapy for a markedly short stature."", ""supports"": ""SUPPORT""}"
7068	6872	293	Salla Disease	Salla_Disease.yaml	treatments	0	evidence	0	PMID:37727271	SUPPORT	IN_VITRO	There are currently no therapies for FSASDs.	Standard treatment remains supportive pending development of specific disease-modifying therapies.	"{""evidence_source"": ""IN_VITRO"", ""explanation"": ""Standard treatment remains supportive pending development of specific disease-modifying therapies."", ""reference"": ""PMID:37727271"", ""snippet"": ""There are currently no therapies for FSASDs."", ""supports"": ""SUPPORT""}"
7069	6873	293	Salla Disease	Salla_Disease.yaml	treatments	1	evidence	0	PMID:37727271	SUPPORT	IN_VITRO	ABE treatment of either homozygous or compound heterozygous SLC17A5 c.115C>T human dermal fibroblasts demonstrated significant FSA reduction, supporting amelioration of disease pathology.	Base editing approach successfully corrects the founder variant and reduces sialic acid accumulation in patient-derived cells and animal models.	"{""evidence_source"": ""IN_VITRO"", ""explanation"": ""Base editing approach successfully corrects the founder variant and reduces sialic acid accumulation in patient-derived cells and animal models."", ""reference"": ""PMID:37727271"", ""snippet"": ""ABE treatment of either homozygous or compound heterozygous SLC17A5 c.115C>T human dermal fibroblasts demonstrated significant FSA reduction, supporting amelioration of disease pathology."", ""supports"": ""SUPPORT""}"
7077	6902	295	Scabies	Scabies.yaml	treatments	0	evidence	0	PMID:35298417	SUPPORT		Mass treatment with permethrin cream or ivermectin can be given directly to patients.	The abstract notes permethrin cream or ivermectin for treatment.	"{""explanation"": ""The abstract notes permethrin cream or ivermectin for treatment."", ""reference"": ""PMID:35298417"", ""snippet"": ""Mass treatment with permethrin cream or ivermectin can be given directly to patients."", ""supports"": ""SUPPORT""}"
7086	6911	296	Schistosomiasis	Schistosomiasis.yaml	treatments	0	evidence	0	PMID:24698483	SUPPORT		treatment once every 1 or 2 years with the isoquinolinone drug, praziquantel, to suppress morbidity	The review describes periodic praziquantel treatment as standard preventive therapy.	"{""explanation"": ""The review describes periodic praziquantel treatment as standard preventive therapy."", ""reference"": ""PMID:24698483"", ""snippet"": ""treatment once every 1 or 2 years with the isoquinolinone drug, praziquantel, to suppress morbidity"", ""supports"": ""SUPPORT""}"
7176	6945	297	Schizophrenia	Schizophrenia.yaml	treatments	0	evidence	0	PMID:12769630	PARTIAL		With the use of chlorpromazine and other traditional antipsychotics for psychosis, it was soon discovered that the antipsychotic efficacy of this class of medications was closely associated with their ability to block dopamine D(2) receptors in the brain.	This reference supports the statement that antipsychotic medications act through dopamine D2 receptor antagonism. It also mentions medications like clozapine, risperidone, and others, but does not specifically mention olanzapine in this context.	"{""explanation"": ""This reference supports the statement that antipsychotic medications act through dopamine D2 receptor antagonism. It also mentions medications like clozapine, risperidone, and others, but does not specifically mention olanzapine in this context."", ""reference"": ""PMID:12769630"", ""snippet"": ""With the use of chlorpromazine and other traditional antipsychotics for psychosis, it was soon discovered that the antipsychotic efficacy of this class of medications was closely associated with their ability to block dopamine D(2) receptors in the brain."", ""supports"": ""PARTIAL""}"
7177	6945	297	Schizophrenia	Schizophrenia.yaml	treatments	0	evidence	1	PMID:14514482	NO_EVIDENCE			The title suggests a focus on schizophrenia treatments, but no abstract provided to verify the contents in relation to the detailed mechanism of action of risperidone, olanzapine, or clozapine.	"{""explanation"": ""The title suggests a focus on schizophrenia treatments, but no abstract provided to verify the contents in relation to the detailed mechanism of action of risperidone, olanzapine, or clozapine."", ""reference"": ""PMID:14514482"", ""snippet"": """", ""supports"": ""NO_EVIDENCE""}"
7178	6945	297	Schizophrenia	Schizophrenia.yaml	treatments	0	evidence	2	PMID:8626371	PARTIAL		The introduction of novel antipsychotic agents, such as clozapine and risperidone, has enhanced the clinicians' ability to manage schizophrenic patients.	This supports the usage of clozapine and risperidone but does not detail the mechanism focused on dopamine D2 receptor antagonism.	"{""explanation"": ""This supports the usage of clozapine and risperidone but does not detail the mechanism focused on dopamine D2 receptor antagonism."", ""reference"": ""PMID:8626371"", ""snippet"": ""The introduction of novel antipsychotic agents, such as clozapine and risperidone, has enhanced the clinicians' ability to manage schizophrenic patients."", ""supports"": ""PARTIAL""}"
7179	6945	297	Schizophrenia	Schizophrenia.yaml	treatments	0	evidence	3	PMID:15846745	NO_EVIDENCE			The reference compares the clinical effects of risperidone and olanzapine, but does not provide information on the mechanism of action through dopamine D2 receptor antagonism.	"{""explanation"": ""The reference compares the clinical effects of risperidone and olanzapine, but does not provide information on the mechanism of action through dopamine D2 receptor antagonism."", ""reference"": ""PMID:15846745"", ""snippet"": """", ""supports"": ""NO_EVIDENCE""}"
7180	6945	297	Schizophrenia	Schizophrenia.yaml	treatments	0	evidence	4	PMID:8823348	PARTIAL		Clozapine has shown to be effective in some poor or partially responsive patients in three prospective, random assignment, double-blind trials.	Supports effectiveness of clozapine in treatment-resistant patients but does not address dopamine D2 receptor antagonism directly.	"{""explanation"": ""Supports effectiveness of clozapine in treatment-resistant patients but does not address dopamine D2 receptor antagonism directly."", ""reference"": ""PMID:8823348"", ""snippet"": ""Clozapine has shown to be effective in some poor or partially responsive patients in three prospective, random assignment, double-blind trials."", ""supports"": ""PARTIAL""}"
7181	6945	297	Schizophrenia	Schizophrenia.yaml	treatments	0	evidence	5	PMID:32464195	PARTIAL		To improve treatment efficacy during the critical early stages of schizophrenia, we aimed to identify molecular signatures at baseline (T0) for prediction of a positive response to the atypical antipsychotics olanzapine and risperidone after 6 weeks (T6) treatment.	This supports the use of olanzapine and risperidone but does not detail the mechanism involving dopamine D2 receptor antagonism.	"{""explanation"": ""This supports the use of olanzapine and risperidone but does not detail the mechanism involving dopamine D2 receptor antagonism."", ""reference"": ""PMID:32464195"", ""snippet"": ""To improve treatment efficacy during the critical early stages of schizophrenia, we aimed to identify molecular signatures at baseline (T0) for prediction of a positive response to the atypical antipsychotics olanzapine and risperidone after 6 weeks (T6) treatment."", ""supports"": ""PARTIAL""}"
7182	6945	297	Schizophrenia	Schizophrenia.yaml	treatments	0	evidence	6	PMID:17845145	PARTIAL		The drug discovery process has focused mostly on targeting D2 dopamine receptors.	This reference supports the focus on D2 dopamine receptors in drug discovery, which aligns with the mechanism described.	"{""explanation"": ""This reference supports the focus on D2 dopamine receptors in drug discovery, which aligns with the mechanism described."", ""reference"": ""PMID:17845145"", ""snippet"": ""The drug discovery process has focused mostly on targeting D2 dopamine receptors."", ""supports"": ""PARTIAL""}"
7183	6946	297	Schizophrenia	Schizophrenia.yaml	treatments	1	evidence	0	PMID:20880828	SUPPORT		There is good evidence from a considerable number of clinical trials that CBTp has a consistent clinical benefit when used in addition to standard care.	This indicates that Cognitive Behavioral Therapy (CBT) is a recognized treatment for schizophrenia that aims at changing maladaptive thought patterns and behaviors.	"{""explanation"": ""This indicates that Cognitive Behavioral Therapy (CBT) is a recognized treatment for schizophrenia that aims at changing maladaptive thought patterns and behaviors."", ""reference"": ""PMID:20880828"", ""snippet"": ""There is good evidence from a considerable number of clinical trials that CBTp has a consistent clinical benefit when used in addition to standard care."", ""supports"": ""SUPPORT""}"
7184	6946	297	Schizophrenia	Schizophrenia.yaml	treatments	1	evidence	1	PMID:27335156	SUPPORT		Cognitive behavioural therapy for psychosis and cognitive remediation are 2 psychosocial interventions that have demonstrated positive outcomes for violence in SCZ.	This highlights that CBT, which focuses on changing maladaptive thought patterns and behaviors, is effective in treating certain symptoms of schizophrenia.	"{""explanation"": ""This highlights that CBT, which focuses on changing maladaptive thought patterns and behaviors, is effective in treating certain symptoms of schizophrenia."", ""reference"": ""PMID:27335156"", ""snippet"": ""Cognitive behavioural therapy for psychosis and cognitive remediation are 2 psychosocial interventions that have demonstrated positive outcomes for violence in SCZ."", ""supports"": ""SUPPORT""}"
7185	6946	297	Schizophrenia	Schizophrenia.yaml	treatments	1	evidence	2	PMID:17716100	SUPPORT		A theoretical analysis of schizophrenia based on a cognitive model integrates the complex interaction of predisposing neurobiological, environmental, cognitive, and behavioral factors with the diverse symptomatology.	The statement aligns with the cognitive approach to schizophrenia, which underpins CBT.	"{""explanation"": ""The statement aligns with the cognitive approach to schizophrenia, which underpins CBT."", ""reference"": ""PMID:17716100"", ""snippet"": ""A theoretical analysis of schizophrenia based on a cognitive model integrates the complex interaction of predisposing neurobiological, environmental, cognitive, and behavioral factors with the diverse symptomatology."", ""supports"": ""SUPPORT""}"
7186	6946	297	Schizophrenia	Schizophrenia.yaml	treatments	1	evidence	3	PMID:31699627	SUPPORT		Cognitive remediation is now widely recognized as an effective treatment for cognitive deficits in schizophrenia.	Although this reference focuses on cognitive remediation, it aligns with the efficacy of cognitive therapies like CBT.	"{""explanation"": ""Although this reference focuses on cognitive remediation, it aligns with the efficacy of cognitive therapies like CBT."", ""reference"": ""PMID:31699627"", ""snippet"": ""Cognitive remediation is now widely recognized as an effective treatment for cognitive deficits in schizophrenia."", ""supports"": ""SUPPORT""}"
7187	6947	297	Schizophrenia	Schizophrenia.yaml	treatments	2	evidence	0	PMID:16885207	SUPPORT		Social skills training consists of learning activities utilizing behavioral techniques that enable persons with schizophrenia and other disabling mental disorders to acquire interpersonal disease management and independent living skills for improved functioning in their communities.	The study states that social skills training helps individuals with schizophrenia to improve functioning in their communities by acquiring interpersonal and independent living skills.	"{""explanation"": ""The study states that social skills training helps individuals with schizophrenia to improve functioning in their communities by acquiring interpersonal and independent living skills."", ""reference"": ""PMID:16885207"", ""snippet"": ""Social skills training consists of learning activities utilizing behavioral techniques that enable persons with schizophrenia and other disabling mental disorders to acquire interpersonal disease management and independent living skills for improved functioning in their communities."", ""supports"": ""SUPPORT""}"
7188	6947	297	Schizophrenia	Schizophrenia.yaml	treatments	2	evidence	1	PMID:31708048	SUPPORT		Common elements to these interventions include building a therapeutic alliance, recovery orientation, education, and skills training, which can be directed to a range of targets, including problem-solving, communication, social skills, and social cognition.	Clinical therapies for first-episode psychosis as part of coordinated specialty care (CSC) include skills training directed at social skills.	"{""explanation"": ""Clinical therapies for first-episode psychosis as part of coordinated specialty care (CSC) include skills training directed at social skills."", ""reference"": ""PMID:31708048"", ""snippet"": ""Common elements to these interventions include building a therapeutic alliance, recovery orientation, education, and skills training, which can be directed to a range of targets, including problem-solving, communication, social skills, and social cognition."", ""supports"": ""SUPPORT""}"
7189	6947	297	Schizophrenia	Schizophrenia.yaml	treatments	2	evidence	2	PMID:23773889	SUPPORT		METHODOLOGY: Social skills training, cognitive behavioral therapy, cognitive remediation, and social cognitive training therapy paradigms were searched and the extant literature is summarized for each, with particular focus on: 1) the rationale for treatment methodology; 2) particular methods of treatment; and, 3) meta-analytic data regarding their efficacy and/or effectiveness.	This reference indicates that social skills training is a recognized psychosocial method used to treat schizophrenia and discusses its efficacy.	"{""explanation"": ""This reference indicates that social skills training is a recognized psychosocial method used to treat schizophrenia and discusses its efficacy."", ""reference"": ""PMID:23773889"", ""snippet"": ""METHODOLOGY: Social skills training, cognitive behavioral therapy, cognitive remediation, and social cognitive training therapy paradigms were searched and the extant literature is summarized for each, with particular focus on: 1) the rationale for treatment methodology; 2) particular methods of treatment; and, 3) meta-analytic data regarding their efficacy and/or effectiveness."", ""supports"": ""SUPPORT""}"
7190	6947	297	Schizophrenia	Schizophrenia.yaml	treatments	2	evidence	3	PMID:36050663	SUPPORT		Although pharmacological treatments can often lessen the psychotic symptoms that are a hallmark of schizophrenia, they do not lessen the social and cognitive deficits that create the greatest impediments to community engagement and functional recovery.	The study compares Cognitive Enhancement Therapy and Social Skills Training (HOPES/SST), highlighting their role in improving social and community functioning.	"{""explanation"": ""The study compares Cognitive Enhancement Therapy and Social Skills Training (HOPES/SST), highlighting their role in improving social and community functioning."", ""reference"": ""PMID:36050663"", ""snippet"": ""Although pharmacological treatments can often lessen the psychotic symptoms that are a hallmark of schizophrenia, they do not lessen the social and cognitive deficits that create the greatest impediments to community engagement and functional recovery."", ""supports"": ""SUPPORT""}"
7191	6947	297	Schizophrenia	Schizophrenia.yaml	treatments	2	evidence	4	PMID:32614046	SUPPORT		To address this need, we have developed SocialVille-an online, plasticity-based training program that targets SC deficits in schizophrenia...These results provide support for the efficacy of a remote, plasticity-based social cognitive training program in improving SC and social functioning in schizophrenia.	The study shows that social cognitive training programs, which could include elements similar to Social Skills Training, improve social functioning in schizophrenia patients.	"{""explanation"": ""The study shows that social cognitive training programs, which could include elements similar to Social Skills Training, improve social functioning in schizophrenia patients."", ""reference"": ""PMID:32614046"", ""snippet"": ""To address this need, we have developed SocialVille-an online, plasticity-based training program that targets SC deficits in schizophrenia...These results provide support for the efficacy of a remote, plasticity-based social cognitive training program in improving SC and social functioning in schizophrenia."", ""supports"": ""SUPPORT""}"
7192	6947	297	Schizophrenia	Schizophrenia.yaml	treatments	2	evidence	5	PMID:21860049	SUPPORT		Intention-to-treat analyses found significantly larger pre-post improvements with TAR than with CRT in prosodic affect recognition, ToM, and social competence and a trend effect in global social functioning.	The study indicates that training aimed at social cognition, such as TAR, may improve social skills and functions, relevant to social skills training programs.	"{""explanation"": ""The study indicates that training aimed at social cognition, such as TAR, may improve social skills and functions, relevant to social skills training programs."", ""reference"": ""PMID:21860049"", ""snippet"": ""Intention-to-treat analyses found significantly larger pre-post improvements with TAR than with CRT in prosodic affect recognition, ToM, and social competence and a trend effect in global social functioning."", ""supports"": ""SUPPORT""}"
7193	6948	297	Schizophrenia	Schizophrenia.yaml	treatments	3	evidence	0	PMID:15176765	SUPPORT		This article posits that the positive findings for supportive therapy (ST) in recent trials may indicate an important but undervalued aspect of psychosocial interventions for schizophrenia.	The article discusses the benefits of supportive therapy in schizophrenia treatment and emphasizes mechanisms such as the therapeutic alliance and social support, indicating that ongoing support helps manage daily life and stress.	"{""explanation"": ""The article discusses the benefits of supportive therapy in schizophrenia treatment and emphasizes mechanisms such as the therapeutic alliance and social support, indicating that ongoing support helps manage daily life and stress."", ""reference"": ""PMID:15176765"", ""snippet"": ""This article posits that the positive findings for supportive therapy (ST) in recent trials may indicate an important but undervalued aspect of psychosocial interventions for schizophrenia."", ""supports"": ""SUPPORT""}"
7194	6948	297	Schizophrenia	Schizophrenia.yaml	treatments	3	evidence	1	PMID:23244011	SUPPORT		The intervention group improved significantly on measures of both PANSS and GAF scores, with large effect sizes at two years follow-up after inclusion. Further, improvement on GAF(function) (p = 0.000) and GAF(symptom) (p = 0.010) significantly favored SPP in combination with TaU over TaU alone.	Supportive psychodynamic psychotherapy, a variant of supportive therapy, was found to significantly improve symptoms and functional outcomes, underscoring its role in ongoing support for managing stress and daily life in schizophrenia.	"{""explanation"": ""Supportive psychodynamic psychotherapy, a variant of supportive therapy, was found to significantly improve symptoms and functional outcomes, underscoring its role in ongoing support for managing stress and daily life in schizophrenia."", ""reference"": ""PMID:23244011"", ""snippet"": ""The intervention group improved significantly on measures of both PANSS and GAF scores, with large effect sizes at two years follow-up after inclusion. Further, improvement on GAF(function) (p = 0.000) and GAF(symptom) (p = 0.010) significantly favored SPP in combination with TaU over TaU alone."", ""supports"": ""SUPPORT""}"
7195	6948	297	Schizophrenia	Schizophrenia.yaml	treatments	3	evidence	2	PMID:31708048	SUPPORT		Group, individual, and family therapies in CSC aim to help the client and family understand and cope with the experience of psychosis, promote symptomatic and functional recovery and improve quality of life, and support the pursuit of personally meaningful goals of the client.	Coordinated specialty care, including supportive interventions, focuses on coping, recovery, and quality of life, indicating the importance of ongoing support.	"{""explanation"": ""Coordinated specialty care, including supportive interventions, focuses on coping, recovery, and quality of life, indicating the importance of ongoing support."", ""reference"": ""PMID:31708048"", ""snippet"": ""Group, individual, and family therapies in CSC aim to help the client and family understand and cope with the experience of psychosis, promote symptomatic and functional recovery and improve quality of life, and support the pursuit of personally meaningful goals of the client."", ""supports"": ""SUPPORT""}"
7196	6949	297	Schizophrenia	Schizophrenia.yaml	treatments	4	evidence	0	PMID:8749891	PARTIAL		Most vocational rehabilitation programs have a positive influence on work-related activities, but most have failed to show substantial and enduring impacts on independent, competitive employment.	While vocational rehabilitation programs have positive influences on work-related activities, they have not generally shown substantial and enduring impacts on competitive employment.	"{""explanation"": ""While vocational rehabilitation programs have positive influences on work-related activities, they have not generally shown substantial and enduring impacts on competitive employment."", ""reference"": ""PMID:8749891"", ""snippet"": ""Most vocational rehabilitation programs have a positive influence on work-related activities, but most have failed to show substantial and enduring impacts on independent, competitive employment."", ""supports"": ""PARTIAL""}"
7197	6949	297	Schizophrenia	Schizophrenia.yaml	treatments	4	evidence	1	PMID:31327504	PARTIAL		At the end of two years in the service, 829 (70.4%) patients were meaningfully employed and 348 (29.6%) patients were unemployed.	Vocational programs have shown promise with a significant portion of patients being gainfully employed, but it does not necessarily indicate maintaining stable employment over long periods.	"{""explanation"": ""Vocational programs have shown promise with a significant portion of patients being gainfully employed, but it does not necessarily indicate maintaining stable employment over long periods."", ""reference"": ""PMID:31327504"", ""snippet"": ""At the end of two years in the service, 829 (70.4%) patients were meaningfully employed and 348 (29.6%) patients were unemployed."", ""supports"": ""PARTIAL""}"
7198	6949	297	Schizophrenia	Schizophrenia.yaml	treatments	4	evidence	2	PMID:18715755	SUPPORT		NET training improved vocational outcomes, suggesting the value of combining cognitive remediation with other rehabilitation methods to enhance functional outcomes.	Neurocognitive enhancement therapy combined with vocational services showed improved employment outcomes, supporting the positive impact on gaining and maintaining employment.	"{""explanation"": ""Neurocognitive enhancement therapy combined with vocational services showed improved employment outcomes, supporting the positive impact on gaining and maintaining employment."", ""reference"": ""PMID:18715755"", ""snippet"": ""NET training improved vocational outcomes, suggesting the value of combining cognitive remediation with other rehabilitation methods to enhance functional outcomes."", ""supports"": ""SUPPORT""}"
7199	6949	297	Schizophrenia	Schizophrenia.yaml	treatments	4	evidence	3	PMID:32393158	SUPPORT		Veterans in the hybrid condition, compared with the AFVP alone, were more likely to find employment, had higher rates of full-time employment, and earned significantly more money over the course of the study.	Blended vocational services significantly improved employment outcomes, supporting the effectiveness of vocational rehabilitation in gaining and maintaining employment.	"{""explanation"": ""Blended vocational services significantly improved employment outcomes, supporting the effectiveness of vocational rehabilitation in gaining and maintaining employment."", ""reference"": ""PMID:32393158"", ""snippet"": ""Veterans in the hybrid condition, compared with the AFVP alone, were more likely to find employment, had higher rates of full-time employment, and earned significantly more money over the course of the study."", ""supports"": ""SUPPORT""}"
7200	6949	297	Schizophrenia	Schizophrenia.yaml	treatments	4	evidence	4	PMID:29135426	SUPPORT		Significantly higher employment rate and longer job tenure were found in the ISE group (63.0%, 29.56 wk) compared with the IPS group (50.0%, 25.47 wk) and TVR group (33.3%, 9.91 wk).	Integrated supported employment led to higher employment rates and longer job tenure, indicating that such vocational rehabilitation can help with gaining and maintaining employment.	"{""explanation"": ""Integrated supported employment led to higher employment rates and longer job tenure, indicating that such vocational rehabilitation can help with gaining and maintaining employment."", ""reference"": ""PMID:29135426"", ""snippet"": ""Significantly higher employment rate and longer job tenure were found in the ISE group (63.0%, 29.56 wk) compared with the IPS group (50.0%, 25.47 wk) and TVR group (33.3%, 9.91 wk)."", ""supports"": ""SUPPORT""}"
7245	6980	298	Scimitar Syndrome	Scimitar_Syndrome.yaml	treatments	0	evidence	0	PMID:34396590	SUPPORT	HUMAN_CLINICAL	Overall operative mortality has been cited between 4.8% and 5.9%. Mortality was highest in patients with preoperative pulmonary hypertension, and those undergoing surgery in infancy. Despite timely surgical intervention, post-repair obstruction of the scimitar vein, intra-atrial baffle obstruction, or stenosis of the inferior caval vein were reported in up to two-thirds of cases.	Comprehensive review of surgical outcomes noting 5-6% operative mortality but significant postoperative vein obstruction rates.	"{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""Comprehensive review of surgical outcomes noting 5-6% operative mortality but significant postoperative vein obstruction rates."", ""reference"": ""PMID:34396590"", ""snippet"": ""Overall operative mortality has been cited between 4.8% and 5.9%. Mortality was highest in patients with preoperative pulmonary hypertension, and those undergoing surgery in infancy. Despite timely surgical intervention, post-repair obstruction of the scimitar vein, intra-atrial baffle obstruction, or stenosis of the inferior caval vein were reported in up to two-thirds of cases."", ""supports"": ""SUPPORT""}"
7246	6980	298	Scimitar Syndrome	Scimitar_Syndrome.yaml	treatments	0	evidence	1	PMID:34318016	SUPPORT	HUMAN_CLINICAL	None of the 11 patients who only had the new procedure developed pulmonary vein obstruction during postoperative monitoring up to 3.6 years.	Boston Children's Hospital series showing a new multipatch technique eliminated postoperative pulmonary vein obstruction in 11 patients, compared to 45% obstruction rate with traditional techniques.	"{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""Boston Children's Hospital series showing a new multipatch technique eliminated postoperative pulmonary vein obstruction in 11 patients, compared to 45% obstruction rate with traditional techniques."", ""reference"": ""PMID:34318016"", ""snippet"": ""None of the 11 patients who only had the new procedure developed pulmonary vein obstruction during postoperative monitoring up to 3.6 years."", ""supports"": ""SUPPORT""}"
7247	6980	298	Scimitar Syndrome	Scimitar_Syndrome.yaml	treatments	0	evidence	2	PMID:29054305	SUPPORT	HUMAN_CLINICAL	Multivariable analyses identified infantile onset as an independent risk factor for stenosis or obstruction after repair (hazard ratio 9.34, p = 0.048)	Columbia cohort identifying infantile onset as a 9-fold independent risk factor for postoperative stenosis.	"{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""Columbia cohort identifying infantile onset as a 9-fold independent risk factor for postoperative stenosis."", ""reference"": ""PMID:29054305"", ""snippet"": ""Multivariable analyses identified infantile onset as an independent risk factor for stenosis or obstruction after repair (hazard ratio 9.34, p = 0.048)"", ""supports"": ""SUPPORT""}"
7248	6981	298	Scimitar Syndrome	Scimitar_Syndrome.yaml	treatments	1	evidence	0	PMID:36093138	SUPPORT	HUMAN_CLINICAL	Eight patients received interventional catheter therapy, including occlusion of aortopulmonary collateral arteries (APCs) and other intracardiac malformations, without the following surgery.	East China center series showing catheter-based therapy is effective as a standalone intervention in selected patients.	"{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""East China center series showing catheter-based therapy is effective as a standalone intervention in selected patients."", ""reference"": ""PMID:36093138"", ""snippet"": ""Eight patients received interventional catheter therapy, including occlusion of aortopulmonary collateral arteries (APCs) and other intracardiac malformations, without the following surgery."", ""supports"": ""SUPPORT""}"
7249	6981	298	Scimitar Syndrome	Scimitar_Syndrome.yaml	treatments	1	evidence	1	PMID:41556875	SUPPORT	HUMAN_CLINICAL	All the patients underwent successfully a transcatheter occlusion of SV at the IVC junction using occlusion devices allowing proximal re-rerouting to the left atrium through the fistula. Aberrant systemic artery arising from the abdominal aorta was embolized in 2 cases during the same intervention.	French series of 3 patients with dual-drainage scimitar variant successfully treated by transcatheter occlusion of the IVC connection, redirecting flow to the left atrium.	"{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""French series of 3 patients with dual-drainage scimitar variant successfully treated by transcatheter occlusion of the IVC connection, redirecting flow to the left atrium."", ""reference"": ""PMID:41556875"", ""snippet"": ""All the patients underwent successfully a transcatheter occlusion of SV at the IVC junction using occlusion devices allowing proximal re-rerouting to the left atrium through the fistula. Aberrant systemic artery arising from the abdominal aorta was embolized in 2 cases during the same intervention."", ""supports"": ""SUPPORT""}"
7250	6981	298	Scimitar Syndrome	Scimitar_Syndrome.yaml	treatments	1	evidence	2	PMID:41070433	SUPPORT	HUMAN_CLINICAL	All four patients (three children, one adult) had dual drainage of right pulmonary veins into the inferior caval vein and to the left atrium via a connecting vein. All patients underwent a successful catheter occlusion of the anomalous connection to the systemic vein without complication.	International multicentre series of 4 patients confirming transcatheter correction of the dual-drainage scimitar variant as a safe and effective alternative to surgery.	"{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""International multicentre series of 4 patients confirming transcatheter correction of the dual-drainage scimitar variant as a safe and effective alternative to surgery."", ""reference"": ""PMID:41070433"", ""snippet"": ""All four patients (three children, one adult) had dual drainage of right pulmonary veins into the inferior caval vein and to the left atrium via a connecting vein. All patients underwent a successful catheter occlusion of the anomalous connection to the systemic vein without complication."", ""supports"": ""SUPPORT""}"
7251	6982	298	Scimitar Syndrome	Scimitar_Syndrome.yaml	treatments	2	evidence	0	PMID:38634941	SUPPORT	HUMAN_CLINICAL	Medical management is effective for mild to moderate cases.	Clinical series confirming conservative management is appropriate for mild to moderate scimitar syndrome.	"{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""Clinical series confirming conservative management is appropriate for mild to moderate scimitar syndrome."", ""reference"": ""PMID:38634941"", ""snippet"": ""Medical management is effective for mild to moderate cases."", ""supports"": ""SUPPORT""}"
7265	6993	299	Scurvy	Scurvy.yaml	treatments	0	evidence	0	PMID:37366866	SUPPORT		It can be adequately treated and prevented via vitamin C supplementation.	This confirms that vitamin C supplementation is the adequate treatment and prevention for scurvy.	"{""explanation"": ""This confirms that vitamin C supplementation is the adequate treatment and prevention for scurvy."", ""reference"": ""PMID:37366866"", ""snippet"": ""It can be adequately treated and prevented via vitamin C supplementation."", ""supports"": ""SUPPORT""}"
7274	7002	301	Semantic Dementia	Semantic_Dementia.yaml	treatments	0	evidence	0	PMID:28286641	SUPPORT		The purpose of this paper is to gain consensus regarding the clinical priorities and tasks required in supporting communication needs in those living with semantic dementia and their families, by specialist speech and language therapists (SLTs), working in clinical practice within dementia care settings in the UK.	The abstract describes speech and language therapist-led communication support for semantic dementia.	"{""explanation"": ""The abstract describes speech and language therapist-led communication support for semantic dementia."", ""reference"": ""PMID:28286641"", ""snippet"": ""The purpose of this paper is to gain consensus regarding the clinical priorities and tasks required in supporting communication needs in those living with semantic dementia and their families, by specialist speech and language therapists (SLTs), working in clinical practice within dementia care settings in the UK."", ""supports"": ""SUPPORT""}"
7294	7018	302	Semicircular Canal Dehiscence Syndrome	Semicircular_Canal_Dehiscence_Syndrome.yaml	treatments	0	evidence	0	PMID:32982922	SUPPORT		Patients with mild symptoms can reduce exposure to loud sounds and avoid physical straining, and those with pressure sensitivity can benefit from a tympanostomy tube	Conservative management options are described for patients with mild symptoms.	"{""explanation"": ""Conservative management options are described for patients with mild symptoms."", ""reference"": ""PMID:32982922"", ""snippet"": ""Patients with mild symptoms can reduce exposure to loud sounds and avoid physical straining, and those with pressure sensitivity can benefit from a tympanostomy tube"", ""supports"": ""SUPPORT""}"
7295	7019	302	Semicircular Canal Dehiscence Syndrome	Semicircular_Canal_Dehiscence_Syndrome.yaml	treatments	1	evidence	0	PMID:16222184	SUPPORT		Canal plugging was performed in 9 and resurfacing of the canal without plugging of the lumen in 11 patients. Complete resolution of vestibular symptoms and signs was achieved in 8 of the 9 patients after canal plugging.	Clinical data demonstrates high success rate of canal plugging surgery.	"{""explanation"": ""Clinical data demonstrates high success rate of canal plugging surgery."", ""reference"": ""PMID:16222184"", ""snippet"": ""Canal plugging was performed in 9 and resurfacing of the canal without plugging of the lumen in 11 patients. Complete resolution of vestibular symptoms and signs was achieved in 8 of the 9 patients after canal plugging."", ""supports"": ""SUPPORT""}"
7296	7019	302	Semicircular Canal Dehiscence Syndrome	Semicircular_Canal_Dehiscence_Syndrome.yaml	treatments	1	evidence	1	PMID:32982922	SUPPORT		Canal plugging achieves long-term control more often than resurfacing and is usually the procedure of choice	Canal plugging is established as the preferred surgical treatment.	"{""explanation"": ""Canal plugging is established as the preferred surgical treatment."", ""reference"": ""PMID:32982922"", ""snippet"": ""Canal plugging achieves long-term control more often than resurfacing and is usually the procedure of choice"", ""supports"": ""SUPPORT""}"
7297	7020	302	Semicircular Canal Dehiscence Syndrome	Semicircular_Canal_Dehiscence_Syndrome.yaml	treatments	2	evidence	0	PMID:16222184	SUPPORT		Complete resolution of vestibular symptoms and signs was achieved in 8 of the 9 patients after canal plugging and in 7 of the 11 patients after resurfacing.	Resurfacing can achieve symptom resolution, though less reliably than plugging.	"{""explanation"": ""Resurfacing can achieve symptom resolution, though less reliably than plugging."", ""reference"": ""PMID:16222184"", ""snippet"": ""Complete resolution of vestibular symptoms and signs was achieved in 8 of the 9 patients after canal plugging and in 7 of the 11 patients after resurfacing."", ""supports"": ""SUPPORT""}"
7298	7020	302	Semicircular Canal Dehiscence Syndrome	Semicircular_Canal_Dehiscence_Syndrome.yaml	treatments	2	evidence	1	PMID:36742050	SUPPORT		The changes observed also reverse and return to baseline as the SSCD heals by bone resurfacing (with the lumen intact).	Animal model demonstrates that bony resurfacing can restore normal function while preserving canal lumen patency.	"{""explanation"": ""Animal model demonstrates that bony resurfacing can restore normal function while preserving canal lumen patency."", ""reference"": ""PMID:36742050"", ""snippet"": ""The changes observed also reverse and return to baseline as the SSCD heals by bone resurfacing (with the lumen intact)."", ""supports"": ""SUPPORT""}"
7330	7043	303	Sengers syndrome	Sengers_syndrome.yaml	treatments	0	evidence	0	PMID:34164355	SUPPORT		Supplementation with coenzyme Q10, carnitine, B-vitamins, and biotin (called mitochondrial cocktail) was given daily, associated with angiotensin converting enzyme (ACE) inhibitors for cardiomyopathy management.	This case report lists coenzyme Q10 as part of a mitochondrial cocktail for Sengers syndrome.	"{""explanation"": ""This case report lists coenzyme Q10 as part of a mitochondrial cocktail for Sengers syndrome."", ""reference"": ""PMID:34164355"", ""snippet"": ""Supplementation with coenzyme Q10, carnitine, B-vitamins, and biotin (called mitochondrial cocktail) was given daily, associated with angiotensin converting enzyme (ACE) inhibitors for cardiomyopathy management."", ""supports"": ""SUPPORT""}"
7331	7043	303	Sengers syndrome	Sengers_syndrome.yaml	treatments	0	evidence	1	PMID:34164355	SUPPORT		Levocarnitine (100 mg/kg daily), coenzyme Q10 (1 mg/kg daily), and vitamin B complex (vitamin B1 20 mg/day and riboflavin 10 mg/day) were administered to improve metabolic status;	This provides dosing detail confirming coenzyme Q10 use in Sengers syndrome.	"{""explanation"": ""This provides dosing detail confirming coenzyme Q10 use in Sengers syndrome."", ""reference"": ""PMID:34164355"", ""snippet"": ""Levocarnitine (100 mg/kg daily), coenzyme Q10 (1 mg/kg daily), and vitamin B complex (vitamin B1 20 mg/day and riboflavin 10 mg/day) were administered to improve metabolic status;"", ""supports"": ""SUPPORT""}"
7332	7044	303	Sengers syndrome	Sengers_syndrome.yaml	treatments	1	evidence	0	PMID:34164355	SUPPORT		Supplementation with coenzyme Q10, carnitine, B-vitamins, and biotin (called mitochondrial cocktail) was given daily, associated with angiotensin converting enzyme (ACE) inhibitors for cardiomyopathy management.	This case report lists carnitine within the mitochondrial cocktail for Sengers syndrome.	"{""explanation"": ""This case report lists carnitine within the mitochondrial cocktail for Sengers syndrome."", ""reference"": ""PMID:34164355"", ""snippet"": ""Supplementation with coenzyme Q10, carnitine, B-vitamins, and biotin (called mitochondrial cocktail) was given daily, associated with angiotensin converting enzyme (ACE) inhibitors for cardiomyopathy management."", ""supports"": ""SUPPORT""}"
7333	7044	303	Sengers syndrome	Sengers_syndrome.yaml	treatments	1	evidence	1	PMID:34164355	SUPPORT		Levocarnitine (100 mg/kg daily), coenzyme Q10 (1 mg/kg daily), and vitamin B complex (vitamin B1 20 mg/day and riboflavin 10 mg/day) were administered to improve metabolic status;	This provides dosing detail confirming levocarnitine use in Sengers syndrome.	"{""explanation"": ""This provides dosing detail confirming levocarnitine use in Sengers syndrome."", ""reference"": ""PMID:34164355"", ""snippet"": ""Levocarnitine (100 mg/kg daily), coenzyme Q10 (1 mg/kg daily), and vitamin B complex (vitamin B1 20 mg/day and riboflavin 10 mg/day) were administered to improve metabolic status;"", ""supports"": ""SUPPORT""}"
7334	7045	303	Sengers syndrome	Sengers_syndrome.yaml	treatments	2	evidence	0	PMID:34164355	SUPPORT		Supplementation with coenzyme Q10, carnitine, B-vitamins, and biotin (called mitochondrial cocktail) was given daily, associated with angiotensin converting enzyme (ACE) inhibitors for cardiomyopathy management.	This case report lists B-vitamins within the mitochondrial cocktail for Sengers syndrome.	"{""explanation"": ""This case report lists B-vitamins within the mitochondrial cocktail for Sengers syndrome."", ""reference"": ""PMID:34164355"", ""snippet"": ""Supplementation with coenzyme Q10, carnitine, B-vitamins, and biotin (called mitochondrial cocktail) was given daily, associated with angiotensin converting enzyme (ACE) inhibitors for cardiomyopathy management."", ""supports"": ""SUPPORT""}"
7335	7045	303	Sengers syndrome	Sengers_syndrome.yaml	treatments	2	evidence	1	PMID:34164355	SUPPORT		Levocarnitine (100 mg/kg daily), coenzyme Q10 (1 mg/kg daily), and vitamin B complex (vitamin B1 20 mg/day and riboflavin 10 mg/day) were administered to improve metabolic status;	This provides dosing detail confirming vitamin B complex use in Sengers syndrome.	"{""explanation"": ""This provides dosing detail confirming vitamin B complex use in Sengers syndrome."", ""reference"": ""PMID:34164355"", ""snippet"": ""Levocarnitine (100 mg/kg daily), coenzyme Q10 (1 mg/kg daily), and vitamin B complex (vitamin B1 20 mg/day and riboflavin 10 mg/day) were administered to improve metabolic status;"", ""supports"": ""SUPPORT""}"
7336	7046	303	Sengers syndrome	Sengers_syndrome.yaml	treatments	3	evidence	0	PMID:34164355	SUPPORT		Supplementation with coenzyme Q10, carnitine, B-vitamins, and biotin (called mitochondrial cocktail) was given daily, associated with angiotensin converting enzyme (ACE) inhibitors for cardiomyopathy management.	This case report notes ACE inhibitor use alongside mitochondrial cocktail therapy.	"{""explanation"": ""This case report notes ACE inhibitor use alongside mitochondrial cocktail therapy."", ""reference"": ""PMID:34164355"", ""snippet"": ""Supplementation with coenzyme Q10, carnitine, B-vitamins, and biotin (called mitochondrial cocktail) was given daily, associated with angiotensin converting enzyme (ACE) inhibitors for cardiomyopathy management."", ""supports"": ""SUPPORT""}"
7337	7046	303	Sengers syndrome	Sengers_syndrome.yaml	treatments	3	evidence	1	PMID:34164355	SUPPORT		The patient received milrinone, diuretics (furosemide and spironolactone), and captopril to improve heart function.	This provides direct evidence of ACE inhibitor (captopril) therapy in Sengers syndrome.	"{""explanation"": ""This provides direct evidence of ACE inhibitor (captopril) therapy in Sengers syndrome."", ""reference"": ""PMID:34164355"", ""snippet"": ""The patient received milrinone, diuretics (furosemide and spironolactone), and captopril to improve heart function."", ""supports"": ""SUPPORT""}"
7338	7046	303	Sengers syndrome	Sengers_syndrome.yaml	treatments	3	evidence	2	PMID:38933059	SUPPORT		Baby was on regular follow-up and was thriving well on diuretics, sacubitril-valsartan and weekly levosimendan infusions.	This neonatal case reports ongoing pharmacologic heart failure management including a neprilysin inhibitor/ARB regimen.	"{""explanation"": ""This neonatal case reports ongoing pharmacologic heart failure management including a neprilysin inhibitor/ARB regimen."", ""reference"": ""PMID:38933059"", ""snippet"": ""Baby was on regular follow-up and was thriving well on diuretics, sacubitril-valsartan and weekly levosimendan infusions."", ""supports"": ""SUPPORT""}"
7339	7047	303	Sengers syndrome	Sengers_syndrome.yaml	treatments	4	evidence	0	PMID:8526648	SUPPORT		This report describes cardiac transplantation for the treatment of the cardiomyopathy associated with Sengers' syndrome.	This case report documents cardiac transplantation as a treatment for Sengers-associated cardiomyopathy.	"{""explanation"": ""This case report documents cardiac transplantation as a treatment for Sengers-associated cardiomyopathy."", ""reference"": ""PMID:8526648"", ""snippet"": ""This report describes cardiac transplantation for the treatment of the cardiomyopathy associated with Sengers' syndrome."", ""supports"": ""SUPPORT""}"
7340	7047	303	Sengers syndrome	Sengers_syndrome.yaml	treatments	4	evidence	1	PMID:38933059	SUPPORT		At 8 months of age, cardiac transplantation was successfully done and baby has been doing well post-transplantation.	This neonatal case report describes successful cardiac transplantation in Sengers syndrome.	"{""explanation"": ""This neonatal case report describes successful cardiac transplantation in Sengers syndrome."", ""reference"": ""PMID:38933059"", ""snippet"": ""At 8 months of age, cardiac transplantation was successfully done and baby has been doing well post-transplantation."", ""supports"": ""SUPPORT""}"
7341	7048	303	Sengers syndrome	Sengers_syndrome.yaml	treatments	5	evidence	0	PMID:38933059	SUPPORT		Baby was on regular follow-up and was thriving well on diuretics, sacubitril-valsartan and weekly levosimendan infusions.	This case report documents ongoing diuretic therapy as part of heart failure management.	"{""explanation"": ""This case report documents ongoing diuretic therapy as part of heart failure management."", ""reference"": ""PMID:38933059"", ""snippet"": ""Baby was on regular follow-up and was thriving well on diuretics, sacubitril-valsartan and weekly levosimendan infusions."", ""supports"": ""SUPPORT""}"
7342	7048	303	Sengers syndrome	Sengers_syndrome.yaml	treatments	5	evidence	1	PMID:34164355	SUPPORT		The patient received milrinone, diuretics (furosemide and spironolactone), and captopril to improve heart function.	This provides direct evidence of diuretic use in Sengers syndrome.	"{""explanation"": ""This provides direct evidence of diuretic use in Sengers syndrome."", ""reference"": ""PMID:34164355"", ""snippet"": ""The patient received milrinone, diuretics (furosemide and spironolactone), and captopril to improve heart function."", ""supports"": ""SUPPORT""}"
7343	7049	303	Sengers syndrome	Sengers_syndrome.yaml	treatments	6	evidence	0	PMID:38933059	SUPPORT		Baby was on regular follow-up and was thriving well on diuretics, sacubitril-valsartan and weekly levosimendan infusions.	This neonatal case report describes levosimendan infusions in Sengers syndrome.	"{""explanation"": ""This neonatal case report describes levosimendan infusions in Sengers syndrome."", ""reference"": ""PMID:38933059"", ""snippet"": ""Baby was on regular follow-up and was thriving well on diuretics, sacubitril-valsartan and weekly levosimendan infusions."", ""supports"": ""SUPPORT""}"
7374	7079	304	Shigellosis	Shigellosis.yaml	treatments	0	evidence	0	PMID:29493962	SUPPORT		antibiotics could shorten the duration of illness or prevent complications, particularly in individuals at increased risk for severe disease	Antimicrobial therapy is indicated to reduce bacterial load and prevent systemic complications	"{""explanation"": ""Antimicrobial therapy is indicated to reduce bacterial load and prevent systemic complications"", ""reference"": ""PMID:29493962"", ""snippet"": ""antibiotics could shorten the duration of illness or prevent complications, particularly in individuals at increased risk for severe disease"", ""supports"": ""SUPPORT""}"
7375	7079	304	Shigellosis	Shigellosis.yaml	treatments	0	evidence	1	PMID:36409683	SUPPORT		WHO-recommended 1st line antibiotic ciprofloxacin resistance gradually reached more than 70% in both the urban and rural site by 2020	Rising antimicrobial resistance, especially to fluoroquinolones, necessitates susceptibility-guided therapy	"{""explanation"": ""Rising antimicrobial resistance, especially to fluoroquinolones, necessitates susceptibility-guided therapy"", ""reference"": ""PMID:36409683"", ""snippet"": ""WHO-recommended 1st line antibiotic ciprofloxacin resistance gradually reached more than 70% in both the urban and rural site by 2020"", ""supports"": ""SUPPORT""}"
7376	7080	304	Shigellosis	Shigellosis.yaml	treatments	1	evidence	0	PMID:29493962	SUPPORT		Supportive care may be required, and antibiotics could shorten the duration of illness or prevent complications	Oral rehydration is the first-line approach to managing fluid and electrolyte losses	"{""explanation"": ""Oral rehydration is the first-line approach to managing fluid and electrolyte losses"", ""reference"": ""PMID:29493962"", ""snippet"": ""Supportive care may be required, and antibiotics could shorten the duration of illness or prevent complications"", ""supports"": ""SUPPORT""}"
7377	7081	304	Shigellosis	Shigellosis.yaml	treatments	2	evidence	0	PMID:40915309	SUPPORT		an inoculum of only 10-100 organisms is required for infection	Severe fluid losses from Shigella-mediated diarrhea may necessitate intravenous fluid replacement	"{""explanation"": ""Severe fluid losses from Shigella-mediated diarrhea may necessitate intravenous fluid replacement"", ""reference"": ""PMID:40915309"", ""snippet"": ""an inoculum of only 10-100 organisms is required for infection"", ""supports"": ""SUPPORT""}"
7395	7108	305	Sickle Cell Disease	Sickle_Cell_Disease.yaml	treatments	0	evidence	0	PMID:7715639	SUPPORT		the 152 patients assigned to hydroxyurea treatment had lower annual rates of crises than the 147 patients given placebo (median, 2.5 vs. 4.5 crises per year, P < 0.001)	Landmark RCT demonstrating hydroxyurea reduces painful crises by nearly half in sickle cell disease.	"{""explanation"": ""Landmark RCT demonstrating hydroxyurea reduces painful crises by nearly half in sickle cell disease."", ""reference"": ""PMID:7715639"", ""snippet"": ""the 152 patients assigned to hydroxyurea treatment had lower annual rates of crises than the 147 patients given placebo (median, 2.5 vs. 4.5 crises per year, P < 0.001)"", ""supports"": ""SUPPORT""}"
7396	7116	305	Sickle Cell Disease	Sickle_Cell_Disease.yaml	treatments	8	evidence	0	PMID:38661449	SUPPORT		Exagamglogene autotemcel (exa-cel) is a nonviral cell therapy designed to reactivate fetal hemoglobin synthesis by means of ex vivo clustered regularly interspaced short palindromic repeats (CRISPR)-Cas9 gene editing of autologous CD34+ hematopoietic stem and progenitor cells (HSPCs) at the erythroid-specific enhancer region of BCL11A.	CRISPR-Cas9 gene editing of the BCL11A enhancer reactivates fetal hemoglobin, which prevents sickling.	"{""explanation"": ""CRISPR-Cas9 gene editing of the BCL11A enhancer reactivates fetal hemoglobin, which prevents sickling."", ""reference"": ""PMID:38661449"", ""snippet"": ""Exagamglogene autotemcel (exa-cel) is a nonviral cell therapy designed to reactivate fetal hemoglobin synthesis by means of ex vivo clustered regularly interspaced short palindromic repeats (CRISPR)-Cas9 gene editing of autologous CD34+ hematopoietic stem and progenitor cells (HSPCs) at the erythroid-specific enhancer region of BCL11A."", ""supports"": ""SUPPORT""}"
7397	7116	305	Sickle Cell Disease	Sickle_Cell_Disease.yaml	treatments	8	evidence	1	PMID:38661449	SUPPORT		Treatment with exa-cel eliminated vaso-occlusive crises in 97% of patients with sickle cell disease for a period of 12 months or more.	In phase 3 clinical trials, exagamglogene autotemcel (exa-cel) eliminated vaso-occlusive crises in 97% of patients for 12+ months, demonstrating high therapeutic efficacy.	"{""explanation"": ""In phase 3 clinical trials, exagamglogene autotemcel (exa-cel) eliminated vaso-occlusive crises in 97% of patients for 12+ months, demonstrating high therapeutic efficacy."", ""reference"": ""PMID:38661449"", ""snippet"": ""Treatment with exa-cel eliminated vaso-occlusive crises in 97% of patients with sickle cell disease for a period of 12 months or more."", ""supports"": ""SUPPORT""}"
7410	7127	306	Silent Sinus Syndrome	Silent_Sinus_Syndrome.yaml	treatments	0	evidence	0	PMID:23946747	SUPPORT		Treatment involves functional endoscopic surgery.	FESS is identified as the primary treatment for SSS.	"{""explanation"": ""FESS is identified as the primary treatment for SSS."", ""reference"": ""PMID:23946747"", ""snippet"": ""Treatment involves functional endoscopic surgery."", ""supports"": ""SUPPORT""}"
7411	7127	306	Silent Sinus Syndrome	Silent_Sinus_Syndrome.yaml	treatments	0	evidence	1	PMID:11404606	SUPPORT		All four underwent successful functional endoscopic sinus surgery and transconjunctival orbital floor repair.	Case series confirms successful treatment with functional endoscopic sinus surgery.	"{""explanation"": ""Case series confirms successful treatment with functional endoscopic sinus surgery."", ""reference"": ""PMID:11404606"", ""snippet"": ""All four underwent successful functional endoscopic sinus surgery and transconjunctival orbital floor repair."", ""supports"": ""SUPPORT""}"
7412	7128	306	Silent Sinus Syndrome	Silent_Sinus_Syndrome.yaml	treatments	1	evidence	0	PMID:11404606	SUPPORT		All four underwent successful functional endoscopic sinus surgery and transconjunctival orbital floor repair.	Transconjunctival orbital floor repair is described as part of the successful treatment approach.	"{""explanation"": ""Transconjunctival orbital floor repair is described as part of the successful treatment approach."", ""reference"": ""PMID:11404606"", ""snippet"": ""All four underwent successful functional endoscopic sinus surgery and transconjunctival orbital floor repair."", ""supports"": ""SUPPORT""}"
7438	7197	310	Snakebite envenoming	Snakebite_Envenoming.yaml	treatments	0	evidence	0	PMID:28905944	SUPPORT		Intravenous administration of antivenom is the only specific treatment to counteract envenoming.	The abstract states antivenom is the only specific treatment.	"{""explanation"": ""The abstract states antivenom is the only specific treatment."", ""reference"": ""PMID:28905944"", ""snippet"": ""Intravenous administration of antivenom is the only specific treatment to counteract envenoming."", ""supports"": ""SUPPORT""}"
7447	7206	311	Soil-transmitted helminthiases	Soil_Transmitted_Helminthiases.yaml	treatments	0	evidence	0	PMID:16679166	SUPPORT		The benzimidazole anthelmintics, mebendazole and albendazole, are commonly used to remove these infections.	Albendazole and mebendazole are standard anthelmintic therapies.	"{""explanation"": ""Albendazole and mebendazole are standard anthelmintic therapies."", ""reference"": ""PMID:16679166"", ""snippet"": ""The benzimidazole anthelmintics, mebendazole and albendazole, are commonly used to remove these infections."", ""supports"": ""SUPPORT""}"
7457	7223	312	Spinal Muscular Atrophy	Spinal_Muscular_Atrophy.yaml	treatments	0	evidence	0	PMID:29091570	SUPPORT		Among infants with spinal muscular atrophy, those who received nusinersen were more likely to be alive and have improvements in motor function than those in the control group.	ENDEAR trial demonstrates nusinersen improves survival and motor function in infantile SMA.	"{""explanation"": ""ENDEAR trial demonstrates nusinersen improves survival and motor function in infantile SMA."", ""reference"": ""PMID:29091570"", ""snippet"": ""Among infants with spinal muscular atrophy, those who received nusinersen were more likely to be alive and have improvements in motor function than those in the control group."", ""supports"": ""SUPPORT""}"
7458	7223	312	Spinal Muscular Atrophy	Spinal_Muscular_Atrophy.yaml	treatments	0	evidence	1	PMID:29091570	SUPPORT		Nusinersen is an antisense oligonucleotide drug that modifies pre-messenger RNA splicing of the SMN2 gene and thus promotes increased production of full-length SMN protein.	NEJM paper confirms mechanism of action of nusinersen.	"{""explanation"": ""NEJM paper confirms mechanism of action of nusinersen."", ""reference"": ""PMID:29091570"", ""snippet"": ""Nusinersen is an antisense oligonucleotide drug that modifies pre-messenger RNA splicing of the SMN2 gene and thus promotes increased production of full-length SMN protein."", ""supports"": ""SUPPORT""}"
7459	7224	312	Spinal Muscular Atrophy	Spinal_Muscular_Atrophy.yaml	treatments	1	evidence	0	PMID:35715567	SUPPORT		Onasemnogene abeparvovec was effective and well-tolerated for presymptomatic infants at risk of SMA type 2, underscoring the urgency of early identification and intervention.	SPR1NT trial demonstrates gene therapy is effective in presymptomatic SMA infants.	"{""explanation"": ""SPR1NT trial demonstrates gene therapy is effective in presymptomatic SMA infants."", ""reference"": ""PMID:35715567"", ""snippet"": ""Onasemnogene abeparvovec was effective and well-tolerated for presymptomatic infants at risk of SMA type 2, underscoring the urgency of early identification and intervention."", ""supports"": ""SUPPORT""}"
7460	7225	312	Spinal Muscular Atrophy	Spinal_Muscular_Atrophy.yaml	treatments	2	evidence	0	PMID:34320287	SUPPORT		In this study involving infants with type 1 SMA, risdiplam resulted in higher percentages of infants who met motor milestones and who showed improvements in motor function than the percentages observed in historical cohorts.	FIREFISH trial demonstrates risdiplam improves motor function in infants with type 1 SMA.	"{""explanation"": ""FIREFISH trial demonstrates risdiplam improves motor function in infants with type 1 SMA."", ""reference"": ""PMID:34320287"", ""snippet"": ""In this study involving infants with type 1 SMA, risdiplam resulted in higher percentages of infants who met motor milestones and who showed improvements in motor function than the percentages observed in historical cohorts."", ""supports"": ""SUPPORT""}"
7490	7274	315	Stickler Syndrome Type 1	Stickler_Syndrome_Type_1.yaml	treatments	0	evidence	0	PMID:17675240	SUPPORT	HUMAN_CLINICAL	"Of 62 patients who had bilateral prophylactic cryotherapy (group 2; mean age, 21 years), 8% (5/62) suffered failure of prophylaxis. There were no cases of bilateral detachments. The mean follow-up period was 11.5 years.
"	"Large retrospective study demonstrates prophylactic cryotherapy reduces retinal detachment from 73% to 8% in STL1 patients.
"	"{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""Large retrospective study demonstrates prophylactic cryotherapy reduces retinal detachment from 73% to 8% in STL1 patients.\n"", ""reference"": ""PMID:17675240"", ""snippet"": ""Of 62 patients who had bilateral prophylactic cryotherapy (group 2; mean age, 21 years), 8% (5/62) suffered failure of prophylaxis. There were no cases of bilateral detachments. The mean follow-up period was 11.5 years.\n"", ""supports"": ""SUPPORT""}"
7491	7274	315	Stickler Syndrome Type 1	Stickler_Syndrome_Type_1.yaml	treatments	0	evidence	1	PMID:17675240	SUPPORT	HUMAN_CLINICAL	"Prophylactic cryotherapy substantially reduces the risk of RD in type 1 Stickler syndrome and, in this series, eliminated the risk of bilateral detachments.
"	"Study conclusion confirms effectiveness of prophylactic treatment.
"	"{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""Study conclusion confirms effectiveness of prophylactic treatment.\n"", ""reference"": ""PMID:17675240"", ""snippet"": ""Prophylactic cryotherapy substantially reduces the risk of RD in type 1 Stickler syndrome and, in this series, eliminated the risk of bilateral detachments.\n"", ""supports"": ""SUPPORT""}"
7517	7296	316	Stiff Person Syndrome	Stiff_Person_Syndrome.yaml	treatments	0	evidence	0	PMID:35084720	SUPPORT		details on symptomatic GABA-enhancing drugs and the currently available immunotherapies in a step-by-step approach	Benzodiazepines are established as first-line symptomatic GABA-enhancing therapy.	"{""explanation"": ""Benzodiazepines are established as first-line symptomatic GABA-enhancing therapy."", ""reference"": ""PMID:35084720"", ""snippet"": ""details on symptomatic GABA-enhancing drugs and the currently available immunotherapies in a step-by-step approach"", ""supports"": ""SUPPORT""}"
7518	7297	316	Stiff Person Syndrome	Stiff_Person_Syndrome.yaml	treatments	1	evidence	0	PMID:37059468	SUPPORT		combination therapies with the preferred gamma-aminobutyric acid-enhancing antispasmodic drugs, such as baclofen, tizanidine, benzodiazepines, and gabapentin	Baclofen is listed as a preferred GABA-enhancing antispasmodic drug for symptomatic treatment of SPS.	"{""explanation"": ""Baclofen is listed as a preferred GABA-enhancing antispasmodic drug for symptomatic treatment of SPS."", ""reference"": ""PMID:37059468"", ""snippet"": ""combination therapies with the preferred gamma-aminobutyric acid-enhancing antispasmodic drugs, such as baclofen, tizanidine, benzodiazepines, and gabapentin"", ""supports"": ""SUPPORT""}"
7519	7298	316	Stiff Person Syndrome	Stiff_Person_Syndrome.yaml	treatments	2	evidence	0	PMID:11756577	SUPPORT		Among patients who received immune globulin first, stiffness scores decreased significantly (P=0.02)	Randomized controlled trial demonstrated significant efficacy of IVIg.	"{""explanation"": ""Randomized controlled trial demonstrated significant efficacy of IVIg."", ""reference"": ""PMID:11756577"", ""snippet"": ""Among patients who received immune globulin first, stiffness scores decreased significantly (P=0.02)"", ""supports"": ""SUPPORT""}"
7520	7298	316	Stiff Person Syndrome	Stiff_Person_Syndrome.yaml	treatments	2	evidence	1	PMID:11756577	SUPPORT		Intravenous immune globulin is a well-tolerated and effective, albeit costly, therapy for patients with stiff-person syndrome and anti-GAD65 antibodies.	The trial conclusion establishes IVIg as effective treatment.	"{""explanation"": ""The trial conclusion establishes IVIg as effective treatment."", ""reference"": ""PMID:11756577"", ""snippet"": ""Intravenous immune globulin is a well-tolerated and effective, albeit costly, therapy for patients with stiff-person syndrome and anti-GAD65 antibodies."", ""supports"": ""SUPPORT""}"
7521	7298	316	Stiff Person Syndrome	Stiff_Person_Syndrome.yaml	treatments	2	evidence	2	PMID:37059468	SUPPORT		detailing the application of current immunotherapies with intravenous immunoglobulin (IVIg) plasmapheresis, and rituximab	The 2023 review confirms IVIg as a key immunotherapy option in the treatment algorithm.	"{""explanation"": ""The 2023 review confirms IVIg as a key immunotherapy option in the treatment algorithm."", ""reference"": ""PMID:37059468"", ""snippet"": ""detailing the application of current immunotherapies with intravenous immunoglobulin (IVIg) plasmapheresis, and rituximab"", ""supports"": ""SUPPORT""}"
7522	7299	316	Stiff Person Syndrome	Stiff_Person_Syndrome.yaml	treatments	3	evidence	0	PMID:37059468	SUPPORT		detailing the application of current immunotherapies with intravenous immunoglobulin (IVIg) plasmapheresis, and rituximab	Rituximab is included as part of the current immunotherapy options for SPS treatment.	"{""explanation"": ""Rituximab is included as part of the current immunotherapy options for SPS treatment."", ""reference"": ""PMID:37059468"", ""snippet"": ""detailing the application of current immunotherapies with intravenous immunoglobulin (IVIg) plasmapheresis, and rituximab"", ""supports"": ""SUPPORT""}"
7523	7299	316	Stiff Person Syndrome	Stiff_Person_Syndrome.yaml	treatments	3	evidence	1	PMID:35084720	SUPPORT		focuses on therapies providing details on symptomatic GABA-enhancing drugs and the currently available immunotherapies in a step-by-step approach	Rituximab is part of the step-by-step therapeutic approach for refractory cases.	"{""explanation"": ""Rituximab is part of the step-by-step therapeutic approach for refractory cases."", ""reference"": ""PMID:35084720"", ""snippet"": ""focuses on therapies providing details on symptomatic GABA-enhancing drugs and the currently available immunotherapies in a step-by-step approach"", ""supports"": ""SUPPORT""}"
7649	7367	318	Systemic Lupus Erythematosus	Systemic_Lupus_Erythematosus.yaml	treatments	0	evidence	0	PMID:28130918	SUPPORT		Anifrolumab substantially reduced disease activity compared with placebo across multiple clinical end points in the patients with moderate-to-severe SLE	This phase IIb trial demonstrated that anifrolumab significantly reduced SLE disease activity, with greater efficacy in patients with high interferon gene signatures.	"{""explanation"": ""This phase IIb trial demonstrated that anifrolumab significantly reduced SLE disease activity, with greater efficacy in patients with high interferon gene signatures."", ""reference"": ""PMID:28130918"", ""snippet"": ""Anifrolumab substantially reduced disease activity compared with placebo across multiple clinical end points in the patients with moderate-to-severe SLE"", ""supports"": ""SUPPORT""}"
7650	7369	318	Systemic Lupus Erythematosus	Systemic_Lupus_Erythematosus.yaml	treatments	2	evidence	0	PMID:22127708	SUPPORT		Belimumab plus standard therapy significantly improved SRI response rate, reduced SLE disease activity and severe flares, and was generally well tolerated in SLE	This phase III BLISS-76 trial demonstrated that belimumab significantly improved SLE outcomes compared to placebo.	"{""explanation"": ""This phase III BLISS-76 trial demonstrated that belimumab significantly improved SLE outcomes compared to placebo."", ""reference"": ""PMID:22127708"", ""snippet"": ""Belimumab plus standard therapy significantly improved SRI response rate, reduced SLE disease activity and severe flares, and was generally well tolerated in SLE"", ""supports"": ""SUPPORT""}"
7673	7409	320	TARP syndrome	TARP_syndrome.yaml	treatments	0	evidence	0	PMID:36944446	SUPPORT		At birth, he had an ASD and Robin sequence, two of the eponymous features	Lane et al. 2023 case report of a TARP patient with ASD requiring cardiac management for survival beyond neonatal period.	"{""explanation"": ""Lane et al. 2023 case report of a TARP patient with ASD requiring cardiac management for survival beyond neonatal period."", ""reference"": ""PMID:36944446"", ""snippet"": ""At birth, he had an ASD and Robin sequence, two of the eponymous features"", ""supports"": ""SUPPORT""}"
7674	7410	320	TARP syndrome	TARP_syndrome.yaml	treatments	1	evidence	0	PMID:36944446	SUPPORT		TARP (talipes equinovarus, atrial septal defect (ASD), Robin sequence, persistent left superior vena cava) syndrome	Lane et al. 2023 documents Robin sequence (which includes cleft palate) as a defining feature of TARP, requiring surgical intervention for airway management and feeding.	"{""explanation"": ""Lane et al. 2023 documents Robin sequence (which includes cleft palate) as a defining feature of TARP, requiring surgical intervention for airway management and feeding."", ""reference"": ""PMID:36944446"", ""snippet"": ""TARP (talipes equinovarus, atrial septal defect (ASD), Robin sequence, persistent left superior vena cava) syndrome"", ""supports"": ""SUPPORT""}"
7675	7411	320	TARP syndrome	TARP_syndrome.yaml	treatments	2	evidence	0	PMID:36944446	SUPPORT		TARP (talipes equinovarus, atrial septal defect (ASD), Robin sequence, persistent left superior vena cava) syndrome	Lane et al. 2023 case report of TARP patient with talipes equinovarus, which typically requires orthopedic surgical intervention.	"{""explanation"": ""Lane et al. 2023 case report of TARP patient with talipes equinovarus, which typically requires orthopedic surgical intervention."", ""reference"": ""PMID:36944446"", ""snippet"": ""TARP (talipes equinovarus, atrial septal defect (ASD), Robin sequence, persistent left superior vena cava) syndrome"", ""supports"": ""SUPPORT""}"
7676	7412	320	TARP syndrome	TARP_syndrome.yaml	treatments	3	evidence	0	PMID:36944446	SUPPORT		At birth, he had an ASD and Robin sequence, two of the eponymous features	Lane et al. 2023 case report documents Robin sequence (which includes micrognathia and glossoptosis) requiring airway management to prevent obstruction and maintain adequate oxygenation.	"{""explanation"": ""Lane et al. 2023 case report documents Robin sequence (which includes micrognathia and glossoptosis) requiring airway management to prevent obstruction and maintain adequate oxygenation."", ""reference"": ""PMID:36944446"", ""snippet"": ""At birth, he had an ASD and Robin sequence, two of the eponymous features"", ""supports"": ""SUPPORT""}"
7677	7413	320	TARP syndrome	TARP_syndrome.yaml	treatments	4	evidence	0	PMID:36944446	SUPPORT		our patient's survival past the neonatal period	Lane et al. 2023 demonstrates that coordinated multidisciplinary management of TARP syndrome features enables survival beyond the historically fatal neonatal period.	"{""explanation"": ""Lane et al. 2023 demonstrates that coordinated multidisciplinary management of TARP syndrome features enables survival beyond the historically fatal neonatal period."", ""reference"": ""PMID:36944446"", ""snippet"": ""our patient's survival past the neonatal period"", ""supports"": ""SUPPORT""}"
7681	7417	321	Taeniasis/cysticercosis	Taeniasis_Cysticercosis.yaml	treatments	0	evidence	0	PMID:12932389	SUPPORT		Available therapeutic measures include steroids, treatments for symptoms, surgery, and, more controversially, antiparasitic drugs to kill brain parasites.	The abstract lists antiparasitic drugs among available treatments.	"{""explanation"": ""The abstract lists antiparasitic drugs among available treatments."", ""reference"": ""PMID:12932389"", ""snippet"": ""Available therapeutic measures include steroids, treatments for symptoms, surgery, and, more controversially, antiparasitic drugs to kill brain parasites."", ""supports"": ""SUPPORT""}"
7682	7418	321	Taeniasis/cysticercosis	Taeniasis_Cysticercosis.yaml	treatments	1	evidence	0	PMID:12932389	SUPPORT		Available therapeutic measures include steroids, treatments for symptoms, surgery, and, more controversially, antiparasitic drugs to kill brain parasites.	The abstract includes surgery as a treatment option.	"{""explanation"": ""The abstract includes surgery as a treatment option."", ""reference"": ""PMID:12932389"", ""snippet"": ""Available therapeutic measures include steroids, treatments for symptoms, surgery, and, more controversially, antiparasitic drugs to kill brain parasites."", ""supports"": ""SUPPORT""}"
7697	7436	322	Tay-Sachs Disease	Tay-Sachs_Disease.yaml	treatments	0	evidence	0	PMID:27491214	SUPPORT		Both are devastating diseases without cure or specific treatment however, with the use of supportive aggressive medical management, the lifespan and quality of life has been extended for both diseases.	Review confirms supportive care extends lifespan and quality of life in GM2 gangliosidoses including Tay-Sachs disease.	"{""explanation"": ""Review confirms supportive care extends lifespan and quality of life in GM2 gangliosidoses including Tay-Sachs disease."", ""reference"": ""PMID:27491214"", ""snippet"": ""Both are devastating diseases without cure or specific treatment however, with the use of supportive aggressive medical management, the lifespan and quality of life has been extended for both diseases."", ""supports"": ""SUPPORT""}"
7698	7437	322	Tay-Sachs Disease	Tay-Sachs_Disease.yaml	treatments	1	evidence	0	PMID:12108829	SUPPORT		Carrier testing for Tay-Sachs disease should be offered to couples when at least one individual is of Ashkenazi Jewish (carrier frequency 1/30), Pennsylvania Dutch, Southern Louisiana Cajun, or Eastern Quebec French Canadian descent.	Review establishes carrier screening recommendations for high-risk populations including Ashkenazi Jews.	"{""explanation"": ""Review establishes carrier screening recommendations for high-risk populations including Ashkenazi Jews."", ""reference"": ""PMID:12108829"", ""snippet"": ""Carrier testing for Tay-Sachs disease should be offered to couples when at least one individual is of Ashkenazi Jewish (carrier frequency 1/30), Pennsylvania Dutch, Southern Louisiana Cajun, or Eastern Quebec French Canadian descent."", ""supports"": ""SUPPORT""}"
7699	7438	322	Tay-Sachs Disease	Tay-Sachs_Disease.yaml	treatments	2	evidence	0	PMID:27491214	SUPPORT		Treatment with FDA-approved glucose analogs to reduce the amount of ganglioside substrate is used as off-label treatments for some patients.	Review confirms substrate reduction therapy using glucose analogs is being used off-label in GM2 gangliosidoses.	"{""explanation"": ""Review confirms substrate reduction therapy using glucose analogs is being used off-label in GM2 gangliosidoses."", ""reference"": ""PMID:27491214"", ""snippet"": ""Treatment with FDA-approved glucose analogs to reduce the amount of ganglioside substrate is used as off-label treatments for some patients."", ""supports"": ""SUPPORT""}"
7700	7439	322	Tay-Sachs Disease	Tay-Sachs_Disease.yaml	treatments	3	evidence	0	PMID:35145305	SUPPORT		This study provides early safety and proof-of-concept data in humans for treatment of patients with TSD by AAV gene therapy.	First-in-human AAV gene therapy trial demonstrates safety and proof-of-concept for Tay-Sachs disease treatment.	"{""explanation"": ""First-in-human AAV gene therapy trial demonstrates safety and proof-of-concept for Tay-Sachs disease treatment."", ""reference"": ""PMID:35145305"", ""snippet"": ""This study provides early safety and proof-of-concept data in humans for treatment of patients with TSD by AAV gene therapy."", ""supports"": ""SUPPORT""}"
7714	7454	323	Tetanus	Tetanus.yaml	treatments	0	evidence	0	PMID:40543524	SUPPORT		Treatment is multifaceted, requiring source control, antibiotic therapy, and antitoxin administration.	Antitoxin (TIG) is a core component of recommended management.	"{""explanation"": ""Antitoxin (TIG) is a core component of recommended management."", ""reference"": ""PMID:40543524"", ""snippet"": ""Treatment is multifaceted, requiring source control, antibiotic therapy, and antitoxin administration."", ""supports"": ""SUPPORT""}"
7715	7455	323	Tetanus	Tetanus.yaml	treatments	1	evidence	0	PMID:40543524	SUPPORT		Treatment is multifaceted, requiring source control, antibiotic therapy, and antitoxin administration.	Debridement provides the source control described in standard care.	"{""explanation"": ""Debridement provides the source control described in standard care."", ""reference"": ""PMID:40543524"", ""snippet"": ""Treatment is multifaceted, requiring source control, antibiotic therapy, and antitoxin administration."", ""supports"": ""SUPPORT""}"
7716	7456	323	Tetanus	Tetanus.yaml	treatments	2	evidence	0	PMID:40543524	SUPPORT		Treatment is multifaceted, requiring source control, antibiotic therapy, and antitoxin administration.	Confirms antibiotics as part of standard tetanus management.	"{""explanation"": ""Confirms antibiotics as part of standard tetanus management."", ""reference"": ""PMID:40543524"", ""snippet"": ""Treatment is multifaceted, requiring source control, antibiotic therapy, and antitoxin administration."", ""supports"": ""SUPPORT""}"
7717	7457	323	Tetanus	Tetanus.yaml	treatments	3	evidence	0	PMID:38822438	SUPPORT		these studies have shown potential benefits of treating tetanus infections with benzodiazepines, magnesium sulfate and baclofen	This case report reviews evidence supporting the use of benzodiazepines as part of tetanus treatment.	"{""explanation"": ""This case report reviews evidence supporting the use of benzodiazepines as part of tetanus treatment."", ""reference"": ""PMID:38822438"", ""snippet"": ""these studies have shown potential benefits of treating tetanus infections with benzodiazepines, magnesium sulfate and baclofen"", ""supports"": ""SUPPORT""}"
7718	7458	323	Tetanus	Tetanus.yaml	treatments	4	evidence	0	PMID:40543524	SUPPORT		With prolonged, quality intensive care, many patients survive with good functional outcome.	Highlights the importance of ICU-level supportive care for survival.	"{""explanation"": ""Highlights the importance of ICU-level supportive care for survival."", ""reference"": ""PMID:40543524"", ""snippet"": ""With prolonged, quality intensive care, many patients survive with good functional outcome."", ""supports"": ""SUPPORT""}"
7719	7459	323	Tetanus	Tetanus.yaml	treatments	5	evidence	0	PMID:34790820	SUPPORT		The pooled estimate of receiving at least two doses of tetanus toxoid immunization coverage in Ethiopia was 52.2% (95% CI: 42.47-61.93, I 2 = 98.4%).	Underscores need for vaccination and boosters due to incomplete coverage.	"{""explanation"": ""Underscores need for vaccination and boosters due to incomplete coverage."", ""reference"": ""PMID:34790820"", ""snippet"": ""The pooled estimate of receiving at least two doses of tetanus toxoid immunization coverage in Ethiopia was 52.2% (95% CI: 42.47-61.93, I 2 = 98.4%)."", ""supports"": ""SUPPORT""}"
7723	7489	326	Trachoma	Trachoma.yaml	treatments	0	evidence	0	PMID:35618795	SUPPORT		Surgery is offered to individuals with trichiasis and antibiotic mass drug administration and interventions to stimulate facial cleanliness and environmental improvement are designed to reduce infection prevalence and transmission.	The abstract describes antibiotic mass drug administration as part of SAFE.	"{""explanation"": ""The abstract describes antibiotic mass drug administration as part of SAFE."", ""reference"": ""PMID:35618795"", ""snippet"": ""Surgery is offered to individuals with trichiasis and antibiotic mass drug administration and interventions to stimulate facial cleanliness and environmental improvement are designed to reduce infection prevalence and transmission."", ""supports"": ""SUPPORT""}"
7763	7509	327	Transient Neonatal Pustular Melanosis	Transient_Neonatal_Pustular_Melanosis.yaml	treatments	0	evidence	0	PMID:7091064	SUPPORT		Transient neonatal pustular melanosis.	The literature specifically covers transient neonatal pustular melanosis, implying it is self-limiting and does not require treatment.	"{""explanation"": ""The literature specifically covers transient neonatal pustular melanosis, implying it is self-limiting and does not require treatment."", ""reference"": ""PMID:7091064"", ""snippet"": ""Transient neonatal pustular melanosis."", ""supports"": ""SUPPORT""}"
7764	7509	327	Transient Neonatal Pustular Melanosis	Transient_Neonatal_Pustular_Melanosis.yaml	treatments	0	evidence	1	PMID:27192509	SUPPORT		However, the majority of neonatal skin pustules is not infectious, comprising the benign neonatal pustulosis. Benign neonatal pustuloses are a group of clinical disease characterized by pustular eruptions in which a contagious agent is not responsible for its etiology. The most common ones are erythema toxicum neonatorum, the transient neonatal pustular melanosis and the benign cephalic pustulosis. These dermatoses are usually benign, asymptomatic and self-limited.		"{""reference"": ""PMID:27192509"", ""snippet"": ""However, the majority of neonatal skin pustules is not infectious, comprising the benign neonatal pustulosis. Benign neonatal pustuloses are a group of clinical disease characterized by pustular eruptions in which a contagious agent is not responsible for its etiology. The most common ones are erythema toxicum neonatorum, the transient neonatal pustular melanosis and the benign cephalic pustulosis. These dermatoses are usually benign, asymptomatic and self-limited."", ""supports"": ""SUPPORT""}"
7778	7522	328	Transverse Myelitis	Transverse_Myelitis.yaml	treatments	0	evidence	0	PMID:26009577	SUPPORT		Standard treatment is steroids, and patients with more severe disease appear to respond to plasma exchange (PLEX).	The abstract states steroids are standard treatment for transverse myelitis.	"{""explanation"": ""The abstract states steroids are standard treatment for transverse myelitis."", ""reference"": ""PMID:26009577"", ""snippet"": ""Standard treatment is steroids, and patients with more severe disease appear to respond to plasma exchange (PLEX)."", ""supports"": ""SUPPORT""}"
7779	7523	328	Transverse Myelitis	Transverse_Myelitis.yaml	treatments	1	evidence	0	PMID:26009577	SUPPORT		Standard treatment is steroids, and patients with more severe disease appear to respond to plasma exchange (PLEX).	The abstract notes plasma exchange responsiveness in severe transverse myelitis.	"{""explanation"": ""The abstract notes plasma exchange responsiveness in severe transverse myelitis."", ""reference"": ""PMID:26009577"", ""snippet"": ""Standard treatment is steroids, and patients with more severe disease appear to respond to plasma exchange (PLEX)."", ""supports"": ""SUPPORT""}"
7789	7534	329	Traveler's Diarrhea	Travelers_Diarrhea.yaml	treatments	0	evidence	0	PMID:35839362	SUPPORT		In all cases, management begins with replacing water, electrolytes, and nutrients. Oral rehydration is preferred; however, signs of severe dehydration or sepsis warrant intravenous rehydration.	Review emphasizes oral rehydration as first-line management for acute diarrheal illness.	"{""explanation"": ""Review emphasizes oral rehydration as first-line management for acute diarrheal illness."", ""reference"": ""PMID:35839362"", ""snippet"": ""In all cases, management begins with replacing water, electrolytes, and nutrients. Oral rehydration is preferred; however, signs of severe dehydration or sepsis warrant intravenous rehydration."", ""supports"": ""SUPPORT""}"
7790	7535	329	Traveler's Diarrhea	Travelers_Diarrhea.yaml	treatments	1	evidence	0	PMID:39453259	SUPPORT		"Knowledge gaps persisted: over 50% were unaware of TD's self-limited nature, 30% did not recognize loperamide as a symptom reliever, and 36% believed all travelers should take antibiotics to prevent TD.
"	Pre-travel consultation study identifies loperamide as a recognized symptomatic reliever for traveler's diarrhea.	"{""explanation"": ""Pre-travel consultation study identifies loperamide as a recognized symptomatic reliever for traveler's diarrhea."", ""reference"": ""PMID:39453259"", ""snippet"": ""Knowledge gaps persisted: over 50% were unaware of TD's self-limited nature, 30% did not recognize loperamide as a symptom reliever, and 36% believed all travelers should take antibiotics to prevent TD.\n"", ""supports"": ""SUPPORT""}"
7791	7536	329	Traveler's Diarrhea	Travelers_Diarrhea.yaml	treatments	2	evidence	0	PMID:35839362	SUPPORT		Empiric antibiotics are rarely warranted, except in sepsis and some cases of travelers' or inflammatory diarrhea. Targeted antibiotic therapy may be appropriate following microbiologic stool assessment.	Clinical review notes selective use of antibiotics, including in some traveler's diarrhea cases.	"{""explanation"": ""Clinical review notes selective use of antibiotics, including in some traveler's diarrhea cases."", ""reference"": ""PMID:35839362"", ""snippet"": ""Empiric antibiotics are rarely warranted, except in sepsis and some cases of travelers' or inflammatory diarrhea. Targeted antibiotic therapy may be appropriate following microbiologic stool assessment."", ""supports"": ""SUPPORT""}"
7792	7536	329	Traveler's Diarrhea	Travelers_Diarrhea.yaml	treatments	2	evidence	1	PMID:40024692	SUPPORT		Resistant strains to representative therapeutic agents such as ciprofloxacin and azithromycin have been reported in recent years, and multidrug-resistant ETEC has also emerged.	Resistance trends in ETEC underscore reserving fluoroquinolones for indicated cases and adjusting based on susceptibility.	"{""explanation"": ""Resistance trends in ETEC underscore reserving fluoroquinolones for indicated cases and adjusting based on susceptibility."", ""reference"": ""PMID:40024692"", ""snippet"": ""Resistant strains to representative therapeutic agents such as ciprofloxacin and azithromycin have been reported in recent years, and multidrug-resistant ETEC has also emerged."", ""supports"": ""SUPPORT""}"
7793	7537	329	Traveler's Diarrhea	Travelers_Diarrhea.yaml	treatments	3	evidence	0	PMID:32966000	SUPPORT		Rifaximin is an antibiotic used to treat irritable bowel syndrome with diarrhea, reduce the risk of overt hepatic encephalopathy recurrence in adults, and treat travelers diarrhea caused by noninvasive strains of Escherichia coli.	StatPearls entry lists rifaximin as indicated for traveler's diarrhea from noninvasive E. coli.	"{""explanation"": ""StatPearls entry lists rifaximin as indicated for traveler's diarrhea from noninvasive E. coli."", ""reference"": ""PMID:32966000"", ""snippet"": ""Rifaximin is an antibiotic used to treat irritable bowel syndrome with diarrhea, reduce the risk of overt hepatic encephalopathy recurrence in adults, and treat travelers diarrhea caused by noninvasive strains of Escherichia coli."", ""supports"": ""SUPPORT""}"
7794	7537	329	Traveler's Diarrhea	Travelers_Diarrhea.yaml	treatments	3	evidence	1	PMID:36221413	SUPPORT		Compared with placebo, both probiotics and rifaximin were associated with lower incidence of TD (probiotics, RR 0.85, 95% CI 0.76-0.95; rifaximin, RR 0.47, 95% CI 0.35-0.63).	Network meta-analysis shows rifaximin reduces travelers diarrhea incidence more than probiotics, supporting its preventive use.	"{""explanation"": ""Network meta-analysis shows rifaximin reduces travelers diarrhea incidence more than probiotics, supporting its preventive use."", ""reference"": ""PMID:36221413"", ""snippet"": ""Compared with placebo, both probiotics and rifaximin were associated with lower incidence of TD (probiotics, RR 0.85, 95% CI 0.76-0.95; rifaximin, RR 0.47, 95% CI 0.35-0.63)."", ""supports"": ""SUPPORT""}"
7795	7538	329	Traveler's Diarrhea	Travelers_Diarrhea.yaml	treatments	4	evidence	0	PMID:32809532	SUPPORT		This educational activity focuses on bismuth subsalicylate's applications in managing gastrointestinal discomfort and traveler's diarrhea.	StatPearls review describes bismuth subsalicylate use for managing traveler's diarrhea symptoms.	"{""explanation"": ""StatPearls review describes bismuth subsalicylate use for managing traveler's diarrhea symptoms."", ""reference"": ""PMID:32809532"", ""snippet"": ""This educational activity focuses on bismuth subsalicylate's applications in managing gastrointestinal discomfort and traveler's diarrhea."", ""supports"": ""SUPPORT""}"
7796	7538	329	Traveler's Diarrhea	Travelers_Diarrhea.yaml	treatments	4	evidence	1	PMID:33064636	SUPPORT		The antisecretory, anti-inflammatory, and antibacterial properties of bismuth make it a suitable therapy for symptomatic treatment of diarrhea.	Narrative review highlights bismuths multimodal activity for diarrheal symptom relief, including travelers diarrhea.	"{""explanation"": ""Narrative review highlights bismuths multimodal activity for diarrheal symptom relief, including travelers diarrhea."", ""reference"": ""PMID:33064636"", ""snippet"": ""The antisecretory, anti-inflammatory, and antibacterial properties of bismuth make it a suitable therapy for symptomatic treatment of diarrhea."", ""supports"": ""SUPPORT""}"
7797	7539	329	Traveler's Diarrhea	Travelers_Diarrhea.yaml	treatments	5	evidence	0	PMID:38458507	SUPPORT		Based on this systematic review and meta-analysis, specific probiotic strains, including L. acidophilus, L. rhamnosus, L. fermentum, S. cerevisiae, and S. boulardii, may prevent TD.	Meta-analysis finds several probiotic strains reduce risk of traveler's diarrhea, supporting prophylactic use.	"{""explanation"": ""Meta-analysis finds several probiotic strains reduce risk of traveler's diarrhea, supporting prophylactic use."", ""reference"": ""PMID:38458507"", ""snippet"": ""Based on this systematic review and meta-analysis, specific probiotic strains, including L. acidophilus, L. rhamnosus, L. fermentum, S. cerevisiae, and S. boulardii, may prevent TD."", ""supports"": ""SUPPORT""}"
7798	7539	329	Traveler's Diarrhea	Travelers_Diarrhea.yaml	treatments	5	evidence	1	PMID:36221413	SUPPORT		Both probiotics and rifaximin were associated with lower incidence of TD (probiotics, RR 0.85, 95% CI 0.76-0.95).	Network meta-analysis quantifies reduced travelers diarrhea incidence with probiotic prophylaxis.	"{""explanation"": ""Network meta-analysis quantifies reduced travelers diarrhea incidence with probiotic prophylaxis."", ""reference"": ""PMID:36221413"", ""snippet"": ""Both probiotics and rifaximin were associated with lower incidence of TD (probiotics, RR 0.85, 95% CI 0.76-0.95)."", ""supports"": ""SUPPORT""}"
7799	7540	329	Traveler's Diarrhea	Travelers_Diarrhea.yaml	treatments	6	evidence	0	PMID:39453259	SUPPORT		The EG/post-consultation group showed significant improvement in knowledge, with correct answers increasing from 63% to 75%... knowledge gaps persisted... indicating the need for targeted interventions to increase travelers' literacy and optimize pre-travel consultations.	Study shows pre-travel counseling improves knowledge about travelers diarrhea prevention, underscoring value of education.	"{""explanation"": ""Study shows pre-travel counseling improves knowledge about travelers diarrhea prevention, underscoring value of education."", ""reference"": ""PMID:39453259"", ""snippet"": ""The EG/post-consultation group showed significant improvement in knowledge, with correct answers increasing from 63% to 75%... knowledge gaps persisted... indicating the need for targeted interventions to increase travelers' literacy and optimize pre-travel consultations."", ""supports"": ""SUPPORT""}"
7800	7540	329	Traveler's Diarrhea	Travelers_Diarrhea.yaml	treatments	6	evidence	1	PMID:40035303	SUPPORT		Traveling abroad carries the risk of traveler's diarrhea, which affects 20 to 50% of individuals. This article focuses on the definition, classification, epidemiology, etiology, prevention, and treatment management of traveler's diarrhea. It also describes recommendations for patients traveling to higher-risk areas, which can be used by pharmacists in counceling activities in the pharmacy.	Pharmacy guidance resource supports counseling travelers on prevention and treatment choices.	"{""explanation"": ""Pharmacy guidance resource supports counseling travelers on prevention and treatment choices."", ""reference"": ""PMID:40035303"", ""snippet"": ""Traveling abroad carries the risk of traveler's diarrhea, which affects 20 to 50% of individuals. This article focuses on the definition, classification, epidemiology, etiology, prevention, and treatment management of traveler's diarrhea. It also describes recommendations for patients traveling to higher-risk areas, which can be used by pharmacists in counceling activities in the pharmacy."", ""supports"": ""SUPPORT""}"
7801	7541	329	Traveler's Diarrhea	Travelers_Diarrhea.yaml	treatments	7	evidence	0	PMID:36221413	SUPPORT		Compared with placebo, both probiotics and rifaximin were associated with lower incidence of TD (probiotics, RR 0.85, 95% CI 0.76-0.95; rifaximin, RR 0.47, 95% CI 0.35-0.63), and rifaximin was more effective than probiotics (RR 0.56, 95% CI 0.4-0.78).	Network meta-analysis shows rifaximin prophylaxis significantly reduces travelers diarrhea incidence compared with placebo and probiotics.	"{""explanation"": ""Network meta-analysis shows rifaximin prophylaxis significantly reduces travelers diarrhea incidence compared with placebo and probiotics."", ""reference"": ""PMID:36221413"", ""snippet"": ""Compared with placebo, both probiotics and rifaximin were associated with lower incidence of TD (probiotics, RR 0.85, 95% CI 0.76-0.95; rifaximin, RR 0.47, 95% CI 0.35-0.63), and rifaximin was more effective than probiotics (RR 0.56, 95% CI 0.4-0.78)."", ""supports"": ""SUPPORT""}"
7811	7559	330	Triple-Negative Breast Cancer	Triple_Negative_Breast_Cancer.yaml	treatments	0	evidence	0	PMID:32046998	SUPPORT		Patients with a pCR after NAT had significantly better EFS (HR = 0.31; 95% PI, 0.24-0.39), particularly for triple-negative (HR = 0.18; 95% PI, 0.10-0.31) and HER2+ (HR = 0.32; 95% PI, 0.21-0.47) disease.	Meta-analysis confirms that achieving pCR after neoadjuvant therapy is strongly associated with improved event-free survival, particularly for TNBC.	"{""explanation"": ""Meta-analysis confirms that achieving pCR after neoadjuvant therapy is strongly associated with improved event-free survival, particularly for TNBC."", ""reference"": ""PMID:32046998"", ""snippet"": ""Patients with a pCR after NAT had significantly better EFS (HR = 0.31; 95% PI, 0.24-0.39), particularly for triple-negative (HR = 0.18; 95% PI, 0.10-0.31) and HER2+ (HR = 0.32; 95% PI, 0.21-0.47) disease."", ""supports"": ""SUPPORT""}"
7812	7560	330	Triple-Negative Breast Cancer	Triple_Negative_Breast_Cancer.yaml	treatments	1	evidence	0	PMID:32101663	SUPPORT		Among patients with early triple-negative breast cancer, the percentage with a pathological complete response was significantly higher among those who received pembrolizumab plus neoadjuvant chemotherapy than among those who received placebo plus neoadjuvant chemotherapy.	KEYNOTE-522 demonstrated significantly higher pCR rates with pembrolizumab plus chemotherapy versus chemotherapy alone in early TNBC.	"{""explanation"": ""KEYNOTE-522 demonstrated significantly higher pCR rates with pembrolizumab plus chemotherapy versus chemotherapy alone in early TNBC."", ""reference"": ""PMID:32101663"", ""snippet"": ""Among patients with early triple-negative breast cancer, the percentage with a pathological complete response was significantly higher among those who received pembrolizumab plus neoadjuvant chemotherapy than among those who received placebo plus neoadjuvant chemotherapy."", ""supports"": ""SUPPORT""}"
7813	7561	330	Triple-Negative Breast Cancer	Triple_Negative_Breast_Cancer.yaml	treatments	2	evidence	0	PMID:33475295	SUPPORT		PARP inhibition causes synthetic lethality in breast cancers associated with germline BRCA1 and BRCA2 mutations and is routinely used in clinical practice for metastatic breast cancer.	Review confirms PARP inhibitors cause synthetic lethality in BRCA-mutated breast cancers and are standard of care for metastatic disease.	"{""explanation"": ""Review confirms PARP inhibitors cause synthetic lethality in BRCA-mutated breast cancers and are standard of care for metastatic disease."", ""reference"": ""PMID:33475295"", ""snippet"": ""PARP inhibition causes synthetic lethality in breast cancers associated with germline BRCA1 and BRCA2 mutations and is routinely used in clinical practice for metastatic breast cancer."", ""supports"": ""SUPPORT""}"
7814	7562	330	Triple-Negative Breast Cancer	Triple_Negative_Breast_Cancer.yaml	treatments	3	evidence	0	PMID:33882206	SUPPORT		Progression-free and overall survival were significantly longer with sacituzumab govitecan than with single-agent chemotherapy among patients with metastatic triple-negative breast cancer.	ASCENT trial demonstrated significant PFS and OS benefit with sacituzumab govitecan versus chemotherapy in metastatic TNBC.	"{""explanation"": ""ASCENT trial demonstrated significant PFS and OS benefit with sacituzumab govitecan versus chemotherapy in metastatic TNBC."", ""reference"": ""PMID:33882206"", ""snippet"": ""Progression-free and overall survival were significantly longer with sacituzumab govitecan than with single-agent chemotherapy among patients with metastatic triple-negative breast cancer."", ""supports"": ""SUPPORT""}"
7815	7563	330	Triple-Negative Breast Cancer	Triple_Negative_Breast_Cancer.yaml	treatments	4	evidence	0	PMID:21633166	SUPPORT		BL1 and BL2 subtypes had higher expression of cell cycle and DNA damage response genes, and representative cell lines preferentially responded to cisplatin.	Basal-like TNBC subtypes with DNA damage response gene expression preferentially respond to platinum chemotherapy.	"{""explanation"": ""Basal-like TNBC subtypes with DNA damage response gene expression preferentially respond to platinum chemotherapy."", ""reference"": ""PMID:21633166"", ""snippet"": ""BL1 and BL2 subtypes had higher expression of cell cycle and DNA damage response genes, and representative cell lines preferentially responded to cisplatin."", ""supports"": ""SUPPORT""}"
7902	7596	331	Tuberculosis	Tuberculosis.yaml	treatments	0	evidence	0	PMID:33106268	SUPPORT		Isoniazid (INH), one of the first-line drugs used for the treatment of tuberculosis, is a prodrug which is activated by the intracellular KatG enzyme of Mycobacterium tuberculosis.	The description of Isoniazid as a first-line antibiotic for TB treatment and its activation by the KatG enzyme is supported. This aligns with the provided mechanism of prodrug activation.	"{""explanation"": ""The description of Isoniazid as a first-line antibiotic for TB treatment and its activation by the KatG enzyme is supported. This aligns with the provided mechanism of prodrug activation."", ""reference"": ""PMID:33106268"", ""snippet"": ""Isoniazid (INH), one of the first-line drugs used for the treatment of tuberculosis, is a prodrug which is activated by the intracellular KatG enzyme of Mycobacterium tuberculosis."", ""supports"": ""SUPPORT""}"
7903	7596	331	Tuberculosis	Tuberculosis.yaml	treatments	0	evidence	1	PMID:12164478	SUPPORT		The drugs shown to inhibit mycolic acid biosynthesis are isoniazid, ethionamide, isoxyl, thiolactomycin, and triclosan.	The inhibition of mycolic acid biosynthesis by Isoniazid aligns with the described mechanism of action in the statement.	"{""explanation"": ""The inhibition of mycolic acid biosynthesis by Isoniazid aligns with the described mechanism of action in the statement."", ""reference"": ""PMID:12164478"", ""snippet"": ""The drugs shown to inhibit mycolic acid biosynthesis are isoniazid, ethionamide, isoxyl, thiolactomycin, and triclosan."", ""supports"": ""SUPPORT""}"
7904	7597	331	Tuberculosis	Tuberculosis.yaml	treatments	1	evidence	0	PMID:11290327	SUPPORT		Rifampicin (Rif) is one of the most potent and broad spectrum antibiotics against bacterial pathogens and is a key component of anti-tuberculosis therapy, stemming from its inhibition of the bacterial RNA polymerase (RNAP).	This reference explains that Rifampicin is a key component of anti-tuberculosis therapy due to its inhibition of bacterial RNA polymerase.	"{""explanation"": ""This reference explains that Rifampicin is a key component of anti-tuberculosis therapy due to its inhibition of bacterial RNA polymerase."", ""reference"": ""PMID:11290327"", ""snippet"": ""Rifampicin (Rif) is one of the most potent and broad spectrum antibiotics against bacterial pathogens and is a key component of anti-tuberculosis therapy, stemming from its inhibition of the bacterial RNA polymerase (RNAP)."", ""supports"": ""SUPPORT""}"
7905	7597	331	Tuberculosis	Tuberculosis.yaml	treatments	1	evidence	1	PMID:27553018	SUPPORT		For the treatment of TB, administration of multiple antibiotics such as isoniazid, rifampicin, pyrazinamide, and ethambutol is required for a long period of time to kill bacteria.	This reference confirms that rifampicin is used for the treatment of TB.	"{""explanation"": ""This reference confirms that rifampicin is used for the treatment of TB."", ""reference"": ""PMID:27553018"", ""snippet"": ""For the treatment of TB, administration of multiple antibiotics such as isoniazid, rifampicin, pyrazinamide, and ethambutol is required for a long period of time to kill bacteria."", ""supports"": ""SUPPORT""}"
7906	7597	331	Tuberculosis	Tuberculosis.yaml	treatments	1	evidence	2	PMID:34400805	SUPPORT		Rifamycins exhibit bactericidal activity against many Gram-positive and Gram-negative bacteria by inhibiting RNA polymerase (RNAP).	This reference supports the statement by confirming that Rifamycins, including rifampicin, exhibit bactericidal activity by inhibiting RNA polymerase.	"{""explanation"": ""This reference supports the statement by confirming that Rifamycins, including rifampicin, exhibit bactericidal activity by inhibiting RNA polymerase."", ""reference"": ""PMID:34400805"", ""snippet"": ""Rifamycins exhibit bactericidal activity against many Gram-positive and Gram-negative bacteria by inhibiting RNA polymerase (RNAP)."", ""supports"": ""SUPPORT""}"
7907	7597	331	Tuberculosis	Tuberculosis.yaml	treatments	1	evidence	3	PMID:33199626	SUPPORT		Rif targets the enzyme RNA polymerase (RNAP).	This reference affirms the mechanism of rifampicin targeting RNA polymerase, which validates its use in TB treatment.	"{""explanation"": ""This reference affirms the mechanism of rifampicin targeting RNA polymerase, which validates its use in TB treatment."", ""reference"": ""PMID:33199626"", ""snippet"": ""Rif targets the enzyme RNA polymerase (RNAP)."", ""supports"": ""SUPPORT""}"
7908	7597	331	Tuberculosis	Tuberculosis.yaml	treatments	1	evidence	4	PMID:28803492	SUPPORT		Rifamycin antibiotics, like rifampin and rifapentine, have unique sterilizing activity against M.tb.	This reference supports the use of rifampicin (a Rifamycin antibiotic) for TB treatment due to its sterilizing activity against Mycobacterium tuberculosis.	"{""explanation"": ""This reference supports the use of rifampicin (a Rifamycin antibiotic) for TB treatment due to its sterilizing activity against Mycobacterium tuberculosis."", ""reference"": ""PMID:28803492"", ""snippet"": ""Rifamycin antibiotics, like rifampin and rifapentine, have unique sterilizing activity against M.tb."", ""supports"": ""SUPPORT""}"
7909	7598	331	Tuberculosis	Tuberculosis.yaml	treatments	2	evidence	0	PMID:16209089	SUPPORT		Ethambutol (EMB), the first line drug in the treatment of tuberculosis, is an inhibitor of the biosynthesis of the cell wall compound - arabinogalactan.	The literature states that ethambutol interferes with the biosynthesis of arabinogalactan, supporting the mechanism described in the statement.	"{""explanation"": ""The literature states that ethambutol interferes with the biosynthesis of arabinogalactan, supporting the mechanism described in the statement."", ""reference"": ""PMID:16209089"", ""snippet"": ""Ethambutol (EMB), the first line drug in the treatment of tuberculosis, is an inhibitor of the biosynthesis of the cell wall compound - arabinogalactan."", ""supports"": ""SUPPORT""}"
7910	7598	331	Tuberculosis	Tuberculosis.yaml	treatments	2	evidence	1	PMID:9949810	PARTIAL		Isoniazid is the most widely used antituberculosis drug.	The statement specifies ethambutol as a bacteriostatic antibiotic used for TB treatment, whereas this reference talks about isoniazid. It is partially relevant since ethambutol is also an antituberculosis drug, but this reference does not fully address ethambutol's function.	"{""explanation"": ""The statement specifies ethambutol as a bacteriostatic antibiotic used for TB treatment, whereas this reference talks about isoniazid. It is partially relevant since ethambutol is also an antituberculosis drug, but this reference does not fully address ethambutol's function."", ""reference"": ""PMID:9949810"", ""snippet"": ""Isoniazid is the most widely used antituberculosis drug."", ""supports"": ""PARTIAL""}"
7911	7598	331	Tuberculosis	Tuberculosis.yaml	treatments	2	evidence	2	PMID:37289062	SUPPORT		In combination with TB antibiotics, wollamide B1 synergistically enhances the activity of several antibiotics... and wollamide B1 did not compromise the antimycobacterial activity of the isoniazid/rifampicin/ethambutol combination.	This reference confirms that ethambutol is used in combination with other antitubercular drugs, aligning with the notes in the statement about preventing the emergence of drug resistance.	"{""explanation"": ""This reference confirms that ethambutol is used in combination with other antitubercular drugs, aligning with the notes in the statement about preventing the emergence of drug resistance."", ""reference"": ""PMID:37289062"", ""snippet"": ""In combination with TB antibiotics, wollamide B1 synergistically enhances the activity of several antibiotics... and wollamide B1 did not compromise the antimycobacterial activity of the isoniazid/rifampicin/ethambutol combination."", ""supports"": ""SUPPORT""}"
7912	7599	331	Tuberculosis	Tuberculosis.yaml	treatments	3	evidence	0	PMID:17943789	SUPPORT		Directly observed therapy (DOT), which involves people directly observing patients taking their antituberculous drugs.	The abstract clearly states that DOT involves someone directly observing patients taking their antituberculous drugs to ensure adherence.	"{""explanation"": ""The abstract clearly states that DOT involves someone directly observing patients taking their antituberculous drugs to ensure adherence."", ""reference"": ""PMID:17943789"", ""snippet"": ""Directly observed therapy (DOT), which involves people directly observing patients taking their antituberculous drugs."", ""supports"": ""SUPPORT""}"
7913	7599	331	Tuberculosis	Tuberculosis.yaml	treatments	3	evidence	1	PMID:29461901	SUPPORT		The World Health Organization (WHO) propagates Directly Observed Therapy Short-course (DOTS) as an effective way to stop the spread of TB in communities with a high burden.	The abstract indicates that DOTS is endorsed by WHO as a method to ensure patients adhere to TB treatment.	"{""explanation"": ""The abstract indicates that DOTS is endorsed by WHO as a method to ensure patients adhere to TB treatment."", ""reference"": ""PMID:29461901"", ""snippet"": ""The World Health Organization (WHO) propagates Directly Observed Therapy Short-course (DOTS) as an effective way to stop the spread of TB in communities with a high burden."", ""supports"": ""SUPPORT""}"
7914	7599	331	Tuberculosis	Tuberculosis.yaml	treatments	3	evidence	2	PMID:28410705	SUPPORT		A flexible, patient centered approach were a family member can act as the DOT provider with guidance from a trained health worker was evolved as the most acceptable and comfortable mode of treatment to majority of the TB patients	The abstract reinforces the involvement of a health worker in observing DOT, even if it's flexible to involve family members.	"{""explanation"": ""The abstract reinforces the involvement of a health worker in observing DOT, even if it's flexible to involve family members."", ""reference"": ""PMID:28410705"", ""snippet"": ""A flexible, patient centered approach were a family member can act as the DOT provider with guidance from a trained health worker was evolved as the most acceptable and comfortable mode of treatment to majority of the TB patients"", ""supports"": ""SUPPORT""}"
7915	7599	331	Tuberculosis	Tuberculosis.yaml	treatments	3	evidence	3	PMID:27598709	SUPPORT		To best ensure compliance, directly observed therapy (DOT) is considered the standard of practice.	Emphasizes DOT as a standard practice to ensure compliance by observing the patient directly.	"{""explanation"": ""Emphasizes DOT as a standard practice to ensure compliance by observing the patient directly."", ""reference"": ""PMID:27598709"", ""snippet"": ""To best ensure compliance, directly observed therapy (DOT) is considered the standard of practice."", ""supports"": ""SUPPORT""}"
7916	7600	331	Tuberculosis	Tuberculosis.yaml	treatments	4	evidence	0	PMID:29910114	SUPPORT		The 3-month isoniazid-rifapentine regimen is as safe and effective as other recommended latent tuberculosis infection regimens and achieves significantly higher treatment completion rates.	This source supports the statement mentioning that a regimen of isoniazid and rifapentine is used for latent TB infection.	"{""explanation"": ""This source supports the statement mentioning that a regimen of isoniazid and rifapentine is used for latent TB infection."", ""reference"": ""PMID:29910114"", ""snippet"": ""The 3-month isoniazid-rifapentine regimen is as safe and effective as other recommended latent tuberculosis infection regimens and achieves significantly higher treatment completion rates."", ""supports"": ""SUPPORT""}"
7917	7600	331	Tuberculosis	Tuberculosis.yaml	treatments	4	evidence	1	PMID:19496388	SUPPORT		The treatment of choice for LTBI is isoniazid for nine months.	This source supports the use of isoniazid for the prevention of latent tuberculosis infection (LTBI).	"{""explanation"": ""This source supports the use of isoniazid for the prevention of latent tuberculosis infection (LTBI)."", ""reference"": ""PMID:19496388"", ""snippet"": ""The treatment of choice for LTBI is isoniazid for nine months."", ""supports"": ""SUPPORT""}"
7918	7600	331	Tuberculosis	Tuberculosis.yaml	treatments	4	evidence	2	PMID:32551948	SUPPORT		The World Health Organization recommends the use of isoniazid (INH) alone or in combination with rifapentine to treat latent tuberculosis infections.	This supports the statement by specifying that WHO recommends isoniazid and rifapentine for the treatment of latent tuberculosis infections.	"{""explanation"": ""This supports the statement by specifying that WHO recommends isoniazid and rifapentine for the treatment of latent tuberculosis infections."", ""reference"": ""PMID:32551948"", ""snippet"": ""The World Health Organization recommends the use of isoniazid (INH) alone or in combination with rifapentine to treat latent tuberculosis infections."", ""supports"": ""SUPPORT""}"
7940	7635	332	Type 2 Diabetes Mellitus	Type_2_Diabetes_Mellitus.yaml	treatments	2	evidence	0	PMID:38831203	SUPPORT		Dual glucagon like peptide 1 (GLP1) and glucose-dependent insulinotropic peptide (GIP) receptor agonists are among the new pharmacological strategies recently developed to address this challenge.	This establishes GLP-1/GIP receptor agonists as effective pharmacological strategies for T2D treatment.	"{""explanation"": ""This establishes GLP-1/GIP receptor agonists as effective pharmacological strategies for T2D treatment."", ""reference"": ""PMID:38831203"", ""snippet"": ""Dual glucagon like peptide 1 (GLP1) and glucose-dependent insulinotropic peptide (GIP) receptor agonists are among the new pharmacological strategies recently developed to address this challenge."", ""supports"": ""SUPPORT""}"
7941	7638	332	Type 2 Diabetes Mellitus	Type_2_Diabetes_Mellitus.yaml	treatments	5	evidence	0	PMID:38831203	SUPPORT		Tirzepatide, characterized by its ability to selectively bind and activate receptors for the intestinal hormones GIP and GLP-1, has been tested in numerous clinical studies and is already currently authorized in several countries for the treatment of type 2 diabetes and obesity.	This confirms tirzepatide as an authorized dual GLP-1/GIP agonist for T2D and obesity treatment.	"{""explanation"": ""This confirms tirzepatide as an authorized dual GLP-1/GIP agonist for T2D and obesity treatment."", ""reference"": ""PMID:38831203"", ""snippet"": ""Tirzepatide, characterized by its ability to selectively bind and activate receptors for the intestinal hormones GIP and GLP-1, has been tested in numerous clinical studies and is already currently authorized in several countries for the treatment of type 2 diabetes and obesity."", ""supports"": ""SUPPORT""}"
8051	7683	333	Type I Diabetes	Type_I_Diabetes.yaml	treatments	0	evidence	0	PMID:21584767	SUPPORT		Insulin therapy is a vital hormone replacement therapy in type 1 diabetes mellitus.		"{""reference"": ""PMID:21584767"", ""snippet"": ""Insulin therapy is a vital hormone replacement therapy in type 1 diabetes mellitus."", ""supports"": ""SUPPORT""}"
8052	7683	333	Type I Diabetes	Type_I_Diabetes.yaml	treatments	0	evidence	1	PMID:36476434	SUPPORT		The current standard method for type 1 diabetes (T1D) management majorly focuses on controlling blood glucose levels with exogeneous insulin administration.		"{""reference"": ""PMID:36476434"", ""snippet"": ""The current standard method for type 1 diabetes (T1D) management majorly focuses on controlling blood glucose levels with exogeneous insulin administration."", ""supports"": ""SUPPORT""}"
8053	7683	333	Type I Diabetes	Type_I_Diabetes.yaml	treatments	0	evidence	2	PMID:32342453	SUPPORT		T1DM is caused by absolute lack of insulin secretion, so the current treatment for T1DM patients is exogenous insulin replacement therapy.		"{""reference"": ""PMID:32342453"", ""snippet"": ""T1DM is caused by absolute lack of insulin secretion, so the current treatment for T1DM patients is exogenous insulin replacement therapy."", ""supports"": ""SUPPORT""}"
8054	7683	333	Type I Diabetes	Type_I_Diabetes.yaml	treatments	0	evidence	3	PMID:20723814	NO_EVIDENCE			The reference lacks specific details pertaining to treatment.	"{""explanation"": ""The reference lacks specific details pertaining to treatment."", ""reference"": ""PMID:20723814"", ""snippet"": """", ""supports"": ""NO_EVIDENCE""}"
8055	7683	333	Type I Diabetes	Type_I_Diabetes.yaml	treatments	0	evidence	4	PMID:31426099	PARTIAL		Although a cure for T1D remains the ultimate goal, technology holds the promise of keeping youth with T1D in targeted control and minimize the burden of this chronic medical condition.	The reference acknowledges insulin therapy but focuses more on technological advancements rather than confirming insulin therapy as the essential treatment.	"{""explanation"": ""The reference acknowledges insulin therapy but focuses more on technological advancements rather than confirming insulin therapy as the essential treatment."", ""reference"": ""PMID:31426099"", ""snippet"": ""Although a cure for T1D remains the ultimate goal, technology holds the promise of keeping youth with T1D in targeted control and minimize the burden of this chronic medical condition."", ""supports"": ""PARTIAL""}"
8056	7683	333	Type I Diabetes	Type_I_Diabetes.yaml	treatments	0	evidence	5	PMID:28685788	PARTIAL		Replacing C-peptide, a hormone normally co-secreted with insulin, has been shown to reduce diabetes-related complications.	This reference discusses auxiliary therapy but does not diminish the essential role of insulin therapy.	"{""explanation"": ""This reference discusses auxiliary therapy but does not diminish the essential role of insulin therapy."", ""reference"": ""PMID:28685788"", ""snippet"": ""Replacing C-peptide, a hormone normally co-secreted with insulin, has been shown to reduce diabetes-related complications."", ""supports"": ""PARTIAL""}"
8057	7683	333	Type I Diabetes	Type_I_Diabetes.yaml	treatments	0	evidence	6	PMID:33970586	SUPPORT		The mainstay of management is a regimen of multiple daily injections of insulin or continuous subcutaneous insulin delivered via an insulin pump.		"{""reference"": ""PMID:33970586"", ""snippet"": ""The mainstay of management is a regimen of multiple daily injections of insulin or continuous subcutaneous insulin delivered via an insulin pump."", ""supports"": ""SUPPORT""}"
8058	7683	333	Type I Diabetes	Type_I_Diabetes.yaml	treatments	0	evidence	7	PMID:15306833	SUPPORT		There is, however, a limit to what can be achieved with existing exogenous insulin therapies due to their imperfect pharmacokinetic and pharmacodynamic profiles		"{""reference"": ""PMID:15306833"", ""snippet"": ""There is, however, a limit to what can be achieved with existing exogenous insulin therapies due to their imperfect pharmacokinetic and pharmacodynamic profiles"", ""supports"": ""SUPPORT""}"
8059	7683	333	Type I Diabetes	Type_I_Diabetes.yaml	treatments	0	evidence	8	PMID:6749365	SUPPORT		The results of epidemiological and clinical studies of diabetes in man and of studies of experimental diabetes in animals provide strong evidence: (1) that insulin-dependent diabetes mellitus is due to absolute or severe deficiency of insulin; (2) that replacement treatment with insulin is potentially capable of normalizing the metabolic abnormalities; and (3) that normalization of the metabolic abnormalities can be expected to prevent or ameliorate the complications of the disease		"{""reference"": ""PMID:6749365"", ""snippet"": ""The results of epidemiological and clinical studies of diabetes in man and of studies of experimental diabetes in animals provide strong evidence: (1) that insulin-dependent diabetes mellitus is due to absolute or severe deficiency of insulin; (2) that replacement treatment with insulin is potentially capable of normalizing the metabolic abnormalities; and (3) that normalization of the metabolic abnormalities can be expected to prevent or ameliorate the complications of the disease"", ""supports"": ""SUPPORT""}"
8060	7683	333	Type I Diabetes	Type_I_Diabetes.yaml	treatments	0	evidence	9	PMID:20666700	PARTIAL		Insulin is the primary medication in the treatment of type 1 diabetes. New therapeutic options and prevention strategies (cellular therapies, immunomodulation and vaccination) aim to preserve residual beta-cell function.	The focus on insulin as primary treatment supports the statement, despite mentioning new therapeutic options.	"{""explanation"": ""The focus on insulin as primary treatment supports the statement, despite mentioning new therapeutic options."", ""reference"": ""PMID:20666700"", ""snippet"": ""Insulin is the primary medication in the treatment of type 1 diabetes. New therapeutic options and prevention strategies (cellular therapies, immunomodulation and vaccination) aim to preserve residual beta-cell function."", ""supports"": ""PARTIAL""}"
8061	7684	333	Type I Diabetes	Type_I_Diabetes.yaml	treatments	1	evidence	0	PMID:30215903	SUPPORT		There is considerable benefit of tight glucose control in patients with type 1 diabetes mellitus. ... Greater frequency of glucose monitoring and continuous glucose monitoring are both associated with lower A1C levels.	The abstract emphasizes the importance of glucose monitoring in managing type 1 diabetes, supporting the statement that regular monitoring is crucial for effective glucose level management.	"{""explanation"": ""The abstract emphasizes the importance of glucose monitoring in managing type 1 diabetes, supporting the statement that regular monitoring is crucial for effective glucose level management."", ""reference"": ""PMID:30215903"", ""snippet"": ""There is considerable benefit of tight glucose control in patients with type 1 diabetes mellitus. ... Greater frequency of glucose monitoring and continuous glucose monitoring are both associated with lower A1C levels."", ""supports"": ""SUPPORT""}"
8062	7684	333	Type I Diabetes	Type_I_Diabetes.yaml	treatments	1	evidence	1	PMID:32256447	SUPPORT		Regular self-monitoring of blood glucose levels, and ketones when indicated, is an essential component of type 1 diabetes (T1D) management.	The abstract reaffirms that regular monitoring of blood glucose is essential for managing type 1 diabetes, supporting the statement.	"{""explanation"": ""The abstract reaffirms that regular monitoring of blood glucose is essential for managing type 1 diabetes, supporting the statement."", ""reference"": ""PMID:32256447"", ""snippet"": ""Regular self-monitoring of blood glucose levels, and ketones when indicated, is an essential component of type 1 diabetes (T1D) management."", ""supports"": ""SUPPORT""}"
8063	7684	333	Type I Diabetes	Type_I_Diabetes.yaml	treatments	1	evidence	2	PMID:38551884	SUPPORT		Blood glucose monitoring has been an integral part of diabetes treatment for many years, whether for type 1 diabetic patients on multiple daily injections of insulin, insulin pumps or artificial pancreas, and now for patients with type 2 diabetes...	The abstract describes blood glucose monitoring as a cornerstone in diabetes treatment, which includes the management of type 1 diabetes, thus supporting the statement.	"{""explanation"": ""The abstract describes blood glucose monitoring as a cornerstone in diabetes treatment, which includes the management of type 1 diabetes, thus supporting the statement."", ""reference"": ""PMID:38551884"", ""snippet"": ""Blood glucose monitoring has been an integral part of diabetes treatment for many years, whether for type 1 diabetic patients on multiple daily injections of insulin, insulin pumps or artificial pancreas, and now for patients with type 2 diabetes..."", ""supports"": ""SUPPORT""}"
8064	7684	333	Type I Diabetes	Type_I_Diabetes.yaml	treatments	1	evidence	3	PMID:11149158	SUPPORT		Sick-day management requires increased monitoring of blood glucose and assessment for ketosis.	The abstract highlights that during illness, increased blood glucose monitoring is necessary for managing type 1 diabetes, further supporting the statement about regular monitoring.	"{""explanation"": ""The abstract highlights that during illness, increased blood glucose monitoring is necessary for managing type 1 diabetes, further supporting the statement about regular monitoring."", ""reference"": ""PMID:11149158"", ""snippet"": ""Sick-day management requires increased monitoring of blood glucose and assessment for ketosis."", ""supports"": ""SUPPORT""}"
8065	7685	333	Type I Diabetes	Type_I_Diabetes.yaml	treatments	2	evidence	0	PMID:9314011	SUPPORT		Nutrition therapy and physical activity can assist persons with diabetes to achieve metabolic goals. Several lifestyle strategies can be used.	The text supports the assertion that maintaining a balanced diet and regular physical activity can assist in managing diabetes through lifestyle modifications.	"{""explanation"": ""The text supports the assertion that maintaining a balanced diet and regular physical activity can assist in managing diabetes through lifestyle modifications."", ""reference"": ""PMID:9314011"", ""snippet"": ""Nutrition therapy and physical activity can assist persons with diabetes to achieve metabolic goals. Several lifestyle strategies can be used."", ""supports"": ""SUPPORT""}"
8066	7685	333	Type I Diabetes	Type_I_Diabetes.yaml	treatments	2	evidence	1	PMID:16529680	SUPPORT		The patient and physician must work together to optimize glucose control involving both insulin administration and caloric intake. Exercise has numerous benefits and the type 1 diabetic should take advantage of these benefits.	This supports the statement that lifestyle modifications, including diet and physical activity, are important in managing type 1 diabetes.	"{""explanation"": ""This supports the statement that lifestyle modifications, including diet and physical activity, are important in managing type 1 diabetes."", ""reference"": ""PMID:16529680"", ""snippet"": ""The patient and physician must work together to optimize glucose control involving both insulin administration and caloric intake. Exercise has numerous benefits and the type 1 diabetic should take advantage of these benefits."", ""supports"": ""SUPPORT""}"
8067	7685	333	Type I Diabetes	Type_I_Diabetes.yaml	treatments	2	evidence	2	PMID:24485215	SUPPORT		Poor lifestyle habits (poor diet quality, sedentary behaviours and smoking) are known to be driving factors for increased CMR factors in the general population.	The text underlines the significance of maintaining a good lifestyle, including a balanced diet and physical activity, as part of diabetes management.	"{""explanation"": ""The text underlines the significance of maintaining a good lifestyle, including a balanced diet and physical activity, as part of diabetes management."", ""reference"": ""PMID:24485215"", ""snippet"": ""Poor lifestyle habits (poor diet quality, sedentary behaviours and smoking) are known to be driving factors for increased CMR factors in the general population."", ""supports"": ""SUPPORT""}"
8068	7685	333	Type I Diabetes	Type_I_Diabetes.yaml	treatments	2	evidence	3	PMID:32312302	SUPPORT		Innovative, cost-effective interventions along with beneficial lifestyle modifications can improve home-based self-monitoring of blood glucose in T1D patients.	This reference highlights the role of lifestyle modifications in managing type 1 diabetes through controlling blood glucose levels.	"{""explanation"": ""This reference highlights the role of lifestyle modifications in managing type 1 diabetes through controlling blood glucose levels."", ""reference"": ""PMID:32312302"", ""snippet"": ""Innovative, cost-effective interventions along with beneficial lifestyle modifications can improve home-based self-monitoring of blood glucose in T1D patients."", ""supports"": ""SUPPORT""}"
8069	7685	333	Type I Diabetes	Type_I_Diabetes.yaml	treatments	2	evidence	4	PMID:37820077	SUPPORT		Weight loss treatments provide a wide-range of benefits in reducing both morbidity and mortality in those who are obese.	It mentions lifestyle interventions as a part of weight loss treatments that benefit T1D management, highlighting their efficacy and safety.	"{""explanation"": ""It mentions lifestyle interventions as a part of weight loss treatments that benefit T1D management, highlighting their efficacy and safety."", ""reference"": ""PMID:37820077"", ""snippet"": ""Weight loss treatments provide a wide-range of benefits in reducing both morbidity and mortality in those who are obese."", ""supports"": ""SUPPORT""}"
8070	7686	333	Type I Diabetes	Type_I_Diabetes.yaml	treatments	3	evidence	0	PMID:36877454	SUPPORT		In November 2022, teplizumab was approved in the USA to delay the onset of Stage 3 T1D in adults and pediatric patients 8 years of age and older with Stage 2 T1D	This article documents the FDA approval of teplizumab as the first immunotherapy for delaying type 1 diabetes progression.	"{""explanation"": ""This article documents the FDA approval of teplizumab as the first immunotherapy for delaying type 1 diabetes progression."", ""reference"": ""PMID:36877454"", ""snippet"": ""In November 2022, teplizumab was approved in the USA to delay the onset of Stage 3 T1D in adults and pediatric patients 8 years of age and older with Stage 2 T1D"", ""supports"": ""SUPPORT""}"
8071	7687	333	Type I Diabetes	Type_I_Diabetes.yaml	treatments	4	evidence	0	PMID:34872983	SUPPORT		After CGM introduction, the odds ratio (OR) of achieving the HbA1c target of <7.0% improved at 12 months (OR 2.5, P < 0.001) and was maintained at 24 months	This population-based study demonstrates that continuous glucose monitoring significantly improves glycemic control with sustained improvements in HbA1c target achievement.	"{""explanation"": ""This population-based study demonstrates that continuous glucose monitoring significantly improves glycemic control with sustained improvements in HbA1c target achievement."", ""reference"": ""PMID:34872983"", ""snippet"": ""After CGM introduction, the odds ratio (OR) of achieving the HbA1c target of <7.0% improved at 12 months (OR 2.5, P < 0.001) and was maintained at 24 months"", ""supports"": ""SUPPORT""}"
8126	7762	337	Visual Snow Syndrome	Visual_Snow_Syndrome.yaml	treatments	0	evidence	0	PMID:31213497	SUPPORT		Lamotrigine was prescribed most frequently (26/58) and resulted in partial remission of symptoms in 5/26 (19.2%). No patients reported complete remission.	Lamotrigine provides partial symptom relief in about 19% of patients, though complete remission is rare.	"{""explanation"": ""Lamotrigine provides partial symptom relief in about 19% of patients, though complete remission is rare."", ""reference"": ""PMID:31213497"", ""snippet"": ""Lamotrigine was prescribed most frequently (26/58) and resulted in partial remission of symptoms in 5/26 (19.2%). No patients reported complete remission."", ""supports"": ""SUPPORT""}"
8127	7762	337	Visual Snow Syndrome	Visual_Snow_Syndrome.yaml	treatments	0	evidence	1	PMID:33008511	SUPPORT		The best data is available for lamotrigine being effective in 8/36 (22.2%, including one total response and no worsening), followed by topiramate being effective in 2/13 (15.4%, no total response and one worsening).	Systematic review confirms lamotrigine has the best evidence for effectiveness in VSS.	"{""explanation"": ""Systematic review confirms lamotrigine has the best evidence for effectiveness in VSS."", ""reference"": ""PMID:33008511"", ""snippet"": ""The best data is available for lamotrigine being effective in 8/36 (22.2%, including one total response and no worsening), followed by topiramate being effective in 2/13 (15.4%, no total response and one worsening)."", ""supports"": ""SUPPORT""}"
8128	7762	337	Visual Snow Syndrome	Visual_Snow_Syndrome.yaml	treatments	0	evidence	2	PMID:40129600	SUPPORT		benzodiazepines and lamotrigine had the best effect (71.4% and 61.5% of patients had an improvement of VS symptoms on each medication, respectively).	Recent 2025 review shows lamotrigine among the most effective pharmacological treatments.	"{""explanation"": ""Recent 2025 review shows lamotrigine among the most effective pharmacological treatments."", ""reference"": ""PMID:40129600"", ""snippet"": ""benzodiazepines and lamotrigine had the best effect (71.4% and 61.5% of patients had an improvement of VS symptoms on each medication, respectively)."", ""supports"": ""SUPPORT""}"
8129	7762	337	Visual Snow Syndrome	Visual_Snow_Syndrome.yaml	treatments	0	evidence	3	PMID:28349350	SUPPORT		Our preferred treatment options include: (1) oral lamotrigine with a slow increase from 25 mg daily to a maintenance dose of 200-300 mg daily in divided doses as tolerated	Expert recommendations support lamotrigine as a first-line pharmacological option.	"{""explanation"": ""Expert recommendations support lamotrigine as a first-line pharmacological option."", ""reference"": ""PMID:28349350"", ""snippet"": ""Our preferred treatment options include: (1) oral lamotrigine with a slow increase from 25 mg daily to a maintenance dose of 200-300 mg daily in divided doses as tolerated"", ""supports"": ""SUPPORT""}"
8130	7763	337	Visual Snow Syndrome	Visual_Snow_Syndrome.yaml	treatments	1	evidence	0	PMID:38465699	SUPPORT		Promising nonpharmacological treatments include mindfulness-based cognitive therapy, the use of chromatic filters, and research on visual noise adaption and neuro-optometric visual rehabilitation therapy (NORT).	Chromatic filters are identified as a promising nonpharmacological treatment option.	"{""explanation"": ""Chromatic filters are identified as a promising nonpharmacological treatment option."", ""reference"": ""PMID:38465699"", ""snippet"": ""Promising nonpharmacological treatments include mindfulness-based cognitive therapy, the use of chromatic filters, and research on visual noise adaption and neuro-optometric visual rehabilitation therapy (NORT)."", ""supports"": ""SUPPORT""}"
8131	7763	337	Visual Snow Syndrome	Visual_Snow_Syndrome.yaml	treatments	1	evidence	1	PMID:40129600	SUPPORT		FL-41 tinted lenses consistently provide symptom relief, with cognitive behavioral therapy showing promise as an emerging intervention.	FL-41 tinted lenses consistently provide symptom relief in VSS patients.	"{""explanation"": ""FL-41 tinted lenses consistently provide symptom relief in VSS patients."", ""reference"": ""PMID:40129600"", ""snippet"": ""FL-41 tinted lenses consistently provide symptom relief, with cognitive behavioral therapy showing promise as an emerging intervention."", ""supports"": ""SUPPORT""}"
8132	7763	337	Visual Snow Syndrome	Visual_Snow_Syndrome.yaml	treatments	1	evidence	2	PMID:33008511	SUPPORT		The nonpharmacological approach using color filters of the yellow-blue color spectrum might also be helpful in some patients.	Color filters in the yellow-blue spectrum may provide benefit for some VSS patients.	"{""explanation"": ""Color filters in the yellow-blue spectrum may provide benefit for some VSS patients."", ""reference"": ""PMID:33008511"", ""snippet"": ""The nonpharmacological approach using color filters of the yellow-blue color spectrum might also be helpful in some patients."", ""supports"": ""SUPPORT""}"
8133	7764	337	Visual Snow Syndrome	Visual_Snow_Syndrome.yaml	treatments	2	evidence	0	PMID:40129600	SUPPORT		FL-41 tinted lenses consistently provide symptom relief, with cognitive behavioral therapy showing promise as an emerging intervention.	CBT shows promise as an emerging intervention for VSS.	"{""explanation"": ""CBT shows promise as an emerging intervention for VSS."", ""reference"": ""PMID:40129600"", ""snippet"": ""FL-41 tinted lenses consistently provide symptom relief, with cognitive behavioral therapy showing promise as an emerging intervention."", ""supports"": ""SUPPORT""}"
8134	7764	337	Visual Snow Syndrome	Visual_Snow_Syndrome.yaml	treatments	2	evidence	1	PMID:38465699	SUPPORT		Promising nonpharmacological treatments include mindfulness-based cognitive therapy, the use of chromatic filters, and research on visual noise adaption and neuro-optometric visual rehabilitation therapy (NORT).	Mindfulness-based cognitive therapy is identified as a promising treatment approach.	"{""explanation"": ""Mindfulness-based cognitive therapy is identified as a promising treatment approach."", ""reference"": ""PMID:38465699"", ""snippet"": ""Promising nonpharmacological treatments include mindfulness-based cognitive therapy, the use of chromatic filters, and research on visual noise adaption and neuro-optometric visual rehabilitation therapy (NORT)."", ""supports"": ""SUPPORT""}"
8135	7765	337	Visual Snow Syndrome	Visual_Snow_Syndrome.yaml	treatments	3	evidence	0	PMID:40129600	SUPPORT		benzodiazepines and lamotrigine had the best effect (71.4% and 61.5% of patients had an improvement of VS symptoms on each medication, respectively).	Benzodiazepines show the highest improvement rate at 71.4% of patients.	"{""explanation"": ""Benzodiazepines show the highest improvement rate at 71.4% of patients."", ""reference"": ""PMID:40129600"", ""snippet"": ""benzodiazepines and lamotrigine had the best effect (71.4% and 61.5% of patients had an improvement of VS symptoms on each medication, respectively)."", ""supports"": ""SUPPORT""}"
8213	7798	338	Vitiligo	Vitiligo.yaml	treatments	0	evidence	0	PMID:19178066	SUPPORT	HUMAN_CLINICAL	Topical corticosteroids are one of the oldest and most useful treatments for dermatologic conditions... evidence of effectiveness exists only for select conditions, such as psoriasis, vitiligo...	The use of topical corticosteroids as a treatment for vitiligo is supported, indicating it as a common and effective treatment option.	"{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""The use of topical corticosteroids as a treatment for vitiligo is supported, indicating it as a common and effective treatment option."", ""reference"": ""PMID:19178066"", ""snippet"": ""Topical corticosteroids are one of the oldest and most useful treatments for dermatologic conditions... evidence of effectiveness exists only for select conditions, such as psoriasis, vitiligo..."", ""supports"": ""SUPPORT""}"
8214	7798	338	Vitiligo	Vitiligo.yaml	treatments	0	evidence	1	PMID:38477910	SUPPORT	HUMAN_CLINICAL	Evidence supports the use of... topical corticosteroids... as effective therapeutics for vitiligo...	The recommendations include topical corticosteroids as a first-line treatment for vitiligo in pediatric, adolescent, and young adult patients.	"{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""The recommendations include topical corticosteroids as a first-line treatment for vitiligo in pediatric, adolescent, and young adult patients."", ""reference"": ""PMID:38477910"", ""snippet"": ""Evidence supports the use of... topical corticosteroids... as effective therapeutics for vitiligo..."", ""supports"": ""SUPPORT""}"
8215	7798	338	Vitiligo	Vitiligo.yaml	treatments	0	evidence	2	PMID:33350506	SUPPORT	HUMAN_CLINICAL	The mainstay of treatment for unstable vitiligo has been topical agents (corticosteroids, calcineurin inhibitors)...	This article highlights topical corticosteroids as a primary treatment for vitiligo, supporting the statement.	"{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""This article highlights topical corticosteroids as a primary treatment for vitiligo, supporting the statement."", ""reference"": ""PMID:33350506"", ""snippet"": ""The mainstay of treatment for unstable vitiligo has been topical agents (corticosteroids, calcineurin inhibitors)..."", ""supports"": ""SUPPORT""}"
8216	7798	338	Vitiligo	Vitiligo.yaml	treatments	0	evidence	3	PMID:20445292	SUPPORT	HUMAN_CLINICAL	Topical therapy is employed as first-line treatment in localized vitiligo. Currently, several topical agents are available... corticosteroids...	Topical corticosteroids are mentioned as a first-line treatment, aligning with the provided statement.	"{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""Topical corticosteroids are mentioned as a first-line treatment, aligning with the provided statement."", ""reference"": ""PMID:20445292"", ""snippet"": ""Topical therapy is employed as first-line treatment in localized vitiligo. Currently, several topical agents are available... corticosteroids..."", ""supports"": ""SUPPORT""}"
8217	7800	338	Vitiligo	Vitiligo.yaml	treatments	2	evidence	0	PMID:27638438	SUPPORT	HUMAN_CLINICAL	Acting on multiple steps in vitiligo pathogenesis, narrowband ultraviolet B is one of the few therapies that can effectively induce stabilization and stimulate repigmentation.	The article supports the use of narrowband UVB for stimulating repigmentation in vitiligo.	"{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""The article supports the use of narrowband UVB for stimulating repigmentation in vitiligo."", ""reference"": ""PMID:27638438"", ""snippet"": ""Acting on multiple steps in vitiligo pathogenesis, narrowband ultraviolet B is one of the few therapies that can effectively induce stabilization and stimulate repigmentation."", ""supports"": ""SUPPORT""}"
8218	7800	338	Vitiligo	Vitiligo.yaml	treatments	2	evidence	1	PMID:28317529	SUPPORT	HUMAN_CLINICAL	The most potent stimulus for repigmentation is the UV light.	This reference directly supports that UV light, including UVB, is a potent stimulus for repigmentation in vitiligo.	"{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""This reference directly supports that UV light, including UVB, is a potent stimulus for repigmentation in vitiligo."", ""reference"": ""PMID:28317529"", ""snippet"": ""The most potent stimulus for repigmentation is the UV light."", ""supports"": ""SUPPORT""}"
8219	7800	338	Vitiligo	Vitiligo.yaml	treatments	2	evidence	2	PMID:20149899	SUPPORT	HUMAN_CLINICAL	There have been many treatments to cure vitiligo such as use of steroid creams, PUVA (psoralen and ultraviolet A light), narrow band UVB (ultraviolet B), various surgical techniques, vitamin D analogues and pseudocatalase.	It lists both PUVA and narrowband UVB as standard treatments for vitiligo.	"{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""It lists both PUVA and narrowband UVB as standard treatments for vitiligo."", ""reference"": ""PMID:20149899"", ""snippet"": ""There have been many treatments to cure vitiligo such as use of steroid creams, PUVA (psoralen and ultraviolet A light), narrow band UVB (ultraviolet B), various surgical techniques, vitamin D analogues and pseudocatalase."", ""supports"": ""SUPPORT""}"
8220	7800	338	Vitiligo	Vitiligo.yaml	treatments	2	evidence	3	PMID:34806278	SUPPORT	HUMAN_CLINICAL	OBJECTIVE: To study whether the colorimeter and point counting technique can be used as objective methods in monitoring vitiligo lesions during treatment with Nb-UVB...	The study demonstrates the effectiveness of narrowband UVB in increasing the melanin index, indicating pigment production in vitiligo lesions.	"{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""The study demonstrates the effectiveness of narrowband UVB in increasing the melanin index, indicating pigment production in vitiligo lesions."", ""reference"": ""PMID:34806278"", ""snippet"": ""OBJECTIVE: To study whether the colorimeter and point counting technique can be used as objective methods in monitoring vitiligo lesions during treatment with Nb-UVB..."", ""supports"": ""SUPPORT""}"
8221	7801	338	Vitiligo	Vitiligo.yaml	treatments	3	evidence	0	PMID:38038734	SUPPORT	HUMAN_CLINICAL	For patients with stable vitiligo who have not achieved satisfactory results with medical treatments, the melanocyte-keratinocyte transplantation procedure (MKTP) is a viable option.	MKTP is a type of autologous non-cultured cellular grafting procedure used for treating stable vitiligo.	"{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""MKTP is a type of autologous non-cultured cellular grafting procedure used for treating stable vitiligo."", ""reference"": ""PMID:38038734"", ""snippet"": ""For patients with stable vitiligo who have not achieved satisfactory results with medical treatments, the melanocyte-keratinocyte transplantation procedure (MKTP) is a viable option."", ""supports"": ""SUPPORT""}"
8222	7801	338	Vitiligo	Vitiligo.yaml	treatments	3	evidence	1	PMID:37000977	SUPPORT	HUMAN_CLINICAL	Surgical therapies are effective methods to treat resistant stable vitiligo, with each method having advantages and disadvantages.	This study compares ultrathin skin grafting (UTSG) and suction blister epidermal grafting (SBEG), both of which are skin grafting methods used to treat stable vitiligo.	"{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""This study compares ultrathin skin grafting (UTSG) and suction blister epidermal grafting (SBEG), both of which are skin grafting methods used to treat stable vitiligo."", ""reference"": ""PMID:37000977"", ""snippet"": ""Surgical therapies are effective methods to treat resistant stable vitiligo, with each method having advantages and disadvantages."", ""supports"": ""SUPPORT""}"
8223	7801	338	Vitiligo	Vitiligo.yaml	treatments	3	evidence	2	PMID:34169570	SUPPORT	HUMAN_CLINICAL	Cultured epidermal autografts (CEA) are surgical therapeutic alternatives for patients with stable vitiligo resistant to conventional medical treatments.	CEA is mentioned as an option for treating stable vitiligo, indicating the use of skin grafting.	"{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""CEA is mentioned as an option for treating stable vitiligo, indicating the use of skin grafting."", ""reference"": ""PMID:34169570"", ""snippet"": ""Cultured epidermal autografts (CEA) are surgical therapeutic alternatives for patients with stable vitiligo resistant to conventional medical treatments."", ""supports"": ""SUPPORT""}"
8224	7801	338	Vitiligo	Vitiligo.yaml	treatments	3	evidence	3	PMID:22994670	SUPPORT	HUMAN_CLINICAL	A number of new therapeutic options for vitiligo have become available...One among them is the smashed skin grafting or simply smash grafting	This reference discusses smash grafting as a method used in vitiligo treatment.	"{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""This reference discusses smash grafting as a method used in vitiligo treatment."", ""reference"": ""PMID:22994670"", ""snippet"": ""A number of new therapeutic options for vitiligo have become available...One among them is the smashed skin grafting or simply smash grafting"", ""supports"": ""SUPPORT""}"
8225	7801	338	Vitiligo	Vitiligo.yaml	treatments	3	evidence	4	PMID:27274556	SUPPORT	HUMAN_CLINICAL	Medical treatments are usually reasonably effective for nonstable vitiligo patches; however, for vitiligo patches that have been stable for a substantial period of time, surgical intervention should be considered.	It supports the use of surgical interventions, including skin grafting, for stable vitiligo.	"{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""It supports the use of surgical interventions, including skin grafting, for stable vitiligo."", ""reference"": ""PMID:27274556"", ""snippet"": ""Medical treatments are usually reasonably effective for nonstable vitiligo patches; however, for vitiligo patches that have been stable for a substantial period of time, surgical intervention should be considered."", ""supports"": ""SUPPORT""}"
8226	7802	338	Vitiligo	Vitiligo.yaml	treatments	4	evidence	0	PMID:12709002	SUPPORT	HUMAN_CLINICAL	This surgical treatment gives its best results in segmental and focal vitiligo, even with large affected areas, and in at least 50% of patients with generalized vitiligo.	This implies that melanocyte-keratinocyte transplantation can be effective for stable vitiligo.	"{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""This implies that melanocyte-keratinocyte transplantation can be effective for stable vitiligo."", ""reference"": ""PMID:12709002"", ""snippet"": ""This surgical treatment gives its best results in segmental and focal vitiligo, even with large affected areas, and in at least 50% of patients with generalized vitiligo."", ""supports"": ""SUPPORT""}"
8227	7802	338	Vitiligo	Vitiligo.yaml	treatments	4	evidence	1	PMID:26728804	SUPPORT	HUMAN_CLINICAL	Melanocyte-keratinocyte transplantation procedure: A few insights.	The procedure involves melanocyte transplantation which supports the statement for treating stable vitiligo.	"{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""The procedure involves melanocyte transplantation which supports the statement for treating stable vitiligo."", ""reference"": ""PMID:26728804"", ""snippet"": ""Melanocyte-keratinocyte transplantation procedure: A few insights."", ""supports"": ""SUPPORT""}"
8228	7802	338	Vitiligo	Vitiligo.yaml	treatments	4	evidence	2	PMID:28445194	SUPPORT	HUMAN_CLINICAL	Cultured autologous melanocyte transplantation (CMT) is an effective treatment for stable vitiligo.	This confirms the use of melanocyte transplantation for stable vitiligo.	"{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""This confirms the use of melanocyte transplantation for stable vitiligo."", ""reference"": ""PMID:28445194"", ""snippet"": ""Cultured autologous melanocyte transplantation (CMT) is an effective treatment for stable vitiligo."", ""supports"": ""SUPPORT""}"
8229	7802	338	Vitiligo	Vitiligo.yaml	treatments	4	evidence	3	PMID:35457678	SUPPORT	HUMAN_CLINICAL	Both the development of new techniques and modifications to the already available treatment of cell and tissue transplantation give hope to numerous patients around the world.	Surgical treatments including melanocyte transplantation are viable for stable vitiligo according to the literature.	"{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""Surgical treatments including melanocyte transplantation are viable for stable vitiligo according to the literature."", ""reference"": ""PMID:35457678"", ""snippet"": ""Both the development of new techniques and modifications to the already available treatment of cell and tissue transplantation give hope to numerous patients around the world."", ""supports"": ""SUPPORT""}"
8230	7803	338	Vitiligo	Vitiligo.yaml	treatments	5	evidence	0	PMID:3168334	SUPPORT	HUMAN_CLINICAL	When large areas of skin are involved or when the patient is unresponsive to therapy, serious consideration should be given to depigmentation with monobenzone (Benoquin).	This supports the use of monobenzone cream for removing remaining pigment in cases of extensive vitiligo.	"{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""This supports the use of monobenzone cream for removing remaining pigment in cases of extensive vitiligo."", ""reference"": ""PMID:3168334"", ""snippet"": ""When large areas of skin are involved or when the patient is unresponsive to therapy, serious consideration should be given to depigmentation with monobenzone (Benoquin)."", ""supports"": ""SUPPORT""}"
8231	7803	338	Vitiligo	Vitiligo.yaml	treatments	5	evidence	1	PMID:21054565	SUPPORT	HUMAN_CLINICAL	If vitiligo involves most of the body, it might be easier to depigment the normal remaining skin rather than to attempt repigmentation...Our review revealed that...Monobenzyl ether of hydroquinone (MBEH) is the most widely used depigmenting agent and has few side-effects.	The reference supports the use of monobenzone (MBEH) for depigmentation in extensive vitiligo cases.	"{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""The reference supports the use of monobenzone (MBEH) for depigmentation in extensive vitiligo cases."", ""reference"": ""PMID:21054565"", ""snippet"": ""If vitiligo involves most of the body, it might be easier to depigment the normal remaining skin rather than to attempt repigmentation...Our review revealed that...Monobenzyl ether of hydroquinone (MBEH) is the most widely used depigmenting agent and has few side-effects."", ""supports"": ""SUPPORT""}"
8242	7826	339	Von Hippel-Lindau Disease	Von_Hippel-Lindau_Disease.yaml	treatments	2	evidence	0	PMID:34818478	SUPPORT		Belzutifan was associated with predominantly grade 1 and 2 adverse events and showed activity in patients with renal cell carcinomas and non-renal cell carcinoma neoplasms associated with VHL disease.	Phase 2 clinical trial demonstrates belzutifan efficacy and tolerability across VHL-associated tumor types.	"{""explanation"": ""Phase 2 clinical trial demonstrates belzutifan efficacy and tolerability across VHL-associated tumor types."", ""reference"": ""PMID:34818478"", ""snippet"": ""Belzutifan was associated with predominantly grade 1 and 2 adverse events and showed activity in patients with renal cell carcinomas and non-renal cell carcinoma neoplasms associated with VHL disease."", ""supports"": ""SUPPORT""}"
8273	7848	340	Whipple Disease	Whipple_Disease.yaml	treatments	0	evidence	0	PMID:26288590	SUPPORT		The German treatment recommendations include a two-week intravenous induction therapy with ceftriaxone, which is followed by a three-month oral maintenance therapy with trimethoprim/sulfamethoxazole.	Details standard ceftriaxone induction and TMP-SMX maintenance regimen.	"{""explanation"": ""Details standard ceftriaxone induction and TMP-SMX maintenance regimen."", ""reference"": ""PMID:26288590"", ""snippet"": ""The German treatment recommendations include a two-week intravenous induction therapy with ceftriaxone, which is followed by a three-month oral maintenance therapy with trimethoprim/sulfamethoxazole."", ""supports"": ""SUPPORT""}"
8274	7849	340	Whipple Disease	Whipple_Disease.yaml	treatments	1	evidence	0	PMID:26288590	SUPPORT		A French group favors a combination of doxycycline and hydroxychloroquine for 1 year, followed by a lifelong administration of doxycycline.	Review reports alternative long-course doxycycline plus hydroxychloroquine approach.	"{""explanation"": ""Review reports alternative long-course doxycycline plus hydroxychloroquine approach."", ""reference"": ""PMID:26288590"", ""snippet"": ""A French group favors a combination of doxycycline and hydroxychloroquine for 1 year, followed by a lifelong administration of doxycycline."", ""supports"": ""SUPPORT""}"
8318	7900	342	Wilson Disease	Wilsons_Disease.yaml	treatments	0	evidence	0	PMID:38731973	SUPPORT		Patients with Wilson disease are well-treated first-line with copper chelators like D-penicillamine that facilitate the removal of circulating copper bound to albumin and increase in urinary copper excretion. Early chelation therapy improves prognosis.	Establishes D-penicillamine as first-line chelation therapy with evidence for improved prognosis.	"{""explanation"": ""Establishes D-penicillamine as first-line chelation therapy with evidence for improved prognosis."", ""reference"": ""PMID:38731973"", ""snippet"": ""Patients with Wilson disease are well-treated first-line with copper chelators like D-penicillamine that facilitate the removal of circulating copper bound to albumin and increase in urinary copper excretion. Early chelation therapy improves prognosis."", ""supports"": ""SUPPORT""}"
8319	7901	342	Wilson Disease	Wilsons_Disease.yaml	treatments	1	evidence	0	PMID:37741465	SUPPORT		Current treatment protocols are limited to either sequestration of copper via chelation or reduction of copper absorption in the gut	Confirms chelation therapy as a primary treatment approach for Wilson's disease.	"{""explanation"": ""Confirms chelation therapy as a primary treatment approach for Wilson's disease."", ""reference"": ""PMID:37741465"", ""snippet"": ""Current treatment protocols are limited to either sequestration of copper via chelation or reduction of copper absorption in the gut"", ""supports"": ""SUPPORT""}"
8320	7902	342	Wilson Disease	Wilsons_Disease.yaml	treatments	2	evidence	0	PMID:37741465	SUPPORT		reduction of copper absorption in the gut (zinc therapy)	Confirms zinc therapy works by reducing intestinal copper absorption.	"{""explanation"": ""Confirms zinc therapy works by reducing intestinal copper absorption."", ""reference"": ""PMID:37741465"", ""snippet"": ""reduction of copper absorption in the gut (zinc therapy)"", ""supports"": ""SUPPORT""}"
8321	7903	342	Wilson Disease	Wilsons_Disease.yaml	treatments	3	evidence	0	PMID:38731973	SUPPORT		copper, which is found ubiquitously on earth and normally enters the human body in small amounts via the food chain	Establishes that dietary intake is a source of copper, supporting dietary restriction as an adjunctive treatment approach.	"{""explanation"": ""Establishes that dietary intake is a source of copper, supporting dietary restriction as an adjunctive treatment approach."", ""reference"": ""PMID:38731973"", ""snippet"": ""copper, which is found ubiquitously on earth and normally enters the human body in small amounts via the food chain"", ""supports"": ""SUPPORT""}"
8322	7904	342	Wilson Disease	Wilsons_Disease.yaml	treatments	4	evidence	0	PMID:37741465	SUPPORT		Current treatment protocols are limited to either sequestration of copper via chelation or reduction of copper absorption in the gut	Tetrathiomolybdate represents an emerging chelation approach that tightly complexes copper.	"{""explanation"": ""Tetrathiomolybdate represents an emerging chelation approach that tightly complexes copper."", ""reference"": ""PMID:37741465"", ""snippet"": ""Current treatment protocols are limited to either sequestration of copper via chelation or reduction of copper absorption in the gut"", ""supports"": ""SUPPORT""}"
8323	7905	342	Wilson Disease	Wilsons_Disease.yaml	treatments	5	evidence	0	PMID:38731973	SUPPORT		Liver transplantation is an option viewed as ultima ratio in end-stage liver disease with untreatable complications or acute liver failure. Liver transplantation finally may thus be a life-saving approach and curative treatment of the disease by replacing the hepatic gene mutation.	Confirms liver transplantation as curative treatment that replaces the defective gene.	"{""explanation"": ""Confirms liver transplantation as curative treatment that replaces the defective gene."", ""reference"": ""PMID:38731973"", ""snippet"": ""Liver transplantation is an option viewed as ultima ratio in end-stage liver disease with untreatable complications or acute liver failure. Liver transplantation finally may thus be a life-saving approach and curative treatment of the disease by replacing the hepatic gene mutation."", ""supports"": ""SUPPORT""}"
8346	7924	343	Wissler syndrome	Wissler_syndrome.yaml	treatments	0	evidence	0	PMID:27843372	SUPPORT		A combination of nonsteroidal anti-inflammatory drugs and steroids achieved complete remission.	The case report documents remission with NSAID therapy.	"{""explanation"": ""The case report documents remission with NSAID therapy."", ""reference"": ""PMID:27843372"", ""snippet"": ""A combination of nonsteroidal anti-inflammatory drugs and steroids achieved complete remission."", ""supports"": ""SUPPORT""}"
8347	7925	343	Wissler syndrome	Wissler_syndrome.yaml	treatments	1	evidence	0	PMID:27843372	SUPPORT		A combination of nonsteroidal anti-inflammatory drugs and steroids achieved complete remission.	The case report notes complete remission with steroids plus NSAIDs.	"{""explanation"": ""The case report notes complete remission with steroids plus NSAIDs."", ""reference"": ""PMID:27843372"", ""snippet"": ""A combination of nonsteroidal anti-inflammatory drugs and steroids achieved complete remission."", ""supports"": ""SUPPORT""}"
8348	7925	343	Wissler syndrome	Wissler_syndrome.yaml	treatments	1	evidence	1	PMID:1210460	SUPPORT		In the present case the disease could successfully be controlled using imuran in combination with corticosteroids.	The abstract indicates corticosteroids were part of successful therapy.	"{""explanation"": ""The abstract indicates corticosteroids were part of successful therapy."", ""reference"": ""PMID:1210460"", ""snippet"": ""In the present case the disease could successfully be controlled using imuran in combination with corticosteroids."", ""supports"": ""SUPPORT""}"
8349	7926	343	Wissler syndrome	Wissler_syndrome.yaml	treatments	2	evidence	0	PMID:27843372	SUPPORT		A combination of naproxen, dapsone, and prednisolone therapy resulted in significant improvement of the patients arthralgias and rash.	The case report documents improvement with dapsone as part of combination therapy.	"{""explanation"": ""The case report documents improvement with dapsone as part of combination therapy."", ""reference"": ""PMID:27843372"", ""snippet"": ""A combination of naproxen, dapsone, and prednisolone therapy resulted in significant improvement of the patients arthralgias and rash."", ""supports"": ""SUPPORT""}"
8350	7927	343	Wissler syndrome	Wissler_syndrome.yaml	treatments	3	evidence	0	PMID:1210460	SUPPORT		In the present case the disease could successfully be controlled using imuran in combination with corticosteroids.	The abstract reports successful control with azathioprine (imuran) plus steroids.	"{""explanation"": ""The abstract reports successful control with azathioprine (imuran) plus steroids."", ""reference"": ""PMID:1210460"", ""snippet"": ""In the present case the disease could successfully be controlled using imuran in combination with corticosteroids."", ""supports"": ""SUPPORT""}"
8384	7947	344	Wolf-Hirschhorn_Syndrome	Wolf-Hirschhorn_Syndrome.yaml	treatments	0	evidence	0	PMID:37075791	SUPPORT		The most effective ASM was levetiracetam. Although WHS-associated epilepsy is intractable with frequent SE occurrence during infancy, improvement in seizure control is expected with age. Levetiracetam may be a novel ASM for WHS.	This study found levetiracetam to be the most effective antiseizure medication for Wolf-Hirschhorn syndrome.	"{""explanation"": ""This study found levetiracetam to be the most effective antiseizure medication for Wolf-Hirschhorn syndrome."", ""reference"": ""PMID:37075791"", ""snippet"": ""The most effective ASM was levetiracetam. Although WHS-associated epilepsy is intractable with frequent SE occurrence during infancy, improvement in seizure control is expected with age. Levetiracetam may be a novel ASM for WHS."", ""supports"": ""SUPPORT""}"
8385	7947	344	Wolf-Hirschhorn_Syndrome	Wolf-Hirschhorn_Syndrome.yaml	treatments	0	evidence	1	PMID:41303083	SUPPORT		Valproic acid and levetiracetam were the most commonly used treatments.	This cohort study confirms that levetiracetam is one of the most commonly used antiseizure medications for WHS.	"{""explanation"": ""This cohort study confirms that levetiracetam is one of the most commonly used antiseizure medications for WHS."", ""reference"": ""PMID:41303083"", ""snippet"": ""Valproic acid and levetiracetam were the most commonly used treatments."", ""supports"": ""SUPPORT""}"
8386	7948	344	Wolf-Hirschhorn_Syndrome	Wolf-Hirschhorn_Syndrome.yaml	treatments	1	evidence	0	PMID:41303083	SUPPORT		Valproic acid and levetiracetam were the most commonly used treatments.	This large cohort study indicates valproic acid is one of the most frequently prescribed antiseizure medications for WHS.	"{""explanation"": ""This large cohort study indicates valproic acid is one of the most frequently prescribed antiseizure medications for WHS."", ""reference"": ""PMID:41303083"", ""snippet"": ""Valproic acid and levetiracetam were the most commonly used treatments."", ""supports"": ""SUPPORT""}"
8387	7949	344	Wolf-Hirschhorn_Syndrome	Wolf-Hirschhorn_Syndrome.yaml	treatments	2	evidence	0	PMID:41017003	SUPPORT		Across 11 years of rhGH, height improved from ~ - 4.2 to ~ - 1.3 SDS with normalized height velocity and a prolonged but uneventful pubertal course. No major adverse effects were observed. Muscle tone improvement was also noted with treatment initiation.	This case report demonstrates long-term efficacy and safety of recombinant human growth hormone therapy in WHS patients with growth hormone deficiency.	"{""explanation"": ""This case report demonstrates long-term efficacy and safety of recombinant human growth hormone therapy in WHS patients with growth hormone deficiency."", ""reference"": ""PMID:41017003"", ""snippet"": ""Across 11 years of rhGH, height improved from ~ - 4.2 to ~ - 1.3 SDS with normalized height velocity and a prolonged but uneventful pubertal course. No major adverse effects were observed. Muscle tone improvement was also noted with treatment initiation."", ""supports"": ""SUPPORT""}"
8388	7950	344	Wolf-Hirschhorn_Syndrome	Wolf-Hirschhorn_Syndrome.yaml	treatments	3	evidence	0	PMID:41303083	SUPPORT		While some patients show improvement with age, early aggressive management using appropriate ASMs may be critical to improve neurological prognosis.	This study suggests early aggressive seizure management may improve long-term neurological outcomes in WHS.	"{""explanation"": ""This study suggests early aggressive seizure management may improve long-term neurological outcomes in WHS."", ""reference"": ""PMID:41303083"", ""snippet"": ""While some patients show improvement with age, early aggressive management using appropriate ASMs may be critical to improve neurological prognosis."", ""supports"": ""SUPPORT""}"
8392	7954	345	Yaws	Yaws.yaml	treatments	0	evidence	0	PMID:40036381	SUPPORT		Though yaws can be treated with benzathine penicillin, oral azithromycin has become the preferred treatment due to its ease of administration.	The abstract notes oral azithromycin as the preferred treatment.	"{""explanation"": ""The abstract notes oral azithromycin as the preferred treatment."", ""reference"": ""PMID:40036381"", ""snippet"": ""Though yaws can be treated with benzathine penicillin, oral azithromycin has become the preferred treatment due to its ease of administration."", ""supports"": ""SUPPORT""}"
8402	7966	346	You-Hoover-Fong Syndrome	You-Hoover-Fong_Syndrome.yaml	treatments	1	evidence	0	PMID:37215500	SUPPORT		After bilateral cataract surgery, the infant obtained better visual acuity and showed more responses and interactions with her parents	Demonstrates benefit of cataract surgery for improving visual function and patient engagement.	"{""explanation"": ""Demonstrates benefit of cataract surgery for improving visual function and patient engagement."", ""reference"": ""PMID:37215500"", ""snippet"": ""After bilateral cataract surgery, the infant obtained better visual acuity and showed more responses and interactions with her parents"", ""supports"": ""SUPPORT""}"
